studies O
on O
magnesiums O
mechanism O
of O
action O
in O
digitalis B-Plant
induced O
arrhythmias B-Disease

the O
mechanism O
by O
which O
magnesium O
affects O
digitalis B-Plant
induced O
arrhythmias B-Disease
was O
studied O
in O
dogs O
with O
and O
without O
beta O
receptor O
blockade O

magnesium O
direct O
effect O
on O
calcium O
and O
potassium O
fluxes O
across O
the O
myocardial O
cell O
membrane O
may O
be O
the O
mechanism O
of O
its O
antiarrhythmic O
action O
in O
digitalis B-Plant
toxic O
arrhythmias B-Disease

inhibitory O
effect O
of O
green B-Plant
tea I-Plant
on O
the O
growth O
of O
established O
skin B-Disease
papillomas I-Disease
in O
mice O

in O
10 O
separate O
experiments O
mice O
with O
established O
chemically O
induced O
or O
uv O
light O
induced O
skin B-Disease
papillomas I-Disease
were O
treated O
continuously O
with O
green B-Plant
tea I-Plant
in O
the O
drinking O
water O
or O
with O
injections O
of O
a O
green B-Plant
tea I-Plant
polyphenol O
fraction O
or O
epigallocatechin O
gallate O
three O
times O
a O
week O
for O
4 O
10 O

examination O
of O
the O
data O
from O
all O
ten O
experiments O
revealed O
that O
complete O
tumor B-Disease
regression O
occurred O
in O
14 O
of O
346 O
papilloma O
bearing O
mice O
4 O
that O
were O
treated O
with O
green B-Plant
tea I-Plant
in O
the O
drinking O
water O
or O
with O
ip O
injections O
of O
green B-Plant
tea I-Plant
constituents O
whereas O
none O
of O
the O
220 O
papilloma O
bearing O
control O
mice O
treated O
with O
only O
vehicle O
exhibited O
complete O
tumor B-Disease
regression O

these O
observations O
indicate O
that O
oral O
administration O
of O
green B-Plant
tea I-Plant
administration O
of O
a O
green B-Plant
tea I-Plant
polyphenol O
fraction O
or O
administration O
of O
epigallocatechin O
gallate O
inhibited O
the O
growth O
and O
or O
caused O
the O
regression O
of O
established O
experimentally O
induced O
skin B-Disease
papillomas I-Disease

the O
consumption O
of O
coffee B-Plant
is O
a O
self O
reinforcing O
behavior O
and O
caffeine O
dependence O
and O
addiction B-Disease
are O
common O

initial O
trials O
showing O
coffee B-Plant
association O
with O
coronary B-Disease
disease I-Disease
and O
myocardial B-Disease
infarction I-Disease
have O
been O
difficult O
to O
reproduce O
and O
have O
many O
confounding O
variable O

at O
present O
there O
is O
no O
convincing O
evidence O
that O
caffeine O
or O
coffee B-Plant
consumption O
increases O
the O
risk O
for O
any O
solid B-Disease
tumor I-Disease

our O
data O
suggest O
that O
long O
term O
exposure O
to O
hemp B-Plant
dust O
may O
cause O
the O
development O
of O
chronic O
respiratory B-Disease
symptoms I-Disease
and O
impairment O
of O
ventilatory O
capacity O

atrial B-Disease
tachyarrhythmias I-Disease
are O
a O
common O
manifestation O
of O
digitalis B-Plant
toxicity O

halothane O
is O
known O
to O
oppose O
digitalis B-Plant
induced O
ventricular B-Disease
arrhythmias I-Disease

its O
effect O
on O
digitalis B-Plant
caused O
atrial B-Disease
arrhythmias I-Disease
is O
unknown O

first O
increasing O
ouabain O
concentrations O
would O
enhance O
automaticity O
of O
sap O
compared O
to O
the O
sa O
node O
and O
that O
such O
enhanced O
automaticity O
could O
explain O
digitalis B-Plant
caused O
atrial B-Disease
tachyarrhythmias I-Disease

second O
halothane O
would O
oppose O
such O
enhanced O
automaticity O
of O
sap O
thereby O
opposing O
digitalis B-Plant
caused O
atrial B-Disease
tachyarrhythmias I-Disease

both O
cases O
proved O
to O
be O
cotton B-Plant
material O
induced O
granulomas B-Disease

coffee B-Plant
caffeine O
and O
cardiovascular B-Disease
disease I-Disease
in O
men O

coffee B-Plant
consumption O
and O
the O
risk O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
has O
been O
suspected O

recent O
coffee B-Plant
drinking O
and O
the O
incidence O
of O
cardiovascular B-Disease
disease I-Disease

methods O
we O
examined O
prospectively O
the O
relation O
of O
coffee B-Plant
consumption O
with O
the O
risk O
of O
myocardial B-Disease
infarction I-Disease
need O
for O
coronary O
artery O
bypass O
grafting O
or O
angioplasty O
and O
risk O
of O
stroke B-Disease
in O
a O
cohort O
of O
45 O
589 O
us O
men O
who O
were O
40 O
to O
75 O
years O
old O
in O
1986 O
and O
who O
had O
no O
history O
of O
cardiovascular B-Disease
diasease I-Disease

total O
coffee B-Plant
consumption O
was O
not O
associated O
with O
an O
increased O
risk O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
or O
stroke B-Disease

the O
age O
adjusted O
relative O
risk O
for O
all O
cardiovascular B-Disease
disease I-Disease
among O
participants O
who O
drank O
four O
or O
more O
cups O
of O
coffee B-Plant
per O
day O
was O
1 O
4 O
95 O
percent O
confidence O
intervals O
74 O
to O
146 O

increasing O
levels O
of O
consumption O
of O
caffeinated O
coffee B-Plant
were O
not O
associated O
with O
higher O
risks O
of O
cardiovascular B-Disease
disease I-Disease

higher O
consumption O
of O
decaffeinated O
coffee B-Plant
however O
was O
associated O
with O
a O
marginally O
significant O
increase O
in O
the O
risk O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
relative O
risk O
163 O
95 O
percent O
confidence O
interval O
102 O
to O
260 O

conclusions O
these O
findings O
do O
not O
support O
the O
hypothesis O
that O
coffee B-Plant
or O
caffeine O
consumption O
increases O
the O
risk O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
or O
stroke B-Disease

a O
wide O
variety O
of O
tobacco B-Plant
habits O
prevalent O
in O
the O
country O
are O
primarily O
responsible O
for O
the O
occurrence O
of O
these O
cancers B-Disease

among O
them O
bidi O
smoking O
tobacco B-Plant
chewing O
and O
cigarette O
smoking O
in O
that O
order O
account O
for O
a O
large O
majority O
of O
these O
cancers B-Disease

the O
government O
of O
india O
has O
accorded O
a O
high O
priority O
to O
prevention O
of O
tobacco B-Plant
related O
cancers B-Disease
by O
the O
turn O
of O
the O
century O
in O
its O
national O
cancer B-Disease
control O
programme O

intragastric O
bile O
acid O
concentrations O
in O
healthy O
subjects O
and O
in O
patients O
with O
gastric B-Disease
and O
duodenal B-Disease
ulcer I-Disease
and O
the O
influence O
of O
fiber O
enriched O
wheat B-Plant
bran O
in O
patients O
with O
gastric B-Disease
ulcer I-Disease

fiber O
enriched O
wheat B-Plant
bran O
reduced O
bile O
acid O
concentrations O
significantly O
in O
patients O
with O
gastric B-Disease
ulcer I-Disease
disease I-Disease

approximately O
90 O
of O
indian O
oral B-Disease
cancers I-Disease
are O
tobacco B-Plant
related O
the O
possibility O
of O
developing O
the O
lesion O
being O
ten O
times O
higher O
if O
the O
habit O
is O
formed O
below O
the O
age O
of O
14 O
years O

public O
awareness O
about O
tobacco B-Plant
related O
oral B-Disease
cancer I-Disease
is O
low O
at O
present O
and O
new O
approaches O
to O
this O
problem O
should O
include O
education O
in O
the O
schools O
on O
oral B-Disease
cancer I-Disease
formulation O
of O
legislative O
action O
to O
ban O
the O
sale O
of O
tobacco B-Plant
near O
schools O
and O
colleges O
and O
imposition O
of O
societal O
barriers O
that O
would O
make O
the O
nonchewing O
of O
tobacco B-Plant
socially O
more O
acceptable O
than O
chewing O
it O

the O
effects O
of O
vitamin O
c O
on O
the O
growth O
of O
human O
lung O
cultures O
and O
of O
vitamin O
c O
or O
l O
cysteine O
on O
a O
human O
breast B-Disease
cancer I-Disease
culture O
sk O
br O
3 O
were O
assessed O
with O
and O
without O
exposure O
to O
fresh O
smoke O
from O
tobacco B-Plant
or O
marijuana B-Plant
cigarettes O

nonexposed O
or O
tobacco B-Plant
smoke O
exposed O
breast B-Disease
cancer I-Disease
cultures O
when O
grown O
in O
the O
presence O
of O
vitamin O
c O
also O
showed O
acceleration O
of O
growth O
of O
epithelial O
cells O
significant O
reduction O
in O
mitotic O
abnormalities O
and O
occurrence O
of O
pseudoglandular O
structures O
indicating O
differentiation O

in O
contrast O
vitamin O
c O
did O
not O
reduce O
mitotic O
abnormalities O
in O
marijuana B-Plant
smoke O
exposed O
breast B-Disease
cancer I-Disease
cultures O
but O
stimulated O
abnormal O
growth O
and O
dedifferentiation O

in O
nonexposed O
tobacco B-Plant
or O
marijuana B-Plant
smoke O
exposed O
breast B-Disease
cancer I-Disease
cultures O

efficacy O
of O
cancer B-Disease
prevention O
by O
high O
selenium O
garlic B-Plant
is O
primarily O
dependent O
on O
the O
action O
of O
selenium O

we O
reported O
previously O
that O
garlic B-Plant
cultivated O
with O
selenite O
fertilization O
showed O
powerful O
chemopreventive O
activity O
in O
the O
rat O
dimethylbenz O
anthracene O
dmba O
induced O
mammary B-Disease
tumor I-Disease
model O

in O
order O
to O
ascertain O
that O
the O
efficacy O
of O
the O
high O
selenium O
garlic B-Plant
in O
cancer B-Disease
protection O
is O
primarily O
dependent O
on O
the O
action O
of O
selenium O
we O
compared O
the O
effects O
of O
two O
batches O
of O
garlic B-Plant
powder O
with O
marked O
differences O
in O
their O
level O
of O
selenium O
enrichment O
112 O
or O
1355 O

furthermore O
the O
magnitude O
tumor B-Disease
suppression O
as O
well O
as O
the O
extent O
of O
dmba O
dna O
adduct O
inhibition O
were O
very O
similar O
with O
the O
two O
batches O
of O
garlic B-Plant
even O
though O
the O
amounts O
of O
garlic B-Plant
in O
the O
diet O
varied O
considerably O
between O
them O
18 O
for O
the O
112 O

thus O
based O
on O
the O
results O
of O
several O
biological O
responses O
it O
appears O
that O
the O
ability O
of O
the O
high O
selenium O
garlic B-Plant
to O
protect O
against O
tumorigenesis B-Disease
is O
primarily O
dependent O
on O
increased O
intake O
of O
selenium O
provided O
by O
the O
vegetable O

coffee B-Plant
consumption O
not O
associated O
with O
risk O
of O
pancreas B-Disease
cancer I-Disease
in O
finland O

background O
coffee B-Plant
consumption O
has O
been O
brought O
to O
focus O
as O
a O
possible O
risk O
factor O
for O
pancreas B-Disease
cancer I-Disease

after O
having O
reviewed O
the O
available O
evidence O
an O
international O
agency O
for O
research O
on O
cancer B-Disease
working O
group O
concluded O
in O
1991 O
that O
the O
evidence O
in O
humans O
that O
coffee B-Plant
drinking O
is O
carcinogenic O
in O
the O
pancreas O
is O
inadequate O
since O
the O
available O
data O
were O
considered O
suggestive O
of O
a O
weak O
relationship O
with O
high O
levels O
of O
coffee B-Plant
consumption O
but O
the O
possibility O
that O
this O
was O
due O
to O
bias O
or O
confounding O
was O
judged O
tenable O

methods O
the O
association O
between O
coffee B-Plant
consumption O
and O
pancreas B-Disease
cancer I-Disease
risk O
was O
examined O
in O
a O
case O
referent O
study O
in O
finland O

data O
on O
coffee B-Plant
consumption O
20 O
years O
prior O
to O
the O
diagnosis O
of O
cancer B-Disease
were O
obtained O
from O
the O
next O
of O
kin O
of O
662 O
cases O
of O
pancreas B-Disease
cancer I-Disease
and O
1 O
770 O
referent O
stomach B-Disease
colon B-Disease
and O
rectum B-Disease
cancers B-Disease

the O
results O
were O
expressed O
as O
crude O
and O
age O
gender O
and O
tobacco B-Plant
smoking O
adjusted O
odds O
ratios O
and O
95 O
confidence O
intervals O
for O
three O
daily O
coffee B-Plant
dose O
categories O
20 O
years O
prior O
to O
cancer B-Disease
diagnosis O

results O
the O
data O
failed O
to O
demonstrate O
any O
association O
between O
coffee B-Plant
consumption O
and O
risk O
for O
pancreas B-Disease
cancer I-Disease

conclusions O
the O
results O
are O
unlikely O
to O
be O
negatively O
biased O
and O
are O
compatible O
with O
the O
majority O
of O
epidemiologic O
results O
advanced O
suggesting O
no O
positive O
association O
between O
coffee B-Plant
consumption O
and O
the O
risk O
of O
pancreas B-Disease
cancer I-Disease

past O
and O
current O
salted O
meat O
consumption O
was O
associated O
with O
increased O
risks O
of O
laryngeal B-Disease
cancer I-Disease
after O
controlling O
for O
the O
effects O
of O
tobacco B-Plant
and O
alcohol O

optimal O
dose O
of O
garlic B-Plant
to O
inhibit O
dimethylhydrazine O
induced O
colon B-Disease
cancer I-Disease

this O
study O
was O
designed O
to O
investigate O
the O
optimal O
dose O
of O
garlic B-Plant
during O
long O
term O
feeding O
and O
its O
preventive O
and O
therapeutic O
effects O
on O
colon B-Disease
cancer I-Disease
in O
rats O
induced O
by O
dimethylhydrazine O

the O
incidence O
of O
colon B-Disease
tumor I-Disease
was O
significantly O
decreased O
in O
the O
groups O
fed O
with O
2 O
5 O
and O
10 O
garlic B-Plant
diets O
p O

therefore O
the O
minimal O
optimal O
dose O
of O
garlic B-Plant
to O
inhibit O
colon B-Disease
cancer I-Disease
was O
25 O

in O
a O
therapeutic O
study O
the O
tumor B-Disease
inducing O
interval O
in O
nude O
mice O
subcutaneously O
injected O
with O
colon O
cancer O
cells O
cc O
m2 O
was O
prolonged O
by O
a O
2 O
5 O
garlic B-Plant
diet O
p O

thus O
smaller O
tumor B-Disease
volume O
and O
longer O
survival O
time O
were O
found O
in O
the O
garlic B-Plant
group O
than O
in O
the O
controls O
p O

however O
the O
growth O
rate O
of O
tumors B-Disease
was O
not O
markedly O
inhibited O
by O
garlic B-Plant

this O
study O
suggested O
that O
a O
25 O
garlic B-Plant
dose O
may O
be O
used O
mainly O
as O
an O
inhibitor O
to O
prevent O
colon B-Disease
cancers I-Disease
and O
improve O
survival O
time O

the O
evidence O
for O
soybean B-Plant
products O
as O
cancer B-Disease
preventive O
agents O

there O
is O
much O
evidence O
to O
suggest O
that O
diets O
containing O
large O
amounts O
of O
soybean B-Plant
products O
are O
associated O
with O
overall O
low O
cancer B-Disease
mortality O
rates O
particularly O
for O
cancers B-Disease
of O
the O
colon B-Disease
breast B-Disease
and O
prostate B-Disease

it O
is O
believed O
that O
supplementation O
of O
human O
diets O
with O
certain O
soybean B-Plant
products O
shown O
to O
suppress O
carcinogenesis B-Disease
in O
animals O
could O
markedly O
reduce O
human O
cancer B-Disease
mortality O
rates O
there O

is O
much O
evidence O
suggesting O
that O
compounds O
present O
in O
soybeans B-Plant
can O
prevent O
cancer B-Disease
in O
many O
different O
organ O
systems O

the O
evidence O
for O
specific O
soybean B-Plant
derived O
compounds O
having O
a O
suppressive O
effect O
on O
carcinogenesis B-Disease
in O
animal O
model O
systems O
is O
limited O
however O

there O
is O
evidence O
that O
the O
following O
isolated O
soybean B-Plant
derived O
products O
suppress O
carcinogenesis B-Disease
in O
vivo O
a O
protease O
inhibitor O
the O
bowman O
birk O
inhibitor O
inositol O
hexaphosphate O
phytic O
acid O
and O
the O
sterol O
beta O

sitosterol O
other O
compounds O
that O
may O
be O
able O
to O
suppress O
carcinogenesis B-Disease
in O
animals O
are O
the O
soybean B-Plant
isoflavones O

detection O
and O
cloning O
of O
potent O
transforming O
genes O
from O
chewing O
tobacco B-Plant
related O
human O
oral B-Disease
carcinomas I-Disease

the O
lack O
of O
association O
of O
the O
nude O
mice O
tumour B-Disease
dna O
with O
myc O
ras O
egf O
showing O
aberrations O
in O
the O
primary O
human O
tumour B-Disease
implies O
activation O
of O
an O
alternative O
potent O
transforming O
genes O
in O
the O
chewing O
tobacco B-Plant
related O
oral B-Disease
carcinomas I-Disease
in O
india O

policy O
advocacy O
strategies O
have O
proven O
themselves O
effective O
in O
cancer B-Disease
prevention O
efforts O
involving O
tobacco B-Plant
use O
and O
nutrition O

after O
injection O
of O
garlic B-Plant
oil O
in O
tumor B-Disease
focus O
a O
large O
amount O
of O
neutrophils O
macrophages O
and O
lymphocytes O
appeared O

this O
result O
showed O
that O
garlic B-Plant
oil O
could O
induce O
neutrophils O
and O
macrophages O
against O
tumor B-Disease

induced O
cytotoxicity B-Disease
and O
cell O
proliferation O
in O
the O
hepatocarcinogenicity O
of O
chloroform O
in O
female O
b6c3f1 O
mice O
comparison O
of O
administration O
by O
gavage O
in O
corn B-Plant
oil O
vs O
ad O
libitum O
in O
drinking O
water O

chloroform O
increases O
the O
incidence O
of O
liver B-Disease
tumors I-Disease
in O
b6c3f1 O
mice O
when O
administered O
in O
by O
gavage O
in O
corn B-Plant
oil O
but O
not O
when O
given O
in O
the O
drinking O
water O
at O
similar O
daily O
doses O

dose O
dependent O
changes O
included O
centrilobular O
necrosis B-Disease
and O
markedly O
elevated O
li O
in O
mice O
given O
238 O
or O
477 O
mg O
kg O
chloroform O
in O
corn B-Plant
oil O
the O
average O
daily O
doses O
that O
produced O
tumors B-Disease
in O
the O
cancer B-Disease
bioassay O

the O
sustained O
increase O
in O
li O
in O
the O
livers O
of O
mice O
administered O
hepatocarcinogenic B-Disease
doses O
of O
chloroform O
in O
corn B-Plant
oil O
but O
not O
for O
chloroform O
in O
drinking O
water O
is O
evidence O
that O
chloroform O
induced O
mouse O
liver B-Disease
cancer I-Disease
is O
secondary O
to O
events O
associated O
with O
induced O
cytolethality O
and O
cell O
proliferation O

preventive O
action O
of O
garlic B-Plant
on O
aflatoxin O
b1 O
induced O
carcinogenesis B-Disease
in O
the O
toad O
bufo O
regularis O

the O
action O
of O
fresh O
minced O
garlic B-Plant
and O
garlic B-Plant
oil O
on O
aflatoxin O
b1 O
afb1 O
induced O
carcinogenesis B-Disease
in O
the O
toad O
bufo O
regularis O
was O
studied O

animals O
given O
afb1 O
together O
with O
fresh O
garlic B-Plant
or O
garlic B-Plant
oil O
showed O
a O
significant O
reduction O
in O
tumor B-Disease
incidence O

the O
tumor B-Disease
incidences O
were O
3 O
and O
9 O
in O
animals O
given O
afb1 O
plus O
garlic B-Plant
and O
afb1 O
plus O
garlic B-Plant
oil O
respectively O

in O
all O
three O
groups O
the O
tumors B-Disease
were O
located O
in O
the O
liver O
hepatocellular B-Disease
carcinomas I-Disease
in O
addition O
to O
the O
kidney O
in O
animals O
treated O
with O
afb1 O
alone O
and O
together O
with O
garlic B-Plant

it O
is O
speculated O
that O
one O
or O
more O
constituents O
of O
garlic B-Plant
may O
be O
responsible O
for O
inhibition O
of O
afb1 O
induced O
carcinogenesis B-Disease
in O
b O
regularis O

ten O
organosulfur O
compounds O
from O
garlic B-Plant
and O
onions B-Plant
were O
studied O
for O
their O
modifying O
effects O
on O
diethylnitrosamine O
induced O
neoplasia B-Disease
of O
liver I-Disease
in O
male O
f344 O
rats O
using O
the O
medium O
term O
bioassay O
system O
of O
ito O
based O
on O
the O
two O
step O
model O
of O
hepatocarcinogenesis B-Disease

in O
evaluating O
relationships O
between O
diet O
and O
cancer B-Disease
it O
is O
appropriate O
to O
consider O
not O
only O
the O
possible O
protective O
role O
of O
garlic B-Plant
and O
onions B-Plant
but O
also O
their O
enhancing O
effects O

we O
examined O
the O
risk O
of O
obstructive O
respiratory B-Disease
disease I-Disease
associated O
with O
tobacco B-Plant
smoke O
in O
indoor O
air O
independent O
of O
active O
smoking O
ambient O
air O
pollution O
and O
some O
of O
the O
other O
sources O
of O
residential O
indoor O
air O
pollution O

the O
majority O
of O
all O
sixth O
grade O
students O
surveyed O
were O
aware O
of O
the O
health O
risks O
of O
smokeless O
tobacco B-Plant
use O
in O
that O
it O
is O
an O
increased O
risk O
for O
cancer B-Disease

alcohol O
and O
tobacco B-Plant
habits O
have O
been O
identified O
as O
strong O
risk O
factors O
for O
esophageal B-Disease
cancer I-Disease

this O
study O
examined O
whether O
they O
may O
prevent O
the O
occurrence O
of O
upper O
aerodigestive B-Disease
cancer I-Disease
in O
subjects O
heavily O
exposed O
to O
tobacco B-Plant
smoking O
such O
as O
patients O
already O
cured O
of O
an O
early O
stage O
lung B-Disease
cancer I-Disease

conclusion O
daily O
oral O
administration O
of O
high O
dose O
vitamin O
a O
is O
effective O
in O
reducing O
the O
number O
of O
new O
primary O
tumors B-Disease
related O
to O
tobacco B-Plant
consumption O
and O
may O
improve O
the O
disease O
free O
interval O
in O
patients O
curatively O
resected O
for O
stage O
i O
lung B-Disease
cancer I-Disease

here O
we O
report O
that O
genistein O
a O
soybean B-Plant
isoflavone O
strongly O
inhibits O
tumor B-Disease
promoter O
induced O
h2o2 O
formation O
both O
in O
vivo O
and O
in O
vitro O

garlic B-Plant
and O
its O
significance O
for O
the O
prevention O
of O
cancer B-Disease
in O
humans O
a O
critical O
view O

recently O
published O
results O
of O
epidemiologic O
case O
control O
studies O
in O
china O
and O
italy O
on O
gastric B-Disease
carcinoma I-Disease
in O
relation O
to O
diet O
suggest O
that O
consuming O
garlic B-Plant
may O
reduce O
the O
risk O
of O
gastric B-Disease
cancer I-Disease

chemical O
constituents O
of O
garlic B-Plant
have O
been O
tested O
for O
their O
inhibiting O
effect O
on O
carcinogenesis B-Disease
using O
in O
vitro O
and O
in O
vivo O
models O

in O
most O
experiments O
inhibition O
of O
tumour B-Disease
growth O
was O
established O
using O
fresh O
garlic B-Plant
extract O
garlic B-Plant
compounds O
or O
synthetically O
prepared O
analogs O

in O
this O
review O
the O
strengths O
and O
weaknesses O
of O
the O
experiments O
are O
discussed O
and O
the O
outcomes O
are O
evaluated O
to O
assess O
the O
possible O
significance O
of O
garlic B-Plant
or O
garlic B-Plant
compounds O
for O
the O
prevention O
of O
cancer B-Disease
in O
humans O

however O
the O
available O
evidence O
warrants O
further O
research O
into O
the O
possible O
role O
of O
garlic B-Plant
in O
the O
prevention O
of O
cancer B-Disease
in O
humans O

consumption O
of O
black B-Plant
tea I-Plant
and O
cancer B-Disease
risk O
a O
prospective O
cohort O
study O

despite O
indications O
from O
experimental O
studies O
that O
tea B-Plant
may O
protect O
against O
cancer B-Disease
epidemiologic O
evidence O
has O
been O
inconclusive O

purpose O
the O
association O
between O
black B-Plant
tea I-Plant
consumption O
and O
the O
subsequent O
risk O
of O
stomach B-Disease
colorectal B-Disease
lung I-Disease
and O
breast B-Disease
cancers I-Disease
was O
investigated O
in O
the O
netherlands O
cohort O
study O
on O
diet O
and O
cancer B-Disease
among O
58 O
279 O
men O
and O
62 O
573 O
women O
aged O
55 O
69 O
years O

the O
questionnaire O
data O
of O
case O
subjects O
and O
those O
of O
a O
random O
subcohort O
n O
3500 O
were O
used O
to O
calculate O
rate O
ratios O
rrs O
of O
cancer B-Disease
in O
categories O
of O
consumers O
of O
black B-Plant
tea I-Plant
compared O
with O
nonconsumers O

no O
association O
was O
observed O
between O
tea B-Plant
consumption O
and O
risk O
of O
colorectal B-Disease
cancer I-Disease
the O
risk O
among O
tea B-Plant
drinkers O
in O
each O
consumption O
category O
was O
similar O
to O
that O
among O
nondrinkers O

the O
rr O
of O
breast B-Disease
cancer I-Disease
among O
consumers O
of O
five O
or O
more O
cups O
of O
tea B-Plant
per O
day O
was O
13 O
95 O
confidence O
interval O
9 O
20 O
no O
dose O
response O
association O
was O
observed O

in O
age O
and O
sex O
adjusted O
analyses O
consumption O
of O
tea B-Plant
was O
inversely O
associated O
with O
stomach O
two O
sided O
p O
for O
trend O
147 O
and O
lung O
two O
sided O
p O
for O
trend O
< O
1 O
cancers B-Disease

when O
smoking O
and O
dietary O
factors O
were O
taken O
into O
account O
tea B-Plant
in O
itself O
did O
not O
appear O
to O
protect O
against O
stomach B-Disease
and O
lung B-Disease
cancers I-Disease
the O
rrs O
in O
all O
consumption O
categories O
were O
close O
to O
unity O

analysis O
of O
the O
tea B-Plant
and O
cancer B-Disease
relationship O
in O
a O
subgroup O
that O
included O
subjects O
in O
the O
lowest O
two O
quintiles O
of O
consumption O
of O
vegetables O
and O
fruits O
also O
failed O
to O
reveal O
a O
protective O
effect O
of O
tea B-Plant
consumption O
on O
the O
risk O
of O
three O
cancer O
types O
studied O
colorectal B-Disease
lung B-Disease
and O
breast B-Disease
cancers I-Disease

conclusions O
this O
investigation O
does O
not O
support O
the O
hypothesis O
that O
consumption O
of O
black B-Plant
tea I-Plant
protects O
against O
four O
of O
the O
major O
cancers B-Disease
in O
humans O
a O
cancer B-Disease
enhancing O
effect O
was O
not O
evident O

3 O
different O
malignancies B-Disease
of O
the O
aerodigestive O
tract O
after O
chronic O
abuse O
of O
cannabis B-Plant
products O

the O
occurrence O
of O
multilocular O
malignant B-Disease
tumors I-Disease
in O
the O
upper O
aerodigestive O
tract O
in O
young O
patients O
with O
known O
marijuana B-Plant
abuse O
has O
been O
described O
by O
other O
authors O

this O
case O
is O
the O
first O
reported O
that O
shows O
the O
occurrence O
of O
three O
separate O
malignant B-Disease
tumors I-Disease
with O
different O
histologies O
in O
the O
aerodigestive O
tract O
which O
could O
be O
related O
to O
a O
chronic O
abuse O
of O
cannabis B-Plant

consumption O
of O
corn B-Plant
contaminated O
at O
these O
high O
levels O
has O
been O
associated O
with O
a O
high O
incidence O
of O
esophageal B-Disease
cancer I-Disease
in O
these O
areas O

tobacco B-Plant
related O
cancers B-Disease
in O
madras O
india O

tobacco B-Plant
related O
cancer B-Disease
trc O
cases O
constitute O
482 O
in O
men O
and O
201 O
in O
women O
of O
the O
total O
cancers B-Disease
seen O
in O
india O
per O
year O

the O
feeding O
of O
the O
lactobacillus O
gg O
before O
and O
during O
carcinogen O
treatment O
resulted O
in O
a O
significant O
decrease O
in O
the O
incidence O
of O
colon B-Disease
tumors I-Disease
and O
the O
number O
of O
small O
intestinal O
and O
colon B-Disease
tumors I-Disease
per O
tumor B-Disease
bearing O
animal O
for O
rats O
fed O
a O
20 O
corn B-Plant
oil O
diet O

animals O
fed O
a O
5 O
corn B-Plant
oil O
diet O
had O
a O
lower O
tumor B-Disease
incidence O
and O
number O
of O
tumors B-Disease
resulting O
from O
the O
decrease O
in O
dietary O
fat O
in O
addition O
the O
feeding O
of O
lactobacillus O
gg O
before O
the O
carcinogen O
challenge O
resulted O
in O
a O
lower O
incidence O
of O
colon B-Disease
tumors I-Disease

the O
importance O
of O
the O
pecan B-Plant
tree O
pollen O
in O
allergic B-Disease
manifestations O
objective O
to O
study O
the O
role O
of O
pecan B-Plant
tree O
pollen O
in O
the O
development O
of O
allergy B-Disease

of O
the O
pecan B-Plant
atopics B-Disease
65 O
2 O
had O
clinical O
symptoms O
coinciding O
only O
with O
the O
pecan B-Plant
pollen O
season O
and O
an O
additional O
10 O
9 O
had O
perennial O
symptonms O

conclusion O
pecan B-Plant
tree O
releases O
highly O
allergenic O
pollen O
grains O
which O
are O
correlated O
to O
the O
incidence O
of O
hay B-Disease
fever I-Disease
in O
the O
exposed O
population O

in O
children O
the O
pecan B-Plant
tree O
constitutes O
a O
possible O
etiologic O
agent O
for O
the O
development O
of O
asthma B-Disease

effectiveness O
of O
oleum O
menthae B-Plant
piperitae I-Plant
and O
paracetamol O
in O
therapy O
of O
headache B-Disease
of O
the O
tension O
type O

the O
effect O
of O
a O
locally O
applied O
peppermint B-Plant
oil O
preparation O
on O
tension B-Disease
type I-Disease
headache I-Disease
was O
examined O
in O
the O
design O
of O
a O
randomized O
placebo O
controlled O
double O
blind O
crossover O
study O
for O
the O
first O
time O

each O
headache B-Disease
attack O
was O
treated O
by O
the O
application O
of O
2 O
capsules O
of O
the O
oral O
medication O
1 O
0 O
mg O
of O
acetaminophen O
or O
placebo O
and O
the O
cutaneous O
application O
of O
the O
oil O
preparation O
peppermint B-Plant
oil O
or O
placebo O
solution O

compared O
to O
the O
application O
of O
placebo O
a O
10 O
peppermint B-Plant
oil O
in O
ethanol O
solution O
significantly O
reduced O
the O
clinical O
headache B-Disease
intensity O
already O
after O
15 O
minutes O
p O

this O
controlled O
study O
showed O
for O
the O
first O
time O
that O
a O
10 O
peppermint B-Plant
oil O
in O
ethanol O
solution O
efficiently O
alleviates O
tension O
type B-Disease
headache I-Disease

effect O
on O
an O
aqueous O
extract O
of O
selenium O
enriched O
garlic B-Plant
on O
in O
vitro O
markers O
and O
in O
vivo O
efficacy O
in O
cancer B-Disease
prevention O

previous O
work O
has O
shown O
that O
the O
efficacy O
of O
cancer B-Disease
prevention O
by O
selenium O
enriched O
garlic B-Plant
se O
garlic B-Plant
is O
primarily O
dependent O
on O
the O
action O
of O
selenium O

the O
chemopreventive O
efficacy O
of O
the O
two O
garlic B-Plant
extracts O
was O
also O
investigated O
in O
the O
rat O
methylnitrosourea O
mammary O
tumor B-Disease
model O

significant O
cancer B-Disease
protection O
was O
observed O
with O
treatment O
by O
the O
se O
garlic B-Plant
extract O
at O
3 O
ppm O

data O
from O
a O
large O
hospital O
based O
case O
control O
study O
are O
used O
to O
examine O
the O
association O
of O
smoking O
related O
risk O
factors O
amount O
smoked O
filter O
status O
mentholation O
and O
differences O
in O
smoking O
habits O
between O
blacks O
and O
whites O
and O
selected O
factors O
other O
than O
smoking O
environmental O
tobacco B-Plant
smoke O
previous O
primary O
cancer B-Disease
and O
radiotherapy O
reproductive O
and O
endocrine O
factors O
and O
body O
mass O
index O
with O
lung B-Disease
cancer I-Disease

in O
blacks O
and O
whites O
of O
both O
sexes O
odds O
ratios O
for O
lung B-Disease
cancer I-Disease
increased O
with O
increasing O
cumulative O
tobacco B-Plant
tar O
intake O
and O
decreased O
with O
years O
since O
quitting O
smoking O

exposure O
to O
environmental O
tobacco B-Plant
smoke O
generally O
showed O
little O
relation O
to O
lung B-Disease
cancer I-Disease
risk O

in O
conclusion O
variation O
in O
lung B-Disease
cancer I-Disease
rates O
between O
populations O
may O
be O
due O
to O
1 O
differences O
in O
effective O
exposure O
to O
tobacco B-Plant
smoke O
carcinogens O
2 O
differences O
in O
factors O
which O
modify O
the O
effect O
of O
tobacco B-Plant
smoke O
including O
differences O
in O
host O
susceptibility O
and O
metabolism O
of O
carcinogens O
or O
3 O
differences O
in O
exposure O
to O
other O
independent O
risk O
factors O
for O
lung B-Disease
cancer I-Disease

the O
overall O
findings O
of O
this O
study O
suggest O
that O
eppl O
is O
a O
valuable O
indicator O
of O
lung B-Disease
cancer I-Disease
risk O
and O
that O
exposure O
to O
environmental O
tobacco B-Plant
smoke O
is O
associated O
with O
higher O
eppl O
levels O
and O
therefore O
with O
higher O
lung B-Disease
cancer I-Disease

in O
a O
tribal O
village O
in O
kerala O
india O
local O
volunteers O
were O
trained O
to O
work O
in O
a O
programme O
for O
the O
primary O
prevention O
of O
tobacco B-Plant
related O
cancers B-Disease
and O
the O
secondary O
prevention O
of O
common O
cancers B-Disease

they O
gathered O
data O
on O
the O
use O
of O
tobacco B-Plant
and O
alcohol O
in O
a O
population O
of O
some O
19 O
0 O
people O
and O
identified O
one O
or O
more O
warning O
signals O
of O
cancer B-Disease
in O
430 O
persons O
who O
were O
subsequently O
examined O
by O
physicians O

sabal B-Plant
serrulata I-Plant
extract O
in O
the O
management O
of O
symptoms O
of O
prostatic B-Disease
hypertrophy I-Disease

the O
effectiveness O
of O
sabal B-Plant
serrulata I-Plant
dwarf B-Plant
palm I-Plant
extract O
was O
evaluated O
in O
the O
treatment O
of O
38 O
patients O
with O
symptomatic O
prostatic B-Disease
hyperplasia I-Disease

on O
the O
basis O
of O
their O
favorable O
experience O
the O
authors O
recommend O
the O
administration O
of O
sabal B-Plant
serrulata I-Plant
extract O
in O
the O
treatment O
of O
patients O
with O
mild O
or O
moderate O
symptoms O
of O
prostatic B-Disease
hyperplasia I-Disease

the O
incidence O
of O
stomach B-Disease
cancer I-Disease
is O
lower O
in O
individuals O
and O
populations O
with O
high O
allium B-Plant
vegetable O
intakes O

as O
part O
of O
our O
study O
of O
the O
role O
of O
allium B-Plant
vegetable O
intake O
on O
cancer B-Disease
prevention O
we O
wished O
to O
investigate O
its O
antimicrobial O
activity O
against O
h O
pylori O

it O
is O
plausible O
that O
the O
sensitivity O
of O
h O
pylori O
to O
garlic B-Plant
extract O
at O
such O
low O
concentration O
may O
be O
related O
to O
the O
reported O
lower O
risk O
of O
stomach B-Disease
cancer I-Disease
in O
those O
with O
a O
high O
allium B-Plant
vegetable O
intake O

influence O
of O
dietary O
capsaicin O
and O
onion B-Plant
on O
the O
metabolic B-Disease
abnormalities B-Disease
associated O
with O
streptozotocin O
induced O
diabetes B-Disease
mellitus I-Disease

effect O
of O
feeding O
15 O
mg O
capsaicin O
diet O
or O
3 O
freeze O
dried O
onion B-Plant
powder O
containing O
diet O
were O
examined O
in O
albino O
rats O
rendered O
diabetic B-Disease
with O
streptozotocin O
injection O

diabetic B-Disease
rats O
maintained O
on O
onion B-Plant
diet O
for O
8 O
weeks O
excreted O
comparatively O
less O
amounts O
of O
albumin O
urea O
creatinine O
and O
inorganic O
phosporus O

dietary O
onion B-Plant
also O
partially O
reversed O
the O
abnormalities O
in O
plasma O
albumin O
urea O
creatinine O
and O
inorganic O
phosphorus O
in O
diabetic B-Disease
animals O

onion B-Plant
also O
produced O
a O
significant O
reduction O
in O
hyperglycemic B-Disease
status O
of O
diabetic O
animals O

diabetic B-Disease
rats O
maintained O
on O
onion B-Plant
diet O
had O
a O
lowered O
relative O
liver O
weight O
at O
the O
end O
of O
the O
study O
compared O
to O
diabetic B-Disease
control O
group O

diabetic B-Disease
rats O
fed O
onion B-Plant
diet O
also O
exhibited O
lowered O
lipid O
peroxides O
in O
circulation O
and O
in O
urine O
when O
compared O
to O
diabetic B-Disease
control O
group O

blood O
cholesterol O
was O
lowered O
significantly O
by O
dietary O
onion B-Plant
in O
diabetic B-Disease
animals O

hepatic O
cholesterol O
triglycerides O
phospholipids O
which O
were O
elevated O
under O
diabetic B-Disease
condition O
were O
countered O
significantly O
by O
dietary O
onion B-Plant

thus O
the O
study O
reveals O
that O
onion B-Plant
feeding O
improves O
the O
metabolic O
status O
in O
diabetic B-Disease
condition O
probably O
because O
of O
its O
hypoglycemic B-Disease
as O
well O
as O
hypocholesterolemic B-Disease
effect O

garlic B-Plant
prevents O
hypertension B-Disease
induced O
by O
chronic O
inhibition O
of O
nitric O
oxide O
synthesis O

it O
has O
been O
reported O
that O
garlic B-Plant
activates O
nitric O
oxide O
synthase O
in O
vitro O
and O
that O
chronic O
inhibition O
of O
nitric O
oxide O
no O
synthesis O
by O
n O
omega O
nitro O
l O
arginine O
methyl O
ester O
l O
name O
induces O
arterial B-Disease
hypertension I-Disease
in O
rats O

it O
was O
found O
that O
l O
name O
induced O
arterial B-Disease
hypertension I-Disease
on O
weeks O
1 O
4 O
inch O
control O
rats O
but O
not O
in O
garlic B-Plant
fed O
rats O
whose O
blood O
pressure O
remained O
essentially O
as O
the O
basal O

it O
was O
concluded O
that O
garlic B-Plant
blocks O
the O
l O
name O
induced O
hypertension B-Disease
by O
antagonizing O
in O
vivo O
the O
inhibitory O
effect O
of O
l O
name O
on O
no O
production O

we O
studied O
whether O
common O
shared O
environmental O
or O
behavioral O
risk O
factors O
other O
than O
tobacco B-Plant
smoking O
underlie O
both O
atherosclerotic B-Disease
diseases I-Disease
and O
cancer B-Disease

there O
was O
no O
consistent O
excess O
over O
the O
expected O
figures O
for O
any O
of O
the O
categories O
of O
cancer B-Disease
not O
related O
to O
tobacco B-Plant
smoking O

we O
found O
a O
moderate O
increase O
in O
the O
risk O
for O
tobacco B-Plant
related O
cancers B-Disease
which O
was O
strongest O
for O
patients O
with O
early O
onset O
of O
acute O
myocardial B-Disease
infarct I-Disease
and O
for O
female O
patients O

an O
excess O
risk O
of O
dying O
of O
lung B-Disease
cancer I-Disease
and O
heart B-Disease
diseases I-Disease
probably O
reflects O
a O
high O
tobacco B-Plant
consumption O

epidemiologic O
and O
clinical O
studies O
suggest O
that O
tomato B-Plant
consumption O
may O
reduce O
the O
risk O
of O
cancer B-Disease

lycopene O
a O
hydrocarbon O
carotenoid O
is O
the O
major O
carotenoid O
in O
tomato B-Plant
es O
and O
as O
a O
potent O
singlet O
oxygen O
quencher O
has O
been O
considered O
by O
some O
to O
be O
the O
biologically O
active O
agent O
responsible O
for O
the O
reduction O
of O
cancer B-Disease
risk O
associated O
with O
tomato B-Plant
consumption O

objective O
to O
determine O
the O
lipid O
lowering O
effect O
of O
garlic B-Plant
powder O
tablets O
in O
patients O
with O
hypercholesterolemia B-Disease

conclusion O
garlic B-Plant
powder O
900 O
mg O
d O
treatment O
for O
12 O
weeks O
was O
ineffective O
in O
lowering O
cholesterol O
levels O
in O
patients O
with O
hypercholesterolemia B-Disease

the O
effects O
of O
phenethyl O
isothiocyanate O
n O
acetylcysteine O
and O
green B-Plant
tea I-Plant
on O
tobacco B-Plant
smoke O
induced O
lung B-Disease
tumors I-Disease
in O
strain O
mice O

exposure O
to O
tobacco B-Plant
smoke O
increased O
lung B-Disease
tumor I-Disease
multiplicity O
to O
11 O
16 O
tumors B-Disease
lung B-Disease
significantly O
higher O
than O
control O
values O
tumors B-Disease
lung B-Disease

in O
positive O
control O
experiments O
peitc O
significantly O
reduced O
both O
lung B-Disease
tumor I-Disease
multiplicity O
and O
incidence O
in O
mice O
treated O
with O
the O
tobacco B-Plant
smoke O
specific O
carcinogen O
methylnitrosamino O
pyridyl O
butanone O
nnk O

green B-Plant
tea I-Plant
extract O
did O
not O
reduce O
lung B-Disease
tumor I-Disease
multiplicity O
in O
animals O
treated O
with O
a O
single O
dose O
of O
nnk O

the O
efficacy O
of O
ginkgo B-Plant
biloba I-Plant
on O
cognitive O
function O
in O
alzheimer B-Disease
disease I-Disease

objective O
to O
determine O
the O
effect O
of O
treatment O
with O
ginkgo B-Plant
biloba I-Plant
extract O
on O
objective O
measures O
of O
cognitive O
function O
in O
patients O
with O
alzheimer B-Disease
disease I-Disease
ad B-Disease
based O
on O
formal O
review O
of O
the O
current O
literature O

methods O
an O
attempt O
was O
made O
to O
identify O
all O
english O
and O
non O
english O
language O
articles O
in O
which O
g B-Plant
biloba I-Plant
extract O
was O
given O
to O
subjects O
with O
dementia B-Disease
or O
cognitive B-Disease
impairment I-Disease

inclusion O
criteria O
for O
the O
meta O
analysis O
were O
1 O
sufficiently O
characterized O
patients O
such O
that O
it O
was O
clearly O
stated O
there O
was O
a O
diagnosis O
of O
ad B-Disease
by O
either O
diagnostic O
and O
statistical O
manual O
of O
mental B-Disease
disorders I-Disease
revised O
third O
edition O
or O
national O
institute O
of O
neurological B-Disease
disorders I-Disease
and O
stroke B-Disease
alzheimer B-Disease
disease I-Disease
and O
related O
disorders O
association O
criteria O
or O
there O
was O
enough O
clinical O
detail O
to O
determine O
this O
by O
our O
review O
2 O
clearly O
stated O
study O
exclusion O
criteria O
ie O
those O
studies O
that O
did O
not O
have O
stated O
exclusions O
for O
depression B-Disease
other O
neurologic B-Disease
disease I-Disease
and O
central O
nervous O
system O
active O
medications O
were O
excluded O
3 O
use O
of O
standardized O
ginkgo B-Plant
extract O
in O
any O
stated O
dose O
4 O
randomized O
placebo O
controlled O
and O

double O
blind O
study O
design O
5 O
at O
least O
1 O
outcome O
measure O
was O
an O
objective O
assessment O
of O
cognitive O
function O
and O
6 O
sufficient O
statistical O
information O
to O
allow O
for O
meta O
analysis O

conclusions O
based O
on O
a O
quantitative O
analysis O
of O
the O
literature O
there O
is O
a O
small O
but O
significant O
effect O
of O
3 O
to O
6 O
month O
treatment O
with O
120 O
to O
240 O
mg O
of O
g B-Plant
biloba I-Plant
extract O
on O
objective O
measures O
of O
cognitive O
function O
in O
ad B-Disease

additional O
research O
will O
be O
needed O
to O
define O
which O
ingredients O
in O
the O
ginkgo B-Plant
extract O
are O
producing O
its O
effect O
in O
individuals O
with O
ad B-Disease

wheat B-Plant
bran O
decreases O
aberrant B-Disease
crypt I-Disease
foci I-Disease
preserves O
normal O
proliferation O
and O
increases O
intraluminal O
butyrate O
levels O
in O
experimental O
colon B-Disease
cancer I-Disease

background O
dietary O
wheat B-Plant
bran O
protects O
against O
colon B-Disease
cancer I-Disease
but O
the O
mechanisms O
of O
this O
effect O
is O
not O
known O

butyrate O
produced O
by O
colonic O
bacterial O
fermentation O
of O
dietary O
polysaccharides O
such O
as O
wheat B-Plant
bran O
induces O
apoptosis O
and O
decreases O
proliferation O
in O
colon B-Disease
cancer I-Disease
cell O
lines O

results O
during O
tumor B-Disease
initiation O
wheat B-Plant
bran O
produced O
greater O
apoptosis O
p O
1 O
a O
trend O
toward O
less O
proliferation O
and O
preserved O
the O
normal O
zone O
of O
proliferation O
p O

at O
tumor B-Disease
promotion O
wheat B-Plant
bran O
decreased O
the O
number O
of O
acf B-Disease
proximal O
colon O
p O
5 O
distal O
colon O
p O
47 O
and O
maintained O
the O
normal O
proliferative O
zone O

wheat B-Plant
bran O
produced O
significantly O
higher O
fecal O
butyrate O
p O
1 O
4 O
1 O
levels O
than O
the O
fiber O
free O
diet O
throughout O
the O
tumor B-Disease
promotion O
study O

conclusions O
wheat B-Plant
bran O
increased O
apoptosis O
and O
controlled O
proliferation O
during O
tumor B-Disease
initiation O
and O
resulted O
in O
decreased O
acf B-Disease

among O
specific O
foods O
high O
in O
carotenoids O
broccoli B-Plant
and O
spinach B-Plant
were O
most O
consistently O
associated O
with O
a O
lower O
risk O
of O
cataract B-Disease

effects O
of O
soybean B-Plant
diet O
on O
the O
beta O
cells O
in O
the O
streptozotocin O
treated O
rats O
for O
induction O
of O
diabetes B-Disease

moreover O
a O
prolonged O
hyperglycemia B-Disease
was O
not O
observed O
in O
rats O
fed O
raw O
soybean B-Plant
even O
when O
this O
was O
substituted O
by O
the O
normal O
diet O
after O
streptozotocin O
injection O

in O
the O
present O
study O
we O
showed O
that O
dietary O
soybean B-Plant
prevents O
induction O
of O
experimental O
hyperglycemia B-Disease
by O
retaining O
beta O
cell O
activity O

therefore O
we O
suggest O
that O
dietary O
soybean B-Plant
protected O
the O
streptozotocin O
induced O
beta O
cell O
damage O
and O
restrained O
the O
development O
of O
hyperglycemia B-Disease
in O
rats O

several O
epidemiologic O
studies O
have O
suggested O
a O
role O
of O
tomato B-Plant
products O
in O
protecting O
against O
cancer B-Disease
and O
chronic B-Disease
diseases I-Disease

histopathological O
studies O
of O
the O
specimens O
obtained O
from O
basilar O
arteries O
showed O
that O
pathological O
signs O
of O
proliferative B-Disease
vasculopathy I-Disease
including O
narrowing O
of O
the O
vessel B-Disease
lumen I-Disease
corrugation O
of O
the O
lamina O
elastica O
and O
subendothelial O
thickening O
were O
present O
in O
all O
the O
animals O
in O
the O
control O
group O
while O
they O
could O
not O
be O
demonstrated O
in O
the O
ginkgo B-Plant
biloba I-Plant
group O

these O
results O
suggest O
that O
ginkgo B-Plant
biloba I-Plant
may O
have O
a O
protective O
effect O
against O
subarachnoid B-Disease
hemorrhage I-Disease
induced O
vasospasm B-Disease
and O
vasculopathy B-Disease
as O
a O
result O
of O
antioxidants O

hepatitis B-Disease
was O
induced O
by O
the O
oral O
administration O
of O
10 O
solution O
ccl4 O
in O
olive B-Plant
oil O
at O
a O
dosage O
of O
3 O
ml O
kg O
body O
weight O
every O
day O
during O
7 O
days O

prevalence O
extent O
and O
severity O
of O
periodontitis B-Disease
as O
well O
as O
tooth B-Disease
loss I-Disease
and O
edentulism B-Disease
are O
influenced O
by O
tobacco B-Plant
consumption O
in O
a O
dose O
dependent O
manner O

the O
effect O
of O
unfiltered O
coffee B-Plant
on O
potential O
biomarkers O
for O
colonic B-Disease
cancer I-Disease
risk O
in O
healthy O
volunteers O
a O
randomized O
trial O

background O
epidemiologic O
studies O
suggest O
that O
coffee B-Plant
use O
might O
protect O
against O
colorectal B-Disease
cancer I-Disease

inconsistencies O
as O
to O
the O
effect O
of O
coffee B-Plant
use O
and O
colorectal B-Disease
cancer I-Disease
between O
epidemiologic O
studies O
might O
be O
related O
to O
the O
type O
of O
coffee B-Plant
brew O

objective O
we O
studied O
the O
effect O
of O
unfiltered O
coffee B-Plant
consumption O
on O
putative O
biomarkers O
for O
colonic B-Disease
cancer I-Disease
risk O

garlic B-Plant
consumption O
and O
cancer B-Disease
prevention O
meta O
analyses O
of O
colorectal O
and O
stomach B-Disease
cancer I-Disease

objective O
the O
objective O
was O
to O
conduct O
meta O
analyses O
of O
the O
epidemiologic O
literature O
on O
the O
association O
between O
garlic B-Plant
consumption O
and O
risk O
of O
stomach B-Disease
colon B-Disease
head B-Disease
and O
neck B-Disease
lung B-Disease
breast B-Disease
and O
prostate B-Disease
cancers I-Disease

design O
meta O
analyses O
were O
conducted O
for O
all O
cancers B-Disease
mutually O
and O
separately O
for O
colorectal B-Disease
and O
stomach B-Disease
cancers I-Disease
in O
relation O
to O
consumption O
of O
exclusively O
raw O
garlic B-Plant
cooked O
garlic B-Plant
or O
both O
rc O
garlic B-Plant

a O
relative O
risk O
estimate O
for O
rc O
garlic B-Plant
consumption O
and O
cancer B-Disease
risk O

the O
random O
effects O
relative O
risk O
rr O
estimate O
of O
colorectal B-Disease
cancer I-Disease
and O
rc O
garlic B-Plant
consumption O
excluding O
garlic B-Plant
supplements O
was O
69 O
95 O
ci O
55 O

an O
indication O
of O
publication O
bias O
for O
all O
cancers B-Disease
combined O
is O
evident O
from O
a O
funnel O
plot O
of O
rc O
garlic B-Plant
consumption O
and O
cancer O
risk O
and O
from O
the O
results O
of O
the O
begg O
and O
mazumdar O
test O
p O

conclusions O
high O
intake O
of O
rc O
garlic B-Plant
may O
be O
associated O
with O
a O
protective O
effect O
against O
stomach O
and O
colorectal B-Disease
cancers I-Disease

in O
animal O
models O
cow O
milk O
proteins O
are O
modestly O
and O
variably O
diabetogenic B-Disease
wheat B-Plant
or O
soybean B-Plant
proteins O
in O
the O
diet O
cause O
higher O
rates O
of O
autoimmune B-Disease
diabetes I-Disease

association O
of O
coffee B-Plant
consumption O
with O
gallbladder B-Disease
disease I-Disease

coffee B-Plant
consumption O
was O
recently O
shown O
to O
protect O
against O
symptomatic O
gallbladder B-Disease
disease I-Disease
in O
men O

the O
authors O
examined O
the O
relation O
of O
ultrasound O
documented O
gallbladder B-Disease
disease I-Disease
with O
coffee B-Plant
drinking O
in O
13 O
938 O
adult O
participants O
in O
the O
third O
national O
health O
and O
nutrition O
examination O
survey O

the O
prevalence O
of O
total O
gallbladder B-Disease
disease I-Disease
was O
unrelated O
to O
coffee B-Plant
consumption O
in O
either O
men O
or O
women O

however O
among O
women O
a O
decreased O
prevalence O
of O
previously O
diagnosed O
gallbladder B-Disease
disease I-Disease
was O
found O
with O
increasing O
coffee B-Plant
drinking O
p O

these O
findings O
do O
not O
support O
a O
protective O
effect O
of O
coffee B-Plant
consumption O
on O
total O
gallbladder B-Disease
disease I-Disease
although O
coffee B-Plant
may O
decrease O
the O
risk O
of O
symptomatic O
gallstones B-Disease
in O
women O

mutational O
hotspots O
within O
the O
p53 O
gene O
e O
g O
codon O
157 O
have O
been O
identified O
for O
tobacco B-Plant
related O
lung B-Disease
cancer I-Disease
whereas O
these O
same O
mutations O
are O
found O
rarely O
in O
other O
cancers B-Disease

because O
limited O
data O
exist O
concerning O
the O
p53 O
mutation O
frequency O
and O
spectra O
in O
ex O
smokers O
and O
nonsmokers O
we O
have O
analyzed O
p53 O
and O
k O
ras O
mutations O
in O
126 O
lung B-Disease
cancers I-Disease
from O
a O
population O
based O
case O
control O
study O
of O
nonsmoking O
n O
117 O
or O
ex O
smoking O
n O
9 O
women O
from O
missouri O
with O
quantitative O
assessments O
of O
exposure O
to O
environmental O
tobacco B-Plant
smoke O

such O
comparisons O
provide O
additional O
evidence O
of O
genetic O
damage O
caused O
by O
tobacco B-Plant
smoke O
during O
lung B-Disease
carcinogenesis I-Disease

background O
the O
goals O
for O
health O
project O
is O
designed O
to O
change O
the O
cancer B-Disease
related O
behaviors O
of O
tobacco B-Plant
use O
and O
dietary O
fat O
and O
fiber O
consumption O

a O
low O
familial O
income O
and O
tobacco B-Plant
smoking O
were O
associated O
with O
wheezing B-Disease
asthma B-Disease
chronic B-Disease
bronchitis I-Disease
and O
emphysema B-Disease

this O
study O
emphasizes O
the O
role O
of O
reducing O
tobacco B-Plant
smoking O
in O
the O
prevention O
of O
chronic O
respiratory B-Disease
diseases I-Disease

suppressive O
effect O
of O
coffee B-Plant
on O
lipopolysaccharide O
induced O
hepatitis B-Disease
in O
d O
galactosamine O
sensitized O
rats O

a O
coffee B-Plant
extract O
significantly O
suppressed O
lipopolysaccharide O
lps O
induced O
hepatitis B-Disease
in O
d O
galactosamine O
sensitized O
rats O
as O
assessed O
by O
the O
plasma O
alanine O
and O
aspartate O
aminotransferase O
activities O
when O
it O
was O
added O
to O
the O
diet O
30 O
g O
kg O
and O
fed O
to O
rats O
for O
14 O
days O

the O
coffee B-Plant
extract O
suppressed O
lps O
induced O
hepatitis B-Disease
when O
singly O
force O
fed O
12 O
g O
kg O
15 O
h O
prior O
to O
the O
injection O
of O
the O
drugs O
whereas O
a O
decaffeinated O
coffee B-Plant
extract O
had O
no O
significant O
effect O

these O
results O
indicate O
that O
coffee B-Plant
can O
protect O
animals O
from O
lps O
induced O
hepatitis B-Disease
and O
that O
the O
effect O
of O
coffee B-Plant
might O
be O
mainly O
due O
to O
caffeine B-Plant

for O
females O
in O
contrast O
both O
the O
absolute O
number O
of O
lung B-Disease
cancer I-Disease
deaths O
and O
the O
age O
standardized O
rate O
of O
79 O
100000 O
were O
among O
the O
highest O
values O
ever O
registered O
reflecting O
the O
different O
pattern O
of O
spread O
of O
the O
tobacco B-Plant
related O
lung B-Disease
cancer I-Disease
epidemic O
in O
the O
two O
sexes O

among O
neoplasms B-Disease
showing O
favorable O
trends O
there O
were O
other O
tobacco B-Plant
related O
neoplasms B-Disease
in O
men O
plus O
the O
continuing O
fall O
in O
stomach O
and O
cervix O
uteri O

conclusions O
the O
fall O
in O
cancer O
mortality O
observed O
over O
the O
last O
decade O
in O
italy O
is O
attributable O
to O
a O
decline O
in O
lung O
and O
other O
tobacco B-Plant
related O
neoplasms B-Disease
in O
males O
together O
with O
a O
persistent O
fall O
in O
stomach B-Disease
and O
uterine B-Disease
cervical I-Disease
cancer I-Disease

mortality O
trends O
in O
cancer B-Disease
attributable O
to O
tobacco B-Plant
in O
mexico O

objective O
to O
describe O
the O
mortality O
trends O
of O
cancer B-Disease
attributable O
to O
tobacco B-Plant
smoking O
particularly O
lung B-Disease
cancer I-Disease
for O
the O
1980 O
1997 O
period O
in O
mexico O

material O
and O
methods O
mortality O
trends O
were O
analyzed O
for O
each O
type O
of O
cancer B-Disease
associated O
to O
tobacco B-Plant
smoking O
according O
to O
the O
international O
classification O
of O
diseases O
icd O

the O
gender O
ratio O
for O
laryngeal B-Disease
cancer I-Disease
was O
striking O
421 O
100 O
probably O
due O
to O
the O
higher O
prevalence O
of O
male O
tobacco B-Plant
smokers O

previous O
tobacco B-Plant
smoking O
was O
correlated O
with O
the O
mortality O
rate O
trends O
for O
lung B-Disease
cancer I-Disease
beta O
910 O
ic O
95 O
1097 O
1797 O
r2 O
827 O

conclusions O
in O
mexico O
increased O
tobacco B-Plant
smoking O
improved O
cancer B-Disease
diagnosis O
and O
the O
demographic O
transition O
are O
probably O
the O
main O
factors O
determining O
cancer B-Disease
mortality O
rates O

although O
tobacco B-Plant
related O
cancer B-Disease
is O
a O
fast O
growing O
public O
health O
problem O
having O
a O
poor O
prognosis O
tobacco B-Plant
smoking O
the O
main O
risk O
factor O
could O
be O
eliminated O
by O
health O
education O
and O
promotion O
together O
with O
publicity O
regulation O
and O
healthy O
taxation O
policies O

inhibition O
of O
712 O
dimethylbenz O
a O
anthracene O
dmba O
induced O
oral B-Disease
carcinogenesis I-Disease
in O
hamsters O
by O
tea B-Plant
and O
curcumin B-Plant

in O
this O
study O
we O
studied O
the O
effects O
of O
tea B-Plant
and O
curcumin O
on O
712 O
dimethylbenz O
a O
anthracene O
dmba O
induced O
oral B-Disease
carcinogenesis I-Disease
in O
hamster O

the O
combination O
of O
tea B-Plant
and O
curcumin O
significantly O
decreased O
the O
oral O
visible O
tumor B-Disease
incidence O
from O
92 O
3 O
24 O
26 O
to O
69 O
2 O
18 O
26 O
and O
the O
squamous B-Disease
cell I-Disease
carcinoma I-Disease
scc B-Disease
incidence O
from O
769 O
20 O
26 O
to O
423 O

the O
combination O
of O
tea B-Plant
and O
curcumin B-Plant
also O
decreased O
the O
number O
of O
visible O
tumors B-Disease
and O
the O
tumor B-Disease
volume O
by O
524 O
and O
698 O
as O
well O
as O
the O
numbers O
of O
scc B-Disease
dysplasic B-Disease
lesions I-Disease
and O
papillomas B-Disease
by O
62 O
375 O
and O
487 O
respectively O

green B-Plant
tea I-Plant
or O
curcumin B-Plant
treatment O
decreased O
the O
number O
of O
visible O
tumors B-Disease
by O
351 O
or O
396 O
the O
tumor B-Disease
volume O
by O
416 O
or O
613 O
and O
the O
number O
of O
scc B-Disease
by O
533 O
or O
513 O
respectively O

green B-Plant
tea I-Plant
also O
decreased O
the O
number O
of O
dysplasic B-Disease
lesions I-Disease

tea B-Plant
and O
curcumin O
singly O
or O
in O
combination O
decreased O
the O
proliferation O
index O
in O
hyperplasia B-Disease
dysplasia B-Disease
and O
papillomas B-Disease

tea B-Plant
alone O
and O
in O
combination O
with O
curcumin O
significantly O
increased O
the O
apoptotic O
index O
in O
dysplasia B-Disease
and O
scc B-Disease

curcumin O
alone O
and O
in O
combination O
with O
tea B-Plant
significantly O
inhibited O
the O
angiogenesis O
in O
papilloma B-Disease
and O
scc B-Disease

the O
results O
suggested O
that O
green B-Plant
tea I-Plant
and O
curcumin O
had O
inhibitory O
effects O
against O
oral B-Disease
carcinogenesis I-Disease
at O
the O
post O
initiation O
stage O
and O
such O
inhibition O
may O
be O
related O
to O
the O
suppression O
of O
cell O
proliferation O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O

cigarette O
smoking O
use O
of O
other O
tobacco B-Plant
products O
and O
stomach B-Disease
cancer O
mortality O
in O
us O
adults O
the O
cancer B-Disease
prevention O
study O

cigarette O
smoking O
is O
associated O
with O
increased O
risk O
of O
stomach B-Disease
cancer I-Disease
in O
many O
studies O
but O
there O
are O
limited O
data O
on O
this O
relationship O
in O
women O
and O
on O
risk O
associated O
with O
use O
of O
tobacco B-Plant
products O
other O
than O
cigarettes O

we O
examined O
stomach B-Disease
cancer I-Disease
death O
rates O
in O
relation O
to O
cigarette O
smoking O
in O
women O
and O
use O
of O
cigarette O
cigar O
pipe O
or O
smokeless O
tobacco B-Plant
in O
men O
in O
a O
nationwide O
prospective O
mortality O
study O
in O
the O
united O
states O
us O

if O
causal O
the O
estimated O
proportion O
of O
stomach B-Disease
cancer I-Disease
deaths O
attributable O
to O
tobacco B-Plant
use O
would O
be O
28 O
in O
us O
men O
and O
14 O
in O
women O

we O
conclude O
that O
prolonged O
use O
of O
tobacco B-Plant
products O
is O
associated O
with O
increased O
stomach B-Disease
cancer I-Disease
mortality O
in O
men O
and O
women O

the O
accumulated O
evidence O
from O
this O
and O
other O
studies O
support O
reconsidering O
stomach B-Disease
cancer I-Disease
as O
a O
tobacco B-Plant
related O
cancer B-Disease

on O
the O
other O
hand O
high O
intake O
of O
nonhydrogenated O
soybean B-Plant
cooking O
oil O
was O
related O
to O
a O
reduced O
risk O
of O
breast B-Disease
cancer I-Disease
among O
women O
who O
never O
deep O
fried O
animal O
foods O
odds O
ratio O
48 O
95 O
confidence O
interval O
28 O
82 O
for O
the O
highest O
versus O
the O
lowest O
quintile O
p O
for O
trend O

this O
study O
also O
suggests O
that O
nonhydrogenated O
soybean B-Plant
oil O
if O
not O
used O
in O
high O
temperature O
cooking O
may O
be O
associated O
with O
a O
reduced O
risk O
of O
breast B-Disease
cancer I-Disease

tobacco B-Plant
smoke O
carcinogens O
dna O
damage O
and O
p53 O
mutations O
in O
smoking O
associated O
cancers B-Disease

it O
is O
estimated O
that O
cigarette O
smoking O
kills O
over O
1 O
0 O
0 O
people O
each O
year O
by O
causing O
lung B-Disease
cancer I-Disease
as O
well O
as O
many O
other O
neoplasmas B-Disease
p53 O
mutations O
are O
frequent O
in O
tobacco B-Plant
related O
cancers B-Disease
and O
the O
mutation O
load O
is O
often O
higher O
in O
cancers B-Disease
from O
smokers O
than O
from O
nonsmokers O

at O
several O
p53 O
mutational O
hotspots O
common O
to O
all O
cancers B-Disease
such O
as O
codons O
248 O
and O
273 O
a O
large O
fraction O
of O
the O
mutations O
are O
g O
to O
t O
events O
in O
lung B-Disease
cancers I-Disease
but O
are O
almost O
exclusively O
g O
to O
a O
transitions O
in O
non O
tobacco B-Plant
related O
cancers B-Disease

patients O
with O
anaphylaxis O
to O
pea B-Plant
can O
have O
pea B-Plant
nut O
allergy O
caused O
by O
cross O
reactive O
ige O
to O
vicilin O
ara O
h O

in O
this O
study O
3 O
patients O
with O
a O
history O
of O
anaphylaxis B-Disease
to O
pea B-Plant
are O
described O
who O
subsequently O
had O
symptoms O
after O
ingestion O
of O
peanut B-Plant

results O
peanut B-Plant
related O
symptoms O
consisted O
of O
oral O
symptoms O
in O
all O
patients O
with O
additional O
urticaria O
and O
dyspnea O
or O
angioedema B-Disease
in O
2 O
patients O

results O
seven O
patients O
had O
TRUE O
juxta O
anastomotic O
aneurysms O
40 O
mm O
in O
the O
residual O
infra O
renal O
abdominal O
aorta O
the O
occurrence O
of O
which O
was O
associated O
with O
tobacco B-Plant
smoking O
and O
hypertension B-Disease

tobacco B-Plant
smoking O
and O
hypertension B-Disease
are O
significant O
factors O
associated O
with O
the O
development O
of O
these O
aneurysms B-Disease

conversely O
soy B-Plant
beverage O
was O
associated O
with O
an O
increased O
risk O
of O
current O
asthma B-Disease
205 O
119 O
353 O
doctor O
diagnosed O
asthma B-Disease
169 O
104 O
277 O
and O
bhr O
165 O
100 O
271 O

apples B-Plant
and O
pears B-Plant
appeared O
to O
protect O
against O
current O
asthma B-Disease
83 O
71 O
98 O
asthma B-Disease
88 O
78 O
100 O
and O
bhr B-Disease
88 O
77 O
100 O

conclusions O
the O
consumption O
of O
dairy O
products O
soy B-Plant
beverages O
and O
apples B-Plant
and O
pears B-Plant
but O
not O
of O
nutrients O
per O
se O
was O
associated O
with O
a O
range O
of O
asthma B-Disease
definitions O

the O
herbal O
medicine O
dipsacus B-Plant
asper I-Plant
wall O
extract O
reduces O
the O
cognitive B-Disease
deficits I-Disease
and O
overexpression O
of O
beta O
amyloid O
protein O
induced O
by O
aluminum O
exposure O

in O
the O
present O
study O
we O
sought O
to O
evaluate O
the O
protective O
effects O
of O
the O
herbal O
medicine O
dipsacus B-Plant
asper I-Plant
extract O
against O
the O
cognitive B-Disease
impairment I-Disease
and O
overexpression O
of O
hippocampal O
beta O
amyloid O
protein O
abeta O
induced O
by O
chronic O
al O
exposure O
in O
rats O

the O
present O
results O
suggest O
that O
dipsacus B-Plant
asper I-Plant
extract O
may O
possess O
therapeutic O
effects O
against O
alzheimer B-Disease
disease I-Disease

since O
the O
increasing O
epidemic B-Disease
of O
lung B-Disease
cancer I-Disease
in O
men O
as O
well O
as O
other O
tobacco B-Plant
related O
cancers B-Disease
is O
observed O
in O
portugal O
the O
important O
component O
of O
such O
a O
programme O
should O
be O
a O
nationwide O
tobacco B-Plant
control O
programme O

coffee B-Plant
consumption O
and O
risk O
of O
rheumatoid B-Disease
arthritis I-Disease

objective O
recent O
reports O
have O
suggested O
an O
association O
between O
consumption O
of O
coffee B-Plant
or O
decaffeinated O
coffee B-Plant
and O
the O
risk O
of O
rheumatoid B-Disease
arthritis I-Disease
ra B-Disease
although O
data O
are O
sparse O
and O
somewhat O
inconsistent O

we O
studied O
whether O
coffee B-Plant
decaffeinated O
coffee B-Plant
total O
coffee B-Plant
tea B-Plant
or O
overall O
caffeine O
consumption O
was O
associated O
with O
the O
risk O
of O
ra B-Disease
using O
the O
nurses O
health O
study O
a O
longitudinal O
cohort O
study O
of O
121 O
701 O
women O

results O
we O
did O
not O
find O
a O
significant O
association O
between O
decaffeinated O
coffee B-Plant
consumption O
of O
4 O
cups O
day O
compared O
with O
no O
decaffeinated O
coffee B-Plant
consumption O
and O
subsequent O
risk O
of O
incident O
ra B-Disease
in O
either O
an O
adjusted O
multivariate O
model O
relative O
risk O
rr O
11 O
95 O
confidence O
interval O
95 O
ci O
5 O
22 O
or O
a O
multivariate O
model O
using O
only O
baseline O
reports O
of O
decaffeinated O
coffee B-Plant
consumption O
rr O
10 O
95 O
ci O
6 O
17 O

similarly O
there O
was O
no O
relationship O
between O
cumulative O
caffeinated O
coffee B-Plant
consumption O
and O
ra B-Disease
risk O
rr O
11 O
95 O
ci O
8 O
16 O
for O
4 O
cups O
per O
day O
versus O
none O
or O
between O
tea B-Plant
consumption O
and O
ra B-Disease
risk O
rr O
11 O
95 O
ci O
7 O
18 O
for O
3 O
cups O
day O
versus O
none O

total O
coffee B-Plant
and O
total O
caffeine O
consumption O
were O
also O
not O
associated O
with O
the O
risk O
of O
ra B-Disease

conclusion O
in O
this O
large O
prospective O
study O
we O
find O
little O
evidence O
of O
an O
association O
between O
coffee B-Plant
decaffeinated O
coffee B-Plant
or O
tea B-Plant
consumption O
and O
the O
risk O
of O
ra B-Disease
among O
women O

while O
alcohol O
was O
initially O
described O
as O
a O
risk O
enhancer O
only O
in O
smokers O
a O
number O
of O
epidemiological O
studies O
have O
now O
shown O
that O
chronic O
alcohol O
consumption O
increases O
the O
risk O
of O
head B-Disease
and O
neck B-Disease
cancer I-Disease
independently O
of O
exposure O
to O
tobacco B-Plant

the O
study O
was O
part O
of O
a O
community O
based O
comprehensive O
cross O
sectional O
study O
designed O
to O
assess O
a O
broad O
array O
of O
knowledge O
attitudes O
and O
behaviors O
on O
tobacco B-Plant
use O
and O
tobacco B-Plant
related O
cancer B-Disease
issues O
in O
the O
target O
multi O
ethnic O
and O
multi O
lingual O
asian O
american O
community O

increased O
consumption O
of O
tomato B-Plant
products O
is O
associated O
with O
a O
decreased O
risk O
of O
cancer B-Disease

phase O
ii O
double O
blind O
randomized O
study O
comparing O
oral O
aloe B-Plant
vera I-Plant
versus O
placebo O
to O
prevent O
radiation O
related O
mucositis O
in O
patients O
with O
head B-Disease
and O
neck O
neoplasms I-Disease

purpose O
in O
a O
single O
institution O
double O
blind O
prospective O
randomized O
trial O
we O
determined O
whether O
oral O
aloe B-Plant
vera I-Plant
gel O
can O
reduce O
radiation O
induced O
mucositis B-Disease
in O
head B-Disease
and O
neck B-Disease
cancer I-Disease
patients O

methods O
and O
materials O
we O
randomized O
58 O
head B-Disease
and O
neck B-Disease
cancer I-Disease
patients O
between O
oral O
aloe B-Plant
vera I-Plant
and O
placebo B-Plant

oral O
aloe B-Plant
vera I-Plant
did O
not O
improve O
tolerance O
to O
head O
and O
neck O
radiotherapy O
decrease O
mucositis B-Disease
reduce O
soreness B-Disease
or O
otherwise O
improve O
patient O
well O
being O

with O
the O
highest O
tobacco B-Plant
abuse O
prevalence O
among O
all O
minorities O
american O
indians O
incur O
high O
rates O
of O
tobacco B-Plant
related O
cancers B-Disease

effects O
of O
ginkgo B-Plant
biloba I-Plant
on O
exhaled O
nasal O
nitric O
oxide O
during O
normobaric B-Disease

hypoxia I-Disease
in O
humans O
ginkgo B-Plant
biloba I-Plant
an O
extract O
of O
the O
ginkgo B-Plant
tree O
may O
prevent O
or O
lessen O
symptoms O
of O
acute B-Disease
mountain I-Disease
sickness I-Disease
in O
humans O

we O
measured O
exhaled O
nasal O
no O
output O
in O
humans O
n O
9 O
during O
normoxia O
and O
then O
during O
acute O
normobaric O
hypoxia B-Disease
goal O
oxyhemoglobin O
saturation O
75 O
to O
85 O
before O
and O
after O
administration O
of O
a O
standardized O
extract O
of O
ginkgo B-Plant
biloba I-Plant
120 O
mg O
twice O
daily O
for O
5 O
days O

exhaled O
nasal O
no O
output O
was O
increased O
during O
normoxia O
following O
ginkgo B-Plant
p O
2 O
and O
reduced O
during O
normobaric O
hypoxia B-Disease
both O
before O
p O
2 O
and O
following O
p O
3 O
ginkgo B-Plant

exhaled O
nasal O
no O
output O
during O
normobaric O
hypoxia B-Disease
was O
lowest O
following O
ginkgo B-Plant
p O

we O
conclude O
that O
ginkgo B-Plant
biloba I-Plant
increases O
exhaled O
nasal O
no O
output O
during O
normoxia O
and O
enhances O
reduced O
exhaled O
nasal O
no O
output O
during O
normobaric O
hypoxia B-Disease

we O
investigated O
whether O
tobacco B-Plant
use O
causes O
cutaneous B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease
cscc B-Disease
in O
a O
large O
cohort O
study O
with O
complete O
and O
long O
term O
follow O
up O

a O
total O
of O
756 O
incident O
cases O
occurred O
in O
a O
cohort O
of O
337 O
311 O
men O
during O
a O
30 O
year O
follow O
up O
period O
but O
no O
association O
was O
found O
between O
any O
kind O
of O
smoking O
tobacco B-Plant
use O
and O
cscc B-Disease
risk O
nor O
any O
risk O
change O
with O
increasing O
dose O
duration O
or O
time O
since O
smoking O
cessation O

overall O
our O
study O
provides O
no O
evidence O
that O
tobacco B-Plant
use O
increases O
the O
risk O
of O
cscc B-Disease

experimental O
study O
on O
treatment O
of O
minimal B-Disease
change I-Disease
nephropathy I-Disease
with O
lespedeza B-Plant
michx I-Plant

objective O
to O
study O
the O
therapeutic O
effect O
of O
lespedeza B-Plant
michx I-Plant
in O
experimental O
rat O
model O
of O
minimal B-Disease
change I-Disease
nephropathy I-Disease
mcn B-Disease

result O
lespedeza B-Plant
michx I-Plant
could O
decrease O
the O
contents O
of O
urine B-Disease
proteinuria I-Disease
mda O
il O
8 O
and O
tnf O
alpha O
in O
serum O
increase O
sod O
level O
and O
improved O
the O
pathological O
change O
of O
glomeruli O

conclusion O
lespedeza B-Plant
michx I-Plant
was O
effective O
on O
mcn B-Disease

coffee B-Plant
and O
risk O
of O
death O
from O
hepatocellular B-Disease
carcinoma I-Disease
in O
a O
large O
cohort O
study O
in O
japan O

we O
examined O
the O
relation O
between O
coffee B-Plant
drinking O
and O
hepatocellular B-Disease
carcinoma I-Disease
hcc B-Disease
mortality O
in O
the O
japan O
collaborative O
cohort O
study O
for O
evaluation O
of O
cancer O
risk O
jacc O
study O

cox O
proportional O
hazards O
model O
by O
sas O
was O
used O
to O
obtain O
hazard O
ratio O
of O
hcc B-Disease
mortality O
for O
each O
coffee B-Plant
consumption O
category O

the O
hazard O
ratio O
of O
death O
due O
to O
hcc B-Disease
for O
drinkers O
of O
one O
and O
more O
cups O
of O
coffee B-Plant
per O
day O
compared O
with O
non O
coffee B-Plant
drinkers O
was O
50 O
95 O
confidence O
interval O
31 O
79 O
and O
the O
ratio O
for O
drinkers O
of O
less O
than O
one O
cup O
per O
day O
was O
83 O
95 O
confidence O
interval O

our O
data O
confirmed O
an O
inverse O
association O
between O
coffee B-Plant
consumption O
and O
hcc B-Disease
mortality O

plantago B-Plant
major I-Plant
plantaginaceae B-Plant
is O
popularly O
used O
to O
treat O
tumors B-Disease
infections O
and O
as O
a O
blood O
purifier O

results O
after O
adjustment O
for O
other O
food O
items O
vegetables O
fruits O
different O
types O
of O
meat O
processed O
meat O
and O
fish O
dairy O
and O
starchy O
products O
coffee B-Plant
green B-Plant
tea I-Plant
that O
were O
related O
to O
outcome O
smoking O
alcohol O
use O
family O
history O
on O
cancer B-Disease
education O
level O
and O
residence O
stomach B-Disease
cancer I-Disease
risk O
was O
inversely O
associated O
with O
consumption O
of O
raw O
vegetables O
such O
as O
cabbage B-Plant
carrots B-Plant
and O
garlic B-Plant

there O
were O
no O
statistically O
significant O
associations O
between O
stomach B-Disease
cancer I-Disease
risk O
and O
consumption O
of O
citrus B-Plant
or O
others O
fruits O

in O
conclusion O
higher O
consumption O
of O
raw O
vegetables O
such O
as O
cabbage B-Plant
carrots B-Plant
garlic B-Plant
as O
well O
as O
broccoli B-Plant
may O
decrease O
a O
risk O
of O
stomach B-Disease
cancer I-Disease
whereas O
intake O
of O
citrus B-Plant
fruits O
has O
no O
relation O
with O
a O
reduced O
risk O
of O
the O
disease O

components O
of O
olive B-Plant
oil O
and O
chemoprevention O
of O
colorectal B-Disease
cancer I-Disease

higher O
consumption O
of O
olive B-Plant
oil O
is O
considered O
the O
hallmark O
of O
the O
traditional O
mediterranean O
diet O
which O
has O
been O
associated O
with O
low O
incidence O
and O
prevalence O
of O
cancer B-Disease
including O
colorectal B-Disease
cancer I-Disease

nevertheless O
there O
is O
a O
growing O
interest O
in O
studying O
the O
role O
of O
olive B-Plant
oil O
phenolics O
in O
carcinogenesis B-Disease

this O
review O
aims O
to O
provide O
an O
overview O
of O
the O
relationship O
between O
olive B-Plant
oil O
phenolics O
and O
colorectal B-Disease
cancer I-Disease
in O
particular O
summarizing O
the O
epidemiologic O
in O
vitro O
cellular O
and O
animal O
studies O
on O
antioxidant O
and O
anticarcinogenic O
effects O
of O
olive B-Plant
oil O
phenoloc O

methods O
il O
10 O
mice O
were O
fed O
chow O
supplemented O
with O
corn B-Plant
oil O
co O
control O
n O
28 O
olive B-Plant
oil O
oo O
n O
29 O
or O
fish O
oil O
fo O
n O
35 O
for O
12 O
wk O
and O
their O
colons O
were O
studied O
for O
colitis B-Disease
score O
premalignant O
changes O
and O
cox O
2 O

conversely O
olive B-Plant
oil O
inhibits O
cox O
2 O
immunostaining O
and O
decreases O
the O
risk O
of O
neoplasia B-Disease
associated O
with O
chronic O
colitics O

role O
of O
dau O
c O
1inch O
three O
different O
patterns O
of O
carrot B-Plant
induced O
asthma B-Disease

objective O
to O
assess O
the O
role O
of O
dau O
c O
1inch O
three O
patients O
with O
carrot B-Plant
induced O
asthma B-Disease

material O
and O
methods O
patient O
1 O
had O
asthma B-Disease
when O
handling O
raw O
carrots B-Plant

she O
had O
asthma B-Disease
due O
to O
raw O
carrot B-Plant
ingestion O
and O
inhalation O

she O
had O
asthma B-Disease
when O
handling O
raw O
carrots B-Plant

conclusions O
airborne O
carrot B-Plant
allergens O
are O
able O
to O
sensitize O
without O
the O
implication O
of O
a O
previous O
pollen B-Disease
allergy I-Disease

allergy B-Disease
to O
carrot B-Plant
in O
patient O
3 O
seems O
to O
be O
related O
to O
her O
allergy B-Disease
to O
different O
pollens O
however O
it O
wasnt O
related O
to O
birch B-Plant
pollen O

we O
examined O
the O
relationship O
of O
environmental O
tobacco B-Plant
smoke O
ets O
and O
visible O
mold O
exposures O
on O
the O
development O
of O
allergic B-Disease
rhinitis I-Disease
rhinitis B-Disease
and O
upper B-Disease
respiratory I-Disease
infection I-Disease
uri O
in O
a O
birth O
cohort O
where O
at O
least O
one O
parent O
was O
skin O
prick O
test O
spt O
positive O

the O
use O
of O
tobacco B-Plant
products O
is O
associated O
with O
an O
increased O
incidence O
of O
periodontal O
disease O
poor O
response O
to O
periodontal O
therapy O
and O
a O
high O
risk O
for O
developing O
head B-Disease
and O
neck B-Disease
cancer I-Disease

elucidation O
of O
this O
novel O
mechanism O
of O
nicotine O
dependent O
nuclear O
transactivation O
of O
stat O
3 O
identifies O
oral O
alpha7 O
nachr O
as O
a O
promising O
molecular O
target O
to O
prevent O
reverse O
or O
retard O
tobacco B-Plant
related O
periodontal O
disease O
and O
progression O
of O
head B-Disease
and I-Disease
neck I-Disease
cancer I-Disease
by O
receptor O
inhibitors O

coffee B-Plant
consumption O
and O
the O
risk O
of O
gestational B-Disease
diabetes I-Disease
mellitus I-Disease

background O
coffee B-Plant
consumption O
has O
been O
associated O
with O
a O
decreased O
risk O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
mellitus I-Disease

we O
examined O
the O
relationship O
between O
coffee B-Plant
consumption O
and O
the O
risk O
of O
gestational B-Disease
diabetes I-Disease
mellitus I-Disease
gdm B-Disease

we O
studied O
the O
association O
of O
coffee B-Plant
consumption O
before O
and O
during O
pregnancy O
and O
the O
subsequent O
risk O
of O
gdm B-Disease

results O
women O
who O
reported O
moderate O
pre O
pregnancy O
caffeinated O
coffee B-Plant
intake O
had O
a O
significantly O
reduced O
risk O
of O
gdm B-Disease
adjusted O
compared O
with O
non O
consumers O

conclusions O
moderate O
pre O
pregnancy O
caffeinated O
coffee B-Plant
consumption O
may O
have O
a O
protective O
association O
with O
gdm B-Disease

the O
effect O
of O
lifestyle O
factors O
including O
tobacco B-Plant
chewing O
smoking O
and O
alcohol O
drinking O
diet O
and O
dental O
care O
on O
the O
risk O
of O
oral B-Disease
cancer I-Disease
was O
investigated O
in O
a O
case O
control O
study O
conducted O
in O
rajah O
muthiah O
dental O
college O
and O
hospital O
annamalainagar O
annamalai O
university O
chidambaram O
tamil O
nadu O
india O
during O
the O
period O
1991 O
2003 O

all O
participants O
were O
interviewed O
using O
a O
structured O
questionnaire O
that O
contained O
data O
on O
demographic O
factors O
family O
history O
of O
cancer B-Disease
tobacco B-Plant
habits O
use O
of O
alcohol O
frequency O
duration O
cessation O
of O
these O
habits O
dietary O
practices O
and O
oral O
hygiene O

intraperitoneal O
injection O
of O
ginkgo B-Plant
biloba I-Plant
extract O
enhances O
antioxidation O
ability O
of O
retina O
and O
protects O
photoreceptors O
after O
light O
induced O
retinal B-Disease
damage I-Disease
in O
rats O

purpose O
to O
investigate O
the O
effect O
of O
ginkgo B-Plant
biloba I-Plant
extract O
egb O
761 O
a O
free O
radical O
scavenger O
on O
the O
antioxidation O
capability O
of O
retina O
after O
light O
induced O
retinal B-Disease
damage I-Disease
in O
rats O
in O
an O
attempt O
to O
understand O
the O
mechanism O
by O
which O
egb O
761 O
protects O
the O
photoreceptors O
after O
light O
induced O
retinal B-Disease
damage I-Disease

tobacco B-Plant
smoke O
induced O
lung B-Disease
cancer I-Disease
in O
animals O
a O
challenge O
to O
toxicology O

tobacco B-Plant
smoke O
is O
a O
known O
human O
carcinogen O
that O
primarily O
produces O
malignant B-Disease
lesions I-Disease
in O
the O
respiratory O
tract O
although O
it O
also O
affects O
multiple O
other O
sites O

a O
reliable O
and O
practical O
animal O
model O
of O
tobacco B-Plant
smoke O
induced O
lung B-Disease
cancer I-Disease
would O
be O
helpful O
for O
in O
studies O
of O
product O
modification O
and O
chemoprevention O

over O
the O
years O
many O
attempts O
to O
reproduce O
lung B-Disease
cancer I-Disease
in O
experimental O
animals O
exposed O
to O
tobacco B-Plant
smoke O
have O
been O
made O
most O
often O
with O
negative O
or O
only O
marginally O
positive O
results O

female O
rats O
and O
female O
b6c3f1 O
mice O
when O
exposed O
over O
lifetime O
to O
tobacco B-Plant
smoke O
develop O
tumors B-Disease
in O
the O
nasal O
passages O
and O
also O
in O
the O
lung B-Disease

male O
and O
female O
strain O
a O
mice O
exposed O
to O
5 O
months O
to O
tobacco B-Plant
smoke O
and O
then O
kept O
for O
another O
4 O
months O
in O
air O
respond O
to O
tobacco B-Plant
smoke O
with O
increased O
lung B-Disease
tumor I-Disease
multiplicities O

background O
vr3848 O
is O
a O
novel O
cycloheptapeptide O
isolated O
from O
a O
euphorbiaceae B-Plant
plant I-Plant
which O
can O
suppress O
proliferation O
of O
various O
tumor B-Disease
cells O
at O
nanomolar O
concentration O

findings O
results O
indicate O
that O
differences O
in O
risk O
indicators O
along O
the O
tobacco B-Plant
disease O
continuum O
do O
not O
explain O
fully O
tobacco B-Plant
related O
cancer B-Disease
consequences O
among O
some O
minority O
racial O
ethnic O
groups O
particularly O
among O
the O
aggregate O
groups O
blacks O
african O
americans O
and O
american O
indians O
alaska O
natives O

our O
findings O
provide O
insights O
into O
the O
mechanisms O
leading O
to O
reversible O
and O
persistent O
effects O
of O
tobacco B-Plant
smoke O
that O
may O
explain O
former O
smokers O
increased O
risk O
for O
developing O
tobacco B-Plant
induced O
lung B-Disease
disease I-Disease
and O
provide O
novel O
targets O
for O
chemoprophylaxis O

the O
anti O
inflammatory O
activity O
in O
vivo O
of O
the O
methylene O
chloride O
methanol O
extract O
methanol O
and O
methylene O
chloride O
fractions O
of O
stem O
barks O
of O
allanblackia B-Plant
monticola I-Plant
administered O
orally O
at O
doses O
of O
375 O
75 O
150 O
and O
300 O
mg O
kg O
was O
evaluated O
on O
carrageenan O
induced O
oedema B-Disease
in O
rats O
to O
determine O
the O
most O
active O
fraction O

the O
results O
showed O
that O
the O
methylene O
chloride O
fraction O
of O
allanblackia B-Plant
monticola I-Plant
was O
more O
effective O
on O
the O
oedema B-Disease
caused O
by O
the O
carrageenan O

allanblackia B-Plant
monticola I-Plant
75 O
300 O
mg O
kg O
did O
not O
cause O
significant O
modification O
of O
the O
oedema B-Disease
induced O
by O
serotonin O

we O
recently O
showed O
that O
nexrutine O
a O
phellodendron B-Plant
amurense I-Plant
bark O
extract O
suppresses O
proliferation O
of O
prostate B-Disease
cancer I-Disease
cell O
lines O
and O
tumor B-Disease
development O
in O
the O
transgenic O
adenocarcinoma O
of O
mouse O
prostate O
tramp O
model O

here O
we O
report O
ehrlich B-Disease
ascites I-Disease
carcinoma I-Disease
eac B-Disease
induced O
hepatotoxicity O
and O
its O
protection O
by O
antitumor O
dose O
of O
black B-Plant
tea I-Plant
in O
mice O

treatment O
with O
antitumor O
dose O
of O
black B-Plant
tea I-Plant
could O
replenish O
the O
hosts O
antioxidant O
system O
and O
regress O
cancer B-Disease
induced O
ros O
significantly O
thereby O
protecting O
the O
hosts O
liver O
from O
lipid O
peroxidation O
and O
subsequent O
degenaration O

thus O
unlike O
many O
other O
anticancer O
agents O
black B-Plant
tea I-Plant
not O
only O
has O
antitumor O
and O
immunorestoring O
properties O
but O
it O
also O
protects O
host O
liver O
from O
tumor B-Disease
induced O
toxicity B-Disease

these O
results O
thus O
raise O
the O
possibility O
of O
inclusion O
of O
black B-Plant
tea I-Plant
in O
a O
successful O
therapeutic O
regimen O
against O
cancer B-Disease

association O
of O
tnf O
alpha O
and O
tnfr1 O
promoters O
and O
3 O
utr O
region O
of O
tnfr2 O
gene O
polymorphisms O
with O
genetic O
susceptibility O
to O
tobacco B-Plant
related O
oral B-Disease
carcinoma I-Disease
in O
asian O
indians O

tobacco B-Plant
related O
oral B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease
is O
a O
common O
malignancy B-Disease
in O
asian O
indians O

smokeless O
tobacco B-Plant
has O
been O
shown O
to O
induce O
tumor O
necrosis O
factor O
alpha O
tnf O
alpha O
which O
along O
with O
its O
receptors O
is O
over O
expressed O
in O
people O
with O
oral B-Disease
carcinoma I-Disease

single O
nucleotide O
polymorphisms O
snps O
in O
tnf O
alpha O
and O
tnf O
receptor O
genes O
may O
affect O
their O
expression O
and O
may O
be O
a O
potential O
determinant O
of O
susceptibility O
to O
tobacco B-Plant
related O
oral B-Disease
carcinomas I-Disease

it O
seems O
that O
tnf O
alpha O
308 O
ga O
may O
be O
related O
to O
susceptibility O
whereas O
609 O
tt O
tnfr1 O
and O
1690 O
ct O
tnfr2 O
snps O
may O
be O
protective O
to O
tobacco B-Plant
related O
oral B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease

joint O
effects O
of O
coffee B-Plant
consumption O
and O
serum O
gamma O
glutamyltransferase O
on O
the O
risk O
of O
liver B-Disease
cancer I-Disease

only O
three O
japanese O
prospective O
studies O
have O
suggested O
an O
inverse O
association O
between O
coffee B-Plant
drinking O
and O
liver B-Disease
cancer I-Disease

we O
aimed O
to O
determine O
the O
single O
and O
joint O
associations O
of O
coffee B-Plant
consumption O
and O
serum O
ggt O
with O
the O
risk O
of O
primary O
liver B-Disease
cancer I-Disease

the O
multivariable O
adjusted O
age O
sex O
alcohol O
consumption O
education O
smoking O
diabetes B-Disease
and O
chronic B-Disease
liver I-Disease
disease I-Disease
at O
baseline O
and O
during O
follow O
up O
and O
body O
mass O
index O
hazards O
ratios O
of O
liver B-Disease
cancer I-Disease
in O
participants O
who O
drank O
0 O
1 O
2 O
3 O
4 O
5 O
6 O
7 O
and O
or O
8 O
cups O
of O
coffee B-Plant
daily O
were O
100 O
66 O
44 O
38 O
and O
32 O
p O
for O
trend O
3 O
respectively O

the O
multivariable O
adjusted O
and O
coffee B-Plant
adjusted O
hazard O
ratio O
of O
liver B-Disease
cancer I-Disease
for O
the O
highest O
versus O
the O
lowest O
quartile O
of O
serum O
ggt O
was O
313 O
95 O
confidence O
interval O
122 O
807 O

the O
multivariable O
adjusted O
inverse O
association O
between O
coffee B-Plant
consumption O
and O
liver B-Disease
cancer I-Disease
risk O
persisted O
when O
stratified O
by O
baseline O
factors O
age O
more O
less O
than O
50 O
years O
current O
smoker O
never O
smoked O
ever O
smoked O
alcohol O
drinker O
never O
drinker O
obese B-Disease
non B-Disease
obese I-Disease
and O
the O
highest O
lowest O
three O
quartiles O
of O
serum O
ggt O

conclusion O
coffee B-Plant
drinking O
has O
an O
inverse O
and O
graded O
association O
with O
the O
risk O
of O
liver B-Disease
cancer I-Disease

with O
interest O
in O
complementary O
medicine O
for O
hypertension B-Disease
increasing O
it O
is O
timely O
to O
update O
a O
systematic O
review O
and O
meta O
analysis O
from O
1994 O
of O
studies O
investigating O
the O
effect O
of O
garlic B-Plant
preparations O
on O
blood O
pressure O

meta O
analysis O
of O
all O
studies O
showed O
a O
mean O
decrease O
of O
46 O
28 O
mm O
hg O
for O
sbp O
in O
the O
garlic B-Plant
group O
compared O
to O
placebo O
n O
10 O
p O
1 O
while O
the O
mean O
decrease O
in O
the O
hypertensive B-Disease
subgroup O
was O
84 O
28 O
mm O
hg O
for O
sbp O
n O
4 O
p O
1 O
and O
73 O
15 O
mm O
hg O
for O
dbp O
n O
3 O
p O

conclusion O
our O
meta O
analysis O
suggests O
that O
garlic B-Plant
preparations O
are O
superior O
to O
placebo O
in O
reducing O
blood O
pressure O
in O
individuals O
with O
hypertension B-Disease

the O
antioxidant O
response O
induced O
by O
lonicera B-Plant
caerulaea I-Plant
berry I-Plant
extracts O
in O
animals O
bearing O
experimental O
solid B-Disease
tumors I-Disease

the O
aim O
of O
our O
work O
was O
to O
investigate O
the O
in O
vivo O
effects O
of O
the O
antioxidant O
action O
of O
lonicera B-Plant
caerulea I-Plant
berry I-Plant
extracts O
on O
the O
dynamics O
of O
experimentally O
induced O
tumors B-Disease

our O
data O
showed O
that O
aqueous O
lonicera B-Plant
caerulaea I-Plant
extracts O
reduced O
the O
tumor B-Disease
volume O
when O
administered O
continuously O
during O
the O
tumor B-Disease
growth O
and O
development O
stages O
but O
augmented O
the O
tumor B-Disease
growth O
when O
the O
administration O
of O
extracts O
started O
three O
weeks O
before O
tumor B-Disease
grafting O

prolonged O
administration O
of O
lonicera B-Plant
caerulaea I-Plant
berry I-Plant
extracts O
induced O
the O
antioxidant O
defense O
mechanism O
in O
the O
tumor B-Disease
tissues O
while O
surprisingly O
amplifying O
the O
peripheral O
oxidative O
stress O

beneficial O
effects O
of O
lepidium B-Plant
meyenii I-Plant
maca B-Plant
on O
psychological B-Disease
symptoms I-Disease
and O
measures O
of O
sexual B-Disease
dysfunction I-Disease
in O
postmenopausal O
women O
are O
not O
related O
to O
estrogen O
or O
androgen O
content O

the O
greene O
climacteric O
scale O
revealed O
a O
significant O
reduction O
in O
scores O
in O
the O
areas O
of O
psychological B-Disease
symptoms I-Disease
including O
the O
subscales O
for O
anxiety B-Disease
and O
depression B-Disease
and O
sexual B-Disease
dysfunction I-Disease
after O
maca B-Plant
consumption O
compared O
with O
both O
baseline O
and O
placebo O
p O

conclusions O
preliminary O
findings O
show O
that O
lepidium B-Plant
meyenii I-Plant
maca B-Plant
35 O
gd O
reduces O
psychological B-Disease
symptoms I-Disease
including O
anxiety B-Disease
and O
depression B-Disease
and O
lowers B-Disease
measures I-Disease
of O
sexual B-Disease
dysfunction I-Disease
in O
postmenopausal O
women O
independent O
of O
estrogenic O
and O
androgenic O
activity O

ccsps O
4870 O
patients O
follow O
up O
4 O
years O
a O
secondary O
prevention O
trial O
using O
xuezhikang O
a O
commercial O
red O
yeast O
rice B-Plant
preparation O
produced O
a O
46 O
reduction O
in O
nonfatal O
myocardial B-Disease
infarction I-Disease
and O
coronary B-Disease
death I-Disease

red O
yeast O
rice B-Plant
reduces O
adverse O
cardiac B-Disease
events I-Disease
to O
a O
similar O
degree O
as O
the O
statins O

it O
is O
unlikely O
that O
garlic B-Plant
is O
useful O
in O
preventing O
cardiovascular B-Disease
disease I-Disease

evaluation O
of O
the O
use O
of O
coconut B-Plant
to O
treat O
chronic O
diarrhea B-Disease
in O
rhesus O
macaques O
macaca O
mulatta O

coconut B-Plant
has O
been O
used O
as O
a O
dietary O
supplement O
for O
people O
with O
inflammatory B-Disease
bowel I-Disease
disease I-Disease
with O
anecdotal O
reports O
of O
decreased O
diarrhea B-Disease
following O
the O
dietary O
addition O

a O
dietary O
trial O
in O
rhesus O
macaques O
was O
initiated O
to O
evaluate O
the O
hypothesis O
that O
dietary O
coconut B-Plant
decreases O
symptoms O
of O
chronic O
diarrhea B-Disease
in O
rhesus O
macaqus O

results O
and O
conclusions O
data O
of O
chi O
squared O
analysis O
obtained O
from O
eight O
rhesus O
macaques O
with O
chronic O
diarrhea B-Disease
showed O
that O
the O
use O
of O
coconut B-Plant
macaroons O
as O
a O
dietary O
supplement O
did O
not O
have O
a O
statistically O
significant O
effect O
on O
their O
diarrhea B-Disease

coffee B-Plant
consumption O
and O
risk O
of O
type O
2 O
diabetes B-Disease
cardiovascular B-Disease
diseases I-Disease
and O
cancer B-Disease

numerous O
epidemiological O
studies O
have O
evaluated O
the O
association O
between O
coffee B-Plant
consumption O
and O
risk O
of O
type O
2 O
diabetes O
coronary O
heart O
disease O
and O
various O
cancers B-Disease

several O
early O
studies O
suggested O
that O
coffee B-Plant
consumption O
could O
result O
in O
a O
marked O
increase O
in O
risk O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
and O
several O
types O
of O
cancer B-Disease

however O
evidence O
has O
been O
accumulating O
that O
frequent O
consumption O
of O
coffee B-Plant
may O
reduce O
risk O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
and O
liver B-Disease
cancer I-Disease

in O
sum O
the O
currently O
available O
evidence O
on O
coffee B-Plant
and O
risk O
of O
cardiovascular B-Disease
diseases I-Disease
and O
cancer B-Disease
is O
largely O
reassuring O
and O
suggests O
that O
for O
the O
general O
population O
addressing O
other O
health O
related O
behaviors O
has O
priority O
for O
the O
prevention O
of O
chronic B-Disease
diasease I-Disease

estrogen O
activities O
and O
the O
cellular O
effects O
of O
natural O
progesterone O
from O
wild O
yam B-Plant
extract O
in O
mcf O
7 O
human O
breast B-Disease
cancer I-Disease

we O
studied O
the O
estrogenic O
activity O
and O
cellular O
effect O
of O
wild O
yam B-Plant
extract O
in O
mcf O
7 O
human O
breast B-Disease
cancer I-Disease

these O
data O
indicate O
that O
wild O
yam B-Plant
extract O
acts O
as O
a O
weak O
phytoestrogen O
and O
protects O
against O
proliferation O
in O
human O
breast B-Disease
carcinoma I-Disease
mcf O
7 O
cells O

relationship O
between O
long O
term O
coffee B-Plant
consumption O
and O
components O
of O
the O
metabolic B-Disease
syndrome I-Disease
the O
amsterdam O
growth O
and O
health O
longitudinal O
study O

it O
is O
known O
that O
the O
risk O
of O
dm B-Disease
ii I-Disease
can O
be O
decreased O
by O
coffee B-Plant
consumption O

therefore O
we O
examined O
the O
association O
between O
coffee B-Plant
consumption O
and O
the O
components O
of O
the O
metabolic B-Disease
syndrome I-Disease

prospective O
data O
from O
the O
amsterdam O
growth O
and O
health O
longitudinal O
study O
agahls O
is O
used O
to O
analyse O
the O
associations O
between O
coffee B-Plant
consumption O
averaged O
over O
a O
period O
from O
27 O
till O
42 O
years O
and O
the O
components O
of O
the O
metabolic B-Disease
syndrome I-Disease
at O
the O
age O
of O
42 O
years O

for O
men O
coffee B-Plant
consumption O
was O
not O
associated O
with O
any O
of O
the O
components O
of O
the O
metabolic B-Disease
syndrome I-Disease

the O
species O
of O
passiflora B-Plant
are O
popularly O
used O
as O
a O
sedative O
or O
tranquillizer O
and O
also O
against O
intermittent O
fever O
and O
skin B-Disease
inflammation I-Disease

in O
this O
study O
we O
evaluated O
the O
anti O
inflammatory O
activity O
of O
four O
sub O
fractions O
and O
three O
isolated O
compounds O
from O
the O
butanolic O
fraction O
of O
p B-Plant
edulis I-Plant
var I-Plant
flavicarpa I-Plant
leaves O
using O
the O
mouse O
model O
of O
pleurisy B-Disease
induced O
by O
carrageenan O

the O
present O
study O
showed O
that O
the O
c O
glucosylflavones O
isolated O
from O
p B-Plant
edulis I-Plant
leaves O
can O
be O
responsible O
for O
the O
anti O
inflammatory O
effect O
of O
p B-Plant
edulis I-Plant
on O
the O
mouse O
model O
of O
pleurisy B-Disease

chinese O
green B-Plant
tea I-Plant
ameliorates O
lung B-Disease
injury I-Disease
in O
cigarette O
smoke O
exposed O
rats O

this O
study O
was O
to O
investigate O
whether O
cigarette O
smoke O
cs O
exposure O
would O
induce O
lung O
morphological O
changes O
and O
oxidative O
stress O
in O
the O
cs O
exposed O
rat O
model O
and O
whether O
chinese O
green O
tea B-Plant
lung O
chen O
tea B-Plant
with O
egcg O
as O
its O
main O
active O
ingredient O
consumption O
would O
alter O
oxidative O
stress O
in O
sera O
and O
lung O
leading O
to O
protection O
of O
cs O
induced O
lung B-Disease
damage I-Disease

results O
airspace O
enlargement O
and O
goblet B-Disease
cell I-Disease
hyperplasia I-Disease
were O
observed O
after O
56 O
day O
cs O
exposure O
alone O
which O
were O
abolished O
in O
the O
presence O
of O
green B-Plant
tea I-Plant
consumption O

chinese O
green B-Plant
tea I-Plant
may O
have O
the O
ability O
to O
suppress O
cs O
induced O
oxidative O
stress O
that O
leads O
to O
protection O
of O
lung B-Disease
injury I-Disease

olive B-Plant
oil O
consumption O
is O
protective O
against O
risk O
factors O
for O
cardiovascular B-Disease
and I-Disease
cancer I-Disease
diseases I-Disease

garlic B-Plant
is O
generally O
used O
as O
a O
therapeutic O
reagent O
against O
various O
diseases O
and O
numerous O
studies O
have O
indicated O
that O
garlic B-Plant
and O
its O
derivatives O
can O
reduce O
the O
risk O
of O
various O
types O
of O
human O
cancer B-Disease

diallyl O
trisulfide O
dats O
a O
major O
member O
of O
garlic B-Plant
derivatives O
could O
inhibit O
the O
cell O
proliferation O
by O
triggering O
either O
cell O
cycle O
arrest O
or O
apoptosis O
in O
a O
variety O
of O
cancer B-Disease
cell O
lines O
as O
shown O
in O
many O
studies O

background O
garlic B-Plant
or O
allium B-Plant
sativum I-Plant
as B-Plant
shows O
therapeutic O
effects O
such O
as O
reduction O
of O
blood O
pressure O
or O
hypercholesterolemia B-Disease
but O
side O
effects O
on O
reproductive O
functions O
remain O
poorly O
investigated O

induction O
of O
apoptosis O
by O
tea B-Plant
polyphenols O
mediated O
through O
mitochondrial O
cell O
death O
pathway O
in O
mouse O
skin B-Disease
tumors I-Disease

in O
the O
present O
study O
cancer B-Disease
chemopreventive O
properties O
of O
both O
black B-Plant
tea I-Plant
polyphenols O
btp O
and O
green B-Plant
tea I-Plant
polyphenols O
gtp O
on O
712 O
dimethylbenz O
a O
anthracene O
dmba O
induced O
mouse O
skin B-Disease
carcinogenesis I-Disease
were O
studied O

thus O
we O
can O
conclude O
that O
the O
polyphenolic O
constituents O
present O
in O
black O
tea O
and O
green B-Plant
tea I-Plant
induce O
mitochondrial O
pathway O
of O
apoptosis O
and O
hence O
can O
be O
used O
as O
a O
potential O
chemopreventive O
agents O
against O
skin B-Disease
cancer I-Disease

background O
consumption O
of O
plantago B-Plant
ovata I-Plant
may O
protect O
against O
colorectal B-Disease
cancer I-Disease

to O
test O
this O
hypothesis O
an O
ecological O
study O
was O
performed O
to O
determine O
mortality O
rates O
and O
distribution O
of O
colorectal B-Disease
cancer I-Disease
and O
the O
consumption O
and O
distribution O
of O
p B-Plant
ovata I-Plant
in O
different O
provinces O
in O
spain O

the O
putative O
association O
between O
p B-Plant
ovata I-Plant
consumption O
and O
mortality O
from O
colorectal B-Disease
cancer I-Disease
was O
then O
evaluated O

results O
consumption O
of O
p B-Plant
ovata I-Plant
tended O
to O
be O
inversely O
correlated O
with O
mortality O
from O
colorectal B-Disease
cancer I-Disease

conclusions O
our O
results O
show O
an O
inverse O
trend O
between O
the O
consumption O
of O
p B-Plant
ovata I-Plant
and O
colorectal B-Disease
cancer I-Disease

neuroprotective O
evaluation O
of O
extract O
of O
ginger O
zingiber B-Plant
officinale I-Plant
root O
in O
monosodium O
glutamate O
induced O
toxicity B-Disease
in O
different O
brain O
areas O
male O
albino O
rats O

in O
this O
study O
the O
neuroprotective O
effect O
of O
the O
extract O
of O
ginger O
zingiber B-Plant
officinale I-Plant
was O
investigated O
against O
msg O
induced O
neurotoxicity B-Disease
of O
male O
albino O
rats O

from O
these O
results O
we O
can O
say O
that O
the O
ginger B-Plant
extract O
has O
a O
neuroprotective O
role O
against O
monosodium O
glutamate O
toxicity B-Disease
effect O

green B-Plant
tea I-Plant
and O
death O
from O
pneumonia B-Disease
in O
japan O
the O
ohsaki O
cohort O
study O

no O
data O
are O
available O
on O
the O
association O
between O
green B-Plant
tea I-Plant
consumption O
and O
the O
risk O
of O
pneumonia B-Disease
in O
humans O

objective O
we O
examined O
the O
association O
between O
green B-Plant
tea I-Plant
consumption O
and O
death O
from O
pneumonia B-Disease
in O
humans O

we O
excluded O
participants O
for O
whom O
data O
on O
green B-Plant
tea I-Plant
consumption O
frequency O
were O
missing O
or O
who O
had O
reported O
a O
history O
of O
cancer O
myocardial B-Disease
infarction I-Disease
stroke B-Disease
and O
extreme O
daily O
energy O
intake O
at O
baseline O

we O
used O
cox O
proportional O
hazards O
regression O
analysis O
to O
calculate O
hazard O
ratios O
hrs O
and O
their O
95 O
cis O
for O
death O
from O
pneumonia B-Disease
according O
to O
green B-Plant
tea I-Plant
consumption O

in O
women O
the O
multivariate O
hrs O
of O
death O
from O
pneumonia B-Disease
that O
were O
associated O
with O
different O
frequencies O
of O
green B-Plant
tea I-Plant
consumption O
were O
100 O
reference O
for O
1 O
cup O
d O
59 O
95 O
ci O
36 O
98 O
for O
1 O
2 O
cups O
d O
55 O
95 O
ci O
33 O
91 O
for O
3 O
4 O
cups O
d O
and O
53 O
95 O
ci O
33 O
83 O
for O
or O
5 O
cups O
respectively O
p O
for O
trend O

conclusion O
green B-Plant
tea I-Plant
consumption O
was O
associated O
with O
a O
lower O
risk O
of O
death O
from O
pneumonia B-Disease
in O
japanese O
women O

recent O
studies O
have O
documented O
a O
role O
for O
stabilized O
rice B-Plant
bran O
srb B-Plant
in O
treating O
diabetes B-Disease
and O
arthritis B-Disease
although O
little O
is O
known O
of O
the O
bioactive O
compounds O
that O
impart O
these O
health O
benefits O

here O
we O
characterize O
the O
chemical O
composition O
of O
three O
extracts O
of O
srb B-Plant
and O
identify O
the O
functional O
bioactives O
contributing O
to O
the O
inhibitory O
properties O
against O
three O
key O
pro O
inflammatory O
enzymes O
cyclooxygenase O
cox O
1 O
cox2 O
and O
5 O
lipoxygenase O
5 O
lox O
that O
control O
the O
inflammatory O
cascade O
involved O
in O
impaired O
joint O
health O
pain B-Disease
and O
arthritis B-Disease

these O
srb B-Plant
extracts O
have O
applications O
for O
functional O
foods O
and O
dietary O
supplements O
for O
control O
of O
inflammation B-Disease
and O
joint O
health O

systematic O
review O
of O
the O
relation O
between O
smokeless O
tobacco B-Plant
and O
cancer B-Disease
in O
europe O
and O
north O
america O

background O
interest O
is O
rising O
in O
smokeless O
tobacco B-Plant
as O
a O
safer O
alternative O
to O
smoking O
but O
published O
reviews O
on O
smokeless O
tobacco B-Plant
and O
cancer B-Disease
are O
limited O

methods O
we O
obtained O
papers O
from O
medline O
searches O
published O
reviews O
and O
secondary O
references O
describing O
epidemiological O
cohort O
and O
case O
control O
studies O
relating O
any O
form O
of O
cancer B-Disease
to O
smokeless O
tobacco B-Plant
use O

for O
each O
study O
details O
were O
abstracted O
on O
design O
smokeless O
tobacco B-Plant
exposure O
cancers B-Disease
studied O
analysis O
methods O
and O
adjustment O
for O
smoking O
and O
other O
factors O

for O
seven O
cancers B-Disease
smoking O
attributable O
deaths O
in O
us O
men O
in O
2005 O
were O
compared O
with O
deaths O
attributable O
to O
introducing O
smokeless O
tobacco B-Plant
into O
a O
population O
of O
never O
smoking O

some O
meta O
analyses O
suggest O
a O
possible O
effect O
for O
oesophagus B-Disease
pancreas B-Disease
larynx B-Disease
and O
kidney B-Disease
cancer I-Disease
but O
other O
cancers B-Disease
show O
no O
effect O
of O
smokeless O
tobacco B-Plant

conclusion O
an O
increased O
risk O
of O
oropharyngeal B-Disease
cancer I-Disease
is O
evident O
most O
clearly O
for O
past O
smokeless O
tobacco B-Plant
use O
in O
the O
usa O
but O
not O
for O
scandinavian O
nuff O

effects O
of O
smokeless O
tobacco B-Plant
use O
on O
other O
cancers B-Disease
are O
not O
clearly O
demonstrated O

antitumor O
effects O
of O
a O
water O
soluble O
extract O
from O
maitake B-Plant
grifola O
frondosa O
on O
human O
gastric B-Disease
cancer I-Disease
cell O
lines O

we O
investigated O
the O
effects O
of O
a O
water O
soluble O
extract O
of O
maitake B-Plant
grifola B-Plant
frondosa I-Plant
a O
japanese O
edible O
mushroom B-Plant
on O
the O
proliferation O
and O
cell O
death O
of O
four O
human O
gastric B-Disease
cancer I-Disease
cell O
lines O
tmk O
1 O
mkn28 O
mkn45 O
and O
mkn74 O

taken O
together O
these O
results O
suggest O
that O
me B-Plant
induces O
apoptosis O
of O
tmk O
1 O
cells O
by O
caspase O
3 O
dependent O
and O
independent O
pathways O
resulting O
in O
potential O
antitumor O
effects O
on O
ena O
me B-Plant
x O
gastric B-Disease
cancer I-Disease

coffee B-Plant
intake O
is O
associated O
with O
lower O
rates O
of O
liver O
disease O
progression O
in O
chronic B-Disease
hepatitis I-Disease
c I-Disease

higher O
coffee B-Plant
consumption O
has O
been O
associated O
inversely O
with O
the O
incidence O
of O
chronic B-Disease
liver I-Disease
disease I-Disease
in O
population O
studies O

we O
examined O
the O
relationship O
of O
coffee B-Plant
consumption O
with O
liver B-Disease
disease I-Disease
progression O
in O
individuals O
with O
advanced O
hepatitis B-Disease
c I-Disease
related O
liver B-Disease
disease I-Disease

baseline O
coffee B-Plant
and O
tea B-Plant
intake O
were O
assessed O
in O
766 O
participants O
of O
the O
hepatitis B-Disease
c I-Disease
antiviral O
long O
term O
treatment O
against O
cirrhosis O
halt O
c O
trial O
who O
had O
hepatitis B-Disease
c I-Disease
related O
bridging O
fibrosis B-Disease
or O
cirrhosis O
on O
liver O
biopsy O
and O
failed O
to O
achieve O
a O
sustained O
virological O
response O
to O
peginterferon O
plus O
ribavirin O
treatment O

at O
baseline O
higher O
coffee B-Plant
consumption O
was O
associated O
with O
less O
severe O
steatosis B-Disease
on O
biopsy O
lower O
serum O
aspartate O
aminotransferase O
ast O
alanine O
aminotransferase O
alt O
ratio O
alpha O
fetoprotein O
insulin O
and O
homeostatic O
model O
assessment O
homa2 O
score O
and O
higher O
albumin O
p O
5 O
for O
all O

conclusion O
in O
a O
large O
prospective O
study O
of O
participants O
with O
advanced O
hepatitis B-Disease
c I-Disease
related O
liver B-Disease
disease I-Disease
regular O
coffee B-Plant
consumption O
was O
associated O
with O
lower O
rates O
of O
disease O
progression O

hawthorn B-Plant
extract O
reduces O
infarct B-Disease
volume O
and O
improves O
neurological O
score O
by O
reducing O
oxidative O
stress O
in O
rat O
brain O
following O
middle B-Disease
cerebral I-Disease
artery I-Disease
occlusion I-Disease

in O
our O
present O
investigation O
the O
neuroprotective O
effect O
of O
alcoholic O
extract O
of O
hawthorn B-Plant
crataegus B-Plant
oxycantha I-Plant
was O
evaluated O
against O
middle B-Disease
cerebral I-Disease
artery I-Disease
occlusion O
induced O
ischemia B-Disease
reperfusion I-Disease
injury I-Disease
in O
rats O

conclusion O
our O
results O
suggest O
that O
hawthorn B-Plant
extract O
which O
is O
a O
well O
known O
prophylactic O
for O
cardiac O
conditions O
may O
very O
well O
protect O
the O
brain O
against O
ischemia B-Disease
reperfusion I-Disease

the O
reduced O
brain B-Disease
damage I-Disease
and O
improved O
neurological O
behavior O
after O
24 O
h O
of O
reperfusion B-Disease
in O
hawthorn B-Plant
extract O
pretreated O
group O
may O
be O
attributed O
to O
its O
antioxidant O
property O
which O
restores O
glutathione O
levels O
circumvents O
the O
increase O
in O
lipid O
peroxidation O
and O
nitric O
oxide O
levels O
thereby O
reducing O
peroxynitrite O
formation O
and O
free O
radical O
induced O
brain B-Disease
damage I-Disease

the O
mediterranean O
diet O
in O
which O
olive B-Plant
oil O
is O
the O
primary O
source O
of O
fat O
is O
associated O
with O
a O
low O
mortality O
for O
cardiovascular B-Disease
disease I-Disease

data O
concerning O
olive B-Plant
oil O
consumption O
and O
primary O
end O
points O
for O
cardiovascular B-Disease
disease I-Disease
are O
scarce O

the O
wide O
range O
of O
benefits O
associated O
with O
olive B-Plant
oil O
consumption O
could O
contribute O
to O
explaining O
the O
low O
rate O
of O
cardiovascular B-Disease
mortality I-Disease
found O
in O
southern O
european O
mediterranean O
countries O
in O
comparison O
with O
other O
westernized O
countries O
despite O
a O
high O
prevalence O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
risk O
factors O

effective O
tobacco B-Plant
control O
efforts O
have O
resulted O
in O
substantial O
declines O
in O
tobacco B-Plant
use O
and O
tobacco B-Plant
related O
cancer B-Disease
deaths O
in O
the O
united O
states O

clinical O
observation O
on O
therapeutic O
effect O
of O
combination O
of O
acupuncture O
and O
ginger B-Plant
partition O
moxibustion O
for O
treatment O
of O
patients O
with O
cardiac B-Disease
arrhythmia I-Disease

objective O
to O
compare O
the O
therapeutic O
effect O
of O
the O
combined O
method O
of O
acupuncture O
and O
ginger B-Plant
partition O
moxibustion O
with O
that O
of O
routine O
western O
medicine O
on O
the O
patients O
with O
cardiac B-Disease
arrhythmia I-Disease

conclusion O
the O
therapeutic O
effect O
of O
the O
combined O
method O
of O
acupuncture O
and O
ginger B-Plant
partition O
moxibustion O
on O
the O
patients O
with O
cardiac B-Disease
arrhythmia I-Disease
is O
obviously O
better O
than O
that O
of O
routine O
western O
medicine O

confronting O
a O
neglected O
epidemic O
tobacco B-Plant
cessation O
for O
persons O
with O
mental B-Disease
illnesses I-Disease
and O
substance B-Disease
abuse I-Disease
problems I-Disease
tobacco B-Plant
use O
exerts O
a O
huge O
toll O
on O
persons O
with O
mental B-Disease
illnesses I-Disease
and O
substance B-Disease
abuse I-Disease
disorders I-Disease
accounting O
for O

200000 O
of O
the O
annual O
443 O
0 O
annual O
tobacco B-Plant
related O
deaths O
in O
the O
united O
states O

hypolipidemic O
effect O
of O
ginger B-Plant
in O
12 O
dimethyl O
hydrazine O
induced O
experimental O
colon B-Disease
carcinogenesis I-Disease

in O
our O
laboratory O
we O
studied O
the O
chemopreventive O
and O
hypolipidemic O
effect O
of O
ginger B-Plant
a O
dietary O
spice O
in O
12 O
dimethylhydrazine O
dmh O
induced O
colon B-Disease
cancer I-Disease

ginger B-Plant
50 O
mg O
kg O
body O
weight O
po O
was O
given O
at O
the O
initiation O
and O
also O
at O
the O
postinitiation O
stages O
of O
carcinogenesis B-Disease

on O
administering O
ginger B-Plant
at O
the O
initiation O
and O
also O
at O
the O
postinitiation O
stages O
of O
colon B-Disease
carcinogenesis I-Disease
the O
levels O
of O
fecal O
bile O
acids O
neutral O
sterols O
tissue O
cholesterol O
hmg O
coa O
reductase O
free O
fatty O
acids O
triglycerides O
phospholipase O
a O
and O
phospholipase O
c O
were O
significantly O
decreased O
whereas O
the O
levels O
of O
phospholipids O
were O
increased O
as O
compared O
to O
unsupplemented O
dmh O
treated O
rats O

thus O
ginger B-Plant
supplementation O
was O
found O
to O
reduce O
the O
risk O
of O
colon B-Disease
cancer I-Disease
markedly O
by O
virtue O
of O
its O
hypolipidemic O
and O
antioxidative O
effects O

aloe B-Plant
emodin O
induces O
cell O
death O
through O
phase O
arrest O
and O
caspase O
dependent O
pathways O
in O
human O
tongue B-Disease
squamous I-Disease
cancer B-Disease
scc O
4 O
cells O
lines O

aloe B-Plant
emodin O
promoted O
the O
release O
of O
apoptosis O
inducing O
factor O
aif O
endonuclease O
g O
endo O
g O
pro O
caspase O
9 O
and O
cytochrome O
c O
from O
the O
mitochondria O
via O
a O
loss O
of O
the O
mitochondrial O
membrane O
potential O
deltapsi O
m O
which O
was O
associated O
with O
a O
increase O
in O
the O
ratio O
of O
b B-Disease
cell I-Disease
lymphoma I-Disease
2 O
associated O
x O
protein O
bax O
b O
cell O
lymphoma B-Disease
leukemia B-Disease
2 O
bcl O
2 O
and O
activation O
of O
caspase O
9 O
and O
3 O

aloe B-Plant
emodin O
could O
be O
a O
novel O
chemotherapeutic O
drug O
candidate O
for O
the O
treatment O
of O
human O
tongue B-Disease
squamous I-Disease
cancer I-Disease
in O
the O
future O

mutagen O
sensitivity O
tobacco B-Plant
smoking O
and O
breast B-Disease
cancer I-Disease
risk O
a O
case O
control O
study O

the O
mutagen O
sensitivity O
assay O
msa O
a O
phenotypic O
marker O
of O
dna O
damage O
response O
and O
repair O
capacity O
has O
been O
consistently O
shown O
to O
associate O
with O
the O
risk O
of O
tobacco B-Plant
related O
cancers B-Disease

our O
data O
also O
suggest O
that O
bleomycin O
sensitivity O
may O
modulate O
the O
effect O
of O
tobacco B-Plant
smoking O
on O
breast B-Disease
cancer I-Disease
risk O

among O
women O
with O
hypersensitivity O
to O
bleomycin O
ever O
smokers O
had O
a O
16 O
fold O
increased O
risk O
of O
breast B-Disease
cancer I-Disease
for O
interaction O
between O
tobacco B-Plant
smoking O
and O
bleomycin O
sensitivity O

our O
observation O
that O
the O
effect O
of O
tobacco B-Plant
smoking O
on O
breast B-Disease
cancer I-Disease
risk O
may O
differ O
based O
on O
mutagen O
sensitivity O
status O
warrants O
further O
investigation O

further O
associations O
between O
almond B-Plant
oil O
and O
improved O
bowel O
transit O
have O
been O
made O
which O
consequently O
reduces O
irritable B-Disease
bowel I-Disease
syndrome I-Disease
symptoms O

historically O
almond B-Plant
oil O
had O
been O
used O
in O
ancient O
chinese O
ayurvedic O
and O
greco O
persian O
schools O
of O
medicine O
to O
treat O
dry O
skin O
conditions O
such O
as O
psoriasis B-Disease
and O
eczema B-Disease

further O
it O
is O
through O
anecdotal O
evidence O
and O
clinical O
experiences O
that O
almond B-Plant
oil O
seemingly O
reduces O
hypertrophic B-Disease
scarring O
post O
operatively O
smoothes O
and O
rejuvenates O
skin O

a O
lipid O
soluble O
red O
ginseng B-Plant
extract O
inhibits O
the O
growth O
of O
human O
lung B-Disease
tumor I-Disease
xenografts O
in O
nude O
mice O

balb O
c O
nu O
mice O
were O
inoculated O
with O
human O
lung B-Disease
cancer I-Disease
nci O
h460 O
cells O
to O
establish O
a O
human O
tumor B-Disease
xenograft O
model O
in O
nude O
mice O
and O
the O
lipid O
soluble O
ginseng B-Plant
extract O
was O
orally O
administered O

the O
tumor B-Disease
inhibitory O
rates O
of O
the O
lipid O
soluble O
ginseng B-Plant
extract O
at O
doses O
of O
1 O
3 O
and O
10 O
g O
kg O
day O
were O
189 O
p O
5 O
600 O
p O
1 O
and O
675 O
p O
1 O
respectively O

the O
oral O
administration O
of O
the O
lipid O
soluble O
extract O
of O
red O
ginseng B-Plant
showed O
a O
potent O
anticancer O
effect O
in O
nude O
mice O
bearing O
human O
lung B-Disease
cancer I-Disease
cells O
in O
a O
dose O
dependent O
manner O
without O
any O
apparent O
toxicity B-Disease

this O
lipid O
soluble O
ginseng B-Plant
extract O
is O
a O
potential O
nontoxic O
anticancer O
supplement O
for O
the O
prevention O
and O
intervention O
of O
lung B-Disease
tumor I-Disease
growth O
through O
an O
oral O
administration O
route O

epidemiological O
data O
suggest O
that O
consumption O
of O
coffee B-Plant
and O
tea B-Plant
is O
associated O
with O
a O
reduced O
risk O
of O
several O
chronic O
and O
degenerative B-Disease
diseases I-Disease
including O
cardiovascular B-Disease
disorders I-Disease
diabetes B-Disease
obesity B-Disease
and O
neurodegenerative B-Disease
disorder I-Disease

cancer B-Disease
chemoprevention O
by O
pomegranate B-Plant
laboratory O
and O
clinical O
evidence O

recent O
research O
has O
shown O
that O
pomegranate B-Plant
extracts O
selectively O
inhibit O
the O
growth O
of O
breast B-Disease
prostate B-Disease
colon B-Disease
and O
lung B-Disease
cancer I-Disease
cells O
in O
culture O

in O
preclinical O
animal O
studies O
oral O
consumption O
of O
pomegranate B-Plant
extract O
inhibited O
growth O
of O
lung B-Disease
skin B-Disease
colon B-Disease
and O
prostate B-Disease
tumors I-Disease

an O
initial O
phase O
ii O
clinical O
trial O
of O
pomegranate B-Plant
juice O
in O
patients O
with O
prostate B-Disease
cancer I-Disease
reported O
significant O
prolongation O
of O
prostate O
specific O
antigen O
doubling O
time O

this O
review O
focuses O
on O
recent O
investigations O
into O
the O
effects O
of O
pomegranate B-Plant
fruit I-Plant
on O
cancer B-Disease

caffeine O
and O
coffee B-Plant
as O
therapeutics O
against O
alzheimers B-Disease
disease I-Disease

epidemiologic O
studies O
have O
increasingly O
suggested O
that O
caffeine O
coffee B-Plant
could O
be O
an O
effective O
therapeutic O
against O
alzheimer B-Disease
disease I-Disease
ad B-Disease

we O
have O
utilized O
a O
transgenic O
mouse O
model O
for O
ad B-Disease
in O
well O
controlled O
studies O
to O
determine O
if O
caffeine O
and O
or O
coffee B-Plant
have O
beneficial O
actions O
to O
protect O
against O
or O
reverse O
ad B-Disease
like O
cognitive O
impairment O
and O
ad B-Disease
pathology O

caffeinated O
coffee B-Plant
provided O
to O
ad B-Disease
mice O
also O
quickly O
decreased O
plasma O
abeta O
levels O
but O
not O
decaffeinated O
coffee B-Plant
suggesting O
that O
caffeine O
is O
critical O
to O
decreasing O
blood O
abeta O
level O

these O
results O
indicate O
a O
surprising O
ability O
of O
moderate O
caffeine O
intake O
the O
human O
equivalent O
of O
500 O
mg O
caffeine O
or O
5 O
cups O
of O
coffee B-Plant
per O
day O
to O
protect O
against O
or O
treat O
ad B-Disease
in O
a O
mouse O
model O
for O
the O
disease O
and O
a O
therapeutic O
potential O
for O
caffeine O
against O
ad B-Disease
in O
humans O

protective O
effects O
of O
nigella B-Plant
sativa I-Plant
on O
intestinal B-Disease
ischemia O
reperfusion I-Disease
injury I-Disease
in O
rats O

background O
in O
previous O
studies O
it O
has O
been O
demonstrated O
that O
nigella B-Plant
sativa I-Plant
ns B-Plant
has O
protective O
effects O
against O
ischemia B-Disease
reperfusion I-Disease
injury I-Disease
on O
various O
organs O

we O
aimed O
to O
determine O
whether O
ns B-Plant
prevents O
intestinal B-Disease
ischemia O
reperfusion I-Disease
injury I-Disease
in O
rats O

rats O
in O
the O
group O
3 O
received O
ns B-Plant
2 O
ml O
kg O
intraperitoneally O
before O
ischemia B-Disease
and O
before O
reperfusion O

conclusion O
our O
results O
suggest O
that O
ns B-Plant
treatment O
protected O
the O
rats O
intestinal O
tissue O
against O
intestinal B-Disease
ischemia I-Disease
reperfusion I-Disease
injury I-Disease

introduction O
garlic B-Plant
allium B-Plant
sativum I-Plant
traditionally O
being O
used O
as O
a O
spice O
worldwide O
has O
different O
applications O
and O
is O
claimed O
to O
possess O
beneficial O
effects O
in O
several O
health O
ailments O
such O
as O
tumor B-Disease
and O
atherosclerosis B-Disease

cytotoxicity B-Disease
of O
macrophages O
supernatant O
on O
wehi O
164 O
fibrosarcoma B-Disease
cells I-Disease
was O
not O
affected O
by O
garlic B-Plant
protein O
fractions O
p O
66 O
for O
14 O
kda O
and O
p O
85 O
for O
47 O
kda O
fraction O

study O
on O
antiinflammatory O
effect O
of O
different O
chemotype O
of O
cinnamomum B-Plant
camphora I-Plant
on O
rat O
arthritis B-Disease
model O
induced O
by O
freunds O
adjuvant O

objective O
to O
study O
the O
antiinflammatory O
effects O
of O
naphtha O
from O
different O
chemotypes O
of O
cinnamomum B-Plant
camphora I-Plant
and O
natural O
borneol O
on O
the O
rat O
arthritis B-Disease
model O
induced O
by O
freunds O

a O
population O
based O
twin O
study O
of O
the O
genetic O
and O
environmental O
relationship O
of O
major B-Disease
depression I-Disease
regular O
tobacco B-Plant
use O
and O
nicotine B-Disease
dependence I-Disease

background O
numerous O
epidemiological O
studies O
have O
reported O
a O
positive O
association O
between O
major O
depression O
md O
and O
regular O
tobacco B-Plant
use O
ru O
or O
nicotine B-Disease
dependence I-Disease
nd B-Disease

method O
we O
assessed O
md B-Disease
ru B-Plant
and O
nd B-Disease
in O
same O
sex O
twins O
from O
the O
population O
based O
swedish O
twin O
registry O

we O
used O
structural O
equation O
modeling O
to O
examine O
the O
relationship O
between O
md B-Disease
ru B-Plant
and O
nd B-Disease
given O
ru B-Plant

results O
the O
results O
suggest O
modest O
correlations O
between O
md B-Disease
and O
ru B-Plant
and O
between O
md B-Disease
and O
nd B-Disease

in O
males O
the O
liability O
shared O
between O
md B-Disease
and O
ru B-Plant
is O
solely O
genetic O
for O
both O
cigarettes O
and O
snus O
while O
md B-Disease
and O
nd B-Disease
share O
both O
genetic O
and O
unique O
environmental O
influences O

the O
continuation O
to O
nd B-Disease
given O
ru B-Plant
differed O
considerably O
between O
cigarette O
and O
snus O
users O

in O
females O
both O
md B-Disease
ru B-Plant
and O
md B-Disease
nd B-Disease
relationships O
are O
partially O
attributable O
to O
genetic O
and O
unique O
environmental O
correlations O

onclusions O
the O
relationship O
among O
md O
ru B-Plant
and O
nd B-Disease
is O
at O
least O
partially O
attributable O
to O
shared O
genetic O
and O
environmental O
risk O
factors O

in O
this O
study O
we O
assessed O
the O
anti O
arthritic O
effects O
of O
red O
ginseng B-Plant
saponin O
extract O
rgse B-Plant
including O
ginsenosides O
rg3 O
rk1 O
and O
rg5 O
as O
major O
components O
on O
a O
murine O
type O
ii O
collagen O
cii O
induced O
arthritis B-Disease
cia B-Disease
which O
is O
a O
valid O
animal O
model O
of O
human O

arthritis B-Disease
oral O
administration O
of O
rgse B-Plant
at O
10 O
mg O
kg O
reduced O
the O
clinical O
arthritis B-Disease
score O
and O
paw O
swelling O
in O
the O
cia B-Disease
mice O
and O
inhibited O
joint O
space O
narrowing O
and O
histological O
arthritis B-Disease
illustrating O
the O
severity O
of O
synovial B-Disease
hyperplasia I-Disease
inflammatory B-Disease
cell B-Disease
infiltration B-Disease
pannus O
formation O
and O
erosion B-Disease
of O
cartilage I-Disease

rgse B-Plant
inhibited O
the O
expression O
of O
matrix O
metalloproteinase O
3 O
and O
nitrotyrosine O
formation O
and O
recovered O
the O
expression O
of O
superoxide O
dismutase O
in O
the O
joints O
of O
the O
cia B-Disease
mice O

orally O
administered O
rgse B-Plant
also O
reduced O
the O
levels O
of O
serum O
tumor O
necrosis O
factor O
alpha O
and O
interleukin O
1beta O
in O
the O
cia B-Disease

mice O
cii O
or O
lipopolysaccharide O
stimulated O
cytokine O
production O
in O
addition O
to O
cii O
specific O
proliferation O
was O
reduced O
in O
the O
spleen O
cells O
of O
the O
rgse B-Plant
treated O
cia B-Disease
mice O
as O
compared O
with O
those O
from O
vehicle O
treated O
cia B-Disease
mice O

krg B-Plant
treatment O
reversed O
abnormal B-Disease
locomotor I-Disease
activity I-Disease
and O
sensitivity O
to O
electric O
shock O
to O
control O
level O

in O
vivo O
prophylactic O
effects O
of O
oleanolic O
acid O
isolated O
from O
chloroform O
extract O
of O
flaveria B-Plant
trinervia I-Plant
against O
ethanol O
induced O
liver B-Disease
toxicity I-Disease
in O
rats O

the O
prophylactic O
effects O
of O
oleanolic O
acid O
oa O
isolated O
from O
chloroform O
extract O
ce O
of O
flaveria B-Plant
trinervia I-Plant
against O
ethanol O
induced O
liver B-Disease
toxicity I-Disease
was O
investigated O
using O
rats O

interpretation O
our O
data O
confirmed O
the O
north O
west O
to O
south O
east O
europe O
gradient O
of O
increasing O
incidence O
and O
mortality O
rates O
of O
tobacco B-Plant
related O
cancers B-Disease
as O
well O
as O
increasing O
mortality O
rates O
of O
screen O
detectable O
cancers B-Disease

nhibitory O
effects O
of O
onion O
allium B-Plant
cepa I-Plant
l I-Plant
extract O
on O
proliferation O
of O
cancer B-Disease
cells O
and O
adipocytes O
via O
inhibiting O
fatty O
acid O
synthase O

our O
studies O
showed O
that O
ethyl O
acetate O
extract O
of O
onion B-Plant
eeo B-Plant
had O
potent O
inhibitory O
effects O
on O
animal O
fatty O
acid O
synthase O
fas O
and O
could O
induce O
apoptosis O
in O
fas O
over O
expressing O
human O
breast B-Disease
cancer I-Disease
mda O
cells O

since O
obesity B-Disease
is O
closely O
related O
to O
breast B-Disease
cancer I-Disease
and O
obese B-Disease
patients O
are O
at O
elevated O
risk O
of O
developing O
various O
cancers B-Disease
these O
findings O
suggested O
that O
onion B-Plant
might O
be O
useful O
for O
preventing O
obesity B-Disease
related O
malignancy B-Disease

20 O
glucopyranosyl O
20 O
protopanaxadiol O
a O
metabolite O
of O
ginseng B-Plant
inhibits O
colon B-Disease
cancer I-Disease
growth O
by O
targeting O
trpc O
channel O
mediated O
calcium O
influx O

here O
we O
show O
that O
20 O
glucopyranosyl O
20 O
protopanaxadiol O
20 O
gppd O
a O
metabolite O
of O
ginseng B-Plant
saponin O
causes O
apoptosis O
of O
colon B-Disease
cancer I-Disease
cells O
through O
the O
induction O
of O
cytoplasmic O
ca O

inonotus B-Plant
obliquus I-Plant
is O
a O
medicinal O
mushroom B-Plant
used O
in O
russian O
and O
eastern O
european O
folk O
medicine O
for O
the O
treatment O
of O
gastrointestinal B-Disease
cancer I-Disease
cardiovascular B-Disease
disease I-Disease
and O
diabetes B-Disease

previous O
studies O
in O
our O
laboratory O
have O
demonstrated O
that O
the O
mycelium O
powders O
of O
i B-Plant
obliquus I-Plant
possess O
significant O
antihyperglycemic O
effects O
in O
a O
mouse O
model O
of O
diabetic B-Disease
disease I-Disease
induced O
by O
alloxan O

this O
study O
aims O
to O
identify O
the O
active O
ingredients O
of O
i B-Plant
obliquus I-Plant
mycelium O
powders O
by O
a O
bioassay O
guided O
fractionation O
approach O
and O
explore O
the O
mechanism O
of O
action O
of O
these O
active O
ingredients O
by O
using O
a O
well O
established O
dpp O
4 O
an O
important O
enzyme O
as O
a O
new O
therapeutic O
target O
for O
diabetes B-Disease
inhibitory O
assay O
model O

gardenia B-Plant
jasminoides I-Plant
attenuates O
hepatocellular B-Disease
injury O
and O
fibrosis B-Disease
in O
bile O
duct O
ligated O
rats O
and O
human O
hepatic O
stellate O
cells O

aim O
to O
investigate O
the O
anti O
hepatofibrotic O
effects O
of O
gardenia B-Plant
jasminoides I-Plant
in O
liver B-Disease
fibrosis I-Disease

the O
effects O
of O
gardenia B-Plant
jasminoides I-Plant
on O
liver B-Disease
fibrosis I-Disease
and O
the O
detailed O
molecular O
mechanisms O
were O
also O
assessed O
in O
human O
hepatic O
stellate O
cells O
lx O
2 O
in O

conclusion O
gardenia B-Plant
jasminoides I-Plant
exerts O
antifibrotic O
effects O
in O
the O
liver B-Disease
fibrosis I-Disease
and O
may O
represent O
a O
novel O
antifibrotic O
agent O

secnidazole O
was O
89 O
5 O
effective O
for O
the O
treatment O
of O
equine O
balantidiasis B-Disease
compared O
to O
40 O
0 O
for O
nigella B-Plant
sativa I-Plant

tea B-Plant
and O
coffee B-Plant
consumption O
and O
risk O
of O
oral B-Disease
cavity I-Disease
cancer I-Disease
results O
of O
a O
large O
population O
based O
case O
control O
study O
the O
icare O
study O

background O
results O
on O
the O
relationship O
between O
coffee B-Plant
and O
tea O
drinking O
and O
the O
risk O
of O
oral B-Disease
cavity I-Disease
cancer I-Disease
are O
contrasted O

the O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
relation O
between O
coffee B-Plant
and O
tea B-Plant
drinking O
and O
the O
risk O
of O
oral B-Disease
cavity I-Disease
cancer I-Disease
in O
france O
a O
high O
incidence O
area O

results O
we O
observed O
inverse O
associations O
between O
oral B-Disease
cavity I-Disease
cancer I-Disease
and O
tea B-Plant
or O
coffee B-Plant
consumption O
odds O
ratio O
39 O
95 O
ci O
21 O
70 O
for O
the O
highest O
quartile O
of O
tea B-Plant
consumption O
and O
60 O
95 O
ci O
34 O
105 O
for O
the O
highest O
quartile O
of O
coffee B-Plant
consumption O

exclusive O
tea B-Plant
or O
coffee B-Plant
consumption O
was O
associated O
with O
a O
reduced O
risk O
of O
oral B-Disease
cavity I-Disease
cancer I-Disease
and O
their O
joint O
effect O
was O
multiplicative O

conclusions O
tea B-Plant
and O
coffee B-Plant
drinking O
may O
decrease O
the O
risk O
of O
oral B-Disease
cavity I-Disease
cancer I-Disease
through O
antioxidant O
components O
which O
play O
a O
role O
in O
the O
repair O
of O
cellular O
damages O

scope O
the O
molecular O
mechanisms O
underlying O
the O
potential O
health O
benefit O
effects O
of O
soybean B-Plant
proteins O
on O
obesity B-Disease
associated O
metabolic B-Disease
disorders I-Disease
have O
not O
been O
fully O
clarified O

these O
effects O
of O
sph O
might O
be O
important O
for O
the O
health O
benefit O
effects O
of O
soybean B-Plant
proteins O
on O
obesity B-Disease
associated O
metabolic B-Disease
disorders I-Disease

cardioprotective O
effects O
of O
sour B-Plant
cherry I-Plant
seed O
extract O
scse B-Plant
on O
the O
hypercholesterolemic B-Disease
rabbit O
heart O

hypothesis O
the O
present O
study O
evaluates O
the O
hypothesis O
that O
sour B-Plant
cherry I-Plant
seed O
extract O
scse B-Plant
protects O
against O
cardiovascular B-Disease
disease I-Disease
and O
inflammation B-Disease
in O
hypercholesterolemic B-Disease
rabbits O
and O
that O
this O
protection O
correlates O
with O
scse B-Plant
induced O
activity O
of O
heme O
oxygenase O
1 O
ho O
1 O
a O
cytoprotective O
enzyme O
contributing O
to O
oxidative O
stress O
responses O

results O
relative O
to O
cholesterol O
treated O
animals O
not O
receiving O
scse B-Plant
scse B-Plant
treated O
animals O
exhibited O
significantly O
improved O
cardiac O
function O
and O
improved O
peak O
early O
diastolic O
velocity O
to O
peak O
atrial O
velocity O
ratio O
along O
with O
decreased O
atherosclerotic B-Disease
plaque I-Disease
formation O
and O
infarct B-Disease
size O

coffee B-Plant
consumption O
delays O
the O
hepatitis B-Disease
and O
suppresses O
the O
inflammation B-Disease
related O
gene O
expression O
in O
the O
long O
evans O
cinnamon O
rat O

background O
and O
aims O
large O
scale O
epidemiological O
studies O
have O
shown O
that O
drinking O
more O
than O
two O
cups O
of O
coffee B-Plant
per O
day O
reduces O
the O
risks O
of O
hepatitis B-Disease
and O
liver B-Disease
disease I-Disease

however O
the O
heterogeneity O
of O
the O
human O
genome O
requires O
studies O
of O
experimental O
animal O
models O
with O
defined O
genetic O
backgrounds O
to O
evaluate O
the O
coffee B-Plant
effects O
on O
liver B-Disease
diseases I-Disease

results O
coffee B-Plant
administration O
for O
25 O
weeks O
delayed O
the O
occurrence O
of O
hepatitis B-Disease
by O
two O
weeks O
significantly O
improved O
survival O
reduced O
the O
expression O
of O
inflammatory O
cytokines O
and O
reduced O
the O
incidence O
of O
small O
pre O
neoplastic O
liver O
foci O
in O
lec O
rats O

these O
findings O
indicate O
that O
drinking O
coffee B-Plant
potentially O
prevents O
hepatitis B-Disease
and O
liver B-Disease
carcinogenesis I-Disease
through O
its O
anti O
inflammatory O
effects O

conclusion O
this O
study O
showed O
the O
efficacy O
of O
coffee B-Plant
in O
the O
prevention O
of O
hepatitis B-Disease
and O
liver B-Disease
carcinogenesis I-Disease
in O
the O
lec O
model O

tobacco B-Plant
related O
cancer B-Disease
mortality O
projections O
for O
different O
geographical O
regions O
in O
switzerland O

this O
study O
aimed O
to O
project O
gender O
specific O
tobacco B-Plant
related O
cancer B-Disease
mortality O
in O
switzerland O
at O
different O
geographical O
levels O
for O
the O
periods O
2009 O
2013 O
and O
2014 O
2018 O

methods O
in O
this O
analysis O
data O
on O
swiss O
tobacco B-Plant
related O
cancer B-Disease
mortality O
from O
1984 O
until O
2008 O
were O
used O

bayesian O
age O
period O
cohort O
models O
were O
formulated O
to O
assess O
past O
trends O
of O
gender O
specific O
tobacco B-Plant
related O
cancer B-Disease
mortality O
and O
to O
project O
them O
up O
to O
2018 O
at O
cantonal O
and O
language O
region O
levels O

results O
model O
based O
estimates O
at O
cantonal O
level O
identified O
regions O
with O
low O
and O
high O
tobacco B-Plant
related O
cancer B-Disease
mortality O
rates O
for O
the O
observed O
and O
projected O
periods O

the O
gap O
in O
tobacco B-Plant
related O
cancer B-Disease
mortality O
rates O
between O
younger O
and O
older O
males O
seems O
to O
be O
shrinking O

conclusion O
our O
findings O
indicate O
region O
sex O
and O
age O
related O
differences O
in O
tobacco B-Plant
related O
cancer B-Disease
mortality O
in O
switzerland O
and O
this O
could O
be O
useful O
for O
healthcare O
planning O
and O
for O
evaluating O
the O
impact O
of O
canton O
specific O
tobacco B-Plant
related O
policies O
and O
interventions O

gliadin O
from O
wheat B-Plant
is O
a O
common O
food O
allergen O
that O
can O
induce O
baker O
asthma B-Disease
wheat B-Plant
dependent O
exercise O
induced O
anaphylaxis B-Disease
atopic B-Disease
dermatitis I-Disease
and O
celiac B-Disease
disease I-Disease

the O
increased O
risk O
is O
mainly O
expected O
to O
be O
observed O
in O
tobacco B-Plant
related O
tumours B-Disease
among O
women O
and O
in O
colorectal B-Disease
and O
liver B-Disease
cancers I-Disease
among O
men O

many O
epidemiological O
studies O
have O
indicated O
that O
coffee B-Plant
consumption O
may O
reduce O
the O
risks O
of O
developing O
obesity B-Disease
and O
diabetes B-Disease
but O
the O
underlying O
mechanisms O
of O
these O
effects O
are O
poorly O
understood O

this O
mechanism O
may O
play O
an O
important O
part O
in O
the O
suppressive O
effects O
of O
coffee B-Plant
consumption O
on O
obesity O
inflammation B-Disease
and O
hepatosteatosis B-Disease

this O
study O
newly O
revealed O
global O
metabolic O
alterations O
induced O
by O
coffee B-Plant
intake O
providing O
significant O
insights O
into O
the O
association O
between O
coffee B-Plant
intake O
and O
the O
prevention O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
utilizing O
the O
benefits O
of O
multi O
omics O
analyses O

effect O
of O
vitex B-Plant
agnus I-Plant
castus I-Plant
extract O
and O
magnesium O
supplementation O
alone O
and O
in O
combination O
on O
osteogenic O
and O
angiogenic O
factors B-Disease
and O
fracture B-Disease
healing O
in O
women O
with O
long O
bone O
fracture B-Disease

background O
the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
the O
combination O
of O
vitex B-Plant
agnus I-Plant
castus I-Plant
extract O
as O
a O
source O
of O
phytoestrogens O
plus O
magnesium O
supplementation O
on O
osteogenic O
and O
angiogenic O
factors O
and O
callus O
formation O
in O
women O
with O
long O
bone B-Disease
fracture I-Disease

material O
and O
methods O
in O
a O
double O
blind O
randomized O
placebo O
controlled O
trial O
64 O
women O
with O
long O
bone B-Disease
fracture I-Disease
20 O
45 O
years O
old O
were O
randomly O
allocated O
to O
receive O
1 O
one O
agnugol O
tablet O
4 O
mg O
dried O
fruit O
extract O
of O
vitex B-Plant
agnus I-Plant
castus I-Plant
plus O
250 O
mg O
magnesium O
oxide O
vac O
mg O
group O
n O
10 O
2 O
one O
agnugol O
tablet O
plus O
placebo O
vac O
group O
n O
15 O
3 O
placebo O
plus O
250 O
mg O
magnesium O
oxide O
mg O
group O
n O
12 O
or O
4 O
placebo O
plus O
placebo O
placebo O
group O
n O
14 O
per O
day O
for O
8 O
weeks O

conclusion O
our O
results O
suggest O
that O
administration O
of O
vitex B-Plant
agnus I-Plant
castus I-Plant
plus O
magnesium O
may O
promote O
fracture B-Disease
healing O

however O
more O
studies O
need O
to O
further O
explore O
the O
roles O
of O
vitex B-Plant
agnus I-Plant
castus I-Plant
in O
fracture B-Disease
repair O
processes O

additional O
information O
on O
xerostomia B-Disease
oral O
health O
behaviors O
coffee B-Plant
tea B-Plant
intake O
and O
nasal O
congestion O
was O
collected O
via O
a O
questionnaire O

xerostomia B-Disease
was O
associated O
with O
coffee B-Plant
tea O
intake O
p O
0 O
1 O
and O
nasal O
congestion O
p O
0 O
1 O

nasal O
congestion O
and O
coffee B-Plant
tea B-Plant
intake O
also O
affected O
xerostomia B-Disease

serenoa B-Plant
repens I-Plant
induces O
growth O
arrest O
apoptosis O
and O
inactivation O
of O
stat3 O
signaling O
in O
human O
glioma B-Disease
cells O

serenoa B-Plant
repens I-Plant
the O
extract O
of O
berry O
in O
southeastern O
united O
states O
is O
one O
of O
several O
phytotherapeutic O
agents O
available O
for O
the O
treatment O
of O
benign B-Disease
prostatic I-Disease
hyperplasia I-Disease
bph B-Disease

flow O
cytometry O
assay O
showed O
that O
serenoa B-Plant
repens I-Plant
induced O
apoptosis O
of O
u87 O
and O
u251 O
glioma B-Disease
cells O
in O
a O
dose O
dependent O
manner O

in O
addition O
we O
found O
that O
serenoa B-Plant
repens I-Plant
down O
regulated O
basal O
level O
of O
phosphorylated O
form O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
stat O
3 O
in O
both O
u87 O
and O
u251 O
glioma B-Disease
cells O

furthermore O
it O
was O
discovered O
that O
a O
janus O
family O
of O
tyrosine O
kinase O
jak O
inhibitor O
ag490 O
inhibit O
the O
growth O
of O
human O
u87 O
and O
u251 O
glioma B-Disease
cells O
and O
ag490 O
enhanced O
the O
ability O
of O
serenoa B-Plant
repens I-Plant
to O
inhibit O
the O
growth O
of O
u87 O
and O
u251 O
glioma B-Disease
cells O
as O
measured O
by O
the O
dimethylthiazol O
diphenyltetrazolium O
bromide O
mtt O
assay O

these O
results O
indicate O
that O
serenoa B-Plant
repens I-Plant
reduces O
the O
growth O
causes O
apoptosis O
of O
glioma B-Disease
cells O
and O
inhibits O
stat O
3 O
signaling O

a O
randomized O
controlled O
clinical O
trial O
of O
ocimum B-Plant
sanctum I-Plant
and O
chlorhexidine O
mouthwash O
on O
dental B-Disease
plaque I-Disease
and O
gingival O
inflammation O

objective O
in O
the O
present O
study O
we O
assessed O
the O
effectiveness O
of O
ocimum B-Plant
sanctum I-Plant
on O
dental B-Disease
plaque I-Disease
gingival B-Disease
inflammation I-Disease
and O
comparison O
with O
gold O
standard O
chlorhexidine O
and O
normal O
saline O
placebo O

results O
our O
result O
showed O
that O
ocimum B-Plant
sanctum I-Plant
mouthrinse O
is O
equally O
effective O
in O
reducing O
plaque B-Disease
and O
gingivitis B-Disease
as O
chlorhexidine O

conclusion O
the O
results O
of O
the O
present O
study O
indicate O
that O
ocimum B-Plant
sanctum I-Plant
mouthrinse O
may O
prove O
to O
be O
an O
effective O
mouthwash O
owing O
to O
its O
ability O
in O
decreasing O
periodontal O
indices O
by O
reducing O
plaque B-Disease
accumulation O
gingival B-Disease
inflammation I-Disease
and O
bleeding B-Disease

genetic O
predisposition O
to O
schizophrenia B-Disease
associated O
with O
increased O
use O
of O
cannabis B-Plant

one O
established O
association O
is O
that O
between O
cannabis B-Plant
use O
and O
schizophrenia B-Disease
a O
debilitating O
psychiatric B-Disease
disorder I-Disease
affecting O
1 O
of O
the O
population O
over O
their O
lifetime O

although O
considerable O
evidence O
implicates O
cannabis B-Plant
use O
as O
a O
component O
cause O
of O
schizophrenia B-Disease
it O
remains O
unclear O
whether O
this O
is O
entirely O
due O
to O
cannabis B-Plant
directly O
raising O
risk O
of O
psychosis B-Disease
or O
whether O
the O
same O
genes O
that O
increases O
psychosis B-Disease
risk O
may O
also O
increase O
risk O
of O
cannabis B-Plant

an O
individuals O
burden O
of O
schizophrenia B-Disease
risk O
alleles O
and O
use O
of O
cannabis B-Plant

although O
directly O
predicting O
only O
a O
small O
amount O
of O
the O
variance O
in O
cannabis B-Plant
use O
these O
findings O
suggest O
that O
part O
of O
the O
association O
between O
schizophrenia B-Disease
and O
cannabis B-Plant
is O
due O
to O
a O
shared O
genetic O
aetiology O

schizophrenia B-Disease
and O
cannabis B-Plant
is O
due O
to O
shared O
genetic O
aetiology O

torsade B-Disease
de I-Disease
pointes I-Disease
ventricular B-Disease
tachycardia I-Disease
during O
low O
dose O
intermittent O
dobutamine O
treatment O
in O
a O
patient O
with O
dilated B-Disease
cardiomyopathy I-Disease
and O
congestive B-Disease
heart I-Disease
failure I-Disease
. O

the O
authors O
describe O
the O
case O
of O
a O
56 O
- O
year O
- O
old O
woman O
with O
chronic O
, O
severe O
heart B-Disease
failure I-Disease
secondary O
to O
dilated B-Disease
cardiomyopathy I-Disease
and O
absence O
of O
significant O
ventricular B-Disease
arrhythmias I-Disease
who O
developed O
qt B-Disease
prolongation I-Disease
and O
torsade B-Disease
de I-Disease
pointes I-Disease
ventricular B-Disease
tachycardia I-Disease
during O
one O
cycle O
of O
intermittent O
low O
dose O
( O
2 O
. O
5 O
mcg O
/ O
kg O
per O
min O
) O
dobutamine O
. O

this O
report O
of O
torsade B-Disease
de I-Disease
pointes I-Disease
ventricular B-Disease
tachycardia I-Disease
during O
intermittent O
dobutamine O
supports O
the O
hypothesis O
that O
unpredictable O
fatal O
arrhythmias B-Disease
may O
occur O
even O
with O
low O
doses O
and O
in O
patients O
with O
no O
history O
of O
significant O
rhythm O
disturbances O
. O

the O
mechanisms O
of O
proarrhythmic O
effects O
of O
dubutamine O
are O
discussed O
. O

positive O
skin O
tests O
in O
late O
reactions O
to O
radiographic O
contrast O
media O
. O

in O
the O
last O
few O
years O
delayed O
reactions O
several O
hours O
after O
the O
injection O
of O
radiographic O
and O
contrast O
materials O
( O
prc O
) O
have O
been O
described O
with O
increasing O
frequency O
. O

the O
authors O
report O
two O
observations O
on O
patients O
with O
delayed O
reactions O
in O
whom O
intradermoreactions O
( O
idr O
) O
and O
patch O
tests O
to O
a O
series O
of O
ionic O
and O
non O
ionic O
prc O
were O
studied O
. O

after O
angiography O
by O
the O
venous O
route O
in O
patient O
n O
degree O
1 O
a O
biphasic O
reaction O
with O
an O
immediate O
reaction O
( O
dyspnea B-Disease
, O
loss B-Disease
of I-Disease
consciousness I-Disease
) O
and O
delayed O
macro B-Disease
- I-Disease
papular I-Disease
rash I-Disease
appeared O
, O
whilst O
patient O
n O
degree O
2 O
developed O
a O
generalised O
sensation O
of O
heat O
, O
persistent O
pain B-Disease
at O
the O
site O
of O
injection O
immediately O
and O
a O
generalised O
macro O
- O
papular O
reaction O
after O
24 O
hours O
. O

the O
skin O
tests O
revealed O
positive O
delayed O
reactions O
of O
24 O
hours O
and O
48 O
hours O
by O
idr O
and O
patch O
tests O
to O
only O
some O
prc O
with O
common O
chains O
in O
their O
structures O
. O

the O
positive O
skin O
tests O
are O
in O
favour O
of O
immunological O
reactions O
and O
may O
help O
in O
diagnosis O
of O
allergy B-Disease
in O
the O
patients O
. O

risk O
of O
transient O
hyperammonemic B-Disease
encephalopathy I-Disease
in O
cancer B-Disease
patients O
who O
received O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
with O
the O
complication O
of O
dehydration B-Disease
and O
infection B-Disease
. O

from O
1986 O
to O
1998 O
, O
29 O
cancer B-Disease
patients O
who O
had O
32 O
episodes O
of O
transient O
hyperammonemic B-Disease
encephalopathy I-Disease
related O
to O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
were O
identified O
. O

none O
of O
the O
patients O
had O
decompensated O
liver B-Disease
disease I-Disease
. O

onset O
of O
hyperammonemic B-Disease
encephalopathy I-Disease
varied O
from O
0 O
. O
5 O
to O
5 O
days O
( O
mean O
: O
2 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
days O
) O
after O
the O
initiation O
of O
chemotherapy O
. O

plasma O
ammonium O
level O
ranged O
from O
248 O
to O
2387 O
microg O
% O
( O
mean O
: O
626 O
+ O
/ O
- O
431 O
microg O
% O
) O
. O

among O
the O
32 O
episodes O
, O
26 O
( O
81 O
% O
) O
had O
various O
degrees O
of O
azotemia B-Disease
, O
18 O
( O
56 O
% O
) O
occurred O
during O
bacterial B-Disease
infections I-Disease
and O
14 O
( O
44 O
% O
) O
without O
infection B-Disease
occurred O
during O
periods O
of O
dehydration B-Disease
. O

higher O
plasma O
ammonium O
levels O
and O
more O
rapid O
onset O
of O
hyperammonemia B-Disease
were O
seen O
in O
18 O
patients O
with O
bacterial B-Disease
infections I-Disease
( O
p O
= O
0 O
. O
003 O
and O
0 O
. O
0006 O
, O
respectively O
) O
and O
in O
nine O
patients O
receiving O
high O
daily O
doses O
( O
2600 O
or O
1800 O
mg O
/ O
m2 O
) O
of O
5 O
- O
fu O
( O
p O
= O
0 O
. O
0001 O
and O
< O
0 O
. O
0001 O
, O
respectively O
) O
. O

in O
25 O
out O
of O
32 O
episodes O
( O
78 O
% O
) O
, O
plasma O
ammonium O
levels O
and O
mental O
status O
returned O
to O
normal O
within O
2 O
days O
after O
adequate O
management O
. O

in O
conclusion O
, O
hyperammonemic B-Disease
encephalopathy I-Disease
can O
occur O
in O
patients O
receiving O
continuous O
infusion O
of O
5 O
- O
fu O
. O

azotemia B-Disease
, O
body O
fluid O
insufficiency O
and O
bacterial B-Disease
infections I-Disease
were O
frequently O
found O
in O
these O
patients O
. O

it O
is O
therefore O
important O
to O
recognize O
this O
condition O
in O
patients O
receiving O
continuous O
infusion O
of O
5 O
- O
fu O
. O

the O
effects O
of O
quinine O
and O
4 O
- O
aminopyridine O
on O
conditioned O
place O
preference O
and O
changes O
in O
motor O
activity O
induced O
by O
morphine O
in O
rats O
. O

1 O
. O

the O
effects O
of O
two O
unselective O
potassium O
( O
k O
( O
+ O
) O
- O
) O
channel O
blockers O
, O
quinine O
( O
12 O
. O
5 O
, O
25 O
and O
50 O
mg O
/ O
kg O
) O
and O
4 O
- O
aminopyridine O
( O
1 O
and O
2 O
mg O
/ O
kg O
) O
, O
on O
conditioned O
place O
preference O
and O
biphasic O
changes O
in O
motor O
activity O
induced O
by O
morphine O
( O
10 O
mg O
/ O
kg O
) O
were O
tested O
in O
wistar O
rats O
. O

quinine O
is O
known O
to O
block O
voltage O
- O
, O
calcium O
- O
and O
atp O
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
while O
4 O
- O
aminopyridine O
is O
known O
to O
block O
voltage O
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
. O

2 O
. O

in O
the O
counterbalanced O
method O
, O
quinine O
attenuated O
morphine O
- O
induced O
place O
preference O
, O
whereas O
4 O
- O
aminopyridine O
was O
ineffective O
. O

in O
the O
motor O
activity O
test O
measured O
with O
an O
animex O
- O
activity O
meter O
neither O
of O
the O
k O
( O
+ O
) O
- O
channel O
blockers O
affected O
morphine O
- O
induced O
hypoactivity B-Disease
, O
but O
both O
k O
( O
+ O
) O
- O
channel O
blockers O
prevented O
morphine O
- O
induced O
secondary O
hyperactivity B-Disease
. O

3 O
. O

these O
results O
suggest O
the O
involvement O
of O
quinine O
- O
sensitive O
but O
not O
4 O
- O
aminopyridine O
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
in O
morphine O
reward O
. O

it O
is O
also O
suggested O
that O
the O
blockade O
of O
k O
( O
+ O
) O
- O
channels O
sensitive O
to O
these O
blockers O
is O
not O
sufficient O
to O
prevent O
morphine O
- O
induced O
hypoactivity B-Disease
whereas O
morphine O
- O
induced O
hyperactivity B-Disease
seems O
to O
be O
connected O
to O
both O
quinine O
- O
and O
4 O
- O
aminopyridine O
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
. O

nociceptin O
/ O
orphanin O
fq O
and O
nocistatin O
on O
learning B-Disease
and I-Disease
memory I-Disease
impairment I-Disease
induced O
by O
scopolamine O
in O
mice O
. O

1 O
. O

nociceptin O
, O
also O
known O
as O
orphanin O
fq O
, O
is O
an O
endogenous O
ligand O
for O
the O
orphan O
opioid O
receptor O
- O
like O
receptor O
1 O
( O
orl1 O
) O
and O
involves O
in O
various O
functions O
in O
the O
central O
nervous O
system O
( O
cns O
) O
. O

on O
the O
other O
hand O
, O
nocistatin O
is O
recently O
isolated O
from O
the O
same O
precursor O
as O
nociceptin O
and O
blocks O
nociceptin O
- O
induced O
allodynia B-Disease
and O
hyperalgesia B-Disease
. O

2 O
. O

although O
orl1 O
receptors O
which O
display O
a O
high O
degree O
of O
sequence O
homology O
with O
classical O
opioid O
receptors O
are O
abundant O
in O
the O
hippocampus O
, O
little O
is O
known O
regarding O
their O
role O
in O
learning O
and O
memory O
. O

3 O
. O

the O
present O
study O
was O
designed O
to O
investigate O
whether O
nociceptin O
/ O
orphanin O
fq O
and O
nocistatin O
could O
modulate O
impairment B-Disease
of I-Disease
learning I-Disease
and I-Disease
memory I-Disease
induced O
by O
scopolamine O
, O
a O
muscarinic O
cholinergic O
receptor O
antagonist O
, O
using O
spontaneous O
alternation O
of O
y O
- O
maze O
and O
step O
- O
down O
type O
passive O
avoidance O
tasks O
in O
mice O
. O

4 O
. O

while O
nocistatin O
( O
0 O
. O
5 O
- O
5 O
. O
0 O
nmol O
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
administered O
30 O
min O
before O
spontaneous O
alternation O
performance O
or O
the O
training O
session O
of O
the O
passive O
avoidance O
task O
, O
had O
no O
effect O
on O
spontaneous O
alternation O
or O
passive O
avoidance O
behaviours O
, O
a O
lower O
per O
cent O
alternation O
and O
shorter O
median O
step O
- O
down O
latency O
in O
the O
retention O
test O
were O
obtained O
in O
nociceptin O
( O
1 O
. O
5 O
and O
/ O
or O
5 O
. O
0 O
nmol O
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
- O
treated O
normal O
mice O
. O

5 O
. O

administration O
of O
nocistatin O
( O
1 O
. O
5 O
and O
/ O
or O
5 O
. O
0 O
nmol O
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
30 O
min O
before O
spontaneous O
alternation O
performance O
or O
the O
training O
session O
of O
the O
passive O
avoidance O
task O
, O
attenuated O
the O
scopolamine O
- O
induced O
impairment O
of O
spontaneous O
alternation O
and O
passive O
avoidance O
behaviours O
. O

6 O
. O

these O
results O
indicated O
that O
nocistatin O
, O
a O
new O
biologically O
active O
peptide O
, O
ameliorates O
impairments O
of O
spontaneous O
alternation O
and O
passive O
avoidance O
induced O
by O
scopolamine O
, O
and O
suggested O
that O
these O
peptides O
play O
opposite O
roles O
in O
learning O
and O
memory O
. O

meloxicam O
- O
induced O
liver B-Disease
toxicity I-Disease
. O

we O
report O
the O
case O
of O
a O
female O
patient O
with O
rheumatoid B-Disease
arthritis I-Disease
who O
developed O
acute O
cytolytic O
hepatitis B-Disease
due O
to O
meloxicam O
. O

recently O
introduced O
in O
belgium O
, O
meloxicam O
is O
the O
first O
nonsteroidal O
antiinflammatory O
drug O
with O
selective O
action O
on O
the O
inducible O
form O
of O
cyclooxygenase O
2 O
. O

the O
acute O
cytolytic O
hepatitis B-Disease
occurred O
rapidly O
after O
meloxicam O
administration O
and O
was O
associated O
with O
the O
development O
of O
antinuclear O
antibodies O
suggesting O
a O
hypersensitivity B-Disease
mechanism O
. O

this O
first O
case O
of O
meloxicam O
related O
liver B-Disease
toxicity I-Disease
demonstrates O
the O
potential O
of O
this O
drug O
to O
induce O
hepatic B-Disease
damage I-Disease
. O

induction O
of O
apoptosis O
by O
remoxipride O
metabolites O
in O
hl60 O
and O
cd34 O
+ O
/ O
cd19 O
- O
human O
bone O
marrow O
progenitor O
cells O
: O
potential O
relevance O
to O
remoxipride O
- O
induced O
aplastic B-Disease
anemia I-Disease
. O

the O
antipsychotic O
agent O
, O
remoxipride O
[ O
( O
s O
) O
- O
( O
- O
) O
- O
3 O
- O
bromo O
- O
n O
- O
[ O
( O
1 O
- O
ethyl O
- O
2 O
- O
pyrrolidinyl O
) O
methyl O
] O
- O
2 O
, O
6 O
- O
dimethoxybenz O
amide O
] O
has O
been O
associated O
with O
acquired O
aplastic B-Disease
anemia I-Disease
. O

we O
have O
examined O
the O
ability O
of O
remoxipride O
, O
three O
pyrrolidine O
ring O
metabolites O
and O
five O
aromatic O
ring O
metabolites O
of O
the O
parent O
compound O
to O
induce O
apoptosis O
in O
hl60 O
cells O
and O
human O
bone O
marrow O
progenitor O
( O
hbmp O
) O
cells O
. O

cells O
were O
treated O
for O
0 O
- O
24 O
h O
with O
each O
compound O
( O
0 O
- O
200 O
microm O
) O
. O

apoptosis O
was O
assessed O
by O
fluorescence O
microscopy O
in O
hoechst O
33342 O
- O
and O
propidium O
iodide O
stained O
cell O
samples O
. O

results O
were O
confirmed O
by O
determination O
of O
internucleosomal O
dna O
fragmentation O
using O
gel O
electrophoresis O
for O
hl60 O
cell O
samples O
and O
terminal O
deoxynucleotidyl O
transferase O
assay O
in O
hbmp O
cells O
. O

the O
catechol O
and O
hydroquinone O
metabolites O
, O
ncq436 O
and O
ncq344 O
, O
induced O
apoptosis O
in O
hl60 O
and O
hbmp O
cells O
in O
a O
time O
- O
and O
concentration O
dependent O
manner O
, O
while O
the O
phenols O
, O
ncr181 O
, O
fla873 O
, O
and O
fla797 O
, O
and O
the O
derivatives O
formed O
by O
oxidation O
of O
the O
pyrrolidine O
ring O
, O
fla838 O
, O
ncm001 O
, O
and O
ncl118 O
, O
had O
no O
effect O
. O

no O
necrosis B-Disease
was O
observed O
in O
cells O
treated O
with O
ncq436 O
but O
ncq344 O
had O
a O
biphasic O
effect O
in O
both O
cell O
types O
, O
inducing O
apoptosis O
at O
lower O
concentrations O
and O
necrosis B-Disease
at O
higher O
concentrations O
. O

these O
data O
show O
that O
the O
catechol O
and O
hydroquinone O
metabolites O
of O
remoxipride O
have O
direct O
toxic O
effects O
in O
hl60 O
and O
hbmp O
cells O
, O
leading O
to O
apoptosis O
, O
while O
the O
phenol O
metabolites O
were O
inactive O
. O

similarly O
, O
benzene O
- O
derived O
catechol O
and O
hydroquinone O
, O
but O
not O
phenol O
, O
induce O
apoptosis O
in O
hbmp O
cells O
[ O
moran O
et O
al O
. O
, O
mol O
. O
pharmacol O
. O
, O
50 O
( O
1996 O
) O
610 O
- O
615 O
] O
. O

we O
propose O
that O
remoxipride O
and O
benzene O
may O
induce O
aplastic B-Disease
anemia I-Disease
via O
production O
of O
similar O
reactive O
metabolites O
and O
that O
the O
ability O
of O
ncq436 O
and O
ncq344 O
to O
induce O
apoptosis O
in O
hbmp O
cells O
may O
contribute O
to O
the O
mechanism O
underlying O
acquired O
aplastic B-Disease
anemia I-Disease
that O
has O
been O
associated O
with O
remoxipride O
. O

synthesis O
and O
preliminary O
pharmacological O
investigations O
of O
1 O
- O
( O
1 O
, O
2 O
- O
dihydro O
- O
2 O
- O
acenaphthylenyl O
) O
piperazine O
derivatives O
as O
potential O
atypical O
antipsychotic O
agents O
in O
mice O
. O

in O
research O
towards O
the O
development O
of O
new O
atypical O
antipsychotic O
agents O
, O
one O
strategy O
is O
that O
the O
dopaminergic O
system O
can O
be O
modulated O
through O
manipulation O
of O
the O
serotonergic O
system O
. O

the O
synthesis O
and O
preliminary O
pharmacological O
evaluation O
of O
a O
series O
of O
potential O
atypical O
antipsychotic O
agents O
based O
on O
the O
structure O
of O
1 O
- O
( O
1 O
, O
2 O
- O
dihydro O
- O
2 O
- O
acenaphthylenyl O
) O
piperazine O
( O
7 O
) O
is O
described O
. O

compound O
7e O
, O
5 O
- O
{ O
2 O
- O
[ O
4 O
- O
( O
1 O
, O
2 O
- O
dihydro O
- O
2 O
- O
acenaphthylenyl O
) O
piperazinyl O
] O
ethyl O
} O
- O
2 O
, O
3 O
- O
dihy O
dro O
- O
1h O
- O
indol O
- O
2 O
- O
one O
, O
from O
this O
series O
showed O
significant O
affinities O
at O
the O
5 O
- O
ht1a O
and O
5 O
- O
ht2a O
receptors O
and O
moderate O
affinity O
at O
the O
d2 O
receptor O
. O

7e O
exhibits O
a O
high O
reversal O
of O
catalepsy B-Disease
induced O
by O
haloperidol O
indicating O
its O
atypical O
antipsychotic O
nature O
. O

sub O
- O
chronic O
inhibition O
of O
nitric O
- O
oxide O
synthesis O
modifies O
haloperidol O
- O
induced O
catalepsy B-Disease
and O
the O
number O
of O
nadph O
- O
diaphorase O
neurons O
in O
mice O
. O

rationale O
: O
ng O
- O
nitro O
- O
l O
- O
arginine O
( O
l O
- O
noarg O
) O
, O
an O
inhibitor O
of O
nitric O
- O
oxide O
synthase O
( O
nos O
) O
, O
induces O
catalepsy B-Disease
in O
mice O
. O

this O
effect O
undergoes O
rapid O
tolerance O
, O
showing O
a O
significant O
decrease O
after O
2 O
days O
of O
sub O
- O
chronic O
l O
- O
noarg O
treatment O
. O

nitric O
oxide O
( O
no O
) O
has O
been O
shown O
to O
influence O
dopaminergic O
neurotransmission O
in O
the O
striatum O
. O

neuroleptic O
drugs O
such O
as O
haloperidol O
, O
which O
block O
dopamine O
receptors O
, O
also O
cause O
catalepsy B-Disease
in O
rodents O
. O

objectives O
: O
to O
investigate O
the O
effects O
of O
subchronic O
l O
- O
noarg O
treatment O
in O
haloperidol O
- O
induced O
catalepsy B-Disease
and O
the O
number O
of O
nos O
neurons O
in O
areas O
related O
to O
motor O
control O
. O

methods O
: O
male O
albino O
swiss O
mice O
were O
treated O
sub O
- O
chronically O
( O
twice O
a O
day O
for O
4 O
days O
) O
with O
l O
- O
noarg O
( O
40 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
or O
haloperidol O
( O
1 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

catalepsy B-Disease
was O
evaluated O
at O
the O
beginning O
and O
the O
end O
of O
the O
treatments O
. O

reduced O
nicotinamide O
adenine O
dinucleotide O
phosphate O
- O
diaphorase O
( O
nadph O
- O
d O
) O
histochemistry O
was O
also O
employed O
to O
visualize O
nos O
as O
an O
index O
of O
enzyme O
expression O
in O
mice O
brain O
regions O
related O
to O
motor O
control O
. O

results O
: O
l O
- O
noarg O
sub O
- O
chronic O
administration O
produced O
tolerance O
of O
l O
- O
noarg O
and O
of O
haloperidol O
- O
induced O
catalepsy B-Disease
. O

it O
also O
induced O
an O
increase O
in O
the O
number O
of O
nadph O
- O
d O
- O
positive O
cells O
in O
the O
dorsal O
part O
of O
the O
caudate O
and O
accumbens O
nuclei O
compared O
with O
haloperidol O
and O
in O
the O
pedunculopontine O
tegmental O
nucleus O
compared O
with O
saline O
. O

in O
contrast O
, O
there O
was O
a O
decrease O
in O
nadph O
- O
d O
neuron O
number O
in O
the O
substantia O
nigra O
, O
pars O
compacta O
in O
both O
haloperidol O
- O
treated O
and O
l O
- O
noarg O
- O
treated O
animals O
. O

conclusions O
: O
the O
results O
give O
further O
support O
to O
the O
hypothesis O
that O
no O
plays O
a O
role O
in O
motor O
behavior O
control O
and O
suggest O
that O
it O
may O
take O
part O
in O
the O
synaptic O
changes O
produced O
by O
antipsychotic O
treatment O
. O

prolonged O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
occurs O
in O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
after O
both O
dobutamine O
and O
exercise O
induced O
myocardial B-Disease
ischaemia I-Disease
. O

objective O
: O
to O
determine O
whether O
pharmacological O
stress O
leads O
to O
prolonged O
but O
reversible O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
in O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
similar O
to O
that O
seen O
after O
exercise O
. O

design O
: O
a O
randomised O
crossover O
study O
of O
recovery O
time O
of O
systolic O
and O
diastolic O
left O
ventricular O
function O
after O
exercise O
and O
dobutamine O
induced O
ischaemia B-Disease
. O

subjects O
: O
10 O
patients O
with O
stable B-Disease
angina I-Disease
, O
angiographically O
proven O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
and O
normal O
left O
ventricular O
function O
. O

interventions O
: O
treadmill O
exercise O
and O
dobutamine O
stress O
were O
performed O
on O
different O
days O
. O

quantitative O
assessment O
of O
systolic O
and O
diastolic O
left O
ventricular O
function O
was O
performed O
using O
transthoracic O
echocardiography O
at O
baseline O
and O
at O
regular O
intervals O
after O
each O
test O
. O

results O
: O
both O
forms O
of O
stress O
led O
to O
prolonged O
but O
reversible O
systolic O
and O
diastolic O
dysfunction O
. O

there O
was O
no O
difference O
in O
the O
maximum O
double O
product O
( O
p O
= O
0 O
. O
53 O
) O
or O
st O
depression B-Disease
( O
p O
= O
0 O
. O
63 O
) O
with O
either O
form O
of O
stress O
. O

after O
exercise O
, O
ejection O
fraction O
was O
reduced O
at O
15 O
and O
30 O
minutes O
compared O
with O
baseline O
( O
mean O
( O
sem O
) O
, O
- O
5 O
. O
6 O
( O
1 O
. O
5 O
) O
% O
, O
p O
< O
0 O
. O
05 O
; O
and O
- O
6 O
. O
1 O
( O
2 O
. O
2 O
) O
% O
, O
p O
< O
0 O
. O
01 O
) O
, O
and O
at O
30 O
and O
45 O
minutes O
after O
dobutamine O
( O
- O
10 O
. O
8 O
( O
1 O
. O
8 O
) O
% O
and O
- O
5 O
. O
5 O
( O
1 O
. O
8 O
) O
% O
, O
both O
p O
< O
0 O
. O
01 O
) O
. O

regional O
analysis O
showed O
a O
reduction O
in O
the O
worst O
affected O
segment O
15 O
and O
30 O
minutes O
after O
exercise O
( O
- O
27 O
. O
9 O
( O
7 O
. O
2 O
) O
% O
and O
- O
28 O
. O
6 O
( O
5 O
. O
7 O
) O
% O
, O
both O
p O
< O
0 O
. O
01 O
) O
, O
and O
at O
30 O
minutes O
after O
dobutamine O
( O
- O
32 O
( O
5 O
. O
3 O
) O
% O
, O
p O
< O
0 O
. O
01 O
) O
. O

the O
isovolumic O
relaxation O
period O
was O
prolonged O
45 O
minutes O
after O
each O
form O
of O
stress O
( O
p O
< O
0 O
. O
05 O
) O
. O

conclusions O
: O
in O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
dobutamine O
induced O
ischaemia B-Disease
results O
in O
prolonged O
reversible O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
, O
presumed O
to O
be O
myocardial B-Disease
stunning I-Disease
, O
similar O
to O
that O
seen O
after O
exercise O
. O

dobutamine O
induced O
ischaemia B-Disease
could O
therefore O
be O
used O
to O
study O
the O
pathophysiology O
of O
this O
phenomenon O
further O
in O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
. O

anorexigens O
and O
pulmonary B-Disease
hypertension I-Disease
in O
the O
united O
states O
: O
results O
from O
the O
surveillance O
of O
north O
american O
pulmonary B-Disease
hypertension I-Disease
. O

background O
: O
the O
use O
of O
appetite O
suppressants O
in O
europe O
has O
been O
associated O
with O
the O
development O
of O
primary B-Disease
pulmonary I-Disease
hypertension I-Disease
( O
pph B-Disease
) O
. O

recently O
, O
fenfluramine O
appetite O
suppressants O
became O
widely O
used O
in O
the O
united O
states O
but O
were O
withdrawn O
in O
september O
1997 O
because O
of O
concerns O
over O
adverse O
effects O
. O

materials O
and O
methods O
: O
we O
conducted O
a O
prospective O
surveillance O
study O
on O
patients O
diagnosed O
with O
pulmonary B-Disease
hypertension I-Disease
at O
12 O
large O
referral O
centers O
in O
north O
america O
. O

data O
collected O
on O
patients O
seen O
from O
september O
1 O
, O
1996 O
, O
to O
december O
31 O
, O
1997 O
, O
included O
the O
cause O
of O
the O
pulmonary B-Disease
hypertension I-Disease
and O
its O
severity O
. O

patients O
with O
no O
identifiable O
cause O
of O
pulmonary B-Disease
hypertension I-Disease
were O
classed O
as O
pph B-Disease
. O

a O
history O
of O
drug O
exposure O
also O
was O
taken O
with O
special O
attention O
on O
the O
use O
of O
antidepressants O
, O
anorexigens O
, O
and O
amphetamines O
. O

results O
: O
five O
hundred O
seventy O
- O
nine O
patients O
were O
studied O
, O
205 O
with O
pph B-Disease
and O
374 O
with O
pulmonary B-Disease
hypertension I-Disease
from O
other O
causes O
( O
secondary O
pulmonary B-Disease
hypertension I-Disease
[ O
sph O
] O
) O
. O

the O
use O
of O
anorexigens O
was O
common O
in O
both O
groups O
. O

however O
, O
of O
the O
medications O
surveyed O
, O
only O
the O
fenfluramines O
had O
a O
significant O
preferential O
association O
with O
pph B-Disease
as O
compared O
with O
sph O
( O
adjusted O
odds O
ratio O
for O
use O
> O
6 O
months O
, O
7 O
. O
5 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O
7 O
to O
32 O
. O
4 O
) O
. O

the O
association O
was O
stronger O
with O
longer O
duration O
of O
use O
when O
compared O
to O
shorter O
duration O
of O
use O
and O
was O
more O
pronounced O
in O
recent O
users O
than O
in O
remote O
users O
. O

an O
unexpectedly O
high O
( O
11 O
. O
4 O
% O
) O
number O
of O
patients O
with O
sph O
had O
used O
anorexigens O
. O

conclusion O
: O
the O
magnitude O
of O
the O
association O
with O
pph B-Disease
, O
the O
increase O
of O
association O
with O
increasing O
duration O
of O
use O
, O
and O
the O
specificity O
for O
fenfluramines O
are O
consistent O
with O
previous O
studies O
indicating O
that O
fenfluramines O
are O
causally O
related O
to O
pph B-Disease
. O

the O
high O
prevalence O
of O
anorexigen O
use O
in O
patients O
with O
sph O
also O
raises O
the O
possibility O
that O
these O
drugs O
precipitate O
pulmonary B-Disease
hypertension I-Disease
in O
patients O
with O
underlying O
conditions O
associated O
with O
sph O
. O

clinical O
aspects O
of O
heparin O
- O
induced O
thrombocytopenia B-Disease
and O
thrombosis B-Disease
and O
other O
side O
effects O
of O
heparin O
therapy O
. O

heparin O
, O
first O
used O
to O
prevent O
the O
clotting O
of O
blood O
in O
vitro O
, O
has O
been O
clinically O
used O
to O
treat O
thrombosis B-Disease
for O
more O
than O
50 O
years O
. O

although O
several O
new O
anticoagulant O
drugs O
are O
in O
development O
, O
heparin O
remains O
the O
anticoagulant O
of O
choice O
to O
treat O
acute O
thrombotic B-Disease
episodes O
. O

the O
clinical O
effects O
of O
heparin O
are O
meritorious O
, O
but O
side O
effects O
do O
exist O
. O

bleeding B-Disease
is O
the O
primary O
untoward O
effect O
of O
heparin O
. O

major O
bleeding B-Disease
is O
of O
primary O
concern O
in O
patients O
receiving O
heparin O
therapy O
. O

however O
, O
additional O
important O
untoward O
effects O
of O
heparin O
therapy O
include O
heparin O
- O
induced O
thrombocytopenia B-Disease
, O
heparin O
- O
associated O
osteoporosis B-Disease
, O
eosinophilia B-Disease
, O
skin B-Disease
reactions I-Disease
, O
allergic B-Disease
reactions I-Disease
other O
than O
thrombocytopenia B-Disease
, O
alopecia B-Disease
, O
transaminasemia O
, O
hyperkalemia B-Disease
, O
hypoaldosteronism B-Disease
, O
and O
priapism B-Disease
. O

these O
side O
effects O
are O
relatively O
rare O
in O
a O
given O
individual O
, O
but O
given O
the O
extremely O
widespread O
use O
of O
heparin O
, O
some O
are O
quite O
common O
, O
particularly O
hitt B-Disease
and O
osteoporosis B-Disease
. O

although O
reasonable O
incidences O
of O
many O
of O
these O
side O
effects O
can O
be O
" O
softly O
" O
deduced O
from O
current O
reports O
dealing O
with O
unfractionated O
heparin O
, O
at O
present O
the O
incidences O
of O
these O
side O
effects O
with O
newer O
low O
molecular O
weight O
heparins O
appear O
to O
be O
much O
less O
common O
. O

however O
, O
only O
longer O
experience O
will O
more O
clearly O
define O
the O
incidence O
of O
each O
side O
effect O
with O
low O
molecular O
weight O
preparations O
. O

a O
case O
of O
bilateral O
optic B-Disease
neuropathy I-Disease
in O
a O
patient O
on O
tacrolimus O
( O
fk506 O
) O
therapy O
after O
liver O
transplantation O
. O

purpose O
: O
to O
report O
a O
case O
of O
bilateral O
optic B-Disease
neuropathy I-Disease
in O
a O
patient O
receiving O
tacrolimus O
( O
fk O
506 O
, O
prograf O
; O
fujisawa O
usa O
, O
inc O
, O
deerfield O
, O
illinois O
) O
for O
immunosuppression O
after O
orthotropic O
liver O
transplantation O
. O

method O
: O
case O
report O
. O

in O
a O
58 O
- O
year O
- O
old O
man O
receiving O
tacrolimus O
after O
orthotropic O
liver O
transplantation O
, O
serial O
neuro O
- O
ophthalmologic O
examinations O
and O
laboratory O
studies O
were O
performed O
. O

results O
: O
the O
patient O
had O
episodic O
deterioration O
of O
vision O
in O
both O
eyes O
, O
with O
clinical O
features O
resembling O
ischemic B-Disease
optic I-Disease
neuropathies I-Disease
. O

deterioration B-Disease
of I-Disease
vision I-Disease
occurred O
despite O
discontinuation O
of O
the O
tacrolimus O
. O

conclusion O
: O
tacrolimus O
and O
other O
immunosuppressive O
agents O
may O
be O
associated O
with O
optic B-Disease
nerve I-Disease
toxicity I-Disease
. O

hypercalcemia B-Disease
, O
arrhythmia B-Disease
, O
and O
mood O
stabilizers O
. O

recent O
findings O
in O
a O
bipolar B-Disease
patient O
receiving O
maintenance O
lithium O
therapy O
who O
developed O
hypercalcemia B-Disease
and O
severe O
bradyarrhythmia B-Disease
prompted O
the O
authors O
to O
conduct O
a O
retrospective O
study O
of O
bipolar B-Disease
patients O
with O
lithium O
- O
associated O
hypercalcemia B-Disease
. O

a O
printout O
of O
all O
cases O
of O
hypercalcemia B-Disease
that O
presented O
during O
a O
1 O
- O
year O
period O
was O
generated O
. O

after O
eliminating O
spurious O
hypercalcemias B-Disease
or O
those O
associated O
with O
intravenous O
fluids O
, O
the O
authors O
identified O
18 O
non O
- O
lithium O
- O
treated O
patients O
with O
hypercalcemias B-Disease
related O
to O
malignancies B-Disease
and O
other O
medical O
conditions O
( O
group O
a O
) O
and O
12 O
patients O
with O
lithium O
- O
associated O
hypercalcemia B-Disease
( O
group O
b O
) O
. O

patients O
in O
group O
b O
were O
not O
comparable O
to O
those O
in O
group O
a O
, O
as O
the O
latter O
were O
medically O
compromised O
and O
were O
receiving O
multiple O
pharmacotherapies O
. O

thus O
, O
two O
control O
groups O
were O
generated O
: O
group O
c1 O
, O
which O
included O
age O
- O
and O
sex O
- O
comparable O
lithium O
- O
treated O
bipolar B-Disease
normocalcemic O
patients O
, O
and O
group O
c2 O
, O
which O
included O
bipolar B-Disease
normocalcemic O
patients O
treated O
with O
anticonvulsant O
mood O
stabilizers O
. O

the O
electrocardiographic O
( O
ecg O
) O
findings O
for O
patients O
in O
group O
b O
were O
compared O
with O
those O
of O
patients O
in O
groups O
c1 O
and O
c2 O
. O

it O
was O
found O
that O
these O
groups O
did O
not O
differ O
in O
their O
overall O
frequency O
of O
ecg O
abnormalities O
; O
however O
, O
there O
were O
significant O
differences O
in O
the O
frequency O
of O
conduction O
defects O
. O

patients O
with O
hypercalcemia B-Disease
resulting O
from O
medical O
diseases O
and O
bipolar B-Disease
patients O
with O
lithium O
- O
associated O
hypercalcemia B-Disease
had O
significantly O
higher O
frequencies O
of O
conduction O
defects O
. O

patients O
in O
group O
a O
had O
significant O
mortality O
at O
2 O
- O
year O
follow O
- O
up O
( O
28 O
% O
) O
, O
in O
contrast O
to O
zero O
mortality O
in O
the O
other O
three O
groups O
. O

the O
clinical O
implications O
of O
these O
findings O
are O
discussed O
. O

attenuation O
of O
nephrotoxicity B-Disease
by O
a O
novel O
lipid O
nanosphere O
( O
ns O
- O
718 O
) O
incorporating O
amphotericin O
b O
. O

ns O
- O
718 O
, O
a O
lipid O
nanosphere O
incorporating O
amphotericin O
b O
, O
is O
effective O
against O
pathogenic O
fungi O
and O
has O
low O
toxicity B-Disease
. O

we O
compared O
the O
toxicity B-Disease
of O
ns O
- O
718 O
with O
that O
of O
fungizone O
( O
amphotericin O
b O
- O
sodium O
deoxycholate O
; O
d O
- O
amb O
) O
in O
vitro O
using O
renal O
cell O
cultures O
and O
in O
vivo O
by O
biochemical O
analysis O
, O
histopathological O
study O
of O
the O
kidney O
and O
pharmacokinetic O
study O
of O
amphotericin O
b O
following O
intravenous O
infusion O
of O
the O
formulation O
in O
rats O
. O

incubation O
with O
ns O
- O
718 O
resulted O
in O
significantly O
less O
damage O
of O
cultured O
human O
renal O
proximal O
tubular O
epithelial O
cells O
compared O
with O
d O
- O
amb O
. O

serum O
blood O
urea O
and O
creatinine O
concentrations O
increased O
significantly O
in O
rats O
given O
an O
iv O
infusion O
of O
d O
- O
amb O
3 O
mg O
/ O
kg O
but O
not O
in O
those O
given O
the O
same O
dose O
of O
ns O
- O
718 O
. O

histopathological O
examination O
of O
the O
kidney O
showed O
tubular B-Disease
necrosis I-Disease
in O
d O
- O
amb O
- O
treated O
rats O
but O
no O
change O
in O
ns O
- O
718 O
- O
treated O
rats O
. O

amphotericin O
b O
concentrations O
in O
the O
kidney O
in O
ns O
- O
718 O
- O
treated O
rats O
were O
higher O
than O
those O
in O
d O
- O
amb O
- O
treated O
rats O
. O

our O
in O
vitro O
and O
in O
vivo O
results O
suggest O
that O
incorporation O
of O
amphotericin O
b O
into O
lipid O
nanospheres O
of O
ns O
- O
718 O
attenuates O
the O
nephrotoxicity B-Disease
of O
amphotericin O
b O
. O

patterns O
of O
sulfadiazine O
acute B-Disease
nephrotoxicity I-Disease
. O

sulfadiazine O
acute B-Disease
nephrotoxicity I-Disease
is O
reviving O
specially O
because O
of O
its O
use O
in O
toxoplasmosis B-Disease
in O
hiv O
- O
positive O
patients O
. O

we O
report O
4 O
cases O
, O
one O
of O
them O
in O
a O
previously O
healthy O
person O
. O

under O
treatment O
with O
sulfadiazine O
they O
developed O
oliguria B-Disease
, O
abdominal B-Disease
pain I-Disease
, O
renal B-Disease
failure I-Disease
and O
showed O
multiple O
radiolucent O
renal B-Disease
calculi I-Disease
in O
echography O
. O

all O
patients O
recovered O
their O
previous O
normal O
renal O
function O
after O
adequate O
hydration O
and O
alcalinization O
. O

a O
nephrostomy O
tube O
had O
to O
be O
placed O
in O
one O
of O
the O
patients O
for O
ureteral B-Disease
lithiasis I-Disease
in O
a O
single O
functional O
kidney O
. O

none O
of O
them O
needed O
dialysis O
or O
a O
renal O
biopsy O
because O
of O
a O
typical O
benign O
course O
. O

treatment O
with O
sulfadiazine O
requires O
exquisite O
control O
of O
renal O
function O
, O
an O
increase O
in O
water O
ingestion O
and O
possibly O
the O
alcalinization O
of O
the O
urine O
. O

we O
communicate O
a O
case O
in O
a O
previously O
healthy O
person O
, O
a O
fact O
not O
found O
in O
the O
recent O
literature O
. O

probably O
many O
more O
cases O
are O
not O
detected O
. O

we O
think O
that O
a O
prospective O
study O
would O
be O
useful O
. O

downbeat B-Disease
nystagmus I-Disease
associated O
with O
intravenous O
patient O
- O
controlled O
administration O
of O
morphine O
. O

implications O
: O
this O
case O
documents O
a O
patient O
who O
developed O
dizziness B-Disease
with O
downbeating B-Disease
nystagmus I-Disease
while O
receiving O
a O
relatively O
large O
dose O
of O
iv O
patient O
- O
controlled O
analgesia O
morphine O
. O

although O
there O
have O
been O
case O
reports O
of O
epidural O
morphine O
with O
these O
symptoms O
and O
signs O
, O
this O
has O
not O
been O
previously O
documented O
with O
iv O
or O
patient O
- O
controlled O
analgesia O
morphine O
. O

hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone O
and O
amiodarone O
in O
animals O
with O
a O
healed O
myocardial B-Disease
infarction I-Disease
. O

the O
hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone O
, O
a O
noniodinated O
compound O
structurally O
related O
to O
amiodarone O
, O
were O
compared O
with O
those O
of O
amiodarone O
after O
prolonged O
oral O
administration O
, O
both O
at O
rest O
and O
during O
sympathetic O
stimulation O
in O
conscious O
dogs O
with O
a O
healed O
myocardial B-Disease
infarction I-Disease
. O

all O
dogs O
( O
n O
= O
6 O
) O
randomly O
received O
orally O
dronedarone O
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
, O
amiodarone O
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
, O
and O
placebo O
twice O
daily O
for O
7 O
days O
, O
with O
a O
3 O
- O
week O
washout O
between O
consecutive O
treatments O
. O

heart O
rate O
( O
hr O
) O
, O
mean O
arterial O
pressure O
( O
mbp O
) O
, O
positive O
rate O
of O
increase O
of O
left O
ventricular O
pressure O
( O
+ O
lvdp O
/ O
dt O
) O
, O
echocardiographically O
assessed O
left O
ventricular O
ejection O
fraction O
( O
lvef O
) O
, O
and O
fractional O
shortening O
( O
fs O
) O
, O
as O
well O
as O
chronotropic O
response O
to O
isoproterenol O
and O
exercise O
- O
induced O
sympathetic O
stimulation O
were O
evaluated O
under O
baseline O
and O
posttreatment O
conditions O
. O

resting O
values O
of O
lvef O
, O
fs O
, O
+ O
lvdp O
/ O
dt O
, O
and O
mbp O
remained O
unchanged O
whatever O
the O
drug O
and O
the O
dosing O
regimen O
, O
whereas O
resting O
hr O
was O
significantly O
and O
dose O
- O
dependently O
lowered O
after O
dronedarone O
and O
to O
a O
lesser O
extent O
after O
amiodarone O
. O

both O
dronedarone O
and O
amiodarone O
significantly O
reduced O
the O
exercise O
- O
induced O
tachycardia B-Disease
and O
, O
at O
the O
highest O
dose O
, O
decreased O
the O
isoproterenol O
- O
induced O
tachycardia B-Disease
. O

thus O
, O
dronedarone O
and O
amiodarone O
displayed O
a O
similar O
level O
of O
antiadrenergic O
effect O
and O
did O
not O
impair O
the O
resting O
left O
ventricular O
function O
. O

consequently O
, O
dronedarone O
might O
be O
particularly O
suitable O
for O
the O
treatment O
and O
prevention O
of O
various O
clinical O
arrhythmias B-Disease
, O
without O
compromising O
the O
left O
ventricular O
function O
. O

phase O
2 O
trial O
of O
liposomal O
doxorubicin O
( O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
in O
platinum O
/ O
paclitaxel O
- O
refractory O
ovarian B-Disease
and I-Disease
fallopian I-Disease
tube I-Disease
cancers I-Disease
and O
primary O
carcinoma B-Disease
of I-Disease
the I-Disease
peritoneum I-Disease
. O

background O
: O
several O
studies O
have O
demonstrated O
liposomal O
doxorubicin O
( O
doxil O
) O
to O
be O
an O
active O
antineoplastic O
agent O
in O
platinum O
- O
resistant O
ovarian B-Disease
cancer I-Disease
, O
with O
dose O
limiting O
toxicity B-Disease
of O
the O
standard O
dosing O
regimen O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
) O
being O
severe O
erythrodysesthesia B-Disease
( O
" O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
" O
) O
and O
stomatitis B-Disease
. O

we O
wished O
to O
develop O
a O
more O
tolerable O
liposomal O
doxorubicin O
treatment O
regimen O
and O
document O
its O
level O
of O
activity O
in O
a O
well O
- O
defined O
patient O
population O
with O
platinum O
/ O
paclitaxel O
- O
refractory O
disease O
. O

methods O
and O
materials O
: O
patients O
with O
ovarian B-Disease
or I-Disease
fallopian I-Disease
tube I-Disease
cancers I-Disease
or O
primary O
peritoneal B-Disease
carcinoma I-Disease
with O
platinum O
/ O
paclitaxel O
- O
refractory O
disease O
( O
stable O
or O
progressive O
disease O
following O
treatment O
with O
these O
agents O
or O
previous O
objective O
response O
< O
3 O
months O
in O
duration O
) O
were O
treated O
with O
liposomal O
doxorubicin O
at O
a O
dose O
of O
40 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
. O

results O
: O
a O
total O
of O
49 O
patients O
( O
median O
age O
: O
60 O
; O
range O
41 O
- O
81 O
) O
entered O
this O
phase O
2 O
trial O
. O

the O
median O
number O
of O
prior O
regimens O
was O
2 O
( O
range O
: O
1 O
- O
6 O
) O
. O

six O
( O
12 O
% O
) O
and O
4 O
( O
8 O
% O
) O
patients O
experienced O
grade O
2 O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
and O
stomatitis B-Disease
, O
respectively O
( O
no O
episodes O
of O
grade O
3 O
) O
. O

one O
patient O
developed O
grade O
3 O
diarrhea B-Disease
requiring O
hospitalization O
for O
hydration O
. O

six O
( O
12 O
% O
) O
individuals O
required O
dose O
reductions O
. O

the O
median O
number O
of O
courses O
of O
liposomal O
doxorubicin O
administered O
on O
this O
protocol O
was O
2 O
( O
range O
: O
1 O
- O
12 O
) O
. O

four O
of O
44 O
patients O
( O
9 O
% O
) O
evaluable O
for O
response O
exhibited O
objective O
and O
subjective O
evidence O
of O
an O
antineoplastic O
effect O
of O
therapy O
. O

conclusion O
: O
this O
modified O
liposomal O
doxorubicin O
regimen O
results O
in O
less O
toxicity B-Disease
( O
stomatitis B-Disease
, O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
) O
than O
the O
standard O
fda O
- O
approved O
dose O
schedule O
. O

definite O
, O
although O
limited O
, O
antineoplastic O
activity O
is O
observed O
in O
patients O
with O
well O
- O
defined O
platinum O
- O
and O
paclitaxel O
- O
refractory O
ovarian B-Disease
cancer I-Disease
. O

efficacy O
of O
olanzapine O
in O
acute O
bipolar B-Disease
mania I-Disease
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
. O

the O
olanzipine O
hggw O
study O
group O
. O

background O
: O
we O
compared O
the O
efficacy O
and O
safety O
of O
olanzapine O
vs O
placebo O
for O
the O
treatment O
of O
acute O
bipolar B-Disease
mania I-Disease
. O

methods O
: O
four O
- O
week O
, O
randomized O
, O
double O
- O
blind O
, O
parallel O
study O
. O

a O
total O
of O
115 O
patients O
with O
a O
dsm O
- O
iv O
diagnosis O
of O
bipolar B-Disease
disorder I-Disease
, O
manic B-Disease
or O
mixed O
, O
were O
randomized O
to O
olanzapine O
, O
5 O
to O
20 O
mg O
/ O
d O
( O
n O
= O
55 O
) O
, O
or O
placebo O
( O
n O
= O
60 O
) O
. O

the O
primary O
efficacy O
measure O
was O
the O
young O
- O
mania B-Disease
rating O
scale O
( O
y O
- O
mrs O
) O
total O
score O
. O

response O
and O
euthymia O
were O
defined O
, O
a O
priori O
, O
as O
at O
least O
a O
50 O
% O
improvement O
from O
baseline O
to O
end O
point O
and O
as O
a O
score O
of O
no O
less O
than O
12 O
at O
end O
point O
in O
the O
y O
- O
mrs O
total O
score O
, O
respectively O
. O

safety O
was O
assessed O
using O
adverse O
events O
, O
extrapyramidal B-Disease
symptom I-Disease
( O
eps B-Disease
) O
rating O
scales O
, O
laboratory O
values O
, O
electrocardiograms O
, O
vital O
signs O
, O
and O
weight O
change O
. O

results O
: O
olanzapine O
- O
treated O
patients O
demonstrated O
a O
statistically O
significant O
greater O
mean O
( O
+ O
/ O
- O
sd O
) O
improvement O
in O
y O
- O
mrs O
total O
score O
than O
placebo O
- O
treated O
patients O
( O
- O
14 O
. O
8 O
+ O
/ O
- O
12 O
. O
5 O
and O
- O
8 O
. O
1 O
+ O
/ O
- O
12 O
. O
7 O
, O
respectively O
; O
p O
< O
. O
001 O
) O
, O
which O
was O
evident O
at O
the O
first O
postbaseline O
observation O
1 O
week O
after O
randomization O
and O
was O
maintained O
throughout O
the O
study O
( O
last O
observation O
carried O
forward O
) O
. O

olanzapine O
- O
treated O
patients O
demonstrated O
a O
higher O
rate O
of O
response O
( O
65 O
% O
vs O
43 O
% O
, O
respectively O
; O
p O
= O
. O
02 O
) O
and O
euthymia O
( O
61 O
% O
vs O
36 O
% O
, O
respectively O
; O
p O
= O
. O
01 O
) O
than O
placebo O
- O
treated O
patients O
. O

there O
were O
no O
statistically O
significant O
differences O
in O
epss B-Disease
between O
groups O
. O

however O
, O
olanzapine O
- O
treated O
patients O
had O
a O
statistically O
significant O
greater O
mean O
( O
+ O
/ O
- O
sd O
) O
weight B-Disease
gain I-Disease
than O
placebo O
- O
treated O
patients O
( O
2 O
. O
1 O
+ O
/ O
- O
2 O
. O
8 O
vs O
0 O
. O
45 O
+ O
/ O
- O
2 O
. O
3 O
kg O
, O
respectively O
) O
and O
also O
experienced O
more O
treatment O
- O
emergent O
somnolence B-Disease
( O
21 O
patients O
[ O
38 O
. O
2 O
% O
] O
vs O
5 O
[ O
8 O
. O
3 O
% O
] O
, O
respectively O
) O
. O

conclusion O
: O
olanzapine O
demonstrated O
greater O
efficacy O
than O
placebo O
in O
the O
treatment O
of O
acute O
bipolar B-Disease
mania I-Disease
and O
was O
generally O
well O
tolerated O
. O

the O
effect O
of O
pupil B-Disease
dilation I-Disease
with O
tropicamide O
on O
vision O
and O
driving O
simulator O
performance O
. O

purpose O
: O
to O
assess O
the O
effect O
of O
pupil B-Disease
dilation I-Disease
on O
vision O
and O
driving O
ability O
. O

methods O
: O
a O
series O
of O
tests O
on O
various O
parameters O
of O
visual O
function O
and O
driving O
simulator O
performance O
were O
performed O
on O
12 O
healthy O
drivers O
, O
before O
and O
after O
pupil B-Disease
dilation I-Disease
using O
guttae O
tropicamide O
1 O
% O
. O

a O
driving O
simulator O
( O
transport O
research O
laboratory O
) O
was O
used O
to O
measure O
reaction O
time O
( O
rt O
) O
, O
speed O
maintenance O
and O
steering O
accuracy O
. O

tests O
of O
basic O
visual O
function O
included O
high O
- O
and O
low O
- O
contrast O
visual O
acuity O
( O
hcva O
and O
lcva O
) O
, O
pelli O
- O
robson O
contrast O
threshold O
( O
ct O
) O
and O
goldmann O
perimetry O
( O
fields O
) O
. O

useful O
field O
of O
view O
( O
ufov O
- O
- O
a O
test O
of O
visual O
attention O
) O
was O
also O
undertaken O
. O

the O
mean O
differences O
in O
the O
pre O
- O
and O
post O
- O
dilatation O
measurements O
were O
tested O
for O
statistical O
significance O
at O
the O
95 O
% O
level O
using O
one O
- O
tail O
paired O
t O
- O
tests O
. O

results O
: O
pupillary B-Disease
dilation I-Disease
resulted O
in O
a O
statistically O
significant O
deterioration O
in O
ct O
and O
hcva O
only O
. O

five O
of O
12 O
drivers O
also O
exhibited O
deterioration O
in O
lcva O
, O
ct O
and O
rt O
. O

little O
evidence O
emerged O
for O
deterioration O
in O
fields O
and O
ufov O
. O

also O
, O
7 O
of O
12 O
drivers O
appeared O
to O
adjust O
their O
driving O
behaviour O
by O
reducing O
their O
speed O
on O
the O
driving O
simulator O
, O
leading O
to O
improved O
steering O
accuracy O
. O

conclusions O
: O
pupillary B-Disease
dilation I-Disease
may O
lead O
to O
a O
decrease O
in O
vision O
and O
daylight O
driving O
performance O
in O
young O
people O
. O

a O
larger O
study O
, O
including O
a O
broader O
spectrum O
of O
subjects O
, O
is O
warranted O
before O
guidelines O
can O
be O
recommended O
. O

a O
case O
of O
isotretinoin B-Disease
embryopathy I-Disease
with O
bilateral O
anotia B-Disease
and O
taussig B-Disease
- I-Disease
bing I-Disease
malformation I-Disease
. O

we O
report O
a O
newborn O
infant O
with O
multiple O
congenital O
anomalies O
( O
anotia B-Disease
and O
taussig B-Disease
- I-Disease
bing I-Disease
malformation I-Disease
) O
due O
to O
exposure O
to O
isotretinoin O
within O
the O
first O
trimester O
. O

in O
this O
paper O
we O
aim O
to O
draw O
to O
the O
fact O
that O
caution O
is O
needed O
when O
prescribing O
vitamin O
a O
- O
containing O
drugs O
to O
women O
of O
childbearing O
years O
. O

effect O
of O
methoxamine O
on O
maximum O
urethral O
pressure O
in O
women O
with O
genuine O
stress B-Disease
incontinence I-Disease
: O
a O
placebo O
- O
controlled O
, O
double O
- O
blind O
crossover O
study O
. O

the O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
potential O
role O
for O
a O
selective O
alpha1 O
- O
adrenoceptor O
agonist O
in O
the O
treatment O
of O
urinary B-Disease
stress I-Disease
incontinence I-Disease
. O

a O
randomised O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
crossover O
study O
design O
was O
employed O
. O

half O
log O
incremental O
doses O
of O
intravenous O
methoxamine O
or O
placebo O
( O
saline O
) O
were O
administered O
to O
a O
group O
of O
women O
with O
genuine O
stress B-Disease
incontinence I-Disease
while O
measuring O
maximum O
urethral O
pressure O
( O
mup O
) O
, O
blood O
pressure O
, O
heart O
rate O
, O
and O
symptomatic O
side O
effects O
. O

methoxamine O
evoked O
non O
- O
significant O
increases O
in O
mup O
and O
diastolic O
blood O
pressure O
but O
caused O
a B-Disease
significant I-Disease
rise I-Disease
in I-Disease
systolic I-Disease
blood I-Disease
pressure I-Disease
and O
significant O
fall O
in O
heart O
rate O
at O
maximum O
dosage O
. O

systemic O
side O
effects O
including O
piloerection O
, O
headache B-Disease
, O
and O
cold O
extremities O
were O
experienced O
in O
all O
subjects O
. O

the O
results O
indicate O
that O
the O
clinical O
usefulness O
of O
direct O
, O
peripherally O
acting O
sub O
- O
type O
- O
selective O
alpha1 O
- O
adrenoceptor O
agonists O
in O
the O
medical O
treatment O
of O
stress B-Disease
incontinence I-Disease
may O
be O
limited O
by O
associated O
piloerection O
and O
cardiovascular O
side O
effects O
. O

hyperglycemic B-Disease
effect O
of O
amino O
compounds O
structurally O
related O
to O
caproate O
in O
rats O
. O

the O
chronic O
feeding O
of O
small O
amounts O
( O
0 O
. O
3 O
- O
3 O
% O
of O
diet O
weight O
) O
of O
certain O
amino O
derivatives O
of O
caproate O
resulted O
in O
hyperglycemia B-Disease
, O
an O
elevated O
glucose O
tolerance O
curve O
and O
, O
occasionally O
, O
glucosuria B-Disease
. O

effective O
compounds O
included O
norleucine O
, O
norvaline O
, O
glutamate O
, O
epsilon O
- O
aminocaproate O
, O
methionine O
, O
and O
leucine O
. O

toleration O
of O
high O
doses O
of O
angiotensin O
- O
converting O
enzyme O
inhibitors O
in O
patients O
with O
chronic O
heart B-Disease
failure I-Disease
: O
results O
from O
the O
atlas O
trial O
. O

the O
assessment O
of O
treatment O
with O
lisinopril O
and O
survival O
. O

background O
: O
treatment O
with O
angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
inhibitors O
reduces O
mortality O
and O
morbidity O
in O
patients O
with O
chronic O
heart B-Disease
failure I-Disease
( O
chf B-Disease
) O
, O
but O
most O
affected O
patients O
are O
not O
receiving O
these O
agents O
or O
are O
being O
treated O
with O
doses O
lower O
than O
those O
found O
to O
be O
efficacious O
in O
trials O
, O
primarily O
because O
of O
concerns O
about O
the O
safety O
and O
tolerability O
of O
these O
agents O
, O
especially O
at O
the O
recommended O
doses O
. O

the O
present O
study O
examines O
the O
safety O
and O
tolerability O
of O
high O
- O
compared O
with O
low O
- O
dose O
lisinopril O
in O
chf B-Disease
. O

methods O
: O
the O
assessment O
of O
lisinopril O
and O
survival O
study O
was O
a O
multicenter O
, O
randomized O
, O
double O
- O
blind O
trial O
in O
which O
patients O
with O
or O
without O
previous O
ace O
inhibitor O
treatment O
were O
stabilized O
receiving O
medium O
- O
dose O
lisinopril O
( O
12 O
. O
5 O
or O
15 O
. O
0 O
mg O
once O
daily O
[ O
od O
] O
) O
for O
2 O
to O
4 O
weeks O
and O
then O
randomized O
to O
high O
- O
( O
35 O
. O
0 O
or O
32 O
. O
5 O
mg O
od O
) O
or O
low O
- O
dose O
( O
5 O
. O
0 O
or O
2 O
. O
5 O
mg O
od O
) O
groups O
. O

patients O
with O
new O
york O
heart O
association O
classes O
ii O
to O
iv O
chf B-Disease
and O
left O
ventricular O
ejection O
fractions O
of O
no O
greater O
than O
0 O
. O
30 O
( O
n O
= O
3164 O
) O
were O
randomized O
and O
followed O
up O
for O
a O
median O
of O
46 O
months O
. O

we O
examined O
the O
occurrence O
of O
adverse O
events O
and O
the O
need O
for O
discontinuation O
and O
dose O
reduction O
during O
treatment O
, O
with O
a O
focus O
on O
hypotension B-Disease
and O
renal B-Disease
dysfunction I-Disease
. O

results O
: O
of O
405 O
patients O
not O
previously O
receiving O
an O
ace O
inhibitor O
, O
doses O
in O
only O
4 O
. O
2 O
% O
could O
not O
be O
titrated O
to O
the O
medium O
doses O
required O
for O
randomization O
because O
of O
symptoms O
possibly O
related O
to O
hypotension B-Disease
( O
2 O
. O
0 O
% O
) O
or O
because O
of O
renal B-Disease
dysfunction I-Disease
or O
hyperkalemia B-Disease
( O
2 O
. O
3 O
% O
) O
. O

doses O
in O
more O
than O
90 O
% O
of O
randomized O
patients O
in O
the O
high O
- O
and O
low O
- O
dose O
groups O
were O
titrated O
to O
their O
assigned O
target O
, O
and O
the O
mean O
doses O
of O
blinded O
medication O
in O
both O
groups O
remained O
similar O
throughout O
the O
study O
. O

withdrawals O
occurred O
in O
27 O
. O
1 O
% O
of O
the O
high O
- O
and O
30 O
. O
7 O
% O
of O
the O
low O
- O
dose O
groups O
. O

subgroups O
presumed O
to O
be O
at O
higher O
risk O
for O
ace O
inhibitor O
intolerance O
( O
blood O
pressure O
, O
< O
120 O
mm O
hg O
; O
creatinine O
, O
> O
or O
= O
132 O
. O
6 O
micromol O
/ O
l O
[ O
> O
or O
= O
1 O
. O
5 O
mg O
/ O
dl O
] O
; O
age O
, O
> O
or O
= O
70 O
years O
; O
and O
patients O
with O
diabetes B-Disease
) O
generally O
tolerated O
the O
high O
- O
dose O
strategy O
. O

conclusions O
: O
these O
findings O
demonstrate O
that O
ace O
inhibitor O
therapy O
in O
most O
patients O
with O
chf B-Disease
can O
be O
successfully O
titrated O
to O
and O
maintained O
at O
high O
doses O
, O
and O
that O
more O
aggressive O
use O
of O
these O
agents O
is O
warranted O
. O

cocaine O
, O
ethanol O
, O
and O
cocaethylene O
cardiotoxity B-Disease
in O
an O
animal O
model O
of O
cocaine B-Disease
and I-Disease
ethanol I-Disease
abuse I-Disease
. O

objectives O
: O
simultaneous O
abuse B-Disease
of I-Disease
cocaine I-Disease
and I-Disease
ethanol I-Disease
affects O
12 O
million O
americans O
annually O
. O

in O
combination O
, O
these O
substances O
are O
substantially O
more O
toxic O
than O
either O
drug O
alone O
. O

their O
combined O
cardiac B-Disease
toxicity I-Disease
may O
be O
due O
to O
independent O
effects O
of O
each O
drug O
; O
however O
, O
they O
may O
also O
be O
due O
to O
cocaethylene O
( O
ce O
) O
, O
a O
cocaine O
metabolite O
formed O
only O
in O
the O
presence O
of O
ethanol O
. O

the O
purpose O
of O
this O
study O
was O
to O
delineate O
the O
role O
of O
ce O
in O
the O
combined O
cardiotoxicity B-Disease
of O
cocaine O
and O
ethanol O
in O
a O
model O
simulating O
their O
abuse O
. O

methods O
: O
twenty O
- O
three O
dogs O
were O
randomized O
to O
receive O
either O
1 O
) O
three O
intravenous O
( O
iv O
) O
boluses O
of O
cocaine O
7 O
. O
5 O
mg O
/ O
kg O
with O
ethanol O
( O
1 O
g O
/ O
kg O
) O
as O
an O
iv O
infusion O
( O
c O
+ O
e O
, O
n O
= O
8 O
) O
, O
2 O
) O
three O
cocaine O
boluses O
only O
( O
c O
, O
n O
= O
6 O
) O
, O
3 O
) O
ethanol O
infusion O
only O
( O
e O
, O
n O
= O
5 O
) O
, O
or O
4 O
) O
placebo O
boluses O
and O
infusion O
( O
n O
= O
4 O
) O
. O

hemodynamic O
measurements O
, O
electrocardiograms O
, O
and O
serum O
drug O
concentrations O
were O
obtained O
at O
baseline O
, O
and O
then O
at O
fixed O
time O
intervals O
after O
each O
drug O
was O
administered O
. O

results O
: O
two O
of O
eight O
dogs O
in O
the O
c O
+ O
e O
group O
experienced O
cardiovascular B-Disease
collapse I-Disease
. O

the O
most O
dramatic O
hemodynamic O
changes O
occurred O
after O
each O
cocaine O
bolus O
in O
the O
c O
+ O
e O
and O
c O
only O
groups O
; O
however O
, O
persistent O
hemodynamic O
changes O
occurred O
in O
the O
c O
+ O
e O
group O
. O

peak O
ce O
levels O
were O
associated O
with O
a O
45 O
% O
( O
sd O
+ O
/ O
- O
22 O
% O
, O
95 O
% O
ci O
= O
22 O
% O
to O
69 O
% O
) O
decrease B-Disease
in I-Disease
cardiac I-Disease
output I-Disease
( O
p O
< O
0 O
. O
05 O
) O
, O
a O
56 O
% O
( O
sd O
+ O
/ O
- O
23 O
% O
, O
95 O
% O
ci O
= O
32 O
% O
to O
80 O
% O
) O
decrease O
in O
dp O
/ O
dt O
( O
max O
) O
( O
p O
< O
. O
006 O
) O
, O
and O
a O
23 O
% O
( O
sd O
+ O
/ O
- O
15 O
% O
, O
95 O
% O
ci O
= O
7 O
% O
to O
49 O
% O
) O
decrease O
in O
svo O
( O
2 O
) O
( O
p O
< O
0 O
. O
025 O
) O
. O

ventricular B-Disease
arrhythmias I-Disease
were O
primarily O
observed O
in O
the O
c O
+ O
e O
group O
, O
in O
which O
four O
of O
eight O
dogs O
experienced O
ventricular B-Disease
tachycardia I-Disease
. O

conclusions O
: O
cocaine O
and O
ethanol O
in O
combination O
were O
more O
toxic O
than O
either O
substance O
alone O
. O

co O
- O
administration O
resulted O
in O
prolonged O
cardiac B-Disease
toxicity I-Disease
and O
was O
dysrhythmogenic O
. O

peak O
serum O
cocaethylene O
concentrations O
were O
associated O
with O
prolonged O
myocardial B-Disease
depression I-Disease
. O

worsening O
of O
parkinsonism B-Disease
after O
the O
use O
of O
veralipride O
for O
treatment O
of O
menopause O
: O
case O
report O
. O

we O
describe O
a O
female O
patient O
with O
stable O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
who O
has O
shown O
a O
marked O
worsening O
of O
her O
motor O
functions O
following O
therapy O
of O
menopause O
related O
symptoms O
with O
veralipride O
, O
as O
well O
as O
the O
improvement O
of O
her O
symptoms O
back O
to O
baseline O
after O
discontinuation O
of O
the O
drug O
. O

we O
emphasize O
the O
anti O
- O
dopaminergic O
effect O
of O
veralipride O
. O

viracept O
and O
irregular B-Disease
heartbeat I-Disease
warning O
. O

a O
group O
of O
doctors O
in O
boston O
warn O
that O
the O
protease O
inhibitor O
viracept O
may O
cause O
an O
irregular B-Disease
heart I-Disease
beat I-Disease
, O
known O
as O
bradycardia B-Disease
, O
in O
people O
with O
hiv O
. O

bradycardia B-Disease
occurred O
in O
a O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
viracept O
in O
combination O
with O
other O
anti O
- O
hiv O
drugs O
. O

the O
symptoms O
ceased O
after O
switching O
to O
another O
drug O
combination O
. O

frequency O
of O
appearance O
of O
myeloperoxidase O
- O
antineutrophil O
cytoplasmic O
antibody O
( O
mpo O
- O
anca O
) O
in O
graves B-Disease
' I-Disease
disease I-Disease
patients O
treated O
with O
propylthiouracil O
and O
the O
relationship O
between O
mpo O
- O
anca O
and O
clinical O
manifestations O
. O

objective O
: O
myeloperoxidase O
antineutrophil O
cytoplasmic O
antibody O
( O
mpo O
- O
anca O
) O
- O
positive O
vasculitis B-Disease
has O
been O
reported O
in O
patients O
with O
graves B-Disease
' I-Disease
disease I-Disease
who O
were O
treated O
with O
propylthiouracil O
( O
ptu O
) O
. O

the O
appearance O
of O
mpo O
- O
anca O
in O
these O
cases O
was O
suspected O
of O
being O
related O
to O
ptu O
because O
the O
titres O
of O
mpo O
- O
anca O
decreased O
when O
ptu O
was O
stopped O
. O

nevertheless O
, O
there O
have O
been O
no O
studies O
on O
the O
temporal O
relationship O
between O
the O
appearance O
of O
mpo O
- O
anca O
and O
vasculitis B-Disease
during O
ptu O
therapy O
, O
or O
on O
the O
incidence O
of O
mpo O
- O
anca O
in O
untreated O
graves B-Disease
' I-Disease
disease I-Disease
patients O
. O

therefore O
, O
we O
sought O
to O
address O
these O
parameters O
in O
patients O
with O
graves B-Disease
' I-Disease
disease I-Disease
. O

patients O
: O
we O
investigated O
102 O
untreated O
patients O
with O
hyperthyroidism B-Disease
due O
to O
graves B-Disease
' I-Disease
disease I-Disease
for O
the O
presence O
of O
mpo O
- O
anca O
, O
and O
for O
the O
development O
vasculitis B-Disease
after O
starting O
ptu O
therapy O
. O

twenty O
- O
nine O
of O
them O
were O
later O
excluded O
because O
of O
adverse O
effects O
of O
ptu O
or O
because O
the O
observation O
period O
was O
less O
than O
3 O
months O
. O

the O
remaining O
73 O
patients O
( O
55 O
women O
and O
18 O
men O
) O
, O
all O
of O
whom O
were O
examined O
for O
more O
than O
3 O
months O
, O
were O
adopted O
as O
the O
subjects O
of O
the O
investigation O
. O

the O
median O
observation O
period O
was O
23 O
. O
6 O
months O
( O
range O
: O
3 O
- O
37 O
months O
) O
. O

measurements O
: O
mpo O
- O
anca O
was O
measured O
at O
intervals O
of O
2 O
- O
6 O
months O
. O

results O
: O
before O
treatment O
, O
the O
mpo O
- O
anca O
titres O
of O
all O
102 O
untreated O
graves B-Disease
' I-Disease
disease I-Disease
patients O
were O
within O
the O
reference O
range O
( O
below O
10 O
u O
/ O
ml O
) O
. O

three O
( O
4 O
. O
1 O
% O
) O
of O
the O
73 O
patients O
were O
positive O
for O
mpo O
- O
anca O
at O
13 O
, O
16 O
and O
17 O
months O
, O
respectively O
, O
after O
the O
start O
of O
ptu O
therapy O
. O

in O
two O
of O
them O
, O
the O
mpo O
- O
anca O
titres O
transiently O
increased O
to O
12 O
. O
8 O
and O
15 O
. O
0 O
u O
/ O
ml O
, O
respectively O
, O
despite O
continued O
ptu O
therapy O
, O
but O
no O
vasculitic B-Disease
disorders I-Disease
developed O
. O

in O
the O
third O
patient O
, O
the O
mpo O
- O
anca O
titre O
increased O
to O
204 O
u O
/ O
ml O
and O
she O
developed O
a O
higher O
fever B-Disease
, O
oral B-Disease
ulcers I-Disease
and O
polyarthralgia B-Disease
, O
but O
the O
symptoms O
resolved O
2 O
weeks O
after O
stopping O
ptu O
therapy O
, O
and O
the O
mpo O
- O
anca O
titre O
decreased O
to O
20 O
. O
7 O
u O
/ O
ml O
by O
4 O
months O
after O
discontinuing O
ptu O
. O

conclusions O
: O
ptu O
therapy O
may O
be O
related O
to O
the O
appearance O
of O
mpo O
- O
anca O
, O
but O
mpo O
- O
anca O
does O
not O
appear O
to O
be O
closely O
related O
to O
vasculitis B-Disease
. O

prevalence O
of O
heart B-Disease
disease I-Disease
in O
asymptomatic O
chronic O
cocaine O
users O
. O

to O
determine O
the O
prevalence O
of O
heart B-Disease
disease I-Disease
in O
outpatient O
young O
asymptomatic O
chronic O
cocaine O
users O
, O
35 O
cocaine O
users O
and O
32 O
age O
- O
matched O
controls O
underwent O
resting O
and O
exercise O
electrocardiography O
( O
ecg O
) O
and O
doppler O
echocardiography O
. O

findings O
consistent O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
were O
detected O
in O
12 O
( O
34 O
% O
) O
patients O
and O
3 O
( O
9 O
% O
) O
controls O
( O
p O
= O
0 O
. O
01 O
) O
. O

decreased O
left O
ventricular O
systolic O
function O
was O
demonstrated O
in O
5 O
( O
14 O
% O
) O
patients O
, O
but O
in O
none O
of O
the O
controls O
( O
p O
= O
0 O
. O
055 O
) O
. O

finally O
, O
resting O
and O
peak O
exercise O
abnormal B-Disease
left I-Disease
ventricular I-Disease
filling I-Disease
was O
detected O
in O
38 O
and O
35 O
% O
of O
patients O
as O
compared O
to O
19 O
and O
9 O
% O
of O
controls O
, O
respectively O
( O
p O
= O
0 O
. O
11 O
and O
0 O
. O
02 O
, O
respectively O
) O
. O

we O
conclude O
that O
coronary B-Disease
artery I-Disease
or I-Disease
myocardial I-Disease
disease I-Disease
is O
common O
( O
38 O
% O
) O
in O
young O
asymptomatic O
chronic O
cocaine O
users O
. O

therefore O
, O
screening O
ecg O
and O
echocardiography O
may O
be O
warranted O
in O
these O
patients O
. O

cardioprotective O
effects O
of O
picrorrhiza O
kurroa O
against O
isoproterenol O
- O
induced O
myocardial O
stress O
in O
rats O
. O

the O
cardioprotective O
effect O
of O
the O
ethanol O
extract O
of O
picrorrhiza O
kurroa O
rhizomes O
and O
roots O
( O
pk O
) O
on O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
with O
respect O
to O
lipid O
metabolism O
in O
serum O
and O
heart O
tissue O
has O
been O
investigated O
. O

oral O
pre O
- O
treatment O
with O
pk O
( O
80 O
mg O
kg O
( O
- O
1 O
) O
day O
( O
- O
1 O
) O
for O
15 O
days O
) O
significantly O
prevented O
the O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
and O
maintained O
the O
rats O
at O
near O
normal O
status O
. O

phase O
2 O
early O
afterdepolarization O
as O
a O
trigger O
of O
polymorphic O
ventricular B-Disease
tachycardia I-Disease
in O
acquired O
long B-Disease
- I-Disease
qt I-Disease
syndrome I-Disease
: O
direct O
evidence O
from O
intracellular O
recordings O
in O
the O
intact O
left O
ventricular O
wall O
. O

background O
: O
this O
study O
examined O
the O
role O
of O
phase O
2 O
early O
afterdepolarization O
( O
ead O
) O
in O
producing O
a O
trigger O
to O
initiate O
torsade B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
with O
qt B-Disease
prolongation I-Disease
induced O
by O
dl O
- O
sotalol O
and O
azimilide O
. O

the O
contribution O
of O
transmural O
dispersion O
of O
repolarization O
( O
tdr O
) O
to O
transmural O
propagation O
of O
ead O
and O
the O
maintenance O
of O
tdp B-Disease
was O
also O
evaluated O
. O

methods O
and O
results O
: O
transmembrane O
action O
potentials O
from O
epicardium O
, O
midmyocardium O
, O
and O
endocardium O
were O
recorded O
simultaneously O
, O
together O
with O
a O
transmural O
ecg O
, O
in O
arterially O
perfused O
canine O
and O
rabbit O
left O
ventricular O
preparations O
. O

dl O
- O
sotalol O
preferentially O
prolonged O
action O
potential O
duration O
( O
apd O
) O
in O
m O
cells O
dose O
- O
dependently O
( O
1 O
to O
100 O
micromol O
/ O
l O
) O
, O
leading O
to O
qt B-Disease
prolongation I-Disease
and O
an O
increase O
in O
tdr O
. O

azimilide O
, O
however O
, O
significantly O
prolonged O
apd O
and O
qt O
interval O
at O
concentrations O
from O
0 O
. O
1 O
to O
10 O
micromol O
/ O
l O
but O
shortened O
them O
at O
30 O
micromol O
/ O
l O
. O

unlike O
dl O
- O
sotalol O
, O
azimilide O
( O
> O
3 O
micromol O
/ O
l O
) O
increased O
epicardial O
apd O
markedly O
, O
causing O
a O
diminished O
tdr O
. O

although O
both O
dl O
- O
sotalol O
and O
azimilide O
rarely O
induced O
eads O
in O
canine O
left O
ventricles O
, O
they O
produced O
frequent O
eads O
in O
rabbits O
, O
in O
which O
more O
pronounced O
qt B-Disease
prolongation I-Disease
was O
seen O
. O

an O
increase O
in O
tdr O
by O
dl O
- O
sotalol O
facilitated O
transmural O
propagation O
of O
eads O
that O
initiated O
multiple O
episodes O
of O
spontaneous O
tdp B-Disease
in O
3 O
of O
6 O
rabbit O
left O
ventricles O
. O

of O
note O
, O
although O
azimilide O
( O
3 O
to O
10 O
micromol O
/ O
l O
) O
increased O
apd O
more O
than O
dl O
- O
sotalol O
, O
its O
eads O
often O
failed O
to O
propagate O
transmurally O
, O
probably O
because O
of O
a O
diminished O
tdr O
. O

conclusions O
: O
this O
study O
provides O
the O
first O
direct O
evidence O
from O
intracellular O
action O
potential O
recordings O
that O
phase O
2 O
ead O
can O
be O
generated O
from O
intact O
ventricular O
wall O
and O
produce O
a O
trigger O
to O
initiate O
the O
onset O
of O
tdp B-Disease
under O
qt B-Disease
prolongation I-Disease
. O

a O
pilot O
study O
to O
assess O
the O
safety O
of O
dobutamine O
stress O
echocardiography O
in O
the O
emergency O
department O
evaluation O
of O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
. O

study O
objective O
: O
chest B-Disease
pain I-Disease
in O
the O
setting O
of O
cocaine O
use O
poses O
a O
diagnostic O
dilemma O
. O

dobutamine O
stress O
echocardiography O
( O
dse O
) O
is O
a O
widely O
available O
and O
sensitive O
test O
for O
evaluating O
cardiac O
ischemia B-Disease
. O

because O
of O
the O
theoretical O
concern O
regarding O
administration O
of O
dobutamine O
in O
the O
setting O
of O
cocaine O
use O
, O
we O
conducted O
a O
pilot O
study O
to O
assess O
the O
safety O
of O
dse O
in O
emergency O
department O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
. O

methods O
: O
a O
prospective O
case O
series O
was O
conducted O
in O
the O
intensive O
diagnostic O
and O
treatment O
unit O
in O
the O
ed O
of O
an O
urban O
tertiary O
- O
care O
teaching O
hospital O
. O

patients O
were O
eligible O
for O
dse O
if O
they O
had O
used O
cocaine O
within O
24 O
hours O
preceding O
the O
onset O
of O
chest B-Disease
pain I-Disease
and O
had O
a O
normal O
ecg O
and O
tropinin O
i O
level O
. O

patients O
exhibiting O
signs O
of O
continuing O
cocaine O
toxicity B-Disease
were O
excluded O
from O
the O
study O
. O

all O
patients O
were O
admitted O
to O
the O
hospital O
for O
serial O
testing O
after O
the O
dse O
testing O
in O
the O
intensive O
diagnostic O
and O
treatment O
unit O
. O

results O
: O
twenty O
- O
four O
patients O
were O
enrolled O
. O

two O
patients O
had O
inadequate O
resting O
images O
, O
one O
dse O
was O
terminated O
because O
of O
inferior O
hypokinesis B-Disease
, O
another O
dse O
was O
terminated O
because O
of O
a O
rate O
- O
related O
atrial O
conduction O
deficit O
, O
and O
1 O
patient O
did O
not O
reach O
the O
target O
heart O
rate O
. O

thus O
, O
19 O
patients O
completed O
a O
dse O
and O
reached O
their O
target O
heart O
rates O
. O

none O
of O
the O
patients O
experienced O
signs O
of O
exaggerated O
adrenergic O
response O
, O
which O
was O
defined O
as O
a O
systolic O
blood O
pressure O
of O
greater O
than O
200 O
mm O
hg O
or O
the O
occurrence O
of O
tachydysrhythmias B-Disease
( O
excluding O
sinus B-Disease
tachycardia I-Disease
) O
. O

further O
suggesting O
lack O
of O
exaggerated O
adrenergic O
response O
, O
13 O
( O
65 O
% O
) O
of O
20 O
patients O
required O
supplemental O
atropine O
to O
reach O
their O
target O
heart O
rates O
. O

conclusion O
: O
no O
exaggerated O
adrenergic O
response O
was O
detected O
when O
dobutamine O
was O
administered O
to O
patients O
with O
cocaine O
- O
related O
chest B-Disease
pain I-Disease
. O

prenatal O
cocaine O
exposure O
and O
cranial O
sonographic O
findings O
in O
preterm B-Disease
infants I-Disease
. O

purpose O
: O
prenatal O
cocaine O
exposure O
has O
been O
linked O
with O
subependymal O
hemorrhage B-Disease
and O
the O
formation O
of O
cysts B-Disease
that O
are O
detectable O
on O
cranial O
sonography O
in O
neonates O
born O
at O
term O
. O

we O
sought O
to O
determine O
if O
prenatal O
cocaine O
exposure O
increases O
the O
incidence O
of O
subependymal B-Disease
cysts I-Disease
in O
preterm B-Disease
infants I-Disease
. O

methods O
: O
we O
retrospectively O
reviewed O
the O
medical O
records O
and O
cranial O
sonograms O
obtained O
during O
a O
1 O
- O
year O
period O
on O
122 O
premature B-Disease
( I-Disease
< I-Disease
36 I-Disease
weeks I-Disease
of I-Disease
gestation I-Disease
) I-Disease
infants I-Disease
. O

infants O
were O
categorized O
into O
1 O
of O
2 O
groups O
: O
those O
exposed O
to O
cocaine O
and O
those O
not O
exposed O
to O
cocaine O
. O

infants O
were O
assigned O
to O
the O
cocaine O
- O
exposed O
group O
if O
there O
was O
a O
maternal O
history O
of O
cocaine B-Disease
abuse I-Disease
during O
pregnancy O
or O
if O
maternal O
or O
neonatal O
urine O
toxicology O
results O
were O
positive O
at O
the O
time O
of O
delivery O
. O

results O
: O
five O
of O
the O
122 O
infants O
were O
excluded O
from O
the O
study O
because O
of O
insufficient O
medical O
and O
drug O
histories O
. O

the O
incidence O
of O
subependymal B-Disease
cysts I-Disease
in O
the O
117 O
remaining O
infants O
was O
14 O
% O
( O
16 O
of O
117 O
) O
. O

the O
incidence O
of O
subependymal B-Disease
cysts I-Disease
in O
infants O
exposed O
to O
cocaine O
prenatally O
was O
44 O
% O
( O
8 O
of O
18 O
) O
compared O
with O
8 O
% O
( O
8 O
of O
99 O
) O
in O
the O
unexposed O
group O
( O
p O
< O
0 O
. O
01 O
) O
. O

conclusions O
: O
we O
found O
an O
increased O
incidence O
of O
subependymal B-Disease
cyst I-Disease
formation O
in O
preterm B-Disease
infants I-Disease
who O
were O
exposed O
to O
cocaine O
prenatally O
. O

this O
result O
is O
consistent O
with O
results O
of O
similar O
studies O
in O
term O
infants O
. O

thalidomide O
neuropathy B-Disease
in O
patients O
treated O
for O
metastatic O
prostate B-Disease
cancer I-Disease
. O

we O
prospectively O
evaluated O
thalidomide O
- O
induced O
neuropathy B-Disease
using O
electrodiagnostic O
studies O
. O

sixty O
- O
seven O
men O
with O
metastatic O
androgen O
- O
independent O
prostate B-Disease
cancer I-Disease
in O
an O
open O
- O
label O
trial O
of O
oral O
thalidomide O
underwent O
neurologic O
examinations O
and O
nerve O
conduction O
studies O
( O
ncs O
) O
prior O
to O
and O
at O
3 O
- O
month O
intervals O
during O
treatment O
. O

ncs O
included O
recording O
of O
sensory O
nerve O
action O
potentials O
( O
snaps O
) O
from O
median O
, O
radial O
, O
ulnar O
, O
and O
sural O
nerves O
. O

snap O
amplitudes O
for O
each O
nerve O
were O
expressed O
as O
the O
percentage O
of O
its O
baseline O
, O
and O
the O
mean O
of O
the O
four O
was O
termed O
the O
snap O
index O
. O

a O
40 O
% O
decline O
in O
the O
snap O
index O
was O
considered O
clinically O
significant O
. O

thalidomide O
was O
discontinued O
in O
55 O
patients O
for O
lack O
of O
therapeutic O
response O
. O

of O
67 O
patients O
initially O
enrolled O
, O
24 O
remained O
on O
thalidomide O
for O
3 O
months O
, O
8 O
remained O
at O
6 O
months O
, O
and O
3 O
remained O
at O
9 O
months O
. O

six O
patients O
developed O
neuropathy B-Disease
. O

clinical O
symptoms O
and O
a O
decline O
in O
the O
snap O
index O
occurred O
concurrently O
. O

older O
age O
and O
cumulative O
dose O
were O
possible O
contributing O
factors O
. O

neuropathy B-Disease
may O
thus O
be O
a O
common O
complication O
of O
thalidomide O
in O
older O
patients O
. O

the O
snap O
index O
can O
be O
used O
to O
monitor O
peripheral B-Disease
neuropathy I-Disease
, O
but O
not O
for O
early O
detection O
. O

overexpression O
of O
copper O
/ O
zinc O
- O
superoxide O
dismutase O
protects O
from O
kanamycin O
- O
induced O
hearing B-Disease
loss I-Disease
. O

the O
participation O
of O
reactive O
oxygen O
species O
in O
aminoglycoside O
- O
induced O
ototoxicity B-Disease
has O
been O
deduced O
from O
observations O
that O
aminoglycoside O
- O
iron O
complexes O
catalyze O
the O
formation O
of O
superoxide O
radicals O
in O
vitro O
and O
that O
antioxidants O
attenuate O
ototoxicity B-Disease
in O
vivo O
. O

we O
therefore O
hypothesized O
that O
overexpression O
of O
cu O
/ O
zn O
- O
superoxide O
dismutase O
( O
h O
- O
sod1 O
) O
should O
protect O
transgenic O
mice O
from O
ototoxicity B-Disease
. O

immunocytochemistry O
confirmed O
expression O
of O
h O
- O
sod1 O
in O
inner O
ear O
tissues O
of O
transgenic O
c57bl O
/ O
6 O
- O
tgn O
[ O
sod1 O
] O
3cje O
mice O
. O

transgenic O
and O
nontransgenic O
littermates O
received O
kanamycin O
( O
400 O
mg O
/ O
kg O
body O
weight O
/ O
day O
) O
for O
10 O
days O
beginning O
on O
day O
10 O
after O
birth O
. O

auditory O
thresholds O
were O
tested O
by O
evoked O
auditory O
brain O
stem O
responses O
at O
1 O
month O
after O
birth O
. O

in O
nontransgenic O
animals O
, O
the O
threshold O
in O
the O
kanamycin O
- O
treated O
group O
was O
45 O
- O
50 O
db O
higher O
than O
in O
saline O
- O
injected O
controls O
. O

in O
the O
transgenic O
group O
, O
kanamycin O
increased O
the O
threshold O
by O
only O
15 O
db O
over O
the O
respective O
controls O
. O

the O
effects O
were O
similar O
at O
12 O
and O
24 O
khz O
. O

the O
protection O
by O
overexpression O
of O
superoxide O
dismutase O
supports O
the O
hypothesis O
that O
oxidant O
stress O
plays O
a O
significant O
role O
in O
aminoglycoside O
- O
induced O
ototoxicity B-Disease
. O

the O
results O
also O
suggest O
transgenic O
animals O
as O
suitable O
models O
to O
investigate O
the O
underlying O
mechanisms O
and O
possible O
strategies O
for O
prevention O
. O

fatty B-Disease
liver I-Disease
induced O
by O
tetracycline O
in O
the O
rat O
. O

dose O
- O
response O
relationships O
and O
effect O
of O
sex O
. O

dose O
- O
response O
relationships O
, O
biochemical O
mechanisms O
, O
and O
sex O
differences O
in O
the O
experimental O
fatty B-Disease
liver I-Disease
induced O
by O
tetracycline O
were O
studied O
in O
the O
intact O
rat O
and O
with O
the O
isolated O
perfused O
rat O
liver O
in O
vitro O
. O

in O
the O
intact O
male O
and O
female O
rat O
, O
no O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline O
and O
hepatic O
accumulation O
of O
triglyceride O
. O

with O
provision O
of O
adequate O
oleic O
acid O
as O
a O
substrate O
for O
the O
isolated O
perfused O
liver O
, O
a O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline O
and O
both O
accumulation O
of O
triglyceride O
in O
the O
liver O
and O
depression B-Disease
of O
output O
of O
triglyceride O
by O
livers O
from O
male O
and O
female O
rats O
. O

marked O
differences O
were O
observed O
between O
female O
and O
male O
rats O
with O
regard O
to O
base O
line O
( O
control O
) O
hepatic O
concentration O
of O
triglyceride O
and O
output O
of O
triglyceride O
. O

accumulation O
of O
hepatic O
triglyceride O
, O
as O
a O
per O
cent O
of O
control O
values O
, O
in O
response O
to O
graded O
doses O
of O
tetracycline O
, O
did O
not O
differ O
significantly O
between O
male O
, O
female O
and O
pregnant O
rat O
livers O
. O

however O
, O
livers O
from O
female O
, O
and O
especially O
pregnant O
female O
rats O
, O
were O
strikingly O
resistant O
to O
the O
effects O
of O
tetracycline O
on O
depression B-Disease
of O
output O
of O
triglyceride O
under O
these O
experimental O
conditions O
. O

these O
differences O
between O
the O
sexes O
could O
not O
be O
related O
to O
altered O
disposition O
of O
tetracycline O
or O
altered O
uptake O
of O
oleic O
acid O
. O

depressed O
hepatic O
secretion O
of O
triglyceride O
accounted O
only O
for O
30 O
to O
50 O
% O
of O
accumulated O
hepatic O
triglyceride O
, O
indicating O
that O
additional O
mechanisms O
must O
be O
involved O
in O
the O
production O
of O
the O
triglyceride O
- O
rich O
fatty B-Disease
liver I-Disease
in O
response O
to O
tetracycline O
. O

prednisone O
induces O
anxiety B-Disease
and O
glial O
cerebral O
changes O
in O
rats O
. O

objective O
: O
to O
assess O
whether O
prednisone O
( O
pdn O
) O
produces O
anxiety B-Disease
and O
/ O
or O
cerebral O
glial O
changes O
in O
rats O
. O

methods O
: O
male O
wistar O
rats O
were O
studied O
and O
3 O
groups O
were O
formed O
( O
8 O
rats O
per O
group O
) O
. O

the O
moderate O
- O
dose O
group O
received O
5 O
mg O
/ O
kg O
/ O
day O
pdn O
released O
from O
a O
subcutaneous O
implant O
. O

in O
the O
high O
- O
dose O
group O
, O
implants O
containing O
pdn O
equivalent O
to O
60 O
mg O
/ O
kg O
/ O
day O
were O
applied O
. O

in O
the O
control O
group O
implants O
contained O
no O
pdn O
. O

anxiety B-Disease
was O
assessed O
using O
an O
open O
field O
and O
elevated O
plus O
- O
maze O
devices O
. O

the O
number O
of O
cells O
and O
cytoplasmic O
transformation O
of O
astrocytes O
and O
microglia O
cells O
were O
assessed O
by O
immunohistochemical O
analyses O
. O

results O
: O
anxiety B-Disease
was O
documented O
in O
both O
groups O
of O
pdn O
treated O
rats O
compared O
with O
controls O
. O

the O
magnitude O
of O
transformation O
of O
the O
microglia O
assessed O
by O
the O
number O
of O
intersections O
was O
significantly O
higher O
in O
the O
pdn O
groups O
than O
in O
controls O
in O
the O
prefrontal O
cortex O
( O
moderate O
- O
dose O
, O
24 O
. O
1 O
; O
high O
- O
dose O
, O
23 O
. O
6 O
; O
controls O
18 O
. O
7 O
; O
p O
< O
0 O
. O
01 O
) O
and O
striatum O
( O
moderate O
- O
dose O
25 O
. O
6 O
; O
high O
- O
dose O
26 O
. O
3 O
; O
controls O
18 O
. O
9 O
; O
p O
< O
0 O
. O
01 O
) O
, O
but O
not O
in O
hippocampus O
. O

the O
number O
of O
stained O
microglia O
cells O
was O
significantly O
higher O
in O
the O
pdn O
treated O
groups O
in O
the O
prefrontal O
cortex O
than O
in O
controls O
( O
moderate O
- O
dose O
, O
29 O
. O
1 O
; O
high O
- O
dose O
, O
28 O
. O
4 O
; O
control O
, O
17 O
. O
7 O
cells O
per O
field O
; O
p O
< O
0 O
. O
01 O
) O
. O

stained O
microglia O
cells O
were O
significantly O
more O
numerous O
striatum O
and O
hippocampus O
in O
the O
high O
- O
dose O
group O
compared O
to O
controls O
. O

conclusion O
: O
subacute O
exposure O
to O
pdn O
induced O
anxiety B-Disease
and O
reactivity O
of O
microglia O
. O

the O
relevance O
of O
these O
features O
for O
patients O
using O
pdn O
remains O
to O
be O
elucidated O
. O

phase O
ii O
study O
of O
carboplatin O
and O
liposomal O
doxorubicin O
in O
patients O
with O
recurrent O
squamous B-Disease
cell I-Disease
carcinoma I-Disease
of I-Disease
the I-Disease
cervix I-Disease
. O

background O
: O
the O
activity O
of O
the O
combination O
of O
carboplatin O
and O
liposomal O
doxorubicin O
was O
tested O
in O
a O
phase O
ii O
study O
of O
patients O
with O
recurrent O
cervical B-Disease
carcinoma I-Disease
. O

methods O
: O
the O
combination O
of O
carboplatin O
( O
area O
under O
the O
concentration O
curve O
[ O
auc O
] O
, O
5 O
) O
and O
liposomal O
doxorubicin O
( O
doxil O
; O
starting O
dose O
, O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
was O
administered O
intravenously O
every O
28 O
days O
to O
37 O
patients O
with O
recurrent O
squamous B-Disease
cell I-Disease
cervical I-Disease
carcinoma I-Disease
to O
determine O
antitumor O
activity O
and O
toxicity B-Disease
profile O
. O

results O
: O
twenty O
- O
nine O
patients O
were O
assessable O
for O
response O
, O
and O
35 O
patients O
were O
assessable O
for O
toxicity B-Disease
. O

the O
overall O
response O
rate O
was O
38 O
% O
, O
the O
median O
time O
to O
response O
was O
10 O
weeks O
, O
the O
median O
duration O
of O
response O
was O
26 O
weeks O
, O
and O
the O
median O
survival O
was O
37 O
weeks O
. O

the O
main O
toxic O
effect O
was O
myelosuppression B-Disease
, O
with O
grade O
3 O
and O
4 O
neutropenia B-Disease
in O
16 O
patients O
, O
anemia B-Disease
in O
12 O
patients O
, O
thrombocytopenia B-Disease
in O
11 O
patients O
, O
and O
neutropenic B-Disease
fever I-Disease
in O
3 O
patients O
. O

four O
patients O
had O
five O
infusion O
- O
related O
reactions O
during O
the O
infusion O
of O
liposomal O
doxorubicin O
, O
leading O
to O
treatment O
discontinuation O
in O
three O
patients O
. O

grade O
> O
or O
= O
2 O
nonhematologic O
toxicity B-Disease
included O
nausea B-Disease
in O
17 O
patients O
, O
emesis B-Disease
in O
14 O
patients O
, O
fatigue B-Disease
in O
9 O
patients O
, O
mucositis B-Disease
and O
/ O
or O
stomatitis B-Disease
in O
8 O
patients O
, O
constipation B-Disease
in O
6 O
patients O
, O
weight B-Disease
loss I-Disease
in O
5 O
patients O
, O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
in O
2 O
patients O
, O
and O
skin B-Disease
reactions I-Disease
in O
3 O
patients O
. O

conclusions O
: O
the O
combination O
of O
carboplatin O
and O
liposomal O
doxorubicin O
has O
modest O
activity O
in O
patients O
with O
recurrent O
cervical B-Disease
carcinoma I-Disease
. O

antimicrobial O
- O
induced O
mania B-Disease
( O
antibiomania B-Disease
) O
: O
a O
review O
of O
spontaneous O
reports O
. O

the O
authors O
reviewed O
reported O
cases O
of O
antibiotic O
- O
induced O
manic B-Disease
episodes O
by O
means O
of O
a O
medline O
and O
psychlit O
search O
for O
reports O
of O
antibiotic O
- O
induced O
mania B-Disease
. O

unpublished O
reports O
were O
requested O
from O
the O
world O
health O
organization O
( O
who O
) O
and O
the O
food O
and O
drug O
administration O
( O
fda O
) O
. O

twenty O
- O
one O
reports O
of O
antimicrobial O
- O
induced O
mania B-Disease
were O
found O
in O
the O
literature O
. O

there O
were O
6 O
cases O
implicating O
clarithromycin O
, O
13 O
implicating O
isoniazid O
, O
and O
1 O
case O
each O
implicating O
erythromycin O
and O
amoxicillin O
. O

the O
who O
reported O
82 O
cases O
. O

of O
these O
, O
clarithromycin O
was O
implicated O
in O
23 O
( O
27 O
. O
6 O
% O
) O
cases O
, O
ciprofloxacin O
in O
12 O
( O
14 O
. O
4 O
% O
) O
cases O
, O
and O
ofloxacin O
in O
10 O
( O
12 O
% O
) O
cases O
. O

cotrimoxazole O
, O
metronidazole O
, O
and O
erythromycin O
were O
involved O
in O
15 O
reported O
manic B-Disease
episodes O
. O

cases O
reported O
by O
the O
fda O
showed O
clarithromycin O
and O
ciprofloxacin O
to O
be O
the O
most O
frequently O
associated O
with O
the O
development O
of O
mania B-Disease
. O

statistical O
analysis O
of O
the O
data O
would O
not O
have O
demonstrated O
a O
significant O
statistical O
correlative O
risk O
and O
was O
therefore O
not O
undertaken O
. O

patients O
have O
an O
increased O
risk O
of O
developing O
mania B-Disease
while O
being O
treated O
with O
antimicrobials O
. O

although O
this O
is O
not O
a O
statistically O
significant O
risk O
, O
physicians O
must O
be O
aware O
of O
the O
effect O
and O
reversibility O
. O

further O
research O
clearly O
is O
required O
to O
determine O
the O
incidence O
of O
antimicrobial O
- O
induced O
mania B-Disease
, O
the O
relative O
risk O
factors O
of O
developing O
an O
antimicrobial O
- O
induced O
manic B-Disease
episode O
among O
various O
demographic O
populations O
, O
and O
the O
incidence O
of O
patients O
who O
continue O
to O
have O
persistent O
affective O
disorders O
once O
the O
initial O
episode O
, O
which O
occurs O
while O
the O
patient O
is O
taking O
antibiotics O
, O
subsides O
. O

the O
authors O
elected O
to O
name O
this O
syndrome O
" O
antibiomania B-Disease
. O
" O

levodopa O
- O
induced O
ocular B-Disease
dyskinesias I-Disease
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

levodopa O
- O
induced O
ocular B-Disease
dyskinesias I-Disease
are O
very O
uncommon O
. O

usually O
they O
occur O
simultaneously O
with O
limb O
peak O
- O
dose O
choreatic B-Disease
dyskinesias I-Disease
. O

we O
report O
on O
a O
patient O
with O
leftward O
and O
upward O
deviations O
of O
gaze O
during O
the O
peak O
effect O
of O
levodopa O
, O
and O
hypothesize O
that O
a O
severe O
dopaminergic O
denervation O
in O
the O
caudate O
nucleus O
is O
needed O
for O
the O
appearance O
of O
these O
levodopa O
- O
induce O
ocular B-Disease
dyskinesias I-Disease
. O

a O
comparison O
of O
glyceryl O
trinitrate O
with O
diclofenac O
for O
the O
treatment O
of O
primary O
dysmenorrhea B-Disease
: O
an O
open O
, O
randomized O
, O
cross O
- O
over O
trial O
. O

primary O
dysmenorrhea B-Disease
is O
a O
syndrome O
characterized O
by O
painful O
uterine O
contractility O
caused O
by O
a O
hypersecretion O
of O
endometrial O
prostaglandins O
; O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
are O
the O
first O
choice O
for O
its O
treatment O
. O

however O
, O
in O
vivo O
and O
in O
vitro O
studies O
have O
demonstrated O
that O
myometrial O
cells O
are O
also O
targets O
of O
the O
relaxant O
effects O
of O
nitric O
oxide O
( O
no O
) O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
efficacy O
of O
glyceryl O
trinitrate O
( O
gtn O
) O
, O
an O
no O
donor O
, O
in O
the O
resolution O
of O
primary O
dysmenorrhea B-Disease
in O
comparison O
with O
diclofenac O
( O
dcf O
) O
. O

a O
total O
of O
24 O
patients O
with O
the O
diagnosis O
of O
severe O
primary O
dysmenorrhea B-Disease
were O
studied O
during O
two O
consecutive O
menstrual O
cycles O
. O

in O
an O
open O
, O
cross O
- O
over O
, O
controlled O
design O
, O
patients O
were O
randomized O
to O
receive O
either O
dcf O
per O
os O
or O
gtn O
patches O
the O
first O
days O
of O
menses O
, O
when O
menstrual O
cramps O
became O
unendurable O
. O

in O
the O
subsequent O
cycle O
the O
other O
treatment O
was O
used O
. O

patients O
received O
up O
to O
3 O
doses O
/ O
day O
of O
50 O
mg O
dcf O
or O
2 O
. O
5 O
mg O
/ O
24 O
h O
transdermal O
gtn O
for O
the O
first O
3 O
days O
of O
the O
cycle O
, O
according O
to O
their O
needs O
. O

the O
participants O
recorded O
menstrual O
symptoms O
and O
possible O
side O
- O
effects O
at O
different O
times O
( O
0 O
, O
30 O
, O
60 O
, O
120 O
minutes O
) O
after O
the O
first O
dose O
of O
medication O
on O
the O
first O
day O
of O
the O
cycle O
, O
with O
both O
drugs O
. O

the O
difference O
in O
pain B-Disease
intensity O
score O
( O
dpi O
) O
was O
the O
main O
outcome O
variable O
. O

both O
treatments O
significantly O
reduced O
dpi O
by O
the O
30th O
minute O
( O
gtn O
, O
- O
12 O
. O
8 O
+ O
/ O
- O
17 O
. O
9 O
; O
dcf O
, O
- O
18 O
. O
9 O
+ O
/ O
- O
16 O
. O
6 O
) O
. O

however O
, O
dcf O
continued O
to O
be O
effective O
in O
reducing O
pelvic B-Disease
pain I-Disease
for O
two O
hours O
, O
whereas O
gtn O
scores O
remained O
more O
or O
less O
stable O
after O
30 O
min O
and O
significantly O
higher O
than O
those O
for O
dfc O
( O
after O
one O
hour O
: O
gtn O
, O
- O
12 O
. O
8 O
+ O
/ O
- O
17 O
. O
9 O
; O
dfc O
, O
- O
18 O
. O
9 O
+ O
/ O
- O
16 O
. O
6 O
and O
after O
two O
hours O
: O
gtn O
, O
- O
23 O
. O
7 O
+ O
/ O
- O
20 O
. O
5 O
; O
dfc O
, O
- O
59 O
. O
7 O
+ O
/ O
- O
17 O
. O
9 O
, O
p O
= O
0 O
. O
0001 O
) O
. O

low B-Disease
back I-Disease
pain I-Disease
was O
also O
relieved O
by O
both O
drugs O
. O

headache B-Disease
was O
significantly O
increased O
by O
gtn O
but O
not O
by O
dcf O
. O

eight O
patients O
stopped O
using O
gtn O
because O
headache B-Disease
- O
- O
attributed O
to O
its O
use O
- O
- O
became O
intolerable O
. O

these O
findings O
indicate O
that O
gtn O
has O
a O
reduced O
efficacy O
and O
tolerability O
by O
comparison O
with O
dcf O
in O
the O
treatment O
of O
primary O
dysmenorrhea B-Disease
. O

temocapril O
, O
a O
long O
- O
acting O
non O
- O
sh O
group O
angiotensin O
converting O
enzyme O
inhibitor O
, O
modulates O
glomerular B-Disease
injury I-Disease
in O
chronic O
puromycin O
aminonucleoside O
nephrosis B-Disease
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
determine O
whether O
chronic O
administration O
of O
temocapril O
, O
a O
long O
- O
acting O
non O
- O
sh O
group O
angiotensin O
converting O
enzyme O
( O
ace O
) O
inhibitor O
, O
reduced O
proteinuria B-Disease
, O
inhibited O
glomerular O
hypertrophy B-Disease
and O
prevented O
glomerulosclerosis B-Disease
in O
chronic O
puromycin O
aminonucleoside O
( O
pan O
) O
- O
induced O
nephrotic B-Disease
rats O
. O

nephrosis B-Disease
was O
induced O
by O
injection O
of O
pan O
( O
15mg O
/ O
100g O
body O
weight O
) O
in O
male O
sprague O
- O
dawley O
( O
sd O
) O
rats O
. O

four O
groups O
were O
used O
, O
i O
) O
the O
pan O
group O
( O
14 O
) O
, O
ii O
) O
pan O
/ O
temocapril O
( O
13 O
) O
, O
iii O
) O
temocapril O
( O
14 O
) O
and O
iv O
) O
untreated O
controls O
( O
15 O
) O
. O

temocapril O
( O
8 O
mg O
/ O
kg O
/ O
day O
) O
was O
administered O
to O
the O
rats O
which O
were O
killed O
at O
weeks O
4 O
, O
14 O
or O
20 O
. O

at O
each O
time O
point O
, O
systolic O
blood O
pressure O
( O
bp O
) O
, O
urinary O
protein O
excretion O
and O
renal O
histopathological O
findings O
were O
evaluated O
, O
and O
morphometric O
image O
analysis O
was O
done O
. O

systolic O
bp O
in O
the O
pan O
group O
was O
significantly O
high O
at O
4 O
, O
14 O
and O
20 O
weeks O
, O
but O
was O
normal O
in O
the O
pan O
/ O
temocapril O
group O
. O

urinary O
protein O
excretion O
in O
the O
pan O
group O
increased O
significantly O
, O
peaking O
at O
8 O
days O
, O
then O
decreased O
at O
4 O
weeks O
, O
but O
rose O
again O
significantly O
at O
14 O
and O
20 O
weeks O
. O

temocapril O
did O
not O
attenuate O
proteinuria B-Disease
at O
8 O
days O
, O
but O
it O
did O
markedly O
lower O
it O
from O
weeks O
4 O
to O
20 O
. O

the O
glomerulosclerosis B-Disease
index O
( O
gsi O
) O
was O
6 O
. O
21 O
% O
at O
4 O
weeks O
and O
respectively O
25 O
. O
35 O
% O
and O
30 O
. O
49 O
% O
at O
14 O
and O
20 O
weeks O
in O
the O
pan O
group O
. O

there O
was O
a O
significant O
correlation O
between O
urinary O
protein O
excretion O
and O
gsi O
( O
r O
= O
0 O
. O
808 O
, O
p O
< O
0 O
. O
0001 O
) O
. O

the O
ratio O
of O
glomerular O
tuft O
area O
to O
the O
area O
of O
bowman O
' O
s O
capsules O
( O
gt O
/ O
bc O
) O
in O
the O
pan O
group O
was O
significantly O
increased O
, O
but O
it O
was O
significantly O
lower O
in O
the O
pan O
/ O
temocapril O
group O
. O

it O
appears O
that O
temocapril O
was O
effective O
in O
retarding O
renal O
progression O
and O
protected O
renal O
function O
in O
pan O
neprotic B-Disease
rats O
. O

pulmonary B-Disease
hypertension I-Disease
after O
ibuprofen O
prophylaxis O
in O
very O
preterm O
infants O
. O

we O
report O
three O
cases O
of O
severe O
hypoxaemia B-Disease
after O
ibuprofen O
administration O
during O
a O
randomised O
controlled O
trial O
of O
prophylactic O
treatment O
of O
patent B-Disease
ductus I-Disease
arteriosus I-Disease
with O
ibuprofen O
in O
premature O
infants O
born O
at O
less O
than O
28 O
weeks O
of O
gestation O
. O

echocardiography O
showed O
severely O
decreased O
pulmonary O
blood O
flow O
. O

hypoxaemia B-Disease
resolved O
quickly O
on O
inhaled O
nitric O
oxide O
therapy O
. O

we O
suggest O
that O
investigators O
involved O
in O
similar O
trials O
pay O
close O
attention O
to O
pulmonary O
pressure O
if O
hypoxaemia B-Disease
occurs O
after O
prophylactic O
administration O
of O
ibuprofen O
. O

hyponatremia B-Disease
and O
syndrome B-Disease
of I-Disease
inappropriate I-Disease
anti I-Disease
- I-Disease
diuretic I-Disease
hormone I-Disease
reported O
with O
the O
use O
of O
vincristine O
: O
an O
over O
- O
representation O
of O
asians O
? O

purpose O
: O
this O
retrospective O
study O
used O
a O
pharmaceutical O
company O
' O
s O
global O
safety O
database O
to O
determine O
the O
reporting O
rate O
of O
hyponatremia B-Disease
and O
/ O
or O
syndrome B-Disease
of I-Disease
inappropriate I-Disease
secretion I-Disease
of I-Disease
anti I-Disease
- I-Disease
diuretic I-Disease
hormone I-Disease
( O
siadh B-Disease
) O
among O
vincristine O
- O
treated O
patients O
and O
to O
explore O
the O
possibility O
of O
at O
- O
risk O
population O
subgroups O
. O

method O
: O
we O
searched O
the O
eli O
lilly O
and O
company O
' O
s O
computerized O
adverse O
event O
database O
for O
all O
reported O
cases O
of O
hyponatremia B-Disease
and O
/ O
or O
siadh B-Disease
as O
of O
1 O
november O
1999 O
that O
had O
been O
reported O
during O
the O
use O
of O
vincristine O
. O

results O
: O
a O
total O
of O
76 O
cases O
of O
hyponatremia B-Disease
and O
/ O
or O
siadh B-Disease
associated O
with O
vincristine O
use O
were O
identified O
. O

the O
overall O
reporting O
rate O
was O
estimated O
to O
be O
1 O
. O
3 O
/ O
100 O
, O
000 O
treated O
patients O
. O

the O
average O
age O
of O
patients O
was O
35 O
. O
6 O
+ O
/ O
- O
28 O
. O
3 O
years O
, O
and O
62 O
% O
were O
males O
. O

approximately O
75 O
% O
of O
the O
patients O
were O
receiving O
treatment O
for O
leukemia B-Disease
or O
lymphoma B-Disease
. O

among O
the O
39 O
reports O
that O
included O
information O
on O
race O
, O
the O
racial O
distribution O
was O
: O
1 O
black O
, O
3 O
caucasian O
, O
and O
35 O
asian O
. O

conclusion O
: O
our O
data O
suggest O
that O
asian O
patients O
may O
be O
at O
increased O
risk O
of O
hyponatremia B-Disease
and O
/ O
or O
siadh B-Disease
associated O
with O
vincristine O
use O
. O

although O
the O
overall O
reported O
rate O
of O
siadh B-Disease
associated O
with O
vincristine O
is O
very O
low O
, O
physicians O
caring O
for O
asian O
oncology O
patients O
should O
be O
aware O
of O
this O
potential O
serious O
but O
reversible O
adverse O
event O
. O

delayed O
toxicity B-Disease
of O
cyclophosphamide O
on O
the O
bladder O
of O
dba O
/ O
2 O
and O
c57bl O
/ O
6 O
female O
mouse O
. O

the O
present O
study O
describes O
the O
delayed O
development O
of O
a O
severe O
bladder O
pathology O
in O
a O
susceptible O
strain O
of O
mice O
( O
dba O
/ O
2 O
) O
but O
not O
in O
a O
resistant O
strain O
( O
c57bl O
/ O
6 O
) O
when O
both O
were O
treated O
with O
a O
single O
300 O
mg O
/ O
kg O
dose O
of O
cyclophosphamide O
( O
cy O
) O
. O

inbred O
dba O
/ O
2 O
and O
c57bl O
/ O
6 O
female O
mice O
were O
injected O
with O
cy O
, O
and O
the O
effect O
of O
the O
drug O
on O
the O
bladder O
was O
assessed O
during O
100 O
days O
by O
light O
microscopy O
using O
different O
staining O
procedures O
, O
and O
after O
30 O
days O
by O
conventional O
electron O
microscopy O
. O

early O
cy O
toxicity B-Disease
caused O
a O
typical O
haemorrhagic B-Disease
cystitis B-Disease
in O
both O
strains O
that O
was O
completely O
repaired O
in O
about O
7 O
- O
10 O
days O
. O

after O
30 O
days O
of O
cy O
injection O
ulcerous O
and O
non O
- O
ulcerous O
forms O
of O
chronic O
cystitis B-Disease
appeared O
in O
86 O
% O
of O
dba O
/ O
2 O
mice O
but O
only O
in O
4 O
% O
of O
c57bl O
/ O
6 O
mice O
. O

delayed O
cystitis B-Disease
was O
characterized O
by O
infiltration O
and O
transepithelial O
passage O
into O
the O
lumen O
of O
inflammatory O
cells O
and O
by O
frequent O
exfoliation O
of O
the O
urothelium O
. O

mast O
cells O
appeared O
in O
the O
connective O
and O
muscular O
layers O
of O
the O
bladder O
at O
a O
much O
higher O
number O
in O
dba O
/ O
2 O
mice O
than O
in O
c57bl O
/ O
6 O
mice O
or O
untreated O
controls O
. O

electron O
microscopy O
disclosed O
the O
absence O
of O
the O
typical O
discoidal O
vesicles O
normally O
present O
in O
the O
cytoplasm O
of O
surface O
cells O
. O

instead O
, O
numerous O
abnormal O
vesicles O
containing O
one O
or O
several O
dark O
granules O
were O
observed O
in O
the O
cytoplasm O
of O
cells O
from O
all O
the O
epithelial O
layers O
. O

delayed O
cystitis B-Disease
still O
persisted O
in O
dba O
/ O
2 O
mice O
100 O
days O
after O
treatment O
. O

these O
results O
indicate O
that O
delayed O
toxicity B-Disease
of O
cy O
in O
female O
dba O
/ O
2 O
mice O
causes O
a O
bladder O
pathology O
that O
is O
not O
observed O
in O
c57bl O
/ O
6 O
mice O
. O

this O
pathology O
resembles O
interstitial B-Disease
cystitis I-Disease
in O
humans O
and O
could O
perhaps O
be O
used O
as O
an O
animal O
model O
for O
studies O
on O
the O
disease O
. O

high O
- O
dose O
5 O
- O
fluorouracil O
/ O
folinic O
acid O
in O
combination O
with O
three O
- O
weekly O
mitomycin O
c O
in O
the O
treatment O
of O
advanced O
gastric B-Disease
cancer I-Disease
. O

a O
phase O
ii O
study O
. O

background O
: O
the O
24 O
- O
hour O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
and O
folinic O
acid O
( O
fa O
) O
as O
part O
of O
several O
new O
multidrug O
chemotherapy O
regimens O
in O
advanced O
gastric B-Disease
cancer I-Disease
( O
agc B-Disease
) O
has O
shown O
to O
be O
effective O
, O
with O
low O
toxicity B-Disease
. O

in O
a O
previous O
phase O
ii O
study O
with O
3 O
- O
weekly O
bolus O
5 O
- O
fu O
, O
fa O
and O
mitomycin O
c O
( O
mmc O
) O
we O
found O
a O
low O
toxicity B-Disease
rate O
and O
response O
rates O
comparable O
to O
those O
of O
regimens O
such O
as O
elf O
, O
fam O
or O
famtx O
, O
and O
a O
promising O
median O
overall O
survival O
. O

in O
order O
to O
improve O
this O
mmc O
- O
dependent O
schedule O
we O
initiated O
a O
phase O
ii O
study O
with O
high O
- O
dose O
5 O
- O
fu O
/ O
fa O
and O
3 O
- O
weekly O
bolus O
mmc O
. O

patients O
and O
methods O
: O
from O
february O
, O
1998 O
to O
september O
, O
2000 O
we O
recruited O
33 O
patients O
with O
agc B-Disease
to O
receive O
weekly O
24 O
- O
hour O
5 O
- O
fu O
2 O
, O
600 O
mg O
/ O
m O
( O
2 O
) O
preceded O
by O
2 O
- O
hour O
fa O
500 O
mg O
/ O
m O
( O
2 O
) O
for O
6 O
weeks O
, O
followed O
by O
a O
2 O
- O
week O
rest O
period O
. O

bolus O
mmc O
10 O
mg O
/ O
m O
( O
2 O
) O
was O
added O
in O
3 O
- O
weekly O
intervals O
. O

treatment O
given O
on O
an O
outpatient O
basis O
, O
using O
portable O
pump O
systems O
, O
was O
repeated O
on O
day O
57 O
. O

patients O
' O
characteristics O
were O
: O
male O
/ O
female O
ratio O
20 O
/ O
13 O
; O
median O
age O
57 O
( O
27 O
- O
75 O
) O
years O
; O
median O
who O
status O
1 O
( O
0 O
- O
2 O
) O
. O

18 O
patients O
had O
a O
primary O
agc B-Disease
, O
and O
15 O
showed O
a O
relapsed O
agc B-Disease
. O

median O
follow O
- O
up O
was O
11 O
. O
8 O
months O
( O
range O
of O
those O
surviving O
: O
2 O
. O
7 O
- O
11 O
. O
8 O
months O
) O
. O

results O
: O
32 O
patients O
were O
evaluable O
for O
response O
- O
complete O
remission O
9 O
. O
1 O
% O
( O
n O
= O
3 O
) O
, O
partial O
remission O
45 O
. O
5 O
% O
( O
n O
= O
15 O
) O
, O
no O
change O
27 O
. O
3 O
% O
( O
n O
= O
9 O
) O
, O
progressive O
disease O
15 O
. O
1 O
% O
( O
n O
= O
5 O
) O
. O

median O
overall O
survival O
time O
was O
10 O
. O
2 O
months O
[ O
95 O
% O
confidence O
interval O
( O
ci O
) O
: O
8 O
. O
7 O
- O
11 O
. O
6 O
] O
, O
and O
median O
progression O
- O
free O
survival O
time O
was O
7 O
. O
6 O
months O
( O
95 O
% O
ci O
: O
4 O
. O
4 O
- O
10 O
. O
9 O
) O
. O

the O
worst O
toxicities B-Disease
( O
% O
) O
observed O
were O
( O
ctc O
- O
nci O
1 O
/ O
2 O
/ O
3 O
) O
: O
leukopenia B-Disease
45 O
. O
5 O
/ O
18 O
. O
2 O
/ O
6 O
. O
1 O
, O
thrombocytopenia B-Disease
33 O
. O
3 O
/ O
9 O
. O
1 O
/ O
6 O
. O
1 O
, O
vomitus B-Disease
24 O
. O
2 O
/ O
9 O
. O
1 O
/ O
0 O
, O
diarrhea B-Disease
36 O
. O
4 O
/ O
6 O
. O
1 O
/ O
3 O
. O
0 O
, O
stomatitis B-Disease
18 O
. O
2 O
/ O
9 O
. O
1 O
/ O
0 O
, O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
12 O
. O
1 O
/ O
0 O
/ O
0 O
. O

two O
patients O
developed O
hemolytic B-Disease
- I-Disease
uremic I-Disease
syndrome I-Disease
( O
hus B-Disease
) O
. O

conclusions O
: O
high O
- O
dose O
5 O
- O
fu O
/ O
fa O
/ O
mmc O
is O
an O
effective O
and O
well O
- O
tolerated O
outpatient O
regimen O
for O
agc B-Disease
( O
objective O
response O
rate O
54 O
. O
6 O
% O
) O
. O

it O
may O
serve O
as O
an O
alternative O
to O
cisplatin O
- O
containing O
regimens O
; O
however O
, O
it O
has O
to O
be O
considered O
that O
possibly O
hus B-Disease
may O
occur O
. O

persistent O
sterile O
leukocyturia B-Disease
is O
associated O
with O
impaired B-Disease
renal I-Disease
function I-Disease
in O
human B-Disease
immunodeficiency I-Disease
virus I-Disease
type I-Disease
1 I-Disease
- I-Disease
infected I-Disease
children O
treated O
with O
indinavir O
. O

background O
: O
prolonged O
administration O
of O
indinavir O
is O
associated O
with O
the O
occurrence O
of O
a O
variety O
of O
renal O
complications O
in O
adults O
. O

these O
well O
- O
documented O
side O
effects O
have O
restricted O
the O
use O
of O
this O
potent O
protease O
inhibitor O
in O
children O
. O

design O
: O
a O
prospective O
study O
to O
monitor O
indinavir O
- O
related O
nephrotoxicity B-Disease
in O
a O
cohort O
of O
30 O
human B-Disease
immunodeficiency I-Disease
virus I-Disease
type I-Disease
1 I-Disease
- I-Disease
infected I-Disease
children O
treated O
with O
indinavir O
. O

methods O
: O
urinary O
ph O
, O
albumin O
, O
creatinine O
, O
the O
presence O
of O
erythrocytes O
, O
leukocytes O
, O
bacteria O
and O
crystals O
, O
and O
culture O
were O
analyzed O
every O
3 O
months O
for O
96 O
weeks O
. O

serum O
creatinine O
levels O
were O
routinely O
determined O
at O
the O
same O
time O
points O
. O

steady O
- O
state O
pharmacokinetics O
of O
indinavir O
were O
done O
at O
week O
4 O
after O
the O
initiation O
of O
indinavir O
. O

results O
: O
the O
cumulative O
incidence O
of O
persistent O
sterile O
leukocyturia B-Disease
( O
> O
or O
= O
75 O
cells O
/ O
micro O
l O
in O
at O
least O
2 O
consecutive O
visits O
) O
after O
96 O
weeks O
was O
53 O
% O
. O

persistent O
sterile O
leukocyturia B-Disease
was O
frequently O
associated O
with O
a O
mild O
increase O
in O
the O
urine O
albumin O
/ O
creatinine O
ratio O
and O
by O
microscopic O
hematuria B-Disease
. O

the O
cumulative O
incidence O
of O
serum O
creatinine O
levels O
> O
50 O
% O
above O
normal O
was O
33 O
% O
after O
96 O
weeks O
. O

children O
with O
persistent O
sterile O
leukocyturia B-Disease
more O
frequently O
had O
serum O
creatinine O
levels O
of O
50 O
% O
above O
normal O
than O
those O
children O
without O
persistent O
sterile O
leukocyturia B-Disease
. O

in O
children O
younger O
than O
5 O
. O
6 O
years O
, O
persistent O
sterile O
leukocyturia B-Disease
was O
significantly O
more O
frequent O
than O
in O
older O
children O
. O

a O
higher O
cumulative O
incidence O
of O
persistent O
leukocyturia B-Disease
was O
found O
in O
children O
with O
an O
area O
under O
the O
curve O
> O
19 O
mg O
/ O
l O
x O
h O
or O
a O
peak O
serum O
level O
of O
indinavir O
> O
12 O
mg O
/ O
l O
. O

in O
4 O
children O
, O
indinavir O
was O
discontinued O
because O
of O
nephrotoxicity B-Disease
. O

subsequently O
, O
the O
serum O
creatinine O
levels O
decreased O
, O
the O
urine O
albumin O
/ O
creatinine O
ratios O
returned O
to O
zero O
, O
and O
the O
leukocyturia B-Disease
disappeared O
within O
3 O
months O
. O

conclusions O
: O
children O
treated O
with O
indinavir O
have O
a O
high O
cumulative O
incidence O
of O
persistent O
sterile O
leukocyturia B-Disease
. O

children O
with O
persistent O
sterile O
leukocyturia B-Disease
more O
frequently O
had O
an O
increase O
in O
serum O
creatinine O
levels O
of O
> O
50 O
% O
above O
normal O
. O

younger O
children O
have O
an O
additional O
risk O
for O
renal O
complications O
. O

the O
impairment B-Disease
of I-Disease
the I-Disease
renal I-Disease
function I-Disease
in O
these O
children O
occurred O
in O
the O
absence O
of O
clinical O
symptoms O
of O
nephrolithiasis B-Disease
. O

indinavir O
- O
associated O
nephrotoxicity B-Disease
must O
be O
monitored O
closely O
, O
especially O
in O
children O
with O
risk O
factors O
such O
as O
persistent O
sterile O
leukocyturia B-Disease
, O
age O
< O
5 O
. O
6 O
years O
, O
an O
area O
under O
the O
curve O
of O
indinavir O
> O
19 O
mg O
/ O
l O
x O
h O
, O
and O
a O
c O
( O
max O
) O
> O
12 O
mg O
/ O
l O
. O

utility O
of O
troponin O
i O
in O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
. O

baseline O
electrocardiogram O
abnormalities O
and O
market O
elevations O
not O
associated O
with O
myocardial B-Disease
necrosis I-Disease
make O
accurate O
diagnosis O
of O
myocardial B-Disease
infarction I-Disease
( O
mi B-Disease
) O
difficult O
in O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
. O

troponin O
sampling O
may O
offer O
greater O
diagnostic O
utility O
in O
these O
patients O
. O

objective O
: O
to O
assess O
outcomes O
based O
on O
troponin O
positivity O
in O
patients O
with O
cocaine O
chest B-Disease
pain I-Disease
admitted O
for O
exclusion O
of O
mi B-Disease
. O

methods O
: O
outcomes O
were O
examined O
in O
patients O
admitted O
for O
possible O
mi B-Disease
after O
cocaine O
use O
. O

all O
patients O
underwent O
a O
rapid O
rule O
- O
in O
protocol O
that O
included O
serial O
sampling O
of O
creatine O
kinase O
( O
ck O
) O
, O
ck O
- O
mb O
, O
and O
cardiac O
troponin O
i O
( O
ctni O
) O
over O
eight O
hours O
. O

outcomes O
included O
ck O
- O
mb O
mi B-Disease
( O
ck O
- O
mb O
> O
or O
= O
8 O
ng O
/ O
ml O
with O
a O
relative O
index O
[ O
( O
ck O
- O
mb O
x O
100 O
) O
/ O
total O
ck O
] O
> O
or O
= O
4 O
, O
cardiac B-Disease
death I-Disease
, O
and O
significant O
coronary B-Disease
disease I-Disease
( O
> O
or O
= O
50 O
% O
) O
. O

results O
: O
of O
the O
246 O
admitted O
patients O
, O
34 O
( O
14 O
% O
) O
met O
ck O
- O
mb O
criteria O
for O
mi B-Disease
and O
38 O
( O
16 O
% O
) O
had O
ctni O
elevations O
. O

angiography O
was O
performed O
in O
29 O
of O
38 O
patients O
who O
were O
ctni O
- O
positive O
, O
with O
significant O
disease O
present O
in O
25 O
( O
86 O
% O
) O
. O

three O
of O
the O
four O
patients O
without O
significant O
disease O
who O
had O
ctni O
elevations O
met O
ck O
- O
mb O
criteria O
for O
mi B-Disease
, O
and O
the O
other O
had O
a O
peak O
ck O
- O
mb O
level O
of O
13 O
ng O
/ O
ml O
. O

sensitivities O
, O
specificities O
, O
and O
positive O
and O
negative O
likelihood O
ratios O
for O
predicting O
cardiac B-Disease
death I-Disease
or O
significant O
disease O
were O
high O
for O
both O
ck O
- O
mb O
mi B-Disease
and O
ctni O
and O
were O
not O
significantly O
different O
. O

conclusions O
: O
most O
patients O
with O
ctni O
elevations O
meet O
ck O
- O
mb O
criteria O
for O
mi B-Disease
, O
as O
well O
as O
have O
a O
high O
incidence O
of O
underlying O
significant O
disease O
. O

troponin O
appears O
to O
have O
an O
equivalent O
diagnostic O
accuracy O
compared O
with O
ck O
- O
mb O
for O
diagnosing O
necrosis B-Disease
in O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
and O
suspected O
mi B-Disease
. O

acute O
interstitial B-Disease
nephritis I-Disease
due O
to O
nicergoline O
( O
sermion O
) O
. O

we O
report O
a O
case O
of O
acute O
interstitial B-Disease
nephritis I-Disease
( O
ain B-Disease
) O
due O
to O
nicergoline O
( O
sermion O
) O
. O

a O
50 O
- O
year O
- O
old O
patient O
admitted O
to O
our O
hospital O
for O
fever B-Disease
and O
acute B-Disease
renal I-Disease
failure I-Disease
. O

before O
admission O
, O
he O
had O
been O
taking O
nicergoline O
and O
bendazac O
lysine O
due O
to O
retinal B-Disease
vein I-Disease
occlusion I-Disease
at O
ophthalmologic O
department O
. O

thereafter O
, O
he O
experienced O
intermittent O
fever B-Disease
and O
skin B-Disease
rash I-Disease
. O

on O
admission O
, O
clinical O
symptoms O
( O
i O
. O
e O
. O
arthralgia B-Disease
and O
fever B-Disease
) O
and O
laboratory O
findings O
( O
i O
. O
e O
. O
eosinophilia B-Disease
and O
renal B-Disease
failure I-Disease
) O
suggested O
ain B-Disease
, O
and O
which O
was O
confirmed O
by O
pathologic O
findings O
on O
renal O
biopsy O
. O

a O
lymphocyte O
transformation O
test O
demonstrated O
a O
positive O
result O
against O
nicergoline O
. O

treatment O
was O
consisted O
of O
withdrawal O
of O
nicergoline O
and O
intravenous O
methylprednisolone O
, O
and O
his O
renal O
function O
was O
completely O
recovered O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
nicergoline O
- O
associated O
ain B-Disease
. O

neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
complicated O
by O
massive O
intestinal O
bleeding B-Disease
in O
a O
patient O
with O
chronic B-Disease
renal I-Disease
failure I-Disease
. O

a O
patient O
with O
chronic B-Disease
renal I-Disease
failure I-Disease
( O
crf B-Disease
) O
developed O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
( O
nms B-Disease
) O
after O
administration O
of O
risperidone O
and O
levomepromazine O
. O

in O
addition O
to O
the O
typical O
symptoms O
of O
nms B-Disease
, O
massive O
intestinal O
bleeding B-Disease
was O
observed O
during O
the O
episode O
. O

this O
report O
suggests O
that O
nms B-Disease
in O
a O
patient O
with O
crf B-Disease
may O
be O
complicated O
by O
intestinal O
bleeding B-Disease
and O
needs O
special O
caution O
for O
this O
complication O
. O

blood O
brain O
barrier O
in O
right O
- O
and O
left O
- O
pawed O
female O
rats O
assessed O
by O
a O
new O
staining O
method O
. O

the O
asymmetrical O
breakdown O
of O
the O
blood O
- O
brain O
barrier O
( O
bbb O
) O
was O
studied O
in O
female O
rats O
. O

paw O
preference O
was O
assessed O
by O
a O
food O
reaching O
test O
. O

adrenaline O
- O
induced O
hypertension B-Disease
was O
used O
to O
destroy O
the O
bbb O
, O
which O
was O
evaluated O
using O
triphenyltetrazolium O
( O
ttc O
) O
staining O
of O
the O
brain O
slices O
just O
after O
giving O
adrenaline O
for O
30 O
s O
. O

in O
normal O
rats O
, O
the O
whole O
brain O
sections O
exhibited O
complete O
staining O
with O
ttc O
. O

after O
adrenaline O
infusion O
for O
30 O
s O
, O
there O
were O
large O
unstained O
areas O
in O
the O
left O
brain O
in O
right O
- O
pawed O
animals O
, O
and O
vice O
versa O
in O
left O
- O
pawed O
animals O
. O

similar O
results O
were O
obtained O
in O
seizure B-Disease
- O
induced O
breakdown O
of O
bbb O
. O

these O
results O
were O
explained O
by O
an O
asymmetric O
cerebral O
blood O
flow O
depending O
upon O
the O
paw O
preference O
in O
rats O
. O

it O
was O
suggested O
that O
this O
new O
method O
and O
the O
results O
are O
consistent O
with O
contralateral O
motor O
control O
that O
may O
be O
important O
in O
determining O
the O
dominant O
cerebral O
hemisphere O
in O
animals O
. O

carvedilol O
protects O
against O
doxorubicin O
- O
induced O
mitochondrial O
cardiomyopathy B-Disease
. O

several O
cytopathic O
mechanisms O
have O
been O
suggested O
to O
mediate O
the O
dose O
- O
limiting O
cumulative O
and O
irreversible O
cardiomyopathy B-Disease
caused O
by O
doxorubicin O
. O

recent O
evidence O
indicates O
that O
oxidative O
stress O
and O
mitochondrial B-Disease
dysfunction I-Disease
are O
key O
factors O
in O
the O
pathogenic O
process O
. O

the O
objective O
of O
this O
investigation O
was O
to O
test O
the O
hypothesis O
that O
carvedilol O
, O
a O
nonselective O
beta O
- O
adrenergic O
receptor O
antagonist O
with O
potent O
antioxidant O
properties O
, O
protects O
against O
the O
cardiac O
and O
hepatic O
mitochondrial O
bioenergetic O
dysfunction O
associated O
with O
subchronic O
doxorubicin O
toxicity B-Disease
. O

heart O
and O
liver O
mitochondria O
were O
isolated O
from O
rats O
treated O
for O
7 O
weeks O
with O
doxorubicin O
( O
2 O
mg O
/ O
kg O
sc O
/ O
week O
) O
, O
carvedilol O
( O
1 O
mg O
/ O
kg O
ip O
/ O
week O
) O
, O
or O
the O
combination O
of O
the O
two O
drugs O
. O

heart O
mitochondria O
isolated O
from O
doxorubicin O
- O
treated O
rats O
exhibited O
depressed O
rates O
for O
state O
3 O
respiration O
( O
336 O
+ O
/ O
- O
26 O
versus O
425 O
+ O
/ O
- O
53 O
natom O
o O
/ O
min O
/ O
mg O
protein O
) O
and O
a O
lower O
respiratory O
control O
ratio O
( O
rcr O
) O
( O
4 O
. O
3 O
+ O
/ O
- O
0 O
. O
6 O
versus O
5 O
. O
8 O
+ O
/ O
- O
0 O
. O
4 O
) O
compared O
with O
cardiac O
mitochondria O
isolated O
from O
saline O
- O
treated O
rats O
. O

mitochondrial O
calcium O
- O
loading O
capacity O
and O
the O
activity O
of O
nadh O
- O
dehydrogenase O
were O
also O
suppressed O
in O
cardiac O
mitochondria O
from O
doxorubicin O
- O
treated O
rats O
. O

doxorubicin O
treatment O
also O
caused O
a O
decrease O
in O
rcr O
for O
liver O
mitochondria O
( O
3 O
. O
9 O
+ O
/ O
- O
0 O
. O
9 O
versus O
5 O
. O
6 O
+ O
/ O
- O
0 O
. O
7 O
for O
control O
rats O
) O
and O
inhibition O
of O
hepatic O
cytochrome O
oxidase O
activity O
. O

coadministration O
of O
carvedilol O
decreased O
the O
extent O
of O
cellular O
vacuolization O
in O
cardiac O
myocytes O
and O
prevented O
the O
inhibitory O
effect O
of O
doxorubicin O
on O
mitochondrial O
respiration O
in O
both O
heart O
and O
liver O
. O

carvedilol O
also O
prevented O
the O
decrease O
in O
mitochondrial O
ca O
( O
2 O
+ O
) O
loading O
capacity O
and O
the O
inhibition O
of O
the O
respiratory O
complexes O
of O
heart O
mitochondria O
caused O
by O
doxorubicin O
. O

carvedilol O
by O
itself O
did O
not O
affect O
any O
of O
the O
parameters O
measured O
for O
heart O
or O
liver O
mitochondria O
. O

it O
is O
concluded O
that O
this O
protection O
by O
carvedilol O
against O
both O
the O
structural O
and O
functional O
cardiac O
tissue O
damage O
may O
afford O
significant O
clinical O
advantage O
in O
minimizing O
the O
dose O
- O
limiting O
mitochondrial B-Disease
dysfunction I-Disease
and O
cardiomyopathy B-Disease
that O
accompanies O
long O
- O
term O
doxorubicin O
therapy O
in O
cancer B-Disease
patients O
. O

cocaine O
- O
induced O
hyperactivity B-Disease
is O
more O
influenced O
by O
adenosine O
receptor O
agonists O
than O
amphetamine O
- O
induced O
hyperactivity B-Disease
. O

the O
influence O
of O
adenosine O
receptor O
agonists O
and O
antagonists O
on O
cocaine O
- O
and O
amphetamine O
- O
induced O
hyperactivity B-Disease
was O
examined O
in O
mice O
. O

all O
adenosine O
receptor O
agonists O
significantly O
decreased B-Disease
the I-Disease
locomotor I-Disease
activity I-Disease
in O
mice O
, O
and O
the O
effects O
were O
dose O
- O
dependent O
. O

it O
seems O
that O
adenosine O
a1 O
and O
a2 O
receptors O
might O
be O
involved O
in O
this O
reaction O
. O

moreover O
, O
all O
adenosine O
receptor O
agonists O
: O
2 O
- O
p O
- O
( O
2 O
- O
carboxyethyl O
) O
phenethylamino O
- O
5 O
' O
- O
n O
- O
ethylcarboxamidoadenosine O
( O
cgs O
21680 O
) O
, O
a2a O
receptor O
agonist O
, O
n6 O
- O
cyclopentyladenosine O
( O
cpa O
) O
, O
a1 O
receptor O
agonist O
, O
and O
5 O
' O
- O
n O
- O
ethylcarboxamidoadenosine O
( O
neca O
) O
, O
a2 O
/ O
a1 O
receptor O
agonist O
significantly O
and O
dose O
- O
dependently O
decreased O
cocaine O
- O
induced O
locomotor O
activity O
. O

cpa O
reduced O
cocaine O
action O
at O
the O
doses O
which O
, O
given O
alone O
, O
did O
not O
influence O
motility O
, O
while O
cgs O
21680 O
and O
neca O
decreased O
the O
action O
of O
cocaine O
at O
the O
doses O
which O
, O
given O
alone O
, O
decreased O
locomotor O
activity O
in O
animals O
. O

these O
results O
suggest O
the O
involvement O
of O
both O
adenosine O
receptors O
in O
the O
action O
of O
cocaine O
although O
agonists O
of O
a1 O
receptors O
seem O
to O
have O
stronger O
influence O
on O
it O
. O

the O
selective O
blockade O
of O
a2 O
adenosine O
receptor O
by O
dmpx O
( O
3 O
, O
7 O
- O
dimethyl O
- O
1 O
- O
propargylxanthine O
) O
significantly O
enhanced O
cocaine O
- O
induced O
locomotor O
activity O
of O
animals O
. O

caffeine O
had O
similar O
action O
but O
the O
effect O
was O
not O
significant O
. O

cpt O
( O
8 O
- O
cyclopentyltheophylline O
) O
- O
- O
a1 O
receptor O
antagonist O
, O
did O
not O
show O
any O
influence O
in O
this O
test O
. O

similarly O
, O
all O
adenosine O
receptor O
agonists O
decreased O
amphetamine O
- O
induced O
hyperactivity B-Disease
, O
but O
at O
the O
higher O
doses O
than O
those O
which O
were O
active O
in O
cocaine O
- O
induced O
hyperactivity B-Disease
. O

the O
selective O
blockade O
of O
a2 O
adenosine O
receptors O
( O
dmpx O
) O
and O
non O
- O
selective O
blockade O
of O
adenosine O
receptors O
( O
caffeine O
) O
significantly O
increased O
the O
action O
of O
amphetamine O
in O
the O
locomotor O
activity O
test O
. O

our O
results O
have O
shown O
that O
all O
adenosine O
receptor O
agonists O
( O
a1 O
and O
a2 O
) O
reduce O
cocaine O
- O
and O
amphetamine O
- O
induced O
locomotor O
activity O
and O
indicate O
that O
cocaine O
- O
induced O
hyperactivity B-Disease
is O
more O
influenced O
by O
adenosine O
receptor O
agonists O
( O
particularly O
a1 O
receptors O
) O
than O
amphetamine O
- O
induced O
hyperactivity B-Disease
. O

amiodarone O
and O
the O
risk O
of O
bradyarrhythmia B-Disease
requiring O
permanent O
pacemaker O
in O
elderly O
patients O
with O
atrial B-Disease
fibrillation I-Disease
and O
prior O
myocardial B-Disease
infarction I-Disease
. O

objectives O
: O
the O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
amiodarone O
in O
patients O
with O
atrial B-Disease
fibrillation I-Disease
( O
af B-Disease
) O
increases O
the O
risk O
of O
bradyarrhythmia B-Disease
requiring O
a O
permanent O
pacemaker O
. O

background O
: O
reports O
of O
severe O
bradyarrhythmia B-Disease
during O
amiodarone O
therapy O
are O
infrequent O
and O
limited O
to O
studies O
assessing O
the O
therapy O
' O
s O
use O
in O
the O
management O
of O
patients O
with O
ventricular B-Disease
arrhythmias I-Disease
. O

methods O
: O
a O
study O
cohort O
of O
8 O
, O
770 O
patients O
age O
> O
or O
= O
65 O
years O
with O
a O
new O
diagnosis O
of O
af B-Disease
was O
identified O
from O
a O
provincewide O
database O
of O
quebec O
residents O
with O
a O
myocardial B-Disease
infarction I-Disease
( O
mi B-Disease
) O
between O
1991 O
and O
1999 O
. O

using O
a O
nested O
case O
- O
control O
design O
, O
477 O
cases O
of O
bradyarrhythmia B-Disease
requiring O
a O
permanent O
pacemaker O
were O
matched O
( O
1 O
: O
4 O
) O
to O
1 O
, O
908 O
controls O
. O

multivariable O
logistic O
regression O
was O
used O
to O
estimate O
the O
odds O
ratio O
( O
or O
) O
of O
pacemaker O
insertion O
associated O
with O
amiodarone O
use O
, O
controlling O
for O
baseline O
risk O
factors O
and O
exposure O
to O
sotalol O
, O
class O
i O
antiarrhythmic O
agents O
, O
beta O
- O
blockers O
, O
calcium O
channel O
blockers O
, O
and O
digoxin O
. O

results O
: O
amiodarone O
use O
was O
associated O
with O
an O
increased O
risk O
of O
pacemaker O
insertion O
( O
or O
: O
2 O
. O
14 O
, O
95 O
% O
confidence O
interval O
[ O
ci O
] O
: O
1 O
. O
30 O
to O
3 O
. O
54 O
) O
. O

this O
effect O
was O
modified O
by O
gender O
, O
with O
a O
greater O
risk O
in O
women O
versus O
men O
( O
or O
: O
3 O
. O
86 O
, O
95 O
% O
ci O
: O
1 O
. O
70 O
to O
8 O
. O
75 O
vs O
. O
or O
: O
1 O
. O
52 O
, O
95 O
% O
ci O
: O
0 O
. O
80 O
to O
2 O
. O
89 O
) O
. O

digoxin O
was O
the O
only O
other O
medication O
associated O
with O
an O
increased O
risk O
of O
pacemaker O
insertion O
( O
or O
: O
1 O
. O
78 O
, O
95 O
% O
ci O
: O
1 O
. O
37 O
to O
2 O
. O
31 O
) O
. O

conclusions O
: O
this O
study O
suggests O
that O
the O
use O
of O
amiodarone O
in O
elderly O
patients O
with O
af B-Disease
and O
a O
previous O
mi B-Disease
increases O
the O
risk O
of O
bradyarrhythmia B-Disease
requiring O
a O
permanent O
pacemaker O
. O

the O
finding O
of O
an O
augmented O
risk O
of O
pacemaker O
insertion O
in O
elderly O
women O
receiving O
amiodarone O
requires O
further O
investigation O
. O

indomethacin O
- O
induced O
morphologic O
changes O
in O
the O
rat O
urinary O
bladder O
epithelium O
. O

objectives O
: O
to O
evaluate O
the O
morphologic O
changes O
in O
rat O
urothelium O
induced O
by O
indomethacin O
. O

nonsteroidal O
anti O
- O
inflammatory O
drug O
- O
induced O
cystitis B-Disease
is O
a O
poorly O
recognized O
and O
under O
- O
reported O
condition O
. O

in O
addition O
to O
tiaprofenic O
acid O
, O
indomethacin O
has O
been O
reported O
to O
be O
associated O
with O
this O
condition O
. O

methods O
: O
three O
groups O
were O
established O
: O
a O
control O
group O
( O
n O
= O
10 O
) O
, O
a O
high O
- O
dose O
group O
( O
n O
= O
10 O
) O
, O
treated O
with O
one O
intraperitoneal O
injection O
of O
indomethacin O
20 O
mg O
/ O
kg O
, O
and O
a O
therapeutic O
dose O
group O
( O
n O
= O
10 O
) O
in O
which O
oral O
indomethacin O
was O
administered O
3 O
. O
25 O
mg O
/ O
kg O
body O
weight O
daily O
for O
3 O
weeks O
. O

the O
animals O
were O
then O
killed O
and O
the O
bladders O
removed O
for O
light O
and O
electron O
microscopic O
studies O
. O

results O
: O
the O
light O
microscopic O
findings O
showed O
some O
focal O
epithelial O
degeneration O
that O
was O
more O
prominent O
in O
the O
high O
- O
dose O
group O
. O

when O
compared O
with O
the O
control O
group O
, O
both O
indomethacin O
groups O
revealed O
statistically O
increased O
numbers O
of O
mast O
cells O
in O
the O
mucosa O
( O
p O
< O
0 O
. O
0001 O
) O
and O
penetration O
of O
lanthanum O
nitrate O
through O
intercellular O
areas O
of O
the O
epithelium O
. O

furthermore O
, O
the O
difference O
in O
mast O
cell O
counts O
between O
the O
high O
and O
therapeutic O
dose O
groups O
was O
also O
statistically O
significant O
( O
p O
< O
0 O
. O
0001 O
) O
. O

conclusions O
: O
indomethacin O
resulted O
in O
histopathologic O
findings O
typical O
of O
interstitial B-Disease
cystitis I-Disease
, O
such O
as O
leaky O
bladder O
epithelium O
and O
mucosal O
mastocytosis B-Disease
. O

the O
true O
incidence O
of O
nonsteroidal O
anti O
- O
inflammatory O
drug O
- O
induced O
cystitis B-Disease
in O
humans O
must O
be O
clarified O
by O
prospective O
clinical O
trials O
. O

an O
open O
- O
label O
phase O
ii O
study O
of O
low O
- O
dose O
thalidomide O
in O
androgen O
- O
independent O
prostate B-Disease
cancer I-Disease
. O

the O
antiangiogenic O
effects O
of O
thalidomide O
have O
been O
assessed O
in O
clinical O
trials O
in O
patients O
with O
various O
solid O
and O
haematological B-Disease
malignancies I-Disease
. O

thalidomide O
blocks O
the O
activity O
of O
angiogenic O
agents O
including O
bfgf O
, O
vegf O
and O
il O
- O
6 O
. O

we O
undertook O
an O
open O
- O
label O
study O
using O
thalidomide O
100 O
mg O
once O
daily O
for O
up O
to O
6 O
months O
in O
20 O
men O
with O
androgen O
- O
independent O
prostate B-Disease
cancer I-Disease
. O

the O
mean O
time O
of O
study O
was O
109 O
days O
( O
median O
107 O
, O
range O
4 O
- O
184 O
days O
) O
. O

patients O
underwent O
regular O
measurement O
of O
prostate O
- O
specific O
antigen O
( O
psa O
) O
, O
urea O
and O
electrolytes O
, O
serum O
bfgf O
and O
vegf O
. O

three O
men O
( O
15 O
% O
) O
showed O
a O
decline O
in O
serum O
psa O
of O
at O
least O
50 O
% O
, O
sustained O
throughout O
treatment O
. O

of O
16 O
men O
treated O
for O
at O
least O
2 O
months O
, O
six O
( O
37 O
. O
5 O
% O
) O
showed O
a O
fall O
in O
absolute O
psa O
by O
a O
median O
of O
48 O
% O
. O

increasing O
levels O
of O
serum O
bfgf O
and O
vegf O
were O
associated O
with O
progressive O
disease O
; O
five O
of O
six O
men O
who O
demonstrated O
a O
fall O
in O
psa O
also O
showed O
a O
decline O
in O
bfgf O
and O
vegf O
levels O
, O
and O
three O
of O
four O
men O
with O
a O
rising O
psa O
showed O
an O
increase O
in O
both O
growth O
factors O
. O

adverse O
effects O
included O
constipation B-Disease
, O
morning O
drowsiness B-Disease
, O
dizziness B-Disease
and O
rash B-Disease
, O
and O
resulted O
in O
withdrawal O
from O
the O
study O
by O
three O
men O
. O

evidence O
of O
peripheral B-Disease
sensory I-Disease
neuropathy I-Disease
was O
found O
in O
nine O
of O
13 O
men O
before O
treatment O
. O

in O
the O
seven O
men O
who O
completed O
six O
months O
on O
thalidomide O
, O
subclinical O
evidence O
of O
peripheral B-Disease
neuropathy I-Disease
was O
found O
in O
four O
before O
treatment O
, O
but O
in O
all O
seven O
at O
repeat O
testing O
. O

the O
findings O
indicate O
that O
thalidomide O
may O
be O
an O
option O
for O
patients O
who O
have O
failed O
other O
forms O
of O
therapy O
, O
provided O
close O
follow O
- O
up O
is O
maintained O
for O
development O
of O
peripheral B-Disease
neuropathy I-Disease
. O

central B-Disease
nervous I-Disease
system I-Disease
toxicity I-Disease
following O
the O
administration O
of O
levobupivacaine O
for O
lumbar O
plexus O
block O
: O
a O
report O
of O
two O
cases O
. O

background O
and O
objectives O
: O
central B-Disease
nervous I-Disease
system I-Disease
and I-Disease
cardiac I-Disease
toxicity I-Disease
following O
the O
administration O
of O
local O
anesthetics O
is O
a O
recognized O
complication O
of O
regional O
anesthesia O
. O

levobupivacaine O
, O
the O
pure O
s O
( O
- O
) O
enantiomer O
of O
bupivacaine O
, O
was O
developed O
to O
improve O
the O
cardiac O
safety O
profile O
of O
bupivacaine O
. O

we O
describe O
2 O
cases O
of O
grand B-Disease
mal I-Disease
seizures I-Disease
following O
accidental O
intravascular O
injection O
of O
levobupivacaine O
. O

case O
report O
: O
two O
patients O
presenting O
for O
elective O
orthopedic O
surgery O
of O
the O
lower O
limb O
underwent O
blockade O
of O
the O
lumbar O
plexus O
via O
the O
posterior O
approach O
. O

immediately O
after O
the O
administration O
of O
levobupivacaine O
0 O
. O
5 O
% O
with O
epinephrine O
2 O
. O
5 O
microgram O
/ O
ml O
, O
the O
patients O
developed O
grand B-Disease
mal I-Disease
seizures I-Disease
, O
despite O
negative O
aspiration O
for O
blood O
and O
no O
clinical O
signs O
of O
intravenous O
epinephrine O
administration O
. O

the O
seizures B-Disease
were O
successfully O
treated O
with O
sodium O
thiopental O
in O
addition O
to O
succinylcholine O
in O
1 O
patient O
. O

neither O
patient O
developed O
signs O
of O
cardiovascular B-Disease
toxicity I-Disease
. O

both O
patients O
were O
treated O
preoperatively O
with O
beta O
- O
adrenergic O
antagonist O
medications O
, O
which O
may O
have O
masked O
the O
cardiovascular O
signs O
of O
the O
unintentional O
intravascular O
administration O
of O
levobupivacaine O
with O
epinephrine O
. O

conclusions O
: O
although O
levobupivacaine O
may O
have O
a O
safer O
cardiac B-Disease
toxicity I-Disease
profile O
than O
racemic O
bupivacaine O
, O
if O
adequate O
amounts O
of O
levobupivacaine O
reach O
the O
circulation O
, O
it O
will O
result O
in O
convulsions B-Disease
. O

plasma O
concentrations O
sufficient O
to O
result O
in O
central B-Disease
nervous I-Disease
system I-Disease
toxicity I-Disease
did O
not O
produce O
manifestations O
of O
cardiac B-Disease
toxicity I-Disease
in O
these O
2 O
patients O
. O

amiodarone O
- O
induced O
torsade B-Disease
de I-Disease
pointes I-Disease
during O
bladder O
irrigation O
: O
an O
unusual O
presentation O
- O
- O
a O
case O
report O
. O

the O
authors O
present O
a O
case O
of O
early O
( O
within O
4 O
days O
) O
development O
of O
torsade B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
associated O
with O
oral O
amiodarone O
therapy O
. O

consistent O
with O
other O
reports O
this O
case O
of O
tdp B-Disease
occurred O
in O
the O
context O
of O
multiple O
exacerbating O
factors O
including O
hypokalemia B-Disease
and O
digoxin O
excess O
. O

transient O
prolongation O
of O
the O
qt O
during O
bladder O
irrigation O
prompted O
the O
episode O
of O
tdp B-Disease
. O

it O
is O
well O
known O
that O
bradycardia B-Disease
exacerbates O
acquired O
tdp B-Disease
. O

the O
authors O
speculate O
that O
the O
increased O
vagal O
tone O
during O
bladder O
irrigation O
, O
a O
vagal O
maneuver O
, O
in O
the O
context O
of O
amiodarone O
therapy O
resulted O
in O
amiodarone O
- O
induced O
proarrhythmia B-Disease
. O

in O
the O
absence O
of O
amiodarone O
therapy O
, O
a O
second O
bladder O
irrigation O
did O
not O
induce O
tdp B-Disease
despite O
hypokalemia B-Disease
and O
hypomagnesemia B-Disease
. O

anaesthetic O
complications O
associated O
with O
myotonia B-Disease
congenita I-Disease
: O
case O
study O
and O
comparison O
with O
other O
myotonic B-Disease
disorders I-Disease
. O

myotonia B-Disease
congenita I-Disease
( O
mc B-Disease
) O
is O
caused O
by O
a O
defect O
in O
the O
skeletal O
muscle O
chloride O
channel O
function O
, O
which O
may O
cause O
sustained B-Disease
membrane I-Disease
depolarisation I-Disease
. O

we O
describe O
a O
previously O
healthy O
32 O
- O
year O
- O
old O
woman O
who O
developed O
a O
life O
- O
threatening O
muscle B-Disease
spasm I-Disease
and O
secondary O
ventilation O
difficulties O
following O
a O
preoperative O
injection O
of O
suxamethonium O
. O

the O
muscle B-Disease
spasms I-Disease
disappeared O
spontaneously O
and O
the O
surgery O
proceeded O
without O
further O
problems O
. O

when O
subsequently O
questioned O
, O
she O
reported O
minor O
symptoms O
suggesting O
a O
myotonic B-Disease
condition I-Disease
. O

myotonia B-Disease
was O
found O
on O
clinical O
examination O
and O
emg O
. O

the O
diagnosis O
mc B-Disease
was O
confirmed O
genetically O
. O

neither O
the O
patient O
nor O
the O
anaesthetist O
were O
aware O
of O
the O
diagnosis O
before O
this O
potentially O
lethal O
complication O
occurred O
. O

we O
give O
a O
brief O
overview O
of O
ion B-Disease
channel I-Disease
disorders I-Disease
including O
malignant B-Disease
hyperthermia I-Disease
and O
their O
anaesthetic O
considerations O
. O

respiratory O
pattern O
in O
a O
rat O
model O
of O
epilepsy B-Disease
. O

purpose O
: O
apnea B-Disease
is O
known O
to O
occur O
during O
seizures B-Disease
, O
but O
systematic O
studies O
of O
ictal O
respiratory O
changes O
in O
adults O
are O
few O
. O

data O
regarding O
respiratory O
pattern O
defects O
during O
interictal O
periods O
also O
are O
scarce O
. O

here O
we O
sought O
to O
generate O
information O
with O
regard O
to O
the O
interictal O
period O
in O
animals O
with O
pilocarpine O
- O
induced O
epilepsy B-Disease
. O

methods O
: O
twelve O
rats O
( O
six O
chronically O
epileptic B-Disease
animals O
and O
six O
controls O
) O
were O
anesthetized O
, O
given O
tracheotomies O
, O
and O
subjected O
to O
hyperventilation B-Disease
or O
hypoventilation O
conditions O
. O

breathing O
movements O
caused O
changes O
in O
thoracic O
volume O
and O
forced O
air O
to O
flow O
tidally O
through O
a O
pneumotachograph O
. O

this O
flow O
was O
measured O
by O
using O
a O
differential O
pressure O
transducer O
, O
passed O
through O
a O
polygraph O
, O
and O
from O
this O
to O
a O
computer O
with O
custom O
software O
that O
derived O
ventilation O
( O
ve O
) O
, O
tidal O
volume O
( O
vt O
) O
, O
inspiratory O
time O
( O
ti O
) O
, O
expiratory O
time O
( O
te O
) O
, O
breathing O
frequency O
( O
f O
) O
, O
and O
mean O
inspiratory O
flow O
( O
vt O
/ O
ti O
) O
on O
a O
breath O
- O
by O
- O
breath O
basis O
. O

results O
: O
the O
hyperventilation B-Disease
maneuver O
caused O
a O
decrease O
in O
spontaneous O
ventilation O
in O
pilocarpine O
- O
treated O
and O
control O
rats O
. O

although O
ve O
had O
a O
similar O
decrease O
in O
both O
groups O
, O
in O
the O
epileptic B-Disease
group O
, O
the O
decrease O
in O
ve O
was O
due O
to O
a O
significant O
( O
p O
< O
0 O
. O
05 O
) O
increase O
in O
te O
peak O
in O
relation O
to O
that O
of O
the O
control O
animals O
. O

the O
hypoventilation O
maneuver O
led O
to O
an O
increase O
in O
the O
arterial O
paco2 O
, O
followed O
by O
an O
increase O
in O
ve O
. O

in O
the O
epileptic B-Disease
group O
, O
the O
increase O
in O
ve O
was O
mediated O
by O
a O
significant O
( O
p O
< O
0 O
. O
05 O
) O
decrease O
in O
te O
peak O
compared O
with O
the O
control O
group O
. O

systemic O
application O
of O
kcn O
, O
to O
evaluate O
the O
effects O
of O
peripheral O
chemoreception O
activation O
on O
ventilation O
, O
led O
to O
a O
similar O
increase O
in O
ve O
for O
both O
groups O
. O

conclusions O
: O
the O
data O
indicate O
that O
pilocarpine O
- O
treated O
animals O
have O
an O
altered O
ability O
to O
react O
to O
( O
or O
compensate O
for O
) O
blood O
gas O
changes O
with O
changes O
in O
ventilation O
and O
suggest O
that O
it O
is O
centrally O
determined O
. O

we O
speculate O
on O
the O
possible O
relation O
of O
the O
current O
findings O
on O
treating O
different O
epilepsy B-Disease
- O
associated O
conditions O
. O

fatal O
myeloencephalopathy B-Disease
due O
to O
intrathecal O
vincristine O
administration O
. O

vincristine O
was O
accidentally O
given O
intrathecally O
to O
a O
child O
with O
leukaemia B-Disease
, O
producing O
sensory B-Disease
and I-Disease
motor I-Disease
dysfunction I-Disease
followed O
by O
encephalopathy B-Disease
and O
death O
. O

separate O
times O
for O
administering O
vincristine O
and O
intrathecal O
therapy O
is O
recommended O
. O

progesterone O
potentiation O
of O
bupivacaine O
arrhythmogenicity O
in O
pentobarbital O
- O
anesthetized O
rats O
and O
beating O
rat O
heart O
cell O
cultures O
. O

the O
effects O
of O
progesterone O
treatment O
on O
bupivacaine O
arrhythmogenicity O
in O
beating O
rat O
heart O
myocyte O
cultures O
and O
on O
anesthetized O
rats O
were O
determined O
. O

after O
determining O
the O
bupivacaine O
ad50 O
( O
the O
concentration O
of O
bupivacaine O
that O
caused O
50 O
% O
of O
all O
beating O
rat O
heart O
myocyte O
cultures O
to O
become O
arrhythmic B-Disease
) O
, O
we O
determined O
the O
effect O
of O
1 O
- O
hour O
progesterone O
hcl O
exposure O
on O
myocyte O
contractile O
rhythm O
. O

each O
concentration O
of O
progesterone O
( O
6 O
. O
25 O
, O
12 O
. O
5 O
, O
25 O
, O
and O
50 O
micrograms O
/ O
ml O
) O
caused O
a O
significant O
and O
concentration O
- O
dependent O
reduction O
in O
the O
ad50 O
for O
bupivacaine O
. O

estradiol O
treatment O
also O
increased O
the O
arrhythmogenicity O
of O
bupivacaine O
in O
myocyte O
cultures O
, O
but O
was O
only O
one O
fourth O
as O
potent O
as O
progesterone O
. O

neither O
progesterone O
nor O
estradiol O
effects O
on O
bupivacaine O
arrhythmogenicity O
were O
potentiated O
by O
epinephrine O
. O

chronic O
progesterone O
pretreatment O
( O
5 O
mg O
/ O
kg O
/ O
day O
for O
21 O
days O
) O
caused O
a O
significant O
increase O
in O
bupivacaine O
arrhythmogenicity O
in O
intact O
pentobarbital O
- O
anesthetized O
rats O
. O

there O
was O
a O
significant O
decrease O
in O
the O
time O
to O
onset O
of O
arrhythmia B-Disease
as O
compared O
with O
control O
nonprogesterone O
- O
treated O
rats O
( O
6 O
. O
2 O
+ O
/ O
- O
1 O
. O
3 O
vs O
. O
30 O
. O
8 O
+ O
/ O
- O
2 O
. O
5 O
min O
, O
mean O
+ O
/ O
- O
se O
) O
. O

the O
results O
of O
this O
study O
indicate O
that O
progesterone O
can O
potentiate O
bupivacaine O
arrhythmogenicity O
both O
in O
vivo O
and O
in O
vitro O
. O

potentiation O
of O
bupivacaine O
arrhythmia B-Disease
in O
myocyte O
cultures O
suggests O
that O
this O
effect O
is O
at O
least O
partly O
mediated O
at O
the O
myocyte O
level O
. O

increased O
serum O
soluble O
fas O
in O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
due O
to O
paracetamol O
overdose B-Disease
. O

background O
/ O
aims O
: O
experimental O
studies O
have O
suggested O
that O
apoptosis O
via O
the O
fas O
/ O
fas O
ligand O
signaling O
system O
may O
play O
an O
important O
role O
in O
the O
development O
of O
acute B-Disease
liver I-Disease
failure I-Disease
. O

the O
aim O
of O
the O
study O
was O
to O
investigate O
the O
soluble O
form O
of O
fas O
in O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
. O

methodology O
: O
serum O
levels O
of O
sfas O
( O
soluble O
fas O
) O
were O
measured O
by O
elisa O
in O
24 O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
and O
10 O
normal O
control O
subjects O
. O

serum O
levels O
of O
tumor B-Disease
necrosis B-Disease
factor O
- O
alpha O
and O
interferon O
- O
gamma O
were O
also O
determined O
by O
elisa O
. O

results O
: O
serum O
sfas O
was O
significantly O
increased O
in O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
( O
median O
, O
26 O
. O
8 O
u O
/ O
ml O
; O
range O
, O
6 O
. O
9 O
- O
52 O
. O
7 O
u O
/ O
ml O
) O
compared O
to O
the O
normal O
controls O
( O
median O
, O
8 O
. O
6 O
u O
/ O
ml O
; O
range O
, O
6 O
. O
5 O
- O
12 O
. O
0 O
u O
/ O
ml O
, O
p O
< O
0 O
. O
0001 O
) O
. O

levels O
were O
significantly O
greater O
in O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
due O
to O
paracetamol O
overdose B-Disease
( O
median O
, O
28 O
. O
7 O
u O
/ O
ml O
; O
range O
, O
12 O
. O
8 O
- O
52 O
. O
7 O
u O
/ O
ml O
, O
n O
= O
17 O
) O
than O
those O
due O
to O
non O
- O
a O
to O
e O
hepatitis B-Disease
( O
median O
, O
12 O
. O
5 O
u O
/ O
ml O
; O
range O
, O
6 O
. O
9 O
- O
46 O
. O
0 O
u O
/ O
ml O
, O
n O
= O
7 O
, O
p O
< O
0 O
. O
01 O
) O
. O

there O
was O
no O
relationship O
of O
sfas O
to O
eventual O
outcome O
in O
the O
patients O
. O

a O
significant O
correlation O
was O
observed O
between O
serum O
sfas O
levels O
and O
aspartate O
aminotransferase O
( O
r O
= O
0 O
. O
613 O
, O
p O
< O
0 O
. O
01 O
) O
. O

conclusions O
: O
the O
increased O
concentration O
of O
sfas O
in O
serum O
of O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
may O
reflect O
activation O
of O
fas O
- O
mediated O
apoptosis O
in O
the O
liver O
and O
this O
together O
with O
increased O
tumor B-Disease
necrosis B-Disease
factor O
- O
alpha O
may O
be O
an O
important O
factor O
in O
liver O
cell O
loss O
. O

bilateral O
subthalamic O
nucleus O
stimulation O
for O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

high O
frequency O
stimulation O
of O
the O
subthalamic O
nucleus O
( O
stn O
) O
is O
known O
to O
ameliorate O
the O
signs O
and O
symptoms O
of O
advanced O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

aim O
: O
we O
studied O
the O
effect O
of O
high O
frequency O
stn O
stimulation O
in O
23 O
patients O
. O

method O
: O
twenty O
- O
three O
patients O
suffering O
from O
severe O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
stages O
iii O
- O
v O
on O
hoehn O
and O
yahr O
scale O
) O
and O
, O
particularly O
bradykinesia B-Disease
, O
rigidity B-Disease
, O
and O
levodopa O
- O
induced O
dyskinesias B-Disease
underwent O
bilateral O
implantation O
of O
electrodes O
in O
the O
stn O
. O

preoperative O
and O
postoperative O
assessments O
of O
these O
patients O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
follow O
- O
up O
, O
in O
" O
on O
" O
and O
" O
off O
" O
drug O
conditions O
, O
was O
carried O
out O
using O
unified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
rating O
scale O
, O
hoehn O
and O
yahr O
staging O
, O
england O
activities O
of O
daily O
living O
score O
and O
video O
recordings O
. O

results O
: O
after O
one O
year O
of O
electrical O
stimulation O
of O
the O
stn O
, O
the O
patients O
' O
scores O
for O
activities O
of O
daily O
living O
and O
motor O
examination O
scores O
( O
unified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
rating O
scale O
parts O
ii O
and O
iii O
) O
off O
medication O
improved O
by O
62 O
% O
and O
61 O
% O
respectively O
( O
p O
< O
0 O
. O
0005 O
) O
. O

the O
subscores O
for O
the O
akinesia B-Disease
, O
rigidity B-Disease
, O
tremor B-Disease
and O
gait O
also O
improved O
. O

( O
p O
< O
0 O
. O
0005 O
) O
. O

the O
average O
levodopa O
dose O
decreased O
from O
813 O
mg O
to O
359 O
mg O
. O

the O
cognitive O
functions O
remained O
unchanged O
. O

two O
patients O
developed O
device O
- O
related O
complications O
and O
two O
patients O
experienced O
abnormal O
weight O
gain O
. O

conclusion O
: O
bilateral O
subthalamic O
nucleus O
stimulation O
is O
an O
effective O
treatment O
for O
advanced O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

it O
reduces O
the O
severity O
of O
" O
off O
" O
phase O
symptoms O
, O
improves O
the O
axial O
symptoms O
and O
reduces O
levodopa O
requirements O
. O

the O
reduction O
in O
the O
levodopa O
dose O
is O
useful O
in O
controlling O
drug B-Disease
- I-Disease
induced I-Disease
dyskinesias I-Disease
. O

acute B-Disease
renal I-Disease
failure I-Disease
occurring O
during O
intravenous O
desferrioxamine O
therapy O
: O
recovery O
after O
haemodialysis O
. O

a O
patient O
with O
transfusion O
- O
dependent O
thalassemia B-Disease
was O
undergoing O
home O
intravenous O
desferrioxamine O
( O
dfx O
) O
treatment O
by O
means O
of O
a O
totally O
implanted O
system O
because O
of O
his O
poor O
compliance O
with O
the O
nightly O
subcutaneous O
therapy O
. O

due O
to O
an O
accidental O
malfunctioning O
of O
the O
infusion O
pump O
, O
the O
patient O
was O
inadvertently O
administered O
a O
toxic O
dosage O
of O
the O
drug O
which O
caused O
renal B-Disease
insufficiency I-Disease
. O

given O
the O
progressive O
deterioration O
of O
the O
symptoms O
and O
of O
the O
laboratory O
values O
, O
despite O
adequate O
medical O
treatment O
, O
a O
decision O
was O
made O
to O
introduce O
haemodialytical O
therapy O
in O
order O
to O
remove O
the O
drug O
and O
therapy O
reduce O
the O
nephrotoxicity B-Disease
. O

from O
the O
results O
obtained O
, O
haemodialysis O
can O
therefore O
be O
suggested O
as O
a O
useful O
therapy O
in O
rare O
cases O
of O
progressive O
acute B-Disease
renal I-Disease
failure I-Disease
caused O
by O
desferrioxamine O
. O

ocular O
motility O
changes O
after O
subtenon O
carboplatin O
chemotherapy O
for O
retinoblastoma B-Disease
. O

background O
: O
focal O
subtenon O
carboplatin O
injections O
have O
recently O
been O
used O
as O
a O
presumably O
toxicity B-Disease
- O
free O
adjunct O
to O
systemic O
chemotherapy O
for O
intraocular O
retinoblastoma B-Disease
. O

objective O
: O
to O
report O
our O
clinical O
experience O
with O
abnormal B-Disease
ocular I-Disease
motility I-Disease
in O
patients O
treated O
with O
subtenon O
carboplatin O
chemotherapy O
. O

methods O
: O
we O
noted O
abnormal B-Disease
ocular I-Disease
motility I-Disease
in O
10 O
consecutive O
patients O
with O
retinoblastoma B-Disease
who O
had O
received O
subtenon O
carboplatin O
. O

during O
ocular O
manipulation O
under O
general O
anesthesia O
, O
we O
assessed O
their O
eyes O
by O
forced O
duction O
testing O
, O
comparing O
ocular O
motility O
after O
tumor B-Disease
control O
with O
ocular O
motility O
at O
diagnosis O
. O

eyes O
subsequently O
enucleated O
because O
of O
treatment O
failure O
( O
n O
= O
4 O
) O
were O
examined O
histologically O
. O

results O
: O
limitation O
of O
ocular O
motility O
was O
detected O
in O
all O
12 O
eyes O
of O
10 O
patients O
treated O
for O
intraocular O
retinoblastoma B-Disease
with O
1 O
to O
6 O
injections O
of O
subtenon O
carboplatin O
as O
part O
of O
multimodality O
therapy O
. O

histopathological O
examination O
revealed O
many O
lipophages O
in O
the O
periorbital O
fat O
surrounding O
the O
optic O
nerve O
in O
1 O
eye O
, O
indicative O
of O
phagocytosis O
of O
previously O
existing O
fat O
cells O
and O
suggesting O
prior O
fat O
necrosis B-Disease
. O

the O
enucleations O
were O
technically O
difficult O
and O
hazardous O
for O
globe O
rupture B-Disease
because O
of O
extensive O
orbital O
soft O
tissue O
adhesions O
. O

conclusions O
: O
subtenon O
carboplatin O
chemotherapy O
is O
associated O
with O
significant O
fibrosis B-Disease
of O
orbital O
soft O
tissues O
, O
leading O
to O
mechanical O
restriction O
of O
eye O
movements O
and O
making O
subsequent O
enucleation O
difficult O
. O

subtenon O
carboplatin O
is O
not O
free O
of O
toxicity B-Disease
, O
and O
its O
use O
is O
best O
restricted O
to O
specific O
indications O
. O

ethambutol O
and O
optic B-Disease
neuropathy I-Disease
. O

purpose O
: O
to O
demonstrate O
the O
association O
between O
ethambutol O
and O
optic B-Disease
neuropathy I-Disease
. O

method O
: O
thirteen O
patients O
who O
developed O
optic B-Disease
neuropathy I-Disease
after O
being O
treated O
with O
ethambutol O
for O
tuberculosis B-Disease
of I-Disease
the I-Disease
lung I-Disease
or I-Disease
lymph I-Disease
node I-Disease
at O
siriraj O
hospital O
between O
1997 O
and O
2001 O
were O
retrospectively O
reviewed O
. O

the O
clinical O
characteristics O
and O
initial O
and O
final O
visual O
acuity O
were O
analyzed O
to O
determine O
visual O
outcome O
. O

results O
: O
all O
patients O
had O
optic B-Disease
neuropathy I-Disease
between O
1 O
to O
6 O
months O
( O
mean O
= O
2 O
. O
9 O
months O
) O
after O
starting O
ethambutol O
therapy O
at O
a O
dosage O
ranging O
from O
13 O
to O
20 O
mg O
/ O
kg O
/ O
day O
( O
mean O
= O
17 O
mg O
/ O
kg O
/ O
day O
) O
. O

seven O
( O
54 O
% O
) O
of O
the O
13 O
patients O
experienced O
visual O
recovery O
after O
stopping O
the O
drug O
. O

of O
6 O
patients O
with O
irreversible O
visual B-Disease
impairment I-Disease
, O
4 O
patients O
had O
diabetes B-Disease
mellitus I-Disease
, O
glaucoma B-Disease
and O
a O
history O
of O
heavy O
smoking O
. O

conclusion O
: O
early O
recognition O
of O
optic B-Disease
neuropathy I-Disease
should O
be O
considered O
in O
patients O
with O
ethambutol O
therapy O
. O

a O
low O
dose O
and O
prompt O
discontinuation O
of O
the O
drug O
is O
recommended O
particularly O
in O
individuals O
with O
diabetes B-Disease
mellitus I-Disease
, O
glaucoma B-Disease
or O
who O
are O
heavy O
smokers O
. O

treatment O
of O
compensatory O
gustatory B-Disease
hyperhidrosis I-Disease
with O
topical O
glycopyrrolate O
. O

gustatory B-Disease
hyperhidrosis I-Disease
is O
facial O
sweating B-Disease
usually O
associated O
with O
the O
eating O
of O
hot O
spicy O
food O
or O
even O
smelling O
this O
food O
. O

current O
options O
of O
treatment O
include O
oral O
anticholinergic O
drugs O
, O
the O
topical O
application O
of O
anticholinergics O
or O
aluminum O
chloride O
, O
and O
the O
injection O
of O
botulinum O
toxin O
. O

thirteen O
patients O
have O
been O
treated O
to O
date O
with O
1 O
. O
5 O
% O
or O
2 O
% O
topical O
glycopyrrolate O
. O

all O
patients O
had O
gustatory B-Disease
hyperhidrosis I-Disease
, O
which O
interfered O
with O
their O
social O
activities O
, O
after O
transthroacic O
endoscopic O
sympathectomy O
, O
and O
which O
was O
associated O
with O
compensatory O
focal O
hyperhidrosis B-Disease
. O

after O
applying O
topical O
glycopyrrolate O
, O
the O
subjective O
effect O
was O
excellent O
( O
no O
sweating B-Disease
after O
eating O
hot O
spicy O
food O
) O
in O
10 O
patients O
( O
77 O
% O
) O
, O
and O
fair O
( O
clearly O
reduced O
sweating B-Disease
) O
in O
3 O
patients O
( O
23 O
% O
) O
. O

all O
had O
reported O
incidents O
of O
being O
very O
embarrassed O
whilst O
eating O
hot O
spicy O
foods O
. O

adverse O
effects O
included O
a O
mildly O
dry B-Disease
mouth I-Disease
and O
a O
sore B-Disease
throat I-Disease
in O
2 O
patients O
( O
2 O
% O
glycopyrrolate O
) O
, O
a O
light O
headache B-Disease
in O
1 O
patient O
( O
1 O
. O
5 O
% O
glycopyrrolate O
) O
. O

the O
topical O
application O
of O
a O
glycopyrrolate O
pad O
appeared O
to O
be O
safe O
, O
efficacious O
, O
well O
tolerated O
, O
and O
a O
convenient O
method O
of O
treatment O
for O
moderate O
to O
severe O
symptoms O
of O
gustatory B-Disease
hyperhidrosis I-Disease
in O
post O
transthoracic O
endoscopic O
sympathectomy O
or O
sympathicotomy O
patients O
, O
with O
few O
side O
effects O
. O

neuroleptic O
- O
associated O
hyperprolactinemia B-Disease
. O

can O
it O
be O
treated O
with O
bromocriptine O
? O

six O
stable O
psychiatric O
outpatients O
with O
hyperprolactinemia B-Disease
and O
amenorrhea B-Disease
/ O
oligomenorrhea B-Disease
associated O
with O
their O
neuroleptic O
medications O
were O
treated O
with O
bromocriptine O
. O

daily O
dosages O
of O
5 O
- O
10 O
mg O
corrected O
the O
hyperprolactinemia B-Disease
and O
restored O
menstruation O
in O
four O
of O
the O
six O
patients O
. O

one O
woman O
, O
however O
, O
developed O
worsened O
psychiatric B-Disease
symptoms I-Disease
while O
taking O
bromocriptine O
, O
and O
it O
was O
discontinued O
. O

thus O
, O
three O
of O
six O
patients O
had O
their O
menstrual O
irregularity O
successfully O
corrected O
with O
bromocriptine O
. O

this O
suggests O
that O
bromocriptine O
should O
be O
further O
evaluated O
as O
potential O
therapy O
for O
neuroleptic O
- O
associated O
hyperprolactinemia B-Disease
and O
amenorrhea B-Disease
/ O
galactorrhea B-Disease
. O

ethacrynic O
acid O
- O
induced O
convulsions B-Disease
and O
brain O
neurotransmitters O
in O
mice O
. O

intracerebroventricular O
injection O
of O
ethacrynic O
acid O
( O
50 O
% O
convulsive B-Disease
dose O
; O
50 O
micrograms O
/ O
mouse O
) O
accelerated O
the O
synthesis O
/ O
turnover O
of O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
ht O
) O
but O
suppressed O
the O
synthesis O
of O
gamma O
- O
aminobutyric O
acid O
and O
acetylcholine O
in O
mouse O
brain O
. O

these O
effects O
were O
completely O
antagonized O
by O
pretreatment O
with O
a O
glutamate O
/ O
n O
- O
methyl O
- O
d O
- O
aspartate O
antagonist O
, O
aminophosphonovaleric O
acid O
. O

in O
ethacrynic O
acid O
- O
induced O
convulsions B-Disease
, O
these O
neurotransmitter O
systems O
may O
be O
differentially O
modulated O
, O
probably O
through O
activation O
of O
glutaminergic O
neurons O
in O
the O
brain O
. O

pharmacology O
of O
gamma O
- O
aminobutyric O
acida O
receptor O
complex O
after O
the O
in O
vivo O
administration O
of O
the O
anxioselective O
and O
anticonvulsant O
beta O
- O
carboline O
derivative O
abecarnil O
. O

in O
rodents O
, O
the O
effect O
of O
the O
beta O
- O
carboline O
derivative O
isopropyl O
- O
6 O
- O
benzyloxy O
- O
4 O
- O
methoxymethyl O
- O
beta O
- O
carboline O
- O
3 O
- O
carboxylate O
( O
abecarrnil O
) O
, O
a O
new O
ligand O
for O
benzodiazepine O
receptors O
possessing O
anxiolytic O
and O
anticonvulsant O
properties O
, O
was O
evaluated O
on O
the O
function O
of O
central O
gamma O
- O
aminobutyric O
acid O
( O
gaba O
) O
a O
receptor O
complex O
, O
both O
in O
vitro O
and O
in O
vivo O
. O

added O
in O
vitro O
to O
rat O
cortical O
membrane O
preparation O
, O
abecarnil O
increased O
[ O
3h O
] O
gaba O
binding O
, O
enhanced O
muscimol O
- O
stimulated O
36cl O
- O
uptake O
and O
reduced O
the O
binding O
of O
t O
- O
[ O
35s O
] O
butylbicyclophosphorothionate O
( O
[ O
35s O
] O
tbps O
) O
. O

these O
effects O
were O
similar O
to O
those O
induced O
by O
diazepam O
, O
whereas O
the O
partial O
agonist O
ro O
16 O
- O
6028 O
( O
tert O
- O
butyl O
- O
( O
s O
) O
- O
8 O
- O
bromo O
- O
11 O
, O
12 O
, O
13 O
, O
13a O
- O
tetrahydro O
- O
9 O
- O
oxo O
- O
9h O
- O
imidazo O
[ O
1 O
, O
5 O
- O
a O
] O
- O
pyrrolo O
- O
[ O
2 O
, O
1 O
- O
c O
] O
[ O
1 O
, O
4 O
] O
benzodiazepine O
- O
1 O
- O
carboxylate O
) O
showed O
very O
weak O
efficacy O
in O
these O
biochemical O
tests O
. O

after O
i O
. O
p O
. O
injection O
to O
rats O
, O
abecarnil O
and O
diazepam O
decreased O
in O
a O
time O
- O
dependent O
and O
dose O
- O
related O
( O
0 O
. O
25 O
- O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
manner O
[ O
35s O
] O
tbps O
binding O
measured O
ex O
vivo O
in O
the O
cerebral O
cortex O
. O

moreover O
, O
both O
drugs O
at O
the O
dose O
of O
0 O
. O
5 O
mg O
/ O
kg O
antagonized O
completely O
the O
convulsant O
activity O
and O
the O
increase O
of O
[ O
35s O
] O
tbps O
binding O
induced O
by O
isoniazide O
( O
350 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
as O
well O
as O
the O
increase O
of O
[ O
35s O
] O
tbps O
binding O
induced O
by O
foot O
- O
shock O
stress O
. O

to O
better O
correlate O
the O
biochemical O
and O
the O
pharmacological O
effects O
, O
we O
studied O
the O
action O
of O
abecarnil O
on O
[ O
35s O
] O
tbps O
binding O
, O
exploratory O
motility O
and O
on O
isoniazid O
- O
induced O
biochemical O
and O
pharmacological O
effects O
in O
mice O
. O

in O
these O
animals O
, O
abecarnil O
produced O
a O
paralleled O
dose O
- O
dependent O
( O
0 O
. O
05 O
- O
1 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
reduction O
of O
both O
motor O
behavior O
and O
cortical O
[ O
35s O
] O
tbps O
binding O
. O

moreover O
, O
0 O
. O
05 O
mg O
/ O
kg O
of O
this O
beta O
- O
carboline O
reduced O
markedly O
the O
increase O
of O
[ O
35s O
] O
tbps O
binding O
and O
the O
convulsions B-Disease
induced O
by O
isoniazid O
( O
200 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

recurrent O
myocardial B-Disease
infarction I-Disease
in O
a O
postpartum O
patient O
receiving O
bromocriptine O
. O

myocardial B-Disease
infarction I-Disease
in O
puerperium O
is O
infrequently O
reported O
. O

spasm B-Disease
, O
coronary O
dissection O
, O
or O
atheromatous O
etiology O
has O
been O
described O
. O

bromocriptine O
has O
been O
implicated O
in O
several O
previous O
case O
reports O
of O
myocardial B-Disease
infarction I-Disease
in O
the O
puerperium O
. O

our O
case O
( O
including O
an O
inadvertent O
rechallenge O
) O
suggests O
such O
a O
relationship O
. O

although O
generally O
regarded O
as O
" O
safe O
, O
" O
possible O
serious O
cardiac O
effects O
of O
bromocriptine O
should O
be O
acknowledged O
. O

asterixis B-Disease
induced O
by O
carbamazepine O
therapy O
. O

there O
are O
very O
few O
reports O
about O
asterixis B-Disease
as O
a O
side O
effect O
of O
treatment O
with O
psychopharmacologic O
agents O
. O

in O
this O
report O
we O
present O
four O
patients O
treated O
with O
a O
combination O
of O
different O
psychotropic O
drugs O
, O
in O
whom O
asterixis B-Disease
was O
triggered O
either O
by O
adding O
carbamazepine O
( O
cbz O
) O
to O
a O
treatment O
regimen O
, O
or O
by O
increasing O
its O
dosage O
. O

neither O
dosage O
nor O
serum O
levels O
of O
cbz O
were O
in O
a O
higher O
range O
. O

we O
consider O
asterixis B-Disease
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity B-Disease
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium O
or O
clozapine O
are O
used O
in O
combination O
with O
cbz O
. O

pharmacodynamics O
of O
the O
hypotensive B-Disease
effect O
of O
levodopa O
in O
parkinsonian B-Disease
patients O
. O

blood O
pressure O
effects O
of O
i O
. O
v O
. O
levodopa O
were O
examined O
in O
parkinsonian B-Disease
patients O
with O
stable O
and O
fluctuating O
responses O
to O
levodopa O
. O

the O
magnitude O
of O
the O
hypotensive B-Disease
effect O
of O
levodopa O
was O
concentration O
dependent O
and O
was O
fit O
to O
an O
emax O
model O
in O
fluctuating O
responders O
. O

stable O
responders O
demonstrated O
a O
small O
hypotensive B-Disease
response O
. O

baseline O
blood O
pressures O
were O
higher O
in O
fluctuating O
patients O
; O
a O
higher O
baseline O
blood O
pressure O
correlated O
with O
greater O
hypotensive B-Disease
effects O
. O

antiparkinsonian O
effects O
of O
levodopa O
temporally O
correlated O
with O
blood O
pressure O
changes O
. O

phenylalanine O
, O
a O
large O
neutral O
amino O
acid O
( O
lnaa O
) O
competing O
with O
levodopa O
for O
transport O
across O
the O
blood O
- O
brain O
barrier O
, O
reduced O
the O
hypotensive B-Disease
and O
antiparkinsonian O
effects O
of O
levodopa O
. O

we O
conclude O
that O
levodopa O
has O
a O
central O
hypotensive B-Disease
action O
that O
parallels O
the O
motor O
effects O
in O
fluctuating O
patients O
. O

the O
hypotensive B-Disease
effect O
appears O
to O
be O
related O
to O
the O
higher O
baseline O
blood O
pressure O
we O
observed O
in O
fluctuating O
patients O
relative O
to O
stable O
patients O
. O

syndrome B-Disease
of I-Disease
inappropriate I-Disease
secretion I-Disease
of I-Disease
antidiuretic I-Disease
hormone I-Disease
after O
infusional O
vincristine O
. O

a O
77 O
- O
year O
- O
old O
woman O
with O
refractory O
multiple B-Disease
myeloma I-Disease
was O
treated O
with O
a O
4 O
- O
day O
continuous O
intravenous O
infusion O
of O
vincristine O
and O
doxorubicin O
and O
4 O
days O
of O
oral O
dexamethasone O
. O

nine O
days O
after O
her O
second O
cycle O
she O
presented O
with O
lethargy B-Disease
and O
weakness B-Disease
associated O
with O
hyponatremia B-Disease
. O

evaluation O
revealed O
the O
syndrome B-Disease
of I-Disease
inappropriate I-Disease
secretion I-Disease
of I-Disease
antidiuretic I-Disease
hormone I-Disease
, O
which O
was O
attributed O
to O
the O
vincristine O
infusion O
. O

after O
normal O
serum O
sodium O
levels O
returned O
, O
further O
doxorubicin O
and O
dexamethasone O
chemotherapy O
without O
vincristine O
did O
not O
produce O
this O
complication O
. O

heart B-Disease
failure I-Disease
: O
to O
digitalise O
or O
not O
? O

the O
view O
against O
. O

despite O
extensive O
clinical O
experience O
the O
role O
of O
digoxin O
is O
still O
not O
well O
defined O
. O

in O
patients O
with O
atrial B-Disease
fibrillation I-Disease
digoxin O
is O
beneficial O
for O
ventricular O
rate O
control O
. O

for O
patients O
in O
sinus O
rhythm O
and O
heart B-Disease
failure I-Disease
the O
situation O
is O
less O
clear O
. O

digoxin O
has O
a O
narrow O
therapeutic O
: O
toxic O
ratio O
and O
concentrations O
are O
affected O
by O
a O
number O
of O
drugs O
. O

also O
, O
digoxin O
has O
undesirable O
effects O
such O
as O
increasing O
peripheral O
resistance O
and O
myocardial O
demands O
, O
and O
causing O
arrhythmias B-Disease
. O

there O
is O
a O
paucity O
of O
data O
from O
well O
- O
designed O
trials O
. O

the O
trials O
that O
are O
available O
are O
generally O
small O
with O
limitations O
in O
design O
and O
these O
show O
variation O
in O
patient O
benefit O
. O

more O
convincing O
evidence O
is O
required O
showing O
that O
digoxin O
improves O
symptoms O
or O
exercise O
capacity O
. O

furthermore O
, O
no O
trial O
has O
had O
sufficient O
power O
to O
evaluate O
mortality O
. O

pooled O
analysis O
of O
the O
effects O
of O
other O
inotropic O
drugs O
shows O
an O
excess O
mortality O
and O
there O
is O
a O
possibility O
that O
digoxin O
may O
increase O
mortality O
after O
myocardial B-Disease
infarction I-Disease
( O
mi B-Disease
) O
. O

angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
inhibitors O
should O
be O
used O
first O
as O
they O
are O
safer O
, O
do O
not O
require O
blood O
level O
monitoring O
, O
modify O
progression O
of O
disease O
, O
relieve O
symptoms O
, O
improve O
exercise O
tolerance O
and O
reduce O
mortality O
. O

caution O
should O
be O
exercised O
in O
using O
digoxin O
until O
large O
mortality O
trials O
are O
completed O
showing O
either O
benefit O
or O
harm O
. O

until O
then O
digoxin O
should O
be O
considered O
a O
third O
- O
line O
therapy O
. O

isradipine O
treatment O
for O
hypertension B-Disease
in O
general O
practice O
in O
hong O
kong O
. O

a O
6 O
- O
week O
open O
study O
of O
the O
introduction O
of O
isradipine O
treatment O
was O
conducted O
in O
general O
practice O
in O
hong O
kong O
. O

303 O
chinese O
patients O
with O
mild O
to O
moderate O
hypertension B-Disease
entered O
the O
study O
. O

side O
effects O
were O
reported O
in O
21 O
% O
of O
patients O
and O
caused O
withdrawal O
from O
the O
study O
in O
3 O
patients O
. O

the O
main O
side O
- O
effects O
were O
headache B-Disease
, O
dizziness B-Disease
, O
palpitation B-Disease
and O
flushing B-Disease
and O
these O
were O
not O
more O
frequent O
than O
reported O
in O
other O
studies O
with O
isradipine O
or O
with O
placebo O
. O

supine O
blood O
pressure O
was O
reduced O
( O
p O
less O
than O
0 O
. O
01 O
) O
from O
170 O
+ O
/ O
- O
20 O
/ O
102 O
+ O
/ O
- O
6 O
mmhg O
to O
153 O
+ O
/ O
- O
19 O
/ O
92 O
+ O
/ O
- O
8 O
, O
147 O
+ O
/ O
- O
18 O
/ O
88 O
+ O
/ O
- O
7 O
and O
144 O
+ O
/ O
- O
14 O
/ O
87 O
+ O
/ O
- O
6 O
mmhg O
at O
2 O
, O
4 O
and O
6 O
weeks O
respectively O
in O
evaluable O
patients O
. O

similar O
reductions O
occurred O
in O
standing O
blood O
pressure O
and O
there O
was O
no O
evidence O
of O
postural B-Disease
hypotension I-Disease
. O

normalization O
and O
responder O
rates O
at O
6 O
weeks O
were O
86 O
% O
and O
69 O
% O
respectively O
. O

dosage O
was O
increased O
from O
2 O
. O
5 O
mg O
b O
. O
d O
. O
to O
5 O
mg O
b O
. O
d O
. O
at O
4 O
weeks O
in O
patients O
with O
diastolic O
blood O
pressure O
greater O
than O
90 O
mmhg O
and O
their O
further O
response O
was O
greater O
than O
those O
remaining O
on O
2 O
. O
5 O
mg O
b O
. O
d O
. O

pharmacological O
characteristics O
and O
side O
effects O
of O
a O
new O
galenic O
formulation O
of O
propofol O
without O
soyabean O
oil O
. O

we O
compared O
the O
pharmacokinetics O
, O
pharmacodynamics O
and O
safety O
profile O
of O
a O
new O
galenic O
formulation O
of O
propofol O
( O
am149 O
1 O
% O
) O
, O
which O
does O
not O
contain O
soyabean O
oil O
, O
with O
a O
standard O
formulation O
of O
propofol O
( O
disoprivan O
1 O
% O
) O
. O

in O
a O
randomised O
, O
double O
- O
blind O
, O
cross O
- O
over O
study O
, O
30 O
healthy O
volunteers O
received O
a O
single O
intravenous O
bolus O
injection O
of O
2 O
. O
5 O
mg O
. O
kg O
- O
1 O
propofol O
. O

plasma O
propofol O
levels O
were O
measured O
for O
48 O
h O
following O
drug O
administration O
and O
evaluated O
according O
to O
a O
three O
- O
compartment O
model O
. O

the O
pharmacodynamic O
parameters O
assessed O
included O
induction O
and O
emergence O
times O
, O
respiratory O
and O
cardiovascular O
effects O
, O
and O
pain B-Disease
on O
injection O
. O

patients O
were O
monitored O
for O
side O
effects O
over O
48 O
h O
. O

owing O
to O
a O
high O
incidence O
of O
thrombophlebitis B-Disease
, O
the O
study O
was O
terminated O
prematurely O
and O
only O
the O
data O
of O
the O
two O
parallel O
treatment O
groups O
( O
15 O
patients O
in O
each O
group O
) O
were O
analysed O
. O

plasma O
concentrations O
did O
not O
differ O
significantly O
between O
the O
two O
formulations O
. O

anaesthesia O
induction O
and O
emergence O
times O
, O
respiratory O
and O
cardiovascular O
variables O
showed O
no O
significant O
differences O
between O
the O
two O
treatment O
groups O
. O

pain B-Disease
on O
injection O
( O
80 O
vs O
. O
20 O
% O
, O
p O
< O
0 O
. O
01 O
) O
and O
thrombophlebitis B-Disease
( O
93 O
. O
3 O
vs O
. O
6 O
. O
6 O
% O
, O
p O
< O
0 O
. O
001 O
) O
occurred O
more O
frequently O
with O
am149 O
than O
with O
disoprivan O
. O

although O
both O
formulations O
had O
similar O
pharmacokinetic O
and O
pharmacodynamic O
profiles O
the O
new O
formulation O
is O
not O
suitable O
for O
clinical O
use O
due O
to O
the O
high O
incidence O
of O
thrombophlebitis B-Disease
produced O
. O

pure B-Disease
red I-Disease
cell I-Disease
aplasia I-Disease
, O
toxic B-Disease
dermatitis I-Disease
and O
lymphadenopathy B-Disease
in O
a O
patient O
taking O
diphenylhydantoin O
. O

a O
patient O
taking O
diphenylhydantoin O
for O
3 O
weeks O
developed O
a O
generalized O
skin B-Disease
rash I-Disease
, O
lymphadenopathy B-Disease
and O
pure B-Disease
red I-Disease
cell I-Disease
aplasia I-Disease
. O

after O
withdrawal O
of O
the O
pharmacon O
all O
symptoms O
disappeared O
spontaneously O
. O

skin B-Disease
rash I-Disease
is O
a O
well O
- O
known O
complication O
of O
diphenylhydantoin O
treatment O
as O
is O
benign O
and O
malignant O
lymphadenopathy B-Disease
. O

pure B-Disease
red I-Disease
cell I-Disease
aplasia I-Disease
associated O
with O
diphenylhydantoin O
medication O
has O
been O
reported O
in O
3 O
patients O
. O

the O
exact O
mechanism O
by O
which O
diphenylhydantoin O
exerts O
its O
toxic O
effects O
is O
not O
known O
. O

in O
this O
patient O
the O
time O
relation O
between O
the O
ingestion O
of O
diphenylhydantoin O
and O
the O
occurrence O
of O
the O
skin B-Disease
rash I-Disease
, O
lymphadenopathy B-Disease
and O
pure B-Disease
red I-Disease
cell I-Disease
aplasia I-Disease
is O
very O
suggestive O
of O
a O
direct O
connection O
. O

vinorelbine O
- O
related O
cardiac O
events O
: O
a O
meta O
- O
analysis O
of O
randomized O
clinical O
trials O
. O

several O
cases O
of O
cardiac O
adverse O
reactions O
related O
to O
vinorelbine O
( O
vnr O
) O
have O
been O
reported O
in O
the O
literature O
. O

in O
order O
to O
quantify O
the O
incidence O
of O
these O
cardiac O
events O
, O
we O
performed O
a O
meta O
- O
analysis O
of O
clinical O
trials O
comparing O
vnr O
with O
other O
chemotherapeutic O
agents O
in O
the O
treatment O
of O
various O
malignancies B-Disease
. O

randomized O
clinical O
trials O
comparing O
vnr O
with O
other O
drugs O
in O
the O
treatment O
of O
cancer B-Disease
were O
searched O
in O
medline O
, O
embase O
, O
evidence O
- O
based O
medicine O
reviews O
databases O
and O
the O
cochrane O
library O
from O
1987 O
to O
2002 O
. O

outcomes O
of O
interest O
were O
severe O
cardiac O
events O
, O
toxic O
deaths O
and O
cardiac O
event O
- O
related O
deaths O
reported O
in O
each O
publication O
. O

we O
found O
19 O
trials O
, O
involving O
2441 O
patients O
treated O
by O
vnr O
and O
2050 O
control O
patients O
. O

the O
incidence O
of O
cardiac O
events O
with O
vnr O
was O
1 O
. O
19 O
% O
[ O
95 O
% O
confidence O
interval O
( O
ci O
) O
( O
0 O
. O
75 O
; O
1 O
. O
67 O
) O
] O
. O

there O
was O
no O
difference O
in O
the O
risk O
of O
cardiac O
events O
between O
vnr O
and O
other O
drugs O
[ O
odds O
ratio O
: O
0 O
. O
92 O
, O
95 O
% O
ci O
( O
0 O
. O
54 O
; O
1 O
. O
55 O
) O
] O
. O

the O
risk O
of O
vnr O
cardiac O
events O
was O
similar O
to O
vindesine O
( O
vds O
) O
and O
other O
cardiotoxic B-Disease
drugs O
[ O
fluorouracil O
, O
anthracyclines O
, O
gemcitabine O
( O
gem O
) O
em O
leader O
] O
. O

even O
if O
it O
did O
not O
reach O
statistical O
significance O
because O
of O
a O
few O
number O
of O
cases O
, O
the O
risk O
was O
lower O
in O
trials O
excluding O
patients O
with O
cardiac O
history O
, O
and O
seemed O
to O
be O
higher O
in O
trials O
including O
patients O
with O
pre O
- O
existing O
cardiac B-Disease
diseases I-Disease
. O

vinorelbine O
- O
related O
cardiac O
events O
concern O
about O
1 O
% O
of O
treated O
patients O
in O
clinical O
trials O
. O

however O
, O
the O
risk O
associated O
with O
vnr O
seems O
to O
be O
similar O
to O
that O
of O
other O
chemotherapeutic O
agents O
in O
the O
same O
indications O
. O

mri O
findings O
of O
hypoxic O
cortical O
laminar O
necrosis B-Disease
in O
a O
child O
with O
hemolytic B-Disease
anemia I-Disease
crisis O
. O

we O
present O
magnetic O
resonance O
imaging O
findings O
of O
a O
5 O
- O
year O
- O
old O
girl O
who O
had O
a O
rapidly O
installing O
hemolytic B-Disease
anemia I-Disease
crisis O
induced O
by O
trimethoprim O
- O
sulfomethoxazole O
, O
resulting O
in O
cerebral B-Disease
anoxia I-Disease
leading O
to O
permanent O
damage O
. O

magnetic O
resonance O
imaging O
revealed O
cortical O
laminar O
necrosis B-Disease
in O
arterial O
border O
zones O
in O
both O
cerebral O
hemispheres O
, O
ischemic O
changes O
in O
subcortical O
white O
matter O
of O
left O
cerebral O
hemisphere O
, O
and O
in O
the O
left O
putamen O
. O

although O
cortical O
laminar O
necrosis B-Disease
is O
a O
classic O
entity O
in O
adulthood O
related O
to O
conditions O
of O
energy O
depletions O
, O
there O
are O
few O
reports O
available O
in O
children O
. O

a O
wide O
review O
of O
the O
literature O
is O
also O
presented O
. O

the O
natural O
history O
of O
vigabatrin O
associated O
visual B-Disease
field I-Disease
defects I-Disease
in O
patients O
electing O
to O
continue O
their O
medication O
. O

purpose O
: O
to O
determine O
the O
natural O
history O
of O
visual B-Disease
field I-Disease
defects I-Disease
in O
a O
group O
of O
patients O
known O
to O
have O
vigabatrin O
- O
associated O
changes O
who O
elected O
to O
continue O
the O
medication O
because O
of O
good O
seizure B-Disease
control O
. O

methods O
: O
all O
patients O
taking O
vigabatrin O
alone O
or O
in O
combination O
with O
other O
antiepileptic O
drugs O
for O
at O
least O
5 O
years O
( O
range O
5 O
- O
12 O
years O
) O
were O
entered O
into O
a O
visual O
surveillance O
programme O
. O

patients O
were O
followed O
up O
at O
6 O
- O
monthly O
intervals O
for O
not O
less O
than O
18 O
months O
( O
range O
18 O
- O
43 O
months O
) O
. O

in O
all O
, O
16 O
patients O
with O
unequivocal O
defects O
continued O
the O
medication O
. O

following O
already O
published O
methodology O
( O
eye O
2002 O
; O
16 O
; O
567 O
- O
571 O
) O
monocular O
mean O
radial O
degrees O
( O
mrds O
) O
to O
the O
i O
/ O
4e O
isopter O
on O
goldmann O
perimetry O
was O
calculated O
for O
the O
right O
eye O
at O
the O
time O
of O
discovery O
of O
a O
visual B-Disease
field I-Disease
defect I-Disease
and O
again O
after O
not O
less O
than O
18 O
months O
follow O
- O
up O
. O

results O
: O
mean O
right O
eye O
mrd O
at O
presentation O
was O
36 O
. O
98 O
degrees O
( O
range O
22 O
. O
25 O
- O
51 O
. O
0 O
) O
, O
compared O
to O
38 O
. O
40 O
degrees O
( O
range O
22 O
. O
5 O
- O
49 O
. O
75 O
) O
after O
follow O
- O
up O
; O
p O
= O
0 O
. O
338 O
unpaired O
t O
- O
test O
. O

only O
one O
patient O
demonstrated O
a O
deterioration B-Disease
in I-Disease
visual I-Disease
field I-Disease
during O
the O
study O
period O
and O
discontinued O
treatment O
. O

conclusion O
: O
established O
visual B-Disease
field I-Disease
defects I-Disease
presumed O
to O
be O
due O
to O
vigabatrin O
therapy O
did O
not O
usually O
progress O
in O
spite O
of O
continuing O
use O
of O
the O
medication O
. O

these O
data O
give O
support O
to O
the O
hypothesis O
that O
the O
pathogenesis O
of O
vigabatrin O
- O
associated O
visual B-Disease
field I-Disease
defects I-Disease
may O
be O
an O
idiosyncratic O
adverse O
drug O
reaction O
rather O
than O
dose O
- O
dependent O
toxicity B-Disease
. O

induction O
of O
rosaceiform O
dermatitis B-Disease
during O
treatment O
of O
facial B-Disease
inflammatory I-Disease
dermatoses I-Disease
with O
tacrolimus O
ointment O
. O

background O
: O
tacrolimus O
ointment O
is O
increasingly O
used O
for O
anti O
- O
inflammatory O
treatment O
of O
sensitive O
areas O
such O
as O
the O
face O
, O
and O
recent O
observations O
indicate O
that O
the O
treatment O
is O
effective O
in O
steroid O
- O
aggravated O
rosacea B-Disease
and O
perioral B-Disease
dermatitis I-Disease
. O

we O
report O
on O
rosaceiform O
dermatitis B-Disease
as O
a O
complication O
of O
treatment O
with O
tacrolimus O
ointment O
. O

observations O
: O
six O
adult O
patients O
with O
inflammatory B-Disease
facial I-Disease
dermatoses I-Disease
were O
treated O
with O
tacrolimus O
ointment O
because O
of O
the O
ineffectiveness O
of O
standard O
treatments O
. O

within O
2 O
to O
3 O
weeks O
of O
initially O
effective O
and O
well O
- O
tolerated O
treatment O
, O
3 O
patients O
with O
a O
history O
of O
rosacea B-Disease
and O
1 O
with O
a O
history O
of O
acne B-Disease
experienced O
sudden O
worsening O
with O
pustular O
rosaceiform O
lesions O
. O

biopsy O
revealed O
an O
abundance O
of O
demodex O
mites O
in O
2 O
of O
these O
patients O
. O

in O
1 O
patient O
with O
eyelid O
eczema B-Disease
, O
rosaceiform O
periocular B-Disease
dermatitis I-Disease
gradually O
appeared O
after O
3 O
weeks O
of O
treatment O
. O

in O
1 O
patient O
with O
atopic B-Disease
dermatitis I-Disease
, O
telangiectatic O
and O
papular B-Disease
rosacea I-Disease
insidiously O
appeared O
after O
5 O
months O
of O
treatment O
. O

conclusions O
: O
our O
observations O
suggest O
that O
the O
spectrum O
of O
rosaceiform O
dermatitis B-Disease
as O
a O
complication O
of O
treatment O
with O
tacrolimus O
ointment O
is O
heterogeneous O
. O

a O
variety O
of O
factors O
, O
such O
as O
vasoactive O
properties O
of O
tacrolimus O
, O
proliferation O
of O
demodex O
due O
to O
local O
immunosuppression O
, O
and O
the O
occlusive O
properties O
of O
the O
ointment O
, O
may O
be O
involved O
in O
the O
observed O
phenomena O
. O

future O
studies O
are O
needed O
to O
identify O
individual O
risk O
factors O
. O

intravascular O
hemolysis B-Disease
and O
acute B-Disease
renal I-Disease
failure I-Disease
following O
intermittent O
rifampin O
therapy O
. O

renal B-Disease
failure I-Disease
is O
a O
rare O
complication O
associated O
with O
the O
use O
of O
rifampin O
. O

intravascular O
hemolysis B-Disease
leading O
to O
acute B-Disease
renal I-Disease
failure I-Disease
following O
rifampin O
therapy O
is O
extremely O
rare O
. O

two O
patients O
with O
leprosy B-Disease
who O
developed O
hemolysis B-Disease
and O
acute B-Disease
renal I-Disease
failure I-Disease
following O
rifampin O
are O
reported O
. O

structural O
abnormalities O
in O
the O
brains O
of O
human O
subjects O
who O
use O
methamphetamine O
. O

we O
visualize O
, O
for O
the O
first O
time O
, O
the O
profile O
of O
structural B-Disease
deficits I-Disease
in I-Disease
the I-Disease
human I-Disease
brain I-Disease
associated O
with O
chronic O
methamphetamine O
( O
ma O
) O
abuse O
. O

studies O
of O
human O
subjects O
who O
have O
used O
ma O
chronically O
have O
revealed O
deficits O
in O
dopaminergic O
and O
serotonergic O
systems O
and O
cerebral O
metabolic B-Disease
abnormalities I-Disease
. O

using O
magnetic O
resonance O
imaging O
( O
mri O
) O
and O
new O
computational O
brain O
- O
mapping O
techniques O
, O
we O
determined O
the O
pattern O
of O
structural O
brain O
alterations O
associated O
with O
chronic O
ma O
abuse O
in O
human O
subjects O
and O
related O
these O
deficits O
to O
cognitive B-Disease
impairment I-Disease
. O

we O
used O
high O
- O
resolution O
mri O
and O
surface O
- O
based O
computational O
image O
analyses O
to O
map O
regional O
abnormalities B-Disease
in I-Disease
the I-Disease
cortex I-Disease
, I-Disease
hippocampus I-Disease
, I-Disease
white I-Disease
matter I-Disease
, I-Disease
and I-Disease
ventricles I-Disease
in O
22 O
human O
subjects O
who O
used O
ma O
and O
21 O
age O
- O
matched O
, O
healthy O
controls O
. O

cortical O
maps O
revealed O
severe O
gray O
- O
matter O
deficits O
in O
the O
cingulate O
, O
limbic O
, O
and O
paralimbic O
cortices O
of O
ma O
abusers O
( O
averaging O
11 O
. O
3 O
% O
below O
control O
; O
p O
< O
0 O
. O
05 O
) O
. O

on O
average O
, O
ma O
abusers O
had O
7 O
. O
8 O
% O
smaller O
hippocampal O
volumes O
than O
control O
subjects O
( O
p O
< O
0 O
. O
01 O
; O
left O
, O
p O
= O
0 O
. O
01 O
; O
right O
, O
p O
< O
0 O
. O
05 O
) O
and O
significant O
white O
- O
matter O
hypertrophy B-Disease
( O
7 O
. O
0 O
% O
; O
p O
< O
0 O
. O
01 O
) O
. O

hippocampal O
deficits O
were O
mapped O
and O
correlated O
with O
memory O
performance O
on O
a O
word O
- O
recall O
test O
( O
p O
< O
0 O
. O
05 O
) O
. O

mri O
- O
based O
maps O
suggest O
that O
chronic O
methamphetamine O
abuse O
causes O
a O
selective O
pattern O
of O
cerebral O
deterioration O
that O
contributes O
to O
impaired B-Disease
memory I-Disease
performance I-Disease
. O

ma O
may O
selectively O
damage O
the O
medial O
temporal O
lobe O
and O
, O
consistent O
with O
metabolic O
studies O
, O
the O
cingulate O
- O
limbic O
cortex O
, O
inducing O
neuroadaptation O
, O
neuropil O
reduction O
, O
or O
cell O
death O
. O

prominent O
white O
- O
matter O
hypertrophy B-Disease
may O
result O
from O
altered O
myelination O
and O
adaptive O
glial O
changes O
, O
including O
gliosis B-Disease
secondary O
to O
neuronal B-Disease
damage I-Disease
. O

these O
brain O
substrates O
may O
help O
account O
for O
the O
symptoms O
of O
ma O
abuse O
, O
providing O
therapeutic O
targets O
for O
drug O
- O
induced O
brain B-Disease
injury I-Disease
. O

disruption O
of O
hepatic O
lipid O
homeostasis O
in O
mice O
after O
amiodarone O
treatment O
is O
associated O
with O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
alpha O
target O
gene O
activation O
. O

amiodarone O
, O
an O
efficacious O
and O
widely O
used O
antiarrhythmic O
agent O
, O
has O
been O
reported O
to O
cause O
hepatotoxicity B-Disease
in O
some O
patients O
. O

to O
gain O
insight O
into O
the O
mechanism O
of O
this O
unwanted O
effect O
, O
mice O
were O
administered O
various O
doses O
of O
amiodarone O
and O
examined O
for O
changes O
in O
hepatic O
histology O
and O
gene O
regulation O
. O

amiodarone O
induced O
hepatomegaly B-Disease
, O
hepatocyte O
microvesicular O
lipid O
accumulation O
, O
and O
a O
significant O
decrease O
in O
serum O
triglycerides O
and O
glucose O
. O

northern O
blot O
analysis O
of O
hepatic O
rna O
revealed O
a O
dose O
- O
dependent O
increase O
in O
the O
expression O
of O
a O
number O
of O
genes O
critical O
for O
fatty O
acid O
oxidation O
, O
lipoprotein O
assembly O
, O
and O
lipid O
transport O
. O

many O
of O
these O
genes O
are O
regulated O
by O
the O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
alpha O
( O
pparalpha O
) O
, O
a O
ligand O
- O
activated O
nuclear O
hormone O
receptor O
transcription O
factor O
. O

the O
absence O
of O
induction O
of O
these O
genes O
as O
well O
as O
hepatomegaly B-Disease
in O
pparalpha O
knockout O
[ O
pparalpha O
- O
/ O
- O
] O
mice O
indicated O
that O
the O
effects O
of O
amiodarone O
were O
dependent O
upon O
the O
presence O
of O
a O
functional O
pparalpha O
gene O
. O

compared O
to O
wild O
- O
type O
mice O
, O
treatment O
of O
pparalpha O
- O
/ O
- O
mice O
with O
amiodarone O
resulted O
in O
an O
increased O
rate O
and O
extent O
of O
total O
body O
weight B-Disease
loss I-Disease
. O

the O
inability O
of O
amiodarone O
to O
directly O
activate O
either O
human O
or O
mouse O
pparalpha O
transiently O
expressed O
in O
human O
hepg2 O
hepatoma B-Disease
cells O
indicates O
that O
the O
effects O
of O
amiodarone O
on O
the O
function O
of O
this O
receptor O
were O
indirect O
. O

based O
upon O
these O
results O
, O
we O
conclude O
that O
amiodarone O
disrupts O
hepatic O
lipid O
homeostasis O
and O
that O
the O
increased O
expression O
of O
pparalpha O
target O
genes O
is O
secondary O
to O
this O
toxic O
effect O
. O

these O
results O
provide O
important O
new O
mechanistic O
information O
regarding O
the O
hepatotoxic B-Disease
effects O
of O
amiodarone O
and O
indicate O
that O
pparalpha O
protects O
against O
amiodarone O
- O
induced O
hepatotoxicity B-Disease
. O

safety O
and O
compliance O
with O
once O
- O
daily O
niacin O
extended O
- O
release O
/ O
lovastatin O
as O
initial O
therapy O
in O
the O
impact O
of O
medical O
subspecialty O
on O
patient O
compliance O
to O
treatment O
( O
impact O
) O
study O
. O

niacin O
extended O
- O
release O
/ O
lovastatin O
is O
a O
new O
combination O
product O
approved O
for O
treatment O
of O
primary O
hypercholesterolemia B-Disease
and O
mixed O
dyslipidemia B-Disease
. O

this O
open O
- O
labeled O
, O
multicenter O
study O
evaluated O
the O
safety O
of O
bedtime O
niacin O
extended O
- O
release O
/ O
lovastatin O
when O
dosed O
as O
initial O
therapy O
and O
patient O
compliance O
to O
treatment O
in O
various O
clinical O
practice O
settings O
. O

a O
total O
of O
4 O
, O
499 O
patients O
with O
dyslipidemia B-Disease
requiring O
drug O
intervention O
was O
enrolled O
at O
1 O
, O
081 O
sites O
. O

patients O
were O
treated O
with O
1 O
tablet O
( O
500 O
mg O
of O
niacin O
extended O
- O
release O
/ O
20 O
mg O
of O
lovastatin O
) O
once O
nightly O
for O
4 O
weeks O
and O
then O
2 O
tablets O
for O
8 O
weeks O
. O

patients O
also O
received O
dietary O
counseling O
, O
educational O
materials O
, O
and O
reminders O
to O
call O
a O
toll O
- O
free O
number O
that O
provided O
further O
education O
about O
dyslipidemia B-Disease
and O
niacin O
extended O
- O
release O
/ O
lovastatin O
. O

primary O
end O
points O
were O
study O
compliance O
, O
increases O
in O
liver O
transaminases O
to O
> O
3 O
times O
the O
upper O
limit O
of O
normal O
, O
and O
clinical O
myopathy B-Disease
. O

final O
study O
status O
was O
available O
for O
4 O
, O
217 O
patients O
( O
94 O
% O
) O
. O

compliance O
to O
niacin O
extended O
- O
release O
/ O
lovastatin O
was O
77 O
% O
, O
with O
3 O
, O
245 O
patients O
completing O
the O
study O
. O

patients O
in O
the O
southeast O
and O
those O
enrolled O
by O
endocrinologists O
had O
the O
lowest O
compliance O
and O
highest O
adverse O
event O
rates O
. O

flushing B-Disease
was O
the O
most O
common O
adverse O
event O
, O
reported O
by O
18 O
% O
of O
patients O
and O
leading O
to O
discontinuation O
by O
6 O
% O
. O

incidence O
of O
increased O
aspartate O
aminotransferase O
and O
/ O
or O
alanine O
aminotransferase O
> O
3 O
times O
the O
upper O
limit O
of O
normal O
was O
< O
0 O
. O
3 O
% O
. O

an O
increase O
of O
creatine O
phosphokinase O
to O
> O
5 O
times O
the O
upper O
limit O
of O
normal O
occurred O
in O
0 O
. O
24 O
% O
of O
patients O
, O
and O
no O
cases O
of O
drug O
- O
induced O
myopathy B-Disease
were O
observed O
. O

niacin O
extended O
- O
release O
/ O
lovastatin O
1 O
, O
000 O
/ O
40 O
mg O
, O
dosed O
as O
initial O
therapy O
, O
was O
associated O
with O
good O
compliance O
and O
safety O
and O
had O
very O
low O
incidences O
of O
increased O
liver O
and O
muscle O
enzymes O
. O

protective O
effect O
of O
terminalia O
chebula O
against O
experimental O
myocardial B-Disease
injury I-Disease
induced O
by O
isoproterenol O
. O

cardioprotective O
effect O
of O
ethanolic O
extract O
of O
terminalia O
chebula O
fruits O
( O
500 O
mg O
/ O
kg O
body O
wt O
) O
was O
examined O
in O
isoproterenol O
( O
200 O
mg O
/ O
kg O
body O
wt O
) O
induced O
myocardial B-Disease
damage I-Disease
in O
rats O
. O

in O
isoproterenol O
administered O
rats O
, O
the O
level O
of O
lipid O
peroxides O
increased O
significantly O
in O
the O
serum O
and O
heart O
. O

a O
significant O
decrease O
was O
observed O
in O
the O
activity O
of O
the O
myocardial O
marker O
enzymes O
with O
a O
concomitant O
increase O
in O
their O
activity O
in O
serum O
. O

histopathological O
examination O
was O
carried O
out O
to O
confirm O
the O
myocardial O
necrosis B-Disease
. O

t O
. O
chebula O
extract O
pretreatment O
was O
found O
to O
ameliorate O
the O
effect O
of O
isoproterenol O
on O
lipid O
peroxide O
formation O
and O
retained O
the O
activities O
of O
the O
diagnostic O
marker O
enzymes O
. O

a O
case O
of O
postoperative O
anxiety B-Disease
due O
to O
low O
dose O
droperidol O
used O
with O
patient O
- O
controlled O
analgesia O
. O

a O
multiparous O
woman O
in O
good O
psychological O
health O
underwent O
urgent O
caesarean O
section O
in O
labour O
. O

postoperatively O
, O
she O
was O
given O
a O
patient O
- O
controlled O
analgesia O
device O
delivering O
boluses O
of O
diamorphine O
0 O
. O
5 O
mg O
and O
droperidol O
0 O
. O
025 O
mg O
. O

whilst O
using O
the O
device O
she O
gradually O
became O
anxious O
, O
the O
feeling O
worsening O
after O
each O
bolus O
. O

the O
diagnosis O
of O
droperidol O
- O
induced O
psychological B-Disease
disturbance I-Disease
was O
not O
made O
straight O
away O
although O
on O
subsequent O
close O
questioning O
the O
patient O
gave O
a O
very O
clear O
history O
. O

after O
she O
had O
received O
a O
total O
of O
only O
0 O
. O
9 O
mg O
droperidol O
, O
a O
syringe O
containing O
diamorphine O
only O
was O
substituted O
and O
her O
unease O
resolved O
completely O
. O

we O
feel O
that O
, O
although O
the O
dramatic O
extrapyramidal O
side O
effects O
of O
dopaminergic O
antiemetics O
are O
well O
known O
, O
more O
subtle O
manifestations O
may O
easily O
be O
overlooked O
. O

accurate O
patient O
history O
contributes O
to O
differentiating O
diabetes B-Disease
insipidus I-Disease
: O
a O
case O
study O
. O

this O
case O
study O
highlights O
the O
important O
contribution O
of O
nursing O
in O
obtaining O
an O
accurate O
health O
history O
. O

the O
case O
discussed O
herein O
initially O
appeared O
to O
be O
neurogenic B-Disease
diabetes I-Disease
insipidus I-Disease
( O
di B-Disease
) O
secondary O
to O
a O
traumatic B-Disease
brain I-Disease
injury I-Disease
. O

the O
nursing O
staff O
, O
by O
reviewing O
the O
patient O
' O
s O
health O
history O
with O
his O
family O
, O
discovered O
a O
history O
of O
polydipsia B-Disease
and O
long O
- O
standing O
lithium O
use O
. O

lithium O
is O
implicated O
in O
drug O
- O
induced O
nephrogenic B-Disease
di I-Disease
, O
and O
because O
the O
patient O
had O
not O
received O
lithium O
since O
being O
admitted O
to O
the O
hospital O
, O
his O
treatment O
changed O
to O
focus O
on O
nephrogenic B-Disease
di I-Disease
. O

by O
combining O
information O
from O
the O
patient O
history O
, O
the O
physical O
examination O
, O
and O
radiologic O
and O
laboratory O
studies O
, O
the O
critical O
care O
team O
demonstrated O
that O
the O
patient O
had O
been O
self O
- O
treating O
his O
lithium O
- O
induced O
nephrogenic B-Disease
di I-Disease
and O
developed O
neurogenic B-Disease
di I-Disease
secondary O
to O
brain B-Disease
trauma I-Disease
. O

thus O
successful O
treatment O
required O
that O
nephrogenic O
and O
neurogenic B-Disease
di I-Disease
be O
treated O
concomitantly O
. O

factors O
contributing O
to O
ribavirin O
- O
induced O
anemia B-Disease
. O

background O
and O
aim O
: O
interferon O
and O
ribavirin O
combination O
therapy O
for O
chronic B-Disease
hepatitis I-Disease
c I-Disease
produces O
hemolytic B-Disease
anemia I-Disease
. O

this O
study O
was O
conducted O
to O
identify O
the O
factors O
contributing O
to O
ribavirin O
- O
induced O
anemia B-Disease
. O

methods O
: O
eighty O
- O
eight O
patients O
with O
chronic B-Disease
hepatitis I-Disease
c I-Disease
who O
received O
interferon O
- O
alpha O
- O
2b O
at O
a O
dose O
of O
6 O
mu O
administered O
intramuscularly O
for O
24 O
weeks O
in O
combination O
with O
ribavirin O
administered O
orally O
at O
a O
dose O
of O
600 O
mg O
or O
800 O
mg O
participated O
in O
the O
study O
. O

a O
hemoglobin O
concentration O
of O
< O
10 O
g O
/ O
dl O
was O
defined O
as O
ribavirin O
- O
induced O
anemia B-Disease
. O

results O
: O
ribavirin O
- O
induced O
anemia B-Disease
occurred O
in O
18 O
( O
20 O
. O
5 O
% O
) O
patients O
during O
treatment O
. O

a O
2 O
g O
/ O
dl O
decrease O
in O
hemoglobin O
concentrations O
in O
patients O
with O
anemia B-Disease
was O
observed O
at O
week O
2 O
after O
the O
start O
of O
treatment O
. O

the O
hemoglobin O
concentration O
in O
patients O
with O
> O
or O
= O
2 O
g O
/ O
dl O
decrease O
at O
week O
2 O
was O
observed O
to O
be O
significantly O
lower O
even O
after O
week O
2 O
than O
in O
patients O
with O
< O
2 O
g O
/ O
dl O
decrease O
( O
p O
< O
0 O
. O
01 O
) O
. O

a O
significant O
relationship O
was O
observed O
between O
the O
rate O
of O
reduction O
of O
hemoglobin O
concentrations O
at O
week O
2 O
and O
the O
severity O
of O
anemia B-Disease
( O
p O
< O
0 O
. O
01 O
) O
. O

such O
factors O
as O
sex O
( O
female O
) O
, O
age O
( O
> O
or O
= O
60 O
years O
old O
) O
, O
and O
the O
ribavirin O
dose O
by O
body O
weight O
( O
12 O
mg O
/ O
kg O
or O
more O
) O
were O
significant O
by O
univariate O
analysis O
. O

conclusions O
: O
careful O
administration O
is O
necessary O
in O
patients O
> O
or O
= O
60 O
years O
old O
, O
in O
female O
patients O
, O
and O
in O
patients O
receiving O
a O
ribavirin O
dose O
of O
12 O
mg O
/ O
kg O
or O
more O
. O

patients O
who O
experience O
a O
fall O
in O
hemoglobin O
concentrations O
of O
2 O
g O
/ O
dl O
or O
more O
at O
week O
2 O
after O
the O
start O
of O
treatment O
should O
be O
monitored O
with O
particular O
care O
. O

zidovudine O
- O
induced O
hepatitis B-Disease
. O

a O
case O
of O
acute O
hepatitis B-Disease
induced O
by O
zidovudine O
in O
a O
38 O
- O
year O
- O
old O
patient O
with O
aids B-Disease
is O
presented O
. O

the O
mechanism O
whereby O
the O
hepatitis B-Disease
was O
induced O
is O
not O
known O
. O

however O
, O
the O
patient O
tolerated O
well O
an O
alternative O
reverse O
transcriptase O
inhibitor O
, O
2 O
' O
3 O
' O
dideoxyinosine O
. O

physicians O
caring O
for O
patients O
with O
aids B-Disease
should O
be O
aware O
of O
this O
hitherto O
rarely O
reported O
complication O
. O

oxidative O
damage O
precedes O
nitrative O
damage O
in O
adriamycin O
- O
induced O
cardiac O
mitochondrial B-Disease
injury I-Disease
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
determine O
if O
elevated O
reactive O
oxygen O
( O
ros O
) O
/ O
nitrogen O
species O
( O
rns O
) O
reported O
to O
be O
present O
in O
adriamycin O
( O
adr O
) O
- O
induced O
cardiotoxicity B-Disease
actually O
resulted O
in O
cardiomyocyte O
oxidative O
/ O
nitrative O
damage O
, O
and O
to O
quantitatively O
determine O
the O
time O
course O
and O
subcellular O
localization O
of O
these O
postulated O
damage O
products O
using O
an O
in O
vivo O
approach O
. O

b6c3 O
mice O
were O
treated O
with O
a O
single O
dose O
of O
20 O
mg O
/ O
kg O
adr O
. O

ultrastructural O
damage O
and O
levels O
of O
4 O
- O
hydroxy O
- O
2 O
- O
nonenal O
( O
4hne O
) O
- O
protein O
adducts O
and O
3 O
- O
nitrotyrosine O
( O
3nt O
) O
were O
analyzed O
. O

quantitative O
ultrastructural O
damage O
using O
computerized O
image O
techniques O
showed O
cardiomyocyte O
injury O
as O
early O
as O
3 O
hours O
, O
with O
mitochondria O
being O
the O
most O
extensively O
and O
progressively O
injured O
subcellular O
organelle O
. O

analysis O
of O
4hne O
protein O
adducts O
by O
immunogold O
electron O
microscopy O
showed O
appearance O
of O
4hne O
protein O
adducts O
in O
mitochondria O
as O
early O
as O
3 O
hours O
, O
with O
a O
peak O
at O
6 O
hours O
and O
subsequent O
decline O
at O
24 O
hours O
. O

3nt O
levels O
were O
significantly O
increased O
in O
all O
subcellular O
compartments O
at O
6 O
hours O
and O
subsequently O
declined O
at O
24 O
hours O
. O

our O
data O
showed O
adr O
induced O
4hne O
- O
protein O
adducts O
in O
mitochondria O
at O
the O
same O
time O
point O
as O
when O
mitochondrial B-Disease
injury I-Disease
initially O
appeared O
. O

these O
results O
document O
for O
the O
first O
time O
in O
vivo O
that O
mitochondrial B-Disease
oxidative I-Disease
damage I-Disease
precedes O
nitrative O
damage O
. O

the O
progressive O
nature O
of O
mitochondrial B-Disease
injury I-Disease
suggests O
that O
mitochondria O
, O
not O
other O
subcellular O
organelles O
, O
are O
the O
major O
site O
of O
intracellular O
injury O
. O

sotalol O
- O
induced O
coronary B-Disease
spasm I-Disease
in O
a O
patient O
with O
dilated B-Disease
cardiomyopathy I-Disease
associated O
with O
sustained O
ventricular B-Disease
tachycardia I-Disease
. O

a O
54 O
- O
year O
- O
old O
man O
with O
severe O
left O
ventricular B-Disease
dysfunction I-Disease
due O
to O
dilated B-Disease
cardiomyopathy I-Disease
was O
referred O
to O
our O
hospital O
for O
symptomatic O
incessant O
sustained O
ventricular B-Disease
tachycardia I-Disease
( O
vt B-Disease
) O
. O

after O
the O
administration O
of O
nifekalant O
hydrochloride O
, O
sustained O
vt B-Disease
was O
terminated O
. O

an O
alternate O
class O
iii O
agent O
, O
sotalol O
, O
was O
also O
effective O
for O
the O
prevention O
of O
vt B-Disease
. O

however O
, O
one O
month O
after O
switching O
over O
nifekalant O
to O
sotalol O
, O
a O
short O
duration O
of O
st O
elevation O
was O
documented O
in O
ecg O
monitoring O
at O
almost O
the O
same O
time O
for O
three O
consecutive O
days O
. O

st O
elevation O
with O
chest O
discomfort O
disappeared O
since O
he O
began O
taking O
long O
- O
acting O
diltiazem O
. O

coronary B-Disease
vasospasm I-Disease
may O
be O
induced O
by O
the O
non O
- O
selective O
beta O
- O
blocking O
properties O
of O
sotalol O
. O

effects O
of O
the O
antidepressant O
trazodone O
, O
a O
5 O
- O
ht O
2a O
/ O
2c O
receptor O
antagonist O
, O
on O
dopamine O
- O
dependent O
behaviors O
in O
rats O
. O

rationale O
: O
5 O
- O
hydroxytryptamine O
, O
via O
stimulation O
of O
5 O
- O
ht O
2c O
receptors O
, O
exerts O
a O
tonic O
inhibitory O
influence O
on O
dopaminergic O
neurotransmission O
, O
whereas O
activation O
of O
5 O
- O
ht O
2a O
receptors O
enhances O
stimulated O
daergic O
neurotransmission O
. O

the O
antidepressant O
trazodone O
is O
a O
5 O
- O
ht O
2a O
/ O
2c O
receptor O
antagonist O
. O

objectives O
: O
to O
evaluate O
the O
effect O
of O
trazodone O
treatment O
on O
behaviors O
dependent O
on O
the O
functional O
status O
of O
the O
nigrostriatal O
daergic O
system O
. O

methods O
: O
the O
effect O
of O
pretreatment O
with O
trazodone O
on O
dexamphetamine O
- O
and O
apomorphine O
- O
induced O
oral B-Disease
stereotypies I-Disease
, O
on O
catalepsy B-Disease
induced O
by O
haloperidol O
and O
apomorphine O
( O
0 O
. O
05 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
on O
ergometrine O
- O
induced O
wet O
dog O
shake O
( O
wds O
) O
behavior O
and O
fluoxetine O
- O
induced O
penile O
erections O
was O
studied O
in O
rats O
. O

we O
also O
investigated O
whether O
trazodone O
induces O
catalepsy B-Disease
in O
rats O
. O

results O
: O
trazodone O
at O
2 O
. O
5 O
- O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
did O
not O
induce O
catalepsy B-Disease
, O
and O
did O
not O
antagonize O
apomorphine O
( O
1 O
. O
5 O
and O
3 O
mg O
/ O
kg O
) O
stereotypy O
and O
apomorphine O
( O
0 O
. O
05 O
mg O
/ O
kg O
) O
- O
induced O
catalepsy B-Disease
. O

however O
, O
pretreatment O
with O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
trazodone O
enhanced O
dexamphetamine O
stereotypy O
, O
and O
antagonized O
haloperidol O
catalepsy B-Disease
, O
ergometrine O
- O
induced O
wds O
behavior O
and O
fluoxetine O
- O
induced O
penile O
erections O
. O

trazodone O
at O
30 O
, O
40 O
and O
50 O
mg O
/ O
kg O
i O
. O
p O
. O
induced O
catalepsy B-Disease
and O
antagonized O
apomorphine O
and O
dexamphetamine O
stereotypies O
. O

conclusions O
: O
our O
results O
indicate O
that O
trazodone O
at O
2 O
. O
5 O
- O
20 O
mg O
/ O
kg O
does O
not O
block O
pre O
- O
and O
postsynaptic O
striatal O
d2 O
da O
receptors O
, O
while O
at O
30 O
, O
40 O
and O
50 O
mg O
/ O
kg O
it O
blocks O
postsynaptic O
striatal O
d2 O
da O
receptors O
. O

furthermore O
, O
at O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
, O
trazodone O
blocks O
5 O
- O
ht O
2a O
and O
5 O
- O
ht O
2c O
receptors O
. O

we O
suggest O
that O
trazodone O
( O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
) O
, O
by O
blocking O
the O
5 O
- O
ht O
2c O
receptors O
, O
releases O
the O
nigrostriatal O
daergic O
neurons O
from O
tonic O
inhibition O
caused O
by O
5 O
- O
ht O
, O
and O
thereby O
potentiates O
dexamphetamine O
stereotypy O
and O
antagonizes O
haloperidol O
catalepsy B-Disease
. O

swallowing B-Disease
abnormalities I-Disease
and O
dyskinesia B-Disease
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

gastrointestinal B-Disease
abnormalities I-Disease
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
have O
been O
known O
for O
almost O
two O
centuries O
, O
but O
many O
aspects O
concerning O
their O
pathophysiology O
have O
not O
been O
completely O
clarified O
. O

the O
aim O
of O
this O
study O
was O
to O
characterize O
the O
oropharyngeal O
dynamics O
in O
pd B-Disease
patients O
with O
and O
without O
levodopa O
- O
induced O
dyskinesia B-Disease
. O

fifteen O
dyskinetic B-Disease
, O
12 O
nondyskinetic O
patients O
, O
and O
a O
control O
group O
were O
included O
. O

patients O
were O
asked O
about O
dysphagia B-Disease
and O
evaluated O
with O
the O
unified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
rating O
scale O
parts O
ii O
and O
iii O
and O
the O
hoehn O
and O
yahr O
scale O
. O

deglutition O
was O
assessed O
using O
modified O
barium O
swallow O
with O
videofluoroscopy O
. O

nondyskinetic O
patients O
, O
but O
not O
the O
dyskinetic B-Disease
ones O
, O
showed O
less O
oropharyngeal O
swallowing O
efficiency O
( O
opse O
) O
for O
liquid O
food O
than O
controls O
( O
dunnett O
, O
p O
= O
0 O
. O
02 O
) O
. O

dyskinetic B-Disease
patients O
tended O
to O
have O
a O
greater O
opse O
than O
nondyskinetic O
( O
dunnett O
, O
p O
= O
0 O
. O
06 O
) O
. O

patients O
who O
were O
using O
a O
higher O
dose O
of O
levodopa O
had O
a O
greater O
opse O
and O
a O
trend O
toward O
a O
smaller O
oral O
transit O
time O
( O
pearson O
' O
s O
correlation O
, O
p O
= O
0 O
. O
01 O
and O
0 O
. O
08 O
, O
respectively O
) O
. O

neither O
the O
report O
of O
dysphagia B-Disease
nor O
any O
of O
the O
pd B-Disease
severity O
parameters O
correlated O
to O
the O
videofluoroscopic O
variables O
. O

in O
the O
current O
study O
, O
dyskinetic B-Disease
patients O
performed O
better O
in O
swallowing O
function O
, O
which O
could O
be O
explained O
on O
the O
basis O
of O
a O
greater O
levodopa O
dose O
. O

our O
results O
suggest O
a O
role O
for O
levodopa O
in O
the O
oral O
phase O
of O
deglutition O
and O
confirm O
that O
dysphagia B-Disease
is O
not O
a O
good O
predictor O
of O
deglutition O
alterations O
in O
pd B-Disease
. O

inhibition O
of O
nuclear O
factor O
- O
kappab O
activation O
attenuates O
tubulointerstitial B-Disease
nephritis I-Disease
induced O
by O
gentamicin O
. O

background O
: O
animals O
treated O
with O
gentamicin O
can O
show O
residual O
areas O
of O
interstitial O
fibrosis B-Disease
in O
the O
renal O
cortex O
. O

this O
study O
investigated O
the O
expression O
of O
nuclear O
factor O
- O
kappab O
( O
nf O
- O
kappab O
) O
, O
mitogen O
- O
activated O
protein O
( O
map O
) O
kinases O
and O
macrophages O
in O
the O
renal O
cortex O
and O
structural O
and O
functional O
renal O
changes O
of O
rats O
treated O
with O
gentamicin O
or O
gentamicin O
+ O
pyrrolidine O
dithiocarbamate O
( O
pdtc O
) O
, O
an O
nf O
- O
kappab O
inhibitor O
. O

methods O
: O
38 O
female O
wistar O
rats O
were O
injected O
with O
gentamicin O
, O
40 O
mg O
/ O
kg O
, O
twice O
a O
day O
for O
9 O
days O
, O
38 O
with O
gentamicin O
+ O
pdtc O
, O
and O
28 O
with O
0 O
. O
15 O
m O
nacl O
solution O
. O

the O
animals O
were O
killed O
5 O
and O
30 O
days O
after O
these O
injections O
and O
the O
kidneys O
were O
removed O
for O
histological O
and O
immunohistochemical O
studies O
. O

the O
results O
of O
the O
immunohistochemical O
studies O
were O
scored O
according O
to O
the O
extent O
of O
staining O
. O

the O
fractional O
interstitial O
area O
was O
determined O
by O
morphometry O
. O

results O
: O
gentamicin O
- O
treated O
rats O
presented O
a O
transitory O
increase O
in O
plasma O
creatinine O
levels O
. O

increased O
ed O
- O
1 O
, O
map O
kinases O
and O
nf O
- O
kappab O
staining O
were O
also O
observed O
in O
the O
renal O
cortex O
from O
all O
gentamicin O
- O
treated O
rats O
compared O
to O
control O
( O
p O
< O
0 O
. O
05 O
) O
. O

the O
animals O
killed O
on O
day O
30 O
also O
presented O
fibrosis B-Disease
in O
the O
renal O
cortex O
despite O
the O
recovery O
of O
renal O
function O
. O

treatment O
with O
pdtc O
reduced O
the O
functional O
and O
structural O
changes O
induced O
by O
gentamicin O
. O

conclusions O
: O
these O
data O
show O
that O
inhibition O
of O
nf O
- O
kappab O
activation O
attenuates O
tubulointerstitial B-Disease
nephritis I-Disease
induced O
by O
gentamicin O
. O

glucose O
metabolism O
in O
patients O
with O
schizophrenia B-Disease
treated O
with O
atypical O
antipsychotic O
agents O
: O
a O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
and O
minimal O
model O
analysis O
. O

background O
: O
while O
the O
incidence O
of O
new O
- O
onset O
diabetes B-Disease
mellitus I-Disease
may O
be O
increasing O
in O
patients O
with O
schizophrenia B-Disease
treated O
with O
certain O
atypical O
antipsychotic O
agents O
, O
it O
remains O
unclear O
whether O
atypical O
agents O
are O
directly O
affecting O
glucose O
metabolism O
or O
simply O
increasing O
known O
risk O
factors O
for O
diabetes B-Disease
. O

objective O
: O
to O
study O
the O
2 O
drugs O
most O
clearly O
implicated O
( O
clozapine O
and O
olanzapine O
) O
and O
risperidone O
using O
a O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
. O

design O
: O
a O
cross O
- O
sectional O
design O
in O
stable O
, O
treated O
patients O
with O
schizophrenia B-Disease
evaluated O
using O
a O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
and O
the O
bergman O
minimal O
model O
analysis O
. O

setting O
: O
subjects O
were O
recruited O
from O
an O
urban O
community O
mental O
health O
clinic O
and O
were O
studied O
at O
a O
general O
clinical O
research O
center O
. O

patients O
fifty O
subjects O
signed O
informed O
consent O
and O
41 O
underwent O
the O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
. O

thirty O
- O
six O
nonobese O
subjects O
with O
schizophrenia B-Disease
or O
schizoaffective B-Disease
disorder I-Disease
, O
matched O
by O
body O
mass O
index O
and O
treated O
with O
either O
clozapine O
, O
olanzapine O
, O
or O
risperidone O
, O
were O
included O
in O
the O
analysis O
. O

main O
outcome O
measures O
: O
fasting O
plasma O
glucose O
and O
fasting O
serum O
insulin O
levels O
, O
insulin B-Disease
sensitivity I-Disease
index O
, O
homeostasis O
model O
assessment O
of O
insulin B-Disease
resistance I-Disease
, O
and O
glucose O
effectiveness O
. O

results O
: O
the O
mean O
+ O
/ O
- O
sd O
duration O
of O
treatment O
with O
the O
identified O
atypical O
antipsychotic O
agent O
was O
68 O
. O
3 O
+ O
/ O
- O
28 O
. O
9 O
months O
( O
clozapine O
) O
, O
29 O
. O
5 O
+ O
/ O
- O
17 O
. O
5 O
months O
( O
olanzapine O
) O
, O
and O
40 O
. O
9 O
+ O
/ O
- O
33 O
. O
7 O
( O
risperidone O
) O
. O

fasting O
serum O
insulin O
concentrations O
differed O
among O
groups O
( O
f O
( O
33 O
) O
= O
3 O
. O
35 O
; O
p O
= O
. O
047 O
) O
( O
clozapine O
> O
olanzapine O
> O
risperidone O
) O
with O
significant O
differences O
between O
clozapine O
and O
risperidone O
( O
t O
( O
33 O
) O
= O
2 O
. O
32 O
; O
p O
= O
. O
03 O
) O
and O
olanzapine O
and O
risperidone O
( O
t O
( O
33 O
) O
= O
2 O
. O
15 O
; O
p O
= O
. O
04 O
) O
. O

there O
was O
a O
significant O
difference O
in O
insulin B-Disease
sensitivity I-Disease
index O
among O
groups O
( O
f O
( O
33 O
) O
= O
10 O
. O
66 O
; O
p O
< O
. O
001 O
) O
( O
clozapine O
< O
olanzapine O
< O
risperidone O
) O
, O
with O
subjects O
who O
received O
clozapine O
and O
olanzapine O
exhibiting O
significant O
insulin B-Disease
resistance I-Disease
compared O
with O
subjects O
who O
were O
treated O
with O
risperidone O
( O
clozapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
- O
4 O
. O
29 O
; O
p O
< O
. O
001 O
; O
olanzapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
- O
3 O
. O
62 O
; O
p O
= O
. O
001 O
[ O
p O
< O

. O
001 O
] O
) O
. O

the O
homeostasis O
model O
assessment O
of O
insulin B-Disease
resistance I-Disease
also O
differed O
significantly O
among O
groups O
( O
f O
( O
33 O
) O
= O
4 O
. O
92 O
; O
p O
= O
. O
01 O
) O
( O
clozapine O
> O
olanzapine O
> O
risperidone O
) O
( O
clozapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
2 O
. O
94 O
; O
p O
= O
. O
006 O
; O
olanzapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
2 O
. O
42 O
; O
p O
= O
. O
02 O
) O
. O

there O
was O
a O
significant O
difference O
among O
groups O
in O
glucose O
effectiveness O
( O
f O
( O
30 O
) O
= O
4 O
. O
18 O
; O
p O
= O
. O
02 O
) O
( O
clozapine O
< O
olanzapine O
< O
risperidone O
) O
with O
significant O
differences O
between O
clozapine O
and O
risperidone O
( O
t O
( O
30 O
) O
= O
- O
2 O
. O
59 O
; O
p O
= O
. O
02 O
) O
and O
olanzapine O
and O
risperidone O
( O
t O
( O
30 O
) O
= O
- O
2 O
. O
34 O
, O
p O
= O
. O
03 O
) O
. O

conclusions O
: O
both O
nonobese O
clozapine O
- O
and O
olanzapine O
- O
treated O
groups O
displayed O
significant O
insulin B-Disease
resistance I-Disease
and O
impairment O
of O
glucose O
effectiveness O
compared O
with O
risperidone O
- O
treated O
subjects O
. O

patients O
taking O
clozapine O
and O
olanzapine O
must O
be O
examined O
for O
insulin B-Disease
resistance I-Disease
and O
its O
consequences O
. O

thoracic B-Disease
hematomyelia I-Disease
secondary O
to O
coumadin O
anticoagulant O
therapy O
: O
a O
case O
report O
. O

a O
case O
of O
thoracic B-Disease
hematomyelia I-Disease
secondary O
to O
anticoagulant O
therapy O
is O
presented O
. O

clinical O
features O
, O
similar O
to O
2 O
other O
previously O
reported O
cases O
, O
are O
discussed O
. O

a O
high O
index O
of O
suspicion O
may O
lead O
to O
a O
quick O
diagnostic O
procedure O
and O
successful O
decompressive O
surgery O
. O

mania B-Disease
associated O
with O
fluoxetine O
treatment O
in O
adolescents O
. O

fluoxetine O
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
is O
gaining O
increased O
acceptance O
in O
the O
treatment O
of O
adolescent O
depression B-Disease
. O

generally O
safe O
and O
well O
tolerated O
by O
adults O
, O
fluoxetine O
has O
been O
reported O
to O
induce O
mania B-Disease
. O

the O
cases O
of O
five O
depressed B-Disease
adolescents O
, O
14 O
- O
16 O
years O
of O
age O
, O
who O
developed O
mania B-Disease
during O
pharmacotherapy O
with O
fluoxetine O
, O
are O
reported O
here O
. O

apparent O
risk O
factors O
for O
the O
development O
of O
mania B-Disease
or O
hypomania B-Disease
during O
fluoxetine O
pharmacotherapy O
in O
this O
population O
were O
the O
combination O
of O
attention B-Disease
- I-Disease
deficit I-Disease
hyperactivity I-Disease
disorder I-Disease
and O
affective O
instability O
; O
major O
depression B-Disease
with O
psychotic B-Disease
features O
; O
a O
family O
history O
of O
affective B-Disease
disorder I-Disease
, O
especially O
bipolar B-Disease
disorder I-Disease
; O
and O
a O
diagnosis O
of O
bipolar B-Disease
disorder I-Disease
. O

further O
study O
is O
needed O
to O
determine O
the O
optimal O
dosage O
and O
to O
identify O
risk O
factors O
that O
increase O
individual O
vulnerability O
to O
fluoxetine O
induced O
mania B-Disease
in O
adolescents O
. O

acute B-Disease
renal I-Disease
insufficiency I-Disease
after O
high O
- O
dose O
melphalan O
in O
patients O
with O
primary B-Disease
systemic I-Disease
amyloidosis I-Disease
during O
stem O
cell O
transplantation O
. O

background O
: O
patients O
with O
primary B-Disease
systemic I-Disease
amyloidosis I-Disease
( O
al B-Disease
) O
have O
a O
poor O
prognosis O
. O

median O
survival O
time O
from O
standard O
treatments O
is O
only O
17 O
months O
. O

high O
- O
dose O
intravenous O
melphalan O
followed O
by O
peripheral O
blood O
stem O
cell O
transplant O
( O
pbsct O
) O
appears O
to O
be O
the O
most O
promising O
therapy O
, O
but O
treatment O
mortality O
can O
be O
high O
. O

the O
authors O
have O
noted O
the O
development O
of O
acute B-Disease
renal I-Disease
insufficiency I-Disease
immediately O
after O
melphalan O
conditioning O
. O

this O
study O
was O
undertaken O
to O
further O
examine O
its O
risk O
factors O
and O
impact O
on O
posttransplant O
mortality O
. O

methods O
: O
consecutive O
al B-Disease
patients O
who O
underwent O
pbsct O
were O
studied O
retrospectively O
. O

acute B-Disease
renal I-Disease
insufficiency I-Disease
( O
ari B-Disease
) O
after O
high O
- O
dose O
melphalan O
was O
defined O
by O
a O
minimum O
increase O
of O
0 O
. O
5 O
mg O
/ O
dl O
( O
44 O
micromol O
/ O
l O
) O
in O
the O
serum O
creatinine O
level O
that O
is O
greater O
than O
50 O
% O
of O
baseline O
immediately O
after O
conditioning O
. O

urine O
sediment O
score O
was O
the O
sum O
of O
the O
individual O
types O
of O
sediment O
identified O
on O
urine O
microscopy O
. O

results O
: O
of O
the O
80 O
patients O
studied O
, O
ari B-Disease
developed O
in O
18 O
. O
8 O
% O
of O
the O
patients O
after O
high O
- O
dose O
melphalan O
. O

univariate O
analysis O
identified O
age O
, O
hypoalbuminemia B-Disease
, O
heavy O
proteinuria B-Disease
, O
diuretic O
use O
, O
and O
urine O
sediment O
score O
( O
> O
3 O
) O
as O
risk O
factors O
. O

age O
and O
urine O
sediment O
score O
remained O
independently O
significant O
risk O
factors O
in O
the O
multivariate O
analysis O
. O

patients O
who O
had O
ari B-Disease
after O
high O
- O
dose O
melphalan O
underwent O
dialysis O
more O
often O
( O
p O
= O
0 O
. O
007 O
) O
, O
and O
had O
a O
worse O
1 O
- O
year O
survival O
( O
p O
= O
0 O
. O
03 O
) O
. O

conclusion O
: O
the O
timing O
of O
renal B-Disease
injury I-Disease
strongly O
suggests O
melphalan O
as O
the O
causative O
agent O
. O

ongoing O
tubular B-Disease
injury I-Disease
may O
be O
a O
prerequisite O
for O
renal B-Disease
injury I-Disease
by O
melphalan O
as O
evidenced O
by O
the O
active O
urinary O
sediment O
. O

development O
of O
ari B-Disease
adversely O
affected O
the O
outcome O
after O
pbsct O
. O

effective O
preventive O
measures O
may O
help O
decrease O
the O
treatment O
mortality O
of O
pbsct O
in O
al B-Disease
patients O
. O

focal O
cerebral B-Disease
ischemia I-Disease
in O
rats O
: O
effect O
of O
phenylephrine O
- O
induced O
hypertension B-Disease
during O
reperfusion O
. O

after O
180 O
min O
of O
temporary O
middle B-Disease
cerebral I-Disease
artery I-Disease
occlusion I-Disease
in O
spontaneously O
hypertensive B-Disease
rats O
, O
the O
effect O
of O
phenylephrine O
- O
induced O
hypertension B-Disease
on O
ischemic B-Disease
brain I-Disease
injury I-Disease
and O
blood O
- O
brain O
barrier O
permeability O
was O
determined O
. O

blood O
pressure O
was O
manipulated O
by O
one O
of O
the O
following O
schedules O
during O
120 O
min O
of O
reperfusion O
: O
control O
, O
normotensive O
reperfusion O
; O
90 O
/ O
hypertension B-Disease
( O
90 O
/ O
htn B-Disease
) O
, O
blood O
pressure O
was O
increased O
by O
35 O
mm O
hg O
during O
the O
initial O
90 O
min O
of O
reperfusion O
only O
; O
15 O
/ O
hypertension B-Disease
( O
15 O
/ O
htn B-Disease
) O
, O
normotensive O
reperfusion O
for O
30 O
min O
followed O
by O
15 O
min O
of O
hypertension B-Disease
and O
75 O
min O
of O
normotension O
. O

part O
a O
, O
for O
eight O
rats O
in O
each O
group O
brain B-Disease
injury I-Disease
was O
evaluated O
by O
staining O
tissue O
using O
2 O
, O
3 O
, O
5 O
- O
triphenyltetrazolium O
chloride O
and O
edema B-Disease
was O
evaluated O
by O
microgravimetry O
. O

part O
b O
, O
for O
eight O
different O
rats O
in O
each O
group O
blood O
- O
brain O
barrier O
permeability O
was O
evaluated O
by O
measuring O
the O
amount O
and O
extent O
of O
extravasation O
of O
evans O
blue O
dye O
. O

brain B-Disease
injury I-Disease
( O
percentage O
of O
the O
ischemic B-Disease
hemisphere I-Disease
) O
was O
less O
in O
the O
15 O
/ O
htn B-Disease
group O
( O
16 O
+ O
/ O
- O
6 O
, O
mean O
+ O
/ O
- O
sd O
) O
versus O
the O
90 O
/ O
htn B-Disease
group O
( O
30 O
+ O
/ O
- O
6 O
) O
, O
which O
was O
in O
turn O
less O
than O
the O
control O
group O
( O
42 O
+ O
/ O
- O
5 O
) O
. O

specific O
gravity O
was O
greater O
in O
the O
15 O
/ O
htn B-Disease
group O
( O
1 O
. O
043 O
+ O
/ O
- O
0 O
. O
002 O
) O
versus O
the O
90 O
/ O
htn B-Disease
( O
1 O
. O
036 O
+ O
/ O
- O
0 O
. O
003 O
) O
and O
control O
( O
1 O
. O
037 O
+ O
/ O
- O
0 O
. O
003 O
) O
groups O
. O

evans O
blue O
( O
mug O
g O
- O
1 O
of O
brain O
tissue O
) O
was O
greater O
in O
the O
90 O
/ O
htn B-Disease
group O
( O
24 O
. O
4 O
+ O
/ O
- O
6 O
. O
0 O
) O
versus O
the O
control O
group O
( O
12 O
. O
3 O
+ O
/ O
- O
4 O
. O
1 O
) O
, O
which O
was O
in O
turn O
greater O
than O
the O
15 O
/ O
htn B-Disease
group O
( O
7 O
. O
3 O
+ O
/ O
- O
3 O
. O
2 O
) O
. O

this O
study O
supports O
a O
hypothesis O
that O
during O
reperfusion O
, O
a O
short O
interval O
of O
hypertension B-Disease
decreases O
brain B-Disease
injury I-Disease
and O
edema B-Disease
; O
and O
that O
sustained O
hypertension B-Disease
increases O
the O
risk O
of O
vasogenic B-Disease
edema I-Disease
. O

people O
aged O
over O
75 O
in O
atrial B-Disease
fibrillation I-Disease
on O
warfarin O
: O
the O
rate O
of O
major O
hemorrhage B-Disease
and O
stroke B-Disease
in O
more O
than O
500 O
patient O
- O
years O
of O
follow O
- O
up O
. O

objectives O
: O
to O
determine O
the O
incidence O
of O
major O
hemorrhage B-Disease
and O
stroke B-Disease
in O
people O
aged O
76 O
and O
older O
with O
atrial B-Disease
fibrillation I-Disease
on O
adjusted O
- O
dose O
warfarin O
who O
had O
been O
recently O
been O
admitted O
to O
hospital O
. O

design O
: O
a O
retrospective O
observational O
cohort O
study O
. O

setting O
: O
a O
major O
healthcare O
network O
involving O
four O
tertiary O
hospitals O
. O

participants O
: O
two O
hundred O
thirty O
- O
five O
patients O
aged O
76 O
and O
older O
admitted O
to O
a O
major O
healthcare O
network O
between O
july O
1 O
, O
2001 O
, O
and O
june O
30 O
, O
2002 O
, O
with O
atrial B-Disease
fibrillation I-Disease
on O
warfarin O
were O
enrolled O
. O

measurements O
: O
information O
regarding O
major O
bleeding B-Disease
episodes O
, O
strokes B-Disease
, O
and O
warfarin O
use O
was O
obtained O
from O
patients O
, O
relatives O
, O
primary O
physicians O
, O
and O
medical O
records O
. O

results O
: O
two O
hundred O
twenty O
- O
eight O
patients O
( O
42 O
% O
men O
) O
with O
a O
mean O
age O
of O
81 O
. O
1 O
( O
range O
76 O
- O
94 O
) O
were O
included O
in O
the O
analysis O
. O

total O
follow O
- O
up O
on O
warfarin O
was O
530 O
years O
( O
mean O
28 O
months O
) O
. O

there O
were O
53 O
major O
hemorrhages B-Disease
, O
for O
an O
annual O
rate O
of O
10 O
. O
0 O
% O
, O
including O
24 O
( O
45 O
. O
3 O
% O
) O
life O
- O
threatening O
and O
five O
( O
9 O
. O
4 O
% O
) O
fatal O
bleeds O
. O

the O
annual O
stroke B-Disease
rate O
after O
initiation O
of O
warfarin O
was O
2 O
. O
6 O
% O
. O

conclusion O
: O
the O
rate O
of O
major O
hemorrhage B-Disease
was O
high O
in O
this O
old O
, O
frail O
group O
, O
but O
excluding O
fatalities O
, O
resulted O
in O
no O
long O
- O
term O
sequelae O
, O
and O
the O
stroke B-Disease
rate O
on O
warfarin O
was O
low O
, O
demonstrating O
how O
effective O
warfarin O
treatment O
is O
. O

safety O
of O
celecoxib O
in O
patients O
with O
adverse O
skin B-Disease
reactions I-Disease
to O
acetaminophen O
( O
paracetamol O
) O
and O
nimesulide O
associated O
or O
not O
with O
common O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
. O

background O
: O
acetaminophen O
( O
paracetamol O
- O
- O
p O
) O
and O
nimesulide O
( O
n O
) O
are O
widely O
used O
analgesic O
- O
antipyretic O
/ O
anti O
- O
inflammatory O
drugs O
. O

the O
rate O
of O
adverse O
hypersensitivity B-Disease
reactions O
to O
these O
agents O
is O
generally O
low O
. O

on O
the O
contrary O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
are O
commonly O
involved O
in O
such O
reactions O
. O

celecoxib O
( O
ce O
) O
is O
a O
novel O
drug O
, O
with O
high O
selectivity O
and O
affinity O
for O
cox O
- O
2 O
enzyme O
. O

objective O
: O
we O
evaluated O
the O
tolerability O
of O
ce O
in O
a O
group O
of O
patients O
with O
documented O
history O
of O
adverse O
cutaneous B-Disease
reactions I-Disease
to O
p O
and O
n O
associated O
or O
not O
to O
classic O
nsaids O
. O

methods O
: O
we O
studied O
9 O
patients O
with O
hypersensitivity B-Disease
to O
p O
and O
n O
with O
or O
without O
associated O
reactions O
to O
classic O
nsaids O
. O

the O
diagnosis O
of O
p O
and O
n O
- O
induced O
skin B-Disease
reactions I-Disease
was O
based O
in O
vivo O
challenge O
. O

the O
placebo O
was O
blindly O
administered O
at O
the O
beginning O
of O
each O
challenge O
. O

after O
three O
days O
, O
a O
cumulative O
dosage O
of O
200 O
mg O
of O
ce O
in O
refracted O
doses O
were O
given O
. O

after O
2 O
- O
3 O
days O
, O
a O
single O
dose O
of O
200 O
mg O
was O
administered O
. O

all O
patients O
were O
observed O
for O
6 O
hours O
after O
each O
challenge O
, O
and O
controlled O
again O
after O
24 O
hours O
to O
exclude O
delayed O
reactions O
. O

the O
challenge O
was O
considered O
positive O
if O
one O
or O
more O
of O
the O
following O
appeared O
: O
erythema B-Disease
, O
rush O
or O
urticaria B-Disease
- O
angioedema B-Disease
. O

results O
: O
no O
reaction O
was O
observed O
with O
placebo O
and O
eight O
patients O
( O
88 O
. O
8 O
% O
) O
tolerated O
ce O
. O

only O
one O
patient O
developed O
a O
moderate O
angioedema B-Disease
of O
the O
lips O
. O

conclusion O
: O
only O
one O
hypersensitivity B-Disease
reaction O
to O
ce O
was O
documented O
among O
9 O
p O
and O
n O
- O
highly O
nsaids O
intolerant O
patients O
. O

thus O
, O
we O
conclude O
that O
ce O
is O
a O
reasonably O
safe O
alternative O
to O
be O
used O
in O
subjects O
who O
do O
not O
tolerate O
p O
and O
n O
. O

case O
- O
control O
study O
of O
regular O
analgesic O
and O
nonsteroidal O
anti O
- O
inflammatory O
use O
and O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
. O

background O
: O
studies O
on O
the O
association O
between O
the O
long O
- O
term O
use O
of O
aspirin O
and O
other O
analgesic O
and O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
and O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
( O
esrd B-Disease
) O
have O
given O
conflicting O
results O
. O

in O
order O
to O
examine O
this O
association O
, O
a O
case O
- O
control O
study O
with O
incident O
cases O
of O
esrd B-Disease
was O
carried O
out O
. O

methods O
: O
the O
cases O
were O
all O
patients O
entering O
the O
local O
dialysis O
program O
because O
of O
esrd B-Disease
in O
the O
study O
area O
between O
june O
1 O
, O
1995 O
and O
november O
30 O
, O
1997 O
. O

they O
were O
classified O
according O
to O
the O
underlying O
disease O
, O
which O
had O
presumably O
led O
them O
to O
esrd B-Disease
. O

controls O
were O
patients O
admitted O
to O
the O
same O
hospitals O
from O
where O
the O
cases O
arose O
, O
also O
matched O
by O
age O
and O
sex O
. O

odds O
ratios O
were O
calculated O
using O
a O
conditional O
logistic O
model O
, O
including O
potential O
confounding O
factors O
, O
both O
for O
the O
whole O
study O
population O
and O
for O
the O
various O
underlying O
diseases O
. O

results O
: O
five O
hundred O
and O
eighty O
- O
three O
cases O
and O
1190 O
controls O
were O
included O
in O
the O
analysis O
. O

long O
- O
term O
use O
of O
any O
analgesic O
was O
associated O
with O
an O
overall O
odds O
ratio O
of O
1 O
. O
22 O
( O
95 O
% O
ci O
, O
0 O
. O
89 O
- O
1 O
. O
66 O
) O
. O

for O
specific O
groups O
of O
drugs O
, O
the O
risks O
were O
1 O
. O
56 O
( O
1 O
. O
05 O
- O
2 O
. O
30 O
) O
for O
aspirin O
, O
1 O
. O
03 O
( O
0 O
. O
60 O
- O
1 O
. O
76 O
) O
for O
pyrazolones O
, O
0 O
. O
80 O
( O
0 O
. O
39 O
- O
1 O
. O
63 O
) O
for O
paracetamol O
, O
and O
0 O
. O
94 O
( O
0 O
. O
57 O
- O
1 O
. O
56 O
) O
for O
nonaspirin O
nsaids O
. O

the O
risk O
of O
esrd B-Disease
associated O
with O
aspirin O
was O
related O
to O
the O
cumulated O
dose O
and O
duration O
of O
use O
, O
and O
it O
was O
particularly O
high O
among O
the O
subset O
of O
patients O
with O
vascular O
nephropathy B-Disease
as O
underlying O
disease O
[ O
2 O
. O
35 O
( O
1 O
. O
17 O
- O
4 O
. O
72 O
) O
] O
. O

conclusion O
: O
our O
data O
indicate O
that O
long O
- O
term O
use O
of O
nonaspirin O
analgesic O
drugs O
and O
nsaids O
is O
not O
associated O
with O
an O
increased O
risk O
of O
esrd B-Disease
. O

however O
, O
the O
chronic O
use O
of O
aspirin O
may O
increase O
the O
risk O
of O
esrd B-Disease
. O

two O
cases O
of O
amisulpride O
overdose B-Disease
: O
a O
cause O
for O
prolonged B-Disease
qt I-Disease
syndrome I-Disease
. O

two O
cases O
of O
deliberate O
self O
- O
poisoning B-Disease
with O
5 O
g O
and O
3 O
. O
6 O
g O
of O
amisulpride O
, O
respectively O
, O
are O
reported O
. O

in O
both O
cases O
, O
qt B-Disease
prolongation I-Disease
and O
hypocalcaemia B-Disease
were O
noted O
. O

the O
qt B-Disease
prolongation I-Disease
appeared O
to O
respond O
to O
administration O
of O
i O
. O
v O
. O
calcium O
gluconate O
. O

growth O
- O
associated O
protein O
43 O
expression O
in O
hippocampal O
molecular O
layer O
of O
chronic O
epileptic B-Disease
rats O
treated O
with O
cycloheximide O
. O

purpose O
: O
gap43 O
has O
been O
thought O
to O
be O
linked O
with O
mossy O
fiber O
sprouting O
( O
mfs O
) O
in O
various O
experimental O
models O
of O
epilepsy B-Disease
. O

to O
investigate O
how O
gap43 O
expression O
( O
gap43 O
- O
ir O
) O
correlates O
with O
mfs O
, O
we O
assessed O
the O
intensity O
( O
densitometry O
) O
and O
extension O
( O
width O
) O
of O
gap43 O
- O
ir O
in O
the O
inner O
molecular O
layer O
of O
the O
dentate O
gyrus O
( O
iml O
) O
of O
rats O
subject O
to O
status B-Disease
epilepticus I-Disease
induced O
by O
pilocarpine O
( O
pilo O
) O
, O
previously O
injected O
or O
not O
with O
cycloheximide O
( O
chx O
) O
, O
which O
has O
been O
shown O
to O
inhibit O
mfs O
. O

methods O
: O
chx O
was O
injected O
before O
the O
pilo O
injection O
in O
adult O
wistar O
rats O
. O

the O
pilo O
group O
was O
injected O
with O
the O
same O
drugs O
, O
except O
for O
chx O
. O

animals O
were O
killed O
between O
30 O
and O
60 O
days O
later O
, O
and O
brain O
sections O
were O
processed O
for O
gap43 O
immunohistochemistry O
. O

results O
: O
densitometry O
showed O
no O
significant O
difference O
regarding O
gap43 O
- O
ir O
in O
the O
iml O
between O
pilo O
, O
chx O
+ O
pilo O
, O
and O
control O
groups O
. O

however O
, O
the O
results O
of O
the O
width O
of O
the O
gap43 O
- O
ir O
band O
in O
the O
iml O
showed O
that O
chx O
+ O
pilo O
and O
control O
animals O
had O
a O
significantly O
larger O
band O
( O
p O
= O
0 O
. O
03 O
) O
as O
compared O
with O
that O
in O
the O
pilo O
group O
. O

conclusions O
: O
our O
current O
finding O
that O
animals O
in O
the O
chx O
+ O
pilo O
group O
have O
a O
gap43 O
- O
ir O
band O
in O
the O
iml O
, O
similar O
to O
that O
of O
controls O
, O
reinforces O
prior O
data O
on O
the O
blockade O
of O
mfs O
in O
these O
animals O
. O

the O
change O
in O
gap43 O
- O
ir O
present O
in O
pilo O
- O
treated O
animals O
was O
a O
thinning O
of O
the O
band O
to O
a O
very O
narrow O
layer O
just O
above O
the O
granule O
cell O
layer O
that O
is O
likely O
to O
be O
associated O
with O
the O
loss O
of O
hilar O
cell O
projections O
that O
express O
gap O
- O
43 O
. O

nicotine O
antagonizes O
caffeine O
- O
but O
not O
pentylenetetrazole O
- O
induced O
anxiogenic O
effect O
in O
mice O
. O

rationale O
: O
nicotine O
and O
caffeine O
are O
widely O
consumed O
licit O
psychoactive O
drugs O
worldwide O
. O

epidemiological O
studies O
showed O
that O
they O
were O
generally O
used O
concurrently O
. O

although O
some O
studies O
in O
experimental O
animals O
indicate O
clear O
pharmacological O
interactions O
between O
them O
, O
no O
studies O
have O
shown O
a O
specific O
interaction O
on O
anxiety B-Disease
responses O
. O

objectives O
: O
the O
present O
study O
investigates O
the O
effects O
of O
nicotine O
on O
anxiety B-Disease
induced O
by O
caffeine O
and O
another O
anxiogenic O
drug O
, O
pentylenetetrazole O
, O
in O
mice O
. O

the O
elevated O
plus O
- O
maze O
( O
epm O
) O
test O
was O
used O
to O
evaluate O
the O
effects O
of O
drugs O
on O
anxiety B-Disease
. O

methods O
: O
adult O
male O
swiss O
webster O
mice O
( O
25 O
- O
32 O
g O
) O
were O
given O
nicotine O
( O
0 O
. O
05 O
- O
0 O
. O
25 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
or O
saline O
10 O
min O
before O
caffeine O
( O
70 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
or O
pentylenetetrazole O
( O
15 O
and O
30 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
injections O
. O

after O
15 O
min O
, O
mice O
were O
evaluated O
for O
their O
open O
- O
and O
closed O
- O
arm O
time O
and O
entries O
on O
the O
epm O
for O
a O
10 O
- O
min O
session O
. O

locomotor O
activity O
was O
recorded O
for O
individual O
groups O
by O
using O
the O
same O
treatment O
protocol O
with O
the O
epm O
test O
. O

results O
: O
nicotine O
( O
0 O
. O
05 O
- O
0 O
. O
25 O
mg O
/ O
kg O
) O
itself O
did O
not O
produce O
any O
significant O
effect O
in O
the O
epm O
test O
, O
whereas O
caffeine O
( O
70 O
mg O
/ O
kg O
) O
and O
pentylenetetrazole O
( O
30 O
mg O
/ O
kg O
) O
produced O
an O
anxiogenic O
effect O
, O
apparent O
with O
decreases O
in O
open O
- O
arm O
time O
and O
entry O
. O

nicotine O
( O
0 O
. O
25 O
mg O
/ O
kg O
) O
pretreatment O
blocked O
the O
caffeine O
- O
but O
not O
pentylenetetrazole O
- O
induced O
anxiety B-Disease
. O

administration O
of O
each O
drug O
and O
their O
combinations O
did O
not O
produce O
any O
effect O
on O
locomotor O
activity O
. O

conclusions O
: O
our O
results O
suggest O
that O
the O
antagonistic O
effect O
of O
nicotine O
on O
caffeine O
- O
induced O
anxiety B-Disease
is O
specific O
to O
caffeine O
, O
instead O
of O
a O
non O
- O
specific O
anxiolytic O
effect O
. O

thus O
, O
it O
may O
extend O
the O
current O
findings O
on O
the O
interaction O
between O
nicotine O
and O
caffeine O
. O

long O
term O
hormone O
therapy O
for O
perimenopausal O
and O
postmenopausal O
women O
. O

background O
: O
hormone O
therapy O
( O
ht O
) O
is O
widely O
used O
for O
controlling O
menopausal B-Disease
symptoms I-Disease
. O

it O
has O
also O
been O
used O
for O
the O
management O
and O
prevention O
of O
cardiovascular B-Disease
disease I-Disease
, O
osteoporosis B-Disease
and O
dementia B-Disease
in O
older O
women O
but O
the O
evidence O
supporting O
its O
use O
for O
these O
indications O
is O
largely O
observational O
. O

objectives O
: O
to O
assess O
the O
effect O
of O
long O
- O
term O
ht O
on O
mortality O
, O
heart B-Disease
disease I-Disease
, O
venous B-Disease
thromboembolism I-Disease
, O
stroke B-Disease
, O
transient B-Disease
ischaemic I-Disease
attacks I-Disease
, O
breast B-Disease
cancer I-Disease
, O
colorectal B-Disease
cancer I-Disease
, O
ovarian B-Disease
cancer I-Disease
, O
endometrial B-Disease
cancer I-Disease
, O
gallbladder B-Disease
disease I-Disease
, O
cognitive O
function O
, O
dementia B-Disease
, O
fractures B-Disease
and O
quality O
of O
life O
. O

search O
strategy O
: O
we O
searched O
the O
following O
databases O
up O
to O
november O
2004 O
: O
the O
cochrane O
menstrual O
disorders O
and O
subfertility O
group O
trials O
register O
, O
cochrane O
central O
register O
of O
controlled O
trials O
( O
central O
) O
, O
medline O
, O
embase O
, O
biological O
abstracts O
. O

relevant O
non O
- O
indexed O
journals O
and O
conference O
abstracts O
were O
also O
searched O
. O

selection O
criteria O
: O
randomised O
double O
- O
blind O
trials O
of O
ht O
( O
oestrogens O
with O
or O
without O
progestogens O
) O
versus O
placebo O
, O
taken O
for O
at O
least O
one O
year O
by O
perimenopausal O
or O
postmenopausal O
women O
. O

data O
collection O
and O
analysis O
: O
fifteen O
rcts O
were O
included O
. O

trials O
were O
assessed O
for O
quality O
and O
two O
review O
authors O
extracted O
data O
independently O
. O

they O
calculated O
risk O
ratios O
for O
dichotomous O
outcomes O
and O
weighted O
mean O
differences O
for O
continuous O
outcomes O
. O

clinical O
heterogeneity O
precluded O
meta O
- O
analysis O
for O
most O
outcomes O
. O

main O
results O
: O
all O
the O
statistically O
significant O
results O
were O
derived O
from O
the O
two O
biggest O
trials O
. O

in O
relatively O
healthy O
women O
, O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-Disease
thromboembolism I-Disease
or O
coronary O
event O
( O
after O
one O
year O
' O
s O
use O
) O
, O
stroke B-Disease
( O
after O
3 O
years O
) O
, O
breast B-Disease
cancer I-Disease
( O
after O
5 O
years O
) O
and O
gallbladder B-Disease
disease I-Disease
. O

long O
- O
term O
oestrogen O
- O
only O
ht O
also O
significantly O
increased O
the O
risk O
of O
stroke B-Disease
and O
gallbladder B-Disease
disease I-Disease
. O

overall O
, O
the O
only O
statistically O
significant O
benefits O
of O
ht O
were O
a O
decreased O
incidence O
of O
fractures B-Disease
and O
colon B-Disease
cancer I-Disease
with O
long O
- O
term O
use O
. O

among O
relatively O
healthy O
women O
over O
65 O
years O
taking O
continuous O
combined O
ht O
, O
there O
was O
a O
statistically O
significant O
increase O
in O
the O
incidence O
of O
dementia B-Disease
. O

among O
women O
with O
cardiovascular B-Disease
disease I-Disease
, O
long O
- O
term O
use O
of O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-Disease
thromboembolism I-Disease
. O

no O
trials O
focussed O
specifically O
on O
younger O
women O
. O

however O
, O
one O
trial O
analysed O
subgroups O
of O
2839 O
relatively O
healthy O
50 O
to O
59 O
year O
- O
old O
women O
taking O
combined O
continuous O
ht O
and O
1637 O
taking O
oestrogen O
- O
only O
ht O
, O
versus O
similar O
- O
sized O
placebo O
groups O
. O

the O
only O
significantly O
increased O
risk O
reported O
was O
for O
venous B-Disease
thromboembolism I-Disease
in O
women O
taking O
combined O
continuous O
ht O
; O
their O
absolute O
risk O
remained O
very O
low O
. O

authors O
' O
conclusions O
: O
ht O
is O
not O
indicated O
for O
the O
routine O
management O
of O
chronic B-Disease
disease I-Disease
. O

we O
need O
more O
evidence O
on O
the O
safety O
of O
ht O
for O
menopausal O
symptom O
control O
, O
though O
short O
- O
term O
use O
appears O
to O
be O
relatively O
safe O
for O
healthy O
younger O
women O
. O

drug B-Disease
- I-Disease
induced I-Disease
liver I-Disease
injury I-Disease
: O
an O
analysis O
of O
461 O
incidences O
submitted O
to O
the O
spanish O
registry O
over O
a O
10 O
- O
year O
period O
. O

background O
& O
aims O
: O
progress O
in O
the O
understanding O
of O
susceptibility O
factors O
to O
drug B-Disease
- I-Disease
induced I-Disease
liver I-Disease
injury I-Disease
( O
dili B-Disease
) O
and O
outcome O
predictability O
are O
hampered O
by O
the O
lack O
of O
systematic O
programs O
to O
detect O
bona O
fide O
cases O
. O

methods O
: O
a O
cooperative O
network O
was O
created O
in O
1994 O
in O
spain O
to O
identify O
all O
suspicions O
of O
dili B-Disease
following O
a O
prospective O
structured O
report O
form O
. O

the O
liver B-Disease
damage I-Disease
was O
characterized O
according O
to O
hepatocellular O
, O
cholestatic B-Disease
, O
and O
mixed O
laboratory O
criteria O
and O
to O
histologic O
criteria O
when O
available O
. O

further O
evaluation O
of O
causality O
assessment O
was O
centrally O
performed O
. O

results O
: O
since O
april O
1994 O
to O
august O
2004 O
, O
461 O
out O
of O
570 O
submitted O
cases O
, O
involving O
505 O
drugs O
, O
were O
deemed O
to O
be O
related O
to O
dili B-Disease
. O

the O
antiinfective O
group O
of O
drugs O
was O
the O
more O
frequently O
incriminated O
, O
amoxicillin O
- O
clavulanate O
accounting O
for O
the O
12 O
. O
8 O
% O
of O
the O
whole O
series O
. O

the O
hepatocellular O
pattern O
of O
damage O
was O
the O
most O
common O
( O
58 O
% O
) O
, O
was O
inversely O
correlated O
with O
age O
( O
p O
< O
. O
0001 O
) O
, O
and O
had O
the O
worst O
outcome O
( O
cox O
regression O
, O
p O
< O
. O
034 O
) O
. O

indeed O
, O
the O
incidence O
of O
liver O
transplantation O
and O
death O
in O
this O
group O
was O
11 O
. O
7 O
% O
if O
patients O
had O
jaundice B-Disease
at O
presentation O
, O
whereas O
the O
corresponding O
figure O
was O
3 O
. O
8 O
% O
in O
nonjaundiced O
patients O
( O
p O
< O
. O
04 O
) O
. O

factors O
associated O
with O
the O
development O
of O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
were O
female O
sex O
( O
or O
= O
25 O
; O
95 O
% O
ci O
: O
4 O
. O
1 O
- O
151 O
; O
p O
< O
. O
0001 O
) O
, O
hepatocellular O
damage O
( O
or O
= O
7 O
. O
9 O
; O
95 O
% O
ci O
: O
1 O
. O
6 O
- O
37 O
; O
p O
< O
. O
009 O
) O
, O
and O
higher O
baseline O
plasma O
bilirubin O
value O
( O
or O
= O
1 O
. O
15 O
; O
95 O
% O
ci O
: O
1 O
. O
09 O
- O
1 O
. O
22 O
; O
p O
< O
. O
0001 O
) O
. O

conclusions O
: O
patients O
with O
drug O
- O
induced O
hepatocellular O
jaundice B-Disease
have O
11 O
. O
7 O
% O
chance O
of O
progressing O
to O
death O
or O
transplantation O
. O

amoxicillin O
- O
clavulanate O
stands O
out O
as O
the O
most O
common O
drug O
related O
to O
dili B-Disease
. O

morphological O
evaluation O
of O
the O
effect O
of O
d O
- O
ribose O
on O
adriamycin O
- O
evoked O
cardiotoxicity B-Disease
in O
rats O
. O

the O
influence O
of O
d O
- O
ribose O
on O
adriamycin O
- O
induced O
myocardiopathy B-Disease
in O
rats O
was O
studied O
. O

adriamycin O
in O
the O
cumulative O
dose O
of O
25 O
mg O
/ O
kg O
evoked O
fully O
developed O
cardiac B-Disease
toxicity I-Disease
. O

d O
- O
ribose O
in O
the O
multiple O
doses O
of O
200 O
mg O
/ O
kg O
did O
not O
influence O
adr O
cardiotoxicity B-Disease
. O

in O
vivo O
evidences O
suggesting O
the O
role O
of O
oxidative O
stress O
in O
pathogenesis O
of O
vancomycin O
- O
induced O
nephrotoxicity B-Disease
: O
protection O
by O
erdosteine O
. O

the O
aims O
of O
this O
study O
were O
to O
examine O
vancomycin O
( O
vcm O
) O
- O
induced O
oxidative O
stress O
that O
promotes O
production O
of O
reactive O
oxygen O
species O
( O
ros O
) O
and O
to O
investigate O
the O
role O
of O
erdosteine O
, O
an O
expectorant O
agent O
, O
which O
has O
also O
antioxidant O
properties O
, O
on O
kidney O
tissue O
against O
the O
possible O
vcm O
- O
induced O
renal B-Disease
impairment I-Disease
in O
rats O
. O

rats O
were O
divided O
into O
three O
groups O
: O
sham O
, O
vcm O
and O
vcm O
plus O
erdosteine O
. O

vcm O
was O
administrated O
intraperitoneally O
( O
i O
. O
p O
. O
) O
with O
200mgkg O
( O
- O
1 O
) O
twice O
daily O
for O
7 O
days O
. O

erdosteine O
was O
administered O
orally O
. O

vcm O
administration O
to O
control O
rats O
significantly O
increased O
renal O
malondialdehyde O
( O
mda O
) O
and O
urinary O
n O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
( O
nag O
, O
a O
marker O
of O
renal B-Disease
tubular I-Disease
injury I-Disease
) O
excretion O
but O
decreased O
superoxide O
dismutase O
( O
sod O
) O
and O
catalase O
( O
cat O
) O
activities O
. O

erdosteine O
administration O
with O
vcm O
injections O
caused O
significantly O
decreased O
renal O
mda O
and O
urinary O
nag O
excretion O
, O
and O
increased O
sod O
activity O
, O
but O
not O
cat O
activity O
in O
renal O
tissue O
when O
compared O
with O
vcm O
alone O
. O

erdosteine O
showed O
histopathological O
protection O
against O
vcm O
- O
induced O
nephrotoxicity B-Disease
. O

there O
were O
a O
significant O
dilatation O
of O
tubular O
lumens O
, O
extensive O
epithelial O
cell O
vacuolization O
, O
atrophy B-Disease
, O
desquamation B-Disease
, O
and O
necrosis B-Disease
in O
vcm O
- O
treated O
rats O
more O
than O
those O
of O
the O
control O
and O
the O
erdosteine O
groups O
. O

erdosteine O
caused O
a O
marked O
reduction O
in O
the O
extent O
of O
tubular O
damage O
. O

it O
is O
concluded O
that O
oxidative O
tubular O
damage O
plays O
an O
important O
role O
in O
the O
vcm O
- O
induced O
nephrotoxicity B-Disease
and O
the O
modulation O
of O
oxidative O
stress O
with O
erdosteine O
reduces O
the O
vcm O
- O
induced O
kidney B-Disease
damage I-Disease
both O
at O
the O
biochemical O
and O
histological O
levels O
. O

gemfibrozil O
- O
lovastatin O
therapy O
for O
primary O
hyperlipoproteinemias B-Disease
. O

the O
specific O
aim O
of O
this O
retrospective O
, O
observational O
study O
was O
to O
assess O
safety O
and O
efficacy O
of O
long O
- O
term O
( O
21 O
months O
/ O
patient O
) O
, O
open O
- O
label O
, O
gemfibrozil O
- O
lovastatin O
treatment O
in O
80 O
patients O
with O
primary O
mixed O
hyperlipidemia B-Disease
( O
68 O
% O
of O
whom O
had O
atherosclerotic B-Disease
vascular I-Disease
disease I-Disease
) O
. O

because O
ideal O
lipid O
targets O
were O
not O
reached O
( O
low O
- O
density O
lipoprotein O
( O
ldl O
) O
cholesterol O
less O
than O
130 O
mg O
/ O
dl O
, O
high O
- O
density O
lipoprotein O
( O
hdl O
) O
cholesterol O
greater O
than O
35 O
mg O
/ O
dl O
, O
or O
total O
cholesterol O
/ O
hdl O
cholesterol O
less O
than O
4 O
. O
5 O
mg O
/ O
dl O
) O
with O
diet O
plus O
a O
single O
drug O
, O
gemfibrozil O
( O
1 O
. O
2 O
g O
/ O
day O
) O
- O
lovastatin O
( O
primarily O
20 O
or O
40 O
mg O
) O
treatment O
was O
given O
. O

follow O
- O
up O
visits O
were O
scheduled O
with O
2 O
- O
drug O
therapy O
every O
6 O
to O
8 O
weeks O
, O
an O
average O
of O
10 O
. O
3 O
visits O
per O
patient O
, O
with O
741 O
batteries O
of O
6 O
liver O
function O
tests O
and O
714 O
creatine O
phosphokinase O
levels O
measured O
. O

only O
1 O
of O
the O
4 O
, O
446 O
liver O
function O
tests O
( O
0 O
. O
02 O
% O
) O
, O
a O
gamma O
glutamyl O
transferase O
, O
was O
greater O
than O
or O
equal O
to O
3 O
times O
the O
upper O
normal O
limit O
. O

of O
the O
714 O
creatine O
phosphokinase O
levels O
, O
9 O
% O
were O
high O
; O
only O
1 O
( O
0 O
. O
1 O
% O
) O
was O
greater O
than O
or O
equal O
to O
3 O
times O
the O
upper O
normal O
limit O
. O

with O
2 O
- O
drug O
therapy O
, O
mean O
total O
cholesterol O
decreased O
22 O
% O
from O
255 O
to O
200 O
mg O
/ O
dl O
, O
triglyceride O
levels O
decreased O
35 O
% O
from O
236 O
to O
154 O
mg O
/ O
dl O
, O
ldl O
cholesterol O
decreased O
26 O
% O
from O
176 O
to O
131 O
mg O
/ O
dl O
, O
and O
the O
total O
cholesterol O
/ O
hdl O
cholesterol O
ratio O
decreased O
24 O
% O
from O
7 O
. O
1 O
to O
5 O
. O
4 O
, O
all O
p O
less O
than O
or O
equal O
to O
0 O
. O
0001 O
. O

myositis B-Disease
, O
attributable O
to O
the O
drug O
combination O
and O
symptomatic O
enough O
to O
discontinue O
it O
, O
occurred O
in O
3 O
% O
of O
patients O
, O
and O
in O
1 O
% O
with O
concurrent O
high O
creatine O
phosphokinase O
( O
769 O
u O
/ O
liter O
) O
; O
no O
patients O
had O
rhabdomyolysis B-Disease
or O
myoglobinuria B-Disease
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

does O
domperidone O
potentiate O
mirtazapine O
- O
associated O
restless B-Disease
legs I-Disease
syndrome I-Disease
? O

there O
is O
now O
evidence O
to O
suggest O
a O
central O
role O
for O
the O
dopaminergic O
system O
in O
restless B-Disease
legs I-Disease
syndrome I-Disease
( O
rls B-Disease
) O
. O

for O
example O
, O
the O
symptoms O
of O
rls B-Disease
can O
be O
dramatically O
improved O
by O
levodopa O
and O
dopamine O
agonists O
, O
whereas O
central O
dopamine O
d2 O
receptor O
antagonists O
can O
induce O
or O
aggravate O
rls B-Disease
symptoms O
. O

to O
our O
knowledge O
, O
there O
is O
no O
previous O
report O
regarding O
whether O
domperidone O
, O
a O
peripheral O
dopamine O
d2 O
receptor O
antagonist O
, O
can O
also O
induce O
or O
aggravate O
symptoms O
of O
rls B-Disease
. O

mirtazapine O
, O
the O
first O
noradrenergic O
and O
specific O
serotonergic O
antidepressant O
( O
nassa O
) O
, O
has O
been O
associated O
with O
rls B-Disease
in O
several O
recent O
publications O
. O

the O
authors O
report O
here O
a O
depressed O
patient O
comorbid O
with O
postprandial B-Disease
dyspepsia I-Disease
who O
developed O
rls B-Disease
after O
mirtazapine O
had O
been O
added O
to O
his O
domperidone O
therapy O
. O

our O
patient O
started O
to O
have O
symptoms O
of O
rls B-Disease
only O
after O
he O
had O
been O
treated O
with O
mirtazapine O
, O
and O
his O
rls B-Disease
symptoms O
resolved O
completely O
upon O
discontinuation O
of O
his O
mirtazapine O
. O

such O
a O
temporal O
relationship O
between O
the O
use O
of O
mirtazapine O
and O
the O
symptoms O
of O
rls B-Disease
in O
our O
patient O
did O
not O
support O
a O
potentiating O
effect O
of O
domperione O
on O
mirtazapine O
- O
associated O
rls B-Disease
. O

however O
, O
physicians O
should O
be O
aware O
of O
the O
possibility O
that O
mirtazapine O
can O
be O
associated O
with O
rls B-Disease
in O
some O
individuals O
, O
especially O
those O
receiving O
concomitant O
dopamine O
d2 O
receptor O
antagonists O
. O

antiandrogenic O
therapy O
can O
cause O
coronary B-Disease
arterial I-Disease
disease I-Disease
. O

aim O
: O
to O
study O
the O
change O
of O
lipid O
metabolism O
by O
antiandrogen O
therapy O
in O
patients O
with O
prostate B-Disease
cancer I-Disease
. O

materials O
and O
methods O
: O
we O
studied O
with O
a O
2 O
. O
5 O
years O
follow O
- O
up O
the O
changes O
in O
plasma O
cholesterols O
( O
c O
) O
, O
triglycerides O
( O
tg O
) O
, O
lipoproteins O
( O
lp O
) O
, O
and O
apolipoproteins O
( O
apo O
) O
b O
- O
100 O
, O
a O
- O
i O
, O
and O
a O
- O
ii O
pro O
fi O
les O
in O
24 O
patients O
of O
mean O
age O
60 O
years O
with O
low O
risk O
prostate B-Disease
cancer I-Disease
( O
stage O
: O
t1cn0m0 O
, O
gleason O
score O
: O
2 O
- O
5 O
) O
during O
treatment O
with O
cyproterone O
acetate O
( O
cpa O
) O
without O
surgical O
management O
or O
radiation O
therapy O
. O

results O
: O
significant O
decreases O
of O
hdl O
- O
c O
, O
apo O
a O
- O
i O
and O
apo O
a O
- O
ii O
and O
an O
increase O
of O
triglyceride O
levels O
in O
vldl O
were O
induced O
by O
cpa O
. O

after O
a O
period O
of O
2 O
. O
5 O
years O
on O
cpa O
treatment O
, O
four O
patients O
out O
of O
twenty O
- O
four O
were O
found O
to O
be O
affected O
by O
coronary B-Disease
heart I-Disease
disease I-Disease
. O

conclusions O
: O
ischaemic O
coronary B-Disease
arteriosclerosis I-Disease
with O
an O
incidence O
rate O
of O
16 O
. O
6 O
% O
as O
caused O
by O
prolonged O
cpa O
therapy O
is O
mediated O
through O
changes O
in O
hdl O
cholesterol O
, O
apo O
a O
- O
i O
and O
apo O
a O
- O
ii O
pro O
fi O
les O
, O
other O
than O
the O
well O
- O
known O
hyperglyceridemic B-Disease
effect I-Disease
caused O
by O
estrogen O
. O

5 O
- O
fluorouracil O
cardiotoxicity B-Disease
induced O
by O
alpha O
- O
fluoro O
- O
beta O
- O
alanine O
. O

cardiotoxicity B-Disease
is O
a O
rare O
complication O
occurring O
during O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
treatment O
for O
malignancies B-Disease
. O

we O
herein O
report O
the O
case O
of O
a O
70 O
- O
year O
- O
old O
man O
with O
5 O
- O
fu O
- O
induced O
cardiotoxicity B-Disease
, O
in O
whom O
a O
high O
serum O
level O
of O
alpha O
- O
fluoro O
- O
beta O
- O
alanine O
( O
fbal O
) O
was O
observed O
. O

the O
patient O
, O
who O
had O
unresectable O
colon B-Disease
cancer I-Disease
metastases O
to O
the O
liver O
and O
lung O
, O
was O
referred O
to O
us O
for O
chemotherapy O
from O
an O
affiliated O
hospital O
; O
he O
had O
no O
cardiac O
history O
. O

after O
admission O
, O
the O
patient O
received O
a O
continuous O
intravenous O
infusion O
of O
5 O
- O
fu O
( O
1000 O
mg O
/ O
day O
) O
, O
during O
which O
precordial B-Disease
pain I-Disease
with O
right B-Disease
bundle I-Disease
branch I-Disease
block I-Disease
occurred O
concomitantly O
with O
a O
high O
serum O
fbal O
concentration O
of O
1955 O
ng O
/ O
ml O
. O

both O
the O
precordial B-Disease
pain I-Disease
and O
the O
electrocardiographic O
changes O
disappeared O
spontaneously O
after O
the O
discontinuation O
of O
5 O
- O
fu O
. O

as O
the O
precordial B-Disease
pain I-Disease
in O
this O
patient O
was O
considered O
to O
have O
been O
due O
to O
5 O
- O
fu O
- O
induced O
cardiotoxicity B-Disease
, O
the O
administration O
of O
5 O
- O
fu O
was O
abandoned O
. O

instead O
, O
oral O
administration O
of O
s O
- O
1 O
( O
a O
derivative O
of O
5 O
- O
fu O
) O
, O
at O
200 O
mg O
/ O
day O
twice O
a O
week O
, O
was O
instituted O
, O
because O
s O
- O
1 O
has O
a O
strong O
inhibitory O
effect O
on O
dihydropyrimidine O
dehydrogenase O
, O
which O
catalyzes O
the O
degradative O
of O
5 O
- O
fu O
into O
fbal O
. O

the O
serum O
fbal O
concentration O
subsequently O
decreased O
to O
352 O
ng O
/ O
ml O
, O
the O
same O
as O
the O
value O
measured O
on O
the O
first O
day O
of O
s O
- O
1 O
administration O
. O

thereafter O
, O
no O
cardiac B-Disease
symptoms I-Disease
were O
observed O
. O

the O
patient O
achieved O
a O
partial O
response O
6 O
months O
after O
the O
initiation O
of O
the O
s O
- O
1 O
treatment O
. O

the O
experience O
of O
this O
case O
, O
together O
with O
a O
review O
of O
the O
literature O
, O
suggests O
that O
fbal O
is O
related O
to O
5 O
- O
fu O
- O
induced O
cardiotoxicity B-Disease
. O

s O
- O
1 O
may O
be O
administered O
safely O
to O
patients O
with O
5 O
- O
fu O
- O
induced O
cardiotoxicity B-Disease
. O

hepatocellular B-Disease
carcinoma I-Disease
in O
fanconi B-Disease
' I-Disease
s I-Disease
anemia I-Disease
treated O
with O
androgen O
and O
corticosteroid O
. O

the O
case O
of O
an O
11 O
- O
year O
- O
old O
boy O
is O
reported O
who O
was O
known O
to O
have O
fanconi B-Disease
' I-Disease
s I-Disease
anemia I-Disease
for O
3 O
years O
and O
was O
treated O
with O
androgens O
, O
corticosteroids O
and O
transfusions O
. O

two O
weeks O
before O
his O
death O
he O
was O
readmitted O
because O
of O
aplastic O
crisis O
with O
septicemia B-Disease
and O
marked O
abnormalities O
in O
liver O
function O
and O
died O
of O
hemorrhagic B-Disease
bronchopneumonia I-Disease
. O

at O
autopsy O
peliosis B-Disease
and O
multiple O
hepatic B-Disease
tumors I-Disease
were O
found O
which O
histologically O
proved O
to O
be O
well O
- O
differentiated O
hepatocellular B-Disease
carcinoma I-Disease
. O

this O
case O
contributes O
to O
the O
previous O
observations O
that O
non O
- O
metastasizing O
hepatic B-Disease
neoplasms I-Disease
and O
peliosis B-Disease
can O
develop O
in O
patients O
with O
androgen O
- O
and O
corticosteroid O
- O
treated O
fanconi B-Disease
' I-Disease
s I-Disease
anemia I-Disease
. O

the O
influence O
of O
the O
time O
interval O
between O
monoher O
and O
doxorubicin O
administration O
on O
the O
protection O
against O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
in O
mice O
. O

purpose O
: O
despite O
its O
well O
- O
known O
cardiotoxicity B-Disease
, O
the O
anthracyclin O
doxorubicin O
( O
dox O
) O
continues O
to O
be O
an O
effective O
and O
widely O
used O
chemotherapeutic O
agent O
. O

dox O
- O
induced O
cardiac B-Disease
damage I-Disease
presumably O
results O
from O
the O
formation O
of O
free O
radicals O
by O
dox O
. O

reactive O
oxygen O
species O
particularly O
affect O
the O
cardiac O
myocytes O
because O
these O
cells O
seem O
to O
have O
a O
relatively O
poor O
antioxidant O
defense O
system O
. O

the O
semisynthetic O
flavonoid O
monohydroxyethylrutoside O
( O
monoher O
) O
showed O
cardioprotection O
against O
dox O
- O
induced O
cardiotoxicity B-Disease
through O
its O
radical O
scavenging O
and O
iron O
chelating O
properties O
. O

because O
of O
the O
relatively O
short O
final O
half O
- O
life O
of O
monoher O
( O
about O
30 O
min O
) O
, O
it O
is O
expected O
that O
the O
time O
interval O
between O
monoher O
and O
dox O
might O
be O
of O
influence O
on O
the O
cardioprotective O
effect O
of O
monoher O
. O

therefore O
, O
the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
this O
possible O
effect O
. O

methods O
: O
six O
groups O
of O
6 O
balb O
/ O
c O
mice O
were O
treated O
with O
saline O
, O
dox O
alone O
or O
dox O
( O
4 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
preceded O
by O
monoher O
( O
500 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
with O
an O
interval O
of O
10 O
, O
30 O
, O
60 O
or O
120 O
min O
. O

after O
a O
6 O
- O
week O
treatment O
period O
and O
additional O
observation O
for O
2 O
weeks O
, O
the O
mice O
were O
sacrificed O
. O

their O
cardiac O
tissues O
were O
processed O
for O
light O
microscopy O
, O
after O
which O
cardiomyocyte B-Disease
damage I-Disease
was O
evaluated O
according O
to O
billingham O
( O
in O
cancer B-Disease
treat O
rep O
62 O
( O
6 O
) O
: O
865 O
- O
872 O
, O
1978 O
) O
. O

microscopic O
evaluation O
revealed O
that O
treatment O
with O
dox O
alone O
induced O
significant O
cardiac B-Disease
damage I-Disease
in O
comparison O
to O
the O
saline O
control O
group O
( O
p O
< O
0 O
. O
001 O
) O
. O

results O
: O
the O
number O
of O
damaged O
cardiomyocytes O
was O
9 O
. O
6 O
- O
fold O
( O
95 O
% O
ci O
4 O
. O
4 O
- O
21 O
. O
0 O
) O
higher O
in O
mice O
treated O
with O
dox O
alone O
than O
that O
in O
animals O
of O
the O
control O
group O
. O

the O
ratio O
of O
aberrant O
cardiomyocytes O
in O
mice O
treated O
with O
dox O
preceded O
by O
monoher O
and O
those O
in O
mice O
treated O
with O
saline O
ranged O
from O
1 O
. O
6 O
to O
2 O
. O
8 O
( O
mean O
2 O
. O
2 O
, O
95 O
% O
ci O
1 O
. O
2 O
- O
4 O
. O
1 O
, O
p O
= O
0 O
. O
019 O
) O
. O

the O
mean O
protective O
effect O
by O
adding O
monoher O
before O
dox O
led O
to O
a O
significant O
4 O
. O
4 O
- O
fold O
reduction O
( O
p O
< O
0 O
. O
001 O
, O
95 O
% O
ci O
2 O
. O
3 O
- O
8 O
. O
2 O
) O
of O
abnormal O
cardiomyocytes O
. O

this O
protective O
effect O
did O
not O
depend O
on O
the O
time O
interval O
between O
monoher O
and O
dox O
administration O
( O
p O
= O
0 O
. O
345 O
) O
. O

conclusion O
: O
the O
results O
indicate O
that O
in O
an O
outpatient O
clinical O
setting O
monoher O
may O
be O
administered O
shortly O
before O
dox O
. O

clinical O
evaluation O
of O
adverse O
effects O
during O
bepridil O
administration O
for O
atrial B-Disease
fibrillation I-Disease
and I-Disease
flutter I-Disease
. O

background O
: O
bepridil O
hydrochloride O
( O
bpd O
) O
has O
attracted O
attention O
as O
an O
effective O
drug O
for O
atrial B-Disease
fibrillation I-Disease
( O
af B-Disease
) O
and O
atrial B-Disease
flutter I-Disease
( O
afl B-Disease
) O
. O

however O
, O
serious O
adverse O
effects O
, O
including O
torsade B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
, O
have O
been O
reported O
. O

methods O
and O
results O
: O
adverse O
effects O
of O
bpd O
requiring O
discontinuation O
of O
treatment O
were O
evaluated O
. O

bpd O
was O
administered O
to O
459 O
patients O
( O
361 O
males O
, O
63 O
+ O
/ O
- O
12 O
years O
old O
) O
comprising O
378 O
af B-Disease
and O
81 O
afl B-Disease
cases O
. O

mean O
left O
ventricular O
ejection O
fraction O
and O
atrial O
dimension O
( O
lad O
) O
were O
66 O
+ O
/ O
- O
11 O
% O
and O
40 O
+ O
/ O
- O
6 O
mm O
, O
respectively O
. O

adverse O
effects O
were O
observed O
in O
19 O
patients O
( O
4 O
% O
) O
during O
an O
average O
follow O
- O
up O
of O
20 O
months O
. O

there O
was O
marked O
qt B-Disease
prolongation I-Disease
greater O
than O
0 O
. O
55 O
s O
in O
13 O
patients O
, O
bradycardia B-Disease
less O
than O
40 O
beats O
/ O
min O
in O
6 O
patients O
, O
dizziness B-Disease
and O
general O
fatigue B-Disease
in O
1 O
patient O
each O
. O

in O
4 O
of O
13 O
patients O
with O
qt B-Disease
prolongation I-Disease
, O
tdp B-Disease
occurred O
. O

the O
major O
triggering O
factors O
of O
tdp B-Disease
were O
hypokalemia B-Disease
and O
sudden O
decrease O
in O
heart O
rate O
. O

there O
were O
no O
differences O
in O
the O
clinical O
backgrounds O
of O
the O
patients O
with O
and O
without O
tdp B-Disease
other O
than O
lad O
and O
age O
, O
which O
were O
larger O
and O
older O
in O
the O
patients O
with O
tdp B-Disease
. O

conclusion O
: O
careful O
observation O
of O
serum O
potassium O
concentration O
and O
the O
ecg O
should O
always O
be O
done O
during O
bpd O
administration O
, O
particularly O
in O
elderly O
patients O
. O

enhanced O
isoproterenol O
- O
induced O
cardiac B-Disease
hypertrophy I-Disease
in O
transgenic O
rats O
with O
low O
brain O
angiotensinogen O
. O

we O
have O
previously O
shown O
that O
a O
permanent O
deficiency O
in O
the O
brain O
renin O
- O
angiotensin O
system O
( O
ras O
) O
may O
increase O
the O
sensitivity O
of O
the O
baroreflex O
control O
of O
heart O
rate O
. O

in O
this O
study O
we O
aimed O
at O
studying O
the O
involvement O
of O
the O
brain O
ras O
in O
the O
cardiac O
reactivity O
to O
the O
beta O
- O
adrenoceptor O
( O
beta O
- O
ar O
) O
agonist O
isoproterenol O
( O
iso O
) O
. O

transgenic O
rats O
with O
low O
brain O
angiotensinogen O
( O
tgr O
) O
were O
used O
. O

in O
isolated O
hearts O
, O
iso O
induced O
a O
significantly O
greater O
increase O
in O
left O
ventricular O
( O
lv O
) O
pressure O
and O
maximal O
contraction O
( O
+ O
dp O
/ O
dt O
( O
max O
) O
) O
in O
the O
tgr O
than O
in O
the O
sprague O
- O
dawley O
( O
sd O
) O
rats O
. O

lv B-Disease
hypertrophy I-Disease
induced O
by O
iso O
treatment O
was O
significantly O
higher O
in O
tgr O
than O
in O
sd O
rats O
( O
in O
g O
lv O
wt O
/ O
100 O
g O
body O
wt O
, O
0 O
. O
28 O
+ O
/ O
- O
0 O
. O
004 O
vs O
. O
0 O
. O
24 O
+ O
/ O
- O
0 O
. O
004 O
, O
respectively O
) O
. O

the O
greater O
lv B-Disease
hypertrophy I-Disease
in O
tgr O
rats O
was O
associated O
with O
more O
pronounced O
downregulation O
of O
beta O
- O
ar O
and O
upregulation O
of O
lv O
beta O
- O
ar O
kinase O
- O
1 O
mrna O
levels O
compared O
with O
those O
in O
sd O
rats O
. O

the O
decrease O
in O
the O
heart O
rate O
( O
hr O
) O
induced O
by O
the O
beta O
- O
ar O
antagonist O
metoprolol O
in O
conscious O
rats O
was O
significantly O
attenuated O
in O
tgr O
compared O
with O
sd O
rats O
( O
- O
9 O
. O
9 O
+ O
/ O
- O
1 O
. O
7 O
% O
vs O
. O
- O
18 O
. O
1 O
+ O
/ O
- O
1 O
. O
5 O
% O
) O
, O
whereas O
the O
effect O
of O
parasympathetic O
blockade O
by O
atropine O
on O
hr O
was O
similar O
in O
both O
strains O
. O

these O
results O
indicate O
that O
tgr O
are O
more O
sensitive O
to O
beta O
- O
ar O
agonist O
- O
induced O
cardiac B-Disease
inotropic I-Disease
response O
and O
hypertrophy B-Disease
, O
possibly O
due O
to O
chronically O
low O
sympathetic O
outflow O
directed O
to O
the O
heart O
. O

drug O
- O
induced O
long B-Disease
qt I-Disease
syndrome I-Disease
in O
injection O
drug O
users O
receiving O
methadone O
: O
high O
frequency O
in O
hospitalized O
patients O
and O
risk O
factors O
. O

background O
: O
drug O
- O
induced O
long B-Disease
qt I-Disease
syndrome I-Disease
is O
a O
serious O
adverse O
drug O
reaction O
. O

methadone O
prolongs O
the O
qt O
interval O
in O
vitro O
in O
a O
dose O
- O
dependent O
manner O
. O

in O
the O
inpatient O
setting O
, O
the O
frequency O
of O
qt B-Disease
interval I-Disease
prolongation I-Disease
with O
methadone O
treatment O
, O
its O
dose O
dependence O
, O
and O
the O
importance O
of O
cofactors O
such O
as O
drug O
- O
drug O
interactions O
remain O
unknown O
. O

methods O
: O
we O
performed O
a O
systematic O
, O
retrospective O
study O
comparing O
active O
or O
former O
intravenous O
drug O
users O
receiving O
methadone O
and O
those O
not O
receiving O
methadone O
among O
all O
patients O
hospitalized O
over O
a O
5 O
- O
year O
period O
in O
a O
tertiary O
care O
hospital O
. O

a O
total O
of O
167 O
patients O
receiving O
methadone O
fulfilled O
the O
inclusion O
criteria O
and O
were O
compared O
with O
a O
control O
group O
of O
80 O
injection O
drug O
users O
not O
receiving O
methadone O
. O

in O
addition O
to O
methadone O
dose O
, O
15 O
demographic O
, O
biological O
, O
and O
pharmacological O
variables O
were O
considered O
as O
potential O
risk O
factors O
for O
qt B-Disease
prolongation I-Disease
. O

results O
: O
among O
167 O
methadone O
maintenance O
patients O
, O
the O
prevalence O
of O
qtc O
prolongation O
to O
0 O
. O
50 O
second O
( O
( O
1 O
/ O
2 O
) O
) O
or O
longer O
was O
16 O
. O
2 O
% O
compared O
with O
0 O
% O
in O
80 O
control O
subjects O
. O

six O
patients O
( O
3 O
. O
6 O
% O
) O
in O
the O
methadone O
group O
presented O
torsades B-Disease
de I-Disease
pointes I-Disease
. O

qtc O
length O
was O
weakly O
but O
significantly O
associated O
with O
methadone O
daily O
dose O
( O
spearman O
rank O
correlation O
coefficient O
, O
0 O
. O
20 O
; O
p O
< O
. O
01 O
) O
. O

multivariate O
regression O
analysis O
allowed O
attribution O
of O
31 O
. O
8 O
% O
of O
qtc O
variability O
to O
methadone O
dose O
, O
cytochrome O
p O
- O
450 O
3a4 O
drug O
- O
drug O
interactions O
, O
hypokalemia B-Disease
, O
and O
altered O
liver O
function O
. O

conclusions O
: O
qt B-Disease
interval I-Disease
prolongation I-Disease
in O
methadone O
maintenance O
patients O
hospitalized O
in O
a O
tertiary O
care O
center O
is O
a O
frequent O
finding O
. O

methadone O
dose O
, O
presence O
of O
cytochrome O
p O
- O
450 O
3a4 O
inhibitors O
, O
potassium O
level O
, O
and O
liver O
function O
contribute O
to O
qt B-Disease
prolongation I-Disease
. O

long B-Disease
qt I-Disease
syndrome I-Disease
can O
occur O
with O
low O
doses O
of O
methadone O
. O

mechanisms O
of O
hypertension B-Disease
induced O
by O
nitric O
oxide O
( O
no O
) O
deficiency O
: O
focus O
on O
venous O
function O
. O

loss O
of O
endothelial O
cell O
- O
derived O
nitric O
oxide O
( O
no O
) O
in O
hypertension B-Disease
is O
a O
hallmark O
of O
arterial B-Disease
dysfunction I-Disease
. O

experimental O
hypertension B-Disease
created O
by O
the O
removal O
of O
no O
, O
however O
, O
involves O
mechanisms O
in O
addition O
to O
decreased O
arterial O
vasodilator O
activity O
. O

these O
include O
augmented O
endothelin O
- O
1 O
( O
et O
- O
1 O
) O
release O
, O
increased O
sympathetic O
nervous O
system O
activity O
, O
and O
elevated O
tissue O
oxidative O
stress O
. O

we O
hypothesized O
that O
increased O
venous O
smooth O
muscle O
( O
venomotor O
) O
tone O
plays O
a O
role O
in O
nomega O
- O
nitro O
- O
l O
- O
arginine O
( O
lnna O
) O
hypertension B-Disease
through O
these O
mechanisms O
. O

rats O
were O
treated O
with O
the O
no O
synthase O
inhibitor O
lnna O
( O
0 O
. O
5 O
g O
/ O
l O
in O
drinking O
water O
) O
for O
2 O
weeks O
. O

mean O
arterial O
pressure O
of O
conscious O
rats O
was O
119 O
+ O
/ O
- O
2 O
mm O
hg O
in O
control O
and O
194 O
+ O
/ O
- O
5 O
mm O
hg O
in O
lnna O
rats O
( O
p O
< O
0 O
. O
05 O
) O
. O

carotid O
arteries O
and O
vena O
cava O
were O
removed O
for O
measurement O
of O
isometric O
contraction O
. O

maximal O
contraction O
to O
norepinephrine O
was O
modestly O
reduced O
in O
arteries O
from O
lnna O
compared O
with O
control O
rats O
whereas O
the O
maximum O
contraction O
to O
et O
- O
1 O
was O
significantly O
reduced O
( O
54 O
% O
control O
) O
. O

maximum O
contraction O
of O
vena O
cava O
to O
norepinephrine O
( O
37 O
% O
control O
) O
also O
was O
reduced O
but O
no O
change O
in O
response O
to O
et O
- O
1 O
was O
observed O
. O

mean O
circulatory O
filling O
pressure O
, O
an O
in O
vivo O
measure O
of O
venomotor O
tone O
, O
was O
not O
elevated O
in O
lnna O
hypertension B-Disease
at O
1 O
or O
2 O
weeks O
after O
lnna O
. O

the O
superoxide O
scavenger O
tempol O
( O
30 O
, O
100 O
, O
and O
300 O
micromol O
kg O
( O
- O
1 O
) O
, O
iv O
) O
did O
not O
change O
arterial O
pressure O
in O
control O
rats O
but O
caused O
a O
dose O
- O
dependent O
decrease O
in O
lnna O
rats O
( O
- O
18 O
+ O
/ O
- O
8 O
, O
- O
26 O
+ O
/ O
- O
15 O
, O
and O
- O
54 O
+ O
/ O
- O
11 O
mm O
hg O
) O
. O

similarly O
, O
ganglionic O
blockade O
with O
hexamethonium O
caused O
a O
significantly O
greater O
fall O
in O
lnna O
hypertensive B-Disease
rats O
( O
76 O
+ O
/ O
- O
9 O
mm O
hg O
) O
compared O
with O
control O
rats O
( O
35 O
+ O
/ O
- O
10 O
mm O
hg O
) O
. O

carotid O
arteries O
, O
vena O
cava O
, O
and O
sympathetic O
ganglia O
from O
lnna O
rats O
had O
higher O
basal O
levels O
of O
superoxide O
compared O
with O
those O
from O
control O
rats O
. O

these O
data O
suggest O
that O
while O
no O
deficiency O
increases O
oxidative O
stress O
and O
sympathetic O
activity O
in O
both O
arterial O
and O
venous O
vessels O
, O
the O
impact O
on O
veins O
does O
not O
make O
a O
major O
contribution O
to O
this O
form O
of O
hypertension B-Disease
. O

association O
of O
drd2 O
polymorphisms O
and O
chlorpromazine O
- O
induced O
extrapyramidal B-Disease
syndrome I-Disease
in O
chinese O
schizophrenic B-Disease
patients O
. O

aim O
: O
extrapyramidal B-Disease
syndrome I-Disease
( O
eps B-Disease
) O
is O
most O
commonly O
affected O
by O
typical O
antipsychotic O
drugs O
that O
have O
a O
high O
affinity O
with O
the O
d2 O
receptor O
. O

recently O
, O
many O
research O
groups O
have O
reported O
on O
the O
positive O
relationship O
between O
the O
genetic O
variations O
in O
the O
drd2 O
gene O
and O
the O
therapeutic O
response O
in O
schizophrenia B-Disease
patients O
as O
a O
result O
of O
the O
role O
of O
variations O
in O
the O
receptor O
in O
modulating O
receptor O
expression O
. O

in O
this O
study O
, O
we O
evaluate O
the O
role O
drd2 O
plays O
in O
chlorpromazine O
- O
induced O
eps B-Disease
in O
schizophrenic B-Disease
patients O
. O

methods O
: O
we O
identified O
seven O
snp O
( O
single O
nucleotide O
polymorphism O
) O
( O
- O
141cins O
> O
del O
, O
taqib O
, O
taqid O
, O
ser311cys O
, O
rs6275 O
, O
rs6277 O
and O
taqia O
) O
in O
the O
drd2 O
gene O
in O
146 O
schizophrenic B-Disease
inpatients O
( O
59 O
with O
eps B-Disease
and O
87 O
without O
eps B-Disease
according O
to O
the O
simpson O
- O
angus O
scale O
) O
treated O
with O
chlorpromazine O
after O
8 O
weeks O
. O

the O
alleles O
of O
all O
loci O
were O
determined O
by O
pcr O
( O
polymerase O
chain O
reaction O
) O
. O

results O
: O
polymorphisms O
taqid O
, O
ser311cys O
and O
rs6277 O
were O
not O
polymorphic O
in O
the O
population O
recruited O
in O
the O
present O
study O
. O

no O
statistical O
significance O
was O
found O
in O
the O
allele O
distribution O
of O
- O
141cins O
> O
del O
, O
taqib O
, O
rs6275 O
and O
taqia O
or O
in O
the O
estimated O
haplotypes O
( O
constituted O
by O
taqib O
, O
rs6275 O
and O
taqia O
) O
in O
linkage O
disequilibrium O
between O
the O
two O
groups O
. O

conclusion O
: O
our O
results O
did O
not O
lend O
strong O
support O
to O
the O
view O
that O
the O
genetic O
variation O
of O
the O
drd2 O
gene O
plays O
a O
major O
role O
in O
the O
individually O
variable O
adverse O
effect O
induced O
by O
chlorpromazine O
, O
at O
least O
in O
chinese O
patients O
with O
schizophrenia B-Disease
. O

our O
results O
confirmed O
a O
previous O
study O
on O
the O
relationship O
between O
drd2 O
and O
eps B-Disease
in O
caucasians O
. O

physical O
training O
decreases O
susceptibility O
to O
subsequent O
pilocarpine O
- O
induced O
seizures B-Disease
in O
the O
rat O
. O

regular O
motor O
activity O
has O
many O
benefits O
for O
mental O
and O
physical O
condition O
but O
its O
implications O
for O
epilepsy B-Disease
are O
still O
controversial O
. O

in O
order O
to O
elucidate O
this O
problem O
, O
we O
have O
studied O
the O
effect O
of O
long O
- O
term O
physical O
activity O
on O
susceptibility O
to O
subsequent O
seizures B-Disease
. O

male O
wistar O
rats O
were O
subjected O
to O
repeated O
training O
sessions O
in O
a O
treadmill O
and O
swimming O
pool O
. O

thereafter O
, O
seizures B-Disease
were O
induced O
by O
pilocarpine O
injections O
in O
trained O
and O
non O
- O
trained O
control O
groups O
. O

during O
the O
acute O
period O
of O
status B-Disease
epilepticus I-Disease
, O
we O
measured O
: O
( O
1 O
) O
the O
latency O
of O
the O
first O
motor O
sign O
, O
( O
2 O
) O
the O
intensity O
of O
seizures B-Disease
, O
( O
3 O
) O
the O
time O
when O
it O
occurred O
within O
the O
6 O
- O
h O
observation O
period O
, O
and O
( O
4 O
) O
the O
time O
when O
the O
acute O
period O
ended O
. O

all O
these O
behavioral O
parameters O
showed O
statistically O
significant O
changes O
suggesting O
that O
regular O
physical O
exercises O
decrease O
susceptibility O
to O
subsequently O
induced O
seizures B-Disease
and O
ameliorate O
the O
course O
of O
experimentally O
induced O
status B-Disease
epilepticus I-Disease
. O

tonic O
dopaminergic O
stimulation O
impairs B-Disease
associative I-Disease
learning I-Disease
in O
healthy O
subjects O
. O

endogenous O
dopamine O
plays O
a O
central O
role O
in O
salience O
coding O
during O
associative O
learning O
. O

administration O
of O
the O
dopamine O
precursor O
levodopa O
enhances O
learning O
in O
healthy O
subjects O
and O
stroke B-Disease
patients O
. O

because O
levodopa O
increases O
both O
phasic O
and O
tonic O
dopaminergic O
neurotransmission O
, O
the O
critical O
mechanism O
mediating O
the O
enhancement O
of O
learning O
is O
unresolved O
. O

we O
here O
probed O
how O
selective O
tonic O
dopaminergic O
stimulation O
affects O
associative O
learning O
. O

forty O
healthy O
subjects O
were O
trained O
in O
a O
novel O
vocabulary O
of O
45 O
concrete O
nouns O
over O
the O
course O
of O
5 O
consecutive O
training O
days O
in O
a O
prospective O
, O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
design O
. O

subjects O
received O
the O
tonically O
stimulating O
dopamine O
- O
receptor O
agonist O
pergolide O
( O
0 O
. O
1 O
mg O
) O
vs O
placebo O
120 O
min O
before O
training O
on O
each O
training O
day O
. O

the O
dopamine O
agonist O
significantly O
impaired B-Disease
novel I-Disease
word I-Disease
learning I-Disease
compared O
to O
placebo O
. O

this O
learning O
decrement O
persisted O
up O
to O
the O
last O
follow O
- O
up O
4 O
weeks O
post O
- O
training O
. O

subjects O
treated O
with O
pergolide O
also O
showed O
restricted O
emotional O
responses O
compared O
to O
the O
placebo O
group O
. O

the O
extent O
of O
' O
flattened O
' O
affect O
with O
pergolide O
was O
related O
to O
the O
degree O
of O
learning O
inhibition O
. O

these O
findings O
suggest O
that O
tonic O
occupation O
of O
dopamine O
receptors O
impairs O
learning O
by O
competition O
with O
phasic O
dopamine O
signals O
. O

thus O
, O
phasic O
signaling O
seems O
to O
be O
the O
critical O
mechanism O
by O
which O
dopamine O
enhances O
associative O
learning O
in O
healthy O
subjects O
and O
stroke B-Disease
patients O
. O

minocycline O
- O
induced O
vasculitis B-Disease
fulfilling O
the O
criteria O
of O
polyarteritis B-Disease
nodosa I-Disease
. O

a O
47 O
- O
year O
- O
old O
man O
who O
had O
been O
taking O
minocycline O
for O
palmoplantar B-Disease
pustulosis I-Disease
developed O
fever B-Disease
, O
myalgias B-Disease
, O
polyneuropathy B-Disease
, O
and O
testicular B-Disease
pain I-Disease
, O
with O
elevated O
c O
- O
reactive O
protein O
( O
crp O
) O
. O

neither O
myeloperoxidase O
- O
nor O
proteinase O
- O
3 O
- O
antineutrophil O
cytoplasmic O
antibody O
was O
positive O
. O

these O
manifestations O
met O
the O
american O
college O
of O
rheumatology O
1990 O
criteria O
for O
the O
classification O
of O
polyarteritis B-Disease
nodosa I-Disease
. O

stopping O
minocycline O
led O
to O
amelioration O
of O
symptoms O
and O
normalization O
of O
crp O
level O
. O

to O
our O
knowledge O
, O
this O
is O
the O
second O
case O
of O
minocycline O
- O
induced O
vasculitis B-Disease
satisfying O
the O
criteria O
. O

differential O
diagnosis O
for O
drug O
- O
induced O
disease O
is O
invaluable O
even O
for O
patients O
with O
classical O
polyarteritis B-Disease
nodosa I-Disease
. O

intramuscular O
hepatitis B-Disease
b I-Disease
immune O
globulin O
combined O
with O
lamivudine O
in O
prevention O
of O
hepatitis B-Disease
b I-Disease
recurrence O
after O
liver O
transplantation O
. O

background O
: O
combined O
hepatitis B-Disease
b I-Disease
immune O
globulin O
( O
hbig O
) O
and O
lamivudine O
in O
prophylaxis O
of O
the O
recurrence O
of O
hepatitis B-Disease
b I-Disease
after O
liver O
transplantation O
has O
significantly O
improved O
the O
survival O
of O
hbsag O
positive O
patients O
. O

this O
study O
was O
undertaken O
to O
evaluate O
the O
outcomes O
of O
liver O
transplantation O
for O
patients O
with O
hepatitis B-Disease
b I-Disease
virus O
( O
hbv O
) O
. O

methods O
: O
a O
retrospective O
chart O
analysis O
and O
a O
review O
of O
the O
organ O
transplant O
database O
identified O
51 O
patients O
( O
43 O
men O
and O
8 O
women O
) O
transplanted O
for O
benign O
hbv O
- O
related O
cirrhotic B-Disease
diseases I-Disease
between O
june O
2002 O
and O
december O
2004 O
who O
had O
survived O
more O
than O
3 O
months O
. O

hbig O
was O
administered O
intravenously O
during O
the O
first O
week O
and O
intramuscularly O
thereafter O
. O

results O
: O
at O
a O
median O
follow O
- O
up O
of O
14 O
. O
1 O
months O
, O
the O
overall O
recurrence O
rate O
in O
the O
51 O
patients O
was O
3 O
. O
9 O
% O
( O
2 O
/ O
51 O
) O
. O

the O
overall O
patient O
survival O
was O
88 O
. O
3 O
% O
, O
and O
82 O
. O
4 O
% O
after O
1 O
and O
2 O
years O
, O
respectively O
. O

a O
daily O
oral O
dose O
of O
100 O
mg O
lamivudine O
for O
2 O
weeks O
before O
transplantation O
for O
10 O
patients O
enabled O
57 O
. O
1 O
% O
( O
4 O
/ O
7 O
) O
and O
62 O
. O
5 O
% O
( O
5 O
/ O
8 O
) O
of O
hbv O
- O
dna O
and O
hbeag O
positive O
patients O
respectively O
to O
convert O
to O
be O
negative O
. O

intramuscular O
hbig O
was O
well O
tolerated O
in O
all O
patients O
. O

conclusion O
: O
lamivudine O
combined O
with O
intramuscular O
hbig O
can O
effectively O
prevent O
allograft O
from O
the O
recurrence O
of O
hbv O
after O
liver O
transplantation O
. O

anticonvulsant O
effect O
of O
eslicarbazepine O
acetate O
( O
bia O
2 O
- O
093 O
) O
on O
seizures B-Disease
induced O
by O
microperfusion O
of O
picrotoxin O
in O
the O
hippocampus O
of O
freely O
moving O
rats O
. O

eslicarbazepine O
acetate O
( O
bia O
2 O
- O
093 O
, O
s O
- O
( O
- O
) O
- O
10 O
- O
acetoxy O
- O
10 O
, O
11 O
- O
dihydro O
- O
5h O
- O
dibenzo O
/ O
b O
, O
f O
/ O
azepine O
- O
5 O
- O
carboxamide O
) O
is O
a O
novel O
antiepileptic O
drug O
, O
now O
in O
phase O
iii O
clinical O
trials O
, O
designed O
with O
the O
aim O
of O
improving O
efficacy O
and O
safety O
in O
comparison O
with O
the O
structurally O
related O
drugs O
carbamazepine O
( O
cbz O
) O
and O
oxcarbazepine O
( O
oxc O
) O
. O

we O
have O
studied O
the O
effects O
of O
oral O
treatment O
with O
eslicarbazepine O
acetate O
on O
a O
whole O
- O
animal O
model O
in O
which O
partial O
seizures B-Disease
can O
be O
elicited O
repeatedly O
on O
different O
days O
without O
changes O
in O
threshold O
or O
seizure B-Disease
patterns O
. O

in O
the O
animals O
treated O
with O
threshold O
doses O
of O
picrotoxin O
, O
the O
average O
number O
of O
seizures B-Disease
was O
2 O
. O
3 O
+ O
/ O
- O
1 O
. O
2 O
, O
and O
average O
seizure B-Disease
duration O
was O
39 O
. O
5 O
+ O
/ O
- O
8 O
. O
4s O
. O

pre O
- O
treatment O
with O
a O
dose O
of O
30 O
mg O
/ O
kg O
2h O
before O
picrotoxin O
microperfusion O
prevented O
seizures B-Disease
in O
the O
75 O
% O
of O
the O
rats O
. O

lower O
doses O
( O
3 O
and O
10mg O
/ O
kg O
) O
did O
not O
suppress O
seizures B-Disease
, O
however O
, O
after O
administration O
of O
10mg O
/ O
kg O
, O
significant O
reductions O
in O
seizures B-Disease
duration O
( O
24 O
. O
3 O
+ O
/ O
- O
6 O
. O
8s O
) O
and O
seizure B-Disease
number O
( O
1 O
. O
6 O
+ O
/ O
- O
0 O
. O
34 O
) O
were O
found O
. O

no O
adverse O
effects O
of O
eslicarbazepine O
acetate O
were O
observed O
in O
the O
behavioral O
/ O
eeg O
patterns O
studied O
, O
including O
sleep O
/ O
wakefulness O
cycle O
, O
at O
the O
doses O
studied O
. O

acute B-Disease
renal I-Disease
failure I-Disease
associated O
with O
prolonged O
intake O
of O
slimming O
pills O
containing O
anthraquinones O
. O

chinese O
herbal O
medicine O
preparations O
are O
widely O
available O
and O
often O
regarded O
by O
the O
public O
as O
natural O
and O
safe O
remedies O
for O
a O
variety O
of O
medical O
conditions O
. O

nephropathy B-Disease
caused O
by O
chinese O
herbs O
has O
previously O
been O
reported O
, O
usually O
involving O
the O
use O
of O
aristolochic O
acids O
. O

we O
report O
a O
23 O
- O
year O
- O
old O
woman O
who O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
following O
prolonged O
use O
of O
a O
proprietary O
chinese O
herbal O
slimming O
pill O
that O
contained O
anthraquinone O
derivatives O
, O
extracted O
from O
rhizoma O
rhei O
( O
rhubarb O
) O
. O

the O
renal B-Disease
injury I-Disease
was O
probably O
aggravated O
by O
the O
concomitant O
intake O
of O
a O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
, O
diclofenac O
. O

renal O
pathology O
was O
that O
of O
hypocellular O
interstitial O
fibrosis B-Disease
. O

spontaneous O
renal O
recovery O
occurred O
upon O
cessation O
of O
the O
slimming O
pills O
, O
but O
mild O
interstitial O
fibrosis B-Disease
and O
tubular O
atrophy B-Disease
was O
still O
evident O
histologically O
4 O
months O
later O
. O

although O
a O
causal O
relationship O
between O
the O
use O
of O
an O
anthraquinone O
- O
containing O
herbal O
agent O
and O
renal B-Disease
injury I-Disease
remains O
to O
be O
proven O
, O
phytotherapy O
- O
associated O
interstitial O
nephropathy B-Disease
should O
be O
considered O
in O
patients O
who O
present O
with O
unexplained O
renal B-Disease
failure I-Disease
. O

chloroacetaldehyde O
as O
a O
sulfhydryl O
reagent O
: O
the O
role O
of O
critical O
thiol O
groups O
in O
ifosfamide O
nephropathy B-Disease
. O

chloroacetaldehyde O
( O
caa O
) O
is O
a O
metabolite O
of O
the O
alkylating O
agent O
ifosfamide O
( O
ifo O
) O
and O
putatively O
responsible O
for O
renal B-Disease
damage I-Disease
following O
anti O
- O
tumor B-Disease
therapy O
with O
ifo O
. O

depletion O
of O
sulfhydryl O
( O
sh O
) O
groups O
has O
been O
reported O
from O
cell O
culture O
, O
animal O
and O
clinical O
studies O
. O

in O
this O
work O
the O
effect O
of O
caa O
on O
human O
proximal O
tubule O
cells O
in O
primary O
culture O
( O
hrptec O
) O
was O
investigated O
. O

toxicity B-Disease
of O
caa O
was O
determined O
by O
protein O
content O
, O
cell O
number O
, O
ldh O
release O
, O
trypan O
blue O
exclusion O
assay O
and O
caspase O
- O
3 O
activity O
. O

free O
thiols O
were O
measured O
by O
the O
method O
of O
ellman O
. O

caa O
reduced O
hrptec O
cell O
number O
and O
protein O
, O
induced O
a O
loss O
in O
free O
intracellular O
thiols O
and O
an O
increase O
in O
necrosis B-Disease
markers O
. O

caa O
but O
not O
acrolein O
inhibited O
the O
cysteine O
proteases O
caspase O
- O
3 O
, O
caspase O
- O
8 O
and O
cathepsin O
b O
. O

caspase O
activation O
by O
cisplatin O
was O
inhibited O
by O
caa O
. O

in O
cells O
stained O
with O
fluorescent O
dyes O
targeting O
lysosomes O
, O
caa O
induced O
an O
increase O
in O
lysosomal O
size O
and O
lysosomal O
leakage O
. O

the O
effects O
of O
caa O
on O
cysteine O
protease O
activities O
and O
thiols O
could O
be O
reproduced O
in O
cell O
lysate O
. O

acidification O
, O
which O
slowed O
the O
reaction O
of O
caa O
with O
thiol O
donors O
, O
could O
also O
attenuate O
effects O
of O
caa O
on O
necrosis B-Disease
markers O
, O
thiol O
depletion O
and O
cysteine O
protease O
inhibition O
in O
living O
cells O
. O

thus O
, O
caa O
directly O
reacts O
with O
cellular O
protein O
and O
non O
- O
protein O
thiols O
, O
mediating O
its O
toxicity B-Disease
on O
hrptec O
. O

this O
effect O
can O
be O
reduced O
by O
acidification O
. O

therefore O
, O
urinary O
acidification O
could O
be O
an O
option O
to O
prevent O
ifo O
nephropathy B-Disease
in O
patients O
. O

stereological O
methods O
reveal O
the O
robust O
size O
and O
stability O
of O
ectopic O
hilar O
granule O
cells O
after O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
in O
the O
adult O
rat O
. O

following O
status B-Disease
epilepticus I-Disease
in O
the O
rat O
, O
dentate O
granule O
cell O
neurogenesis O
increases O
greatly O
, O
and O
many O
of O
the O
new O
neurons O
appear O
to O
develop O
ectopically O
, O
in O
the O
hilar O
region O
of O
the O
hippocampal O
formation O
. O

it O
has O
been O
suggested O
that O
the O
ectopic O
hilar O
granule O
cells O
could O
contribute O
to O
the O
spontaneous O
seizures B-Disease
that O
ultimately O
develop O
after O
status B-Disease
epilepticus I-Disease
. O

however O
, O
the O
population O
has O
never O
been O
quantified O
, O
so O
it O
is O
unclear O
whether O
it O
is O
substantial O
enough O
to O
have O
a O
strong O
influence O
on O
epileptogenesis O
. O

to O
quantify O
this O
population O
, O
the O
total O
number O
of O
ectopic O
hilar O
granule O
cells O
was O
estimated O
using O
unbiased O
stereology O
at O
different O
times O
after O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
. O

the O
number O
of O
hilar O
neurons O
immunoreactive O
for O
prox O
- O
1 O
, O
a O
granule O
- O
cell O
- O
specific O
marker O
, O
was O
estimated O
using O
the O
optical O
fractionator O
method O
. O

the O
results O
indicate O
that O
the O
size O
of O
the O
hilar O
ectopic O
granule O
cell O
population O
after O
status B-Disease
epilepticus I-Disease
is O
substantial O
, O
and O
stable O
over O
time O
. O

interestingly O
, O
the O
size O
of O
the O
population O
appears O
to O
be O
correlated O
with O
the O
frequency O
of O
behavioral O
seizures B-Disease
, O
because O
animals O
with O
more O
ectopic O
granule O
cells O
in O
the O
hilus O
have O
more O
frequent O
behavioral O
seizures B-Disease
. O

the O
hilar O
ectopic O
granule O
cell O
population O
does O
not O
appear O
to O
vary O
systematically O
across O
the O
septotemporal O
axis O
, O
although O
it O
is O
associated O
with O
an O
increase O
in O
volume O
of O
the O
hilus O
. O

the O
results O
provide O
new O
insight O
into O
the O
potential O
role O
of O
ectopic O
hilar O
granule O
cells O
in O
the O
pilocarpine O
model O
of O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
. O

a O
prospective O
, O
open O
- O
label O
trial O
of O
galantamine O
in O
autistic B-Disease
disorder I-Disease
. O

objective O
: O
post O
- O
mortem O
studies O
have O
reported O
abnormalities O
of O
the O
cholinergic O
system O
in O
autism B-Disease
. O

the O
purpose O
of O
this O
study O
was O
to O
assess O
the O
use O
of O
galantamine O
, O
an O
acetylcholinesterase O
inhibitor O
and O
nicotinic O
receptor O
modulator O
, O
in O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism B-Disease
. O

methods O
: O
thirteen O
medication O
- O
free O
children O
with O
autism B-Disease
( O
mean O
age O
, O
8 O
. O
8 O
+ O
/ O
- O
3 O
. O
5 O
years O
) O
participated O
in O
a O
12 O
- O
week O
, O
open O
- O
label O
trial O
of O
galantamine O
. O

patients O
were O
rated O
monthly O
by O
parents O
on O
the O
aberrant O
behavior O
checklist O
( O
abc O
) O
and O
the O
conners O
' O
parent O
rating O
scale O
- O
revised O
, O
and O
by O
a O
physician O
using O
the O
children O
' O
s O
psychiatric O
rating O
scale O
and O
the O
clinical O
global O
impressions O
scale O
. O

results O
: O
patients O
showed O
a O
significant O
reduction O
in O
parent O
- O
rated O
irritability B-Disease
and O
social O
withdrawal O
on O
the O
abc O
as O
well O
as O
significant O
improvements O
in O
emotional O
lability O
and O
inattention O
on O
the O
conners O
' O
parent O
rating O
scale O
- O
- O
revised O
. O

similarly O
, O
clinician O
ratings O
showed O
reductions O
in O
the O
anger O
subscale O
of O
the O
children O
' O
s O
psychiatric O
rating O
scale O
. O

eight O
of O
13 O
participants O
were O
rated O
as O
responders O
on O
the O
basis O
of O
their O
improvement O
scores O
on O
the O
clinical O
global O
impressions O
scale O
. O

overall O
, O
galantamine O
was O
well O
- O
tolerated O
, O
with O
no O
significant O
adverse O
effects O
apart O
from O
headaches B-Disease
in O
one O
patient O
. O

conclusion O
: O
in O
this O
open O
trial O
, O
galantamine O
was O
well O
- O
tolerated O
and O
appeared O
to O
be O
beneficial O
for O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism B-Disease
, O
particularly O
aggression B-Disease
, O
behavioral B-Disease
dyscontrol I-Disease
, O
and O
inattention B-Disease
. O

further O
controlled O
trials O
are O
warranted O
. O

randomized O
comparison O
of O
olanzapine O
versus O
risperidone O
for O
the O
treatment O
of O
first O
- O
episode O
schizophrenia B-Disease
: O
4 O
- O
month O
outcomes O
. O

objective O
: O
the O
authors O
compared O
4 O
- O
month O
treatment O
outcomes O
for O
olanzapine O
versus O
risperidone O
in O
patients O
with O
first O
- O
episode O
schizophrenia B-Disease
spectrum O
disorders O
. O

method O
: O
one O
hundred O
twelve O
subjects O
( O
70 O
% O
male O
; O
mean O
age O
= O
23 O
. O
3 O
years O
[ O
sd O
= O
5 O
. O
1 O
] O
) O
with O
first O
- O
episode O
schizophrenia B-Disease
( O
75 O
% O
) O
, O
schizophreniform B-Disease
disorder I-Disease
( O
17 O
% O
) O
, O
or O
schizoaffective B-Disease
disorder I-Disease
( O
8 O
% O
) O
were O
randomly O
assigned O
to O
treatment O
with O
olanzapine O
( O
2 O
. O
5 O
- O
20 O
mg O
/ O
day O
) O
or O
risperidone O
( O
1 O
- O
6 O
mg O
/ O
day O
) O
. O

results O
: O
response O
rates O
did O
not O
significantly O
differ O
between O
olanzapine O
( O
43 O
. O
7 O
% O
, O
95 O
% O
ci O
= O
28 O
. O
8 O
% O
- O
58 O
. O
6 O
% O
) O
and O
risperidone O
( O
54 O
. O
3 O
% O
, O
95 O
% O
ci O
= O
39 O
. O
9 O
% O
- O
68 O
. O
7 O
% O
) O
. O

among O
those O
responding O
to O
treatment O
, O
more O
subjects O
in O
the O
olanzapine O
group O
( O
40 O
. O
9 O
% O
, O
95 O
% O
ci O
= O
16 O
. O
8 O
% O
- O
65 O
. O
0 O
% O
) O
than O
in O
the O
risperidone O
group O
( O
18 O
. O
9 O
% O
, O
95 O
% O
ci O
= O
0 O
% O
- O
39 O
. O
2 O
% O
) O
had O
subsequent O
ratings O
not O
meeting O
response O
criteria O
. O

negative O
symptom O
outcomes O
and O
measures O
of O
parkinsonism B-Disease
and O
akathisia B-Disease
did O
not O
differ O
between O
medications O
. O

extrapyramidal B-Disease
symptom I-Disease
severity O
scores O
were O
1 O
. O
4 O
( O
95 O
% O
ci O
= O
1 O
. O
2 O
- O
1 O
. O
6 O
) O
with O
risperidone O
and O
1 O
. O
2 O
( O
95 O
% O
ci O
= O
1 O
. O
0 O
- O
1 O
. O
4 O
) O
with O
olanzapine O
. O

significantly O
more O
weight B-Disease
gain I-Disease
occurred O
with O
olanzapine O
than O
with O
risperidone O
: O
the O
increase O
in O
weight O
at O
4 O
months O
relative O
to O
baseline O
weight O
was O
17 O
. O
3 O
% O
( O
95 O
% O
ci O
= O
14 O
. O
2 O
% O
- O
20 O
. O
5 O
% O
) O
with O
olanzapine O
and O
11 O
. O
3 O
% O
( O
95 O
% O
ci O
= O
8 O
. O
4 O
% O
- O
14 O
. O
3 O
% O
) O
with O
risperidone O
. O

body O
mass O
index O
at O
baseline O
and O
at O
4 O
months O
was O
24 O
. O
3 O
( O
95 O
% O
ci O
= O
22 O
. O
8 O
- O
25 O
. O
7 O
) O
versus O
28 O
. O
2 O
( O
95 O
% O
ci O
= O
26 O
. O
7 O
- O
29 O
. O
7 O
) O
with O
olanzapine O
and O
23 O
. O
9 O
( O
95 O
% O
ci O
= O
22 O
. O
5 O
- O
25 O
. O
3 O
) O
versus O
26 O
. O
7 O
( O
95 O
% O
ci O
= O
25 O
. O
2 O
- O
28 O
. O
2 O
) O
with O
risperidone O
. O

conclusions O
: O
clinical O
outcomes O
with O
risperidone O
were O
equal O
to O
those O
with O
olanzapine O
, O
and O
response O
may O
be O
more O
stable O
. O

olanzapine O
may O
have O
an O
advantage O
for O
motor O
side O
effects O
. O

both O
medications O
caused O
substantial O
rapid O
weight B-Disease
gain I-Disease
, O
but O
weight B-Disease
gain I-Disease
was O
greater O
with O
olanzapine O
. O

early O
paracentral O
visual B-Disease
field I-Disease
loss I-Disease
in O
patients O
taking O
hydroxychloroquine O
. O

objective O
: O
to O
review O
the O
natural O
history O
and O
ocular O
and O
systemic O
adverse O
effects O
of O
patients O
taking O
hydroxychloroquine O
sulfate O
who O
attended O
an O
ophthalmic O
screening O
program O
. O

design O
: O
retrospective O
study O
. O

results O
: O
records O
of O
262 O
patients O
who O
were O
taking O
hydroxychloroquine O
and O
screened O
in O
the O
department O
of O
ophthalmology O
were O
reviewed O
. O

of O
the O
262 O
patients O
, O
14 O
( O
18 O
% O
) O
of O
76 O
who O
had O
stopped O
treatment O
at O
the O
time O
of O
the O
study O
experienced O
documented O
adverse O
effects O
. O

systemic O
adverse O
effects O
occurred O
in O
8 O
patients O
( O
10 O
. O
5 O
% O
) O
and O
ocular O
adverse O
effects O
, O
in O
5 O
( O
6 O
. O
5 O
% O
) O
. O

thirty O
- O
five O
patients O
( O
13 O
. O
4 O
% O
) O
had O
visual B-Disease
field I-Disease
abnormalities I-Disease
, O
which O
were O
attributed O
to O
hydroxychloroquine O
treatment O
in O
4 O
patients O
( O
1 O
. O
5 O
% O
) O
. O

three O
of O
the O
4 O
patients O
were O
taking O
less O
than O
6 O
. O
5 O
mg O
/ O
kg O
per O
day O
and O
all O
patients O
had O
normal O
renal O
and O
liver O
function O
test O
results O
. O

conclusions O
: O
the O
current O
study O
used O
a O
protocol O
of O
visual O
acuity O
and O
color O
vision O
assessment O
, O
funduscopy O
, O
and O
humphrey O
10 O
- O
2 O
visual O
field O
testing O
and O
shows O
that O
visual B-Disease
field I-Disease
defects I-Disease
appeared O
before O
any O
corresponding O
changes O
in O
any O
other O
tested O
clinical O
parameters O
; O
the O
defects O
were O
reproducible O
and O
the O
test O
parameters O
were O
reliable O
. O

patients O
taking O
hydroxychloroquine O
can O
demonstrate O
a O
toxic O
reaction O
in O
the O
retina O
despite O
the O
absence O
of O
known O
risk O
factors O
. O

screening O
, O
including O
humphrey O
10 O
- O
2 O
visual O
field O
assessment O
, O
is O
recommended O
2 O
years O
after O
the O
initial O
baseline O
and O
yearly O
thereafter O
. O

peri O
- O
operative O
atrioventricular B-Disease
block I-Disease
as O
a O
result O
of O
chemotherapy O
with O
epirubicin O
and O
paclitaxel O
. O

a O
47 O
- O
year O
- O
old O
woman O
presented O
for O
mastectomy O
and O
immediate O
latissimus O
dorsi O
flap O
reconstruction O
having O
been O
diagnosed O
with O
carcinoma B-Disease
of I-Disease
the I-Disease
breast I-Disease
6 O
months O
previously O
. O

in O
the O
preceding O
months O
she O
had O
received O
neo O
- O
adjuvant O
chemotherapy O
with O
epirubicin O
, O
paclitaxel O
( O
taxol O
) O
and O
cyclophosphamide O
. O

this O
had O
been O
apparently O
uncomplicated O
and O
she O
had O
maintained O
a O
remarkably O
high O
level O
of O
physical O
activity O
. O

she O
was O
found O
to O
be O
bradycardic B-Disease
at O
pre O
- O
operative O
assessment O
but O
had O
no O
cardiac O
symptoms O
. O

second O
degree O
mobitz O
type O
ii O
atrioventricular B-Disease
block I-Disease
was O
diagnosed O
on O
electrocardiogram O
, O
and O
temporary O
transvenous O
ventricular O
pacing O
instituted O
in O
the O
peri O
- O
operative O
period O
. O

we O
discuss O
how O
evidence O
- O
based O
guidelines O
would O
not O
have O
been O
helpful O
in O
this O
case O
, O
and O
how O
chemotherapy O
can O
exhibit O
substantial O
cardiotoxicity B-Disease
that O
may O
develop O
over O
many O
years O
. O

we O
suggest O
that O
patients O
who O
have O
received O
chemotherapy O
at O
any O
time O
should O
have O
a O
pre O
- O
operative O
electrocardiogram O
even O
if O
they O
are O
asymptomatic O
. O

risks O
and O
benefits O
of O
cox O
- O
2 O
inhibitors O
vs O
non O
- O
selective O
nsaids O
: O
does O
their O
cardiovascular O
risk O
exceed O
their O
gastrointestinal O
benefit O
? O

a O
retrospective O
cohort O
study O
. O

objectives O
: O
the O
risk O
of O
acute B-Disease
myocardial I-Disease
infarction I-Disease
( O
ami B-Disease
) O
with O
cox O
- O
2 O
inhibitors O
may O
offset O
their O
gastrointestinal O
( O
gi O
) O
benefit O
compared O
with O
non O
- O
selective O
( O
ns O
) O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
. O

we O
aimed O
to O
compare O
the O
risks O
of O
hospitalization O
for O
ami B-Disease
and O
gi B-Disease
bleeding I-Disease
among O
elderly O
patients O
using O
cox O
- O
2 O
inhibitors O
, O
ns O
- O
nsaids O
and O
acetaminophen O
. O

methods O
: O
we O
conducted O
a O
retrospective O
cohort O
study O
using O
administrative O
data O
of O
patients O
> O
or O
= O
65 O
years O
of O
age O
who O
filled O
a O
prescription O
for O
nsaid O
or O
acetaminophen O
during O
1999 O
- O
2002 O
. O

outcomes O
were O
compared O
using O
cox O
regression O
models O
with O
time O
- O
dependent O
exposures O
. O

results O
: O
person O
- O
years O
of O
exposure O
among O
non O
- O
users O
of O
aspirin O
were O
: O
75 O
, O
761 O
to O
acetaminophen O
, O
42 O
, O
671 O
to O
rofecoxib O
65 O
, O
860 O
to O
celecoxib O
, O
and O
37 O
, O
495 O
to O
ns O
- O
nsaids O
. O

among O
users O
of O
aspirin O
, O
they O
were O
: O
14 O
, O
671 O
to O
rofecoxib O
, O
22 O
, O
875 O
to O
celecoxib O
, O
9 O
, O
832 O
to O
ns O
- O
nsaids O
and O
38 O
, O
048 O
to O
acetaminophen O
. O

among O
non O
- O
users O
of O
aspirin O
, O
the O
adjusted O
hazard O
ratios O
( O
95 O
% O
confidence O
interval O
) O
of O
hospitalization O
for O
ami B-Disease
/ O
gi O
vs O
the O
acetaminophen O
( O
with O
no O
aspirin O
) O
group O
were O
: O
rofecoxib O
1 O
. O
27 O
( O
1 O
. O
13 O
, O
1 O
. O
42 O
) O
, O
celecoxib O
0 O
. O
93 O
( O
0 O
. O
83 O
, O
1 O
. O
03 O
) O
, O
naproxen O
1 O
. O
59 O
( O
1 O
. O
31 O
, O
1 O
. O
93 O
) O
, O
diclofenac O
1 O
. O
17 O
( O
0 O
. O
99 O
, O
1 O
. O
38 O
) O
and O
ibuprofen O
1 O
. O
05 O
( O
0 O
. O
74 O
, O
1 O
. O
51 O
) O

. O

among O
users O
of O
aspirin O
, O
they O
were O
: O
rofecoxib O
1 O
. O
73 O
( O
1 O
. O
52 O
, O
1 O
. O
98 O
) O
, O
celecoxib O
1 O
. O
34 O
( O
1 O
. O
19 O
, O
1 O
. O
52 O
) O
, O
ibuprofen O
1 O
. O
51 O
( O
0 O
. O
95 O
, O
2 O
. O
41 O
) O
, O
diclofenac O
1 O
. O
69 O
( O
1 O
. O
35 O
, O
2 O
. O
10 O
) O
, O
naproxen O
1 O
. O
35 O
( O
0 O
. O
97 O
, O
1 O
. O
88 O
) O
and O
acetaminophen O
1 O
. O
29 O
( O
1 O
. O
17 O
, O
1 O
. O
42 O
) O
. O

conclusion O
: O
among O
non O
- O
users O
of O
aspirin O
, O
naproxen O
seemed O
to O
carry O
the O
highest O
risk O
for O
ami B-Disease
/ O
gi B-Disease
bleeding I-Disease
. O

the O
ami B-Disease
/ O
gi O
toxicity B-Disease
of O
celecoxib O
was O
similar O
to O
that O
of O
acetaminophen O
and O
seemed O
to O
be O
better O
than O
those O
of O
rofecoxib O
and O
ns O
- O
nsaids O
. O

among O
users O
of O
aspirin O
, O
both O
celecoxib O
and O
naproxen O
seemed O
to O
be O
the O
least O
toxic O
. O

quinine O
- O
induced O
arrhythmia B-Disease
in O
a O
patient O
with O
severe B-Disease
malaria I-Disease
. O

it O
was O
reported O
that O
there O
was O
a O
case O
of O
severe B-Disease
malaria I-Disease
patient O
with O
jaundice B-Disease
who O
presented O
with O
arrhythmia B-Disease
( O
premature B-Disease
ventricular I-Disease
contraction I-Disease
) O
while O
getting O
quinine O
infusion O
was O
reported O
. O

a O
man O
, O
25 O
years O
old O
, O
was O
admitted O
to O
hospital O
with O
high O
fever B-Disease
, O
chill B-Disease
, O
vomiting B-Disease
, O
jaundice B-Disease
. O

the O
patient O
was O
fully O
conscious O
, O
blood O
pressure O
120 O
/ O
80 O
mmhg O
, O
pulse O
rate O
100 O
x O
/ O
minute O
, O
regular O
. O

on O
admission O
, O
laboratory O
examination O
showed O
plasmodium O
falciparum O
( O
+ O
+ O
+ O
+ O
) O
, O
total O
bilirubin O
8 O
. O
25 O
mg O
/ O
dl O
, O
conjugated O
bilirubin O
4 O
. O
36 O
mg O
/ O
dl O
, O
unconjugated O
bilirubin O
3 O
. O
89 O
mg O
/ O
dl O
, O
potassium O
3 O
. O
52 O
meq O
/ O
l O
patient O
was O
diagnosed O
as O
severe B-Disease
malaria I-Disease
with O
jaundice B-Disease
and O
got O
quinine O
infusion O
in O
dextrose O
5 O
% O
500 O
mg O
/ O
8 O
hour O
. O

on O
the O
second O
day O
the O
patient O
had O
vomitus B-Disease
, O
diarrhea B-Disease
, O
tinnitus B-Disease
, O
loss B-Disease
of I-Disease
hearing I-Disease
. O

after O
30 O
hours O
of O
quinine O
infusion O
the O
patient O
felt O
palpitation B-Disease
and O
electrocardiography O
( O
ecg O
) O
recording O
showed O
premature B-Disease
ventricular I-Disease
contraction I-Disease
( O
pvc B-Disease
) O
> O
5 O
x O
/ O
minute O
, O
trigemini O
, O
constant O
type O
- O
- O
sinoatrial B-Disease
block I-Disease
, O
positive O
u O
wave O
. O

he O
was O
treated O
with O
lidocaine O
50 O
mg O
intravenously O
followed O
by O
infusion O
1500 O
mg O
in O
dextrose O
5 O
% O
/ O
24 O
hour O
and O
potassium O
aspartate O
tablet O
. O

quinine O
infusion O
was O
discontinued O
and O
changed O
with O
sulfate O
quinine O
tablets O
. O

three O
hours O
later O
the O
patient O
felt O
better O
, O
the O
frequency O
of O
pvc B-Disease
reduced O
to O
4 O
- O
5 O
x O
/ O
minute O
and O
on O
the O
third O
day O
ecg O
was O
normal O
, O
potassium O
level O
was O
3 O
. O
34 O
meq O
/ O
l O
. O

he O
was O
discharged O
on O
7th O
day O
in O
good O
condition O
. O

quinine O
, O
like O
quinidine O
, O
is O
a O
chincona O
alkaloid O
that O
has O
anti O
- O
arrhythmic B-Disease
property O
, O
although O
it O
also O
pro O
- O
arrhythmic B-Disease
that O
can O
cause O
various O
arrhythmias B-Disease
, O
including O
severe O
arrhythmia B-Disease
such O
as O
multiple O
pvc B-Disease
. O

administration O
of O
parenteral O
quinine O
must O
be O
done O
carefully O
and O
with O
good O
observation O
because O
of O
its O
pro O
- O
arrhythmic B-Disease
effect O
, O
especially O
in O
older O
patients O
who O
have O
heart B-Disease
diseases I-Disease
or O
patients O
with O
electrolyte B-Disease
disorder I-Disease
( O
hypokalemia B-Disease
) O
which O
frequently O
occurs O
due O
to O
vomiting B-Disease
and O
or O
diarrhea B-Disease
in O
malaria B-Disease
cases O
. O

penicillamine O
- O
related O
lichenoid B-Disease
dermatitis I-Disease
and O
utility O
of O
zinc O
acetate O
in O
a O
wilson B-Disease
disease I-Disease
patient O
with O
hepatic O
presentation O
, O
anxiety B-Disease
and O
spect O
abnormalities O
. O

wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
is O
an O
autosomal O
recessive O
disorder O
of O
hepatic O
copper O
metabolism O
with O
consequent O
copper O
accumulation O
and O
toxicity B-Disease
in O
many O
tissues O
and O
consequent O
hepatic B-Disease
, I-Disease
neurologic I-Disease
and I-Disease
psychiatric I-Disease
disorders I-Disease
. O

we O
report O
a O
case O
of O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
with O
chronic B-Disease
liver I-Disease
disease I-Disease
; O
moreover O
, O
in O
our O
patient O
, O
presenting O
also O
with O
high O
levels O
of O
state O
anxiety B-Disease
without O
depression B-Disease
, O
99mtc O
- O
ecd O
- O
spect O
showed O
cortical O
hypoperfusion O
in O
frontal O
lobes O
, O
more O
marked O
on O
the O
left O
frontal O
lobe O
. O

during O
the O
follow O
- O
up O
of O
our O
patient O
, O
penicillamine O
was O
interrupted O
after O
the O
appearance O
of O
a O
lichenoid B-Disease
dermatitis I-Disease
, O
and O
zinc O
acetate O
permitted O
to O
continue O
the O
successful O
treatment O
of O
the O
patient O
without O
side O
- O
effects O
. O

in O
our O
case O
the O
therapy O
with O
zinc O
acetate O
represented O
an O
effective O
treatment O
for O
a O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
patient O
in O
which O
penicillamine O
- O
related O
side O
effects O
appeared O
. O

the O
safety O
of O
the O
zinc O
acetate O
allowed O
us O
to O
avoid O
other O
potentially O
toxic O
chelating O
drugs O
; O
this O
observation O
is O
in O
line O
with O
the O
growing O
evidence O
on O
the O
efficacy O
of O
the O
drug O
in O
the O
treatment O
of O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

since O
most O
of O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
penicillamine O
- O
treated O
patients O
do O
not O
seem O
to O
develop O
this O
skin B-Disease
lesion I-Disease
, O
it O
could O
be O
conceivable O
that O
a O
specific O
genetic O
factor O
is O
involved O
in O
drug O
response O
. O

further O
studies O
are O
needed O
for O
a O
better O
clarification O
of O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
therapy O
, O
and O
in O
particular O
to O
differentiate O
specific O
therapies O
for O
different O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
phenotypes O
. O

a O
dramatic O
drop B-Disease
in I-Disease
blood I-Disease
pressure I-Disease
following O
prehospital O
gtn O
administration O
. O

a O
male O
in O
his O
sixties O
with O
no O
history O
of O
cardiac O
chest B-Disease
pain I-Disease
awoke O
with O
chest B-Disease
pain I-Disease
following O
an O
afternoon O
sleep O
. O

the O
patient O
did O
not O
self O
medicate O
. O

the O
patient O
' O
s O
observations O
were O
within O
normal O
limits O
, O
he O
was O
administered O
oxygen O
via O
a O
face O
mask O
and O
glyceryl O
trinitrate O
( O
gtn O
) O
. O

several O
minutes O
after O
the O
gtn O
the O
patient O
experienced O
a O
sudden O
drop B-Disease
in I-Disease
blood I-Disease
pressure I-Disease
and O
heart O
rate O
, O
this O
was O
rectified O
by O
atropine O
sulphate O
and O
a O
fluid O
challenge O
. O

there O
was O
no O
further O
deterioration O
in O
the O
patient O
' O
s O
condition O
during O
transport O
to O
hospital O
. O

there O
are O
very O
few O
documented O
case O
like O
this O
in O
the O
prehospital O
scientific O
literature O
. O

the O
cause O
appears O
to O
be O
the O
bezold O
- O
jarish O
reflex O
, O
stimulation O
of O
the O
ventricular O
walls O
which O
in O
turn O
decreases O
sympathetic O
outflow O
from O
the O
vasomotor O
centre O
. O

prehospital O
care O
providers O
who O
are O
managing O
any O
patient O
with O
a O
syncopal B-Disease
episode I-Disease
that O
fails O
to O
recover O
within O
a O
reasonable O
time O
frame O
should O
consider O
the O
bezold O
- O
jarisch O
reflex O
as O
the O
cause O
and O
manage O
the O
patient O
accordingly O
. O

chronic O
lesion O
of O
rostral O
ventrolateral O
medulla O
in O
spontaneously O
hypertensive B-Disease
rats O
. O

we O
studied O
the O
effects O
of O
chronic O
selective O
neuronal O
lesion O
of O
rostral O
ventrolateral O
medulla O
on O
mean O
arterial O
pressure O
, O
heart O
rate O
, O
and O
neurogenic O
tone O
in O
conscious O
, O
unrestrained O
spontaneously O
hypertensive B-Disease
rats O
. O

the O
lesions O
were O
placed O
via O
bilateral O
microinjections O
of O
30 O
nmol O
/ O
200 O
nl O
n O
- O
methyl O
- O
d O
- O
aspartic O
acid O
. O

the O
restimulation O
of O
this O
area O
with O
n O
- O
methyl O
- O
d O
- O
aspartic O
acid O
15 O
days O
postlesion O
failed O
to O
produce O
a O
pressor O
response O
. O

one O
day O
postlesion O
, O
the O
resting O
mean O
arterial O
pressure O
was O
significantly O
decreased O
in O
lesioned O
rats O
when O
compared O
with O
sham O
rats O
( O
100 O
+ O
/ O
- O
7 O
versus O
173 O
+ O
/ O
- O
4 O
mm O
hg O
, O
p O
less O
than O
0 O
. O
05 O
) O
. O

fifteen O
days O
later O
, O
the O
lesioned O
group O
still O
showed O
values O
significantly O
lower O
than O
the O
sham O
group O
( O
150 O
+ O
/ O
- O
6 O
versus O
167 O
+ O
/ O
- O
5 O
mm O
hg O
, O
p O
less O
than O
0 O
. O
05 O
) O
. O

no O
significant O
heart O
rate O
differences O
were O
observed O
between O
the O
sham O
and O
lesioned O
groups O
. O

the O
ganglionic O
blocker O
trimethaphan O
( O
5 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
caused O
similar O
reductions O
in O
mean O
arterial O
pressure O
in O
both O
lesioned O
and O
sham O
groups O
. O

the O
trimethaphan O
- O
induced O
hypotension B-Disease
was O
accompanied O
by O
a O
significant O
bradycardia B-Disease
in O
lesioned O
rats O
( O
- O
32 O
+ O
/ O
- O
13 O
beats O
per O
minute O
) O
but O
a O
tachycardia B-Disease
in O
sham O
rats O
( O
+ O
33 O
+ O
/ O
- O
12 O
beats O
per O
minute O
) O
1 O
day O
postlesion O
. O

therefore O
, O
rostral O
ventrolateral O
medulla O
neurons O
appear O
to O
play O
a O
significant O
role O
in O
maintaining O
hypertension B-Disease
in O
conscious O
spontaneously O
hypertensive B-Disease
rats O
. O

spinal O
or O
suprabulbar O
structures O
could O
be O
responsible O
for O
the O
gradual O
recovery O
of O
the O
hypertension B-Disease
in O
the O
lesioned O
rats O
. O

acute B-Disease
encephalopathy I-Disease
and O
cerebral B-Disease
vasospasm I-Disease
after O
multiagent O
chemotherapy O
including O
peg O
- O
asparaginase O
and O
intrathecal O
cytarabine O
for O
the O
treatment O
of O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
. O

a O
7 O
- O
year O
- O
old O
girl O
with O
an O
unusual O
reaction O
to O
induction O
chemotherapy O
for O
precursor O
b O
- O
cell O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
( O
all B-Disease
) O
is O
described O
. O

the O
patient O
developed O
acute B-Disease
encephalopathy I-Disease
evidenced O
by O
behavioral O
changes O
, O
aphasia B-Disease
, O
incontinence B-Disease
, O
visual B-Disease
hallucinations I-Disease
, O
and O
right O
- O
sided O
weakness B-Disease
with O
diffuse O
cerebral B-Disease
vasospasm I-Disease
on O
magnetic O
resonance O
angiography O
after O
the O
administration O
of O
intrathecal O
cytarabine O
. O

vincristine O
, O
dexamethasone O
, O
and O
polyethylene O
glycol O
- O
asparaginase O
were O
also O
administered O
before O
the O
episode O
as O
part O
of O
induction O
therapy O
. O

neurologic O
status O
returned O
to O
baseline O
within O
10 O
days O
of O
the O
acute O
event O
, O
and O
magnetic O
resonance O
angiography O
findings O
returned O
to O
normal O
4 O
months O
later O
. O

comparison O
of O
valsartan O
/ O
hydrochlorothiazide O
combination O
therapy O
at O
doses O
up O
to O
320 O
/ O
25 O
mg O
versus O
monotherapy O
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
followed O
by O
long O
- O
term O
combination O
therapy O
in O
hypertensive B-Disease
adults O
. O

background O
: O
one O
third O
of O
patients O
treated O
for O
hypertension B-Disease
attain O
adequate O
blood O
pressure O
( O
bp O
) O
control O
, O
and O
multidrug O
regimens O
are O
often O
required O
. O

given O
the O
lifelong O
nature O
of O
hypertension B-Disease
, O
there O
is O
a O
need O
to O
evaluate O
the O
long O
- O
term O
efficacy O
and O
tolerability O
of O
higher O
doses O
of O
combination O
anti O
- O
hypertensive B-Disease
therapies O
. O

objective O
: O
this O
study O
investigated O
the O
efficacy O
and O
tolerability O
of O
valsartan O
( O
val O
) O
or O
hydrochlorothiazide O
( O
hctz O
) O
- O
monotherapy O
and O
higher O
- O
dose O
combinations O
in O
patients O
with O
essential B-Disease
hypertension I-Disease
. O

methods O
: O
the O
first O
part O
of O
this O
study O
was O
an O
8 O
- O
week O
, O
multicenter O
, O
randomized O
, O
double O
- O
blind O
, O
placebo O
controlled O
, O
parallel O
- O
group O
trial O
. O

patients O
with O
essential B-Disease
hypertension I-Disease
( O
mean O
sitting O
diastolic O
bp O
[ O
msdbp O
] O
, O
> O
or O
= O
95 O
mm O
hg O
and O
< O
110 O
mm O
hg O
) O
were O
randomized O
to O
1 O
of O
8 O
treatment O
groups O
: O
val O
160 O
or O
320 O
mg O
; O
hctz O
12 O
. O
5 O
or O
25 O
mg O
; O
val O
/ O
hctz O
160 O
/ O
12 O
. O
5 O
, O
320 O
/ O
12 O
. O
5 O
, O
or O
320 O
/ O
25 O
mg O
; O
or O
placebo O
. O

mean O
changes O
in O
msdbp O
and O
mean O
sitting O
systolic O
bp O
( O
mssbp O
) O
were O
analyzed O
at O
the O
8 O
- O
week O
core O
study O
end O
point O
. O

val O
/ O
hctz O
320 O
/ O
12 O
. O
5 O
and O
320 O
/ O
25 O
mg O
were O
further O
investigated O
in O
a O
54 O
- O
week O
, O
open O
- O
label O
extension O
. O

response O
was O
defined O
as O
msdbp O
< O
90 O
mm O
hg O
or O
a O
> O
or O
= O
10 O
mm O
hg O
decrease O
compared O
to O
baseline O
. O

control O
was O
defined O
as O
msdbp O
< O
90 O
mm O
hg O
compared O
with O
baseline O
. O

tolerability O
was O
assessed O
by O
monitoring O
adverse O
events O
at O
randomization O
and O
all O
subsequent O
study O
visits O
and O
regular O
evaluation O
of O
hematology O
and O
blood O
chemistry O
. O

results O
: O
a O
total O
of O
1346 O
patients O
were O
randomized O
into O
the O
8 O
- O
week O
core O
study O
( O
734 O
men O
, O
612 O
women O
; O
924 O
white O
, O
291 O
black O
, O
23 O
asian O
, O
108 O
other O
; O
mean O
age O
, O
52 O
. O
7 O
years O
; O
mean O
weight O
, O
92 O
. O
6 O
kg O
) O
. O

all O
active O
treatments O
were O
associated O
with O
significantly O
reduced O
mssbp O
and O
msdbp O
during O
the O
core O
8 O
- O
week O
study O
, O
with O
each O
monotherapy O
significantly O
contributing O
to O
the O
overall O
effect O
of O
combination O
therapy O
( O
val O
and O
hctz O
, O
p O
< O
0 O
. O
001 O
) O
. O

each O
combination O
was O
associated O
with O
significantly O
greater O
reductions O
in O
mssbp O
and O
msdbp O
compared O
with O
the O
monotherapies O
and O
placebo O
( O
all O
, O
p O
< O
0 O
. O
001 O
) O
. O

the O
mean O
reduction O
in O
mssbp O
/ O
msdbp O
with O
val O
/ O
hctz O
320 O
/ O
25 O
mg O
was O
24 O
. O
7 O
/ O
16 O
. O
6 O
mm O
hg O
, O
compared O
with O
5 O
. O
9 O
/ O
7 O
. O
0 O
mm O
hg O
with O
placebo O
. O

the O
reduction O
in O
mssbp O
was O
significantly O
greater O
with O
val O
/ O
hctz O
320 O
/ O
25 O
mg O
compared O
with O
val O
/ O
hctz O
160 O
/ O
12 O
. O
5 O
mg O
( O
p O
< O
0 O
. O
002 O
) O
. O

rates O
of O
response O
and O
bp O
control O
were O
significantly O
higher O
in O
the O
groups O
that O
received O
combination O
treatment O
compared O
with O
those O
that O
received O
monotherapy O
. O

the O
incidence O
of O
hypokalemia B-Disease
was O
lower O
with O
val O
/ O
hctz O
combinations O
( O
1 O
. O
8 O
% O
- O
6 O
. O
1 O
% O
) O
than O
with O
hctz O
monotherapies O
( O
7 O
. O
1 O
% O
- O
13 O
. O
3 O
% O
) O
. O

the O
majority O
of O
adverse O
events O
in O
the O
core O
study O
were O
of O
mild O
to O
moderate O
severity O
. O

the O
efficacy O
and O
tolerability O
of O
val O
/ O
hctz O
combinations O
were O
maintained O
during O
the O
extension O
( O
797 O
patients O
) O
. O

conclusions O
: O
in O
this O
study O
population O
, O
combination O
therapies O
with O
val O
/ O
hctz O
were O
associated O
with O
significantly O
greater O
bp O
reductions O
compared O
with O
either O
monotherapy O
, O
were O
well O
tolerated O
, O
and O
were O
associated O
with O
less O
hypokalemia B-Disease
than O
hctz O
alone O
. O

succimer O
chelation O
improves O
learning O
, O
attention O
, O
and O
arousal O
regulation O
in O
lead O
- O
exposed O
rats O
but O
produces O
lasting O
cognitive B-Disease
impairment I-Disease
in O
the O
absence O
of O
lead O
exposure O
. O

background O
: O
there O
is O
growing O
pressure O
for O
clinicians O
to O
prescribe O
chelation O
therapy O
at O
only O
slightly O
elevated O
blood O
lead O
levels O
. O

however O
, O
very O
few O
studies O
have O
evaluated O
whether O
chelation O
improves O
cognitive O
outcomes O
in O
pb O
- O
exposed O
children O
, O
or O
whether O
these O
agents O
have O
adverse O
effects O
that O
may O
affect O
brain O
development O
in O
the O
absence O
of O
pb O
exposure O
. O

objectives O
: O
the O
present O
study O
was O
designed O
to O
answer O
these O
questions O
, O
using O
a O
rodent O
model O
of O
early O
childhood O
pb O
exposure O
and O
treatment O
with O
succimer O
, O
a O
widely O
used O
chelating O
agent O
for O
the O
treatment O
of O
pb B-Disease
poisoning I-Disease
. O

results O
: O
pb O
exposure O
produced O
lasting O
impairments B-Disease
in I-Disease
learning I-Disease
, I-Disease
attention I-Disease
, I-Disease
inhibitory I-Disease
control I-Disease
, I-Disease
and I-Disease
arousal I-Disease
regulation I-Disease
, O
paralleling O
the O
areas O
of O
dysfunction O
seen O
in O
pb O
- O
exposed O
children O
. O

succimer O
treatment O
of O
the O
pb O
- O
exposed O
rats O
significantly O
improved O
learning O
, O
attention O
, O
and O
arousal O
regulation O
, O
although O
the O
efficacy O
of O
the O
treatment O
varied O
as O
a O
function O
of O
the O
pb O
exposure O
level O
and O
the O
specific O
functional O
deficit O
. O

in O
contrast O
, O
succimer O
treatment O
of O
rats O
not O
previously O
exposed O
to O
pb O
produced O
lasting O
and O
pervasive O
cognitive B-Disease
and I-Disease
affective I-Disease
dysfunction I-Disease
comparable O
in O
magnitude O
to O
that O
produced O
by O
the O
higher O
pb O
exposure O
regimen O
. O

conclusions O
: O
these O
are O
the O
first O
data O
, O
to O
our O
knowledge O
, O
to O
show O
that O
treatment O
with O
any O
chelating O
agent O
can O
alleviate O
cognitive B-Disease
deficits I-Disease
due O
to O
pb O
exposure O
. O

these O
findings O
suggest O
that O
it O
may O
be O
possible O
to O
identify O
a O
succimer O
treatment O
protocol O
that O
improves O
cognitive O
outcomes O
in O
pb O
- O
exposed O
children O
. O

however O
, O
they O
also O
suggest O
that O
succimer O
treatment O
should O
be O
strongly O
discouraged O
for O
children O
who O
do O
not O
have O
elevated O
tissue O
levels O
of O
pb O
or O
other O
heavy O
metals O
. O

caffeine O
challenge O
test O
in O
panic B-Disease
disorder I-Disease
and O
depression B-Disease
with O
panic B-Disease
attacks I-Disease
. O

our O
aim O
was O
to O
observe O
if O
patients O
with O
panic B-Disease
disorder I-Disease
( O
pd B-Disease
) O
and O
patients O
with O
major B-Disease
depression I-Disease
with O
panic B-Disease
attacks I-Disease
( O
mdp B-Disease
) O
( O
diagnostic O
and O
statistical O
manual O
of O
mental B-Disease
disorders I-Disease
, O
fourth O
edition O
criteria O
) O
respond O
in O
a O
similar O
way O
to O
the O
induction O
of O
panic B-Disease
attacks I-Disease
by O
an O
oral O
caffeine O
challenge O
test O
. O

we O
randomly O
selected O
29 O
patients O
with O
pd B-Disease
, O
27 O
with O
mdp B-Disease
, O
25 O
with O
major B-Disease
depression I-Disease
without O
panic B-Disease
attacks I-Disease
( O
md B-Disease
) O
, O
and O
28 O
healthy O
volunteers O
. O

the O
patients O
had O
no O
psychotropic O
drug O
for O
at O
least O
a O
4 O
- O
week O
period O
. O

in O
a O
randomized O
double O
- O
blind O
experiment O
performed O
in O
2 O
occasions O
7 O
days O
apart O
, O
480 O
mg O
caffeine O
and O
a O
caffeine O
- O
free O
( O
placebo O
) O
solution O
were O
administered O
in O
a O
coffee O
form O
and O
anxiety B-Disease
scales O
were O
applied O
before O
and O
after O
each O
test O
. O

a O
total O
of O
58 O
. O
6 O
% O
( O
n O
= O
17 O
) O
of O
patients O
with O
pd B-Disease
, O
44 O
. O
4 O
% O
( O
n O
= O
12 O
) O
of O
patients O
with O
mdp B-Disease
, O
12 O
. O
0 O
% O
( O
n O
= O
3 O
) O
of O
patients O
with O
md B-Disease
, O
and O
7 O
. O
1 O
% O
( O
n O
= O
2 O
) O
of O
control O
subjects O
had O
a O
panic B-Disease
attack I-Disease
after O
the O
480 O
- O
mg O
caffeine O
challenge O
test O
( O
chi O
( O
2 O
) O
( O
3 O
) O
= O
16 O
. O
22 O
, O
p O
= O
. O
001 O
) O
. O

the O
patients O
with O
pd B-Disease
and O
mdp B-Disease
were O
more O
sensitive O
to O
caffeine O
than O
were O
patients O
with O
md B-Disease
and O
healthy O
volunteers O
. O

no O
panic B-Disease
attack I-Disease
was O
observed O
after O
the O
caffeine O
- O
free O
solution O
intake O
. O

the O
patients O
with O
md B-Disease
had O
a O
lower O
heart O
rate O
response O
to O
the O
test O
than O
all O
the O
other O
groups O
( O
2 O
- O
way O
analysis O
of O
variance O
, O
group O
by O
time O
interaction O
with O
greenhouse O
- O
geisser O
correction O
: O
f O
( O
3 O
, O
762 O
) O
= O
2 O
. O
85 O
, O
p O
= O
. O
026 O
) O
. O

our O
data O
suggest O
that O
there O
is O
an O
association O
between O
panic B-Disease
attacks I-Disease
, O
no O
matter O
if O
associated O
with O
pd B-Disease
or O
mdp B-Disease
, O
and O
hyperreactivity O
to O
an O
oral O
caffeine O
challenge O
test O
. O

mitral O
annuloplasty O
as O
a O
ventricular O
restoration O
method O
for O
the O
failing B-Disease
left I-Disease
ventricle I-Disease
: O
a O
pilot O
study O
. O

background O
and O
aim O
of O
the O
study O
: O
undersized O
mitral O
annuloplasty O
( O
map O
) O
is O
effective O
in O
patients O
with O
dilated B-Disease
cardiomyopathy I-Disease
and O
functional O
mitral B-Disease
regurgitation I-Disease
( O
mr B-Disease
) O
since O
, O
as O
well O
as O
addressing O
the O
mr B-Disease
, O
the O
map O
may O
also O
reshape O
the O
dilated O
left O
ventricular O
( O
lv O
) O
base O
. O

however O
, O
the O
direct O
benefits O
of O
this O
possible O
reshaping O
on O
lv O
function O
in O
the O
absence O
of O
underlying O
mr B-Disease
remain O
incompletely O
understood O
. O

the O
study O
aim O
was O
to O
identify O
these O
benefits O
in O
a O
canine O
model O
of O
acute O
heart B-Disease
failure I-Disease
. O

methods O
: O
six O
dogs O
underwent O
map O
with O
a O
prosthetic O
band O
on O
the O
posterior O
mitral O
annulus O
, O
using O
four O
mattress O
sutures O
. O

the O
sutures O
were O
passed O
individually O
through O
four O
tourniquets O
and O
exteriorized O
untied O
via O
the O
left O
atriotomy O
. O

sonomicrometry O
crystals O
were O
implanted O
around O
the O
mitral O
annulus O
and O
left O
ventricle O
to O
measure O
geometry O
and O
regional O
function O
. O

acute O
heart B-Disease
failure I-Disease
was O
induced O
by O
propranolol O
and O
volume O
loading O
after O
weaning O
from O
cardiopulmonary O
bypass O
; O
an O
absence O
of O
mr B-Disease
was O
confirmed O
by O
echocardiography O
. O

map O
was O
accomplished O
by O
cinching O
the O
tourniquets O
. O

data O
were O
acquired O
at O
baseline O
, O
after O
induction O
of O
acute O
heart B-Disease
failure I-Disease
, O
and O
after O
map O
. O

results O
: O
map O
decreased O
mitral O
annular O
dimensions O
in O
both O
commissure O
- O
commissure O
and O
septal O
- O
lateral O
directions O
. O

concomitantly O
, O
the O
diastolic O
diameter O
of O
the O
lv O
base O
and O
lv O
sphericity O
decreased O
( O
i O
. O
e O
. O
, O
improved O
) O
from O
37 O
. O
4 O
+ O
/ O
- O
9 O
. O
3 O
to O
35 O
. O
9 O
+ O
/ O
- O
10 O
mm O
( O
p O
= O
0 O
. O
063 O
) O
, O
and O
from O
67 O
. O
9 O
+ O
/ O
- O
18 O
. O
6 O
% O
to O
65 O
. O
3 O
+ O
/ O
- O
18 O
. O
9 O
% O
( O
p O
= O
0 O
. O
016 O
) O
, O
respectively O
. O

decreases O
were O
evident O
in O
both O
lv O
end O
- O
diastolic O
pressure O
( O
from O
17 O
+ O
/ O
- O
7 O
to O
15 O
+ O
/ O
- O
6 O
mmhg O
, O
p O
= O
0 O
. O
0480 O
and O
tau O
( O
from O
48 O
+ O
/ O
- O
8 O
to O
45 O
+ O
/ O
- O
8 O
ms O
, O
p O
< O
0 O
. O
01 O
) O
, O
while O
fractional O
shortening O
at O
the O
lv O
base O
increased O
from O
7 O
. O
7 O
+ O
/ O
- O
4 O
. O
5 O
% O
to O
9 O
. O
4 O
+ O
/ O
- O
4 O
. O
5 O
% O
( O
p O
= O
0 O
. O
045 O
) O
. O

after O
map O
, O
increases O
were O
identified O
in O
both O
cardiac O
output O
( O
from O
1 O
. O
54 O
+ O
/ O
- O
0 O
. O
57 O
to O
1 O
. O
65 O
+ O
/ O
- O
0 O
. O
57 O
1 O
/ O
min O
) O
and O
emax O
( O
from O
1 O
. O
86 O
+ O
/ O
- O
0 O
. O
9 O
to O
2 O
. O
41 O
+ O
/ O
- O
1 O
. O
31 O
mmhg O
/ O
ml O
) O
. O

conclusion O
: O
the O
data O
acquired O
suggest O
that O
isolated O
map O
may O
have O
certain O
benefits O
on O
lv O
dimension O
/ O
function O
in O
acute O
heart B-Disease
failure I-Disease
, O
even O
in O
the O
absence O
of O
mr B-Disease
. O

however O
, O
further O
investigations O
are O
warranted O
in O
a O
model O
of O
chronic O
heart B-Disease
failure I-Disease
. O

piperacillin O
/ O
tazobactam O
- O
induced O
seizure B-Disease
rapidly O
reversed O
by O
high O
flux O
hemodialysis O
in O
a O
patient O
on O
peritoneal O
dialysis O
. O

despite O
popular O
use O
of O
piperacillin O
, O
the O
dire O
neurotoxicity B-Disease
associated O
with O
piperacillin O
still O
goes O
unrecognized O
, O
leading O
to O
a O
delay O
in O
appropriate O
management O
. O

we O
report O
a O
57 O
- O
year O
- O
old O
woman O
with O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
receiving O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
capd O
) O
, O
who O
developed O
slurred O
speech O
, O
tremor B-Disease
, O
bizarre O
behavior O
, O
progressive O
mental O
confusion B-Disease
, O
and O
2 O
episodes O
of O
generalized O
tonic B-Disease
- I-Disease
clonic I-Disease
seizure I-Disease
( O
gtcs B-Disease
) O
after O
5 O
doses O
of O
piperacillin O
/ O
tazobactam O
( O
2 O
g O
/ O
250 O
mg O
) O
were O
given O
for O
bronchiectasis B-Disease
with O
secondary B-Disease
infection I-Disease
. O

the O
laboratory O
data O
revealed O
normal O
plasma O
electrolyte O
and O
ammonia O
levels O
but O
leukocytosis B-Disease
. O

neurologic O
examinations O
showed O
dysarthria B-Disease
and O
bilateral O
babinski O
sign O
. O

computed O
tomography O
of O
brain O
and O
electroencephalogram O
were O
unremarkable O
. O

despite O
the O
use O
of O
antiepileptic O
agents O
, O
another O
gtcs B-Disease
episode O
recurred O
after O
the O
sixth O
dose O
of O
piperacillin O
/ O
tazobactam O
. O

brain O
magnetic O
resonance O
imaging O
did O
not O
demonstrate O
acute O
infarction B-Disease
and O
organic B-Disease
brain I-Disease
lesions I-Disease
. O

initiation O
of O
high O
- O
flux O
hemodialysis O
rapidly O
reversed O
the O
neurologic O
symptoms O
within O
4 O
hours O
. O

piperacillin O
- O
induced O
encephalopathy B-Disease
should O
be O
considered O
in O
any O
uremic B-Disease
patients O
with O
unexplained O
neurological O
manifestations O
. O

capd O
is O
inefficient O
in O
removing O
piperacillin O
, O
whereas O
hemodialysis O
can O
rapidly O
terminate O
the O
piperacillin O
- O
induced O
encephalopathy B-Disease
. O

frequency O
of O
transient O
ipsilateral O
vocal B-Disease
cord I-Disease
paralysis I-Disease
in O
patients O
undergoing O
carotid O
endarterectomy O
under O
local O
anesthesia O
. O

background O
: O
especially O
because O
of O
improvements O
in O
clinical O
neurologic O
monitoring O
, O
carotid O
endarterectomy O
done O
under O
local O
anesthesia O
has O
become O
the O
technique O
of O
choice O
in O
several O
centers O
. O

temporary O
ipsilateral O
vocal B-Disease
nerve I-Disease
palsies I-Disease
due O
to O
local O
anesthetics O
have O
been O
described O
, O
however O
. O

such O
complications O
are O
most O
important O
in O
situations O
where O
there O
is O
a O
pre O
- O
existing O
contralateral O
paralysis B-Disease
. O

we O
therefore O
examined O
the O
effect O
of O
local O
anesthesia O
on O
vocal O
cord O
function O
to O
better O
understand O
its O
possible O
consequences O
. O

methods O
: O
this O
prospective O
study O
included O
28 O
patients O
undergoing O
carotid O
endarterectomy O
under O
local O
anesthesia O
. O

vocal O
cord O
function O
was O
evaluated O
before O
, O
during O
, O
and O
after O
surgery O
( O
postoperative O
day O
1 O
) O
using O
flexible O
laryngoscopy O
. O

anesthesia O
was O
performed O
by O
injecting O
20 O
to O
40 O
ml O
of O
a O
mixture O
of O
long O
- O
acting O
( O
ropivacaine O
) O
and O
short O
- O
acting O
( O
prilocaine O
) O
anesthetic O
. O

results O
: O
all O
patients O
had O
normal O
vocal O
cord O
function O
preoperatively O
. O

twelve O
patients O
( O
43 O
% O
) O
were O
found O
to O
have O
intraoperative O
ipsilateral O
vocal B-Disease
cord I-Disease
paralysis I-Disease
. O

it O
resolved O
in O
all O
cases O
< O
or O
= O
24 O
hours O
. O

there O
were O
no O
significant O
differences O
in O
operating O
time O
or O
volume O
or O
frequency O
of O
anesthetic O
administration O
in O
patients O
with O
temporary O
vocal B-Disease
cord I-Disease
paralysis I-Disease
compared O
with O
those O
without O
. O

conclusion O
: O
local O
anesthesia O
led O
to O
temporary O
ipsilateral O
vocal B-Disease
cord I-Disease
paralysis I-Disease
in O
almost O
half O
of O
these O
patients O
. O

because O
pre O
- O
existing O
paralysis B-Disease
is O
of O
a O
relevant O
frequency O
( O
up O
to O
3 O
% O
) O
, O
a O
preoperative O
evaluation O
of O
vocal O
cord O
function O
before O
carotid O
endarterectomy O
under O
local O
anesthesia O
is O
recommended O
to O
avoid O
intraoperative O
bilateral O
paralysis B-Disease
. O

in O
patients O
with O
preoperative O
contralateral O
vocal B-Disease
cord I-Disease
paralysis I-Disease
, O
surgery O
under O
general O
anesthesia O
should O
be O
considered O
. O

impaired B-Disease
fear I-Disease
recognition I-Disease
in O
regular O
recreational O
cocaine O
users O
. O

introduction O
: O
the O
ability O
to O
read O
facial O
expressions O
is O
essential O
for O
normal O
human O
social O
interaction O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
conduct O
the O
first O
investigation O
of O
facial O
expression O
recognition O
performance O
in O
recreational O
cocaine O
users O
. O

materials O
and O
methods O
: O
three O
groups O
, O
comprised O
of O
21 O
cocaine O
naive O
participants O
( O
cn O
) O
, O
30 O
occasional O
cocaine O
( O
oc O
) O
, O
and O
48 O
regular O
recreational O
cocaine O
( O
rc O
) O
users O
, O
were O
compared O
. O

an O
emotional O
facial O
expression O
( O
efe O
) O
task O
consisting O
of O
a O
male O
and O
female O
face O
expressing O
six O
basic O
emotions O
( O
happiness O
, O
surprise O
, O
sadness O
, O
anger O
, O
fear O
, O
and O
disgust O
) O
was O
administered O
. O

mean O
percent O
accuracy O
and O
latencies O
for O
correct O
responses O
across O
eight O
presentations O
of O
each O
basic O
emotion O
were O
derived O
. O

participants O
were O
also O
assessed O
with O
the O
" O
eyes O
task O
" O
to O
investigate O
their O
ability O
to O
recognize O
more O
complex O
emotional O
states O
and O
the O
symptom O
checklist O
- O
90 O
- O
revised O
to O
measure O
psychopathology O
. O

results O
: O
there O
were O
no O
group O
differences O
in O
psychopathology O
or O
" O
eyes O
task O
" O
performance O
, O
but O
the O
rc O
group O
, O
who O
otherwise O
had O
similar O
illicit O
substance O
use O
histories O
to O
the O
oc O
group O
, O
exhibited O
impaired B-Disease
fear I-Disease
recognition I-Disease
accuracy O
compared O
to O
the O
oc O
and O
cn O
groups O
. O

the O
rc O
group O
also O
correctly O
identified O
anger O
, O
fear O
, O
happiness O
, O
and O
surprise O
, O
more O
slowly O
than O
cn O
, O
but O
not O
oc O
participants O
. O

the O
oc O
group O
was O
slower O
than O
cn O
when O
correctly O
identifying O
disgust O
. O

the O
selective O
deficit B-Disease
in I-Disease
fear I-Disease
recognition I-Disease
accuracy O
manifested O
by O
the O
rc O
group O
cannot O
be O
explained O
by O
the O
subacute O
effects O
of O
cocaine O
, O
or O
ecstasy O
, O
because O
recent O
and O
less O
recent O
users O
of O
these O
drugs O
within O
this O
group O
were O
similarly O
impaired O
. O

possible O
parallels O
between O
rc O
users O
and O
psychopaths B-Disease
with O
respect O
to O
impaired B-Disease
fear I-Disease
recognition I-Disease
, O
amygdala B-Disease
dysfunction I-Disease
, O
and O
etiology O
are O
discussed O
. O

damage B-Disease
of I-Disease
substantia I-Disease
nigra I-Disease
pars I-Disease
reticulata I-Disease
during O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
in O
the O
rat O
: O
immunohistochemical O
study O
of O
neurons O
, O
astrocytes O
and O
serum O
- O
protein O
extravasation O
. O

the O
substantia O
nigra O
has O
a O
gating O
function O
controlling O
the O
spread O
of O
epileptic B-Disease
seizure I-Disease
activity O
. O

additionally O
, O
in O
models O
of O
prolonged B-Disease
status I-Disease
epilepticus I-Disease
the O
pars O
reticulata O
of O
substantia O
nigra O
( O
snr O
) O
suffers O
from O
a O
massive O
lesion O
which O
may O
arise O
from O
a O
massive O
metabolic B-Disease
derangement I-Disease
and O
hyperexcitation O
developing O
in O
the O
activated O
snr O
. O

in O
this O
study O
, O
status B-Disease
epilepticus I-Disease
was O
induced O
by O
systemic O
injection O
of O
pilocarpine O
in O
rats O
. O

the O
neuropathology O
of O
snr O
was O
investigated O
using O
immunohistochemical O
techniques O
with O
the O
major O
emphasis O
on O
the O
time O
- O
course O
of O
changes O
in O
neurons O
and O
astrocytes O
. O

animals O
surviving O
20 O
, O
30 O
, O
40 O
, O
60 O
min O
, O
2 O
, O
3 O
, O
6 O
hours O
, O
1 O
, O
2 O
, O
and O
3 O
days O
after O
induction O
of O
status B-Disease
epilepticus I-Disease
were O
perfusion O
- O
fixed O
, O
and O
brains O
processed O
for O
immunohistochemical O
staining O
of O
snr O
. O

nissl O
- O
staining O
and O
antibodies O
against O
the O
neuron O
- O
specific O
calcium O
- O
binding O
protein O
, O
parvalbumin O
, O
served O
to O
detect O
neuronal B-Disease
damage I-Disease
in O
snr O
. O

antibodies O
against O
the O
astroglia O
- O
specific O
cytoskeletal O
protein O
, O
glial O
fibrillary O
acidic O
protein O
( O
gfap O
) O
, O
and O
against O
the O
glial O
calcium O
- O
binding O
protein O
, O
s O
- O
100 O
protein O
, O
were O
used O
to O
assess O
the O
status O
of O
astrocytes O
. O

immunohistochemical O
staining O
for O
serum O
- O
albumin O
and O
immunoglobulins O
in O
brain O
tissue O
was O
taken O
as O
indicator O
of O
blood O
- O
brain O
barrier O
disturbances O
and O
vasogenic B-Disease
edema I-Disease
formation O
. O

immunohistochemical O
staining O
indicated O
loss O
of O
gfap O
- O
staining O
already O
at O
30 O
min O
after O
induction O
of O
seizures B-Disease
in O
an O
oval O
focus O
situated O
in O
the O
center O
of O
snr O
while O
sparing O
medial O
and O
lateral O
aspects O
. O

at O
1 O
h O
there O
was O
additional O
vacuolation O
in O
s O
- O
100 O
protein O
staining O
. O

by O
2 O
hours O
, O
parvalbumin O
- O
staining O
changed O
in O
the O
central O
snr O
indicating O
neuronal B-Disease
damage I-Disease
, O
and O
nissl O
- O
staining O
visualized O
some O
neuronal O
distortion O
. O

staining O
for O
serum O
- O
proteins O
occurred O
in O
a O
patchy O
manner O
throughout O
the O
forebrain O
during O
the O
first O
hours O
. O

by O
6 O
h O
, O
vasogenic B-Disease
edema I-Disease
covered O
the O
lesioned B-Disease
snr I-Disease
. O

by O
24 O
h O
, O
glial O
and O
neuronal O
markers O
indicated O
a O
massive O
lesion O
in O
the O
center O
of O
snr O
. O

by O
48 O
- O
72 O
h O
, O
astrocytes O
surrounding O
the O
lesion O
increased O
in O
size O
, O
and O
polymorphic O
phagocytotic O
cells O
invaded O
the O
damaged O
area O
. O

in O
a O
further O
group O
of O
animals O
surviving O
1 O
to O
5 O
days O
, O
conventional O
paraffin O
- O
sections O
confirmed O
the O
neuronal O
and O
glial O
damage B-Disease
of I-Disease
snr I-Disease
. O

additional O
pathology O
of O
similar O
quality O
was O
found O
in O
the O
globus O
pallidus O
. O

since O
astrocytes O
were O
always O
damaged O
in O
parallel O
with O
neurons O
in O
snr O
it O
is O
proposed O
that O
the O
anatomical O
and O
functional O
interrelationship O
between O
neurons O
and O
astrocytes O
is O
particularly O
tight O
in O
snr O
. O

both O
cell O
elements O
may O
suffer O
in O
common O
from O
metabolic O
disturbance O
and O
neurotransmitter B-Disease
dysfunction I-Disease
as O
occur O
during O
massive O
status B-Disease
epilepticus I-Disease
. O

neuroprotective O
effects O
of O
melatonin O
upon O
the O
offspring O
cerebellar O
cortex O
in O
the O
rat O
model O
of O
bcnu O
- O
induced O
cortical B-Disease
dysplasia I-Disease
. O

cortical B-Disease
dysplasia I-Disease
is O
a O
malformation O
characterized O
by O
defects O
in O
proliferation O
, O
migration O
and O
maturation O
. O

this O
study O
was O
designed O
to O
evaluate O
the O
alterations O
in O
offspring O
rat O
cerebellum O
induced O
by O
maternal O
exposure O
to O
carmustine O
- O
[ O
1 O
, O
3 O
- O
bis O
( O
2 O
- O
chloroethyl O
) O
- O
1 O
- O
nitrosoure O
] O
( O
bcnu O
) O
and O
to O
investigate O
the O
effects O
of O
exogenous O
melatonin O
upon O
cerebellar O
bcnu O
- O
induced O
cortical B-Disease
dysplasia I-Disease
, O
using O
histological O
and O
biochemical O
analyses O
. O

pregnant O
wistar O
rats O
were O
assigned O
to O
five O
groups O
: O
intact O
- O
control O
, O
saline O
- O
control O
, O
melatonin O
- O
treated O
, O
bcnu O
- O
exposed O
and O
bcnu O
- O
exposed O
plus O
melatonin O
. O

rats O
were O
exposed O
to O
bcnu O
on O
embryonic O
day O
15 O
and O
melatonin O
was O
given O
until O
delivery O
. O

immuno O
/ O
histochemistry O
and O
electron O
microscopy O
were O
carried O
out O
on O
the O
offspring O
cerebellum O
, O
and O
levels O
of O
malondialdehyde O
and O
superoxide O
dismutase O
were O
determined O
. O

histopathologically O
, O
typical O
findings O
were O
observed O
in O
the O
cerebella O
from O
the O
control O
groups O
, O
but O
the O
findings O
consistent O
with O
early O
embryonic O
development O
were O
noted O
in O
bcnu O
- O
exposed O
cortical B-Disease
dysplasia I-Disease
group O
. O

there O
was O
a O
marked O
increase O
in O
the O
number O
of O
tunel O
positive O
cells O
and O
nestin O
positive O
cells O
in O
bcnu O
- O
exposed O
group O
, O
but O
a O
decreased O
immunoreactivity O
to O
glial O
fibrillary O
acidic O
protein O
, O
synaptophysin O
and O
transforming O
growth O
factor O
beta1 O
was O
observed O
, O
indicating O
a O
delayed O
maturation O
, O
and O
melatonin O
significantly O
reversed O
these O
changes O
. O

malondialdehyde O
level O
in O
bcnu O
- O
exposed O
group O
was O
higher O
than O
those O
in O
control O
groups O
and O
melatonin O
decreased O
malondialdehyde O
levels O
in O
bcnu O
group O
( O
p O
< O
0 O
. O
01 O
) O
, O
while O
there O
were O
no O
significant O
differences O
in O
the O
superoxide O
dismutase O
levels O
between O
these O
groups O
. O

these O
data O
suggest O
that O
exposure O
of O
animals O
to O
bcnu O
during O
pregnancy O
leads O
to O
delayed O
maturation O
of O
offspring O
cerebellum O
and O
melatonin O
protects O
the O
cerebellum O
against O
the O
effects O
of O
bcnu O
. O

reduced O
cardiotoxicity B-Disease
of O
doxorubicin O
given O
in O
the O
form O
of O
n O
- O
( O
2 O
- O
hydroxypropyl O
) O
methacrylamide O
conjugates O
: O
and O
experimental O
study O
in O
the O
rat O
. O

a O
rat O
model O
was O
used O
to O
evaluate O
the O
general O
acute O
toxicity B-Disease
and O
the O
late O
cardiotoxicity B-Disease
of O
4 O
mg O
/ O
kg O
doxorubicin O
( O
dox O
) O
given O
either O
as O
free O
drug O
or O
in O
the O
form O
of O
three O
n O
- O
( O
2 O
- O
hydroxypropyl O
) O
methacrylamide O
( O
hpma O
) O
copolymer O
conjugates O
. O

in O
these O
hpma O
copolymers O
, O
dox O
was O
covalently O
bound O
via O
peptide O
linkages O
that O
were O
either O
non O
- O
biodegradable O
( O
gly O
- O
gly O
) O
or O
degradable O
by O
lysosomal O
proteinases O
( O
gly O
- O
phe O
- O
leu O
- O
gly O
) O
. O

in O
addition O
, O
one O
biodegradable O
conjugate O
containing O
galactosamine O
was O
used O
; O
this O
residue O
was O
targeted O
to O
the O
liver O
. O

over O
the O
first O
3 O
weeks O
after O
the O
i O
. O
v O
. O
administration O
of O
free O
and O
polymer O
- O
bound O
dox O
, O
all O
animals O
showed O
a O
transient O
reduction O
in O
body O
weight O
. O

however O
, O
the O
maximal O
reduction O
in O
body O
weight O
seen O
in O
animals O
that O
received O
polymer O
- O
bound O
dox O
( O
4 O
mg O
/ O
kg O
) O
was O
significantly O
lower O
than O
that O
observed O
in O
those O
that O
received O
free O
dox O
( O
4 O
mg O
/ O
kg O
) O
or O
a O
mixture O
of O
the O
unmodified O
parent O
hpma O
copolymer O
and O
free O
dox O
( O
4 O
mg O
/ O
kg O
; O
p O
less O
than O
0 O
. O
01 O
) O
. O

throughout O
the O
study O
( O
20 O
weeks O
) O
, O
deaths O
related O
to O
cardiotoxicity B-Disease
were O
observed O
only O
in O
animals O
that O
received O
either O
free O
dox O
or O
the O
mixture O
of O
hpma O
copolymer O
and O
free O
dox O
; O
in O
these O
cases O
, O
histological O
investigations O
revealed O
marked O
changes O
in O
the O
heart O
that O
were O
consistent O
with O
dox O
- O
induced O
cardiotoxicity B-Disease
. O

sequential O
measurements O
of O
cardiac O
output O
in O
surviving O
animals O
that O
received O
either O
free O
dox O
or O
the O
mixture O
of O
hpma O
copolymer O
and O
free O
dox O
showed O
a O
reduction O
of O
approximately O
30 O
% O
in O
function O
beginning O
at O
the O
4th O
week O
after O
drug O
administration O
. O

the O
heart O
rate O
in O
these O
animals O
was O
approximately O
12 O
% O
lower O
than O
that O
measured O
in O
age O
- O
matched O
control O
rats O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

animals O
that O
were O
given O
the O
hpma O
copolymer O
conjugates O
containing O
dox O
exhibited O
no O
significant O
change O
in O
cardiac O
output O
throughout O
the O
study O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

in O
addition O
, O
no O
significant O
histological O
change O
was O
observed O
in O
the O
heart O
of O
animals O
that O
received O
dox O
in O
the O
form O
of O
hpma O
copolymer O
conjugates O
and O
were O
killed O
at O
the O
end O
of O
the O
study O
. O

however O
, O
these O
animals O
had O
shown O
a O
significant O
increase O
in O
heart O
rate O
beginning O
at O
8 O
weeks O
after O
drug O
administration O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O
( O
abstract O
truncated O
at O
400 O
words O
) O

corneal B-Disease
ulcers I-Disease
associated O
with O
aerosolized O
crack O
cocaine O
use O
. O

purpose O
: O
we O
report O
4 O
cases O
of O
corneal B-Disease
ulcers I-Disease
associated O
with O
drug B-Disease
abuse I-Disease
. O

the O
pathogenesis O
of O
these O
ulcers B-Disease
and O
management O
of O
these O
patients O
are O
also O
reviewed O
. O

methods O
: O
review O
of O
all O
cases O
of O
corneal B-Disease
ulcers I-Disease
associated O
with O
drug B-Disease
abuse I-Disease
seen O
at O
our O
institution O
from O
july O
2006 O
to O
december O
2006 O
. O

results O
: O
four O
patients O
with O
corneal B-Disease
ulcers I-Disease
associated O
with O
crack O
cocaine O
use O
were O
reviewed O
. O

all O
corneal B-Disease
ulcers I-Disease
were O
cultured O
, O
and O
the O
patients O
were O
admitted O
to O
the O
hospital O
for O
intensive O
topical O
antibiotic O
treatment O
. O

each O
patient O
received O
comprehensive O
health O
care O
, O
including O
medical O
and O
substance B-Disease
abuse I-Disease
consultations O
. O

streptococcal O
organisms O
were O
found O
in O
3 O
cases O
and O
capnocytophaga O
and O
brevibacterium O
casei O
in O
1 O
patient O
. O

the O
infections B-Disease
responded O
to O
antibiotic O
treatment O
. O

two O
patients O
needed O
a O
lateral O
tarsorrhaphy O
for O
persistent O
epithelial B-Disease
defects I-Disease
. O

conclusions O
: O
aerosolized O
crack O
cocaine O
use O
can O
be O
associated O
with O
the O
development O
of O
corneal B-Disease
ulcers I-Disease
. O

drug B-Disease
abuse I-Disease
provides O
additional O
challenges O
for O
management O
. O

not O
only O
treatment O
of O
their O
infections B-Disease
but O
also O
the O
overall O
poor O
health O
of O
the O
patients O
and O
increased O
risk O
of O
noncompliance O
need O
to O
be O
addressed O
. O

comprehensive O
care O
may O
provide O
the O
patient O
the O
opportunity O
to O
discontinue O
their O
substance B-Disease
abuse I-Disease
, O
improve O
their O
overall O
health O
, O
and O
prevent O
future O
corneal O
complications O
. O

topical O
0 O
. O
025 O
% O
capsaicin O
in O
chronic O
post B-Disease
- I-Disease
herpetic I-Disease
neuralgia I-Disease
: O
efficacy O
, O
predictors O
of O
response O
and O
long O
- O
term O
course O
. O

in O
order O
to O
evaluate O
the O
efficacy O
, O
time O
- O
course O
of O
action O
and O
predictors O
of O
response O
to O
topical O
capsaicin O
, O
39 O
patients O
with O
chronic O
post B-Disease
- I-Disease
herpetic I-Disease
neuralgia I-Disease
( O
phn B-Disease
) O
, O
median O
duration O
24 O
months O
, O
were O
treated O
with O
0 O
. O
025 O
% O
capsaicin O
cream O
for O
8 O
weeks O
. O

during O
therapy O
the O
patients O
rated O
their O
pain B-Disease
on O
a O
visual O
analogue O
scale O
( O
vas O
) O
and O
a O
verbal O
outcome O
scale O
. O

a O
follow O
- O
up O
investigation O
was O
performed O
10 O
- O
12 O
months O
after O
study O
onset O
on O
the O
patients O
who O
had O
improved O
. O

nineteen O
patients O
( O
48 O
. O
7 O
% O
) O
substantially O
improved O
after O
the O
8 O
- O
week O
trial O
; O
5 O
( O
12 O
. O
8 O
% O
) O
discontinued O
therapy O
due O
to O
side O
- O
effects O
such O
as O
intolerable O
capsaicin O
- O
induced O
burning O
sensations O
( O
4 O
) O
or O
mastitis B-Disease
( O
1 O
) O
; O
15 O
( O
38 O
. O
5 O
% O
) O
reported O
no O
benefit O
. O

the O
decrease O
in O
vas O
ratings O
was O
significant O
after O
2 O
weeks O
of O
continuous O
application O
. O

of O
the O
responders O
72 O
. O
2 O
% O
were O
still O
improved O
at O
the O
follow O
- O
up O
; O
only O
one O
- O
third O
of O
them O
had O
continued O
application O
irregularly O
. O

treatment O
effect O
was O
not O
dependent O
on O
patient O
' O
s O
age O
, O
duration O
or O
localization O
of O
phn B-Disease
( O
trigeminal O
involvement O
was O
excluded O
) O
, O
sensory B-Disease
disturbance I-Disease
or O
pain B-Disease
character O
. O

treatment O
response O
was O
not O
correlated O
with O
the O
incidence O
, O
time O
- O
course O
or O
severity O
of O
capsaicin O
- O
induced O
burning O
. O

if O
confirmed O
in O
controlled O
trials O
, O
the O
long O
- O
term O
results O
of O
this O
open O
, O
non O
- O
randomized O
study O
might O
indicate O
that O
the O
analgesic O
effect O
of O
capsaicin O
in O
phn B-Disease
is O
mediated O
by O
both O
interference O
with O
neuropeptide O
metabolism O
and O
morphological O
changes O
( O
perhaps O
degeneration O
) O
of O
nociceptive O
afferents O
. O

myo O
- O
inositol O
- O
1 O
- O
phosphate O
( O
mip O
) O
synthase O
inhibition O
: O
in O
- O
vivo O
study O
in O
rats O
. O

lithium O
and O
valproate O
are O
the O
prototypic O
mood O
stabilizers O
and O
have O
diverse O
structures O
and O
targets O
. O

both O
drugs O
influence O
inositol O
metabolism O
. O

lithium O
inhibits O
impase O
and O
valproate O
inhibits O
mip O
synthase O
. O

this O
study O
shows O
that O
mip O
synthase O
inhibition O
does O
not O
replicate O
or O
augment O
the O
effects O
of O
lithium O
in O
the O
inositol O
sensitive O
pilocarpine O
- O
induced O
seizures B-Disease
model O
. O

this O
lack O
of O
effects O
may O
stem O
from O
the O
low O
contribution O
of O
de O
- O
novo O
synthesis O
to O
cellular O
inositol O
supply O
or O
to O
the O
inhibition O
of O
the O
de O
- O
novo O
synthesis O
by O
lithium O
itself O
. O

non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
- O
associated O
acute O
interstitial B-Disease
nephritis I-Disease
with O
granular O
tubular O
basement O
membrane O
deposits O
. O

acute B-Disease
tubulo I-Disease
- I-Disease
interstitial I-Disease
nephritis I-Disease
( O
atin B-Disease
) O
is O
an O
important O
cause O
of O
acute B-Disease
renal I-Disease
failure I-Disease
resulting O
from O
a O
variety O
of O
insults O
, O
including O
immune O
complex O
- O
mediated O
tubulo B-Disease
- I-Disease
interstitial I-Disease
injury I-Disease
, O
but O
drugs O
such O
as O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
are O
a O
far O
more O
frequent O
cause O
. O

overall O
, O
as O
an O
entity O
, O
atin B-Disease
remains O
under O
- O
diagnosed O
, O
as O
symptoms O
resolve O
spontaneously O
if O
the O
medication O
is O
stopped O
. O

we O
report O
on O
a O
14 O
- O
year O
- O
old O
boy O
who O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
2 O
weeks O
after O
aortic O
valve O
surgery O
. O

he O
was O
put O
on O
aspirin O
following O
surgery O
and O
took O
ibuprofen O
for O
fever B-Disease
for O
nearly O
a O
week O
prior O
to O
presentation O
. O

he O
then O
presented O
to O
the O
emergency O
department O
feeling O
quite O
ill O
and O
was O
found O
to O
have O
a O
blood O
urea O
nitrogen O
( O
bun O
) O
concentration O
of O
of O
147 O
mg O
/ O
dl O
, O
creatinine O
of O
15 O
. O
3 O
mg O
/ O
dl O
and O
serum O
potassium O
of O
8 O
. O
7 O
meq O
/ O
l O
. O

dialysis O
was O
immediately O
initiated O
. O

a O
kidney O
biopsy O
showed O
inflammatory O
infiltrate O
consistent O
with O
atin B-Disease
. O

however O
, O
in O
the O
tubular O
basement O
membrane O
( O
tbm O
) O
, O
very O
intense O
granular O
deposits O
of O
polyclonal O
igg O
and O
c3 O
were O
noted O
. O

he O
needed O
dialysis O
for O
2 O
weeks O
and O
was O
treated O
successfully O
with O
steroids O
for O
6 O
months O
. O

his O
renal O
recovery O
and O
disappearance O
of O
proteinuria B-Disease
took O
a O
year O
. O

in O
conclusion O
, O
this O
is O
a O
first O
report O
of O
nsaids O
- O
associated O
atin B-Disease
, O
showing O
deposits O
of O
granular O
immune O
complex O
present O
only O
in O
the O
tbm O
and O
not O
in O
the O
glomeruli O
. O

rifampicin O
- O
associated O
segmental O
necrotizing O
glomerulonephritis B-Disease
in O
staphylococcal B-Disease
endocarditis I-Disease
. O

segmental O
necrotising O
glomerulonephritis B-Disease
has O
been O
reported O
as O
complication O
of O
rifampicin O
therapy O
in O
patients O
receiving O
treatment O
for O
tuberculosis B-Disease
. O

changing O
epidemiology O
of O
infections B-Disease
such O
as O
infective B-Disease
endocarditis I-Disease
( O
ie B-Disease
) O
has O
led O
to O
an O
increase O
in O
the O
use O
of O
rifampicin O
for O
staphylococcal B-Disease
infections I-Disease
. O

we O
describe O
a O
case O
of O
a O
patient O
with O
staphylococcal B-Disease
ie I-Disease
who O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
secondary O
to O
a O
segmental O
necrotising O
glomerulonephritis B-Disease
while O
being O
treated O
with O
rifampicin O
, O
and O
review O
the O
literature O
regarding O
this O
complication O
of O
rifampicin O
therapy O
. O

rate O
of O
ymdd O
motif O
mutants O
in O
lamivudine O
- O
untreated O
iranian O
patients O
with O
chronic B-Disease
hepatitis I-Disease
b I-Disease
virus I-Disease
infection I-Disease
. O

background O
: O
lamivudine O
is O
used O
for O
the O
treatment O
of O
chronic B-Disease
hepatitis I-Disease
b I-Disease
patients O
. O

recent O
studies O
show O
that O
the O
ymdd O
motif O
mutants O
( O
resistant O
hepatitis B-Disease
b I-Disease
virus O
) O
occur O
as O
natural O
genome O
variability O
in O
lamivudine O
- O
untreated O
chronic B-Disease
hepatitis I-Disease
b I-Disease
patients O
. O

in O
this O
study O
we O
aimed O
to O
determine O
the O
rate O
of O
ymdd O
motif O
mutants O
in O
lamivudine O
- O
untreated O
chronic B-Disease
hepatitis I-Disease
b I-Disease
patients O
in O
iran O
. O

patients O
and O
methods O
: O
a O
total O
of O
77 O
chronic B-Disease
hepatitis I-Disease
b I-Disease
patients O
who O
had O
not O
been O
treated O
with O
lamivudine O
were O
included O
in O
the O
study O
. O

serum O
samples O
from O
patients O
were O
tested O
by O
polymerase O
chain O
reaction O
- O
restriction O
fragment O
length O
polymorphism O
( O
pcr O
- O
rflp O
) O
for O
detection O
of O
ymdd O
motif O
mutants O
. O

all O
patients O
were O
also O
tested O
for O
liver O
enzymes O
, O
anti O
- O
hcv O
, O
hbeag O
, O
and O
anti O
- O
hbe O
. O

results O
: O
of O
the O
77 O
patients O
enrolled O
in O
the O
study O
, O
73 O
% O
were O
male O
and O
27 O
% O
were O
female O
. O

mean O
alt O
and O
ast O
levels O
were O
124 O
. O
4 O
+ O
/ O
- O
73 O
. O
4 O
and O
103 O
. O
1 O
+ O
/ O
- O
81 O
iu O
/ O
l O
, O
respectively O
. O

hbeag O
was O
positive O
in O
40 O
% O
and O
anti O
- O
hbe O
in O
60 O
% O
of O
the O
patients O
. O

anti O
- O
hcv O
was O
negative O
in O
all O
of O
them O
. O

ymdd O
motif O
mutants O
were O
not O
detected O
in O
any O
of O
the O
patients O
despite O
the O
liver O
enzyme O
levels O
and O
the O
presence O
of O
hbeag O
or O
anti O
- O
hbe O
. O

conclusion O
: O
although O
the O
natural O
occurrence O
of O
ymdd O
motif O
mutants O
in O
lamivudine O
- O
untreated O
patients O
with O
chronic B-Disease
hepatitis I-Disease
b I-Disease
has O
been O
reported O
, O
these O
mutants O
were O
not O
detected O
in O
iranian O
lamivudine O
- O
untreated O
chronic B-Disease
hepatitis I-Disease
b I-Disease
patients O
. O

branch O
retinal B-Disease
vein I-Disease
occlusion I-Disease
and O
fluoxetine O
. O

a O
case O
of O
branch O
retinal B-Disease
vein I-Disease
occlusion I-Disease
associated O
with O
fluoxetine O
- O
induced O
secondary O
hypertension B-Disease
is O
described O
. O

although O
an O
infrequent O
complication O
of O
selective O
serotonin O
reuptake O
inhibitor O
therapy O
, O
it O
is O
important O
that O
ophthalmologists O
are O
aware O
that O
these O
agents O
can O
cause O
hypertension B-Disease
because O
this O
class O
of O
drugs O
is O
widely O
prescribed O
. O

the O
differential O
effects O
of O
bupivacaine O
and O
lidocaine O
on O
prostaglandin O
e2 O
release O
, O
cyclooxygenase O
gene O
expression O
and O
pain B-Disease
in O
a O
clinical O
pain B-Disease
model O
. O

background O
: O
in O
addition O
to O
blocking O
nociceptive O
input O
from O
surgical O
sites O
, O
long O
- O
acting O
local O
anesthetics O
might O
directly O
modulate O
inflammation B-Disease
. O

in O
the O
present O
study O
, O
we O
describe O
the O
proinflammatory O
effects O
of O
bupivacaine O
on O
local O
prostaglandin O
e2 O
( O
pge2 O
) O
production O
and O
cyclooxygenase O
( O
cox O
) O
gene O
expression O
that O
increases O
postoperative B-Disease
pain I-Disease
in O
human O
subjects O
. O

methods O
: O
subjects O
( O
n O
= O
114 O
) O
undergoing O
extraction O
of O
impacted O
third O
molars O
received O
either O
2 O
% O
lidocaine O
or O
0 O
. O
5 O
% O
bupivacaine O
before O
surgery O
and O
either O
rofecoxib O
50 O
mg O
or O
placebo O
orally O
90 O
min O
before O
surgery O
and O
for O
the O
following O
48 O
h O
. O

oral O
mucosal O
biopsies O
were O
taken O
before O
surgery O
and O
48 O
h O
after O
surgery O
. O

after O
extraction O
, O
a O
microdialysis O
probe O
was O
placed O
at O
the O
surgical O
site O
for O
pge2 O
and O
thromboxane O
b2 O
( O
txb2 O
) O
measurements O
. O

results O
: O
the O
bupivacaine O
/ O
rofecoxib O
group O
reported O
significantly O
less O
pain B-Disease
, O
as O
assessed O
by O
a O
visual O
analog O
scale O
, O
compared O
with O
the O
other O
three O
treatment O
groups O
over O
the O
first O
4 O
h O
. O

however O
, O
the O
bupivacaine O
/ O
placebo O
group O
reported O
significantly O
more O
pain B-Disease
at O
24 O
h O
and O
pge2 O
levels O
during O
the O
first O
4 O
h O
were O
significantly O
higher O
than O
the O
other O
three O
treatment O
groups O
. O

moreover O
, O
bupivacaine O
significantly O
increased O
cox O
- O
2 O
gene O
expression O
at O
48 O
h O
as O
compared O
with O
the O
lidocaine O
/ O
placebo O
group O
. O

thromboxane O
levels O
were O
not O
significantly O
affected O
by O
any O
of O
the O
treatments O
, O
indicating O
that O
the O
effects O
seen O
were O
attributable O
to O
inhibition O
of O
cox O
- O
2 O
, O
but O
not O
cox O
- O
1 O
. O

conclusions O
: O
these O
results O
suggest O
that O
bupivacaine O
stimulates O
cox O
- O
2 O
gene O
expression O
after O
tissue B-Disease
injury I-Disease
, O
which O
is O
associated O
with O
higher O
pge2 O
production O
and O
pain B-Disease
after O
the O
local O
anesthetic O
effect O
dissipates O
. O

p75ntr O
expression O
in O
rat O
urinary O
bladder O
sensory O
neurons O
and O
spinal O
cord O
with O
cyclophosphamide O
- O
induced O
cystitis B-Disease
. O

a O
role O
for O
nerve O
growth O
factor O
( O
ngf O
) O
in O
contributing O
to O
increased O
voiding O
frequency O
and O
altered O
sensation O
from O
the O
urinary O
bladder O
has O
been O
suggested O
. O

previous O
studies O
have O
examined O
the O
expression O
and O
regulation O
of O
tyrosine O
kinase O
receptors O
( O
trks O
) O
in O
micturition O
reflexes O
with O
urinary B-Disease
bladder I-Disease
inflammation I-Disease
. O

the O
present O
studies O
examine O
the O
expression O
and O
regulation O
of O
another O
receptor O
known O
to O
bind O
ngf O
, O
p75 O
( O
ntr O
) O
, O
after O
various O
durations O
of O
bladder B-Disease
inflammation I-Disease
induced O
by O
cyclophosphamide O
( O
cyp O
) O
. O

cyp O
- O
induced O
cystitis B-Disease
increased O
( O
p O
< O
or O
= O
0 O
. O
001 O
) O
p75 O
( O
ntr O
) O
expression O
in O
the O
superficial O
lateral O
and O
medial O
dorsal O
horn O
in O
l1 O
- O
l2 O
and O
l6 O
- O
s1 O
spinal O
segments O
. O

the O
number O
of O
p75 O
( O
ntr O
) O
- O
immunoreactive O
( O
- O
ir O
) O
cells O
in O
the O
lumbosacral O
dorsal O
root O
ganglia O
( O
drg O
) O
also O
increased O
( O
p O
< O
or O
= O
0 O
. O
05 O
) O
with O
cyp O
- O
induced O
cystitis B-Disease
( O
acute O
, O
intermediate O
, O
and O
chronic O
) O
. O

quantitative O
, O
real O
- O
time O
polymerase O
chain O
reaction O
also O
demonstrated O
significant O
increases O
( O
p O
< O
or O
= O
0 O
. O
01 O
) O
in O
p75 O
( O
ntr O
) O
mrna O
in O
drg O
with O
intermediate O
and O
chronic O
cyp O
- O
induced O
cystitis B-Disease
. O

retrograde O
dye O
- O
tracing O
techniques O
with O
fastblue O
were O
used O
to O
identify O
presumptive O
bladder O
afferent O
cells O
in O
the O
lumbosacral O
drg O
. O

in O
bladder O
afferent O
cells O
in O
drg O
, O
p75 O
( O
ntr O
) O
- O
ir O
was O
also O
increased O
( O
p O
< O
or O
= O
0 O
. O
01 O
) O
with O
cystitis B-Disease
. O

in O
addition O
to O
increases O
in O
p75 O
( O
ntr O
) O
- O
ir O
in O
drg O
cell O
bodies O
, O
increases O
( O
p O
< O
or O
= O
0 O
. O
001 O
) O
in O
pericellular O
( O
encircling O
drg O
cells O
) O
p75 O
( O
ntr O
) O
- O
ir O
in O
drg O
also O
increased O
. O

confocal O
analyses O
demonstrated O
that O
pericellular O
p75 O
( O
ntr O
) O
- O
ir O
was O
not O
colocalized O
with O
the O
glial O
marker O
, O
glial O
fibrillary O
acidic O
protein O
( O
gfap O
) O
. O

these O
studies O
demonstrate O
that O
p75 O
( O
ntr O
) O
expression O
in O
micturition O
reflexes O
is O
present O
constitutively O
and O
modified O
by O
bladder B-Disease
inflammation I-Disease
. O

the O
functional O
significance O
of O
p75 O
( O
ntr O
) O
expression O
in O
micturition O
reflexes O
remains O
to O
be O
determined O
. O

azathioprine O
- O
induced O
suicidal O
erythrocyte O
death O
. O

background O
: O
azathioprine O
is O
widely O
used O
as O
an O
immunosuppressive O
drug O
. O

the O
side O
effects O
of O
azathioprine O
include O
anemia B-Disease
, O
which O
has O
been O
attributed O
to O
bone O
marrow O
suppression O
. O

alternatively O
, O
anemia B-Disease
could O
result O
from O
accelerated O
suicidal O
erythrocyte O
death O
or O
eryptosis O
, O
which O
is O
characterized O
by O
exposure O
of O
phosphatidylserine O
( O
ps O
) O
at O
the O
erythrocyte O
surface O
and O
by O
cell O
shrinkage O
. O

methods O
: O
the O
present O
experiments O
explored O
whether O
azathioprine O
influences O
eryptosis O
. O

according O
to O
annexin O
v O
binding O
, O
erythrocytes O
from O
patients O
indeed O
showed O
a O
significant O
increase O
of O
ps O
exposure O
within O
1 O
week O
of O
treatment O
with O
azathioprine O
. O

in O
a O
second O
series O
, O
cytosolic O
ca2 O
+ O
activity O
( O
fluo3 O
fluorescence O
) O
, O
cell O
volume O
( O
forward O
scatter O
) O
, O
and O
ps O
- O
exposure O
( O
annexin O
v O
binding O
) O
were O
determined O
by O
facs O
analysis O
in O
erythrocytes O
from O
healthy O
volunteers O
. O

results O
: O
exposure O
to O
azathioprine O
( O
> O
or O
= O
2 O
microg O
/ O
ml O
) O
for O
48 O
hours O
increased O
cytosolic O
ca2 O
+ O
activity O
and O
annexin O
v O
binding O
and O
decreased O
forward O
scatter O
. O

the O
effect O
of O
azathioprine O
on O
both O
annexin O
v O
binding O
and O
forward O
scatter O
was O
significantly O
blunted O
in O
the O
nominal O
absence O
of O
extracellular O
ca2 O
+ O
. O

conclusions O
: O
azathioprine O
triggers O
suicidal O
erythrocyte O
death O
, O
an O
effect O
presumably O
contributing O
to O
azathioprine O
- O
induced O
anemia B-Disease
. O

levetiracetam O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
suspected O
idiopathic B-Disease
epilepsy I-Disease
. O

objective O
: O
to O
assess O
pharmacokinetics O
, O
efficacy O
, O
and O
tolerability O
of O
oral O
levetiracetam O
administered O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
poorly O
controlled O
suspected O
idiopathic B-Disease
epilepsy I-Disease
. O

design O
- O
open O
- O
label O
, O
noncomparative O
clinical O
trial O
. O

animals O
: O
12 O
cats O
suspected O
to O
have O
idiopathic B-Disease
epilepsy I-Disease
that O
was O
poorly O
controlled O
with O
phenobarbital O
or O
that O
had O
unacceptable O
adverse O
effects O
when O
treated O
with O
phenobarbital O
. O

procedures O
: O
cats O
were O
treated O
with O
levetiracetam O
( O
20 O
mg O
/ O
kg O
[ O
9 O
. O
1 O
mg O
/ O
lb O
] O
, O
po O
, O
q O
8 O
h O
) O
. O

after O
a O
minimum O
of O
1 O
week O
of O
treatment O
, O
serum O
levetiracetam O
concentrations O
were O
measured O
before O
and O
2 O
, O
4 O
, O
and O
6 O
hours O
after O
drug O
administration O
, O
and O
maximum O
and O
minimum O
serum O
concentrations O
and O
elimination O
half O
- O
life O
were O
calculated O
. O

seizure B-Disease
frequencies O
before O
and O
after O
initiation O
of O
levetiracetam O
treatment O
were O
compared O
, O
and O
adverse O
effects O
were O
recorded O
. O

results O
: O
median O
maximum O
serum O
levetiracetam O
concentration O
was O
25 O
. O
5 O
microg O
/ O
ml O
, O
median O
minimum O
serum O
levetiracetam O
concentration O
was O
8 O
. O
3 O
microg O
/ O
ml O
, O
and O
median O
elimination O
half O
- O
life O
was O
2 O
. O
9 O
hours O
. O

median O
seizure B-Disease
frequency O
prior O
to O
treatment O
with O
levetiracetam O
( O
2 O
. O
1 O
seizures B-Disease
/ O
mo O
) O
was O
significantly O
higher O
than O
median O
seizure B-Disease
frequency O
after O
initiation O
of O
levetiracetam O
treatment O
( O
0 O
. O
42 O
seizures B-Disease
/ O
mo O
) O
, O
and O
7 O
of O
10 O
cats O
were O
classified O
as O
having O
responded O
to O
levetiracetam O
treatment O
( O
ie O
, O
reduction O
in O
seizure B-Disease
frequency O
of O
> O
or O
= O
50 O
% O
) O
. O

two O
cats O
had O
transient O
lethargy B-Disease
and O
inappetence B-Disease
. O

conclusions O
and O
clinical O
relevance O
: O
results O
suggested O
that O
levetiracetam O
is O
well O
tolerated O
in O
cats O
and O
may O
be O
useful O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
idiopathic B-Disease
epilepsy I-Disease
. O

serotonin O
reuptake O
inhibitors O
, O
paranoia B-Disease
, O
and O
the O
ventral O
basal O
ganglia O
. O

antidepressants O
have O
previously O
been O
associated O
with O
paranoid B-Disease
reactions O
in O
psychiatric O
patients O
. O

five O
cases O
of O
paranoid B-Disease
exacerbation O
with O
the O
serotonin O
reuptake O
inhibitors O
fluoxetine O
and O
amitriptyline O
are O
reported O
here O
. O

elements O
common O
to O
these O
cases O
included O
a O
history O
of O
paranoid B-Disease
symptomatology O
and O
the O
concomitant O
occurrence O
of O
depressive B-Disease
and I-Disease
psychotic I-Disease
symptoms I-Disease
. O

complicated O
depressive B-Disease
disorders I-Disease
( O
including O
atypicality O
of O
course O
and O
symptomatology O
, O
chronicity O
, O
psychosis B-Disease
, O
bipolarity O
, O
and O
secondary O
onset O
in O
the O
course O
of O
a O
primary O
psychosis B-Disease
) O
may O
present O
particular O
vulnerability O
to O
paranoid B-Disease
exacerbations O
associated O
with O
serotonin O
reuptake O
inhibitors O
. O

although O
the O
pharmacology O
and O
neurobiology O
of O
paranoia B-Disease
remain O
cryptic O
, O
several O
mechanisms O
, O
including O
5ht3 O
receptor O
- O
mediated O
dopamine O
release O
, O
beta O
- O
noradrenergic O
receptor O
downregulation O
, O
or O
gabab O
receptor O
upregulation O
acting O
in O
the O
vicinity O
of O
the O
ventral O
basal O
ganglia O
( O
possibly O
in O
lateral O
orbitofrontal O
or O
anterior O
cingulate O
circuits O
) O
, O
might O
apply O
to O
this O
phenomenon O
. O

these O
cases O
call O
attention O
to O
possible O
paranoid B-Disease
exacerbations O
with O
serotonin O
reuptake O
blockers O
in O
select O
patients O
and O
raise O
neurobiological O
considerations O
regarding O
paranoia B-Disease
. O

clinical O
comparison O
of O
cardiorespiratory O
effects O
during O
unilateral O
and O
conventional O
spinal O
anaesthesia O
. O

background O
: O
spinal O
anaesthesia O
is O
widely O
employed O
in O
clinical O
practice O
but O
has O
the O
main O
drawback O
of O
post O
- O
spinal O
block O
hypotension B-Disease
. O

efforts O
must O
therefore O
continue O
to O
be O
made O
to O
obviate O
this O
setback O
objective O
: O
to O
evaluate O
the O
cardiovascular O
and O
respiratory O
changes O
during O
unilateral O
and O
conventional O
spinal O
anaesthesia O
. O

methods O
: O
with O
ethical O
approval O
, O
we O
studied O
74 O
american O
society O
of O
anesthesiologists O
( O
asa O
) O
, O
physical O
status O
class O
1 O
and O
2 O
patients O
scheduled O
for O
elective O
unilateral O
lower O
limb O
surgery O
. O

patients O
were O
randomly O
allocated O
into O
one O
of O
two O
groups O
: O
lateral O
and O
conventional O
spinal O
anaesthesia O
groups O
. O

in O
the O
lateral O
position O
with O
operative O
side O
down O
, O
patients O
recived O
10 O
mg O
( O
2mls O
) O
of O
0 O
. O
5 O
% O
hyperbaric O
bupivacaine O
through O
a O
25 O
- O
gauge O
spinal O
needle O
. O

patients O
in O
the O
unilateral O
group O
were O
maintained O
in O
the O
lateral O
position O
for O
15 O
minutes O
following O
spinal O
injection O
while O
those O
in O
the O
conventional O
group O
were O
turned O
supine O
immediately O
after O
injection O
. O

blood O
pressure O
, O
heart O
rate O
, O
respiratory O
rate O
and O
oxygen O
saturation O
were O
monitored O
over O
1 O
hour O
. O

results O
: O
three O
patients O
( O
8 O
. O
1 O
% O
) O
in O
the O
unilateral O
group O
and O
5 O
( O
13 O
. O
5 O
% O
) O
in O
the O
conventional O
group O
developed O
hypotension B-Disease
, O
p O
= O
0 O
. O
71 O
. O

four O
( O
10 O
. O
8 O
% O
) O
patients O
in O
the O
conventional O
group O
and O
1 O
( O
2 O
. O
7 O
% O
) O
in O
the O
unilateral O
group O
, O
p O
= O
0 O
. O
17 O
required O
epinephrine O
infusion O
to O
treat O
hypotension B-Disease
. O

patients O
in O
the O
conventional O
group O
had O
statistically O
significant O
greater O
fall O
in O
the O
systolic O
blood O
pressures O
at O
15 O
, O
30 O
and O
45 O
minutes O
when O
compared O
to O
the O
baseline O
( O
p O
= O
0 O
. O
003 O
, O
0 O
. O
001 O
and O
0 O
. O
004 O
) O
. O

the O
mean O
respiratory O
rate O
and O
oxygen O
saturations O
in O
the O
two O
groups O
were O
similar O
. O

conclusion O
: O
compared O
to O
conventional O
spinal O
anaesthesia O
, O
unilateral O
spinal O
anaesthesia O
was O
associated O
with O
fewer O
cardiovascular O
perturbations O
. O

also O
, O
the O
type O
of O
spinal O
block O
instituted O
affected O
neither O
the O
respiratory O
rate O
nor O
the O
arterial O
oxygen O
saturation O
. O

spectrum O
of O
adverse O
events O
after O
generic O
haart O
in O
southern O
indian O
hiv B-Disease
- I-Disease
infected I-Disease
patients O
. O

to O
determine O
the O
incidence O
of O
clinically O
significant O
adverse O
events O
after O
long O
- O
term O
, O
fixed O
- O
dose O
, O
generic O
highly O
active O
antiretroviral O
therapy O
( O
haart O
) O
use O
among O
hiv B-Disease
- I-Disease
infected I-Disease
individuals O
in O
south O
india O
, O
we O
examined O
the O
experiences O
of O
3154 O
hiv B-Disease
- I-Disease
infected I-Disease
individuals O
who O
received O
a O
minimum O
of O
3 O
months O
of O
generic O
haart O
between O
february O
1996 O
and O
december O
2006 O
at O
a O
tertiary O
hiv O
care O
referral O
center O
in O
south O
india O
. O

the O
most O
common O
regimens O
were O
3tc O
+ O
d4t O
+ O
nevirapine O
( O
nvp O
) O
( O
54 O
. O
8 O
% O
) O
, O
zidovudine O
( O
azt O
) O
+ O
3tc O
+ O
nvp O
( O
14 O
. O
5 O
% O
) O
, O
3tc O
+ O
d4t O
+ O
efavirenz O
( O
efv O
) O
( O
20 O
. O
1 O
% O
) O
, O
and O
azt O
+ O
3tc O
+ O
efv O
( O
5 O
. O
4 O
% O
) O
. O

the O
most O
common O
adverse O
events O
and O
median O
cd4 O
at O
time O
of O
event O
were O
rash B-Disease
( O
15 O
. O
2 O
% O
; O
cd4 O
, O
285 O
cells O
/ O
microl O
) O
and O
peripheral B-Disease
neuropathy I-Disease
( O
9 O
. O
0 O
% O
and O
348 O
cells O
/ O
microl O
) O
. O

clinically O
significant O
anemia B-Disease
( O
hemoglobin O
< O
7 O
g O
/ O
dl O
) O
was O
observed O
in O
5 O
. O
4 O
% O
of O
patients O
( O
cd4 O
, O
165 O
cells O
/ O
microl O
) O
and O
hepatitis B-Disease
( O
clinical O
jaundice B-Disease
with O
alanine O
aminotransferase O
> O
5 O
times O
upper O
limits O
of O
normal O
) O
in O
3 O
. O
5 O
% O
of O
patients O
( O
cd4 O
, O
260 O
cells O
/ O
microl O
) O
. O

women O
were O
significantly O
more O
likely O
to O
experience O
lactic B-Disease
acidosis I-Disease
, O
while O
men O
were O
significantly O
more O
likely O
to O
experience O
immune B-Disease
reconstitution I-Disease
syndrome I-Disease
( O
p O
< O
0 O
. O
05 O
) O
. O

among O
the O
patients O
with O
1 O
year O
of O
follow O
- O
up O
, O
nvp O
therapy O
was O
significantly O
associated O
with O
developing O
rash B-Disease
and O
d4t O
therapy O
with O
developing O
peripheral B-Disease
neuropathy I-Disease
( O
p O
< O
0 O
. O
05 O
) O
. O

anemia B-Disease
and O
hepatitis B-Disease
often O
occur O
within O
12 O
weeks O
of O
initiating O
generic O
haart O
. O

frequent O
and O
early O
monitoring O
for O
these O
toxicities B-Disease
is O
warranted O
in O
developing O
countries O
where O
generic O
haart O
is O
increasingly O
available O
. O

thalidomide O
and O
sensory B-Disease
neurotoxicity I-Disease
: O
a O
neurophysiological O
study O
. O

background O
: O
recent O
studies O
confirmed O
a O
high O
incidence O
of O
sensory B-Disease
axonal I-Disease
neuropathy I-Disease
in O
patients O
treated O
with O
different O
doses O
of O
thalidomide O
. O

the O
study O
' O
s O
aims O
were O
to O
measure O
variations O
in O
sural O
nerve O
sensory O
action O
potential O
( O
sap O
) O
amplitude O
in O
patients O
with O
refractory O
cutaneous B-Disease
lupus I-Disease
erythematosus I-Disease
( O
cle B-Disease
) O
treated O
with O
thalidomide O
and O
use O
these O
findings O
to O
identify O
the O
neurotoxic B-Disease
potential O
of O
thalidomide O
and O
the O
recovery O
capacity O
of O
sensory O
fibres O
after O
discontinuation O
of O
treatment O
. O

patients O
and O
methods O
: O
clinical O
and O
electrophysiological O
data O
in O
12 O
female O
patients O
with O
cle B-Disease
during O
treatment O
with O
thalidomide O
and O
up O
to O
47 O
months O
after O
discontinuation O
of O
treatment O
were O
analysed O
. O

sural O
nerve O
sap O
amplitude O
reduction O
> O
or O
= O
40 O
% O
was O
the O
criteria O
for O
discontinuing O
therapy O
. O

results O
: O
during O
treatment O
, O
11 O
patients O
showed O
a O
reduction O
in O
sural O
nerve O
sap O
amplitude O
compared O
to O
baseline O
values O
( O
9 O
with O
a O
reduction O
> O
or O
= O
50 O
% O
and O
2 O
< O
50 O
% O
) O
. O

one O
patient O
showed O
no O
changes O
in O
sap O
amplitude O
. O

five O
patients O
complained O
of O
paresthesias B-Disease
and O
leg O
cramps B-Disease
. O

after O
thalidomide O
treatment O
, O
sural O
sap O
amplitude O
recovered O
in O
3 O
patients O
. O

at O
detection O
of O
reduction O
in O
sural O
nerve O
sap O
amplitude O
, O
the O
median O
thalidomide O
cumulative O
dose O
was O
21 O
. O
4 O
g O
. O

the O
threshold O
neurotoxic B-Disease
dosage O
is O
lower O
than O
previously O
reported O
. O

conclusions O
: O
sural O
nerve O
sap O
amplitude O
reduction O
is O
a O
reliable O
and O
sensitive O
marker O
of O
degeneration O
and O
recovery O
of O
sensory O
fibres O
. O

this O
electrophysiological O
parameter O
provides O
information O
about O
subclinical O
neurotoxic B-Disease
potential O
of O
thalidomide O
but O
is O
not O
helpful O
in O
predicting O
the O
appearance O
of O
sensory O
symptoms O
. O

five O
cases O
of O
encephalitis B-Disease
during O
treatment O
of O
loiasis B-Disease
with O
diethylcarbamazine O
. O

five O
cases O
of O
encephalitis B-Disease
following O
treatment O
with O
diethylcarbamazine O
( O
dec O
) O
were O
observed O
in O
congolese O
patients O
with O
loa O
loa O
filariasis B-Disease
. O

two O
cases O
had O
a O
fatal O
outcome O
and O
one O
resulted O
in O
severe O
sequelae O
. O

the O
notable O
fact O
was O
that O
this O
complication O
occurred O
in O
three O
patients O
hospitalized O
before O
treatment O
began O
, O
with O
whom O
particularly O
strict O
therapeutic O
precautions O
were O
taken O
, O
i O
. O
e O
. O
, O
initial O
dose O
less O
than O
10 O
mg O
of O
dec O
, O
very O
gradual O
dose O
increases O
, O
and O
associated O
anti O
- O
allergic O
treatment O
. O

this O
type O
of O
drug O
- O
induced O
complication O
may O
not O
be O
that O
uncommon O
in O
highly O
endemic O
regions O
. O

it O
occurs O
primarily O
, O
but O
not O
exclusively O
, O
in O
subjects O
presenting O
with O
a O
high O
microfilarial O
load O
. O

the O
relationship O
between O
the O
occurrence O
of O
encephalitis B-Disease
and O
the O
decrease O
in O
microfilaremia B-Disease
is O
evident O
. O

the O
pathophysiological O
mechanisms O
are O
discussed O
in O
the O
light O
of O
these O
observations O
and O
the O
few O
other O
comments O
on O
this O
subject O
published O
in O
the O
literature O
. O

amiodarone O
- O
related O
pulmonary B-Disease
mass I-Disease
and O
unique O
membranous B-Disease
glomerulonephritis I-Disease
in O
a O
patient O
with O
valvular B-Disease
heart I-Disease
disease I-Disease
: O
diagnostic O
pitfall O
and O
new O
findings O
. O

amiodarone O
is O
an O
anti O
- O
arrhythmic B-Disease
drug O
for O
life O
- O
threatening O
tachycardia B-Disease
, O
but O
various O
adverse O
effects O
have O
been O
reported O
. O

reported O
herein O
is O
an O
autopsy O
case O
of O
valvular B-Disease
heart I-Disease
disease I-Disease
, O
in O
a O
patient O
who O
developed O
a O
lung B-Disease
mass I-Disease
( O
1 O
. O
5 O
cm O
in O
diameter O
) O
and O
proteinuria B-Disease
( O
2 O
. O
76 O
g O
/ O
day O
) O
after O
treatment O
with O
amiodarone O
for O
a O
long O
time O
. O

the O
lung B-Disease
mass I-Disease
was O
highly O
suspected O
to O
be O
lung B-Disease
cancer I-Disease
on O
ct O
and O
positron O
emission O
tomography O
, O
but O
histologically O
the O
lesion O
was O
composed O
of O
lymphoplasmacytic O
infiltrates O
in O
alveolar O
walls O
and O
intra O
- O
alveolar O
accumulation O
of O
foamy O
macrophages O
containing O
characteristic O
myelinoid O
bodies O
, O
indicating O
that O
it O
was O
an O
amiodarone O
- O
related O
lesion O
. O

in O
addition O
, O
the O
lung O
tissue O
had O
unevenly O
distributed O
hemosiderin B-Disease
deposition O
, O
and O
abnormally O
tortuous O
capillaries O
were O
seen O
in O
the O
mass O
and O
in O
heavily O
hemosiderotic B-Disease
lung O
portions O
outside O
the O
mass O
. O

in O
the O
kidneys O
, O
glomeruli O
had O
membrane O
spikes O
, O
prominent O
swelling O
of O
podocytes O
and O
subepithelial O
deposits O
, O
which O
were O
sometimes O
large O
and O
hump O
- O
like O
. O

autoimmune B-Disease
diseases I-Disease
, O
viral B-Disease
hepatitis I-Disease
, O
malignant O
neoplasms B-Disease
or O
other O
diseases O
with O
a O
known O
relationship O
to O
membranous B-Disease
glomerulonephritis I-Disease
were O
not O
found O
. O

the O
present O
case O
highlights O
the O
possibility O
that O
differential O
diagnosis O
between O
an O
amiodarone O
- O
related O
pulmonary B-Disease
lesion I-Disease
and O
a O
neoplasm B-Disease
can O
be O
very O
difficult O
radiologically O
, O
and O
suggests O
that O
membranous B-Disease
glomerulonephritis I-Disease
might O
be O
another O
possible O
complication O
of O
amiodarone O
treatment O
. O

risk O
of O
coronary B-Disease
artery I-Disease
disease I-Disease
associated O
with O
initial O
sulphonylurea O
treatment O
of O
patients O
with O
type B-Disease
2 I-Disease
diabetes I-Disease
: O
a O
matched O
case O
- O
control O
study O
. O

aims O
: O
this O
study O
sought O
to O
assess O
the O
risk O
of O
developing O
coronary B-Disease
artery I-Disease
disease I-Disease
( O
cad B-Disease
) O
associated O
with O
initial O
treatment O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
with O
different O
sulphonylureas O
. O

methods O
: O
in O
type B-Disease
2 I-Disease
diabetic I-Disease
patients O
, O
cases O
who O
developed O
cad B-Disease
were O
compared O
retrospectively O
with O
controls O
that O
did O
not O
. O

the O
20 O
- O
year O
risk O
of O
cad B-Disease
at O
diagnosis O
of O
diabetes B-Disease
, O
using O
the O
ukpds O
risk O
engine O
, O
was O
used O
to O
match O
cases O
with O
controls O
. O

results O
: O
the O
76 O
cases O
of O
cad B-Disease
were O
compared O
with O
152 O
controls O
. O

the O
hazard O
of O
developing O
cad B-Disease
( O
95 O
% O
ci O
) O
associated O
with O
initial O
treatment O
increased O
by O
2 O
. O
4 O
- O
fold O
( O
1 O
. O
3 O
- O
4 O
. O
3 O
, O
p O
= O
0 O
. O
004 O
) O
with O
glibenclamide O
; O
2 O
- O
fold O
( O
0 O
. O
9 O
- O
4 O
. O
6 O
, O
p O
= O
0 O
. O
099 O
) O
with O
glipizide O
; O
2 O
. O
9 O
- O
fold O
( O
1 O
. O
6 O
- O
5 O
. O
1 O
, O
p O
= O
0 O
. O
000 O
) O
with O
either O
, O
and O
was O
unchanged O
with O
metformin O
. O

the O
hazard O
decreased O
0 O
. O
3 O
- O
fold O
( O
0 O
. O
7 O
- O
1 O
. O
7 O
, O
p O
= O
0 O
. O
385 O
) O
with O
glimepiride O
, O
0 O
. O
4 O
- O
fold O
( O
0 O
. O
7 O
- O
1 O
. O
3 O
, O
p O
= O
0 O
. O
192 O
) O
with O
gliclazide O
, O
and O
0 O
. O
4 O
- O
fold O
( O
0 O
. O
7 O
- O
1 O
. O
1 O
, O
p O
= O
0 O
. O
09 O
) O
with O
either O
. O

conclusions O
: O
initiating O
treatment O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
with O
glibenclamide O
or O
glipizide O
is O
associated O
with O
increased O
risk O
of O
cad B-Disease
in O
comparison O
to O
gliclazide O
or O
glimepiride O
. O

if O
confirmed O
, O
this O
may O
be O
important O
because O
most O
indian O
patients O
receive O
the O
cheaper O
older O
sulphonylureas O
, O
and O
present O
guidelines O
do O
not O
distinguish O
between O
individual O
agents O
. O

reduced O
progression O
of O
adriamycin O
nephropathy B-Disease
in O
spontaneously O
hypertensive B-Disease
rats O
treated O
by O
losartan O
. O

background O
: O
the O
aim O
of O
the O
study O
was O
to O
investigate O
the O
antihypertensive O
effects O
of O
angiotensin O
ii O
type O
- O
1 O
receptor O
blocker O
, O
losartan O
, O
and O
its O
potential O
in O
slowing O
down O
renal B-Disease
disease I-Disease
progression O
in O
spontaneously O
hypertensive B-Disease
rats O
( O
shr O
) O
with O
adriamycin O
( O
adr O
) O
nephropathy B-Disease
. O

methods O
: O
six O
- O
month O
- O
old O
female O
shr O
were O
randomly O
selected O
in O
six O
groups O
. O

two O
control O
groups O
( O
sh O
( O
6 O
) O
, O
sh O
( O
12 O
) O
) O
received O
vehicle O
. O

groups O
adr O
( O
6 O
) O
, O
adr O
+ O
los O
( O
6 O
) O
and O
adr O
( O
12 O
) O
, O
and O
adr O
+ O
los O
( O
12 O
) O
received O
adr O
( O
2 O
mg O
/ O
kg O
/ O
b O
. O
w O
. O
i O
. O
v O
. O
) O
twice O
in O
a O
3 O
- O
week O
interval O
. O

group O
adr O
+ O
los O
( O
6 O
) O
received O
losartan O
( O
10 O
mg O
/ O
kg O
/ O
b O
. O
w O
. O
/ O
day O
by O
gavages O
) O
for O
6 O
weeks O
and O
group O
adr O
+ O
los O
( O
12 O
) O
for O
12 O
weeks O
after O
second O
injection O
of O
adr O
. O

animals O
were O
killed O
after O
6 O
or O
12 O
weeks O
, O
respectively O
. O

haemodynamic O
measurements O
were O
performed O
on O
anaesthetized O
animals O
, O
blood O
and O
urine O
samples O
were O
taken O
for O
biochemical O
analysis O
and O
the O
left O
kidney O
was O
processed O
for O
morphological O
studies O
. O

results O
: O
short O
- O
term O
losartan O
treatment O
, O
besides O
antihypertensive O
effect O
, O
improved O
glomerular O
filtration O
rate O
and O
ameliorated O
glomerulosclerosis B-Disease
resulting O
in O
decreased O
proteinuria B-Disease
. O

prolonged O
treatment O
with O
losartan O
showed O
further O
reduction O
of O
glomerulosclerosis B-Disease
associated O
with O
reduced O
progression O
of O
tubular O
atrophy B-Disease
and O
interstitial B-Disease
fibrosis I-Disease
, O
thus O
preventing O
heavy O
proteinuria B-Disease
and O
chronic B-Disease
renal I-Disease
failure I-Disease
. O

losartan O
reduced O
uraemia B-Disease
and O
increased O
urea O
clearance O
in O
advanced O
adr O
nephropathy B-Disease
in O
shr O
. O

histological O
examination O
showed O
that O
losartan O
could O
prevent O
tubular O
atrophy B-Disease
, O
interstitial O
infiltration O
and O
fibrosis B-Disease
in O
adr O
nephropathy B-Disease
. O

conclusion O
: O
losartan O
reduces O
the O
rate O
of O
progression O
of O
adr O
- O
induced O
focal B-Disease
segmental I-Disease
glomerulosclerosis I-Disease
to O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
in O
shr O
. O

the O
risks O
of O
aprotinin O
and O
tranexamic O
acid O
in O
cardiac O
surgery O
: O
a O
one O
- O
year O
follow O
- O
up O
of O
1188 O
consecutive O
patients O
. O

background O
: O
our O
aim O
was O
to O
investigate O
postoperative O
complications O
and O
mortality O
after O
administration O
of O
aprotinin O
compared O
to O
tranexamic O
acid O
in O
an O
unselected O
, O
consecutive O
cohort O
. O

methods O
: O
perioperative O
data O
from O
consecutive O
cardiac O
surgery O
patients O
were O
prospectively O
collected O
between O
september O
2005 O
and O
june O
2006 O
in O
a O
university O
- O
affiliated O
clinic O
( O
n O
= O
1188 O
) O
. O

during O
the O
first O
5 O
mo O
, O
596 O
patients O
received O
aprotinin O
( O
group O
a O
) O
; O
in O
the O
next O
5 O
mo O
, O
592 O
patients O
were O
treated O
with O
tranexamic O
acid O
( O
group O
t O
) O
. O

except O
for O
antifibrinolytic O
therapy O
, O
the O
anesthetic O
and O
surgical O
protocols O
remained O
unchanged O
. O

results O
: O
the O
pre O
- O
and O
intraoperative O
variables O
were O
comparable O
between O
the O
treatment O
groups O
. O

postoperatively O
, O
a O
significantly O
higher O
incidence O
of O
seizures B-Disease
was O
found O
in O
group O
t O
( O
4 O
. O
6 O
% O
vs O
1 O
. O
2 O
% O
, O
p O
< O
0 O
. O
001 O
) O
. O

this O
difference O
was O
also O
significant O
in O
the O
primary O
valve O
surgery O
and O
the O
high O
risk O
surgery O
subgroups O
( O
7 O
. O
9 O
% O
vs O
1 O
. O
2 O
% O
, O
p O
= O
0 O
. O
003 O
; O
7 O
. O
3 O
% O
vs O
2 O
. O
4 O
% O
, O
p O
= O
0 O
. O
035 O
, O
respectively O
) O
. O

persistent O
atrial O
fibrillation O
( O
7 O
. O
9 O
% O
vs O
2 O
. O
3 O
% O
, O
p O
= O
0 O
. O
020 O
) O
and O
renal B-Disease
failure I-Disease
( O
9 O
. O
7 O
% O
vs O
1 O
. O
7 O
% O
, O
p O
= O
0 O
. O
002 O
) O
were O
also O
more O
common O
in O
group O
t O
, O
in O
the O
primary O
valve O
surgery O
subgroup O
. O

on O
the O
contrary O
, O
among O
primary O
coronary O
artery O
bypass O
surgery O
patients O
, O
there O
were O
more O
acute O
myocardial B-Disease
infarctions I-Disease
and O
renal B-Disease
dysfunction I-Disease
in O
group O
a O
( O
5 O
. O
8 O
% O
vs O
2 O
. O
0 O
% O
, O
p O
= O
0 O
. O
027 O
; O
22 O
. O
5 O
% O
vs O
15 O
. O
2 O
% O
, O
p O
= O
0 O
. O
036 O
, O
respectively O
) O
. O

the O
1 O
- O
yr O
mortality O
was O
significantly O
higher O
after O
aprotinin O
treatment O
in O
the O
high O
risk O
surgery O
group O
( O
17 O
. O
7 O
% O
vs O
9 O
. O
8 O
% O
, O
p O
= O
0 O
. O
034 O
) O
. O

conclusion O
: O
both O
antifibrinolytic O
drugs O
bear O
the O
risk O
of O
adverse O
outcome O
depending O
on O
the O
type O
of O
cardiac O
surgery O
. O

administration O
of O
aprotinin O
should O
be O
avoided O
in O
coronary O
artery O
bypass O
graft O
and O
high O
risk O
patients O
, O
whereas O
administration O
of O
tranexamic O
acid O
is O
not O
recommended O
in O
valve O
surgery O
. O

delirium B-Disease
in O
an O
elderly O
woman O
possibly O
associated O
with O
administration O
of O
misoprostol O
. O

misoprostol O
has O
been O
associated O
with O
adverse O
reactions O
, O
including O
gastrointestinal O
symptoms O
, O
gynecologic O
problems O
, O
and O
headache B-Disease
. O

changes O
in O
mental O
status O
, O
however O
, O
have O
not O
been O
reported O
. O

we O
present O
a O
case O
in O
which O
an O
89 O
- O
year O
- O
old O
woman O
in O
a O
long O
- O
term O
care O
facility O
became O
confused O
after O
the O
initiation O
of O
misoprostol O
therapy O
. O

the O
patient O
' O
s O
change O
in O
mental O
status O
was O
first O
reported O
nine O
days O
after O
the O
initiation O
of O
therapy O
. O

her O
delirium B-Disease
significantly O
improved O
after O
misoprostol O
was O
discontinued O
and O
her O
mental O
status O
returned O
to O
normal O
within O
a O
week O
. O

because O
no O
other O
factors O
related O
to O
this O
patient O
changed O
significantly O
, O
the O
delirium B-Disease
experienced O
by O
this O
patient O
possibly O
resulted O
from O
misoprostol O
therapy O
. O

the O
biological O
properties O
of O
the O
optical O
isomers O
of O
propranolol O
and O
their O
effects O
on O
cardiac B-Disease
arrhythmias I-Disease
. O

1 O
. O

the O
optical O
isomers O
of O
propranolol O
have O
been O
compared O
for O
their O
beta O
- O
blocking O
and O
antiarrhythmic O
activities O
. O
2 O
. O

in O
blocking O
the O
positive O
inotropic O
and O
chronotropic O
responses O
to O
isoprenaline O
, O
( O
+ O
) O
- O
propranolol O
had O
less O
than O
one O
hundredth O
the O
potency O
of O
( O
- O
) O
- O
propranolol O
. O

at O
dose O
levels O
of O
( O
+ O
) O
- O
propranolol O
which O
attenuated O
the O
responses O
to O
isoprenaline O
, O
there O
was O
a O
significant O
prolongation O
of O
the O
pr O
interval O
of O
the O
electrocardiogram O
. O
3 O
. O

the O
metabolic O
responses O
to O
isoprenaline O
in O
dogs O
( O
an O
increase O
in O
circulating O
glucose O
, O
lactate O
and O
free O
fatty O
acids O
) O
were O
all O
blocked O
by O
( O
- O
) O
- O
propranolol O
. O

( O
+ O
) O
- O
propranolol O
had O
no O
effect O
on O
fatty O
acid O
mobilization O
but O
significantly O
reduced O
the O
increments O
in O
both O
lactate O
and O
glucose O
. O
4 O
. O

both O
isomers O
of O
propranolol O
possessed O
similar O
depressant O
potency O
on O
isolated O
atrial O
muscle O
taken O
from O
guinea O
- O
pigs O
. O
5 O
. O

the O
isomers O
of O
propranolol O
exhibited O
similar O
local O
anaesthetic O
potencies O
on O
an O
isolated O
frog O
nerve O
preparation O
at O
a O
level O
approximately O
three O
times O
that O
of O
procaine O
. O

the O
racemic O
compound O
was O
significantly O
less O
potent O
than O
either O
isomer O
. O
6 O
. O

both O
isomers O
of O
propranolol O
were O
capable O
of O
preventing O
adrenaline O
- O
induced O
cardiac B-Disease
arrhythmias I-Disease
in O
cats O
anaesthetized O
with O
halothane O
, O
but O
the O
mean O
dose O
of O
( O
- O
) O
- O
propranolol O
was O
0 O
. O
09 O
+ O
/ O
- O
0 O
. O
02 O
mg O
/ O
kg O
whereas O
that O
of O
( O
+ O
) O
- O
propranolol O
was O
4 O
. O
2 O
+ O
/ O
- O
1 O
. O
2 O
mg O
/ O
kg O
. O

at O
the O
effective O
dose O
level O
of O
( O
+ O
) O
- O
propranolol O
there O
was O
a O
significant O
prolongation O
of O
the O
pr O
interval O
of O
the O
electrocardiogram O
. O

blockade O
of O
arrhythmias B-Disease
with O
both O
isomers O
was O
surmountable O
by O
increasing O
the O
dose O
of O
adrenaline O
. O
7 O
. O

both O
isomers O
of O
propranolol O
were O
also O
capable O
of O
reversing O
ventricular B-Disease
tachycardia I-Disease
caused O
by O
ouabain O
in O
anaesthetized O
cats O
and O
dogs O
. O

the O
dose O
of O
( O
- O
) O
- O
propranolol O
was O
significantly O
smaller O
than O
that O
of O
( O
+ O
) O
- O
propranolol O
in O
both O
species O
but O
much O
higher O
than O
that O
required O
to O
produce O
evidence O
of O
beta O
- O
blockade O
. O
8 O
. O

the O
implications O
of O
these O
results O
are O
discussed O
. O

topotecan O
in O
combination O
with O
radiotherapy O
in O
unresectable O
glioblastoma B-Disease
: O
a O
phase O
2 O
study O
. O

improving O
glioblastoma B-Disease
multiforme I-Disease
( O
gbm B-Disease
) O
treatment O
with O
radio O
- O
chemotherapy O
remains O
a O
challenge O
. O

topotecan O
is O
an O
attractive O
option O
as O
it O
exhibits O
growth O
inhibition O
of O
human O
glioma B-Disease
as O
well O
as O
brain O
penetration O
. O

the O
present O
study O
assessed O
the O
combination O
of O
radiotherapy O
( O
60 O
gy O
/ O
30 O
fractions O
/ O
40 O
days O
) O
and O
topotecan O
( O
0 O
. O
9 O
mg O
/ O
m O
( O
2 O
) O
/ O
day O
on O
days O
1 O
- O
5 O
on O
weeks O
1 O
, O
3 O
and O
5 O
) O
in O
50 O
adults O
with O
histologically O
proven O
and O
untreated O
gbm B-Disease
. O

the O
incidence O
of O
non O
- O
hematological O
toxicities B-Disease
was O
low O
and O
grade O
3 O
- O
4 O
hematological O
toxicities B-Disease
were O
reported O
in O
20 O
patients O
( O
mainly O
lymphopenia B-Disease
and O
neutropenia B-Disease
) O
. O

partial O
response O
and O
stabilization O
rates O
were O
2 O
% O
and O
32 O
% O
, O
respectively O
, O
with O
an O
overall O
time O
to O
progression O
of O
12 O
weeks O
. O

one O
- O
year O
overall O
survival O
( O
os O
) O
rate O
was O
42 O
% O
, O
with O
a O
median O
os O
of O
40 O
weeks O
. O

topotecan O
in O
combination O
with O
radiotherapy O
was O
well O
tolerated O
. O

however O
, O
while O
response O
and O
stabilization O
concerned O
one O
- O
third O
of O
the O
patients O
, O
the O
study O
did O
not O
show O
increased O
benefits O
in O
terms O
of O
survival O
in O
patients O
with O
unresectable O
gbm B-Disease
. O

long O
- O
term O
lithium O
therapy O
leading O
to O
hyperparathyroidism B-Disease
: O
a O
case O
report O
. O

purpose O
: O
this O
paper O
reviews O
the O
effect O
of O
chronic O
lithium O
therapy O
on O
serum O
calcium O
level O
and O
parathyroid O
glands O
, O
its O
pathogenesis O
, O
and O
treatment O
options O
. O

we O
examined O
the O
case O
of O
a O
lithium O
- O
treated O
patient O
who O
had O
recurrent O
hypercalcemia B-Disease
to O
better O
understand O
the O
disease O
process O
. O

conclusion O
: O
primary B-Disease
hyperparathyroidism I-Disease
is O
a O
rare O
but O
potentially O
life O
- O
threatening O
side O
effect O
of O
long O
- O
term O
lithium O
therapy O
. O

careful O
patient O
selection O
and O
long O
- O
term O
follow O
- O
up O
can O
reduce O
morbidity O
. O

practical O
implications O
: O
as O
much O
as O
15 O
% O
of O
lithium O
- O
treated O
patients O
become O
hypercalcemic B-Disease
. O

by O
routinely O
monitoring O
serum O
calcium O
levels O
, O
healthcare O
providers O
can O
improve O
the O
quality O
of O
life O
of O
this O
patient O
group O
. O

comparison O
of O
laryngeal O
mask O
with O
endotracheal O
tube O
for O
anesthesia O
in O
endoscopic O
sinus O
surgery O
. O

background O
: O
the O
purpose O
of O
this O
study O
was O
to O
compare O
surgical O
conditions O
, O
including O
the O
amount O
of O
intraoperative O
bleeding B-Disease
as O
well O
as O
intraoperative O
blood O
pressure O
, O
during O
functional O
endoscopic O
sinus O
surgery O
( O
fess O
) O
using O
flexible O
reinforced O
laryngeal O
mask O
airway O
( O
frlma O
) O
versus O
endotracheal O
tube O
( O
ett O
) O
in O
maintaining O
controlled O
hypotension B-Disease
anesthesia O
induced O
by O
propofol O
- O
remifentanil O
total O
i O
. O
v O
. O
anesthesia O
( O
tiva O
) O
. O

methods O
: O
sixty O
normotensive O
american O
society O
of O
anesthesiologists O
i O
- O
ii O
adult O
patients O
undergoing O
fess O
under O
controlled O
hypotension B-Disease
anesthesia O
caused O
by O
propofol O
- O
remifentanil O
- O
tiva O
were O
randomly O
assigned O
into O
two O
groups O
: O
group O
i O
, O
frlma O
; O
group O
ii O
, O
ett O
. O

hemorrhage B-Disease
was O
measured O
and O
the O
visibility O
of O
the O
operative O
field O
was O
evaluated O
according O
to O
a O
six O
- O
point O
scale O
. O

results O
: O
controlled O
hypotension B-Disease
was O
achieved O
within O
a O
shorter O
period O
using O
laryngeal O
mask O
using O
lower O
rates O
of O
remifentanil O
infusion O
and O
lower O
total O
dose O
of O
remifentanil O
. O

conclusion O
: O
in O
summary O
, O
our O
results O
indicate O
that O
airway O
management O
using O
frlma O
during O
controlled O
hypotension B-Disease
anesthesia O
provided O
better O
surgical O
conditions O
in O
terms O
of O
quality O
of O
operative O
field O
and O
blood O
loss O
and O
allowed O
for O
convenient O
induced O
hypotension B-Disease
with O
low O
doses O
of O
remifentanil O
during O
tiva O
in O
patients O
undergoing O
fess O
. O

nonalcoholic B-Disease
fatty I-Disease
liver I-Disease
disease I-Disease
during O
valproate O
therapy O
. O

valproic O
acid O
( O
vpa O
) O
is O
effective O
for O
the O
treatment O
of O
many O
types O
of O
epilepsy B-Disease
, O
but O
its O
use O
can O
be O
associated O
with O
an O
increase O
in O
body O
weight O
. O

we O
report O
a O
case O
of O
nonalcoholic B-Disease
fatty I-Disease
liver I-Disease
disease I-Disease
( O
nafld B-Disease
) O
arising O
in O
a O
child O
who O
developed O
obesity B-Disease
during O
vpa O
treatment O
. O

laboratory O
data O
revealed O
hyperinsulinemia B-Disease
with O
insulin B-Disease
resistance I-Disease
. O

after O
the O
withdrawal O
of O
vpa O
therapy O
, O
our O
patient O
showed O
a O
significant O
weight B-Disease
loss I-Disease
, O
a O
decrease O
of O
body O
mass O
index O
, O
and O
normalization O
of O
metabolic O
and O
endocrine O
parameters O
; O
moreover O
, O
ultrasound O
measurements O
showed O
a O
complete O
normalization O
. O

the O
present O
case O
suggests O
that O
obesity B-Disease
, O
hyperinsulinemia B-Disease
, O
insulin B-Disease
resistance I-Disease
, O
and O
long O
- O
term O
treatment O
with O
vpa O
may O
be O
all O
associated O
with O
the O
development O
of O
nafld B-Disease
; O
this O
side O
effect O
is O
reversible O
after O
vpa O
withdrawal O
. O

carbimazole O
induced O
anca B-Disease
positive I-Disease
vasculitis I-Disease
. O

anti O
- O
thyroid O
drugs O
, O
like O
carbimazole O
and O
propylthiouracil O
( O
ptu O
) O
are O
commonly O
prescribed O
for O
the O
treatment O
of O
hyperthyroidism B-Disease
. O

one O
should O
be O
aware O
of O
the O
side O
effects O
of O
antithyroid O
medications O
. O

antineutrophil B-Disease
cytoplasmic I-Disease
antibody I-Disease
( I-Disease
anca I-Disease
) I-Disease
- I-Disease
- I-Disease
associated I-Disease
vasculitis I-Disease
is O
a O
potentially O
life O
- O
threatening O
adverse O
effect O
of O
antithyroidmedications O
. O

we O
report O
a O
patient O
with O
graves B-Disease
' I-Disease
disease I-Disease
who O
developed O
anca O
positive O
carbimazole O
induced O
vasculitis B-Disease
. O

the O
episode O
was O
characterized O
by O
a O
vasculitic B-Disease
skin B-Disease
rash I-Disease
associated O
with O
large O
joint O
arthritis B-Disease
, O
pyrexia B-Disease
and O
parotiditis B-Disease
but O
no O
renal O
or O
pulmonary O
involvement O
. O

he O
was O
referred O
to O
us O
for O
neurological O
evaluation O
because O
he O
had O
difficulty O
in O
getting O
up O
from O
squatting O
position O
and O
was O
suspected O
to O
have O
myositis B-Disease
. O

carbimazole O
and O
methimazole O
have O
a O
lower O
incidence O
of O
reported O
anca O
positive O
side O
effects O
than O
put O
. O

to O
the O
best O
of O
our O
knowledge O
this O
is O
the O
first O
anca O
positive O
carbimazole O
induced O
vasculitis B-Disease
case O
reported O
from O
india O
. O

aspirin O
for O
the O
primary O
prevention O
of O
cardiovascular O
events O
: O
an O
update O
of O
the O
evidence O
for O
the O
u O
. O
s O
. O

preventive O
services O
task O
force O
. O

background O
: O
coronary B-Disease
heart I-Disease
disease I-Disease
and O
cerebrovascular B-Disease
disease I-Disease
are O
leading O
causes O
of O
death O
in O
the O
united O
states O
. O

in O
2002 O
, O
the O
u O
. O
s O
. O

preventive O
services O
task O
force O
( O
uspstf O
) O
strongly O
recommended O
that O
clinicians O
discuss O
aspirin O
with O
adults O
who O
are O
at O
increased O
risk O
for O
coronary B-Disease
heart I-Disease
disease I-Disease
. O

purpose O
: O
to O
determine O
the O
benefits O
and O
harms O
of O
taking O
aspirin O
for O
the O
primary O
prevention O
of O
myocardial B-Disease
infarctions I-Disease
, O
strokes B-Disease
, O
and O
death O
. O

data O
sources O
: O
medline O
and O
cochrane O
library O
( O
search O
dates O
, O
1 O
january O
2001 O
to O
28 O
august O
2008 O
) O
, O
recent O
systematic O
reviews O
, O
reference O
lists O
of O
retrieved O
articles O
, O
and O
suggestions O
from O
experts O
. O

study O
selection O
: O
english O
- O
language O
randomized O
, O
controlled O
trials O
( O
rcts O
) O
; O
case O
- O
control O
studies O
; O
meta O
- O
analyses O
; O
and O
systematic O
reviews O
of O
aspirin O
versus O
control O
for O
the O
primary O
prevention O
of O
cardiovascular B-Disease
disease I-Disease
( O
cvd B-Disease
) O
were O
selected O
to O
answer O
the O
following O
questions O
: O
does O
aspirin O
decrease O
coronary O
heart O
events O
, O
strokes B-Disease
, O
death O
from O
coronary O
heart O
events O
or O
stroke B-Disease
, O
or O
all O
- O
cause O
mortality O
in O
adults O
without O
known O
cvd B-Disease
? O

does O
aspirin O
increase O
gastrointestinal B-Disease
bleeding I-Disease
or O
hemorrhagic B-Disease
strokes I-Disease
? O

data O
extraction O
: O
all O
studies O
were O
reviewed O
, O
abstracted O
, O
and O
rated O
for O
quality O
by O
using O
predefined O
uspstf O
criteria O
. O

data O
synthesis O
: O
new O
evidence O
from O
1 O
good O
- O
quality O
rct O
, O
1 O
good O
- O
quality O
meta O
- O
analysis O
, O
and O
2 O
fair O
- O
quality O
subanalyses O
of O
rcts O
demonstrates O
that O
aspirin O
use O
reduces O
the O
number O
of O
cvd B-Disease
events O
in O
patients O
without O
known O
cvd B-Disease
. O

men O
in O
these O
studies O
experienced O
fewer O
myocardial B-Disease
infarctions I-Disease
and O
women O
experienced O
fewer O
ischemic O
strokes B-Disease
. O

aspirin O
does O
not O
seem O
to O
affect O
cvd B-Disease
mortality O
or O
all O
- O
cause O
mortality O
in O
either O
men O
or O
women O
. O

the O
use O
of O
aspirin O
for O
primary O
prevention O
increases O
the O
risk O
for O
major O
bleeding B-Disease
events O
, O
primarily O
gastrointestinal B-Disease
bleeding I-Disease
events O
, O
in O
both O
men O
and O
women O
. O

men O
have O
an O
increased O
risk O
for O
hemorrhagic B-Disease
strokes I-Disease
with O
aspirin O
use O
. O

a O
new O
rct O
and O
meta O
- O
analysis O
suggest O
that O
the O
risk O
for O
hemorrhagic B-Disease
strokes I-Disease
in O
women O
is O
not O
statistically O
significantly O
increased O
. O

limitations O
: O
new O
evidence O
on O
aspirin O
for O
the O
primary O
prevention O
of O
cvd B-Disease
is O
limited O
. O

the O
dose O
of O
aspirin O
used O
in O
the O
rcts O
varied O
, O
which O
prevented O
the O
estimation O
of O
the O
most O
appropriate O
dose O
for O
primary O
prevention O
. O

several O
of O
the O
rcts O
were O
conducted O
within O
populations O
of O
health O
professionals O
, O
which O
potentially O
limits O
generalizability O
. O

conclusion O
: O
aspirin O
reduces O
the O
risk O
for O
myocardial B-Disease
infarction I-Disease
in O
men O
and O
strokes B-Disease
in O
women O
. O

aspirin O
use O
increases O
the O
risk O
for O
serious O
bleeding B-Disease
events O
. O

reducing O
harm O
associated O
with O
anticoagulation O
: O
practical O
considerations O
of O
argatroban O
therapy O
in O
heparin O
- O
induced O
thrombocytopenia B-Disease
. O

argatroban O
is O
a O
hepatically O
metabolized O
, O
direct O
thrombin O
inhibitor O
used O
for O
prophylaxis O
or O
treatment O
of O
thrombosis B-Disease
in O
heparin O
- O
induced O
thrombocytopenia B-Disease
( O
hit B-Disease
) O
and O
for O
patients O
with O
or O
at O
risk O
of O
hit B-Disease
undergoing O
percutaneous O
coronary O
intervention O
( O
pci O
) O
. O

the O
objective O
of O
this O
review O
is O
to O
summarize O
practical O
considerations O
of O
argatroban O
therapy O
in O
hit B-Disease
. O

the O
us O
fda O
- O
recommended O
argatroban O
dose O
in O
hit B-Disease
is O
2 O
microg O
/ O
kg O
/ O
min O
( O
reduced O
in O
patients O
with O
hepatic B-Disease
impairment I-Disease
and O
in O
paediatric O
patients O
) O
, O
adjusted O
to O
achieve O
activated O
partial O
thromboplastin O
times O
( O
aptts O
) O
1 O
. O
5 O
- O
3 O
times O
baseline O
( O
not O
> O
100 O
seconds O
) O
. O

contemporary O
experiences O
indicate O
that O
reduced O
doses O
are O
also O
needed O
in O
patients O
with O
conditions O
associated O
with O
hepatic O
hypoperfusion O
, O
e O
. O
g O
. O
heart B-Disease
failure I-Disease
, O
yet O
are O
unnecessary O
for O
renal B-Disease
dysfunction I-Disease
, O
adult O
age O
, O
sex O
, O
race O
/ O
ethnicity O
or O
obesity B-Disease
. O

argatroban O
0 O
. O
5 O
- O
1 O
. O
2 O
microg O
/ O
kg O
/ O
min O
typically O
supports O
therapeutic O
aptts O
. O

the O
fda O
- O
recommended O
dose O
during O
pci O
is O
25 O
microg O
/ O
kg O
/ O
min O
( O
350 O
microg O
/ O
kg O
initial O
bolus O
) O
, O
adjusted O
to O
achieve O
activated O
clotting O
times O
( O
acts O
) O
of O
300 O
- O
450 O
sec O
. O

for O
pci O
, O
argatroban O
has O
not O
been O
investigated O
in O
hepatically O
impaired O
patients O
; O
dose O
adjustment O
is O
unnecessary O
for O
adult O
age O
, O
sex O
, O
race O
/ O
ethnicity O
or O
obesity B-Disease
, O
and O
lesser O
doses O
may O
be O
adequate O
with O
concurrent O
glycoprotein O
iib O
/ O
iiia O
inhibition O
. O

argatroban O
prolongs O
the O
international O
normalized O
ratio O
, O
and O
published O
approaches O
for O
monitoring O
the O
argatroban O
- O
to O
- O
warfarin O
transition O
should O
be O
followed O
. O

major O
bleeding B-Disease
with O
argatroban O
is O
0 O
- O
10 O
% O
in O
the O
non O
- O
interventional O
setting O
and O
0 O
- O
5 O
. O
8 O
% O
periprocedurally O
. O

argatroban O
has O
no O
specific O
antidote O
, O
and O
if O
excessive O
anticoagulation O
occurs O
, O
argatroban O
infusion O
should O
be O
stopped O
or O
reduced O
. O

improved O
familiarity O
of O
healthcare O
professionals O
with O
argatroban O
therapy O
in O
hit B-Disease
, O
including O
in O
special O
populations O
and O
during O
pci O
, O
may O
facilitate O
reduction O
of O
harm O
associated O
with O
hit B-Disease
( O
e O
. O
g O
. O
fewer O
thromboses O
) O
or O
its O
treatment O
( O
e O
. O
g O
. O
fewer O
argatroban O
medication O
errors O
) O
. O

rhabdomyolysis B-Disease
and O
brain O
ischemic B-Disease
stroke I-Disease
in O
a O
heroin O
- O
dependent O
male O
under O
methadone O
maintenance O
therapy O
. O

objective O
: O
there O
are O
several O
complications O
associated O
with O
heroin B-Disease
abuse I-Disease
, O
some O
of O
which O
are O
life O
- O
threatening O
. O

methadone O
may O
aggravate O
this O
problem O
. O

method O
: O
a O
clinical O
case O
description O
. O

results O
: O
a O
33 O
- O
year O
- O
old O
man O
presented O
with O
rhabdomyolysis B-Disease
and O
cerebral O
ischemic B-Disease
stroke I-Disease
after O
intravenous O
heroin O
. O

he O
had O
used O
heroin O
since O
age O
20 O
, O
and O
had O
used O
150 O
mg O
methadone O
daily O
for O
6 O
months O
. O

he O
was O
found O
unconsciousness B-Disease
at O
home O
and O
was O
sent O
to O
our O
hospital O
. O

in O
the O
er O
, O
his O
opiate O
level O
was O
4497 O
ng O
/ O
ml O
. O

in O
the O
icu O
, O
we O
found O
rhabdomyolysis B-Disease
, O
acute B-Disease
renal I-Disease
failure I-Disease
and O
acute O
respiratory B-Disease
failure I-Disease
. O

after O
transfer O
to O
an O
internal O
ward O
, O
we O
noted O
aphasia B-Disease
and O
weakness B-Disease
of O
his O
left O
limbs O
. O

after O
mri O
, O
we O
found O
cerebral B-Disease
ischemic I-Disease
infarction I-Disease
. O

conclusion O
: O
those O
using O
methadone O
and O
heroin O
simultaneously O
may O
increase O
risk O
of O
rhabdomyolysis B-Disease
and O
ischemic B-Disease
stroke I-Disease
. O

patients O
under O
methadone O
maintenance O
therapy O
should O
be O
warned O
regarding O
these O
serious O
adverse O
events O
. O

hypotheses O
of O
heroin O
- O
related O
rhabdomyolysis B-Disease
and O
stroke B-Disease
in O
heroin O
abusers O
are O
discussed O
. O

increased O
vulnerability O
to O
6 O
- O
hydroxydopamine O
lesion O
and O
reduced O
development O
of O
dyskinesias B-Disease
in O
mice O
lacking O
cb1 O
cannabinoid O
receptors O
. O

motor O
impairment O
, O
dopamine O
( O
da O
) O
neuronal O
activity O
and O
proenkephalin O
( O
penk O
) O
gene O
expression O
in O
the O
caudate O
- O
putamen O
( O
cpu O
) O
were O
measured O
in O
6 O
- O
ohda O
- O
lesioned O
and O
treated O
( O
l O
- O
dopa O
+ O
benserazide O
) O
cb1 O
ko O
and O
wt O
mice O
. O

a O
lesion O
induced O
by O
6 O
- O
ohda O
produced O
more O
severe O
motor O
deterioration O
in O
cb1 O
ko O
mice O
accompanied O
by O
more O
loss O
of O
da O
neurons O
and O
increased O
penk O
gene O
expression O
in O
the O
cpu O
. O

oxidative O
/ O
nitrosative O
and O
neuroinflammatory O
parameters O
were O
estimated O
in O
the O
cpu O
and O
cingulate O
cortex O
( O
cg O
) O
. O

cb1 O
ko O
mice O
exhibited O
higher O
mda O
levels O
and O
inos O
protein O
expression O
in O
the O
cpu O
and O
cg O
compared O
to O
wt O
mice O
. O

treatment O
with O
l O
- O
dopa O
+ O
benserazide O
( O
12 O
weeks O
) O
resulted O
in O
less O
severe O
dyskinesias B-Disease
in O
cb1 O
ko O
than O
in O
wt O
mice O
. O

the O
results O
revealed O
that O
the O
lack O
of O
cannabinoid O
cb1 O
receptors O
increased O
the O
severity O
of O
motor O
impairment O
and O
da O
lesion O
, O
and O
reduced O
l O
- O
dopa O
- O
induced O
dyskinesias B-Disease
. O

these O
results O
suggest O
that O
activation O
of O
cb1 O
receptors O
offers O
neuroprotection O
against O
dopaminergic O
lesion O
and O
the O
development O
of O
l O
- O
dopa O
- O
induced O
dyskinesias B-Disease
. O

hepatocellular O
oxidant O
stress O
following O
intestinal O
ischemia B-Disease
- O
reperfusion B-Disease
injury I-Disease
. O

reperfusion O
of O
ischemic B-Disease
intestine O
results O
in O
acute O
liver B-Disease
dysfunction I-Disease
characterized O
by O
hepatocellular O
enzyme O
release O
into O
plasma O
, O
reduction O
in O
bile O
flow O
rate O
, O
and O
neutrophil O
sequestration O
within O
the O
liver O
. O

the O
pathophysiology O
underlying O
this O
acute O
hepatic B-Disease
injury I-Disease
is O
unknown O
. O

this O
study O
was O
undertaken O
to O
determine O
whether O
oxidants O
are O
associated O
with O
the O
hepatic B-Disease
injury I-Disease
and O
to O
determine O
the O
relative O
value O
of O
several O
indirect O
methods O
of O
assessing O
oxidant O
exposure O
in O
vivo O
. O

rats O
were O
subjected O
to O
a O
standardized O
intestinal O
ischemia B-Disease
- O
reperfusion B-Disease
injury I-Disease
. O

hepatic O
tissue O
was O
assayed O
for O
lipid O
peroxidation O
products O
and O
oxidized O
and O
reduced O
glutathione O
. O

there O
was O
no O
change O
in O
hepatic O
tissue O
total O
glutathione O
following O
intestinal O
ischemia B-Disease
- O
reperfusion B-Disease
injury I-Disease
. O

oxidized O
glutathione O
( O
gssg O
) O
increased O
significantly O
following O
30 O
and O
60 O
min O
of O
reperfusion O
. O

there O
was O
no O
increase O
in O
any O
of O
the O
products O
of O
lipid O
peroxidation O
associated O
with O
this O
injury O
. O

an O
increase O
in O
gssg O
within O
hepatic O
tissue O
during O
intestinal O
reperfusion O
suggests O
exposure O
of O
hepatocytes O
to O
an O
oxidant O
stress O
. O

the O
lack O
of O
a O
significant O
increase O
in O
products O
of O
lipid O
peroxidation O
suggests O
that O
the O
oxidant O
stress O
is O
of O
insufficient O
magnitude O
to O
result O
in O
irreversible O
injury O
to O
hepatocyte O
cell O
membranes O
. O

these O
data O
also O
suggest O
that O
the O
measurement O
of O
tissue O
gssg O
may O
be O
a O
more O
sensitive O
indicator O
of O
oxidant O
stress O
than O
measurement O
of O
products O
of O
lipid O
peroxidation O
. O

animal O
model O
of O
mania B-Disease
induced O
by O
ouabain O
: O
evidence O
of O
oxidative O
stress O
in O
submitochondrial O
particles O
of O
the O
rat O
brain O
. O

the O
intracerebroventricular O
( O
icv O
) O
administration O
of O
ouabain O
( O
a O
na O
( O
+ O
) O
/ O
k O
( O
+ O
) O
- O
atpase O
inhibitor O
) O
in O
rats O
has O
been O
suggested O
to O
mimic O
some O
symptoms O
of O
human O
bipolar B-Disease
mania I-Disease
. O

clinical O
studies O
have O
shown O
that O
bipolar B-Disease
disorder I-Disease
may O
be O
related O
to O
mitochondrial B-Disease
dysfunction I-Disease
. O

herein O
, O
we O
investigated O
the O
behavioral O
and O
biochemical O
effects O
induced O
by O
the O
icv O
administration O
of O
ouabain O
in O
rats O
. O

to O
achieve O
this O
aim O
, O
the O
effects O
of O
ouabain O
injection O
immediately O
after O
and O
7 O
days O
following O
a O
single O
icv O
administration O
( O
at O
concentrations O
of O
10 O
( O
- O
2 O
) O
and O
10 O
( O
- O
3 O
) O
m O
) O
on O
locomotion O
was O
measured O
using O
the O
open O
- O
field O
test O
. O

additionally O
, O
thiobarbituric O
acid O
reactive O
substances O
( O
tbarss O
) O
and O
superoxide O
production O
were O
measured O
in O
submitochondrial O
particles O
of O
the O
prefrontal O
cortex O
, O
hippocampus O
, O
striatum O
and O
amygdala O
. O

our O
findings O
demonstrated O
that O
ouabain O
at O
10 O
( O
- O
2 O
) O
and O
10 O
( O
- O
3 O
) O
m O
induced O
hyperlocomotion B-Disease
in O
rats O
, O
and O
this O
response O
remained O
up O
to O
7 O
days O
following O
a O
single O
icv O
injection O
. O

in O
addition O
, O
we O
observed O
that O
the O
persistent O
increase O
in O
the O
rat O
spontaneous O
locomotion O
is O
associated O
with O
increased O
tbars O
levels O
and O
superoxide O
generation O
in O
submitochondrial O
particles O
in O
the O
prefrontal O
cortex O
, O
striatum O
and O
amygdala O
. O

in O
conclusion O
, O
ouabain O
- O
induced O
mania B-Disease
- O
like O
behavior O
may O
provide O
a O
useful O
animal O
model O
to O
test O
the O
hypothesis O
of O
the O
involvement O
of O
oxidative O
stress O
in O
bipolar B-Disease
disorder I-Disease
. O

intraoperative O
dialysis O
during O
liver O
transplantation O
with O
citrate O
dialysate O
. O

liver O
transplantation O
for O
acutely O
ill O
patients O
with O
fulminant B-Disease
liver I-Disease
failure I-Disease
carries O
high O
intraoperative O
and O
immediate O
postoperative O
risks O
. O

these O
are O
increased O
with O
the O
presence O
of O
concomitant O
acute B-Disease
kidney I-Disease
injury I-Disease
( O
aki B-Disease
) O
and O
intraoperative O
dialysis O
is O
sometimes O
required O
to O
allow O
the O
transplant O
to O
proceed O
. O

the O
derangements O
in O
the O
procoagulant O
and O
anticoagulant O
pathways O
during O
fulminant B-Disease
liver I-Disease
failure I-Disease
can O
lead O
to O
difficulties O
with O
anticoagulation O
during O
dialysis O
, O
especially O
when O
continued O
in O
the O
operating O
room O
. O

systemic O
anticoagulation O
is O
unsafe O
and O
regional O
citrate O
anticoagulation O
in O
the O
absence O
of O
a O
functional O
liver O
carries O
the O
risk O
of O
citrate O
toxicity B-Disease
. O

citrate O
dialysate O
, O
a O
new O
dialysate O
with O
citric O
acid O
can O
be O
used O
for O
anticoagulation O
in O
patients O
who O
cannot O
tolerate O
heparin O
or O
regional O
citrate O
. O

we O
report O
a O
case O
of O
a O
40 O
- O
year O
- O
old O
female O
with O
acetaminophen O
- O
induced O
fulminant B-Disease
liver I-Disease
failure I-Disease
with O
associated O
aki B-Disease
who O
underwent O
intraoperative O
dialytic O
support O
during O
liver O
transplantation O
anticoagulated O
with O
citrate O
dialysate O
during O
the O
entire O
procedure O
. O

the O
patient O
tolerated O
the O
procedure O
well O
without O
any O
signs O
of O
citrate O
toxicity B-Disease
and O
maintained O
adequate O
anticoagulation O
for O
patency O
of O
the O
dialysis O
circuit O
. O

citrate O
dialysate O
is O
a O
safe O
alternative O
for O
intradialytic O
support O
of O
liver O
transplantation O
in O
fulminant B-Disease
liver I-Disease
failure I-Disease
. O

delirium B-Disease
in O
a O
patient O
with O
toxic O
flecainide O
plasma O
concentrations O
: O
the O
role O
of O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine O
. O

objective O
: O
to O
describe O
a O
case O
of O
flecainide O
- O
induced O
delirium B-Disease
associated O
with O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine O
. O

case O
summary O
: O
a O
69 O
- O
year O
- O
old O
white O
female O
presented O
to O
the O
emergency O
department O
with O
a O
history O
of O
confusion B-Disease
and O
paranoia B-Disease
over O
the O
past O
several O
days O
. O

on O
admission O
the O
patient O
was O
taking O
carvedilol O
12 O
mg O
twice O
daily O
, O
warfarin O
2 O
mg O
/ O
day O
, O
folic O
acid O
1 O
mg O
/ O
day O
, O
levothyroxine O
100 O
microg O
/ O
day O
, O
pantoprazole O
40 O
mg O
/ O
day O
, O
paroxetine O
40 O
mg O
/ O
day O
, O
and O
flecainide O
100 O
mg O
twice O
daily O
. O

flecainide O
had O
been O
started O
2 O
weeks O
prior O
for O
atrial B-Disease
fibrillation I-Disease
. O

laboratory O
test O
findings O
on O
admission O
were O
notable O
only O
for O
a O
flecainide O
plasma O
concentration O
of O
1360 O
microg O
/ O
l O
( O
reference O
range O
200 O
- O
1000 O
) O
. O

a O
metabolic O
drug O
interaction O
between O
flecainide O
and O
paroxetine O
, O
which O
the O
patient O
had O
been O
taking O
for O
more O
than O
5 O
years O
, O
was O
considered O
. O

paroxetine O
was O
discontinued O
and O
the O
dose O
of O
flecainide O
was O
reduced O
to O
50 O
mg O
twice O
daily O
. O

her O
delirium B-Disease
resolved O
3 O
days O
later O
. O

discussion O
: O
flecainide O
and O
pharmacologically O
similar O
agents O
that O
interact O
with O
sodium O
channels O
may O
cause O
delirium B-Disease
in O
susceptible O
patients O
. O

a O
medline O
search O
( O
1966 O
- O
january O
2009 O
) O
revealed O
one O
in O
vivo O
pharmacokinetic O
study O
on O
the O
interaction O
between O
flecainide O
, O
a O
cyp2d6 O
substrate O
, O
and O
paroxetine O
, O
a O
cyp2d6 O
inhibitor O
, O
as O
well O
as O
3 O
case O
reports O
of O
flecainide O
- O
induced O
delirium B-Disease
. O

according O
to O
the O
naranjo O
probability O
scale O
, O
flecainide O
was O
the O
probable O
cause O
of O
the O
patient O
' O
s O
delirium B-Disease
; O
the O
horn O
drug O
interaction O
probability O
scale O
indicates O
a O
possible O
pharmacokinetic O
drug O
interaction O
between O
flecainide O
and O
paroxetine O
. O

conclusions O
: O
supratherapeutic O
flecainide O
plasma O
concentrations O
may O
cause O
delirium B-Disease
. O

because O
toxicity B-Disease
may O
occur O
when O
flecainide O
is O
prescribed O
with O
paroxetine O
and O
other O
potent O
cyp2d6 O
inhibitors O
, O
flecainide O
plasma O
concentrations O
should O
be O
monitored O
closely O
with O
commencement O
of O
cyp2d6 O
inhibitors O
. O

efficacy O
of O
everolimus O
( O
rad001 O
) O
in O
patients O
with O
advanced O
nsclc B-Disease
previously O
treated O
with O
chemotherapy O
alone O
or O
with O
chemotherapy O
and O
egfr O
inhibitors O
. O

background O
: O
treatment O
options O
are O
scarce O
in O
pretreated O
advanced O
non B-Disease
- I-Disease
small I-Disease
- I-Disease
cell I-Disease
lung I-Disease
cancer I-Disease
( O
nsclc B-Disease
) O
patients O
. O

rad001 O
, O
an O
oral O
inhibitor O
of O
the O
mammalian O
target O
of O
rapamycin O
( O
mtor O
) O
, O
has O
shown O
phase O
i O
efficacy O
in O
nsclc B-Disease
. O

methods O
: O
stage O
iiib O
or O
iv O
nsclc B-Disease
patients O
, O
with O
two O
or O
fewer O
prior O
chemotherapy O
regimens O
, O
one O
platinum O
based O
( O
stratum O
1 O
) O
or O
both O
chemotherapy O
and O
epidermal O
growth O
factor O
receptor O
tyrosine O
kinase O
inhibitors O
( O
stratum O
2 O
) O
, O
received O
rad001 O
10 O
mg O
/ O
day O
until O
progression O
or O
unacceptable O
toxicity B-Disease
. O

primary O
objective O
was O
overall O
response O
rate O
( O
orr O
) O
. O

analyses O
of O
markers O
associated O
with O
the O
mtor O
pathway O
were O
carried O
out O
on O
archival O
tumor B-Disease
from O
a O
subgroup O
using O
immunohistochemistry O
( O
ihc O
) O
and O
direct O
mutation O
sequencing O
. O

results O
: O
eighty O
- O
five O
patients O
were O
enrolled O
, O
42 O
in O
stratum O
1 O
and O
43 O
in O
stratum O
. O

orr O
was O
4 O
. O
7 O
% O
( O
7 O
. O
1 O
% O
stratum O
1 O
; O
2 O
. O
3 O
% O
stratum O
2 O
) O
. O

overall O
disease O
control O
rate O
was O
47 O
. O
1 O
% O
. O

median O
progression O
- O
free O
survivals O
( O
pfss O
) O
were O
2 O
. O
6 O
( O
stratum O
1 O
) O
and O
2 O
. O
7 O
months O
( O
stratum O
2 O
) O
. O

common O
> O
or O
= O
grade O
3 O
events O
were O
fatigue B-Disease
, O
dyspnea B-Disease
, O
stomatitis B-Disease
, O
anemia B-Disease
, O
and O
thrombocytopenia B-Disease
. O

pneumonitis B-Disease
, O
probably O
or O
possibly O
related O
, O
mainly O
grade O
1 O
/ O
2 O
, O
occurred O
in O
25 O
% O
. O

cox O
regression O
analysis O
of O
ihc O
scores O
found O
that O
only O
phospho O
akt O
( O
pakt O
) O
was O
a O
significant O
independent O
predictor O
of O
worse O
pfs O
. O

conclusions O
: O
rad001 O
10 O
mg O
/ O
day O
was O
well O
tolerated O
, O
showing O
modest O
clinical O
activity O
in O
pretreated O
nsclc B-Disease
. O

evaluation O
of O
rad001 O
plus O
standard O
therapy O
for O
metastatic O
nsclc B-Disease
continues O
. O

posttransplant O
anemia B-Disease
: O
the O
role O
of O
sirolimus O
. O

posttransplant O
anemia B-Disease
is O
a O
common O
problem O
that O
may O
hinder O
patients O
' O
quality O
of O
life O
. O

it O
occurs O
in O
12 O
to O
76 O
% O
of O
patients O
, O
and O
is O
most O
common O
in O
the O
immediate O
posttransplant O
period O
. O

a O
variety O
of O
factors O
have O
been O
identified O
that O
increase O
the O
risk O
of O
posttransplant O
anemia B-Disease
, O
of O
which O
the O
level O
of O
renal O
function O
is O
most O
important O
. O

sirolimus O
, O
a O
mammalian O
target O
of O
rapamycin O
inhibitor O
, O
has O
been O
implicated O
as O
playing O
a O
special O
role O
in O
posttransplant O
anemia B-Disease
. O

this O
review O
considers O
anemia B-Disease
associated O
with O
sirolimus O
, O
including O
its O
presentation O
, O
mechanisms O
, O
and O
management O
. O

coronary O
computerized O
tomography O
angiography O
for O
rapid O
discharge O
of O
low O
- O
risk O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
. O

background O
: O
most O
patients O
presenting O
to O
emergency O
departments O
( O
eds O
) O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
are O
admitted O
for O
at O
least O
12 O
hours O
and O
receive O
a O
" O
rule O
out O
acute B-Disease
coronary I-Disease
syndrome I-Disease
" O
protocol O
, O
often O
with O
noninvasive O
testing O
prior O
to O
discharge O
. O

in O
patients O
without O
cocaine O
use O
, O
coronary O
computerized O
tomography O
angiography O
( O
cta O
) O
has O
been O
shown O
to O
be O
useful O
for O
identifying O
a O
group O
of O
patients O
at O
low O
risk O
for O
cardiac O
events O
who O
can O
be O
safely O
discharged O
. O

it O
is O
unclear O
whether O
a O
coronary O
cta O
strategy O
would O
be O
efficacious O
in O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
, O
as O
coronary B-Disease
vasospasm I-Disease
may O
account O
for O
some O
of O
the O
ischemia B-Disease
. O

we O
studied O
whether O
a O
negative O
coronary O
cta O
in O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
could O
identify O
a O
subset O
safe O
for O
discharge O
. O

methods O
: O
we O
prospectively O
evaluated O
the O
safety O
of O
coronary O
cta O
for O
low O
- O
risk O
patients O
who O
presented O
to O
the O
ed O
with O
cocaineassociated O
chest B-Disease
pain I-Disease
( O
self O
- O
reported O
or O
positive O
urine O
test O
) O
. O

consecutive O
patients O
received O
either O
immediate O
coronary O
cta O
in O
the O
ed O
( O
without O
serial O
markers O
) O
or O
underwent O
coronary O
cta O
after O
a O
brief O
observation O
period O
with O
serial O
cardiac O
marker O
measurements O
. O

patients O
with O
negative O
coronary O
cta O
( O
maximal O
stenosis B-Disease
less O
than O
50 O
% O
) O
were O
discharged O
. O

the O
main O
outcome O
was O
30 O
- O
day O
cardiovascular O
death O
or O
myocardial B-Disease
infarction I-Disease
. O

results O
: O
a O
total O
of O
59 O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
were O
evaluated O
. O

patients O
had O
a O
mean O
age O
of O
45 O
. O
6 O
+ O
/ O
- O
6 O
. O
6 O
yrs O
and O
were O
86 O
% O
black O
, O
66 O
% O
male O
. O

seventy O
- O
nine O
percent O
had O
a O
normal O
or O
nonspecific O
ecg O
and O
85 O
% O
had O
a O
timi O
score O
< O
2 O
. O

twenty O
patients O
received O
coronary O
cta O
immediately O
in O
the O
ed O
, O
18 O
of O
whom O
were O
discharged O
following O
cta O
( O
90 O
% O
) O
. O

thirty O
- O
nine O
received O
coronary O
cta O
after O
a O
brief O
observation O
period O
, O
with O
37 O
discharged O
home O
following O
cta O
( O
95 O
% O
) O
. O

six O
patients O
had O
coronary B-Disease
stenosis I-Disease
> O
or O
= O
50 O
% O
. O

during O
the O
30 O
- O
day O
follow O
- O
up O
period O
, O
no O
patients O
died O
of O
a O
cardiovascular O
event O
( O
0 O
% O
; O
95 O
% O
ci O
, O
0 O
- O
6 O
. O
1 O
% O
) O
and O
no O
patient O
sustained O
a O
nonfatal O
myocardial B-Disease
infarction I-Disease
( O
0 O
% O
; O
95 O
% O
ci O
, O
0 O
- O
6 O
. O
1 O
% O
) O
. O

conclusions O
: O
although O
cocaine O
- O
associated O
myocardial B-Disease
ischemia I-Disease
can O
result O
from O
coronary O
vasoconstriction O
, O
patients O
with O
cocaine O
associated O
chest B-Disease
pain I-Disease
, O
a O
non O
- O
ischemic B-Disease
ecg O
, O
and O
a O
timi O
risk O
score O
< O
2 O
may O
be O
safely O
discharged O
from O
the O
ed O
after O
a O
negative O
coronary O
cta O
with O
a O
low O
risk O
of O
30 O
- O
day O
adverse O
events O
. O

bilateral O
haemorrhagic B-Disease
infarction I-Disease
of I-Disease
the I-Disease
globus I-Disease
pallidus I-Disease
after O
cocaine O
and O
alcohol O
intoxication O
. O

cocaine O
is O
a O
risk O
factor O
for O
both O
ischemic B-Disease
and I-Disease
haemorrhagic I-Disease
stroke I-Disease
. O

we O
present O
the O
case O
of O
a O
31 O
- O
year O
- O
old O
man O
with O
bilateral O
ischemia B-Disease
of I-Disease
the I-Disease
globus I-Disease
pallidus I-Disease
after O
excessive O
alcohol O
and O
intranasal O
cocaine O
use O
. O

drug O
- O
related O
globus B-Disease
pallidus I-Disease
infarctions I-Disease
are O
most O
often O
associated O
with O
heroin O
. O

bilateral O
basal B-Disease
ganglia I-Disease
infarcts I-Disease
after O
the O
use O
of O
cocaine O
, O
without O
concurrent O
heroin O
use O
, O
have O
never O
been O
reported O
. O

in O
our O
patient O
, O
transient O
cardiac B-Disease
arrhythmia I-Disease
or O
respiratory B-Disease
dysfunction I-Disease
related O
to O
cocaine O
and O
/ O
or O
ethanol O
use O
were O
the O
most O
likely O
causes O
of O
cerebral B-Disease
hypoperfusion I-Disease
. O

late O
fulminant O
posterior B-Disease
reversible I-Disease
encephalopathy I-Disease
syndrome I-Disease
after O
liver O
transplant O
. O

objectives O
: O
posterior B-Disease
leukoencephalopathy I-Disease
due O
to O
calcineurin O
- O
inhibitor O
- O
related O
neurotoxicity B-Disease
is O
a O
rare O
but O
severe O
complication O
that O
results O
from O
treatment O
with O
immunosuppressive O
agents O
( O
primarily O
those O
administered O
after O
a O
liver O
or O
kidney O
transplant O
) O
. O

the O
pathophysiologic O
mechanisms O
of O
that O
disorder O
remain O
unknown O
. O

case O
: O
we O
report O
the O
case O
of O
a O
46 O
- O
year O
- O
old O
woman O
who O
received O
a O
liver O
transplant O
in O
our O
center O
as O
treatment O
for O
alcoholic B-Disease
cirrhosis I-Disease
and O
in O
whom O
either O
a O
fulminant O
course O
of O
posterior B-Disease
leukoencephalopathy I-Disease
or O
posterior B-Disease
reversible I-Disease
encephalopathy I-Disease
syndrome I-Disease
developed O
110 O
days O
after O
transplant O
. O

after O
an O
initially O
uneventful O
course O
after O
the O
transplant O
, O
the O
patient O
rapidly O
fell O
into O
deep O
coma O
. O

results O
: O
cerebral O
mri O
scan O
showed O
typical O
signs O
of O
enhancement O
in O
the O
pontine O
and O
posterior O
regions O
. O

switching O
the O
immunosuppressive O
regimen O
from O
tacrolimus O
to O
cyclosporine O
did O
not O
improve O
the O
clinical O
situation O
. O

the O
termination O
of O
treatment O
with O
any O
calcineurin O
inhibitor O
resulted O
in O
a O
complete O
resolution O
of O
that O
complication O
. O

conclusions O
: O
posterior B-Disease
reversible I-Disease
encephalopathy I-Disease
syndrome I-Disease
after O
liver O
transplant O
is O
rare O
. O

we O
recommend O
a O
complete O
cessation O
of O
any O
calcineurin O
inhibitor O
rather O
than O
a O
dose O
reduction O
. O

prolonged O
hypothermia B-Disease
as O
a O
bridge O
to O
recovery O
for O
cerebral B-Disease
edema I-Disease
and O
intracranial B-Disease
hypertension I-Disease
associated O
with O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
. O

background O
: O
to O
review O
evidence O
- O
based O
treatment O
options O
in O
patients O
with O
cerebral B-Disease
edema I-Disease
complicating O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
( O
fhf B-Disease
) O
and O
discuss O
the O
potential O
applications O
of O
hypothermia B-Disease
. O

method O
: O
case O
- O
based O
observations O
from O
a O
medical O
intensive O
care O
unit O
( O
micu O
) O
in O
a O
tertiary O
care O
facility O
in O
a O
27 O
- O
year O
- O
old O
female O
with O
fhf B-Disease
from O
acetaminophen O
and O
resultant O
cerebral B-Disease
edema I-Disease
. O

results O
: O
our O
patient O
was O
admitted O
to O
the O
micu O
after O
being O
found O
unresponsive O
with O
presumed O
toxicity B-Disease
from O
acetaminophen O
which O
was O
ingested O
over O
a O
2 O
- O
day O
period O
. O

the O
patient O
had O
depressed O
of O
mental O
status O
lasting O
at O
least O
24 O
h O
prior O
to O
admission O
. O

initial O
evaluation O
confirmed O
fhf B-Disease
from O
acetaminophen O
and O
cerebral B-Disease
edema I-Disease
. O

the O
patient O
was O
treated O
with O
hyperosmolar O
therapy O
, O
hyperventilation B-Disease
, O
sedation O
, O
and O
chemical O
paralysis B-Disease
. O

her O
intracranial O
pressure O
remained O
elevated O
despite O
maximal O
medical O
therapy O
. O

we O
then O
initiated O
therapeutic O
hypothermia B-Disease
which O
was O
continued O
for O
5 O
days O
. O

at O
re O
- O
warming O
, O
patient O
had O
resolution O
of O
her O
cerebral B-Disease
edema I-Disease
and O
intracranial B-Disease
hypertension I-Disease
. O

at O
discharge O
, O
she O
had O
complete O
recovery O
of O
neurological O
and O
hepatic O
functions O
. O

conclusion O
: O
in O
patients O
with O
fhf B-Disease
and O
cerebral B-Disease
edema I-Disease
from O
acetaminophen O
overdose B-Disease
, O
prolonged O
therapeutic O
hypothermia B-Disease
could O
potentially O
be O
used O
as O
a O
life O
saving O
therapy O
and O
a O
bridge O
to O
hepatic O
and O
neurological O
recovery O
. O

a O
clinical O
trial O
of O
hypothermia B-Disease
in O
patients O
with O
this O
condition O
is O
warranted O
. O

binasal B-Disease
visual I-Disease
field I-Disease
defects I-Disease
are O
not O
specific O
to O
vigabatrin O
. O

this O
study O
investigated O
the O
visual B-Disease
defects I-Disease
associated O
with O
the O
antiepileptic O
drug O
vigabatrin O
( O
vgb O
) O
. O

two O
hundred O
four O
people O
with O
epilepsy B-Disease
were O
grouped O
on O
the O
basis O
of O
antiepileptic O
drug O
therapy O
( O
current O
, O
previous O
, O
or O
no O
exposure O
to O
vgb O
) O
. O

groups O
were O
matched O
with O
respect O
to O
age O
, O
gender O
, O
and O
seizure B-Disease
frequency O
. O

all O
patients O
underwent O
objective O
assessment O
of O
electrophysiological O
function O
( O
wide O
- O
field O
multifocal O
electroretinography O
) O
and O
conventional O
visual O
field O
testing O
( O
static O
perimetry O
) O
. O

bilateral O
visual O
field O
constriction O
was O
observed O
in O
59 O
% O
of O
patients O
currently O
taking O
vgb O
, O
43 O
% O
of O
patients O
who O
previously O
took O
vgb O
, O
and O
24 O
% O
of O
patients O
with O
no O
exposure O
to O
vgb O
. O

assessment O
of O
retinal O
function O
revealed O
abnormal O
responses O
in O
48 O
% O
of O
current O
vgb O
users O
and O
22 O
% O
of O
prior O
vgb O
users O
, O
but O
in O
none O
of O
the O
patients O
without O
previous O
exposure O
to O
vgb O
. O

bilateral B-Disease
visual I-Disease
field I-Disease
abnormalities I-Disease
are O
common O
in O
the O
treated O
epilepsy B-Disease
population O
, O
irrespective O
of O
drug O
history O
. O

assessment O
by O
conventional O
static O
perimetry O
may O
neither O
be O
sufficiently O
sensitive O
nor O
specific O
to O
reliably O
identify O
retinal B-Disease
toxicity I-Disease
associated O
with O
vgb O
. O

smoking O
of O
crack O
cocaine O
as O
a O
risk O
factor O
for O
hiv B-Disease
infection I-Disease
among O
people O
who O
use O
injection O
drugs O
. O

background O
: O
little O
is O
known O
about O
the O
possible O
role O
that O
smoking O
crack O
cocaine O
has O
on O
the O
incidence O
of O
hiv B-Disease
infection I-Disease
. O

given O
the O
increasing O
use O
of O
crack O
cocaine O
, O
we O
sought O
to O
examine O
whether O
use O
of O
this O
illicit O
drug O
has O
become O
a O
risk O
factor O
for O
hiv B-Disease
infection I-Disease
. O

methods O
: O
we O
included O
data O
from O
people O
participating O
in O
the O
vancouver O
injection O
drug O
users O
study O
who O
reported O
injecting O
illicit O
drugs O
at O
least O
once O
in O
the O
month O
before O
enrolment O
, O
lived O
in O
the O
greater O
vancouver O
area O
, O
were O
hiv O
- O
negative O
at O
enrolment O
and O
completed O
at O
least O
1 O
follow O
- O
up O
study O
visit O
. O

to O
determine O
whether O
the O
risk O
of O
hiv B-Disease
seroconversion I-Disease
among O
daily O
smokers O
of O
crack O
cocaine O
changed O
over O
time O
, O
we O
used O
cox O
proportional O
hazards O
regression O
and O
divided O
the O
study O
into O
3 O
periods O
: O
may O
1 O
, O
1996 O
- O
nov O
. O

30 O
, O
1999 O
( O
period O
1 O
) O
, O
dec O
. O

1 O
, O
1999 O
- O
nov O
. O

30 O
, O
2002 O
( O
period O
2 O
) O
, O
and O
dec O
. O

1 O
, O
2002 O
- O
dec O
. O

30 O
, O
2005 O
( O
period O
3 O
) O
. O

results O
: O
overall O
, O
1048 O
eligible O
injection O
drug O
users O
were O
included O
in O
our O
study O
. O

of O
these O
, O
137 O
acquired O
hiv B-Disease
infection I-Disease
during O
follow O
- O
up O
. O

the O
mean O
proportion O
of O
participants O
who O
reported O
daily O
smoking O
of O
crack O
cocaine O
increased O
from O
11 O
. O
6 O
% O
in O
period O
1 O
to O
39 O
. O
7 O
% O
in O
period O
3 O
. O

after O
adjusting O
for O
potential O
confounders O
, O
we O
found O
that O
the O
risk O
of O
hiv B-Disease
seroconversion I-Disease
among O
participants O
who O
were O
daily O
smokers O
of O
crack O
cocaine O
increased O
over O
time O
( O
period O
1 O
: O
hazard O
ratio O
[ O
hr O
] O
1 O
. O
03 O
, O
95 O
% O
confidence O
interval O
[ O
ci O
] O
0 O
. O
57 O
- O
1 O
. O
85 O
; O
period O
2 O
: O
hr O
1 O
. O
68 O
, O
95 O
% O
ci O
1 O
. O
01 O
- O
2 O
. O
80 O
; O
and O
period O
3 O
: O
hr O
2 O
. O
74 O
, O
95 O
% O
ci O
1 O
. O
06 O
- O
7 O
. O
11 O
) O
. O

interpretation O
: O
smoking O
of O
crack O
cocaine O
was O
found O
to O
be O
an O
independent O
risk O
factor O
for O
hiv B-Disease
seroconversion I-Disease
among O
people O
who O
were O
injection O
drug O
users O
. O

this O
finding O
points O
to O
the O
urgent O
need O
for O
evidence O
- O
based O
public O
health O
initiatives O
targeted O
at O
people O
who O
smoke O
crack O
cocaine O
. O

fluoxetine O
improves O
the O
memory B-Disease
deficits I-Disease
caused O
by O
the O
chemotherapy O
agent O
5 O
- O
fluorouracil O
. O

cancer B-Disease
patients O
who O
have O
been O
treated O
with O
systemic O
adjuvant O
chemotherapy O
have O
described O
experiencing O
deteriorations O
in O
cognition O
. O

a O
widely O
used O
chemotherapeutic O
agent O
, O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
, O
readily O
crosses O
the O
blood O
- O
brain O
barrier O
and O
so O
could O
have O
a O
direct O
effect O
on O
brain O
function O
. O

in O
particular O
this O
anti O
mitotic O
drug O
could O
reduce O
cell O
proliferation O
in O
the O
neurogenic O
regions O
of O
the O
adult O
brain O
. O

in O
contrast O
reports O
indicate O
that O
hippocampal O
dependent O
neurogenesis O
and O
cognition O
are O
enhanced O
by O
the O
ssri O
antidepressant O
fluoxetine O
. O

in O
this O
investigation O
the O
behavioural O
effects O
of O
chronic O
( O
two O
week O
) O
treatment O
with O
5 O
- O
fu O
and O
( O
three O
weeks O
) O
with O
fluoxetine O
either O
separately O
or O
in O
combination O
with O
5 O
- O
fu O
were O
tested O
on O
adult O
lister O
hooded O
rats O
. O

behavioural O
effects O
were O
tested O
using O
a O
context O
dependent O
conditioned O
emotional O
response O
test O
( O
cer O
) O
which O
showed O
that O
animals O
treated O
with O
5 O
- O
fu O
had O
a O
significant O
reduction O
in O
freezing O
time O
compared O
to O
controls O
. O

a O
separate O
group O
of O
animals O
was O
tested O
using O
a O
hippocampal O
dependent O
spatial O
working O
memory O
test O
, O
the O
object O
location O
recognition O
test O
( O
olr O
) O
. O

animals O
treated O
only O
with O
5 O
- O
fu O
showed O
significant O
deficits O
in O
their O
ability O
to O
carry O
out O
the O
olr O
task O
but O
co O
administration O
of O
fluoxetine O
improved O
their O
performance O
. O

5 O
- O
fu O
chemotherapy O
caused O
a O
significant O
reduction O
in O
the O
number O
of O
proliferating O
cells O
in O
the O
sub O
granular O
zone O
of O
the O
dentate O
gyrus O
compared O
to O
controls O
. O

this O
reduction O
was O
eliminated O
when O
fluoxetine O
was O
co O
administered O
with O
5 O
- O
fu O
. O

fluoxetine O
on O
its O
own O
had O
no O
effect O
on O
proliferating O
cell O
number O
or O
behaviour O
. O

these O
findings O
suggest O
that O
5 O
- O
fu O
can O
negatively O
affect O
both O
cell O
proliferation O
and O
hippocampal O
dependent O
working O
memory O
and O
that O
these O
deficits O
can O
be O
reversed O
by O
the O
simultaneous O
administration O
of O
the O
antidepressant O
fluoxetine O
. O

liver O
- O
specific O
ablation O
of O
integrin O
- O
linked O
kinase O
in O
mice O
results O
in O
enhanced O
and O
prolonged O
cell O
proliferation O
and O
hepatomegaly B-Disease
after O
phenobarbital O
administration O
. O

we O
have O
recently O
demonstrated O
that O
disruption O
of O
extracellular O
matrix O
( O
ecm O
) O
/ O
integrin O
signaling O
via O
elimination O
of O
integrin O
- O
linked O
kinase O
( O
ilk O
) O
in O
hepatocytes O
interferes O
with O
signals O
leading O
to O
termination O
of O
liver O
regeneration O
. O

this O
study O
investigates O
the O
role O
of O
ilk O
in O
liver O
enlargement O
induced O
by O
phenobarbital O
( O
pb O
) O
. O

wild O
- O
type O
( O
wt O
) O
and O
ilk O
: O
liver O
- O
/ O
- O
mice O
were O
given O
pb O
( O
0 O
. O
1 O
% O
in O
drinking O
water O
) O
for O
10 O
days O
. O

livers O
were O
harvested O
on O
2 O
, O
5 O
, O
and O
10 O
days O
during O
pb O
administration O
. O

in O
the O
hepatocyte O
- O
specific O
ilk O
/ O
liver O
- O
/ O
- O
mice O
, O
the O
liver O
: O
body O
weight O
ratio O
was O
more O
than O
double O
as O
compared O
to O
0 O
h O
at O
day O
2 O
( O
2 O
. O
5 O
times O
) O
, O
while O
at O
days O
5 O
and O
10 O
, O
it O
was O
enlarged O
three O
times O
. O

in O
the O
wt O
mice O
, O
the O
increase O
was O
as O
expected O
from O
previous O
literature O
( O
1 O
. O
8 O
times O
) O
and O
seems O
to O
have O
leveled O
off O
after O
day O
2 O
. O

there O
were O
slightly O
increased O
proliferating O
cell O
nuclear O
antigen O
- O
positive O
cells O
in O
the O
ilk O
/ O
liver O
- O
/ O
- O
animals O
at O
day O
2 O
as O
compared O
to O
wt O
after O
pb O
administration O
. O

in O
the O
wt O
animals O
, O
the O
proliferative O
response O
had O
come O
back O
to O
normal O
by O
days O
5 O
and O
10 O
. O

hepatocytes O
of O
the O
ilk O
/ O
liver O
- O
/ O
- O
mice O
continued O
to O
proliferate O
up O
until O
day O
10 O
. O

ilk O
/ O
liver O
- O
/ O
- O
mice O
also O
showed O
increased O
expression O
of O
key O
genes O
involved O
in O
hepatocyte O
proliferation O
at O
different O
time O
points O
during O
pb O
administration O
. O

in O
summary O
, O
ecm O
proteins O
communicate O
with O
the O
signaling O
machinery O
of O
dividing O
cells O
via O
ilk O
to O
regulate O
hepatocyte O
proliferation O
and O
termination O
of O
the O
proliferative O
response O
. O

lack O
of O
ilk O
in O
the O
hepatocytes O
imparts O
prolonged O
proliferative O
response O
not O
only O
to O
stimuli O
related O
to O
liver O
regeneration O
but O
also O
to O
xenobiotic O
chemical O
mitogens O
, O
such O
as O
pb O
. O

decreased O
expression O
of O
na O
/ O
k O
- O
atpase O
, O
nhe3 O
, O
nbc1 O
, O
aqp1 O
and O
oat O
in O
gentamicin O
- O
induced O
nephropathy B-Disease
. O

the O
present O
study O
was O
aimed O
to O
determine O
whether O
there O
is O
an O
altered O
regulation O
of O
tubular O
transporters O
in O
gentamicin O
- O
induced O
nephropathy B-Disease
. O

sprague O
- O
dawley O
male O
rats O
( O
200 O
~ O
250 O
g O
) O
were O
subcutaneously O
injected O
with O
gentamicin O
( O
100 O
mg O
/ O
kg O
per O
day O
) O
for O
7 O
days O
, O
and O
the O
expression O
of O
tubular O
transporters O
was O
determined O
by O
immunoblotting O
and O
immunohistochemistry O
. O

the O
mrna O
and O
protein O
expression O
of O
oat O
was O
also O
determined O
. O

gentamicin O
- O
treated O
rats O
exhibited O
significantly O
decreased O
creatinine O
clearance O
along O
with O
increased O
plasma O
creatinine O
levels O
. O

accordingly O
, O
the O
fractional O
excretion O
of O
sodium O
increased O
. O

urine O
volume O
was O
increased O
, O
while O
urine O
osmolality O
and O
free O
water O
reabsorption O
were O
decreased O
. O

immunoblotting O
and O
immunohistochemistry O
revealed O
decreased O
expression O
of O
na O
( O
+ O
) O
/ O
k O
( O
+ O
) O
- O
atpase O
, O
nhe3 O
, O
nbc1 O
, O
and O
aqp1 O
in O
the O
kidney O
of O
gentamicin O
- O
treated O
rats O
. O

the O
expression O
of O
oat1 O
and O
oat3 O
was O
also O
decreased O
. O

gentamicin O
- O
induced O
nephropathy B-Disease
may O
at O
least O
in O
part O
be O
causally O
related O
with O
a O
decreased O
expression O
of O
na O
( O
+ O
) O
/ O
k O
( O
+ O
) O
- O
atpase O
, O
nhe3 O
, O
nbc1 O
, O
aqp1 O
and O
oat O
. O

acute B-Disease
renal I-Disease
failure I-Disease
after O
high O
- O
dose O
methotrexate O
therapy O
in O
a O
patient O
with O
ileostomy O
. O

high O
- O
dose O
methotrexate O
( O
hd O
- O
mtx O
) O
is O
an O
important O
treatment O
for O
burkitt B-Disease
lymphoma I-Disease
, O
but O
can O
cause O
hepatic B-Disease
and I-Disease
renal I-Disease
toxicity I-Disease
when O
its O
clearance O
is O
delayed O
. O

we O
report O
a O
case O
of O
acute B-Disease
renal I-Disease
failure I-Disease
after O
hd O
- O
mtx O
therapy O
in O
a O
patient O
with O
ileostomy O
, O
the O
patient O
was O
a O
3 O
- O
year O
- O
old O
boy O
who O
had O
received O
a O
living O
- O
related O
liver O
transplantation O
for O
congenital O
biliary B-Disease
atresia I-Disease
. O

at O
day O
833 O
after O
the O
transplantation O
, O
he O
was O
diagnosed O
with O
ptld B-Disease
( O
post B-Disease
- I-Disease
transplantation I-Disease
lymphoproliferative I-Disease
disorder I-Disease
, O
burkitt B-Disease
- I-Disease
type I-Disease
malignant I-Disease
lymphoma I-Disease
) O
. O

during O
induction O
therapy O
, O
he O
suffered O
ileal O
perforation O
and O
ileostomy O
was O
performed O
. O

subsequent O
hd O
- O
mtx O
therapy O
caused O
acute B-Disease
renal I-Disease
failure I-Disease
that O
required O
continuous O
hemodialysis O
. O

we O
supposed O
that O
intravascular O
hypovolemia B-Disease
due O
to O
substantial O
drainage O
from O
the O
ileostoma O
caused O
acute B-Disease
prerenal I-Disease
failure I-Disease
. O

after O
recovery O
of O
his O
renal O
function O
, O
we O
could O
safely O
treat O
the O
patient O
with O
hd O
- O
mtx O
therapy O
by O
controlling O
drainage O
from O
ileostoma O
with O
total O
parenteral O
nutrition O
. O

longitudinal O
association O
of O
alcohol O
use O
with O
hiv B-Disease
disease I-Disease
progression O
and O
psychological O
health O
of O
women O
with O
hiv O
. O

we O
evaluated O
the O
association O
of O
alcohol O
consumption O
and O
depression B-Disease
, O
and O
their O
effects O
on O
hiv B-Disease
disease I-Disease
progression O
among O
women O
with O
hiv O
. O

the O
study O
included O
871 O
women O
with O
hiv O
who O
were O
recruited O
from O
1993 O
- O
1995 O
in O
four O
us O
cities O
. O

the O
participants O
had O
physical O
examination O
, O
medical O
record O
extraction O
, O
and O
venipuncture O
, O
cd4 O
+ O
t O
- O
cell O
counts O
determination O
, O
measurement O
of O
depression B-Disease
symptoms O
( O
using O
the O
self O
- O
report O
center O
for O
epidemiological O
studies O
- O
depression B-Disease
scale O
) O
, O
and O
alcohol O
use O
assessment O
at O
enrollment O
, O
and O
semiannually O
until O
march O
2000 O
. O

multilevel O
random O
coefficient O
ordinal O
models O
as O
well O
as O
multilevel O
models O
with O
joint O
responses O
were O
used O
in O
the O
analysis O
. O

there O
was O
no O
significant O
association O
between O
level O
of O
alcohol O
use O
and O
cd4 O
+ O
t O
- O
cell O
counts O
. O

when O
participants O
were O
stratified O
by O
antiretroviral O
therapy O
( O
art O
) O
use O
, O
the O
association O
between O
alcohol O
and O
cd4 O
+ O
t O
- O
cell O
did O
not O
reach O
statistical O
significance O
. O

the O
association O
between O
alcohol O
consumption O
and O
depression B-Disease
was O
significant O
( O
p O
< O
0 O
. O
001 O
) O
. O

depression B-Disease
had O
a O
significant O
negative O
effect O
on O
cd4 O
+ O
t O
- O
cell O
counts O
over O
time O
regardless O
of O
art O
use O
. O

our O
findings O
suggest O
that O
alcohol O
consumption O
has O
a O
direct O
association O
with O
depression B-Disease
. O

moreover O
, O
depression B-Disease
is O
associated O
with O
hiv B-Disease
disease I-Disease
progression O
. O

our O
findings O
have O
implications O
for O
the O
provision O
of O
alcohol O
use O
interventions O
and O
psychological O
resources O
to O
improve O
the O
health O
of O
women O
with O
hiv O
. O

chemokine O
ccl2 O
and O
its O
receptor O
ccr2 O
are O
increased O
in O
the O
hippocampus O
following O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
. O

background O
: O
neuroinflammation B-Disease
occurs O
after O
seizures B-Disease
and O
is O
implicated O
in O
epileptogenesis O
. O

ccr2 O
is O
a O
chemokine O
receptor O
for O
ccl2 O
and O
their O
interaction O
mediates O
monocyte O
infiltration O
in O
the O
neuroinflammatory B-Disease
cascade O
triggered O
in O
different O
brain O
pathologies O
. O

in O
this O
work O
ccr2 O
and O
ccl2 O
expression O
were O
examined O
following O
status B-Disease
epilepticus I-Disease
( O
se B-Disease
) O
induced O
by O
pilocarpine O
injection O
. O

methods O
: O
se B-Disease
was O
induced O
by O
pilocarpine O
injection O
. O

control O
rats O
were O
injected O
with O
saline O
instead O
of O
pilocarpine O
. O

five O
days O
after O
se B-Disease
, O
ccr2 O
staining O
in O
neurons O
and O
glial O
cells O
was O
examined O
using O
imunohistochemical O
analyses O
. O

the O
number O
of O
ccr2 O
positive O
cells O
was O
determined O
using O
stereology O
probes O
in O
the O
hippocampus O
. O

ccl2 O
expression O
in O
the O
hippocampus O
was O
examined O
by O
molecular O
assay O
. O

results O
: O
increased O
ccr2 O
was O
observed O
in O
the O
hippocampus O
after O
se B-Disease
. O

seizures B-Disease
also O
resulted O
in O
alterations O
to O
the O
cell O
types O
expressing O
ccr2 O
. O

increased O
numbers O
of O
neurons O
that O
expressed O
ccr2 O
was O
observed O
following O
se B-Disease
. O

microglial O
cells O
were O
more O
closely O
apposed O
to O
the O
ccr2 O
- O
labeled O
cells O
in O
se B-Disease
rats O
. O

in O
addition O
, O
rats O
that O
experienced O
se B-Disease
exhibited O
ccr2 O
- O
labeling O
in O
populations O
of O
hypertrophied B-Disease
astrocytes O
, O
especially O
in O
ca1 O
and O
dentate O
gyrus O
. O

these O
ccr2 O
+ O
astroctytes O
were O
not O
observed O
in O
control O
rats O
. O

examination O
of O
ccl2 O
expression O
showed O
that O
it O
was O
elevated O
in O
the O
hippocampus O
following O
se B-Disease
. O

conclusion O
: O
the O
data O
show O
that O
ccr2 O
and O
ccl2 O
are O
up O
- O
regulated O
in O
the O
hippocampus O
after O
pilocarpine O
- O
induced O
se B-Disease
. O

seizures B-Disease
also O
result O
in O
changes O
to O
ccr2 O
receptor O
expression O
in O
neurons O
and O
astrocytes O
. O

these O
changes O
might O
be O
involved O
in O
detrimental O
neuroplasticity O
and O
neuroinflammatory B-Disease
changes O
that O
occur O
following O
seizures B-Disease
. O

metallothionein O
induction O
reduces O
caspase O
- O
3 O
activity O
and O
tnfalpha O
levels O
with O
preservation O
of O
cognitive O
function O
and O
intact O
hippocampal O
neurons O
in O
carmustine O
- O
treated O
rats O
. O

hippocampal O
integrity O
is O
essential O
for O
cognitive O
functions O
. O

on O
the O
other O
hand O
, O
induction O
of O
metallothionein O
( O
mt O
) O
by O
znso O
( O
4 O
) O
and O
its O
role O
in O
neuroprotection O
has O
been O
documented O
. O

the O
present O
study O
aimed O
to O
explore O
the O
effect O
of O
mt O
induction O
on O
carmustine O
( O
bcnu O
) O
- O
induced O
hippocampal O
cognitive B-Disease
dysfunction I-Disease
in O
rats O
. O

a O
total O
of O
60 O
male O
wistar O
albino O
rats O
were O
randomly O
divided O
into O
four O
groups O
( O
15 O
/ O
group O
) O
: O
the O
control O
group O
injected O
with O
single O
doses O
of O
normal O
saline O
( O
i O
. O
c O
. O
v O
) O
followed O
24 O
h O
later O
by O
bcnu O
solvent O
( O
i O
. O
v O
) O
. O

the O
second O
group O
administered O
znso O
( O
4 O
) O
( O
0 O
. O
1 O
micromol O
/ O
10 O
microl O
normal O
saline O
, O
i O
. O
c O
. O
v O
, O
once O
) O
then O
bcnu O
solvent O
( O
i O
. O
v O
) O
after O
24 O
h O
. O

third O
group O
received O
bcnu O
( O
20 O
mg O
/ O
kg O
, O
i O
. O
v O
, O
once O
) O
24 O
h O
after O
injection O
with O
normal O
saline O
( O
i O
. O
c O
. O
v O
) O
. O

fourth O
group O
received O
a O
single O
dose O
of O
znso O
( O
4 O
) O
( O
0 O
. O
1 O
micromol O
/ O
10 O
microl O
normal O
saline O
, O
i O
. O
c O
. O
v O
) O
then O
bcnu O
( O
20 O
mg O
/ O
kg O
, O
i O
. O
v O
, O
once O
) O
after O
24 O
h O
. O

the O
obtained O
data O
revealed O
that O
bcnu O
administration O
resulted O
in O
deterioration B-Disease
of I-Disease
learning I-Disease
and I-Disease
short I-Disease
- I-Disease
term I-Disease
memory I-Disease
( O
stm O
) O
, O
as O
measured O
by O
using O
radial O
arm O
water O
maze O
, O
accompanied O
with O
decreased O
hippocampal O
glutathione O
reductase O
( O
gr O
) O
activity O
and O
reduced O
glutathione O
( O
gsh O
) O
content O
. O

also O
, O
bcnu O
administration O
increased O
serum O
tumor B-Disease
necrosis B-Disease
factor O
- O
alpha O
( O
tnfalpha O
) O
, O
hippocampal O
mt O
and O
malondialdehyde O
( O
mda O
) O
contents O
as O
well O
as O
caspase O
- O
3 O
activity O
in O
addition O
to O
histological O
alterations O
. O

znso O
( O
4 O
) O
pretreatment O
counteracted O
bcnu O
- O
induced O
inhibition O
of O
gr O
and O
depletion O
of O
gsh O
and O
resulted O
in O
significant O
reduction O
in O
the O
levels O
of O
mda O
and O
tnfalpha O
as O
well O
as O
the O
activity O
of O
caspase O
- O
3 O
. O

the O
histological O
features O
were O
improved O
in O
hippocampus O
of O
rats O
treated O
with O
znso O
( O
4 O
) O
+ O
bcnu O
compared O
to O
only O
bcnu O
- O
treated O
animals O
. O

in O
conclusion O
, O
mt O
induction O
halts O
bcnu O
- O
induced O
hippocampal O
toxicity B-Disease
as O
it O
prevented O
gr O
inhibition O
and O
gsh O
depletion O
and O
counteracted O
the O
increased O
levels O
of O
tnfalpha O
, O
mda O
and O
caspase O
- O
3 O
activity O
with O
subsequent O
preservation O
of O
cognition O
. O

fatal O
carbamazepine O
induced O
fulminant B-Disease
eosinophilic I-Disease
( O
hypersensitivity B-Disease
) O
myocarditis B-Disease
: O
emphasis O
on O
anatomical O
and O
histological O
characteristics O
, O
mechanisms O
and O
genetics O
of O
drug B-Disease
hypersensitivity I-Disease
and O
differential O
diagnosis O
. O

the O
most O
severe O
adverse O
reactions O
to O
carbamazepine O
have O
been O
observed O
in O
the O
haemopoietic O
system O
, O
the O
liver O
and O
the O
cardiovascular O
system O
. O

a O
frequently O
fatal O
, O
although O
exceptionally O
rare O
side O
effect O
of O
carbamazepine O
is O
necrotizing O
eosinophilic O
( O
hypersensitivity B-Disease
) O
myocarditis B-Disease
. O

we O
report O
a O
case O
of O
hypersensitivity B-Disease
myocarditis B-Disease
secondary O
to O
administration O
of O
carbamazepine O
. O

acute O
hypersensitivity B-Disease
myocarditis B-Disease
was O
not O
suspected O
clinically O
, O
and O
the O
diagnosis O
was O
made O
post O
- O
mortem O
. O

histology O
revealed O
diffuse O
infiltration O
of O
the O
myocardium O
by O
eosinophils O
and O
lymphocytes O
with O
myocyte O
damage O
. O

clinically O
, O
death O
was O
due O
to O
cardiogenic B-Disease
shock I-Disease
. O

to O
best O
of O
our O
knowledge O
this O
is O
the O
second O
case O
of O
fatal O
carbamazepine O
induced O
myocarditis B-Disease
reported O
in O
english O
literature O
. O

neuropsychiatric O
behaviors O
in O
the O
mptp O
marmoset O
model O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

objectives O
: O
neuropsychiatric O
symptoms O
are O
increasingly O
recognised O
as O
a O
significant O
problem O
in O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
. O

these O
symptoms O
may O
be O
due O
to O
' O
sensitisation O
' O
following O
repeated O
levodopa O
treatment O
or O
a O
direct O
effect O
of O
dopamine O
on O
the O
disease O
state O
. O

the O
levodopa O
- O
treated O
mptp O
- O
lesioned O
marmoset O
was O
used O
as O
a O
model O
of O
neuropsychiatric B-Disease
symptoms I-Disease
in O
pd B-Disease
patients O
. O

here O
we O
compare O
the O
time O
course O
of O
levodopa O
- O
induced O
motor O
fluctuations O
and O
neuropsychiatric B-Disease
- I-Disease
like I-Disease
behaviors I-Disease
to O
determine O
the O
relationship O
between O
duration O
of O
treatment O
and O
onset O
of O
symptoms O
. O

methods O
: O
marmosets O
were O
administered O
1 O
- O
methyl O
- O
4 O
- O
phenyl O
- O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridine O
( O
2 O
. O
0 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
for O
five O
days O
, O
resulting O
in O
stable O
parkinsonism B-Disease
. O

levodopa O
( O
15 O
mg O
/ O
kg O
and O
benserazide O
, O
3 O
. O
75 O
mg O
/ O
kg O
) O
p O
. O
o O
. O

b O
. O
i O
. O
d O
, O
was O
administered O
for O
30 O
days O
. O

animals O
were O
evaluated O
for O
parkinsonian B-Disease
disability I-Disease
, O
dyskinesia B-Disease
and O
on O
- O
time O
( O
motor O
fluctuations O
) O
and O
neuropsychiatric B-Disease
- I-Disease
like I-Disease
behaviors I-Disease
on O
day O
0 O
( O
prior O
to O
levodopa O
) O
and O
on O
days O
1 O
, O
7 O
, O
13 O
, O
27 O
and O
30 O
of O
treatment O
using O
post O
hoc O
dvd O
analysis O
by O
a O
trained O
rater O
, O
blind O
to O
the O
treatment O
day O
. O

results O
: O
the O
neuropsychiatric B-Disease
- I-Disease
like I-Disease
behavior I-Disease
rating O
scale O
demonstrated O
high O
interrater O
reliability O
between O
three O
trained O
raters O
of O
differing O
professional O
backgrounds O
. O

as O
anticipated O
, O
animals O
exhibited O
a O
progressive O
increase O
in O
levodopa O
- O
induced O
motor O
fluctuations O
, O
dyskinesia B-Disease
and O
wearing O
- O
off O
, O
that O
correlated O
with O
the O
duration O
of O
levodopa O
therapy O
. O

in O
contrast O
, O
levodopa O
- O
induced O
neuropsychiatric B-Disease
- I-Disease
like I-Disease
behaviors I-Disease
were O
present O
on O
day O
1 O
of O
levodopa O
treatment O
and O
their O
severity O
did O
not O
correlate O
with O
duration O
of O
treatment O
. O

conclusions O
: O
the O
data O
suggest O
that O
neuropsychiatric B-Disease
disorders I-Disease
in O
pd B-Disease
are O
more O
likely O
an O
interaction O
between O
levodopa O
and O
the O
disease O
state O
than O
a O
consequence O
of O
sensitisation O
to O
repeated O
dopaminergic O
therapy O
. O

contrast O
medium O
nephrotoxicity B-Disease
after O
renal O
artery O
and O
coronary O
angioplasty O
. O

background O
: O
renal B-Disease
dysfunction I-Disease
induced O
by O
iodinated O
contrast O
medium O
( O
cm O
) O
administration O
can O
minimize O
the O
benefit O
of O
the O
interventional O
procedure O
in O
patients O
undergoing O
renal O
angioplasty O
( O
ptra O
) O
. O

purpose O
: O
to O
compare O
the O
susceptibility O
to O
nephrotoxic B-Disease
effect O
of O
cm O
in O
patients O
undergoing O
ptra O
with O
that O
of O
patients O
submitted O
to O
percutaneous O
coronary O
intervention O
( O
pci O
) O
. O

material O
and O
methods O
: O
a O
total O
of O
33 O
patients O
successfully O
treated O
with O
ptra O
( O
ptra O
group O
, O
mean O
age O
70 O
+ O
/ O
- O
12 O
years O
, O
23 O
female O
, O
basal O
creatinine O
1 O
. O
46 O
+ O
/ O
- O
0 O
. O
79 O
, O
range O
0 O
. O
7 O
- O
4 O
. O
9 O
mg O
/ O
dl O
) O
were O
compared O
with O
33 O
patients O
undergoing O
successful O
pci O
( O
pci O
group O
) O
, O
matched O
for O
basal O
creatinine O
( O
1 O
. O
44 O
+ O
/ O
- O
0 O
. O
6 O
, O
range O
0 O
. O
7 O
- O
3 O
. O
4 O
mg O
/ O
dl O
) O
, O
gender O
, O
and O
age O
. O

in O
both O
groups O
postprocedural O
( O
48 O
h O
) O
serum O
creatinine O
was O
measured O
. O

results O
: O
postprocedural O
creatinine O
level O
decreased O
nonsignificantly O
in O
the O
ptra O
group O
( O
1 O
. O
46 O
+ O
/ O
- O
0 O
. O
8 O
vs O
. O
1 O
. O
34 O
+ O
/ O
- O
0 O
. O
5 O
mg O
/ O
dl O
, O
p O
= O
ns O
) O
and O
increased O
significantly O
in O
the O
pci O
group O
( O
1 O
. O
44 O
+ O
/ O
- O
0 O
. O
6 O
vs O
. O
1 O
. O
57 O
+ O
/ O
- O
0 O
. O
7 O
mg O
/ O
dl O
, O
p O
< O
0 O
. O
02 O
) O
. O

changes O
in O
serum O
creatinine O
after O
intervention O
( O
after O
- O
before O
) O
were O
significantly O
different O
between O
the O
ptra O
and O
pci O
groups O
( O
- O
0 O
. O
12 O
+ O
/ O
- O
0 O
. O
5 O
vs O
. O
0 O
. O
13 O
+ O
/ O
- O
0 O
. O
3 O
, O
p O
= O
0 O
. O
014 O
) O
. O

this O
difference O
was O
not O
related O
to O
either O
a O
different O
clinical O
risk O
profile O
or O
to O
the O
volume O
of O
cm O
administered O
. O

conclusion O
: O
in O
this O
preliminary O
study O
patients O
submitted O
to O
ptra O
showed O
a O
lower O
susceptibility O
to O
renal B-Disease
damage I-Disease
induced O
by O
cm O
administration O
than O
pci O
patients O
. O

the O
effectiveness O
of O
ptra O
on O
renal O
function O
seems O
to O
be O
barely O
influenced O
by O
cm O
toxicity B-Disease
. O

diphenhydramine O
prevents O
the O
haemodynamic O
changes O
of O
cimetidine O
in O
icu O
patients O
. O

cimetidine O
, O
a O
histamine O
2 O
( O
h2 O
) O
antagonist O
, O
produces O
a O
decrease O
in O
arterial O
pressure O
due O
to O
vasodilatation O
, O
especially O
in O
critically O
ill O
patients O
. O

this O
may O
be O
because O
cimetidine O
acts O
as O
a O
histamine O
agonist O
. O

we O
, O
therefore O
, O
investigated O
the O
effects O
of O
the O
histamine O
1 O
( O
h1 O
) O
receptor O
antagonist O
, O
diphenhydramine O
, O
on O
the O
haemodynamic O
changes O
observed O
after O
cimetidine O
in O
icu O
patients O
. O

each O
patient O
was O
studied O
on O
two O
separate O
days O
. O

in O
a O
random O
fashion O
, O
they O
received O
cimetidine O
200 O
mg O
iv O
on O
one O
day O
, O
and O
on O
the O
other O
, O
a O
pretreatment O
of O
diphenhydramine O
40 O
mg O
iv O
with O
cimetidine O
200 O
mg O
iv O
. O

in O
the O
non O
- O
pretreatment O
group O
, O
mean O
arterial O
pressure O
( O
map O
) O
decreased O
from O
107 O
. O
4 O
+ O
/ O
- O
8 O
. O
4 O
mmhg O
to O
86 O
. O
7 O
+ O
/ O
- O
11 O
. O
4 O
mmhg O
( O
p O
less O
than O
0 O
. O
01 O
) O
two O
minutes O
after O
cimetidine O
. O

also O
, O
systemic O
vascular O
resistance O
( O
svr O
) O
decreased O
during O
the O
eight O
- O
minute O
observation O
period O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

in O
contrast O
, O
in O
the O
pretreatment O
group O
, O
little O
haemodynamic O
change O
was O
seen O
. O

we O
conclude O
that O
an O
h1 O
antagonist O
may O
be O
useful O
in O
preventing O
hypotension B-Disease
caused O
by O
iv O
cimetidine O
, O
since O
the O
vasodilating O
activity O
of O
cimetidine O
is O
mediated O
, O
in O
part O
, O
through O
the O
h1 O
receptor O
. O

medical O
and O
psychiatric O
outcomes O
for O
patients O
transplanted O
for O
acetaminophen O
- O
induced O
acute B-Disease
liver I-Disease
failure I-Disease
: O
a O
case O
- O
control O
study O
. O

background O
: O
acetaminophen O
- O
induced O
hepatotoxicity B-Disease
is O
the O
most O
common O
cause O
of O
acute B-Disease
liver I-Disease
failure I-Disease
( O
alf B-Disease
) O
in O
the O
uk O
. O

patients O
often O
consume O
the O
drug O
with O
suicidal O
intent O
or O
with O
a O
background O
of O
substance O
dependence O
. O

aims O
and O
methods O
: O
we O
compared O
the O
severity O
of O
pretransplant O
illness O
, O
psychiatric O
co O
- O
morbidity O
, O
medical O
and O
psychosocial O
outcomes O
of O
all O
patients O
who O
had O
undergone O
liver O
transplantation O
( O
lt O
) O
emergently O
between O
1999 O
- O
2004 O
for O
acetaminophen O
- O
induced O
alf B-Disease
( O
n O
= O
36 O
) O
with O
age O
- O
and O
sex O
- O
matched O
patients O
undergoing O
emergent O
lt O
for O
non O
- O
acetaminophen O
- O
induced O
alf B-Disease
( O
n O
= O
35 O
) O
and O
elective O
lt O
for O
chronic B-Disease
liver I-Disease
disease I-Disease
( O
cld B-Disease
, O
n O
= O
34 O
) O
. O

results O
: O
acetaminophen O
- O
induced O
alf B-Disease
patients O
undergoing O
lt O
had O
a O
greater O
severity O
of O
pre O
- O
lt O
illness O
reflected O
by O
higher O
acute O
physiology O
and O
chronic O
health O
evaluation O
ii O
scores O
and O
requirement O
for O
organ O
support O
compared O
with O
the O
other O
two O
groups O
. O

twenty O
( O
56 O
% O
) O
acetaminophen O
- O
induced O
alf B-Disease
patients O
had O
a O
formal O
psychiatric O
diagnosis O
before O
lt O
( O
non O
- O
acetaminophen O
- O
induced O
alf B-Disease
= O
0 O
/ O
35 O
, O
cld B-Disease
= O
2 O
/ O
34 O
; O
p O
< O
0 O
. O
01 O
for O
all O
) O
and O
nine O
( O
25 O
% O
) O
had O
a O
previous O
suicide O
attempt O
. O

during O
follow O
- O
up O
( O
median O
5 O
years O
) O
, O
there O
were O
no O
significant O
differences O
in O
rejection O
( O
acute O
and O
chronic O
) O
, O
graft O
failure O
or O
survival O
between O
the O
groups O
( O
acetaminophen O
- O
induced O
alf B-Disease
1 O
year O
87 O
% O
, O
5 O
years O
75 O
% O
; O
non O
- O
acetaminophen O
- O
induced O
alf B-Disease
88 O
% O
, O
78 O
% O
; O
cld B-Disease
93 O
% O
, O
82 O
% O
: O
p O
> O
0 O
. O
6 O
log O
rank O
) O
. O

two O
acetaminophen O
- O
induced O
alf B-Disease
patients O
reattempted O
suicide O
post O
- O
lt O
( O
one O
died O
8 O
years O
post O
- O
lt O
) O
. O

conclusions O
: O
despite O
a O
high O
prevalence O
of O
psychiatric O
disturbance O
, O
outcomes O
for O
patients O
transplanted O
emergently O
for O
acetaminophen O
- O
induced O
alf B-Disease
were O
comparable O
to O
those O
transplanted O
for O
non O
- O
acetaminophen O
- O
induced O
alf B-Disease
and O
electively O
for O
cld B-Disease
. O

multidisciplinary O
approaches O
with O
long O
- O
term O
psychiatric O
follow O
- O
up O
may O
contribute O
to O
low O
post O
- O
transplant O
suicide O
rates O
seen O
and O
low O
rates O
of O
graft O
loss O
because O
of O
non O
- O
compliance O
. O

antithrombotic O
drug O
use O
, O
cerebral B-Disease
microbleeds I-Disease
, O
and O
intracerebral B-Disease
hemorrhage I-Disease
: O
a O
systematic O
review O
of O
published O
and O
unpublished O
studies O
. O

background O
and O
purpose O
: O
cerebral B-Disease
microbleeds I-Disease
( O
mb B-Disease
) O
are O
potential O
risk O
factors O
for O
intracerebral B-Disease
hemorrhage I-Disease
( O
ich B-Disease
) O
, O
but O
it O
is O
unclear O
if O
they O
are O
a O
contraindication O
to O
using O
antithrombotic O
drugs O
. O

insights O
could O
be O
gained O
by O
pooling O
data O
on O
mb B-Disease
frequency O
stratified O
by O
antithrombotic O
use O
in O
cohorts O
with O
ich B-Disease
and O
ischemic B-Disease
stroke I-Disease
( O
is B-Disease
) O
/ O
transient B-Disease
ischemic I-Disease
attack I-Disease
( O
tia B-Disease
) O
. O

methods O
: O
we O
performed O
a O
systematic O
review O
of O
published O
and O
unpublished O
data O
from O
cohorts O
with O
stroke B-Disease
or O
tia B-Disease
to O
compare O
the O
presence O
of O
mb B-Disease
in O
: O
( O
1 O
) O
antithrombotic O
users O
vs O
nonantithrombotic O
users O
with O
ich B-Disease
; O
( O
2 O
) O
antithrombotic O
users O
vs O
nonusers O
with O
is B-Disease
/ O
tia B-Disease
; O
and O
( O
3 O
) O
ich B-Disease
vs O
ischemic B-Disease
events O
stratified O
by O
antithrombotic O
use O
. O

we O
also O
analyzed O
published O
and O
unpublished O
follow O
- O
up O
data O
to O
determine O
the O
risk O
of O
ich B-Disease
in O
antithrombotic O
users O
with O
mb B-Disease
. O

results O
: O
in O
a O
pooled O
analysis O
of O
1460 O
ich B-Disease
and O
3817 O
is B-Disease
/ O
tia B-Disease
, O
mb B-Disease
were O
more O
frequent O
in O
ich B-Disease
vs O
is B-Disease
/ O
tia B-Disease
in O
all O
treatment O
groups O
, O
but O
the O
excess O
increased O
from O
2 O
. O
8 O
( O
odds O
ratio O
; O
range O
, O
2 O
. O
3 O
- O
3 O
. O
5 O
) O
in O
nonantithrombotic O
users O
to O
5 O
. O
7 O
( O
range O
, O
3 O
. O
4 O
- O
9 O
. O
7 O
) O
in O
antiplatelet O
users O
and O
8 O
. O
0 O
( O
range O
, O
3 O
. O
5 O
- O
17 O
. O
8 O
) O
in O
warfarin O
users O
( O
p O
difference O
= O
0 O
. O
01 O
) O
. O

there O
was O
also O
an O
excess O
of O
mb B-Disease
in O
warfarin O
users O
vs O
nonusers O
with O
ich B-Disease
( O
or O
, O
2 O
. O
7 O
; O
95 O
% O
ci O
, O
1 O
. O
6 O
- O
4 O
. O
4 O
; O
p O
< O
0 O
. O
001 O
) O
but O
none O
in O
warfarin O
users O
with O
is B-Disease
/ O
tia B-Disease
( O
or O
, O
1 O
. O
3 O
; O
95 O
% O
ci O
, O
0 O
. O
9 O
- O
1 O
. O
7 O
; O
p O
= O
0 O
. O
33 O
; O
p O
difference O
= O
0 O
. O
01 O
) O
. O

there O
was O
a O
smaller O
excess O
of O
mb B-Disease
in O
antiplatelet O
users O
vs O
nonusers O
with O
ich B-Disease
( O
or O
, O
1 O
. O
7 O
; O
95 O
% O
ci O
, O
1 O
. O
3 O
- O
2 O
. O
3 O
; O
p O
< O
0 O
. O
001 O
) O
, O
but O
findings O
were O
similar O
for O
antiplatelet O
users O
with O
is B-Disease
/ O
tia B-Disease
( O
or O
, O
1 O
. O
4 O
; O
95 O
% O
ci O
, O
1 O
. O
2 O
- O
1 O
. O
7 O
; O
p O
< O
0 O
. O
001 O
; O
p O
difference O
= O
0 O
. O
25 O
) O
. O

in O
pooled O
follow O
- O
up O
data O
for O
768 O
antithrombotic O
users O
, O
presence O
of O
mb B-Disease
at O
baseline O
was O
associated O
with O
a O
substantially O
increased O
risk O
of O
subsequent O
ich B-Disease
( O
or O
, O
12 O
. O
1 O
; O
95 O
% O
ci O
, O
3 O
. O
4 O
- O
42 O
. O
5 O
; O
p O
< O
0 O
. O
001 O
) O
. O

conclusions O
: O
the O
excess O
of O
mb B-Disease
in O
warfarin O
users O
with O
ich B-Disease
compared O
to O
other O
groups O
suggests O
that O
mb B-Disease
increase O
the O
risk O
of O
warfarin O
- O
associated O
ich B-Disease
. O

limited O
prospective O
data O
corroborate O
these O
findings O
, O
but O
larger O
prospective O
studies O
are O
urgently O
required O
. O

studies O
of O
synergy O
between O
morphine O
and O
a O
novel O
sodium O
channel O
blocker O
, O
cnsb002 O
, O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic B-Disease
pain I-Disease
. O

objective O
: O
this O
study O
determined O
the O
antihyperalgesic O
effect O
of O
cnsb002 O
, O
a O
sodium O
channel O
blocker O
with O
antioxidant O
properties O
given O
alone O
and O
in O
combinations O
with O
morphine O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic B-Disease
pain I-Disease
. O

design O
: O
dose O
response O
curves O
for O
nonsedating O
doses O
of O
morphine O
and O
cnsb002 O
given O
intraperitoneally O
alone O
and O
together O
in O
combinations O
were O
constructed O
for O
antihyperalgesic O
effect O
using O
paw O
withdrawal O
from O
noxious O
heat O
in O
two O
rat O
pain B-Disease
models O
: O
carrageenan O
- O
induced O
paw O
inflammation B-Disease
and O
streptozotocin O
( O
stz O
) O
- O
induced O
diabetic B-Disease
neuropathy I-Disease
. O

results O
: O
the O
maximum O
nonsedating O
doses O
were O
: O
morphine O
, O
3 O
. O
2 O
mg O
/ O
kg O
; O
cnsb002 O
10 O
. O
0 O
mg O
/ O
kg O
; O
5 O
. O
0 O
mg O
/ O
kg O
cnsb002 O
with O
morphine O
3 O
. O
2 O
mg O
/ O
kg O
in O
combination O
. O

the O
doses O
calculated O
to O
cause O
50 O
% O
reversal O
of O
hyperalgesia B-Disease
( O
ed50 O
) O
were O
7 O
. O
54 O
( O
1 O
. O
81 O
) O
and O
4 O
. O
83 O
( O
1 O
. O
54 O
) O
in O
the O
carrageenan O
model O
and O
44 O
. O
18 O
( O
1 O
. O
37 O
) O
and O
9 O
. O
14 O
( O
1 O
. O
24 O
) O
in O
the O
stz O
- O
induced O
neuropathy B-Disease
model O
for O
cnsb002 O
and O
morphine O
, O
respectively O
( O
mg O
/ O
kg O
; O
mean O
, O
sem O
) O
. O

these O
values O
were O
greater O
than O
the O
maximum O
nonsedating O
doses O
. O

the O
ed50 O
values O
for O
morphine O
when O
given O
in O
combination O
with O
cnsb002 O
( O
5 O
mg O
/ O
kg O
) O
were O
less O
than O
the O
maximum O
nonsedating O
dose O
: O
0 O
. O
56 O
( O
1 O
. O
55 O
) O
in O
the O
carrageenan O
model O
and O
1 O
. O
37 O
( O
1 O
. O
23 O
) O
in O
the O
neuropathy B-Disease
model O
( O
mg O
/ O
kg O
; O
mean O
, O
sem O
) O
. O

the O
antinociception O
after O
morphine O
( O
3 O
. O
2 O
mg O
/ O
kg O
) O
was O
increased O
by O
co O
- O
administration O
with O
cnsb002 O
from O
28 O
. O
0 O
and O
31 O
. O
7 O
% O
to O
114 O
. O
6 O
and O
56 O
. O
9 O
% O
reversal O
of O
hyperalgesia B-Disease
in O
the O
inflammatory O
and O
neuropathic B-Disease
models O
, O
respectively O
( O
p O
< O
0 O
. O
01 O
; O
one O
- O
way O
analysis O
of O
variance O
- O
significantly O
greater O
than O
either O
drug O
given O
alone O
) O
. O

conclusions O
: O
the O
maximum O
antihyperalgesic O
effect O
achievable O
with O
nonsedating O
doses O
of O
morphine O
may O
be O
increased O
significantly O
when O
the O
drug O
is O
used O
in O
combination O
with O
cnsb002 O
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
: O
a O
practical O
review O
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
( O
hit B-Disease
) O
remains O
under O
- O
recognized O
despite O
its O
potentially O
devastating O
outcomes O
. O

it O
begins O
when O
heparin O
exposure O
stimulates O
the O
formation O
of O
heparin O
- O
platelet O
factor O
4 O
antibodies O
, O
which O
in O
turn O
triggers O
the O
release O
of O
procoagulant O
platelet O
particles O
. O

thrombosis B-Disease
and O
thrombocytopenia B-Disease
that O
follow O
comprise O
the O
2 O
hallmark O
traits O
of O
hit B-Disease
, O
with O
the O
former O
largely O
responsible O
for O
significant O
vascular O
complications O
. O

the O
prevalence O
of O
hit B-Disease
varies O
among O
several O
subgroups O
, O
with O
greater O
incidence O
in O
surgical O
as O
compared O
with O
medical O
populations O
. O

hit B-Disease
must O
be O
acknowledged O
for O
its O
intense O
predilection O
for O
thrombosis B-Disease
and O
suspected O
whenever O
thrombosis B-Disease
occurs O
after O
heparin O
exposure O
. O

early O
recognition O
that O
incorporates O
the O
clinical O
and O
serologic O
clues O
is O
paramount O
to O
timely O
institution O
of O
treatment O
, O
as O
its O
delay O
may O
result O
in O
catastrophic O
outcomes O
. O

the O
treatment O
of O
hit B-Disease
mandates O
an O
immediate O
cessation O
of O
all O
heparin O
exposure O
and O
the O
institution O
of O
an O
antithrombotic O
therapy O
, O
most O
commonly O
using O
a O
direct O
thrombin O
inhibitor O
. O

current O
" O
diagnostic O
" O
tests O
, O
which O
primarily O
include O
functional O
and O
antigenic O
assays O
, O
have O
more O
of O
a O
confirmatory O
than O
diagnostic O
role O
in O
the O
management O
of O
hit B-Disease
. O

special O
attention O
must O
be O
paid O
to O
cardiac O
patients O
who O
are O
often O
exposed O
to O
heparin O
multiple O
times O
during O
their O
course O
of O
treatment O
. O

direct O
thrombin O
inhibitors O
are O
appropriate O
, O
evidence O
- O
based O
alternatives O
to O
heparin O
in O
patients O
with O
a O
history O
of O
hit B-Disease
, O
who O
need O
to O
undergo O
percutaneous O
coronary O
intervention O
. O

as O
heparin O
remains O
one O
of O
the O
most O
frequently O
used O
medications O
today O
with O
potential O
for O
hit B-Disease
with O
every O
heparin O
exposure O
, O
a O
close O
vigilance O
of O
platelet O
counts O
must O
be O
practiced O
whenever O
heparin O
is O
initiated O
. O

abductor O
paralysis B-Disease
after O
botox O
injection O
for O
adductor B-Disease
spasmodic I-Disease
dysphonia I-Disease
. O

objectives O
/ O
hypothesis O
: O
botulinum O
toxin O
( O
botox O
) O
injections O
into O
the O
thyroarytenoid O
muscles O
are O
the O
current O
standard O
of O
care O
for O
adductor B-Disease
spasmodic I-Disease
dysphonia I-Disease
( O
adsd B-Disease
) O
. O

reported O
adverse O
effects O
include O
a O
period O
of O
breathiness O
, O
throat B-Disease
pain I-Disease
, O
and O
difficulty O
with O
swallowing O
liquids O
. O

here O
we O
report O
multiple O
cases O
of O
bilateral O
abductor O
paralysis B-Disease
following O
botox O
injections O
for O
adsd B-Disease
, O
a O
complication O
previously O
unreported O
. O

study O
design O
: O
retrospective O
case O
series O
. O

methods O
: O
patients O
that O
received O
botox O
injections O
for O
spasmodic B-Disease
dysphonia I-Disease
between O
january O
2000 O
and O
october O
2009 O
were O
evaluated O
. O

patients O
with O
adsd B-Disease
were O
identified O
. O

the O
number O
of O
treatments O
received O
and O
adverse O
effects O
were O
noted O
. O

for O
patients O
with O
bilateral O
abductor O
paralysis B-Disease
, O
age O
, O
sex O
, O
paralytic O
botox O
dose O
, O
prior O
botox O
dose O
, O
and O
course O
following O
paralysis B-Disease
were O
noted O
. O

results O
: O
from O
a O
database O
of O
452 O
patients O
receiving O
botox O
, O
352 O
patients O
had O
been O
diagnosed O
with O
adsd B-Disease
. O

of O
these O
352 O
patients O
, O
eight O
patients O
suffered O
bilateral O
abductor O
paralysis B-Disease
, O
and O
two O
suffered O
this O
complication O
twice O
. O

all O
affected O
patients O
were O
females O
over O
the O
age O
of O
50 O
years O
. O

most O
patients O
had O
received O
treatments O
prior O
to O
abductor O
paralysis B-Disease
and O
continued O
receiving O
after O
paralysis B-Disease
. O

seven O
patients O
recovered O
after O
a O
brief O
period O
of O
activity O
restrictions O
, O
and O
one O
underwent O
a O
tracheotomy O
. O

the O
incidence O
of O
abductor O
paralysis B-Disease
after O
botox O
injection O
for O
adsd B-Disease
was O
0 O
. O
34 O
% O
. O

conclusions O
: O
bilateral O
abductor O
paralysis B-Disease
is O
a O
rare O
complication O
of O
botox O
injections O
for O
adsd B-Disease
, O
causing O
difficulty O
with O
breathing O
upon O
exertion O
. O

the O
likely O
mechanism O
of O
paralysis B-Disease
is O
diffusion O
of O
botox O
around O
the O
muscular O
process O
of O
the O
arytenoid O
to O
the O
posterior O
cricoarytenoid O
muscles O
. O

the O
paralysis B-Disease
is O
temporary O
, O
and O
watchful O
waiting O
with O
restriction O
of O
activity O
is O
the O
recommended O
management O
. O

mitochondrial B-Disease
impairment I-Disease
contributes O
to O
cocaine O
- O
induced O
cardiac B-Disease
dysfunction I-Disease
: O
prevention O
by O
the O
targeted O
antioxidant O
mitoq O
. O

the O
goal O
of O
this O
study O
was O
to O
assess O
mitochondrial O
function O
and O
ros O
production O
in O
an O
experimental O
model O
of O
cocaine O
- O
induced O
cardiac B-Disease
dysfunction I-Disease
. O

we O
hypothesized O
that O
cocaine B-Disease
abuse I-Disease
may O
lead O
to O
altered O
mitochondrial O
function O
that O
in O
turn O
may O
cause O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
. O

seven O
days O
of O
cocaine O
administration O
to O
rats O
led O
to O
an O
increased O
oxygen O
consumption O
detected O
in O
cardiac O
fibers O
, O
specifically O
through O
complex O
i O
and O
complex O
iii O
. O

ros O
levels O
were O
increased O
, O
specifically O
in O
interfibrillar O
mitochondria O
. O

in O
parallel O
there O
was O
a O
decrease O
in O
atp O
synthesis O
, O
whereas O
no O
difference O
was O
observed O
in O
subsarcolemmal O
mitochondria O
. O

this O
uncoupling O
effect O
on O
oxidative O
phosphorylation O
was O
not O
detectable O
after O
short O
- O
term O
exposure O
to O
cocaine O
, O
suggesting O
that O
these O
mitochondrial B-Disease
abnormalities I-Disease
were O
a O
late O
rather O
than O
a O
primary O
event O
in O
the O
pathological O
response O
to O
cocaine O
. O

mitoq O
, O
a O
mitochondrial O
- O
targeted O
antioxidant O
, O
was O
shown O
to O
completely O
prevent O
these O
mitochondrial B-Disease
abnormalities I-Disease
as O
well O
as O
cardiac B-Disease
dysfunction I-Disease
characterized O
here O
by O
a O
diastolic B-Disease
dysfunction I-Disease
studied O
with O
a O
conductance O
catheter O
to O
obtain O
pressure O
- O
volume O
data O
. O

taken O
together O
, O
these O
results O
extend O
previous O
studies O
and O
demonstrate O
that O
cocaine O
- O
induced O
cardiac B-Disease
dysfunction I-Disease
may O
be O
due O
to O
a O
mitochondrial B-Disease
defect I-Disease
. O

trimethoprim O
- O
induced O
immune O
hemolytic B-Disease
anemia I-Disease
in O
a O
pediatric O
oncology O
patient O
presenting O
as O
an O
acute O
hemolytic O
transfusion O
reaction O
. O

a O
10 O
- O
year O
- O
old O
male O
with O
acute B-Disease
leukemia I-Disease
presented O
with O
post O
- O
chemotherapy O
anemia B-Disease
. O

during O
red O
cell O
transfusion O
, O
he O
developed O
hemoglobinuria B-Disease
. O

transfusion O
reaction O
workup O
was O
negative O
. O

drug O
- O
induced O
immune O
hemolytic B-Disease
anemia I-Disease
was O
suspected O
because O
of O
positive O
direct O
antiglobulin O
test O
, O
negative O
eluate O
, O
and O
microspherocytes O
on O
smear O
pre O
- O
and O
post O
- O
transfusion O
. O

drug O
studies O
using O
the O
indirect O
antiglobulin O
test O
were O
strongly O
positive O
with O
trimethoprim O
and O
trimethoprim O
- O
sulfamethoxazole O
but O
negative O
with O
sulfamethoxazole O
. O

the O
patient O
recovered O
after O
discontinuing O
the O
drug O
, O
with O
no O
recurrence O
in O
2 O
years O
. O

other O
causes O
of O
anemia B-Disease
should O
be O
considered O
in O
patients O
with O
worse O
- O
than O
- O
expected O
anemia B-Disease
after O
chemotherapy O
. O

furthermore O
, O
hemolysis B-Disease
during O
transfusion O
is O
not O
always O
a O
transfusion O
reaction O
. O

verapamil O
stimulation O
test O
in O
hyperprolactinemia B-Disease
: O
loss O
of O
prolactin O
response O
in O
anatomic O
or O
functional O
stalk O
effect O
. O

aim O
: O
verapamil O
stimulation O
test O
was O
previously O
investigated O
as O
a O
tool O
for O
differential O
diagnosis O
of O
hyperprolactinemia B-Disease
, O
but O
with O
conflicting O
results O
. O

macroprolactinemia B-Disease
was O
never O
considered O
in O
those O
previous O
studies O
. O

here O
, O
we O
aimed O
to O
re O
- O
investigate O
the O
diagnostic O
value O
of O
verapamil O
in O
a O
population O
who O
were O
all O
screened O
for O
macroprolactinemia B-Disease
. O

prolactin O
responses O
to O
verapamil O
in O
65 O
female O
patients O
( O
age O
: O
29 O
. O
9 O
+ O
/ O
- O
8 O
. O
1 O
years O
) O
with O
hyperprolactinemia B-Disease
were O
tested O
in O
a O
descriptive O
, O
matched O
case O
- O
control O
study O
. O

methods O
: O
verapamil O
80 O
mg O
, O
p O
. O
o O
. O
was O
administered O
, O
and O
then O
prl O
levels O
were O
measured O
at O
8th O
and O
16th O
hours O
, O
by O
immunometric O
chemiluminescence O
. O

verapamil O
responsiveness O
was O
determined O
by O
peak O
percent O
change O
in O
basal O
prolactin O
levels O
( O
prl O
) O
. O

results O
: O
verapamil O
significantly O
increased O
prl O
levels O
in O
healthy O
controls O
( O
n O
. O
8 O
, O
prl O
: O
183 O
% O
) O
, O
macroprolactinoma B-Disease
( O
n O
. O
8 O
, O
prl O
: O
7 O
% O
) O
, O
microprolactinoma B-Disease
( O
n O
. O
19 O
, O
prl O
: O
21 O
% O
) O
, O
macroprolactinemia B-Disease
( O
n O
. O
23 O
, O
prl O
: O
126 O
% O
) O
, O
but O
not O
in O
pseudoprolactinoma B-Disease
( O
n O
. O
8 O
, O
prl O
: O
0 O
. O
8 O
% O
) O
, O
and O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
( O
n O
. O
7 O
, O
prl O
: O
3 O
% O
) O
. O

roc O
curve O
analysis O
revealed O
that O
unresponsiveness O
to O
verapamil O
defined O
as O
prl O
< O
7 O
% O
, O
discriminated O
anatomical O
or O
functional O
stalk O
effect O
( O
sensitivity O
: O
74 O
% O
, O
specificity O
: O
73 O
% O
, O
auc O
: O
0 O
. O
855 O
+ O
/ O
- O
0 O
. O
04 O
, O
p O
< O
0 O
. O
001 O
, O
ci O
: O
0 O
. O
768 O
- O
0 O
. O
942 O
) O
associated O
with O
pseudoprolactinoma B-Disease
or O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
, O
respectively O
. O

conclusion O
: O
verapamil O
responsiveness O
is O
not O
a O
reliable O
finding O
for O
the O
differential O
diagnosis O
of O
hyperprolactinemia B-Disease
. O

however O
, O
verapamil O
unresponsiveness O
discriminates O
stalk O
effect O
( O
i O
. O
e O
. O
, O
anatomically O
or O
functionally O
inhibited O
dopaminergic O
tonus O
) O
from O
other O
causes O
of O
hyperprolactinemia B-Disease
with O
varying O
degrees O
of O
responsiveness O
. O

blockade O
of O
endothelial O
- O
mesenchymal O
transition O
by O
a O
smad3 O
inhibitor O
delays O
the O
early O
development O
of O
streptozotocin O
- O
induced O
diabetic B-Disease
nephropathy I-Disease
. O

objective O
: O
a O
multicenter O
, O
controlled O
trial O
showed O
that O
early O
blockade O
of O
the O
renin O
- O
angiotensin O
system O
in O
patients O
with O
type B-Disease
1 I-Disease
diabetes I-Disease
and O
normoalbuminuria O
did O
not O
retard O
the O
progression O
of O
nephropathy B-Disease
, O
suggesting O
that O
other O
mechanism O
( O
s O
) O
are O
involved O
in O
the O
pathogenesis O
of O
early O
diabetic B-Disease
nephropathy I-Disease
( O
diabetic B-Disease
nephropathy I-Disease
) O
. O

we O
have O
previously O
demonstrated O
that O
endothelial O
- O
mesenchymal O
- O
transition O
( O
endomt O
) O
contributes O
to O
the O
early O
development O
of O
renal O
interstitial O
fibrosis B-Disease
independently O
of O
microalbuminuria O
in O
mice O
with O
streptozotocin O
( O
stz O
) O
- O
induced O
diabetes B-Disease
. O

in O
the O
present O
study O
, O
we O
hypothesized O
that O
blocking O
endomt O
reduces O
the O
early O
development O
of O
diabetic B-Disease
nephropathy I-Disease
. O

research O
design O
and O
methods O
: O
endomt O
was O
induced O
in O
a O
mouse O
pancreatic O
microvascular O
endothelial O
cell O
line O
( O
mmec O
) O
in O
the O
presence O
of O
advanced O
glycation O
end O
products O
( O
ages O
) O
and O
in O
the O
endothelial O
lineage O
- O
traceble O
mouse O
line O
tie2 O
- O
cre O
; O
loxp O
- O
egfp O
by O
administration O
of O
ages O
, O
with O
nonglycated O
mouse O
albumin O
serving O
as O
a O
control O
. O

phosphorylated O
smad3 O
was O
detected O
by O
immunoprecipitation O
/ O
western O
blotting O
and O
confocal O
microscopy O
. O

blocking O
studies O
using O
receptor O
for O
age O
sirna O
and O
a O
specific O
inhibitor O
of O
smad3 O
( O
sis3 O
) O
were O
performed O
in O
mmecs O
and O
in O
stz O
- O
induced O
diabetic B-Disease
nephropathy I-Disease
in O
tie2 O
- O
cre O
; O
loxp O
- O
egfp O
mice O
. O

results O
: O
confocal O
microscopy O
and O
real O
- O
time O
pcr O
demonstrated O
that O
ages O
induced O
endomt O
in O
mmecs O
and O
in O
tie2 O
- O
cre O
; O
loxp O
- O
egfp O
mice O
. O

immunoprecipitation O
/ O
western O
blotting O
showed O
that O
smad3 O
was O
activated O
by O
ages O
but O
was O
inhibited O
by O
sis3 O
in O
mmecs O
and O
in O
stz O
- O
induced O
diabetic B-Disease
nephropathy I-Disease
. O

confocal O
microscopy O
and O
real O
- O
time O
pcr O
further O
demonstrated O
that O
sis3 O
abrogated O
endomt O
, O
reduced O
renal O
fibrosis B-Disease
, O
and O
retarded O
progression O
of O
nephropathy B-Disease
. O

conclusions O
: O
endomt O
is O
a O
novel O
pathway O
leading O
to O
early O
development O
of O
diabetic B-Disease
nephropathy I-Disease
. O

blockade O
of O
endomt O
by O
sis3 O
may O
provide O
a O
new O
strategy O
to O
retard O
the O
progression O
of O
diabetic B-Disease
nephropathy I-Disease
and O
other O
diabetes B-Disease
complications I-Disease
. O

cytostatic O
and O
anti O
- O
angiogenic O
effects O
of O
temsirolimus O
in O
refractory O
mantle B-Disease
cell I-Disease
lymphoma I-Disease
. O

mantle B-Disease
cell I-Disease
lymphoma I-Disease
( O
mcl B-Disease
) O
is O
a O
rare O
and O
aggressive O
type O
of O
b B-Disease
- I-Disease
cell I-Disease
non I-Disease
- I-Disease
hodgkin I-Disease
' I-Disease
s I-Disease
lymphoma I-Disease
. O

patients O
become O
progressively O
refractory O
to O
conventional O
chemotherapy O
, O
and O
their O
prognosis O
is O
poor O
. O

however O
, O
a O
38 O
% O
remission O
rate O
has O
been O
recently O
reported O
in O
refractory O
mcl B-Disease
treated O
with O
temsirolimus O
, O
a O
mtor O
inhibitor O
. O
here O
we O
had O
the O
opportunity O
to O
study O
a O
case O
of O
refractory O
mcl B-Disease
who O
had O
tumor B-Disease
regression O
two O
months O
after O
temsirolimus O
treatment O
, O
and O
a O
progression O
- O
free O
survival O
of O
10 O
months O
. O

in O
this O
case O
, O
lymph O
node O
biopsies O
were O
performed O
before O
and O
six O
months O
after O
temsirolimus O
therapy O
. O

comparison O
of O
the O
two O
biopsies O
showed O
that O
temsirolimus O
inhibited O
tumor B-Disease
cell O
proliferation O
through O
cell O
cycle O
arrest O
, O
but O
did O
not O
induce O
any O
change O
in O
the O
number O
of O
apoptotic O
tumor B-Disease
cells O
. O

apart O
from O
this O
cytostatic O
effect O
, O
temsirolimus O
had O
an O
antiangiogenic O
effect O
with O
decrease O
of O
tumor B-Disease
microvessel O
density O
and O
of O
vegf O
expression O
. O

moreover O
, O
numerous O
patchy O
, O
well O
- O
limited O
fibrotic O
areas O
, O
compatible O
with O
post O
- O
necrotic B-Disease
tissue O
repair O
, O
were O
found O
after O
6 O
- O
month O
temsirolimus O
therapy O
. O

thus O
, O
temsirolimus O
reduced O
tumor B-Disease
burden O
through O
associated O
cytostatic O
and O
anti O
- O
angiogenic O
effects O
. O
this O
dual O
effect O
of O
temsirolimus O
on O
tumor B-Disease
tissue O
could O
contribute O
to O
its O
recently O
reported O
efficiency O
in O
refractory O
mcl B-Disease
resistant O
to O
conventional O
chemotherapy O
. O

acute B-Disease
renal I-Disease
failure I-Disease
due O
to O
rifampicin O
. O

a O
23 O
- O
year O
- O
old O
male O
patient O
with O
bacteriologically O
proven O
pulmonary B-Disease
tuberculosis I-Disease
was O
treated O
with O
the O
various O
regimens O
of O
antituberculosis O
drugs O
for O
nearly O
15 O
months O
. O

rifampicin O
was O
administered O
thrice O
as O
one O
of O
the O
3 O
- O
4 O
drug O
regimen O
and O
each O
time O
he O
developed O
untoward O
side O
effects O
like O
nausea B-Disease
, O
vomiting B-Disease
and O
fever B-Disease
with O
chills O
and O
rigors O
. O

the O
last O
such O
episode O
was O
of O
acute O
renal O
failure O
at O
which O
stage O
the O
patient O
was O
seen O
by O
the O
authors O
of O
this O
report O
. O

the O
patient O
, O
however O
, O
made O
a O
full O
recovery O
. O

syncope B-Disease
caused O
by O
hyperkalemia B-Disease
during O
use O
of O
a O
combined O
therapy O
with O
the O
angiotensin O
- O
converting O
enzyme O
inhibitor O
and O
spironolactone O
. O

a O
76 O
year O
- O
old O
woman O
with O
a O
history O
of O
coronary O
artery O
bypass O
grafting O
and O
prior O
myocardial B-Disease
infarction I-Disease
was O
transferred O
to O
the O
emergency O
room O
with O
loss B-Disease
of I-Disease
consciousness I-Disease
due O
to O
marked O
bradycardia B-Disease
caused O
by O
hyperkalemia B-Disease
. O

the O
concentration O
of O
serum O
potassium O
was O
high O
, O
and O
normal O
sinus O
rhythm O
was O
restored O
after O
correction O
of O
the O
serum O
potassium O
level O
. O

the O
cause O
of O
hyperkalemia B-Disease
was O
considered O
to O
be O
several O
doses O
of O
spiranolactone O
, O
an O
aldosterone O
antagonist O
, O
in O
addition O
to O
the O
long O
- O
term O
intake O
of O
ramipril O
, O
an O
ace O
inhibitor O
. O

this O
case O
is O
a O
good O
example O
of O
electrolyte O
imbalance O
causing O
acute O
life O
- O
threatening O
cardiac O
events O
. O

clinicians O
should O
be O
alert O
to O
the O
possibility O
of O
hyperkalemia B-Disease
, O
especially O
in O
elderly O
patients O
using O
ace O
/ O
arb O
in O
combination O
with O
potassium O
sparing O
agents O
and O
who O
have O
mild O
renal B-Disease
disturbance I-Disease
. O

diffuse O
skeletal O
pain B-Disease
after O
administration O
of O
alendronate O
. O

background O
: O
osteoporosis B-Disease
is O
caused O
by O
bone O
resorption O
in O
excess O
of O
bone O
formation O
, O
and O
bisphosphonates O
, O
are O
used O
to O
inhibit O
bone O
resorption O
. O

alendronate O
, O
a O
biphosphonate O
, O
is O
effective O
for O
both O
the O
treatment O
and O
prevention O
of O
osteoporosis B-Disease
in O
postmenopausal O
women O
. O

side O
effects O
are O
relatively O
few O
and O
prominently O
gastrointestinal O
. O

musculoskeletal B-Disease
pain I-Disease
may O
be O
an O
important O
side O
effect O
in O
these O
patients O
. O

we O
presented O
a O
patient O
admitted O
to O
our O
out O
- O
patient O
clinic O
with O
diffuse O
skeletal O
pain B-Disease
after O
three O
consecutive O
administration O
of O
alendronate O
. O

conclusion O
: O
we O
conclude O
that O
patients O
with O
osteoporosis B-Disease
can O
report O
pain B-Disease
, O
and O
bisphosphonate O
- O
related O
pain B-Disease
should O
also O
be O
considered O
before O
ascribing O
this O
complaint O
to O
osteoporosis B-Disease
. O

cerebrospinal O
fluid O
penetration O
of O
high O
- O
dose O
daptomycin O
in O
suspected O
staphylococcus O
aureus O
meningitis B-Disease
. O

objective O
: O
to O
report O
a O
case O
of O
methicillin O
- O
sensitive O
staphylococcus O
aureus O
( O
mssa O
) O
bacteremia B-Disease
with O
suspected O
mssa O
meningitis B-Disease
treated O
with O
high O
- O
dose O
daptomycin O
assessed O
with O
concurrent O
serum O
and O
cerebrospinal O
fluid O
( O
csf O
) O
concentrations O
. O

case O
summary O
: O
a O
54 O
- O
year O
- O
old O
male O
presented O
to O
the O
emergency O
department O
with O
generalized O
weakness B-Disease
and O
presumed O
health O
- O
care O
- O
associated O
pneumonia B-Disease
shown O
on O
chest O
radiograph O
. O

treatment O
was O
empirically O
initiated O
with O
vancomycin O
, O
levofloxacin O
, O
and O
piperacillin O
/ O
tazobactam O
. O

blood O
cultures O
revealed O
s O
. O
aureus O
susceptible O
to O
oxacillin O
. O

empiric O
antibiotic O
treatment O
was O
narrowed O
to O
nafcillin O
on O
day O
4 O
. O

on O
day O
8 O
, O
the O
patient O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
( O
serum O
creatinine O
1 O
. O
9 O
mg O
/ O
dl O
, O
increased O
from O
1 O
. O
2 O
mg O
/ O
dl O
the O
previous O
day O
and O
0 O
. O
8 O
mg O
/ O
dl O
on O
admission O
) O
. O

the O
patient O
' O
s O
glasgow O
coma O
score O
was O
3 O
, O
with O
normal O
findings O
shown O
on O
computed O
tomography O
scan O
of O
the O
head O
72 O
hours O
following O
an O
episode O
of O
cardiac B-Disease
arrest I-Disease
on O
day O
10 O
. O

the O
patient O
experienced O
relapsing O
mssa O
bacteremia B-Disease
on O
day O
9 O
, O
increasing O
the O
suspicion O
for O
a O
central O
nervous O
system O
( O
cns O
) O
infection B-Disease
. O

nafcillin O
was O
discontinued O
and O
daptomycin O
9 O
mg O
/ O
kg O
daily O
was O
initiated O
for O
suspected O
meningitis B-Disease
and O
was O
continued O
until O
the O
patient O
' O
s O
death O
on O
day O
16 O
. O

daptomycin O
serum O
and O
csf O
trough O
concentrations O
were O
11 O
. O
21 O
ug O
/ O
ml O
and O
0 O
. O
52 O
ug O
/ O
ml O
, O
respectively O
, O
prior O
to O
the O
third O
dose O
. O

lumbar O
puncture O
results O
were O
inconclusive O
and O
no O
further O
blood O
cultures O
were O
positive O
for O
mssa O
. O

creatine O
kinase O
levels O
were O
normal O
prior O
to O
daptomycin O
therapy O
and O
were O
not O
reassessed O
. O

discussion O
: O
daptomycin O
was O
initiated O
in O
our O
patient O
secondary O
to O
possible O
nafcillin O
- O
induced O
acute O
interstitial B-Disease
nephritis I-Disease
and O
relapsing O
bacteremia B-Disease
. O

at O
a O
dose O
of O
9 O
mg O
/ O
kg O
, O
resultant O
penetration O
of O
5 O
% O
was O
higher O
than O
in O
previous O
reports O
, O
more O
consistent O
with O
inflamed O
meninges O
. O

conclusions O
: O
high O
- O
dose O
daptomycin O
may O
be O
an O
alternative O
option O
for O
mssa O
bacteremia B-Disease
with O
or O
without O
a O
cns O
source O
in O
patients O
who O
have O
failed O
or O
cannot O
tolerate O
standard O
therapy O
. O

further O
clinical O
evaluation O
in O
patients O
with O
confirmed O
meningitis B-Disease
is O
warranted O
. O

the O
role O
of O
nitric O
oxide O
in O
convulsions B-Disease
induced O
by O
lindane O
in O
rats O
. O

lindane O
is O
an O
organochloride O
pesticide O
and O
scabicide O
. O

it O
evokes O
convulsions B-Disease
mainly O
trough O
the O
blockage O
of O
gaba O
( O
a O
) O
receptors O
. O

nitric O
oxide O
( O
no O
) O
, O
gaseous O
neurotransmitter O
, O
has O
contradictor O
role O
in O
epileptogenesis O
due O
to O
opposite O
effects O
of O
l O
- O
arginine O
, O
precursor O
of O
no O
syntheses O
( O
nos O
) O
, O
and O
l O
- O
name O
( O
nos O
inhibitor O
) O
observed O
in O
different O
epilepsy B-Disease
models O
. O

the O
aim O
of O
the O
current O
study O
was O
to O
determine O
the O
effects O
of O
no O
on O
the O
behavioral O
and O
eeg O
characteristics O
of O
lindane O
- O
induced O
epilepsy B-Disease
in O
male O
wistar O
albino O
rats O
. O

the O
administration O
of O
l O
- O
arginine O
( O
600 O
, O
800 O
and O
1000 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
in O
dose O
- O
dependent O
manner O
significantly O
increased O
convulsion B-Disease
incidence O
and O
severity O
and O
shortened O
latency O
time O
to O
first O
convulsion B-Disease
elicited O
by O
lower O
lindane O
dose O
( O
4 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

on O
the O
contrary O
, O
pretreatment O
with O
l O
- O
name O
( O
500 O
, O
700 O
and O
900 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
decreased O
convulsion B-Disease
incidence O
and O
severity O
and O
prolonged O
latency O
time O
to O
convulsion B-Disease
following O
injection O
with O
a O
convulsive B-Disease
dose O
of O
lindane O
( O
8 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

eeg O
analyses O
showed O
increase O
of O
number O
and O
duration O
of O
ictal O
periods O
in O
eeg O
of O
rats O
receiving O
l O
- O
arginine O
prior O
to O
lindane O
and O
decrease O
of O
this O
number O
in O
rats O
pretreated O
with O
l O
- O
name O
. O

these O
results O
support O
the O
conclusion O
that O
no O
plays O
a O
role O
of O
endogenous O
convulsant O
in O
rat O
model O
of O
lindane O
seizures B-Disease
. O

severe O
polyneuropathy B-Disease
and O
motor O
loss O
after O
intrathecal O
thiotepa O
combination O
chemotherapy O
: O
description O
of O
two O
cases O
. O

two O
cases O
of O
severe O
delayed O
neurologic B-Disease
toxicity I-Disease
related O
to O
the O
administration O
of O
intrathecal O
( O
it O
) O
combination O
chemotherapy O
including O
thiotepa O
( O
tspa O
) O
are O
presented O
. O

both O
cases O
developed O
axonal B-Disease
neuropathy I-Disease
with O
motor O
predominance O
in O
the O
lower O
extremities O
1 O
and O
6 O
months O
after O
it O
chemotherapy O
was O
administered O
. O

neurologic B-Disease
toxicities I-Disease
have O
been O
described O
with O
it O
- O
methotrexate O
, O
it O
- O
cytosine O
arabinoside O
and O
it O
- O
tspa O
. O

to O
our O
knowledge O
, O
however O
, O
axonal B-Disease
neuropathy I-Disease
following O
administration O
of O
these O
three O
agents O
has O
not O
been O
previously O
described O
. O

in O
spite O
of O
the O
fact O
that O
tspa O
is O
a O
useful O
it O
agent O
, O
its O
combination O
with O
mtx O
, O
ara O
- O
c O
and O
radiotherapy O
could O
cause O
severe O
neurotoxicity B-Disease
. O

this O
unexpected O
complication O
indicates O
the O
need O
for O
further O
toxicology O
research O
on O
it O
- O
tspa O
. O

effects O
of O
cromakalim O
and O
pinacidil O
on O
large O
epicardial O
and O
small O
coronary O
arteries O
in O
conscious O
dogs O
. O

the O
effects O
of O
i O
. O
v O
. O
bolus O
administration O
of O
cromakalim O
( O
1 O
- O
10 O
micrograms O
/ O
kg O
) O
and O
pinacidil O
( O
3 O
- O
100 O
micrograms O
/ O
kg O
) O
on O
large O
( O
circumflex O
artery O
) O
and O
small O
coronary O
arteries O
and O
on O
systemic O
hemodynamics O
were O
investigated O
in O
chronically O
instrumented O
conscious O
dogs O
and O
compared O
to O
those O
of O
nitroglycerin O
( O
0 O
. O
03 O
- O
10 O
micrograms O
/ O
kg O
) O
. O

nitroglycerin O
, O
up O
to O
0 O
. O
3 O
micrograms O
/ O
kg O
, O
selectively O
increased O
circumflex O
artery O
diameter O
( O
cxad O
) O
without O
simultaneously O
affecting O
any O
other O
cardiac O
or O
systemic O
hemodynamic O
parameter O
. O

in O
contrast O
, O
cromakalim O
and O
pinacidil O
at O
all O
doses O
and O
nitroglycerin O
at O
doses O
higher O
than O
0 O
. O
3 O
micrograms O
/ O
kg O
simultaneously O
and O
dose O
- O
dependently O
increased O
cxad O
, O
coronary O
blood O
flow O
and O
heart O
rate O
and O
decreased O
coronary O
vascular O
resistance O
and O
aortic O
pressure O
. O

cromakalim O
was O
approximately O
8 O
- O
to O
9 O
. O
5 O
- O
fold O
more O
potent O
than O
pinacidil O
in O
increasing O
cxad O
. O

vasodilation O
of O
large O
and O
small O
coronary O
vessels O
and O
hypotension B-Disease
induced O
by O
cromakalim O
and O
pinacidil O
were O
not O
affected O
by O
prior O
combined O
beta O
adrenergic O
and O
muscarinic O
receptors O
blockade O
but O
drug O
- O
induced O
tachycardia B-Disease
was O
abolished O
. O

when O
circumflex O
artery O
blood O
flow O
was O
maintained O
constant O
, O
the O
increases O
in O
cxad O
induced O
by O
cromakalim O
( O
10 O
micrograms O
/ O
kg O
) O
, O
pinacidil O
( O
30 O
micrograms O
/ O
kg O
) O
and O
nitroglycerin O
( O
10 O
micrograms O
/ O
kg O
) O
were O
reduced O
by O
68 O
+ O
/ O
- O
7 O
, O
54 O
+ O
/ O
- O
9 O
and O
1 O
+ O
/ O
- O
1 O
% O
, O
respectively O
. O

thus O
, O
whereas O
nitroglycerin O
preferentially O
and O
flow O
- O
independently O
dilates O
large O
coronary O
arteries O
, O
cromakalim O
and O
pinacidil O
dilate O
both O
large O
and O
small O
coronary O
arteries O
and O
this O
effect O
is O
not O
dependent O
upon O
the O
simultaneous O
beta O
adrenoceptors O
- O
mediated O
rise O
in O
myocardial O
metabolic O
demand O
. O

finally O
, O
two O
mechanisms O
at O
least O
, O
direct O
vasodilation O
and O
flow O
dependency O
, O
are O
involved O
in O
the O
cromakalim O
- O
and O
pinacidil O
- O
induced O
increase O
in O
cxad O
. O

mefenamic O
acid O
- O
induced O
neutropenia B-Disease
and O
renal B-Disease
failure I-Disease
in O
elderly O
females O
with O
hypothyroidism B-Disease
. O

we O
report O
mefenamic O
acid O
- O
induced O
non O
- O
oliguric O
renal B-Disease
failure I-Disease
and O
severe O
neutropenia B-Disease
occurring O
simultaneously O
in O
two O
elderly O
females O
. O

the O
neutropenia B-Disease
was O
due O
to O
maturation O
arrest O
of O
the O
myeloid O
series O
in O
one O
patient O
. O

both O
patients O
were O
also O
hypothyroid B-Disease
, O
but O
it O
is O
not O
clear O
whether O
this O
was O
a O
predisposing O
factor O
to O
the O
development O
of O
these O
adverse O
reactions O
. O

however O
, O
it O
would O
seem O
prudent O
not O
to O
use O
mefenamic O
acid O
in O
hypothyroid B-Disease
patients O
until O
the O
hypothyroidism B-Disease
has O
been O
corrected O
. O

etiology O
of O
hypercalcemia B-Disease
in O
hemodialysis O
patients O
on O
calcium O
carbonate O
therapy O
. O

fourteen O
of O
39 O
dialysis O
patients O
( O
36 O
% O
) O
became O
hypercalcemic B-Disease
after O
switching O
to O
calcium O
carbonate O
as O
their O
principal O
phosphate O
binder O
. O

in O
order O
to O
identify O
risk O
factors O
associated O
with O
the O
development O
of O
hypercalcemia B-Disease
, O
indirect O
parameters O
of O
intestinal O
calcium O
reabsorption O
and O
bone O
turnover O
rate O
in O
these O
14 O
patients O
were O
compared O
with O
results O
in O
14 O
eucalcemic O
patients O
matched O
for O
age O
, O
sex O
, O
length O
of O
time O
on O
dialysis O
, O
and O
etiology O
of O
renal B-Disease
disease I-Disease
. O

in O
addition O
to O
experiencing O
hypercalcemic B-Disease
episodes O
with O
peak O
calcium O
values O
of O
2 O
. O
7 O
to O
3 O
. O
8 O
mmol O
/ O
l O
( O
10 O
. O
7 O
to O
15 O
. O
0 O
mg O
/ O
dl O
) O
, O
patients O
in O
the O
hypercalcemic B-Disease
group O
exhibited O
a O
significant O
increase O
in O
the O
mean O
calcium O
concentration O
obtained O
during O
6 O
months O
before O
the O
switch O
, O
compared O
with O
the O
mean O
value O
obtained O
during O
the O
7 O
months O
of O
observation O
after O
the O
switch O
( O
2 O
. O
4 O
+ O
/ O
- O
0 O
. O
03 O
to O
2 O
. O
5 O
+ O
/ O
- O
0 O
. O
03 O
mmol O
/ O
l O
[ O
9 O
. O
7 O
+ O
/ O
- O
0 O
. O
2 O
to O
10 O
. O
2 O
+ O
/ O
- O
0 O
. O

1 O
mg O
/ O
dl O
] O
, O
p O
= O
0 O
. O
006 O
) O
. O

in O
contrast O
, O
eucalcemic O
patients O
exhibited O
no O
change O
in O
mean O
calcium O
values O
over O
the O
same O
time O
period O
( O
2 O
. O
3 O
+ O
/ O
- O
0 O
. O
05 O
to O
2 O
. O
3 O
+ O
/ O
- O
0 O
. O
05 O
mmol O
/ O
l O
[ O
9 O
. O
2 O
+ O
/ O
- O
0 O
. O
2 O
to O
9 O
. O
2 O
+ O
/ O
- O
0 O
. O
2 O
mg O
/ O
dl O
] O
) O
. O

caco3 O
dosage O
, O
calculated O
dietary O
calcium O
intake O
, O
and O
circulating O
levels O
of O
vitamin O
d O
metabolites O
were O
similar O
in O
both O
groups O
. O

physical O
activity O
index O
and O
predialysis O
serum O
bicarbonate O
levels O
also O
were O
similar O
in O
both O
groups O
. O

however O
, O
there O
was O
a O
significant O
difference O
in O
parameters O
reflecting O
bone O
turnover O
rates O
between O
groups O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

late O
- O
onset O
scleroderma B-Disease
renal I-Disease
crisis I-Disease
induced O
by O
tacrolimus O
and O
prednisolone O
: O
a O
case O
report O
. O

scleroderma B-Disease
renal I-Disease
crisis I-Disease
( O
src B-Disease
) O
is O
a O
rare O
complication O
of O
systemic B-Disease
sclerosis I-Disease
( O
ssc B-Disease
) O
but O
can O
be O
severe O
enough O
to O
require O
temporary O
or O
permanent O
renal O
replacement O
therapy O
. O

moderate O
to O
high O
dose O
corticosteroid O
use O
is O
recognized O
as O
a O
major O
risk O
factor O
for O
src B-Disease
. O

furthermore O
, O
there O
have O
been O
reports O
of O
thrombotic B-Disease
microangiopathy I-Disease
precipitated O
by O
cyclosporine O
in O
patients O
with O
ssc B-Disease
. O

in O
this O
article O
, O
we O
report O
a O
patient O
with O
src B-Disease
induced O
by O
tacrolimus O
and O
corticosteroids O
. O

the O
aim O
of O
this O
work O
is O
to O
call O
attention O
to O
the O
risk O
of O
tacrolimus O
use O
in O
patients O
with O
ssc B-Disease
. O

methyldopa O
- O
induced O
hemolytic B-Disease
anemia I-Disease
in O
a O
15 O
year O
old O
presenting O
as O
near O
- O
syncope B-Disease
. O

methyldopa O
is O
an O
antihypertensive O
medication O
which O
is O
available O
generically O
and O
under O
the O
trade O
name O
aldomet O
that O
is O
widely O
prescribed O
in O
the O
adult O
population O
and O
infrequently O
used O
in O
children O
. O

methyldopa O
causes O
an O
autoimmune B-Disease
hemolytic I-Disease
anemia I-Disease
in O
a O
small O
percentage O
of O
patients O
who O
take O
the O
drug O
. O

we O
report O
a O
case O
of O
methyldopa O
- O
induced O
hemolytic B-Disease
anemia I-Disease
in O
a O
15 O
- O
year O
- O
old O
boy O
who O
presented O
to O
the O
emergency B-Disease
department I-Disease
with O
near O
- O
syncope B-Disease
. O

the O
boy O
had O
been O
treated O
with O
intravenous O
methyldopa O
during O
a O
trauma B-Disease
admission O
seven O
weeks O
prior O
to O
presentation O
. O

evaluation O
revealed O
a O
hemoglobin O
of O
three O
grams O
, O
3 O
+ O
coombs O
' O
test O
with O
polyspecific O
anti O
- O
human O
globulin O
and O
monospecific O
igg O
reagents O
, O
and O
a O
warm O
reacting O
autoantibody O
. O

transfusion O
and O
corticosteroid O
therapy O
resulted O
in O
a O
complete O
recovery O
of O
the O
patient O
. O

emergency O
physicians O
treating O
children O
must O
be O
aware O
of O
this O
syndrome O
in O
order O
to O
diagnose O
and O
treat O
it O
correctly O
. O

a O
brief O
review O
of O
autoimmune O
and O
drug O
- O
induced O
hemolytic B-Disease
anemias I-Disease
is O
provided O
. O

the O
risk O
and O
associated O
factors O
of O
methamphetamine O
psychosis B-Disease
in O
methamphetamine O
- O
dependent O
patients O
in O
malaysia O
. O

objective O
: O
the O
objective O
of O
this O
study O
was O
to O
determine O
the O
risk O
of O
lifetime O
and O
current O
methamphetamine O
- O
induced O
psychosis B-Disease
in O
patients O
with O
methamphetamine O
dependence O
. O

the O
association O
between O
psychiatric O
co O
- O
morbidity O
and O
methamphetamine O
- O
induced O
psychosis B-Disease
was O
also O
studied O
. O

methods O
: O
this O
was O
a O
cross O
- O
sectional O
study O
conducted O
concurrently O
at O
a O
teaching O
hospital O
and O
a O
drug O
rehabilitation O
center O
in O
malaysia O
. O

patients O
with O
the O
diagnosis O
of O
methamphetamine O
based O
on O
dsm O
- O
iv O
were O
interviewed O
using O
the O
mini O
international O
neuropsychiatric O
interview O
( O
m O
. O
i O
. O
n O
. O
i O
. O
) O
for O
methamphetamine O
- O
induced O
psychosis B-Disease
and O
other O
axis O
i O
psychiatric B-Disease
disorders I-Disease
. O

the O
information O
on O
sociodemographic O
background O
and O
drug O
use O
history O
was O
obtained O
from O
interview O
or O
medical O
records O
. O

results O
: O
of O
292 O
subjects O
, O
47 O
. O
9 O
% O
of O
the O
subjects O
had O
a O
past O
history O
of O
psychotic B-Disease
symptoms I-Disease
and O
13 O
. O
0 O
% O
of O
the O
patients O
were O
having O
current O
psychotic B-Disease
symptoms I-Disease
. O

co O
- O
morbid O
major O
depressive B-Disease
disorder I-Disease
( O
or O
= O
7 O
. O
18 O
, O
95 O
ci O
= O
2 O
. O
612 O
- O
19 O
. O
708 O
) O
, O
bipolar B-Disease
disorder I-Disease
( O
or O
= O
13 O
. O
807 O
, O
95 O
ci O
= O
5 O
. O
194 O
- O
36 O
. O
706 O
) O
, O
antisocial B-Disease
personality I-Disease
disorder I-Disease
( O
or O
= O
12 O
. O
619 O
, O
95 O
ci O
= O
6 O
. O
702 O
- O
23 O
. O
759 O
) O
and O
heavy O
methamphetamine O
uses O
were O
significantly O
associated O
with O
lifetime O
methamphetamine O
- O
induced O
psychosis B-Disease
after O
adjusted O
for O
other O
factors O
. O

major B-Disease
depressive I-Disease
disorder I-Disease
( O
or O
= O
2 O
. O
870 O
, O
ci O
= O
1 O
. O
154 O
- O
7 O
. O
142 O
) O
and O
antisocial B-Disease
personality I-Disease
disorder I-Disease
( O
or O
= O
3 O
. O
299 O
, O
95 O
ci O
= O
1 O
. O
375 O
- O
7 O
. O
914 O
) O
were O
the O
only O
factors O
associated O
with O
current O
psychosis B-Disease
. O

conclusion O
: O
there O
was O
a O
high O
risk O
of O
psychosis B-Disease
in O
patients O
with O
methamphetamine O
dependence O
. O

it O
was O
associated O
with O
co O
- O
morbid O
affective B-Disease
disorder I-Disease
, O
antisocial B-Disease
personality I-Disease
, O
and O
heavy O
methamphetamine O
use O
. O

it O
is O
recommended O
that O
all O
cases O
of O
methamphetamine O
dependence O
should O
be O
screened O
for O
psychotic B-Disease
symptoms I-Disease
. O

cerebellar O
sensory O
processing O
alterations O
impact O
motor O
cortical O
plasticity O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
: O
clues O
from O
dyskinetic B-Disease
patients O
. O

the O
plasticity O
of O
primary O
motor O
cortex O
( O
m1 O
) O
in O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
and O
levodopa O
- O
induced O
dyskinesias B-Disease
( O
lids B-Disease
) O
is O
severely O
impaired O
. O

we O
recently O
reported O
in O
young O
healthy O
subjects O
that O
inhibitory O
cerebellar O
stimulation O
enhanced O
the O
sensorimotor O
plasticity O
of O
m1 O
that O
was O
induced O
by O
paired O
associative O
stimulation O
( O
pas O
) O
. O

this O
study O
demonstrates O
that O
the O
deficient O
sensorimotor O
m1 O
plasticity O
in O
16 O
patients O
with O
lids B-Disease
could O
be O
reinstated O
by O
a O
single O
session O
of O
real O
inhibitory O
cerebellar O
stimulation O
but O
not O
sham O
stimulation O
. O

this O
was O
evident O
only O
when O
a O
sensory O
component O
was O
involved O
in O
the O
induction O
of O
plasticity O
, O
indicating O
that O
cerebellar O
sensory O
processing O
function O
is O
involved O
in O
the O
resurgence O
of O
m1 O
plasticity O
. O

the O
benefit O
of O
inhibitory O
cerebellar O
stimulation O
on O
lids B-Disease
is O
known O
. O

to O
explore O
whether O
this O
benefit O
is O
linked O
to O
the O
restoration O
of O
sensorimotor O
plasticity O
of O
m1 O
, O
we O
conducted O
an O
additional O
study O
looking O
at O
changes O
in O
lids B-Disease
and O
pas O
- O
induced O
plasticity O
after O
10 O
sessions O
of O
either O
bilateral O
, O
real O
inhibitory O
cerebellar O
stimulation O
or O
sham O
stimulation O
. O

only O
real O
and O
not O
sham O
stimulation O
had O
an O
antidyskinetic O
effect O
and O
it O
was O
paralleled O
by O
a O
resurgence O
in O
the O
sensorimotor O
plasticity O
of O
m1 O
. O

these O
results O
suggest O
that O
alterations O
in O
cerebellar O
sensory O
processing O
function O
, O
occurring O
secondary O
to O
abnormal O
basal O
ganglia O
signals O
reaching O
it O
, O
may O
be O
an O
important O
element O
contributing O
to O
the O
maladaptive O
sensorimotor O
plasticity O
of O
m1 O
and O
the O
emergence O
of O
abnormal B-Disease
involuntary I-Disease
movements I-Disease
. O

the O
long O
- O
term O
safety O
of O
danazol O
in O
women O
with O
hereditary B-Disease
angioedema I-Disease
. O

although O
the O
short O
- O
term O
safety O
( O
less O
than O
or O
equal O
to O
6 O
months O
) O
of O
danazol O
has O
been O
established O
in O
a O
variety O
of O
settings O
, O
no O
information O
exists O
as O
to O
its O
long O
- O
term O
safety O
. O

we O
therefore O
investigated O
the O
long O
- O
term O
safety O
of O
danazol O
by O
performing O
a O
retrospective O
chart O
review O
of O
60 O
female O
patients O
with O
hereditary B-Disease
angioedema I-Disease
treated O
with O
danazol O
for O
a O
continuous O
period O
of O
6 O
months O
or O
longer O
. O

the O
mean O
age O
of O
the O
patients O
was O
35 O
. O
2 O
years O
and O
the O
mean O
duration O
of O
therapy O
was O
59 O
. O
7 O
months O
. O

virtually O
all O
patients O
experienced O
one O
or O
more O
adverse O
reactions O
. O

menstrual B-Disease
abnormalities I-Disease
( O
79 O
% O
) O
, O
weight B-Disease
gain I-Disease
( O
60 O
% O
) O
, O
muscle B-Disease
cramps I-Disease
/ O
myalgias B-Disease
( O
40 O
% O
) O
, O
and O
transaminase O
elevations O
( O
40 O
% O
) O
were O
the O
most O
common O
adverse O
reactions O
. O

the O
drug O
was O
discontinued O
due O
to O
adverse O
reactions O
in O
8 O
patients O
. O

no O
patient O
has O
died O
or O
suffered O
any O
apparent O
long O
- O
term O
sequelae O
that O
were O
directly O
attributable O
to O
the O
drug O
. O

we O
conclude O
that O
, O
despite O
a O
relatively O
high O
incidence O
of O
adverse O
reactions O
, O
danazol O
has O
proven O
to O
be O
remarkably O
safe O
over O
the O
long O
- O
term O
in O
this O
group O
of O
patients O
. O

the O
function O
of O
p2x3 O
receptor O
and O
nk1 O
receptor O
antagonists O
on O
cyclophosphamide O
- O
induced O
cystitis B-Disease
in O
rats O
. O

purpose O
: O
the O
purpose O
of O
the O
study O
is O
to O
explore O
the O
function O
of O
p2x3 O
and O
nk1 O
receptors O
antagonists O
on O
cyclophosphamide O
( O
cyp O
) O
- O
induced O
cystitis B-Disease
in O
rats O
. O

methods O
: O
sixty O
female O
sprague O
- O
dawley O
( O
sd O
) O
rats O
were O
randomly O
divided O
into O
three O
groups O
. O

the O
rats O
in O
the O
control O
group O
were O
intraperitoneally O
( O
i O
. O
p O
. O
) O
injected O
with O
0 O
. O
9 O
% O
saline O
( O
4 O
ml O
/ O
kg O
) O
; O
the O
rats O
in O
the O
model O
group O
were O
i O
. O
p O
. O
injected O
with O
cyp O
( O
150 O
mg O
/ O
kg O
) O
; O
and O
the O
rats O
in O
the O
intervention O
group O
were O
i O
. O
p O
. O
injected O
with O
cyp O
with O
subsequently O
perfusion O
of O
bladder O
with O
p2x3 O
and O
nk1 O
receptors O
' O
antagonists O
, O
suramin O
and O
gr O
82334 O
. O

spontaneous O
pain B-Disease
behaviors O
following O
the O
administration O
of O
cyp O
were O
observed O
. O

urodynamic O
parameters O
, O
bladder O
pressure O
- O
volume O
curve O
, O
maximum O
voiding O
pressure O
( O
mvp O
) O
, O
and O
maximum O
cystometric O
capacity O
( O
mcc O
) O
, O
were O
recorded O
. O

pathological O
changes O
in O
bladder O
tissue O
were O
observed O
. O

immunofluorescence O
was O
used O
to O
detect O
the O
expression O
of O
p2x3 O
and O
nk1 O
receptors O
in O
bladder O
. O

results O
: O
cyclophosphamide O
treatment O
increased O
the O
spontaneous O
pain B-Disease
behaviors O
scores O
. O

the O
incidence O
of O
bladder O
instability O
during O
urine O
storage O
period O
of O
model O
group O
was O
significantly O
higher O
than O
intervention O
group O
( O
x O
( O
2 O
) O
= O
7 O
. O
619 O
, O
p O
= O
0 O
. O
007 O
) O
and O
control O
group O
( O
x O
( O
2 O
) O
= O
13 O
. O
755 O
, O
p O
= O
0 O
. O
000 O
) O
. O

mcc O
in O
the O
model O
group O
was O
lower O
than O
the O
control O
and O
intervention O
groups O
( O
p O
< O
0 O
. O
01 O
) O
. O

histological O
changes O
evident O
in O
model O
and O
intervention O
groups O
rats O
' O
bladder O
included O
edema B-Disease
, O
vasodilation O
, O
and O
infiltration O
of O
inflammatory O
cells O
. O

in O
model O
group O
, O
the O
expression O
of O
p2x3 O
receptor O
increased O
in O
urothelium O
and O
suburothelium O
, O
and O
nk1 O
receptor O
increased O
in O
suburothelium O
, O
while O
the O
expression O
of O
them O
in O
intervention O
group O
was O
lower O
. O

conclusions O
: O
in O
cyp O
- O
induced O
cystitis B-Disease
, O
the O
expression O
of O
p2x3 O
and O
nk1 O
receptors O
increased O
in O
urothelium O
and O
/ O
or O
suburothelium O
. O

perfusion O
of O
bladder O
with O
p2x3 O
and O
nk1 O
receptors O
antagonists O
ameliorated O
the O
bladder O
function O
. O

patient O
tolerance O
study O
of O
topical O
chlorhexidine O
diphosphanilate O
: O
a O
new O
topical O
agent O
for O
burns B-Disease
. O

effective O
topical O
antimicrobial O
agents O
decrease O
infection B-Disease
and O
mortality O
in O
burn B-Disease
patients O
. O

chlorhexidine O
phosphanilate O
( O
chp O
) O
, O
a O
new O
broad O
- O
spectrum O
antimicrobial O
agent O
, O
has O
been O
evaluated O
as O
a O
topical O
burn B-Disease
wound O
dressing O
in O
cream O
form O
, O
but O
preliminary O
clinical O
trials O
reported O
that O
it O
was O
painful O
upon O
application O
. O

this O
study O
compared O
various O
concentrations O
of O
chp O
to O
determine O
if O
a O
tolerable O
concentration O
could O
be O
identified O
with O
retention O
of O
antimicrobial O
efficacy O
. O

twenty O
- O
nine O
burn B-Disease
patients O
, O
each O
with O
two O
similar O
burns B-Disease
which O
could O
be O
separately O
treated O
, O
were O
given O
pairs O
of O
treatments O
at O
successive O
12 O
- O
h O
intervals O
over O
a O
3 O
- O
day O
period O
. O

one O
burn B-Disease
site O
was O
treated O
with O
each O
of O
four O
different O
chp O
concentrations O
, O
from O
0 O
. O
25 O
per O
cent O
to O
2 O
per O
cent O
, O
their O
vehicle O
, O
and O
1 O
per O
cent O
silver O
sulphadiazine O
( O
agsd O
) O
cream O
, O
an O
antimicrobial O
agent O
frequently O
used O
for O
topical O
treatment O
of O
burn B-Disease
wounds O
. O

the O
other O
site O
was O
always O
treated O
with O
agsd O
cream O
. O

there O
was O
a O
direct O
relationship O
between O
chp O
concentration O
and O
patients O
' O
ratings O
of O
pain B-Disease
on O
an O
analogue O
scale O
. O

the O
0 O
. O
25 O
per O
cent O
chp O
cream O
was O
closest O
to O
agsd O
in O
pain B-Disease
tolerance O
; O
however O
, O
none O
of O
the O
treatments O
differed O
statistically O
from O
agsd O
or O
from O
each O
other O
. O

in O
addition O
, O
ease O
of O
application O
of O
chp O
creams O
was O
less O
satisfactory O
than O
that O
of O
agsd O
. O

it O
was O
concluded O
that O
formulations O
at O
or O
below O
0 O
. O
5 O
per O
cent O
chp O
may O
prove O
acceptable O
for O
wound O
care O
, O
but O
the O
vehicle O
system O
needs O
pharmaceutical O
improvement O
to O
render O
it O
more O
tolerable O
and O
easier O
to O
use O
. O

acute O
hepatitis B-Disease
associated O
with O
clopidogrel O
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

drug O
- O
induced O
hepatotoxicity B-Disease
is O
a O
common O
cause O
of O
acute O
hepatitis B-Disease
, O
and O
the O
recognition O
of O
the O
responsible O
drug O
may O
be O
difficult O
. O

we O
describe O
a O
case O
of O
clopidogrel O
- O
related O
acute O
hepatitis B-Disease
. O

the O
diagnosis O
is O
strongly O
suggested O
by O
an O
accurate O
medical O
history O
and O
liver O
biopsy O
. O

reports O
about O
cases O
of O
hepatotoxicity B-Disease
due O
to O
clopidogrel O
are O
increasing O
in O
the O
last O
few O
years O
, O
after O
the O
increased O
use O
of O
this O
drug O
. O

in O
conclusion O
, O
we O
believe O
that O
physicians O
should O
carefully O
consider O
the O
risk O
of O
drug O
- O
induced O
hepatic B-Disease
injury I-Disease
when O
clopidogrel O
is O
prescribed O
. O

bortezomib O
and O
dexamethasone O
as O
salvage O
therapy O
in O
patients O
with O
relapsed O
/ O
refractory O
multiple B-Disease
myeloma I-Disease
: O
analysis O
of O
long O
- O
term O
clinical O
outcomes O
. O

bortezomib O
( O
bort O
) O
- O
dexamethasone O
( O
dex O
) O
is O
an O
effective O
therapy O
for O
relapsed O
/ O
refractory O
( O
r O
/ O
r O
) O
multiple B-Disease
myeloma I-Disease
( O
mm B-Disease
) O
. O

this O
retrospective O
study O
investigated O
the O
combination O
of O
bort O
( O
1 O
. O
3 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
4 O
, O
8 O
, O
and O
11 O
every O
3 O
weeks O
) O
and O
dex O
( O
20 O
mg O
on O
the O
day O
of O
and O
the O
day O
after O
bort O
) O
as O
salvage O
treatment O
in O
85 O
patients O
with O
r O
/ O
r O
mm B-Disease
after O
prior O
autologous O
stem O
cell O
transplantation O
or O
conventional O
chemotherapy O
. O

the O
median O
number O
of O
prior O
lines O
of O
therapy O
was O
2 O
. O

eighty O
- O
seven O
percent O
of O
the O
patients O
had O
received O
immunomodulatory O
drugs O
included O
in O
some O
line O
of O
therapy O
before O
bort O
- O
dex O
. O

the O
median O
number O
of O
bort O
- O
dex O
cycles O
was O
6 O
, O
up O
to O
a O
maximum O
of O
12 O
cycles O
. O

on O
an O
intention O
- O
to O
- O
treat O
basis O
, O
55 O
% O
of O
the O
patients O
achieved O
at O
least O
partial O
response O
, O
including O
19 O
% O
cr O
and O
35 O
% O
achieved O
at O
least O
very O
good O
partial O
response O
. O

median O
durations O
of O
response O
, O
time O
to O
next O
therapy O
and O
treatment O
- O
free O
interval O
were O
8 O
, O
11 O
. O
2 O
, O
and O
5 O
. O
1 O
months O
, O
respectively O
. O

the O
most O
relevant O
adverse O
event O
was O
peripheral B-Disease
neuropathy I-Disease
, O
which O
occurred O
in O
78 O
% O
of O
the O
patients O
( O
grade O
ii O
, O
38 O
% O
; O
grade O
iii O
, O
21 O
% O
) O
and O
led O
to O
treatment O
discontinuation O
in O
6 O
% O
. O

with O
a O
median O
follow O
up O
of O
22 O
months O
, O
median O
time O
to O
progression O
, O
progression O
- O
free O
survival O
( O
pfs O
) O
and O
overall O
survival O
( O
os O
) O
were O
8 O
. O
9 O
, O
8 O
. O
7 O
, O
and O
22 O
months O
, O
respectively O
. O

prolonged O
pfs O
and O
os O
were O
observed O
in O
patients O
achieving O
cr O
and O
receiving O
bort O
- O
dex O
a O
single O
line O
of O
prior O
therapy O
. O

bort O
- O
dex O
was O
an O
effective O
salvage O
treatment O
for O
mm B-Disease
patients O
, O
particularly O
for O
those O
in O
first O
relapse O
. O

pubertal O
exposure O
to O
bisphenol O
a O
increases O
anxiety B-Disease
- O
like O
behavior O
and O
decreases O
acetylcholinesterase O
activity O
of O
hippocampus O
in O
adult O
male O
mice O
. O

the O
negative O
effects O
of O
bisphenol O
a O
( O
bpa O
) O
on O
neurodevelopment O
and O
behaviors O
have O
been O
well O
established O
. O

acetylcholinesterase O
( O
ache O
) O
is O
a O
regulatory O
enzyme O
which O
is O
involved O
in O
anxiety B-Disease
- O
like O
behavior O
. O

this O
study O
investigated O
behavioral O
phenotypes O
and O
ache O
activity O
in O
male O
mice O
following O
bpa O
exposure O
during O
puberty O
. O

on O
postnatal O
day O
( O
pnd O
) O
35 O
, O
male O
mice O
were O
exposed O
to O
50mg O
bpa O
/ O
kg O
diet O
per O
day O
for O
a O
period O
of O
35 O
days O
. O

on O
pnd71 O
, O
a O
behavioral O
assay O
was O
performed O
using O
the O
elevated O
plus O
maze O
( O
epm O
) O
and O
the O
light O
/ O
dark O
test O
. O

in O
addition O
, O
ache O
activity O
was O
measured O
in O
the O
prefrontal O
cortex O
, O
hypothalamus O
, O
cerebellum O
and O
hippocampus O
. O

results O
from O
our O
behavioral O
phenotyping O
indicated O
that O
anxiety B-Disease
- O
like O
behavior O
was O
increased O
in O
mice O
exposed O
to O
bpa O
. O

ache O
activity O
was O
significantly O
decreased O
in O
the O
hippocampus O
of O
mice O
with O
bpa O
compared O
to O
control O
mice O
, O
whereas O
no O
difference O
was O
found O
in O
the O
prefrontal O
cortex O
, O
hypothalamus O
and O
cerebellum O
. O

our O
findings O
showed O
that O
pubertal O
bpa O
exposure O
increased O
anxiety B-Disease
- O
like O
behavior O
, O
which O
may O
be O
associated O
with O
decreased O
ache O
activity O
of O
the O
hippocampus O
in O
adult O
male O
mice O
. O

further O
studies O
are O
necessary O
to O
investigate O
the O
cholinergic O
signaling O
of O
the O
hippocampus O
in O
pbe O
induced O
anxiety B-Disease
- O
like O
behaviors O
. O

biochemical O
effects O
of O
solidago O
virgaurea O
extract O
on O
experimental O
cardiotoxicity B-Disease
. O

cardiovascular B-Disease
diseases I-Disease
( O
cvds B-Disease
) O
are O
the O
major O
health O
problem O
of O
advanced O
as O
well O
as O
developing O
countries O
of O
the O
world O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
protective O
effect O
of O
the O
solidago O
virgaurea O
extract O
on O
isoproterenol O
- O
induced O
cardiotoxicity B-Disease
in O
rats O
. O

the O
subcutaneous O
injection O
of O
isoproterenol O
( O
30 O
mg O
/ O
kg O
) O
into O
rats O
twice O
at O
an O
interval O
of O
24 O
h O
, O
for O
two O
consecutive O
days O
, O
led O
to O
a O
significant O
increase O
in O
serum O
lactate O
dehydrogenase O
, O
creatine O
phosphokinase O
, O
alanine O
transaminase O
, O
aspartate O
transaminase O
, O
and O
angiotensin O
- O
converting O
enzyme O
activities O
, O
total O
cholesterol O
, O
triglycerides O
, O
free O
serum O
fatty O
acid O
, O
cardiac O
tissue O
malondialdehyde O
( O
mda O
) O
, O
and O
nitric O
oxide O
levels O
and O
a O
significant O
decrease O
in O

levels O
of O
glutathione O
and O
superoxide O
dismutase O
in O
cardiac O
tissue O
as O
compared O
to O
the O
normal O
control O
group O
( O
p O
< O
0 O
. O
05 O
) O
. O

pretreatment O
with O
s O
. O
virgaurea O
extract O
for O
5 O
weeks O
at O
a O
dose O
of O
250 O
mg O
/ O
kg O
followed O
by O
isoproterenol O
injection O
significantly O
prevented O
the O
observed O
alterations O
. O

captopril O
( O
50 O
mg O
/ O
kg O
/ O
day O
, O
given O
orally O
) O
, O
an O
inhibitor O
of O
angiotensin O
- O
converting O
enzyme O
used O
as O
a O
standard O
cardioprotective O
drug O
, O
was O
used O
as O
a O
positive O
control O
in O
this O
study O
. O

the O
data O
of O
the O
present O
study O
suggest O
that O
s O
. O
virgaurea O
extract O
exerts O
its O
protective O
effect O
by O
decreasing O
mda O
level O
and O
increasing O
the O
antioxidant O
status O
in O
isoproterenol O
- O
treated O
rats O
. O

the O
study O
emphasizes O
the O
beneficial O
action O
of O
s O
. O
virgaurea O
extract O
as O
a O
cardioprotective O
agent O
. O

" O
real O
- O
world O
" O
data O
on O
the O
efficacy O
and O
safety O
of O
lenalidomide O
and O
dexamethasone O
in O
patients O
with O
relapsed O
/ O
refractory O
multiple B-Disease
myeloma I-Disease
who O
were O
treated O
according O
to O
the O
standard O
clinical O
practice O
: O
a O
study O
of O
the O
greek O
myeloma B-Disease
study O
group O
. O

lenalidomide O
and O
dexamethasone O
( O
rd O
) O
is O
a O
standard O
of O
care O
for O
relapsed O
/ O
refractory O
multiple B-Disease
myeloma I-Disease
( O
rrmm B-Disease
) O
, O
but O
there O
is O
limited O
published O
data O
on O
its O
efficacy O
and O
safety O
in O
the O
" O
real O
world O
" O
( O
rw O
) O
, O
according O
to O
the O
international O
society O
of O
pharmacoeconomics O
and O
outcomes O
research O
definition O
. O

we O
studied O
212 O
rrmm B-Disease
patients O
who O
received O
rd O
in O
rw O
. O

objective O
response O
( O
> O
pr O
( O
partial O
response O
) O
) O
rate O
was O
77 O
. O
4 O
% O
( O
complete O
response O
( O
cr O
) O
, O
20 O
. O
2 O
% O
) O
. O

median O
time O
to O
first O
and O
best O
response O
was O
2 O
and O
5 O
months O
, O
respectively O
. O

median O
time O
to O
cr O
when O
rd O
was O
given O
as O
2nd O
or O
> O
2 O
( O
nd O
) O
- O
line O
treatment O
at O
4 O
and O
11 O
months O
, O
respectively O
. O

quality O
of O
response O
was O
independent O
of O
previous O
lines O
of O
therapies O
or O
previous O
exposure O
to O
thalidomide O
or O
bortezomib O
. O

median O
duration O
of O
response O
was O
34 O
. O
4 O
months O
, O
and O
it O
was O
higher O
in O
patients O
who O
received O
rd O
until O
progression O
( O
not O
reached O
versus O
19 O
months O
, O
p O
< O
0 O
. O
001 O
) O
. O

improvement O
of O
humoral O
immunity O
occurred O
in O
60 O
% O
of O
responders O
( O
p O
< O
0 O
. O
001 O
) O
and O
in O
the O
majority O
of O
patients O
who O
achieved O
stable O
disease O
. O

adverse O
events O
were O
reported O
in O
68 O
. O
9 O
% O
of O
patients O
( O
myelosuppression B-Disease
in O
49 O
. O
4 O
% O
) O
and O
12 O
. O
7 O
% O
of O
patients O
needed O
hospitalization O
. O

peripheral B-Disease
neuropathy I-Disease
was O
observed O
only O
in O
2 O
. O
5 O
% O
of O
patients O
and O
deep B-Disease
vein I-Disease
thrombosis I-Disease
in O
5 O
. O
7 O
% O
. O

dose O
reductions O
were O
needed O
in O
31 O
% O
of O
patients O
and O
permanent O
discontinuation O
in O
38 O
. O
9 O
% O
. O

median O
time O
to O
treatment O
discontinuation O
was O
16 O
. O
8 O
months O
. O

performance O
status O
( O
ps O
) O
and O
initial O
lenalidomide O
dose O
predicted O
for O
treatment O
discontinuation O
. O

extra O
- O
medullary O
relapses O
occurred O
in O
3 O
. O
8 O
% O
of O
patients O
. O

our O
study O
confirms O
that O
rd O
is O
effective O
and O
safe O
in O
rrmm B-Disease
in O
the O
rw O
; O
it O
produces O
durable O
responses O
especially O
in O
patients O
who O
continue O
on O
treatment O
till O
progression O
and O
improves O
humoral O
immunity O
even O
in O
patients O
with O
stable O
disease O
. O

the O
cytogenetic O
action O
of O
ifosfamide O
, O
mesna O
, O
and O
their O
combination O
on O
peripheral O
rabbit O
lymphocytes O
: O
an O
in O
vivo O
/ O
in O
vitro O
cytogenetic O
study O
. O

ifosfamide O
( O
ifo O
) O
is O
an O
alkylating O
nitrogen O
mustard O
, O
administrated O
as O
an O
antineoplasmic O
agent O
. O

it O
is O
characterized O
by O
its O
intense O
urotoxic O
action O
, O
leading O
to O
hemorrhagic B-Disease
cystitis I-Disease
. O

this O
side O
effect O
of O
ifo O
raises O
the O
requirement O
for O
the O
co O
- O
administration O
with O
sodium O
2 O
- O
sulfanylethanesulfonate O
( O
mesna O
) O
aiming O
to O
avoid O
or O
minimize O
this O
effect O
. O

ifo O
and O
mesna O
were O
administrated O
separately O
on O
rabbit O
' O
s O
lymphocytes O
in O
vivo O
, O
which O
were O
later O
developed O
in O
vitro O
. O

cytogenetic O
markers O
for O
sister O
chromatid O
exchanges O
( O
sces O
) O
, O
proliferation O
rate O
index O
( O
pri O
) O
and O
mitotic O
index O
were O
recorded O
. O

mesna O
' O
s O
action O
, O
in O
conjunction O
with O
ifo O
reduces O
the O
frequency O
of O
sces O
, O
in O
comparison O
with O
the O
sces O
recordings O
obtained O
when O
ifo O
is O
administered O
alone O
. O

in O
addition O
to O
this O
, O
when O
high O
concentrations O
of O
mesna O
were O
administered O
alone O
significant O
reductions O
of O
the O
pri O
were O
noted O
, O
than O
with O
ifo O
acting O
at O
the O
same O
concentration O
on O
the O
lymphocytes O
. O

mesna O
significantly O
reduces O
ifo O
' O
s O
genotoxicity B-Disease
, O
while O
when O
administered O
in O
high O
concentrations O
it O
acts O
in O
an O
inhibitory O
fashion O
on O
the O
cytostatic O
action O
of O
the O
drug O
. O

risk O
factors O
and O
predictors O
of O
levodopa O
- O
induced O
dyskinesia B-Disease
among O
multiethnic O
malaysians O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

chronic O
pulsatile O
levodopa O
therapy O
for O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
leads O
to O
the O
development O
of O
motor O
fluctuations O
and O
dyskinesia B-Disease
. O

we O
studied O
the O
prevalence O
and O
predictors O
of O
levodopa O
- O
induced O
dyskinesia B-Disease
among O
multiethnic O
malaysian O
patients O
with O
pd B-Disease
. O

methods O
: O
this O
is O
a O
cross O
- O
sectional O
study O
involving O
95 O
patients O
with O
pd B-Disease
on O
uninterrupted O
levodopa O
therapy O
for O
at O
least O
6 O
months O
. O

the O
instrument O
used O
was O
the O
updrs O
questionnaires O
. O

the O
predictors O
of O
dyskinesia B-Disease
were O
determined O
using O
multivariate O
logistic O
regression O
analysis O
. O

results O
: O
the O
mean O
age O
was O
65 O
. O
6 O
+ O
8 O
. O
5 O
years O
. O

the O
mean O
onset O
age O
was O
58 O
. O
5 O
+ O
9 O
. O
8 O
years O
. O

the O
median O
disease O
duration O
was O
6 O
( O
7 O
) O
years O
. O

dyskinesia B-Disease
was O
present O
in O
44 O
% O
( O
n O
= O
42 O
) O
with O
median O
levodopa O
therapy O
of O
3 O
years O
. O

there O
were O
64 O
. O
3 O
% O
chinese O
, O
31 O
% O
malays O
, O
and O
3 O
. O
7 O
% O
indians O
and O
other O
ethnic O
groups O
. O

eighty O
- O
one O
percent O
of O
patients O
with O
dyskinesia B-Disease
had O
clinical O
fluctuations O
. O

patients O
with O
dyskinesia B-Disease
had O
lower O
onset O
age O
( O
p O
< O
0 O
. O
001 O
) O
, O
longer O
duration O
of O
levodopa O
therapy O
( O
p O
< O
0 O
. O
001 O
) O
, O
longer O
disease O
duration O
( O
p O
< O
0 O
. O
001 O
) O
, O
higher O
total O
daily O
levodopa O
dose O
( O
p O
< O
0 O
. O
001 O
) O
, O
and O
higher O
total O
updrs O
scores O
( O
p O
= O
0 O
. O
005 O
) O
than O
patients O
without O
dyskinesia B-Disease
. O

the O
three O
significant O
predictors O
of O
dyskinesia B-Disease
were O
duration O
of O
levodopa O
therapy O
, O
onset O
age O
, O
and O
total O
daily O
levodopa O
dose O
. O

conclusions O
: O
the O
prevalence O
of O
levodopa O
- O
induced O
dyskinesia B-Disease
in O
our O
patients O
was O
44 O
% O
. O

the O
most O
significant O
predictors O
were O
duration O
of O
levodopa O
therapy O
, O
total O
daily O
levodopa O
dose O
, O
and O
onset O
age O
. O

dose O
- O
dependent O
neurotoxicity B-Disease
of O
high O
- O
dose O
busulfan O
in O
children O
: O
a O
clinical O
and O
pharmacological O
study O
. O

busulfan O
is O
known O
to O
be O
neurotoxic B-Disease
in O
animals O
and O
humans O
, O
but O
its O
acute O
neurotoxicity B-Disease
remains O
poorly O
characterized O
in O
children O
. O

we O
report O
here O
a O
retrospective O
study O
of O
123 O
children O
( O
median O
age O
, O
6 O
. O
5 O
years O
) O
receiving O
high O
- O
dose O
busulfan O
in O
combined O
chemotherapy O
before O
bone O
marrow O
transplantation O
for O
malignant O
solid O
tumors B-Disease
, O
brain B-Disease
tumors I-Disease
excluded O
. O

busulfan O
was O
given O
p O
. O
o O
. O
, O
every O
6 O
hours O
for O
16 O
doses O
over O
4 O
days O
. O

two O
total O
doses O
were O
consecutively O
used O
: O
16 O
mg O
/ O
kg O
, O
then O
600 O
mg O
/ O
m2 O
. O

the O
dose O
calculation O
on O
the O
basis O
of O
body O
surface O
area O
results O
in O
higher O
doses O
in O
young O
children O
than O
in O
older O
patients O
( O
16 O
to O
28 O
mg O
/ O
kg O
) O
. O

ninety O
- O
six O
patients O
were O
not O
given O
anticonvulsive O
prophylaxis O
; O
7 O
( O
7 O
. O
5 O
% O
) O
developed O
seizures B-Disease
during O
the O
4 O
days O
of O
the O
busulfan O
course O
or O
within O
24 O
h O
after O
the O
last O
dosing O
. O

when O
the O
total O
busulfan O
dose O
was O
taken O
into O
account O
, O
there O
was O
a O
significant O
difference O
in O
terms O
of O
neurotoxicity B-Disease
incidence O
among O
patients O
under O
16 O
mg O
/ O
kg O
( O
1 O
of O
57 O
, O
1 O
. O
7 O
% O
) O
and O
patients O
under O
600 O
mg O
/ O
m2 O
( O
6 O
of O
39 O
, O
15 O
. O
4 O
% O
) O
( O
p O
less O
than O
0 O
. O
02 O
) O
. O

twenty O
- O
seven O
patients O
were O
given O
a O
600 O
- O
mg O
/ O
m2 O
busulfan O
total O
dose O
with O
continuous O
i O
. O
v O
. O
infusion O
of O
clonazepam O
; O
none O
had O
any O
neurological B-Disease
symptoms I-Disease
. O

busulfan O
levels O
were O
measured O
by O
a O
gas O
chromatographic O
- O
mass O
spectrometry O
assay O
in O
the O
plasma O
and O
cerebrospinal O
fluid O
of O
9 O
children O
without O
central B-Disease
nervous I-Disease
system I-Disease
disease I-Disease
under O
600 O
mg O
/ O
m2 O
busulfan O
with O
clonazepam O
: O
busulfan O
cerebrospinal O
fluid O
: O
plasma O
ratio O
was O
1 O
. O
39 O
. O

this O
was O
significantly O
different O
( O
p O
less O
than O
0 O
. O
02 O
) O
from O
the O
cerebrospinal O
fluid O
: O
plasma O
ratio O
previously O
defined O
in O
children O
receiving O
a O
16 O
- O
mg O
/ O
kg O
total O
dose O
of O
busulfan O
. O

this O
study O
shows O
that O
busulfan O
neurotoxicity B-Disease
is O
dose O
- O
dependent O
in O
children O
and O
efficiently O
prevented O
by O
clonazepam O
. O

a O
busulfan O
dose O
calculated O
on O
the O
basis O
of O
body O
surface O
area O
, O
resulting O
in O
higher O
doses O
in O
young O
children O
, O
was O
followed O
by O
increased O
neurotoxicity B-Disease
, O
close O
to O
neurotoxicity B-Disease
incidence O
observed O
in O
adults O
. O

since O
plasma O
pharmacokinetic O
studies O
showed O
a O
faster O
busulfan O
clearance O
in O
children O
than O
in O
adults O
, O
this O
new O
dose O
may O
approximate O
more O
closely O
the O
adult O
systemic O
exposure O
obtained O
after O
the O
usual O
16 O
- O
mg O
/ O
kg O
total O
dose O
, O
with O
potential O
inferences O
in O
terms O
of O
anticancer O
or O
myeloablative O
effects O
. O

the O
busulfan O
dose O
in O
children O
and O
infants O
undergoing O
bone O
marrow O
transplantation O
should O
be O
reconsidered O
on O
the O
basis O
of O
pharmacokinetic O
studies O
. O

an O
unexpected O
diagnosis O
in O
a O
renal O
- O
transplant O
patient O
with O
proteinuria B-Disease
treated O
with O
everolimus O
: O
al B-Disease
amyloidosis B-Disease
. O

proteinuria B-Disease
is O
an O
expected O
complication O
in O
transplant O
patients O
treated O
with O
mammalian O
target O
of O
rapamycin O
inhibitors O
( O
mtor O
- O
i O
) O
. O

however O
, O
clinical O
suspicion O
should O
always O
be O
supported O
by O
histological O
evidence O
in O
order O
to O
investigate O
potential O
alternate O
diagnoses O
such O
as O
acute O
or O
chronic O
rejection O
, O
interstitial O
fibrosis B-Disease
and O
tubular O
atrophy B-Disease
, O
or O
recurrent O
or O
de O
novo O
glomerulopathy B-Disease
. O

in O
this O
case O
we O
report O
the O
unexpected O
diagnosis O
of O
amyloidosis B-Disease
in O
a O
renal O
- O
transplant O
patient O
with O
pre O
- O
transplant O
monoclonal O
gammapathy O
of O
undetermined O
significance O
who O
developed O
proteinuria B-Disease
after O
conversion O
from O
tacrolimus O
to O
everolimus O
. O

long O
- O
term O
oral O
galactose O
treatment O
prevents O
cognitive B-Disease
deficits I-Disease
in O
male O
wistar O
rats O
treated O
intracerebroventricularly O
with O
streptozotocin O
. O

basic O
and O
clinical O
research O
has O
demonstrated O
that O
dementia B-Disease
of O
sporadic O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
sad O
) O
type O
is O
associated O
with O
dysfunction O
of O
the O
insulin O
- O
receptor O
( O
ir O
) O
system O
followed O
by O
decreased O
glucose O
transport O
via O
glucose O
transporter O
glut4 O
and O
decreased O
glucose O
metabolism O
in O
brain O
cells O
. O

an O
alternative O
source O
of O
energy O
is O
d O
- O
galactose O
( O
the O
c O
- O
4 O
- O
epimer O
of O
d O
- O
glucose O
) O
which O
is O
transported O
into O
the O
brain O
by O
insulin O
- O
independent O
glut3 O
transporter O
where O
it O
might O
be O
metabolized O
to O
glucose O
via O
the O
leloir O
pathway O
. O

exclusively O
parenteral O
daily O
injections O
of O
galactose O
induce O
memory B-Disease
deterioration I-Disease
in O
rodents O
and O
are O
used O
to O
generate O
animal O
aging O
model O
, O
but O
the O
effects O
of O
oral O
galactose O
treatment O
on O
cognitive O
functions O
have O
never O
been O
tested O
. O

we O
have O
investigated O
the O
effects O
of O
continuous O
daily O
oral O
galactose O
( O
200 O
mg O
/ O
kg O
/ O
day O
) O
treatment O
on O
cognitive B-Disease
deficits I-Disease
in O
streptozotocin O
- O
induced O
( O
stz O
- O
icv O
) O
rat O
model O
of O
sad O
, O
tested O
by O
morris O
water O
maze O
and O
passive O
avoidance O
test O
, O
respectively O
. O

one O
month O
of O
oral O
galactose O
treatment O
initiated O
immediately O
after O
the O
stz O
- O
icv O
administration O
, O
successfully O
prevented O
development O
of O
the O
stz O
- O
icv O
- O
induced O
cognitive B-Disease
deficits I-Disease
. O

beneficial O
effect O
of O
oral O
galactose O
was O
independent O
of O
the O
rat O
age O
and O
of O
the O
galactose O
dose O
ranging O
from O
100 O
to O
300 O
mg O
/ O
kg O
/ O
day O
. O

additionally O
, O
oral O
galactose O
administration O
led O
to O
the O
appearance O
of O
galactose O
in O
the O
blood O
. O

the O
increase O
of O
galactose O
concentration O
in O
the O
cerebrospinal O
fluid O
was O
several O
times O
lower O
after O
oral O
than O
after O
parenteral O
administration O
of O
the O
same O
galactose O
dose O
. O

oral O
galactose O
exposure O
might O
have O
beneficial O
effects O
on O
learning O
and O
memory O
ability O
and O
could O
be O
worth O
investigating O
for O
improvement O
of O
cognitive B-Disease
deficits I-Disease
associated O
with O
glucose B-Disease
hypometabolism I-Disease
in O
ad B-Disease
. O

an O
investigation O
of O
the O
pattern O
of O
kidney B-Disease
injury I-Disease
in O
hiv O
- O
positive O
persons O
exposed O
to O
tenofovir O
disoproxil O
fumarate O
: O
an O
examination O
of O
a O
large O
population O
database O
( O
mhra O
database O
) O
. O

the O
potential O
for O
tenofovir O
to O
cause O
a O
range O
of O
kidney O
syndromes O
has O
been O
established O
from O
mechanistic O
and O
randomised O
clinical O
trials O
. O

however O
, O
the O
exact O
pattern O
of O
kidney O
involvement O
is O
still O
uncertain O
. O

we O
undertook O
a O
descriptive O
analysis O
of O
yellow O
card O
records O
of O
407 O
hiv O
- O
positive O
persons O
taking O
tenofovir O
disoproxil O
fumarate O
( O
tdf O
) O
as O
part O
of O
their O
antiretroviral O
therapy O
regimen O
and O
submitted O
to O
the O
medicines O
and O
healthcare O
products O
regulatory O
agency O
( O
mhra O
) O
with O
suspected O
kidney O
adverse O
effects O
. O

reports O
that O
satisfy O
defined O
criteria O
were O
classified O
as O
acute B-Disease
kidney I-Disease
injury I-Disease
, O
kidney B-Disease
tubular I-Disease
dysfunction I-Disease
and O
fanconi B-Disease
syndrome I-Disease
. O

of O
the O
407 O
yellow O
card O
records O
analysed O
, O
106 O
satisfied O
criteria O
for O
tdf O
- O
related O
kidney B-Disease
disease I-Disease
, O
of O
which O
53 O
( O
50 O
% O
) O
had O
features O
of O
kidney B-Disease
tubular I-Disease
dysfunction I-Disease
, O
35 O
( O
33 O
% O
) O
were O
found O
to O
have O
features O
of O
glomerular B-Disease
dysfunction I-Disease
and O
18 O
( O
17 O
% O
) O
had O
fanconi B-Disease
syndrome I-Disease
. O

the O
median O
tdf O
exposure O
was O
316 O
days O
( O
interquartile O
range O
120 O
- O
740 O
) O
. O

the O
incidence O
of O
hospitalisation O
for O
tdf O
kidney O
adverse O
effects O
was O
high O
, O
particularly O
amongst O
patients O
with O
features O
of O
fanconi B-Disease
syndrome I-Disease
. O

the O
pattern O
of O
kidney O
syndromes O
in O
this O
population O
series O
mirrors O
that O
reported O
in O
randomised O
clinical O
trials O
. O

cessation O
of O
tdf O
was O
associated O
with O
complete O
restoration O
of O
kidney O
function O
in O
up O
half O
of O
the O
patients O
in O
this O
report O
. O

incidence O
of O
postoperative B-Disease
delirium I-Disease
is O
high O
even O
in O
a O
population O
without O
known O
risk O
factors O
. O

purpose O
: O
postoperative B-Disease
delirium I-Disease
is O
a O
recognized O
complication O
in O
populations O
at O
risk O
. O

the O
aim O
of O
this O
study O
is O
to O
assess O
the O
prevalence O
of O
early O
postoperative B-Disease
delirium I-Disease
in O
a O
population O
without O
known O
risk O
factors O
admitted O
to O
the O
icu O
for O
postoperative O
monitoring O
after O
elective O
major O
surgery O
. O

the O
secondary O
outcome O
investigated O
is O
to O
identify O
eventual O
independent O
risk O
factors O
among O
demographic O
data O
and O
anesthetic O
drugs O
used O
. O

methods O
: O
an O
observational O
, O
prospective O
study O
was O
conducted O
on O
a O
consecutive O
cohort O
of O
patients O
admitted O
to O
our O
icu O
within O
and O
for O
at O
least O
24 O
h O
after O
major O
surgical O
procedures O
. O

exclusion O
criteria O
were O
any O
preexisting O
predisposing O
factor O
for O
delirium B-Disease
or O
other O
potentially O
confounding O
neurological B-Disease
dysfunctions I-Disease
. O

patients O
were O
assessed O
daily O
using O
the O
confusion B-Disease
assessment O
method O
for O
the O
icu O
scale O
for O
3 O
days O
after O
the O
surgical O
procedure O
. O

early O
postoperative B-Disease
delirium I-Disease
incidence O
risk O
factors O
were O
then O
assessed O
through O
three O
different O
multiple O
regression O
models O
. O

results O
: O
according O
to O
the O
confusion O
assessment O
method O
for O
the O
icu O
scale O
, O
28 O
% O
of O
patients O
were O
diagnosed O
with O
early O
postoperative B-Disease
delirium I-Disease
. O

the O
use O
of O
thiopentone O
was O
significantly O
associated O
with O
an O
eight O
- O
fold O
- O
higher O
risk O
for O
delirium B-Disease
compared O
to O
propofol O
( O
57 O
. O
1 O
% O
vs O
. O
7 O
. O
1 O
% O
, O
rr O
= O
8 O
. O
0 O
, O
x2 O
= O
4 O
. O
256 O
; O
df O
= O
1 O
; O
0 O
. O
05 O
< O
p O
< O
0 O
. O
02 O
) O
. O

conclusion O
: O
in O
this O
study O
early O
postoperative B-Disease
delirium I-Disease
was O
found O
to O
be O
a O
very O
common O
complication O
after O
major O
surgery O
, O
even O
in O
a O
population O
without O
known O
risk O
factors O
. O

thiopentone O
was O
independently O
associated O
with O
an O
increase O
in O
its O
relative O
risk O
. O

a O
single O
neurotoxic B-Disease
dose O
of O
methamphetamine O
induces O
a O
long O
- O
lasting O
depressive B-Disease
- O
like O
behaviour O
in O
mice O
. O

methamphetamine O
( O
meth O
) O
triggers O
a O
disruption O
of O
the O
monoaminergic O
system O
and O
meth O
abuse O
leads O
to O
negative O
emotional O
states O
including O
depressive B-Disease
symptoms I-Disease
during O
drug O
withdrawal O
. O

however O
, O
it O
is O
currently O
unknown O
if O
the O
acute O
toxic O
dosage O
of O
meth O
also O
causes O
a O
long O
- O
lasting O
depressive B-Disease
phenotype O
and O
persistent O
monoaminergic O
deficits O
. O

thus O
, O
we O
now O
assessed O
the O
depressive B-Disease
- O
like O
behaviour O
in O
mice O
at O
early O
and O
long O
- O
term O
periods O
following O
a O
single O
high O
meth O
dose O
( O
30 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

meth O
did O
not O
alter O
the O
motor O
function O
and O
procedural O
memory O
of O
mice O
as O
assessed O
by O
swimming O
speed O
and O
escape O
latency O
to O
find O
the O
platform O
in O
a O
cued O
version O
of O
the O
water O
maze O
task O
. O

however O
, O
meth O
significantly O
increased O
the O
immobility O
time O
in O
the O
tail O
suspension O
test O
at O
3 O
and O
49 O
days O
post O
- O
administration O
. O

this O
depressive B-Disease
- O
like O
profile O
induced O
by O
meth O
was O
accompanied O
by O
a O
marked O
depletion O
of O
frontostriatal O
dopaminergic O
and O
serotonergic O
neurotransmission O
, O
indicated O
by O
a O
reduction O
in O
the O
levels O
of O
dopamine O
, O
dopac O
and O
hva O
, O
tyrosine O
hydroxylase O
and O
serotonin O
, O
observed O
at O
both O
3 O
and O
49 O
days O
post O
- O
administration O
. O

in O
parallel O
, O
another O
neurochemical O
feature O
of O
depression B-Disease
- O
- O
astroglial O
dysfunction O
- O
- O
was O
unaffected O
in O
the O
cortex O
and O
the O
striatal O
levels O
of O
the O
astrocytic O
protein O
marker O
, O
glial O
fibrillary O
acidic O
protein O
, O
were O
only O
transiently O
increased O
at O
3 O
days O
. O

these O
findings O
demonstrate O
for O
the O
first O
time O
that O
a O
single O
high O
dose O
of O
meth O
induces O
long O
- O
lasting O
depressive B-Disease
- O
like O
behaviour O
in O
mice O
associated O
with O
a O
persistent O
disruption O
of O
frontostriatal O
dopaminergic O
and O
serotonergic O
homoeostasis O
. O

linezolid O
- O
induced O
optic B-Disease
neuropathy I-Disease
. O

many O
systemic O
antimicrobials O
have O
been O
implicated O
to O
cause O
ocular O
adverse O
effects O
. O

this O
is O
especially O
relevant O
in O
multidrug O
therapy O
where O
more O
than O
one O
drug O
can O
cause O
a O
similar O
ocular O
adverse O
effect O
. O

we O
describe O
a O
case O
of O
progressive O
loss B-Disease
of I-Disease
vision I-Disease
associated O
with O
linezolid O
therapy O
. O

a O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
on O
treatment O
with O
multiple O
second O
- O
line O
anti O
- O
tuberculous O
drugs O
including O
linezolid O
and O
ethambutol O
for O
extensively B-Disease
drug I-Disease
- I-Disease
resistant I-Disease
tuberculosis I-Disease
( O
xdr B-Disease
- I-Disease
tb I-Disease
) O
presented O
to O
us O
with O
painless O
progressive O
loss B-Disease
of I-Disease
vision I-Disease
in O
both O
eyes O
. O

color O
vision O
was O
defective O
and O
fundus O
examination O
revealed O
optic B-Disease
disc I-Disease
edema I-Disease
in O
both O
eyes O
. O

ethambutol O
- O
induced O
toxic B-Disease
optic I-Disease
neuropathy I-Disease
was O
suspected O
and O
tablet O
ethambutol O
was O
withdrawn O
. O

deterioration B-Disease
of I-Disease
vision I-Disease
occurred O
despite O
withdrawal O
of O
ethambutol O
. O

discontinuation O
of O
linezolid O
resulted O
in O
marked O
improvement O
of O
vision O
. O

our O
report O
emphasizes O
the O
need O
for O
monitoring O
of O
visual O
function O
in O
patients O
on O
long O
- O
term O
linezolid O
treatment O
. O

resuscitation O
with O
lipid O
, O
epinephrine O
, O
or O
both O
in O
levobupivacaine O
- O
induced O
cardiac B-Disease
toxicity I-Disease
in O
newborn O
piglets O
. O

background O
: O
the O
optimal O
dosing O
regimens O
of O
lipid O
emulsion O
, O
epinephrine O
, O
or O
both O
are O
not O
yet O
determined O
in O
neonates O
in O
cases O
of O
local O
anaesthetic O
systemic O
toxicity B-Disease
( O
last O
) O
. O

methods O
: O
newborn O
piglets O
received O
levobupivacaine O
until O
cardiovascular B-Disease
collapse I-Disease
occurred O
. O

standard O
cardiopulmonary O
resuscitation O
was O
started O
and O
electrocardiogram O
( O
ecg O
) O
was O
monitored O
for O
ventricular B-Disease
tachycardia I-Disease
, O
fibrillation B-Disease
, O
or O
qrs O
prolongation O
. O

piglets O
were O
then O
randomly O
allocated O
to O
four O
groups O
: O
control O
( O
saline O
) O
, O
intralipid O
( O
) O
alone O
, O
epinephrine O
alone O
, O
or O
a O
combination O
of O
intralipd O
plus O
epinephrine O
. O

resuscitation O
continued O
for O
30 O
min O
or O
until O
there O
was O
a O
return O
of O
spontaneous O
circulation O
( O
rosc O
) O
accompanied O
by O
a O
mean O
arterial O
pressure O
at O
or O
superior O
to O
the O
baseline O
pressure O
and O
normal O
sinus O
rhythm O
for O
a O
period O
of O
30 O
min O
. O

results O
: O
rosc O
was O
achieved O
in O
only O
one O
of O
the O
control O
piglets O
compared O
with O
most O
of O
the O
treated O
piglets O
. O

mortality O
was O
not O
significantly O
different O
between O
the O
three O
treatment O
groups O
, O
but O
was O
significantly O
lower O
in O
all O
the O
treatment O
groups O
compared O
with O
control O
. O

the O
number O
of O
ecg O
abnormalities O
was O
zero O
in O
the O
intralipid O
only O
group O
, O
but O
14 O
and O
17 O
, O
respectively O
, O
in O
the O
epinephrine O
and O
epinephrine O
plus O
lipid O
groups O
( O
p O
< O
0 O
. O
05 O
) O
. O

conclusions O
: O
lipid O
emulsion O
with O
or O
without O
epinephrine O
, O
or O
epinephrine O
alone O
were O
equally O
effective O
in O
achieving O
a O
return O
to O
spontaneous O
circulation O
in O
this O
model O
of O
last O
. O

epinephrine O
alone O
or O
in O
combination O
with O
lipid O
was O
associated O
with O
an O
increased O
number O
of O
ecg O
abnormalities O
compared O
with O
lipid O
emulsion O
alone O
. O

incidence O
of O
heparin O
- O
induced O
thrombocytopenia B-Disease
type I-Disease
ii I-Disease
and O
postoperative O
recovery O
of O
platelet O
count O
in O
liver O
graft O
recipients O
: O
a O
retrospective O
cohort O
analysis O
. O

background O
: O
thrombocytopenia B-Disease
in O
patients O
with O
end B-Disease
- I-Disease
stage I-Disease
liver I-Disease
disease I-Disease
is O
a O
common O
disorder O
caused O
mainly O
by O
portal B-Disease
hypertension I-Disease
, O
low O
levels O
of O
thrombopoetin O
, O
and O
endotoxemia B-Disease
. O

the O
impact O
of O
immune O
- O
mediated O
heparin O
- O
induced O
thrombocytopenia B-Disease
type I-Disease
ii I-Disease
( O
hit B-Disease
type I-Disease
ii I-Disease
) O
as O
a O
cause O
of O
thrombocytopenia B-Disease
after O
liver O
transplantation O
is O
not O
yet O
understood O
, O
with O
few O
literature O
citations O
reporting O
contradictory O
results O
. O

the O
aim O
of O
our O
study O
was O
to O
demonstrate O
the O
perioperative O
course O
of O
thrombocytopenia B-Disease
after O
liver O
transplantation O
and O
determine O
the O
occurrence O
of O
clinical O
hit B-Disease
type I-Disease
ii I-Disease
. O

method O
: O
we O
retrospectively O
evaluated O
the O
medical O
records O
of O
205 O
consecutive O
adult O
patients O
who O
underwent O
full O
- O
size O
liver O
transplantation O
between O
january O
2006 O
and O
december O
2010 O
due O
to O
end B-Disease
- I-Disease
stage I-Disease
or I-Disease
malignant I-Disease
liver I-Disease
disease I-Disease
. O

preoperative O
platelet O
count O
, O
postoperative O
course O
of O
platelets O
, O
and O
clinical O
signs O
of O
hit B-Disease
type I-Disease
ii I-Disease
were O
analyzed O
. O

results O
: O
a O
total O
of O
155 O
( O
75 O
. O
6 O
% O
) O
of O
205 O
patients O
had O
thrombocytopenia B-Disease
before O
transplantation O
, O
significantly O
influenced O
by O
model O
of O
end B-Disease
- I-Disease
stage I-Disease
liver I-Disease
disease I-Disease
score O
and O
liver B-Disease
cirrhosis I-Disease
. O

the O
platelet O
count O
exceeded O
100 O
, O
000 O
/ O
ul O
in O
most O
of O
the O
patients O
( O
n O
= O
193 O
) O
at O
a O
medium O
of O
7 O
d O
. O

regarding O
hit B-Disease
ii I-Disease
, O
there O
were O
four O
( O
1 O
. O
95 O
% O
) O
patients O
with O
a O
background O
of O
hit B-Disease
type I-Disease
ii I-Disease
. O

conclusions O
: O
the O
incidence O
of O
hit B-Disease
in O
patients O
with O
end B-Disease
- I-Disease
stage I-Disease
hepatic I-Disease
failure I-Disease
is O
, O
with O
about O
1 O
. O
95 O
% O
, O
rare O
. O

for O
further O
reduction O
of O
hit B-Disease
type I-Disease
ii I-Disease
, O
the O
use O
of O
intravenous O
heparin O
should O
be O
avoided O
and O
the O
prophylactic O
anticoagulation O
should O
be O
performed O
with O
low O
- O
molecular O
- O
weight O
heparin O
after O
normalization O
of O
platelet O
count O
. O

takotsubo B-Disease
syndrome I-Disease
( O
or O
apical B-Disease
ballooning I-Disease
syndrome I-Disease
) O
secondary O
to O
zolmitriptan O
. O

takotsubo B-Disease
syndrome I-Disease
( O
ts B-Disease
) O
, O
also O
known O
as O
broken B-Disease
heart I-Disease
syndrome I-Disease
, O
is O
characterized O
by O
left O
ventricle O
apical O
ballooning O
with O
elevated O
cardiac O
biomarkers O
and O
electrocardiographic O
changes O
suggestive O
of O
an O
acute B-Disease
coronary I-Disease
syndrome I-Disease
( O
ie O
, O
st O
- O
segment O
elevation O
, O
t O
wave O
inversions O
, O
and O
pathologic O
q O
waves O
) O
. O

we O
report O
a O
case O
of O
54 O
- O
year O
- O
old O
woman O
with O
medical O
history O
of O
mitral B-Disease
valve I-Disease
prolapse I-Disease
and O
migraines B-Disease
, O
who O
was O
admitted O
to O
the O
hospital O
for O
substernal O
chest B-Disease
pain I-Disease
and O
electrocardiogram O
demonstrated O
1 O
/ O
2 O
mm O
st O
- O
segment O
elevation O
in O
leads O
ii O
, O
iii O
, O
avf O
, O
v5 O
, O
and O
v6 O
and O
positive O
troponin O
i O
. O

emergent O
coronary O
angiogram O
revealed O
normal O
coronary O
arteries O
with O
moderately O
reduced O
left O
ventricular O
ejection O
fraction O
with O
wall O
motion O
abnormalities O
consistent O
with O
ts B-Disease
. O

detailed O
history O
obtained O
retrospectively O
revealed O
that O
the O
patient O
took O
zolmitriptan O
sparingly O
only O
when O
she O
had O
migraines B-Disease
. O

but O
before O
this O
event O
, O
she O
was O
taking O
zolmitriptan O
2 O
- O
3 O
times O
daily O
for O
several O
days O
because O
of O
a O
persistent O
migraine B-Disease
headache I-Disease
. O

she O
otherwise O
reported O
that O
she O
is O
quite O
active O
, O
rides O
horses O
, O
and O
does O
show O
jumping O
without O
any O
limitations O
in O
her O
physical O
activity O
. O

there O
was O
no O
evidence O
of O
any O
recent O
stress O
or O
status B-Disease
migrainosus I-Disease
. O

extensive O
literature O
search O
revealed O
multiple O
cases O
of O
coronary B-Disease
artery I-Disease
vasospasm I-Disease
secondary O
to O
zolmitriptan O
, O
but O
none O
of O
the O
cases O
were O
associated O
with O
ts B-Disease
. O

depression B-Disease
, O
impulsiveness B-Disease
, O
sleep O
, O
and O
memory O
in O
past O
and O
present O
polydrug O
users O
of O
3 O
, O
4 O
- O
methylenedioxymethamphetamine O
( O
mdma O
, O
ecstasy O
) O
. O

rationale O
: O
ecstasy O
( O
3 O
, O
4 O
- O
methylenedioxymethamphetamine O
, O
mdma O
) O
is O
a O
worldwide O
recreational O
drug O
of O
abuse O
. O

unfortunately O
, O
the O
results O
from O
human O
research O
investigating O
its O
psychological O
effects O
have O
been O
inconsistent O
. O

objectives O
: O
the O
present O
study O
aimed O
to O
be O
the O
largest O
to O
date O
in O
sample O
size O
and O
5ht O
- O
related O
behaviors O
; O
the O
first O
to O
compare O
present O
ecstasy O
users O
with O
past O
users O
after O
an O
abstinence O
of O
4 O
or O
more O
years O
, O
and O
the O
first O
to O
include O
robust O
controls O
for O
other O
recreational O
substances O
. O

methods O
: O
a O
sample O
of O
997 O
participants O
( O
52 O
% O
male O
) O
was O
recruited O
to O
four O
control O
groups O
( O
non O
- O
drug O
( O
nd O
) O
, O
alcohol O
/ O
nicotine O
( O
an O
) O
, O
cannabis O
/ O
alcohol O
/ O
nicotine O
( O
can O
) O
, O
non O
- O
ecstasy O
polydrug O
( O
pd O
) O
) O
, O
and O
two O
ecstasy O
polydrug O
groups O
( O
present O
( O
mdma O
) O
and O
past O
users O
( O
ex O
- O
mdma O
) O
. O

participants O
completed O
a O
drug O
history O
questionnaire O
, O
beck O
depression B-Disease
inventory O
, O
barratt O
impulsiveness B-Disease
scale O
, O
pittsburgh O
sleep O
quality O
index O
, O
and O
wechsler O
memory O
scale O
- O
revised O
which O
, O
in O
total O
, O
provided O
13 O
psychometric O
measures O
. O

results O
: O
while O
the O
can O
and O
pd O
groups O
tended O
to O
record O
greater O
deficits O
than O
the O
non O
- O
drug O
controls O
, O
the O
mdma O
and O
ex O
- O
mdma O
groups O
recorded O
greater O
deficits O
than O
all O
the O
control O
groups O
on O
ten O
of O
the O
13 O
psychometric O
measures O
. O

strikingly O
, O
despite O
prolonged O
abstinence O
( O
mean O
, O
4 O
. O
98 O
; O
range O
, O
4 O
- O
9 O
years O
) O
, O
past O
ecstasy O
users O
showed O
few O
signs O
of O
recovery O
. O

compared O
with O
present O
ecstasy O
users O
, O
the O
past O
users O
showed O
no O
change O
for O
ten O
measures O
, O
increased O
impairment O
for O
two O
measures O
, O
and O
improvement O
on O
just O
one O
measure O
. O

conclusions O
: O
given O
this O
record O
of O
impaired B-Disease
memory I-Disease
and O
clinically O
significant O
levels O
of O
depression B-Disease
, O
impulsiveness B-Disease
, O
and O
sleep B-Disease
disturbance I-Disease
, O
the O
prognosis O
for O
the O
current O
generation O
of O
ecstasy O
users O
is O
a O
major O
cause O
for O
concern O
. O

association O
of O
common O
genetic O
variants O
of O
homer1 O
gene O
with O
levodopa O
adverse O
effects O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
patients O
. O

levodopa O
is O
the O
most O
effective O
symptomatic O
therapy O
for O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
, O
but O
its O
chronic O
use O
could O
lead O
to O
chronic O
adverse O
outcomes O
, O
such O
as O
motor O
fluctuations O
, O
dyskinesia B-Disease
and O
visual B-Disease
hallucinations I-Disease
. O

homer1 O
is O
a O
protein O
with O
pivotal O
function O
in O
glutamate O
transmission O
, O
which O
has O
been O
related O
to O
the O
pathogenesis O
of O
these O
complications O
. O

this O
study O
investigates O
whether O
polymorphisms O
in O
the O
homer1 O
gene O
promoter O
region O
are O
associated O
with O
the O
occurrence O
of O
the O
chronic O
complications O
of O
levodopa O
therapy O
. O

a O
total O
of O
205 O
patients O
with O
idiopathic B-Disease
parkinson I-Disease
' I-Disease
s I-Disease
disease I-Disease
were O
investigated O
. O

patients O
were O
genotyped O
for O
rs4704559 O
, O
rs10942891 O
and O
rs4704560 O
by O
allelic O
discrimination O
with O
taqman O
assays O
. O

the O
rs4704559 O
g O
allele O
was O
associated O
with O
a O
lower O
prevalence O
of O
dyskinesia B-Disease
( O
prevalence O
ratio O
( O
pr O
) O
= O
0 O
. O
615 O
, O
95 O
% O
confidence O
interval O
( O
ci O
) O
0 O
. O
426 O
- O
0 O
. O
887 O
, O
p O
= O
0 O
. O
009 O
) O
and O
visual B-Disease
hallucinations I-Disease
( O
pr O
= O
0 O
. O
515 O
, O
95 O
% O
ci O
0 O
. O
295 O
- O
0 O
. O
899 O
, O
p O
= O
0 O
. O
020 O
) O
. O

our O
data O
suggest O
that O
homer1 O
rs4704559 O
g O
allele O
has O
a O
protective O
role O
for O
the O
development O
of O
levodopa O
adverse O
effects O
. O

crocin O
improves O
lipid O
dysregulation O
in O
subacute O
diazinon O
exposure O
through O
erk1 O
/ O
2 O
pathway O
in O
rat O
liver O
. O

introduction O
: O
diazinon O
yis O
one O
of O
the O
most O
broadly O
used O
organophosphorus O
insecticides O
in O
agriculture O
. O

it O
has O
been O
shown O
that O
exposure O
to O
diazinon O
may O
interfere O
with O
lipid O
metabolism O
. O

moreover O
, O
the O
hypolipidemic O
effect O
of O
crocin O
has O
been O
established O
. O

earlier O
studies O
revealed O
the O
major O
role O
of O
extracellular O
signal O
- O
regulated O
kinase O
( O
erk O
) O
pathways O
in O
low O
- O
density O
lipoprotein O
receptor O
( O
ldlr O
) O
expression O
. O

the O
aim O
of O
this O
study O
was O
to O
evaluate O
changes O
in O
the O
regulation O
of O
lipid O
metabolism O
, O
erk O
and O
ldlr O
expression O
in O
the O
liver O
of O
rats O
exposed O
to O
subacute O
diazinon O
. O

furthermore O
ameliorating O
effect O
of O
crocin O
on O
diazinon O
induced O
disturbed O
cholesterol O
homeostasis O
was O
studied O
. O

methods O
: O
24 O
rats O
were O
divided O
into O
4 O
groups O
and O
received O
following O
treatments O
for O
4 O
weeks O
; O
corn O
oil O
( O
control O
) O
, O
diazinon O
( O
15mg O
/ O
kg O
per O
day O
, O
orally O
) O
and O
crocin O
( O
12 O
. O
5 O
and O
25mg O
/ O
kg O
per O
day O
, O
intraperitoneally O
) O
in O
combination O
with O
diazinon O
( O
15 O
mg O
/ O
kg O
) O
. O

the O
levels O
of O
cholesterol O
, O
triglyceride O
and O
ldl O
in O
blood O
of O
rats O
were O
analyzed O
. O

moreover O
mrna O
levels O
of O
ldlr O
and O
erk1 O
/ O
2 O
as O
well O
as O
protein O
levels O
of O
total O
and O
activated O
forms O
of O
erk1 O
/ O
2 O
in O
rat O
liver O
were O
evaluated O
by O
western O
blotting O
and O
quantitative O
real O
time O
polymerase O
chain O
reaction O
analysis O
. O

results O
: O
our O
data O
showed O
that O
subacute O
exposure O
to O
diazinon O
significantly O
increased O
concentrations O
of O
cholesterol O
, O
triglyceride O
and O
ldl O
. O

moreover O
diazinon O
decreased O
erk1 O
/ O
2 O
protein O
phosphorylation O
and O
ldlr O
transcript O
. O

crocin O
reduced O
inhibition O
of O
erk O
activation O
and O
diazinon O
- O
induced O
hyperlipemia B-Disease
and O
increased O
levels O
of O
ldlr O
transcript O
. O

conclusions O
: O
crocin O
may O
be O
considered O
as O
a O
novel O
protective O
agent O
in O
diazinon O
- O
induced O
hyperlipemia B-Disease
through O
modulating O
of O
erk O
pathway O
and O
increase O
of O
ldlr O
expression O
. O

gem O
- O
p O
chemotherapy O
is O
active O
in O
the O
treatment O
of O
relapsed O
hodgkin B-Disease
lymphoma I-Disease
. O

hodgkin B-Disease
lymphoma I-Disease
( O
hl B-Disease
) O
is O
a O
relatively O
chemosensitive O
malignancy B-Disease
. O

however O
, O
for O
those O
who O
relapse O
, O
high O
- O
dose O
chemotherapy O
with O
autologous O
stem O
cell O
transplant O
is O
the O
treatment O
of O
choice O
which O
relies O
on O
adequate O
disease O
control O
with O
salvage O
chemotherapy O
. O

regimens O
commonly O
used O
often O
require O
inpatient O
administration O
and O
can O
be O
difficult O
to O
deliver O
due O
to O
toxicity B-Disease
. O

gemcitabine O
and O
cisplatin O
have O
activity O
in O
hl B-Disease
, O
non O
- O
overlapping O
toxicity B-Disease
with O
first O
- O
line O
chemotherapeutics O
, O
and O
may O
be O
delivered O
in O
an O
outpatient O
setting O
. O

in O
this O
retrospective O
single O
- O
centre O
analysis O
, O
patients O
with O
relapsed O
or O
refractory O
hl B-Disease
treated O
with O
gemcitabine O
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
day O
( O
d O
) O
1 O
, O
d8 O
and O
d15 O
; O
methylprednisolone O
1 O
, O
000 O
mg O
d1 O
- O
5 O
; O
and O
cisplatin O
100 O
mg O
/ O
m O
( O
2 O
) O
d15 O
, O
every O
28 O
days O
( O
gem O
- O
p O
) O
were O
included O
. O

demographic O
, O
survival O
, O
response O
and O
toxicity B-Disease
data O
were O
recorded O
. O

forty O
- O
one O
eligible O
patients O
were O
identified O
: O
median O
age O
27 O
. O

one O
hundred O
and O
twenty O
- O
two O
cycles O
of O
gem O
- O
p O
were O
administered O
in O
total O
( O
median O
3 O
cycles O
; O
range O
1 O
- O
6 O
) O
. O

twenty O
of O
41 O
( O
48 O
% O
) O
patients O
received O
gem O
- O
p O
as O
second O
- O
line O
treatment O
and O
11 O
/ O
41 O
( O
27 O
% O
) O
as O
third O
- O
line O
therapy O
. O

overall O
response O
rate O
( O
orr O
) O
to O
gem O
- O
p O
in O
the O
entire O
cohort O
was O
80 O
% O
( O
complete O
response O
( O
cr O
) O
37 O
% O
, O
partial O
response O
44 O
% O
) O
with O
14 O
/ O
15 O
cr O
confirmed O
as O
a O
metabolic O
cr O
on O
pet O
and O
orr O
of O
85 O
% O
in O
the O
20 O
second O
- O
line O
patients O
. O

the O
most O
common O
grade O
3 O
/ O
4 O
toxicities B-Disease
were O
haematological O
: O
neutropenia B-Disease
54 O
% O
and O
thrombocytopenia B-Disease
51 O
% O
. O

median O
follow O
- O
up O
from O
the O
start O
of O
gem O
- O
p O
was O
4 O
. O
5 O
years O
. O

following O
gem O
- O
p O
, O
5 O
- O
year O
progression O
- O
free O
survival O
was O
46 O
% O
( O
95 O
% O
confidence O
interval O
( O
ci O
) O
, O
30 O
- O
62 O
% O
) O
and O
5 O
- O
year O
overall O
survival O
was O
59 O
% O
( O
95 O
% O
ci O
, O
43 O
- O
74 O
% O
) O
. O

fourteen O
of O
41 O
patients O
proceeded O
directly O
to O
autologous O
transplant O
. O

gem O
- O
p O
is O
a O
salvage O
chemotherapy O
with O
relatively O
high O
response O
rates O
, O
leading O
to O
successful O
transplantation O
in O
appropriate O
patients O
, O
in O
the O
treatment O
of O
relapsed O
or O
refractory O
hl B-Disease
. O

basal O
functioning O
of O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
( O
hpa O
) O
axis O
and O
psychological O
distress O
in O
recreational O
ecstasy O
polydrug O
users O
. O

rationale O
: O
ecstasy O
( O
mdma O
) O
is O
a O
psychostimulant O
drug O
which O
is O
increasingly O
associated O
with O
psychobiological B-Disease
dysfunction I-Disease
. O

while O
some O
recent O
studies O
suggest O
acute O
changes O
in O
neuroendocrine O
function O
, O
less O
is O
known O
about O
long O
- O
term O
changes O
in O
hpa O
functionality O
in O
recreational O
users O
. O

objectives O
: O
the O
current O
study O
is O
the O
first O
to O
explore O
the O
effects O
of O
ecstasy O
- O
polydrug O
use O
on O
psychological O
distress O
and O
basal O
functioning O
of O
the O
hpa O
axis O
through O
assessing O
the O
secretion O
of O
cortisol O
across O
the O
diurnal O
period O
. O

method O
: O
seventy O
- O
six O
participants O
( O
21 O
nonusers O
, O
29 O
light O
ecstasy O
- O
polydrug O
users O
, O
26 O
heavy O
ecstasy O
- O
polydrug O
users O
) O
completed O
a O
substance O
use O
inventory O
and O
measures O
of O
psychological O
distress O
at O
baseline O
, O
then O
two O
consecutive O
days O
of O
cortisol O
sampling O
( O
on O
awakening O
, O
30 O
min O
post O
awakening O
, O
between O
1400 O
and O
1600 O
hours O
and O
pre O
bedtime O
) O
. O

on O
day O
2 O
, O
participants O
also O
attended O
the O
laboratory O
to O
complete O
a O
20 O
- O
min O
multitasking O
stressor O
. O

results O
: O
both O
user O
groups O
exhibited O
significantly O
greater O
levels O
of O
anxiety B-Disease
and O
depression B-Disease
than O
nonusers O
. O

on O
day O
1 O
, O
all O
participants O
exhibited O
a O
typical O
cortisol O
profile O
, O
though O
light O
users O
had O
significantly O
elevated O
levels O
pre O
- O
bed O
. O

on O
day O
2 O
, O
heavy O
users O
demonstrated O
elevated O
levels O
upon O
awakening O
and O
all O
ecstasy O
- O
polydrug O
users O
demonstrated O
elevated O
pre O
- O
bed O
levels O
compared O
to O
non O
- O
users O
. O

significant O
between O
group O
differences O
were O
also O
observed O
in O
afternoon O
cortisol O
levels O
and O
in O
overall O
cortisol O
secretion O
across O
the O
day O
. O

conclusions O
: O
the O
increases O
in O
anxiety B-Disease
and O
depression B-Disease
are O
in O
line O
with O
previous O
observations O
in O
recreational O
ecstasy O
- O
polydrug O
users O
. O

dysregulated O
diurnal O
cortisol O
may O
be O
indicative O
of O
inappropriate O
anticipation O
of O
forthcoming O
demands O
and O
hypersecretion O
may O
lead O
to O
the O
increased O
psychological O
and O
physical O
morbidity O
associated O
with O
heavy O
recreational O
use O
of O
ecstasy O
. O

ifosfamide O
related O
encephalopathy B-Disease
: O
the O
need O
for O
a O
timely O
eeg O
evaluation O
. O

background O
: O
ifosfamide O
is O
an O
alkylating O
agent O
useful O
in O
the O
treatment O
of O
a O
wide O
range O
of O
cancers B-Disease
including O
sarcomas B-Disease
, O
lymphoma B-Disease
, O
gynecologic B-Disease
and I-Disease
testicular I-Disease
cancers I-Disease
. O

encephalopathy B-Disease
has O
been O
reported O
in O
10 O
- O
40 O
% O
of O
patients O
receiving O
high O
- O
dose O
iv O
ifosfamide O
. O

objective O
: O
to O
highlight O
the O
role O
of O
electroencephalogram O
( O
eeg O
) O
in O
the O
early O
detection O
and O
management O
of O
ifosfamide O
related O
encephalopathy B-Disease
. O

methods O
: O
retrospective O
chart O
review O
including O
clinical O
data O
and O
eeg O
recordings O
was O
done O
on O
five O
patients O
, O
admitted O
to O
md O
anderson O
cancer B-Disease
center O
between O
years O
2009 O
and O
2012 O
, O
who O
developed O
ifosfamide O
related O
acute O
encephalopathy B-Disease
. O

results O
: O
all O
five O
patients O
experienced O
symptoms O
of O
encephalopathy B-Disease
soon O
after O
( O
within O
12 O
h O
- O
2 O
days O
) O
receiving O
ifosfamide O
. O

two O
patients O
developed O
generalized O
convulsions B-Disease
while O
one O
patient O
developed O
continuous O
non B-Disease
- I-Disease
convulsive I-Disease
status I-Disease
epilepticus I-Disease
( O
ncse B-Disease
) O
that O
required O
icu O
admission O
and O
intubation O
. O

initial O
eeg O
showed O
epileptiform O
discharges O
in O
three O
patients O
; O
run O
of O
triphasic O
waves O
in O
one O
patient O
and O
moderate O
degree O
diffuse O
generalized O
slowing O
. O

mixed O
pattern O
with O
the O
presence O
of O
both O
sharps O
and O
triphasic O
waves O
were O
also O
noted O
. O

repeat O
eegs O
within O
24 O
_ O
h O
of O
symptom O
onset O
showed O
marked O
improvement O
that O
was O
correlated O
with O
clinical O
improvement O
. O

conclusions O
: O
severity O
of O
ifosfamide O
related O
encephalopathy B-Disease
correlates O
with O
eeg O
changes O
. O

we O
suggest O
a O
timely O
eeg O
evaluation O
for O
patients O
receiving O
ifosfamide O
who O
develop O
features O
of O
encephalopathy B-Disease
. O

incidence O
of O
contrast O
- O
induced O
nephropathy B-Disease
in O
hospitalised O
patients O
with O
cancer B-Disease
. O

objectives O
: O
to O
determine O
the O
frequency O
of O
and O
possible O
factors O
related O
to O
contrast O
- O
induced O
nephropathy B-Disease
( O
cin O
) O
in O
hospitalised O
patients O
with O
cancer B-Disease
. O

methods O
: O
ninety O
adult O
patients O
were O
enrolled O
. O

patients O
with O
risk O
factors O
for O
acute B-Disease
renal I-Disease
failure I-Disease
were O
excluded O
. O

blood O
samples O
were O
examined O
the O
day O
before O
contrast O
- O
enhanced O
computed O
tomography O
( O
ct O
) O
and O
serially O
for O
3 O
days O
thereafter O
. O

cin O
was O
defined O
as O
an O
increase O
in O
serum O
creatinine O
( O
cr O
) O
of O
0 O
. O
5 O
mg O
/ O
dl O
or O
more O
, O
or O
elevation O
of O
cr O
to O
25 O
% O
over O
baseline O
. O

relationships O
between O
cin O
and O
possible O
risk O
factors O
were O
investigated O
. O

results O
: O
cin O
was O
detected O
in O
18 O
/ O
90 O
( O
20 O
% O
) O
patients O
. O

cin O
developed O
in O
25 O
. O
5 O
% O
patients O
who O
underwent O
chemotherapy O
and O
in O
11 O
% O
patients O
who O
did O
not O
( O
p O
= O
0 O
. O
1 O
) O
. O

cin O
more O
frequently O
developed O
in O
patients O
who O
had O
undergone O
ct O
within O
45 O
days O
after O
the O
last O
chemotherapy O
( O
p O
= O
0 O
. O
005 O
) O
; O
it O
was O
also O
an O
independent O
risk O
factor O
( O
p O
= O
0 O
. O
017 O
) O
. O

cin O
was O
significantly O
more O
after O
treatment O
with O
bevacizumab O
/ O
irinotecan O
( O
p O
= O
0 O
. O
021 O
) O
and O
in O
patients O
with O
hypertension B-Disease
( O
p O
= O
0 O
. O
044 O
) O
. O

conclusions O
: O
the O
incidence O
of O
cin O
after O
ct O
in O
hospitalised O
oncological O
patients O
was O
20 O
% O
. O

cin O
developed O
4 O
. O
5 O
- O
times O
more O
frequently O
in O
patients O
with O
cancer B-Disease
who O
had O
undergone O
recent O
chemotherapy O
. O

hypertension B-Disease
and O
the O
combination O
of O
bevacizumab O
/ O
irinotecan O
may O
be O
additional O
risk O
factors O
for O
cin O
development O
. O

key O
points O
: O
. O

contrast O
- O
induced O
nephropathy B-Disease
( O
cin O
) O
is O
a O
concern O
for O
oncological O
patients O
undergoing O
ct O
. O

. O
cin O
occurs O
more O
often O
when O
ct O
is O
performed O
< O
45 O
days O
after O
chemotherapy O
. O

. O
hypertension B-Disease
and O
treatment O
with O
bevacizumab O
appear O
to O
be O
additional O
risk O
factors O
. O

syndrome B-Disease
of I-Disease
inappropriate I-Disease
antidiuretic I-Disease
hormone I-Disease
secretion O
associated O
with O
desvenlafaxine O
. O

objective O
: O
to O
report O
a O
case O
of O
syndrome B-Disease
of I-Disease
inappropriate I-Disease
anti I-Disease
- I-Disease
diuretic I-Disease
hormone I-Disease
( O
siadh B-Disease
) O
secretion O
associated O
with O
desvenlafaxine O
. O

case O
summary O
: O
a O
57 O
- O
year O
old O
female O
with O
hyponatraemia B-Disease
. O

her O
medications O
included O
desvenlafaxine O
, O
and O
symptoms O
included O
nausea B-Disease
, O
anxiety B-Disease
and O
confusion B-Disease
. O

the O
serum O
sodium O
at O
this O
time O
was O
120 O
mmol O
/ O
l O
, O
serum O
osmolality O
was O
263 O
mosmol O
/ O
kg O
, O
urine O
osmolality O
410 O
mosmol O
/ O
kg O
and O
urine O
sodium O
63 O
mmol O
/ O
l O
, O
consistent O
with O
a O
diagnosis O
of O
siadh B-Disease
. O

desvenlafaxine O
was O
ceased O
and O
fluid O
restriction O
implemented O
. O

after O
4 O
days O
the O
sodium O
increased O
to O
128 O
mmol O
/ O
l O
and O
fluid O
restriction O
was O
relaxed O
. O

during O
her O
further O
3 O
weeks O
inpatient O
admission O
the O
serum O
sodium O
ranged O
from O
134 O
to O
137 O
mmol O
/ O
l O
during O
treatment O
with O
mirtazapine O
. O

discussion O
: O
siadh B-Disease
has O
been O
widely O
reported O
with O
a O
range O
of O
antidepressants O
. O

this O
case O
report O
suggests O
that O
desvenlafaxine O
might O
cause O
clinically O
significant O
hyponatremia B-Disease
. O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
the O
potential O
for O
antidepressants O
to O
cause O
hyponatremia B-Disease
, O
and O
take O
appropriate O
corrective O
action O
where O
necessary O
. O

oxidative O
stress O
on O
cardiotoxicity B-Disease
after O
treatment O
with O
single O
and O
multiple O
doses O
of O
doxorubicin O
. O

the O
mechanism O
of O
doxorubicin O
( O
dox O
) O
- O
induced O
cardiotoxicity B-Disease
remains O
controversial O
. O

wistar O
rats O
( O
n O
= O
66 O
) O
received O
dox O
injections O
intraperitoneally O
and O
were O
randomly O
assigned O
to O
2 O
experimental O
protocols O
: O
( O
1 O
) O
rats O
were O
killed O
before O
( O
- O
24 O
h O
, O
n O
= O
8 O
) O
and O
24 O
h O
after O
( O
+ O
24 O
h O
, O
n O
= O
8 O
) O
a O
single O
dose O
of O
dox O
( O
4 O
mg O
/ O
kg O
body O
weight O
) O
to O
determine O
the O
dox O
acute O
effect O
and O
( O
2 O
) O
rats O
( O
n O
= O
58 O
) O
received O
4 O
injections O
of O
dox O
( O
4 O
mg O
/ O
kg O
body O
weight O
/ O
week O
) O
and O
were O
killed O
before O
the O
first O
injection O
( O
m0 O
) O
and O
1 O
week O
after O
each O
injection O
( O

m1 O
, O
m2 O
, O
m3 O
, O
and O
m4 O
) O
to O
determine O
the O
chronological O
effects O
. O

animals O
used O
at O
m0 O
( O
n O
= O
8 O
) O
were O
also O
used O
at O
moment O
- O
24 O
h O
of O
acute O
study O
. O

cardiac O
total O
antioxidant O
performance O
( O
tap O
) O
, O
dna O
damage O
, O
and O
morphology O
analyses O
were O
carried O
out O
at O
each O
time O
point O
. O

single O
dose O
of O
dox O
was O
associated O
with O
increased O
cardiac B-Disease
disarrangement I-Disease
, O
necrosis B-Disease
, O
and O
dna O
damage O
( O
strand O
breaks O
( O
sbs O
) O
and O
oxidized O
pyrimidines O
) O
and O
decreased O
tap O
. O

the O
chronological O
study O
showed O
an O
effect O
of O
a O
cumulative O
dose O
on O
body O
weight O
( O
r O
= O
- O
0 O
. O
99 O
, O
p O
= O
0 O
. O
011 O
) O
, O
necrosis B-Disease
( O
r O
= O
1 O
. O
00 O
, O
p O
= O
0 O
. O
004 O
) O
, O
tap O
( O
r O
= O
0 O
. O
95 O
, O
p O
= O
0 O
. O
049 O
) O
, O
and O
dna O
sbs O
( O
r O
= O
- O
0 O
. O
95 O
, O
p O
= O
0 O
. O
049 O
) O
. O

dna O
sbs O
damage O
was O
negatively O
associated O
with O
tap O
( O
r O
= O
- O
0 O
. O
98 O
, O
p O
= O
0 O
. O
018 O
) O
, O
and O
necrosis B-Disease
( O
r O
= O
- O
0 O
. O
97 O
, O
p O
= O
0 O
. O
027 O
) O
. O

our O
results O
suggest O
that O
oxidative O
damage O
is O
associated O
with O
acute O
cardiotoxicity B-Disease
induced O
by O
a O
single O
dose O
of O
dox O
only O
. O

increased O
resistance O
to O
the O
oxidative O
stress O
is O
plausible O
for O
the O
multiple O
dose O
of O
dox O
. O

thus O
, O
different O
mechanisms O
may O
be O
involved O
in O
acute O
toxicity B-Disease
versus O
chronic O
toxicity B-Disease
. O

tacrolimus O
- O
related O
seizure B-Disease
after O
pediatric O
liver O
transplantation O
- O
- O
a O
single O
- O
center O
experience O
. O

to O
identify O
the O
risk O
factors O
for O
new O
- O
onset O
seizures B-Disease
after O
pediatric O
lt O
and O
to O
assess O
their O
clinical O
implications O
and O
long O
- O
term O
prognosis O
. O

the O
clinical O
and O
laboratory O
data O
of O
27 O
consecutive O
children O
who O
underwent O
lt O
from O
january O
2007 O
to O
december O
2010 O
in O
our O
center O
were O
analyzed O
retrospectively O
. O

patients O
were O
divided O
into O
seizures B-Disease
group O
and O
a O
non O
- O
seizures B-Disease
group O
. O

pre O
- O
operative O
, O
intra O
- O
operative O
, O
and O
post O
- O
operative O
data O
were O
collected O
. O

seizures B-Disease
occurred O
in O
four O
children O
, O
an O
incidence O
of O
14 O
. O
8 O
% O
. O

all O
exhibited O
generalized O
tonic B-Disease
- I-Disease
clonic I-Disease
seizures I-Disease
within O
the O
first O
two O
wk O
after O
lt O
. O

univariate O
analysis O
showed O
that O
the O
risk O
factors O
associated O
with O
seizures B-Disease
after O
pediatric O
lt O
included O
gender O
, O
pediatric O
end B-Disease
- I-Disease
stage I-Disease
liver I-Disease
disease I-Disease
score O
before O
surgery O
, O
child O
- O
pugh O
score O
before O
surgery O
, O
serum O
total O
bilirubin O
after O
surgery O
, O
and O
trough O
tac O
level O
. O

multivariate O
analysis O
showed O
that O
trough O
tac O
level O
was O
the O
only O
independent O
risk O
factor O
associated O
with O
the O
seizures B-Disease
. O

all O
children O
who O
experienced O
seizures B-Disease
survived O
with O
good O
graft O
function O
and O
remained O
seizure B-Disease
- O
free O
without O
anti O
- O
epileptic B-Disease
drugs O
over O
a O
mean O
follow O
- O
up O
period O
of O
33 O
. O
7 O
+ O
14 O
. O
6 O
months O
. O

high O
trough O
tac O
level O
was O
the O
predominant O
factor O
that O
contributed O
to O
seizures B-Disease
in O
the O
early O
post O
- O
operative O
period O
after O
pediatric O
lt O
. O

high O
peld O
and O
child O
- O
pugh O
scores O
before O
lt O
and O
high O
post O
- O
operative O
serum O
tbil O
may O
be O
contributory O
risk O
factors O
for O
tac O
- O
related O
seizures B-Disease
. O

the O
flavonoid O
apigenin O
delays O
forgetting O
of O
passive O
avoidance O
conditioning O
in O
rats O
. O

the O
present O
experiments O
were O
performed O
to O
study O
the O
effect O
of O
the O
flavonoid O
apigenin O
( O
20 O
mg O
/ O
kg O
intraperitoneally O
( O
i O
. O
p O
. O
) O
, O
1 O
h O
before O
acquisition O
) O
, O
on O
24 O
h O
retention O
performance O
and O
forgetting O
of O
a O
step O
- O
through O
passive O
avoidance O
task O
, O
in O
young O
male O
wistar O
rats O
. O

there O
were O
no O
differences O
between O
saline O
- O
and O
apigenin O
- O
treated O
groups O
in O
the O
24 O
h O
retention O
trial O
. O

furthermore O
, O
apigenin O
did O
not O
prevent O
the O
amnesia B-Disease
induced O
by O
scopolamine O
( O
1mg O
/ O
kg O
, O
i O
. O
p O
. O
, O
30 O
min O
before O
the O
acquisition O
) O
. O

the O
saline O
- O
and O
apigenin O
- O
treated O
rats O
that O
did O
not O
step O
through O
into O
the O
dark O
compartment O
during O
the O
cut O
- O
off O
time O
( O
540 O
s O
) O
were O
retested O
weekly O
for O
up O
to O
eight O
weeks O
. O

in O
the O
saline O
treated O
group O
, O
the O
first O
significant O
decline O
in O
passive O
avoidance O
response O
was O
observed O
at O
four O
weeks O
, O
and O
complete O
memory B-Disease
loss I-Disease
was O
found O
five O
weeks O
after O
the O
acquisition O
of O
the O
passive O
avoidance O
task O
. O

at O
the O
end O
of O
the O
experimental O
period O
, O
60 O
% O
of O
the O
animals O
treated O
with O
apigenin O
still O
did O
not O
step O
through O
. O

these O
data O
suggest O
that O
1 O
) O
apigenin O
delays O
the O
long O
- O
term O
forgetting O
but O
did O
not O
modulate O
the O
24 O
h O
retention O
of O
fear O
memory O
and O
2 O
) O
the O
obtained O
beneficial O
effect O
of O
apigenin O
on O
the O
passive O
avoidance O
conditioning O
is O
mediated O
by O
mechanisms O
that O
do O
not O
implicate O
its O
action O
on O
the O
muscarinic O
cholinergic O
system O
. O

histamine O
antagonists O
and O
d O
- O
tubocurarine O
- O
induced O
hypotension B-Disease
in O
cardiac O
surgical O
patients O
. O

hemodynamic O
effects O
and O
histamine O
release O
by O
bolus O
injection O
of O
0 O
. O
35 O
mg O
/ O
kg O
of O
d O
- O
tubocurarine O
were O
studied O
in O
24 O
patients O
. O

h1 O
- O
and O
h2 O
- O
histamine O
antagonists O
or O
placebo O
were O
given O
before O
dosing O
with O
d O
- O
tubocurarine O
in O
a O
randomized O
double O
- O
blind O
fashion O
to O
four O
groups O
: O
group O
1 O
- O
- O
placebo O
; O
group O
2 O
- O
- O
cimetidine O
, O
4 O
mg O
/ O
kg O
, O
plus O
placebo O
; O
group O
3 O
- O
- O
chlorpheniramine O
, O
0 O
. O
1 O
mg O
/ O
kg O
, O
plus O
placebo O
; O
and O
group O
4 O
- O
- O
cimetidine O
plus O
chlorpheniramine O
. O

histamine O
release O
occurred O
in O
most O
patients O
, O
the O
highest O
level O
2 O
minutes O
after O
d O
- O
tubocurarine O
dosing O
. O

group O
1 O
had O
a O
moderate O
negative O
correlation O
between O
plasma O
histamine O
change O
and O
systemic O
vascular O
resistance O
( O
r O
= O
0 O
. O
58 O
; O
p O
less O
than O
0 O
. O
05 O
) O
not O
present O
in O
group O
4 O
. O

prior O
dosing O
with O
antagonists O
partially O
prevented O
the O
fall O
in O
systemic O
vascular O
resistance O
. O

these O
data O
demonstrate O
that O
the O
hemodynamic O
changes O
associated O
with O
d O
- O
tubocurarine O
dosing O
are O
only O
partially O
explained O
by O
histamine O
release O
. O

thus O
prior O
dosing O
with O
h1 O
- O
and O
h2 O
- O
antagonists O
provides O
only O
partial O
protection O
. O

cholecystokinin O
- O
octapeptide O
restored O
morphine O
- O
induced O
hippocampal O
long O
- O
term O
potentiation O
impairment O
in O
rats O
. O

cholecystokinin O
- O
octapeptide O
( O
cck O
- O
8 O
) O
, O
which O
is O
a O
typical O
brain O
- O
gut O
peptide O
, O
exerts O
a O
wide O
range O
of O
biological O
activities O
on O
the O
central O
nervous O
system O
. O

we O
have O
previously O
reported O
that O
cck O
- O
8 O
significantly O
alleviated O
morphine O
- O
induced O
amnesia B-Disease
and O
reversed O
spine O
density O
decreases O
in O
the O
ca1 O
region O
of O
the O
hippocampus O
in O
morphine O
- O
treated O
animals O
. O

here O
, O
we O
investigated O
the O
effects O
of O
cck O
- O
8 O
on O
long O
- O
term O
potentiation O
( O
ltp O
) O
in O
the O
lateral O
perforant O
path O
( O
lpp O
) O
- O
granule O
cell O
synapse O
of O
rat O
dentate O
gyrus O
( O
dg O
) O
in O
acute O
saline O
or O
morphine O
- O
treated O
rats O
. O

population O
spikes O
( O
ps O
) O
, O
which O
were O
evoked O
by O
stimulation O
of O
the O
lpp O
, O
were O
recorded O
in O
the O
dg O
region O
. O

acute O
morphine O
( O
30mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
treatment O
significantly O
attenuated O
hippocampal O
ltp O
and O
cck O
- O
8 O
( O
1ug O
, O
i O
. O
c O
. O
v O
. O
) O
restored O
the O
amplitude O
of O
ps O
that O
was O
attenuated O
by O
morphine O
injection O
. O

furthermore O
, O
microinjection O
of O
cck O
- O
8 O
( O
0 O
. O
1 O
and O
1ug O
, O
i O
. O
c O
. O
v O
. O
) O
also O
significantly O
augmented O
hippocampal O
ltp O
in O
saline O
- O
treated O
( O
1ml O
/ O
kg O
, O
s O
. O
c O
. O
) O
rats O
. O

pre O
- O
treatment O
of O
the O
cck2 O
receptor O
antagonist O
l O
- O
365 O
, O
260 O
( O
10ug O
, O
i O
. O
c O
. O
v O
) O
reversed O
the O
effects O
of O
cck O
- O
8 O
, O
but O
the O
cck1 O
receptor O
antagonist O
l O
- O
364 O
, O
718 O
( O
10ug O
, O
i O
. O
c O
. O
v O
) O
did O
not O
. O

the O
present O
results O
demonstrate O
that O
cck O
- O
8 O
attenuates O
the O
effect O
of O
morphine O
on O
hippocampal O
ltp O
through O
cck2 O
receptors O
and O
suggest O
an O
ameliorative O
function O
of O
cck O
- O
8 O
on O
morphine O
- O
induced O
memory B-Disease
impairment I-Disease
. O

glial O
activation O
and O
post O
- O
synaptic O
neurotoxicity B-Disease
: O
the O
key O
events O
in O
streptozotocin O
( O
icv O
) O
induced O
memory B-Disease
impairment I-Disease
in O
rats O
. O

in O
the O
present O
study O
the O
role O
of O
glial O
activation O
and O
post O
synaptic O
toxicity B-Disease
in O
icv O
streptozotocin O
( O
stz O
) O
induced O
memory B-Disease
impaired I-Disease
rats O
was O
explored O
. O

in O
experiment O
set O
up O
1 O
: O
memory B-Disease
deficit I-Disease
was O
found O
in O
morris O
water O
maze O
test O
on O
14 O
- O
16 O
days O
after O
stz O
( O
icv O
; O
3mg O
/ O
kg O
) O
administration O
. O

stz O
causes O
increased O
expression O
of O
gfap O
, O
cd11b O
and O
tnf O
- O
a O
indicating O
glial O
activation O
and O
neuroinflammation B-Disease
. O

stz O
also O
significantly O
increased O
the O
level O
of O
ros O
, O
nitrite O
, O
ca O
( O
2 O
+ O
) O
and O
reduced O
the O
mitochondrial O
activity O
in O
synaptosomal O
preparation O
illustrating O
free O
radical O
generation O
and O
excitotoxicity B-Disease
. O

increased O
expression O
and O
activity O
of O
caspase O
- O
3 O
was O
also O
observed O
in O
stz O
treated O
rat O
which O
specify O
apoptotic O
cell O
death O
in O
hippocampus O
and O
cortex O
. O

stz O
treatment O
showed O
decrease O
expression O
of O
post O
synaptic O
markers O
camkiia O
and O
psd O
- O
95 O
, O
while O
, O
expression O
of O
pre O
synaptic O
markers O
( O
synaptophysin O
and O
snap O
- O
25 O
) O
remains O
unaltered O
indicating O
selective O
post O
synaptic O
neurotoxicity B-Disease
. O

oral O
treatment O
with O
memantine O
( O
10mg O
/ O
kg O
) O
and O
ibuprofen O
( O
50 O
mg O
/ O
kg O
) O
daily O
for O
13 O
days O
attenuated O
stz O
induced O
glial O
activation O
, O
apoptotic O
cell O
death O
and O
post O
synaptic O
neurotoxicity B-Disease
in O
rat O
brain O
. O

further O
, O
in O
experiment O
set O
up O
2 O
: O
where O
memory O
function O
was O
not O
affected O
i O
. O
e O
. O
7 O
- O
9 O
days O
after O
stz O
treatment O
. O

the O
level O
of O
gfap O
, O
cd11b O
, O
tnf O
- O
a O
, O
ros O
and O
nitrite O
levels O
were O
increased O
. O

on O
the O
other O
hand O
, O
apoptotic O
marker O
, O
synaptic O
markers O
, O
mitochondrial O
activity O
and O
ca O
( O
2 O
+ O
) O
levels O
remained O
unaffected O
. O

collective O
data O
indicates O
that O
neuroinflammatory B-Disease
process O
and O
oxidative O
stress O
occurs O
earlier O
to O
apoptosis O
and O
does O
not O
affect O
memory O
function O
. O

present O
study O
clearly O
suggests O
that O
glial O
activation O
and O
post O
synaptic O
neurotoxicity B-Disease
are O
the O
key O
factors O
in O
stz O
induced O
memory B-Disease
impairment I-Disease
and O
neuronal O
cell O
death O
. O

comparison O
of O
effects O
of O
isotonic O
sodium O
chloride O
with O
diltiazem O
in O
prevention O
of O
contrast O
- O
induced O
nephropathy B-Disease
. O

introduction O
and O
objective O
: O
contrast O
- O
induced O
nephropathy B-Disease
( O
cin O
) O
significantly O
increases O
the O
morbidity O
and O
mortality O
of O
patients O
. O

the O
aim O
of O
this O
study O
is O
to O
investigate O
and O
compare O
the O
protective O
effects O
of O
isotonic O
sodium O
chloride O
with O
sodium O
bicarbonate O
infusion O
and O
isotonic O
sodium O
chloride O
infusion O
with O
diltiazem O
, O
a O
calcium O
channel O
blocker O
, O
in O
preventing O
cin O
. O

materials O
and O
methods O
: O
our O
study O
included O
patients O
who O
were O
administered O
30 O
- O
60 O
ml O
of O
iodinated O
contrast O
agent O
for O
percutaneous O
coronary O
angiography O
( O
pcag O
) O
, O
all O
with O
creatinine O
values O
between O
1 O
. O
1 O
and O
3 O
. O
1 O
mg O
/ O
dl O
. O

patients O
were O
divided O
into O
three O
groups O
and O
each O
group O
had O
20 O
patients O
. O

the O
first O
group O
of O
patients O
was O
administered O
isotonic O
sodium O
chloride O
; O
the O
second O
group O
was O
administered O
a O
solution O
that O
of O
5 O
% O
dextrose O
and O
sodium O
bicarbonate O
, O
while O
the O
third O
group O
was O
administered O
isotonic O
sodium O
chloride O
before O
and O
after O
the O
contrast O
injection O
. O

the O
third O
group O
received O
an O
additional O
injection O
of O
diltiazem O
the O
day O
before O
and O
first O
2 O
days O
after O
the O
contrast O
injection O
. O

all O
of O
the O
patients O
' O
plasma O
blood O
urea O
nitrogen O
( O
bun O
) O
and O
creatinine O
levels O
were O
measured O
on O
the O
second O
and O
seventh O
day O
after O
the O
administration O
of O
intravenous O
contrast O
material O
. O

results O
: O
the O
basal O
creatinine O
levels O
were O
similar O
for O
all O
three O
groups O
( O
p O
> O
0 O
. O
05 O
) O
. O

among O
a O
total O
of O
60 O
patients O
included O
in O
the O
study O
, O
16 O
patients O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
( O
arf B-Disease
) O
on O
the O
second O
day O
after O
contrast O
material O
was O
injected O
( O
26 O
. O
6 O
% O
) O
. O

the O
number O
of O
patients O
who O
developed O
arf B-Disease
on O
the O
second O
day O
after O
the O
injection O
in O
the O
first O
group O
was O
five O
( O
25 O
% O
) O
, O
in O
the O
second O
group O
was O
six O
( O
30 O
% O
) O
and O
the O
third O
group O
was O
five O
( O
25 O
% O
) O
( O
p O
> O
0 O
. O
05 O
) O
. O

conclusion O
: O
there O
was O
no O
significant O
difference O
between O
isotonic O
sodium O
chloride O
, O
sodium O
bicarbonate O
and O
isotonic O
sodium O
chloride O
with O
diltiazem O
application O
in O
prevention O
of O
cin O
. O

neurocognitive O
and O
neuroradiologic O
central O
nervous O
system O
late O
effects O
in O
children O
treated O
on O
pediatric O
oncology O
group O
( O
pog O
) O
p9605 O
( O
standard O
risk O
) O
and O
p9201 O
( O
lesser O
risk O
) O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
protocols O
( O
accl0131 O
) O
: O
a O
methotrexate O
consequence O
? O

a O
report O
from O
the O
children O
' O
s O
oncology O
group O
. O

concerns O
about O
long O
- O
term O
methotrexate O
( O
mtx O
) O
neurotoxicity B-Disease
in O
the O
1990s O
led O
to O
modifications O
in O
intrathecal O
( O
it O
) O
therapy O
, O
leucovorin O
rescue O
, O
and O
frequency O
of O
systemic O
mtx O
administration O
in O
children O
with O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
. O

in O
this O
study O
, O
neurocognitive O
outcomes O
and O
neuroradiologic O
evidence O
of O
leukoencephalopathy B-Disease
were O
compared O
in O
children O
treated O
with O
intense O
central O
nervous O
system O
( O
cns O
) O
- O
directed O
therapy O
( O
p9605 O
) O
versus O
those O
receiving O
fewer O
cns O
- O
directed O
treatment O
days O
during O
intensive O
consolidation O
( O
p9201 O
) O
. O

a O
total O
of O
66 O
children O
from O
16 O
pediatric O
oncology O
group O
institutions O
with O
" O
standard O
- O
risk O
" O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
, O
1 O
. O
00 O
to O
9 O
. O
99 O
years O
at O
diagnosis O
, O
without O
evidence O
of O
cns O
leukemia B-Disease
at O
diagnosis O
were O
enrolled O
on O
accl0131 O
: O
28 O
from O
p9201 O
and O
38 O
from O
p9605 O
. O

magnetic O
resonance O
imaging O
scans O
and O
standard O
neuropsychological O
tests O
were O
performed O
> O
2 O
. O
6 O
years O
after O
the O
end O
of O
treatment O
. O

significantly O
more O
p9605 O
patients O
developed O
leukoencephalopathy B-Disease
compared O
with O
p9201 O
patients O
( O
68 O
% O
, O
95 O
% O
confidence O
interval O
49 O
% O
- O
83 O
% O
vs O
. O
22 O
% O
, O
95 O
% O
confidence O
interval O
5 O
% O
- O
44 O
% O
; O
p O
= O
0 O
. O
001 O
) O
identified O
as O
late O
as O
7 O
. O
7 O
years O
after O
the O
end O
of O
treatment O
. O

overall O
, O
40 O
% O
of O
patients O
scored O
< O
85 O
on O
either O
verbal O
or O
performance O
iq O
. O

children O
on O
both O
studies O
had O
significant O
attention B-Disease
problems I-Disease
, O
but O
p9605 O
children O
scored O
below O
average O
on O
more O
neurocognitive O
measures O
than O
those O
treated O
on O
p9201 O
( O
82 O
% O
, O
14 O
/ O
17 O
measures O
vs O
. O
24 O
% O
, O
4 O
/ O
17 O
measures O
) O
. O

this O
supports O
ongoing O
concerns O
about O
intensive O
mtx O
exposure O
as O
a O
major O
contributor O
to O
cns O
late O
effects O
. O

tranexamic O
acid O
overdosage O
- O
induced O
generalized O
seizure B-Disease
in O
renal B-Disease
failure I-Disease
. O

we O
report O
a O
45 O
- O
year O
- O
old O
lady O
with O
chronic B-Disease
kidney I-Disease
disease I-Disease
stage O
4 O
due O
to O
chronic O
tubulointerstial B-Disease
disease I-Disease
. O

she O
was O
admitted O
to O
our O
center O
for O
severe O
anemia B-Disease
due O
to O
menorrhagia B-Disease
and O
deterioration B-Disease
of I-Disease
renal I-Disease
function I-Disease
. O

she O
was O
infused O
three O
units O
of O
packed O
cells O
during O
a O
session O
of O
hemodialysis O
. O

tranexamic O
acid O
( O
tna O
) O
1 O
g O
8 O
- O
hourly O
was O
administered O
to O
her O
to O
control O
bleeding B-Disease
per O
vaginum O
. O

two O
hours O
after O
the O
sixth O
dose O
of O
tna O
, O
she O
had O
an O
episode O
of O
generalized O
tonic B-Disease
clonic I-Disease
convulsions I-Disease
. O

tna O
was O
discontinued O
. O

investigations O
of O
the O
patient O
revealed O
no O
biochemical O
or O
structural O
central O
nervous B-Disease
system I-Disease
abnormalities I-Disease
that O
could O
have O
provoked O
the O
convulsions B-Disease
. O

she O
did O
not O
require O
any O
further O
dialytic O
support O
. O

she O
had O
no O
further O
episodes O
of O
convulsion B-Disease
till O
dis O
- O
charge O
and O
during O
the O
two O
months O
of O
follow O
- O
up O
. O

thus O
, O
the O
precipitating O
cause O
of O
convulsions B-Disease
was O
believed O
to O
be O
an O
overdose B-Disease
of O
tna O
. O

pre O
- O
treatment O
of O
bupivacaine O
- O
induced O
cardiovascular B-Disease
depression I-Disease
using O
different O
lipid O
formulations O
of O
propofol O
. O

background O
: O
pre O
- O
treatment O
with O
lipid O
emulsions O
has O
been O
shown O
to O
increase O
lethal O
doses O
of O
bupivacaine O
, O
and O
the O
lipid O
content O
of O
propofol O
may O
alleviate O
bupivacaine O
- O
induced O
cardiotoxicity B-Disease
. O

the O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
propofol O
in O
intralipid O
or O
medialipid O
emulsions O
on O
bupivacaine O
- O
induced O
cardiotoxicity B-Disease
. O

methods O
: O
rats O
were O
anaesthetised O
with O
ketamine O
and O
were O
given O
0 O
. O
5 O
mg O
/ O
kg O
/ O
min O
propofol O
in O
intralipid O
( O
group O
p O
) O
, O
propofol O
in O
medialipid O
( O
group O
l O
) O
, O
or O
saline O
( O
group O
c O
) O
over O
20 O
min O
. O

thereafter O
, O
2 O
mg O
/ O
kg O
/ O
min O
bupivacaine O
0 O
. O
5 O
% O
was O
infused O
. O

we O
recorded O
time O
to O
first O
dysrhythmia B-Disease
occurrence O
, O
respective O
times O
to O
25 O
% O
and O
50 O
% O
reduction O
of O
the O
heart O
rate O
( O
hr O
) O
and O
mean O
arterial O
pressure O
, O
and O
time O
to O
asystole B-Disease
and O
total O
amount O
of O
bupivacaine O
consumption O
. O

blood O
and O
tissue O
samples O
were O
collected O
following O
asystole B-Disease
. O

results O
: O
the O
time O
to O
first O
dysrhythmia B-Disease
occurrence O
, O
time O
to O
25 O
% O
and O
50 O
% O
reductions O
in O
hr O
, O
and O
time O
to O
asystole B-Disease
were O
longer O
in O
group O
p O
than O
the O
other O
groups O
. O

the O
cumulative O
bupivacaine O
dose O
given O
at O
those O
time O
points O
was O
higher O
in O
group O
p O
. O
plasma O
bupivacaine O
levels O
were O
significantly O
lower O
in O
group O
p O
than O
in O
group O
c O
. O
bupivacaine O
levels O
in O
the O
brain O
and O
heart O
were O
significantly O
lower O
in O
group O
p O
and O
group O
l O
than O
in O
group O
c O
. O

conclusion O
: O
we O
conclude O
that O
pre O
- O
treatment O
with O
propofol O
in O
intralipid O
, O
compared O
with O
propofol O
in O
medialipid O
or O
saline O
, O
delayed O
the O
onset O
of O
bupivacaine O
- O
induced O
cardiotoxic B-Disease
effects O
as O
well O
as O
reduced O
plasma O
bupivacaine O
levels O
. O

further O
studies O
are O
needed O
to O
explore O
tissue O
bupivacaine O
levels O
of O
propofol O
in O
medialipid O
and O
adapt O
these O
results O
to O
clinical O
practice O
. O

drug B-Disease
- I-Disease
induced I-Disease
acute I-Disease
liver I-Disease
injury I-Disease
within O
12 O
hours O
after O
fluvastatin O
therapy O
. O

although O
statins O
are O
generally O
well O
- O
tolerated O
drugs O
, O
recent O
cases O
of O
drug B-Disease
- I-Disease
induced I-Disease
liver I-Disease
injury I-Disease
associated O
with O
their O
use O
have O
been O
reported O
. O

a O
52 O
- O
year O
- O
old O
chinese O
man O
reported O
with O
liver B-Disease
damage I-Disease
, O
which O
appeared O
12 O
hours O
after O
beginning O
treatment O
with O
fluvastatin O
. O

patient O
presented O
with O
complaints O
of O
increasing O
nausea B-Disease
, O
anorexia B-Disease
, O
and O
upper O
abdominal B-Disease
pain I-Disease
. O

his O
laboratory O
values O
showed O
elevated O
creatine O
kinase O
and O
transaminases O
. O

testing O
for O
autoantibodies O
was O
also O
negative O
. O

the O
liver O
biochemistries O
eventually O
normalized O
within O
3 O
weeks O
of O
stopping O
the O
fluvastatin O
. O

therefore O
, O
when O
prescribing O
statins O
, O
the O
possibility O
of O
hepatic B-Disease
damage I-Disease
should O
be O
taken O
into O
account O
. O

fluconazole O
associated O
agranulocytosis B-Disease
and O
thrombocytopenia B-Disease
. O

case O
: O
we O
describe O
a O
second O
case O
of O
fluconazole O
associated O
agranulocytosis B-Disease
with O
thrombocytopenia B-Disease
and O
recovery O
upon O
discontinuation O
of O
therapy O
. O

the O
patient O
began O
to O
have O
changes O
in O
white O
blood O
cells O
and O
platelets O
within O
48 O
h O
of O
administration O
of O
fluconazole O
and O
began O
to O
recover O
with O
48 O
h O
of O
discontinuation O
. O

this O
case O
highlights O
that O
drug O
- O
induced O
blood B-Disease
dyscrasias I-Disease
can O
occur O
unexpectedly O
as O
a O
result O
of O
treatment O
with O
a O
commonly O
used O
drug O
thought O
to O
be O
" O
safe O
" O
. O

conclusion O
: O
according O
to O
naranjo O
' O
s O
algorithm O
the O
likelihood O
that O
our O
patient O
' O
s O
agranulocytosis B-Disease
and O
thrombocytopenia B-Disease
occurred O
as O
a O
result O
of O
therapy O
with O
fluconazole O
is O
probable O
, O
with O
a O
total O
of O
six O
points O
. O

we O
feel O
that O
the O
weight O
of O
the O
overall O
evidence O
of O
this O
evidence O
is O
strong O
. O

in O
particular O
the O
temporal O
relationship O
of O
bone B-Disease
marrow I-Disease
suppression I-Disease
to O
the O
initiation O
of O
fluconazole O
and O
the O
abatement O
of O
symptoms O
that O
rapidly O
reversed O
immediately O
following O
discontinuation O
. O

two O
- O
dimensional O
speckle O
tracking O
echocardiography O
combined O
with O
high O
- O
sensitive O
cardiac O
troponin O
t O
in O
early O
detection O
and O
prediction O
of O
cardiotoxicity B-Disease
during O
epirubicine O
- O
based O
chemotherapy O
. O

aims O
: O
to O
investigate O
whether O
alterations O
of O
myocardial B-Disease
strain I-Disease
and O
high O
- O
sensitive O
cardiac O
troponin O
t O
( O
ctnt O
) O
could O
predict O
future O
cardiac B-Disease
dysfunction I-Disease
in O
patients O
after O
epirubicin O
exposure O
. O

methods O
: O
seventy O
- O
five O
patients O
with O
non B-Disease
- I-Disease
hodgkin I-Disease
lymphoma I-Disease
treated O
with O
epirubicin O
were O
studied O
. O

blood O
collection O
and O
echocardiography O
were O
performed O
at O
baseline O
, O
1 O
day O
after O
the O
third O
cycle O
, O
and O
1 O
day O
after O
completion O
of O
chemotherapy O
. O

patients O
were O
studied O
using O
echocardiography O
during O
follow O
- O
up O
. O

global O
longitudinal O
( O
gls O
) O
, O
circumferential O
( O
gcs O
) O
, O
and O
radial O
strain O
( O
grs O
) O
were O
calculated O
using O
speckle O
tracking O
echocardiography O
. O

left O
ventricular O
ejection O
fraction O
was O
analysed O
by O
real O
- O
time O
3d O
echocardiography O
. O

cardiotoxicity B-Disease
was O
defined O
as O
a O
reduction O
of O
the O
lvef O
of O
> O
5 O
% O
to O
< O
55 O
% O
with O
symptoms O
of O
heart B-Disease
failure I-Disease
or O
an O
asymptomatic O
reduction O
of O
the O
lvef O
of O
> O
10 O
% O
to O
< O
55 O
% O
. O

results O
: O
fourteen O
patients O
( O
18 O
. O
67 O
% O
) O
developed O
cardiotoxicity B-Disease
after O
treatment O
. O

gls O
( O
- O
18 O
. O
48 O
+ O
1 O
. O
72 O
% O
vs O
. O
- O
15 O
. O
96 O
+ O
1 O
. O
6 O
% O
) O
, O
gcs O
( O
- O
20 O
. O
93 O
+ O
2 O
. O
86 O
% O
vs O
. O
- O
19 O
. O
20 O
+ O
3 O
. O
21 O
% O
) O
, O
and O
grs O
( O
39 O
. O
23 O
+ O
6 O
. O
44 O
% O
vs O
. O
34 O
. O
98 O
+ O
6 O
. O
2 O
% O
) O
were O
markedly O
reduced O
and O
ctnt O
was O
elevated O
from O
0 O
. O
0010 O
+ O
0 O
. O
0020 O
to O
0 O
. O
0073 O
+ O
0 O
. O
0038 O
ng O
/ O
ml O
( O
p O
all O
< O
0 O
. O
01 O
) O
at O
the O
completion O
of O
chemotherapy O
compared O
with O
baseline O

values O
. O

a O
> O
15 O
. O
9 O
% O
decrease O
in O
gls O
[ O
sensitivity O
, O
86 O
% O
; O
specificity O
, O
75 O
% O
; O
area O
under O
the O
curve O
( O
auc O
) O
= O
0 O
. O
815 O
; O
p O
= O
0 O
. O
001 O
] O
and O
a O
> O
0 O
. O
004 O
ng O
/ O
ml O
elevation O
in O
ctnt O
( O
sensitivity O
, O
79 O
% O
; O
specificity O
, O
64 O
% O
; O
auc O
= O
0 O
. O
757 O
; O
p O
= O
0 O
. O
005 O
) O
from O
baseline O
to O
the O
third O
cycle O
of O
chemotherapy O
predicted O
later O
cardiotoxicity B-Disease
. O

the O
decrease O
in O
gls O
remained O
the O
only O
independent O
predictor O
of O
cardiotoxicity B-Disease
( O
p O
= O
0 O
. O
000 O
) O
. O

conclusions O
: O
gls O
combined O
with O
ctnt O
may O
provide O
a O
reliable O
and O
non O
- O
invasive O
method O
to O
predict O
cardiac B-Disease
dysfunction I-Disease
in O
patients O
receiving O
anthracycline O
- O
based O
chemotherapy O
. O

prevention O
of O
etomidate O
- O
induced O
myoclonus B-Disease
: O
which O
is O
superior O
: O
fentanyl O
, O
midazolam O
, O
or O
a O
combination O
? O

a O
retrospective O
comparative O
study O
. O

background O
: O
in O
this O
retrospective O
comparative O
study O
, O
we O
aimed O
to O
compare O
the O
effectiveness O
of O
fentanyl O
, O
midazolam O
, O
and O
a O
combination O
of O
fentanyl O
and O
midazolam O
to O
prevent O
etomidate O
- O
induced O
myoclonus B-Disease
. O

material O
and O
methods O
: O
this O
study O
was O
performed O
based O
on O
anesthesia O
records O
. O

depending O
on O
the O
drugs O
that O
would O
be O
given O
before O
the O
induction O
of O
anesthesia O
with O
etomidate O
, O
the O
patients O
were O
separated O
into O
4 O
groups O
: O
no O
pretreatment O
( O
group O
np O
) O
, O
fentanyl O
1 O
ug O
. O
kg O
- O
1 O
( O
group O
f O
) O
, O
midazolam O
0 O
. O
03 O
mg O
. O
kg O
- O
1 O
( O
group O
m O
) O
, O
and O
midazolam O
0 O
. O
015 O
mg O
. O
kg O
- O
1 O
+ O
fentanyl O
0 O
. O
5 O
ug O
. O
kg O
- O
1 O
( O
group O
fm O
) O
. O

patients O
who O
received O
the O
same O
anesthetic O
procedure O
were O
selected O
: O
2 O
minutes O
after O
intravenous O
injections O
of O
the O
pretreatment O
drugs O
, O
anesthesia O
is O
induced O
with O
0 O
. O
3 O
mg O
. O
kg O
- O
1 O
etomidate O
injected O
intravenously O
over O
a O
period O
of O
20 O
- O
30 O
seconds O
. O

myoclonic B-Disease
movements I-Disease
are O
evaluated O
, O
which O
were O
observed O
and O
graded O
according O
to O
clinical O
severity O
during O
the O
2 O
minutes O
after O
etomidate O
injection O
. O

the O
severity O
of O
pain B-Disease
due O
to O
etomidate O
injection O
, O
mean O
arterial O
pressure O
, O
heart O
rate O
, O
and O
adverse O
effects O
were O
also O
evaluated O
. O

results O
: O
study O
results O
showed O
that O
myoclonus B-Disease
incidence O
was O
85 O
% O
, O
40 O
% O
, O
70 O
% O
, O
and O
25 O
% O
in O
group O
np O
, O
group O
f O
, O
group O
m O
, O
and O
group O
fm O
, O
respectively O
, O
and O
were O
significantly O
lower O
in O
group O
f O
and O
group O
fm O
. O

conclusions O
: O
we O
conclude O
that O
pretreatment O
with O
fentanyl O
or O
combination O
of O
fentanyl O
and O
midazolam O
was O
effective O
in O
preventing O
etomidate O
- O
induced O
myoclonus B-Disease
. O

convulsant O
effect O
of O
lindane O
and O
regional O
brain O
concentration O
of O
gaba O
and O
dopamine O
. O

lindane O
( O
gamma O
- O
hexachlorocyclohexane O
) O
is O
an O
organochlorine O
insecticide O
with O
known O
neurotoxic B-Disease
effects O
. O

its O
mechanism O
of O
action O
is O
not O
well O
understood O
although O
it O
has O
been O
proposed O
that O
lindane O
acts O
as O
a O
non O
- O
competitive O
antagonist O
at O
the O
gamma O
- O
aminobutyric O
acid O
( O
gaba O
) O
- O
a O
receptor O
. O

we O
studied O
the O
effect O
of O
lindane O
( O
150 O
mg O
/ O
kg O
) O
on O
the O
gabaergic O
and O
dopaminergic O
systems O
by O
measuring O
the O
concentration O
of O
gaba O
, O
dopamine O
and O
its O
metabolites O
in O
7 O
brain O
areas O
at O
the O
onset O
of O
seizures B-Disease
. O

all O
animals O
suffered O
tonic O
convulsions B-Disease
at O
18 O
. O
3 O
+ O
/ O
- O
1 O
. O
4 O
min O
after O
lindane O
administration O
. O

the O
concentration O
of O
gaba O
was O
only O
slightly O
but O
significantly O
decreased O
in O
the O
colliculi O
without O
modifications O
in O
the O
other O
areas O
. O

the O
concentration O
of O
dopamine O
was O
increased O
in O
the O
mesencephalon O
and O
that O
of O
its O
metabolite O
dopac O
was O
also O
increased O
in O
the O
mesencephalon O
and O
the O
striatum O
. O

cholestatic B-Disease
presentation O
of O
yellow O
phosphorus O
poisoning B-Disease
. O

yellow O
phosphorus O
, O
a O
component O
of O
certain O
pesticide O
pastes O
and O
fireworks O
, O
is O
well O
known O
to O
cause O
hepatotoxicity B-Disease
. O

poisoning B-Disease
with O
yellow O
phosphorus O
classically O
manifests O
with O
acute B-Disease
hepatitis I-Disease
leading O
to O
acute B-Disease
liver I-Disease
failure I-Disease
which O
may O
need O
liver O
transplantation O
. O

we O
present O
a O
case O
of O
yellow O
phosphorus O
poisoning B-Disease
in O
which O
a O
patient O
presented O
with O
florid O
clinical O
features O
of O
cholestasis B-Disease
highlighting O
the O
fact O
that O
cholestasis B-Disease
can O
rarely O
be O
a O
presenting O
feature O
of O
yellow O
phosphorus O
hepatotoxicity B-Disease
. O

vasovagal B-Disease
syncope I-Disease
and O
severe O
bradycardia B-Disease
following O
intranasal O
dexmedetomidine O
for O
pediatric O
procedural O
sedation O
. O

we O
report O
syncope B-Disease
and O
bradycardia B-Disease
in O
an O
11 O
- O
year O
- O
old O
girl O
following O
administration O
of O
intranasal O
dexmedetomidine O
for O
sedation O
for O
a O
voiding O
cystourethrogram O
. O

following O
successful O
completion O
of O
vcug O
and O
a O
60 O
- O
min O
recovery O
period O
, O
the O
patient O
' O
s O
level O
of O
consciousness O
and O
vital O
signs O
returned O
to O
presedation O
levels O
. O

upon O
leaving O
the O
sedation O
area O
, O
the O
patient O
collapsed O
, O
with O
no O
apparent O
inciting O
event O
. O

the O
patient O
quickly O
regained O
consciousness O
and O
no O
injury O
occurred O
. O

the O
primary O
abnormality O
found O
was O
persistent O
bradycardia B-Disease
, O
and O
she O
was O
admitted O
to O
the O
hospital O
for O
telemetric O
observation O
. O

the O
bradycardia B-Disease
lasted O
~ O
2 O
h O
, O
and O
further O
cardiac O
workup O
revealed O
no O
underlying O
abnormality O
. O

unanticipated O
and O
previously O
unreported O
outcomes O
may O
be O
witnessed O
as O
we O
expand O
the O
use O
of O
certain O
sedatives O
to O
alternative O
routes O
of O
administration O
. O

paradoxical O
severe O
agitation B-Disease
induced O
by O
add O
- O
on O
high O
- O
doses O
quetiapine O
in O
schizo B-Disease
- I-Disease
affective I-Disease
disorder I-Disease
. O

we O
report O
the O
case O
of O
a O
35 O
- O
year O
- O
old O
patient O
suffering O
from O
schizo B-Disease
- I-Disease
affective I-Disease
disorder I-Disease
since O
the O
age O
of O
19 O
years O
, O
treated O
by O
a O
combination O
of O
first O
- O
generation O
antipsychotics O
, O
zuclopenthixol O
( O
100 O
mg O
/ O
day O
) O
and O
lithium O
( O
1200 O
mg O
/ O
day O
) O
( O
serum O
lithium O
= O
0 O
. O
85 O
meq O
/ O
l O
) O
. O

this O
patient O
had O
no O
associated O
personality B-Disease
disorder I-Disease
( O
particularly O
no O
antisocial B-Disease
disorder I-Disease
) O
and O
no O
substance B-Disease
abuse I-Disease
disorder I-Disease
. O

within O
the O
48 O
h O
following O
the O
gradual O
introduction O
of O
quetiapine O
( O
up O
to O
600 O
mg O
/ O
day O
) O
, O
the O
patient O
presented O
severe O
agitation B-Disease
without O
an O
environmental O
explanation O
, O
contrasting O
with O
the O
absence O
of O
a O
history O
of O
aggressiveness B-Disease
or O
personality B-Disease
disorder I-Disease
. O

the O
diagnoses O
of O
manic B-Disease
shift O
and O
akathisia B-Disease
were O
dismissed O
. O

the O
withdrawal O
and O
the O
gradual O
reintroduction O
of O
quetiapine O
2 O
weeks O
later O
, O
which O
led O
to O
another O
severe O
agitation B-Disease
, O
enabled O
us O
to O
attribute O
the O
agitation B-Disease
specifically O
to O
quetiapine O
. O

antioxidant O
effects O
of O
bovine O
lactoferrin O
on O
dexamethasone O
- O
induced O
hypertension B-Disease
in O
rat O
. O

dexamethasone O
- O
( O
dex O
- O
) O
induced O
hypertension B-Disease
is O
associated O
with O
enhanced O
oxidative O
stress O
. O

lactoferrin O
( O
lf O
) O
is O
an O
iron O
- O
binding O
glycoprotein O
with O
antihypertensive O
properties O
. O

in O
this O
study O
, O
we O
investigated O
the O
effect O
of O
chronic O
administration O
of O
lf O
on O
oxidative O
stress O
and O
hypertension B-Disease
upon O
dex O
administration O
. O

male O
wistar O
rats O
were O
treated O
by O
dex O
( O
30 O
u O
g O
/ O
kg O
/ O
day O
subcutaneously O
) O
or O
saline O
for O
14 O
days O
. O

oral O
bovine O
lf O
( O
30 O
, O
100 O
, O
300 O
mg O
/ O
kg O
) O
was O
given O
from O
day O
8 O
to O
14 O
in O
a O
reversal O
study O
. O

in O
a O
prevention O
study O
, O
rats O
received O
4 O
days O
of O
lf O
treatment O
followed O
by O
dex O
and O
continued O
during O
the O
test O
period O
. O

systolic O
blood O
pressure O
( O
sbp O
) O
was O
measured O
using O
tail O
- O
cuff O
method O
. O

thymus O
weight O
was O
used O
as O
a O
marker O
of O
glucocorticoid O
activity O
. O

plasma O
hydrogen O
peroxide O
( O
h2o2 O
) O
concentration O
and O
ferric O
reducing O
antioxidant O
power O
( O
frap O
) O
value O
were O
determined O
. O

dexamethasone O
significantly O
increased O
sbp O
and O
plasma O
h2o2 O
level O
and O
decreased O
thymus O
and O
body O
weights O
. O

lf O
lowered O
( O
p O
< O
0 O
. O
01 O
) O
and O
dose O
dependently O
prevented O
( O
p O
< O
0 O
. O
001 O
) O
dex O
- O
induced O
hypertension B-Disease
. O

lf O
prevented O
body O
weight B-Disease
loss I-Disease
and O
significantly O
reduced O
the O
elevated O
plasma O
h2o2 O
and O
increased O
frap O
values O
. O

chronic O
administration O
of O
lf O
strongly O
reduced O
the O
blood O
pressure O
and O
production O
of O
ros O
and O
improved O
antioxidant O
capacity O
in O
dex O
- O
induced O
hypertension B-Disease
, O
suggesting O
the O
role O
of O
inhibition O
of O
oxidative O
stress O
as O
another O
mechanism O
of O
antihypertensive O
action O
of O
lf O
. O

the O
association O
between O
tranexamic O
acid O
and O
convulsive B-Disease
seizures B-Disease
after O
cardiac O
surgery O
: O
a O
multivariate O
analysis O
in O
11 O
529 O
patients O
. O

because O
of O
a O
lack O
of O
contemporary O
data O
regarding O
seizures B-Disease
after O
cardiac O
surgery O
, O
we O
undertook O
a O
retrospective O
analysis O
of O
prospectively O
collected O
data O
from O
11 O
529 O
patients O
in O
whom O
cardiopulmonary O
bypass O
was O
used O
from O
january O
2004 O
to O
december O
2010 O
. O

a O
convulsive B-Disease
seizure B-Disease
was O
defined O
as O
a O
transient O
episode O
of O
disturbed O
brain O
function O
characterised O
by O
abnormal B-Disease
involuntary I-Disease
motor I-Disease
movements I-Disease
. O

multivariate O
regression O
analysis O
was O
performed O
to O
identify O
independent O
predictors O
of O
postoperative O
seizures B-Disease
. O

a O
total O
of O
100 O
( O
0 O
. O
9 O
% O
) O
patients O
developed O
postoperative O
convulsive B-Disease
seizures B-Disease
. O

generalised B-Disease
and I-Disease
focal I-Disease
seizures I-Disease
were O
identified O
in O
68 O
and O
32 O
patients O
, O
respectively O
. O

the O
median O
( O
iqr O
[ O
range O
] O
) O
time O
after O
surgery O
when O
the O
seizure B-Disease
occurred O
was O
7 O
( O
6 O
- O
12 O
[ O
1 O
- O
216 O
] O
) O
h O
and O
8 O
( O
6 O
- O
11 O
[ O
4 O
- O
18 O
] O
) O
h O
, O
respectively O
. O

epileptiform O
findings O
on O
electroencephalography O
were O
seen O
in O
19 O
patients O
. O

independent O
predictors O
of O
postoperative O
seizures B-Disease
included O
age O
, O
female O
sex O
, O
redo O
cardiac O
surgery O
, O
calcification O
of O
ascending O
aorta O
, O
congestive B-Disease
heart I-Disease
failure I-Disease
, O
deep O
hypothermic B-Disease
circulatory O
arrest O
, O
duration O
of O
aortic O
cross O
- O
clamp O
and O
tranexamic O
acid O
. O

when O
tested O
in O
a O
multivariate O
regression O
analysis O
, O
tranexamic O
acid O
was O
a O
strong O
independent O
predictor O
of O
seizures B-Disease
( O
or O
14 O
. O
3 O
, O
95 O
% O
ci O
5 O
. O
5 O
- O
36 O
. O
7 O
; O
p O
< O
0 O
. O
001 O
) O
. O

patients O
with O
convulsive B-Disease
seizures B-Disease
had O
2 O
. O
5 O
times O
higher O
in O
- O
hospital O
mortality O
rates O
and O
twice O
the O
length O
of O
hospital O
stay O
compared O
with O
patients O
without O
convulsive B-Disease
seizures B-Disease
. O

mean O
( O
iqr O
[ O
range O
] O
) O
length O
of O
stay O
in O
the O
intensive O
care O
unit O
was O
115 O
( O
49 O
- O
228 O
[ O
32 O
- O
481 O
] O
) O
h O
in O
patients O
with O
convulsive B-Disease
seizures B-Disease
compared O
with O
26 O
( O
22 O
- O
69 O
[ O
14 O
- O
1080 O
] O
) O
h O
in O
patients O
without O
seizures B-Disease
( O
p O
< O
0 O
. O
001 O
) O
. O

convulsive B-Disease
seizures B-Disease
are O
a O
serious O
postoperative B-Disease
complication I-Disease
after O
cardiac O
surgery O
. O

as O
tranexamic O
acid O
is O
the O
only O
modifiable O
factor O
, O
its O
administration O
, O
particularly O
in O
doses O
exceeding O
80 O
mg O
. O
kg O
( O
- O
1 O
) O
, O
should O
be O
weighed O
against O
the O
risk O
of O
postoperative O
seizures B-Disease
. O

dysfunctional B-Disease
overnight I-Disease
memory I-Disease
consolidation O
in O
ecstasy O
users O
. O

sleep O
plays O
an O
important O
role O
in O
the O
consolidation O
and O
integration O
of O
memory O
in O
a O
process O
called O
overnight O
memory O
consolidation O
. O

previous O
studies O
indicate O
that O
ecstasy O
users O
have O
marked O
and O
persistent O
neurocognitive O
and O
sleep B-Disease
- I-Disease
related I-Disease
impairments I-Disease
. O

we O
extend O
past O
research O
by O
examining O
overnight O
memory O
consolidation O
among O
regular O
ecstasy O
users O
( O
n O
= O
12 O
) O
and O
drug O
naive O
healthy O
controls O
( O
n O
= O
26 O
) O
. O

memory O
recall O
of O
word O
pairs O
was O
evaluated O
before O
and O
after O
a O
period O
of O
sleep O
, O
with O
and O
without O
interference O
prior O
to O
testing O
. O

in O
addition O
, O
we O
assessed O
neurocognitive O
performances O
across O
tasks O
of O
learning O
, O
memory O
and O
executive O
functioning O
. O

ecstasy O
users O
demonstrated O
impaired B-Disease
overnight I-Disease
memory I-Disease
consolidation O
, O
a O
finding O
that O
was O
more O
pronounced O
following O
associative O
interference O
. O

additionally O
, O
ecstasy O
users O
demonstrated O
impairments O
on O
tasks O
recruiting O
frontostriatal O
and O
hippocampal O
neural O
circuitry O
, O
in O
the O
domains O
of O
proactive O
interference O
memory O
, O
long O
- O
term O
memory O
, O
encoding O
, O
working O
memory O
and O
complex O
planning O
. O

we O
suggest O
that O
ecstasy O
- O
associated O
dysfunction O
in O
fronto O
- O
temporal O
circuitry O
may O
underlie O
overnight O
consolidation O
memory B-Disease
impairments I-Disease
in O
regular O
ecstasy O
users O
. O

normoammonemic O
encephalopathy B-Disease
: O
solely O
valproate O
induced O
or O
multiple O
mechanisms O
? O

a O
77 O
- O
year O
- O
old O
woman O
presented O
with O
subacute O
onset O
progressive O
confusion B-Disease
, O
aggression B-Disease
, O
auditory B-Disease
hallucinations I-Disease
and O
delusions B-Disease
. O

in O
the O
preceding O
months O
, O
the O
patient O
had O
a O
number O
of O
admissions O
with O
transient O
unilateral O
hemiparesis B-Disease
with O
facial O
droop O
, O
and O
had O
been O
started O
on O
valproate O
for O
presumed O
hemiplegic B-Disease
migraine I-Disease
. O

valproate O
was O
withdrawn O
soon O
after O
admission O
and O
her O
cognitive O
abilities O
have O
gradually O
improved O
over O
3 O
months O
of O
follow O
- O
up O
. O

valproate O
levels O
taken O
prior O
to O
withdrawal O
were O
subtherapeutic O
and O
the O
patient O
was O
normoammonaemic O
. O

eeg O
undertaken O
during O
inpatient O
stay O
showed O
changes O
consistent O
with O
encephalopathy B-Disease
, O
and O
low O
titre O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
receptor O
antibodies O
were O
present O
in O
this O
patient O
. O

the O
possible O
aetiologies O
of O
valproate O
- O
induced O
encephalopathy B-Disease
and O
nmda O
receptor O
- O
associated O
encephalitis B-Disease
present O
a O
diagnostic O
dilemma O
. O

we O
present O
a O
putative O
combinatorial O
hypothesis O
to O
explain O
this O
patient O
' O
s O
symptoms O
. O

cerebellar B-Disease
and I-Disease
oculomotor I-Disease
dysfunction I-Disease
induced O
by O
rapid O
infusion O
of O
pethidine O
. O

pethidine O
is O
an O
opioid O
that O
gains O
its O
popularity O
for O
the O
effective O
pain B-Disease
control O
through O
acting O
on O
the O
opioid O
- O
receptors O
. O

however O
, O
rapid O
pain B-Disease
relief O
sometimes O
brings O
about O
unfavourable O
side O
effects O
that O
largely O
limit O
its O
clinical O
utility O
. O

common O
side O
effects O
include O
nausea B-Disease
, O
vomiting B-Disease
and O
hypotension B-Disease
. O

in O
patients O
with O
impaired B-Disease
renal I-Disease
and I-Disease
liver I-Disease
function I-Disease
, O
and O
those O
who O
need O
long O
- O
term O
pain B-Disease
control O
, O
pethidine O
may O
cause O
excitatory O
central O
nervous O
system O
( O
cns O
) O
effects O
through O
its O
neurotoxic B-Disease
metabolite O
, O
norpethidine O
, O
resulting O
in O
irritability B-Disease
and O
seizure B-Disease
attack O
. O

on O
the O
contrary O
, O
though O
not O
clinically O
apparent O
, O
pethidine O
potentially O
causes O
inhibitory O
impacts O
on O
the O
cns O
and O
impairs O
normal O
cerebellar O
and O
oculomotor O
function O
in O
the O
short O
term O
. O

in O
this O
case O
report O
, O
we O
highlight O
opioid O
' O
s O
inhibitory O
side O
effects O
on O
the O
cerebellar O
structure O
that O
causes O
dysmetria B-Disease
, O
dysarthria B-Disease
, O
reduced O
smooth O
pursuit O
gain O
and O
decreased O
saccadic O
velocity O
. O

baboon B-Disease
syndrome I-Disease
induced O
by O
ketoconazole O
. O

a O
27 O
- O
year O
- O
old O
male O
patient O
presented O
with O
a O
maculopapular B-Disease
eruption I-Disease
on O
the O
flexural O
areas O
and O
buttocks O
after O
using O
oral O
ketoconazole O
. O

the O
patient O
was O
diagnosed O
with O
drug O
- O
induced O
baboon B-Disease
syndrome I-Disease
based O
on O
his O
history O
, O
which O
included O
prior O
sensitivity O
to O
topical O
ketoconazole O
, O
a O
physical O
examination O
, O
and O
histopathological O
findings O
. O

baboon B-Disease
syndrome I-Disease
is O
a O
drug O
- O
or O
contact O
allergen O
- O
related O
maculopapular B-Disease
eruption I-Disease
that O
typically O
involves O
the O
flexural O
and O
gluteal O
areas O
. O

to O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
ketoconazole O
- O
induced O
baboon B-Disease
syndrome I-Disease
in O
the O
english O
literature O
. O

a O
case O
of O
sudden B-Disease
cardiac I-Disease
death I-Disease
due O
to O
pilsicainide O
- O
induced O
torsades B-Disease
de I-Disease
pointes I-Disease
. O

an O
84 O
- O
year O
- O
old O
male O
received O
oral O
pilsicainide O
, O
a O
pure O
sodium O
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
his O
paroxysmal O
atrial B-Disease
fibrillation I-Disease
to O
a O
sinus O
rhythm O
; O
the O
patient O
developed O
sudden B-Disease
cardiac I-Disease
death I-Disease
two O
days O
later O
. O

the O
holter O
electrocardiogram O
, O
which O
was O
worn O
by O
chance O
, O
revealed O
torsade B-Disease
de I-Disease
pointes I-Disease
with O
gradually O
prolonged O
qt O
intervals O
. O

this O
drug O
is O
rapidly O
absorbed O
from O
the O
gastrointestinal O
tract O
, O
and O
most O
of O
it O
is O
excreted O
from O
the O
kidney O
. O

although O
the O
patient O
' O
s O
renal O
function O
was O
not O
highly O
impaired O
and O
the O
dose O
of O
pilsicainide O
was O
low O
, O
the O
plasma O
concentration O
of O
pilsicainide O
may O
have O
been O
high O
, O
which O
can O
produce O
torsades B-Disease
de I-Disease
pointes I-Disease
in O
the O
octogenarian O
. O

although O
the O
oral O
administration O
of O
class O
ic O
drugs O
, O
including O
pilsicainide O
, O
is O
effective O
to O
terminate O
atrial B-Disease
fibrillation I-Disease
, O
careful O
consideration O
must O
be O
taken O
before O
giving O
these O
drugs O
to O
octogenarians O
. O

all O
- O
trans O
retinoic O
acid O
- O
induced O
inflammatory O
myositis B-Disease
in O
a O
patient O
with O
acute B-Disease
promyelocytic I-Disease
leukemia I-Disease
. O

all O
- O
trans O
retinoic O
acid O
( O
atra O
) O
, O
a O
component O
of O
standard O
therapy O
for O
acute B-Disease
promyelocytic I-Disease
leukemia I-Disease
( O
apl B-Disease
) O
, O
is O
associated O
with O
potentially O
serious O
but O
treatable O
adverse O
effects O
involving O
numerous O
organ O
systems O
, O
including O
rare O
skeletal O
muscle O
involvement O
. O

only O
a O
handful O
of O
cases O
of O
atra O
- O
induced O
myositis B-Disease
in O
children O
have O
been O
reported O
, O
and O
none O
in O
the O
radiology O
literature O
. O

we O
present O
such O
a O
case O
in O
a O
15 O
- O
year O
- O
old O
boy O
with O
apl B-Disease
, O
where O
recognition O
of O
imaging O
findings O
played O
a O
crucial O
role O
in O
making O
the O
diagnosis O
and O
facilitated O
prompt O
, O
effective O
treatment O
. O

tolerability O
of O
lomustine O
in O
combination O
with O
cyclophosphamide O
in O
dogs O
with O
lymphoma B-Disease
. O

this O
retrospective O
study O
describes O
toxicity B-Disease
associated O
with O
a O
protocol O
of O
lomustine O
( O
ccnu O
) O
and O
cyclophosphamide O
( O
ctx O
) O
in O
dogs O
with O
lymphoma B-Disease
. O

ccnu O
was O
administered O
per O
os O
( O
po O
) O
at O
a O
targeted O
dosage O
of O
60 O
mg O
/ O
m O
( O
2 O
) O
body O
surface O
area O
on O
day O
0 O
, O
ctx O
was O
administered O
po O
at O
a O
targeted O
dosage O
of O
250 O
mg O
/ O
m O
( O
2 O
) O
divided O
over O
days O
0 O
through O
4 O
, O
and O
all O
dogs O
received O
prophylactic O
antibiotics O
. O

ninety O
treatments O
were O
given O
to O
the O
57 O
dogs O
included O
in O
the O
study O
. O

neutropenia B-Disease
was O
the O
principal O
toxic O
effect O
, O
and O
the O
overall O
frequency O
of O
grade O
4 O
neutropenia B-Disease
after O
the O
first O
treatment O
of O
ccnu O
/ O
ctx O
was O
30 O
% O
( O
95 O
% O
confidence O
interval O
, O
19 O
- O
43 O
% O
) O
. O

the O
mean O
body O
weight O
of O
dogs O
with O
grade O
4 O
neutropenia B-Disease
( O
19 O
. O
7 O
kg O
+ O
13 O
. O
4 O
kg O
) O
was O
significantly O
less O
than O
the O
mean O
body O
weight O
of O
dogs O
that O
did O
not O
develop O
grade O
4 O
neutropenia B-Disease
( O
31 O
. O
7 O
kg O
+ O
12 O
. O
4 O
kg O
; O
p O
= O
. O
005 O
) O
. O

one O
dog O
( O
3 O
% O
) O
developed O
hematologic O
changes O
suggestive O
of O
hepatotoxicity B-Disease
. O

no O
dogs O
had O
evidence O
of O
either O
renal B-Disease
toxicity I-Disease
or O
hemorrhagic B-Disease
cystitis I-Disease
. O

adverse O
gastrointestinal O
effects O
were O
uncommon O
. O

on O
the O
basis O
of O
the O
findings O
reported O
herein O
, O
a O
dose O
of O
60 O
mg O
/ O
m O
( O
2 O
) O
of O
ccnu O
combined O
with O
250 O
mg O
/ O
m O
( O
2 O
) O
of O
ctx O
( O
divided O
over O
5 O
days O
) O
q O
4 O
wk O
is O
tolerable O
in O
tumor B-Disease
- O
bearing O
dogs O
. O

nelarabine O
neurotoxicity B-Disease
with O
concurrent O
intrathecal O
chemotherapy O
: O
case O
report O
and O
review O
of O
literature O
. O

severe O
nelarabine O
neurotoxicity B-Disease
in O
a O
patient O
who O
received O
concurrent O
intrathecal O
( O
it O
) O
chemotherapy O
is O
reported O
. O

a O
37 O
- O
year O
- O
old O
caucasian O
woman O
with O
a O
history O
of O
t B-Disease
- I-Disease
cell I-Disease
lymphoblastic I-Disease
lymphoma I-Disease
was O
admitted O
for O
relapsed O
disease O
. O

she O
was O
originally O
treated O
with O
induction O
chemotherapy O
followed O
by O
an O
autologous O
transplant O
. O

she O
developed O
relapsed O
disease O
10 O
months O
later O
with O
leukemic B-Disease
involvement O
. O

she O
was O
re O
- O
induced O
with O
nelarabine O
1500 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
3 O
, O
and O
5 O
with O
1 O
dose O
of O
it O
cytarabine O
100 O
mg O
on O
day O
2 O
as O
central O
nervous O
system O
( O
cns O
) O
prophylaxis O
. O

at O
the O
time O
of O
treatment O
, O
she O
was O
on O
continuous O
renal O
replacement O
therapy O
due O
to O
sequelae O
of O
tumor B-Disease
lysis I-Disease
syndrome I-Disease
( O
tls B-Disease
) O
. O

she O
tolerated O
therapy O
well O
, O
entered O
a O
complete O
remission O
, O
and O
recovered O
her O
renal O
function O
. O

she O
received O
a O
second O
cycle O
of O
nelarabine O
without O
additional O
it O
prophylaxis O
one O
month O
later O
. O

a O
week O
after O
this O
second O
cycle O
, O
she O
noted O
numbness O
in O
her O
lower O
extremities O
. O

predominantly O
sensory O
, O
though O
also O
motor O
and O
autonomic O
, O
peripheral B-Disease
neuropathy I-Disease
started O
in O
her O
feet O
, O
ascended O
proximally O
to O
the O
mid O
- O
thoracic O
region O
, O
and O
eventually O
included O
her O
distal O
upper O
extremities O
. O

a O
magnetic O
resonance O
imaging O
( O
mri O
) O
of O
her O
spine O
demonstrated O
changes O
from O
c2 O
to O
c6 O
consistent O
with O
subacute O
combined O
degeneration O
. O

nelarabine O
was O
felt O
to O
be O
the O
cause O
of O
her O
symptoms O
. O

her O
neuropathy B-Disease
stabilized O
and O
showed O
slight O
improvement O
and O
ultimately O
received O
an O
unrelated O
, O
reduced O
- O
intensity O
allogeneic O
transplant O
while O
in O
complete O
remission O
, O
but O
relapsed O
disease O
10 O
weeks O
later O
. O

she O
is O
currently O
being O
treated O
with O
best O
supportive O
care O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
published O
case O
report O
of O
severe O
neurotoxicity B-Disease
caused O
by O
nelarabine O
in O
a O
patient O
who O
received O
concurrent O
it O
chemotherapy O
. O

valproate O
- O
induced O
hyperammonemic B-Disease
encephalopathy B-Disease
in O
a O
renal O
transplanted O
patient O
. O

neurological B-Disease
complications I-Disease
after O
renal O
transplantation O
constitute O
an O
important O
cause O
of O
morbidity O
and O
mortality O
. O

their O
differential O
diagnosis O
is O
difficult O
and O
essential O
for O
subsequent O
patient O
' O
s O
management O
. O

valproate O
- O
induced O
hyperammonemic B-Disease
encephalopathy B-Disease
is O
an O
uncommon O
but O
serious O
effect O
of O
valproate O
treatment O
. O

here O
, O
we O
describe O
the O
case O
of O
a O
15 O
- O
year O
- O
old O
girl O
who O
was O
on O
a O
long O
- O
term O
therapy O
with O
valproate O
due O
to O
epilepsy B-Disease
and O
revealed O
impaired B-Disease
consciousness I-Disease
with O
hyperammonemia B-Disease
12 O
days O
after O
renal O
transplantation O
. O

after O
withdraw O
of O
valproate O
, O
patients O
' O
symptoms O
resolved O
within O
24 O
h O
. O

clinicians O
should O
increase O
their O
awareness O
for O
potential O
complication O
of O
valproate O
, O
especially O
in O
transplanted O
patients O
. O

necrotising B-Disease
fasciitis I-Disease
after O
bortezomib O
and O
dexamethasone O
- O
containing O
regimen O
in O
an O
elderly O
patient O
of O
waldenstrom B-Disease
macroglobulinaemia I-Disease
. O

bortezomib O
and O
high O
- O
dose O
dexamethasone O
- O
containing O
regimens O
are O
considered O
to O
be O
generally O
tolerable O
with O
few O
severe O
bacterial B-Disease
infections I-Disease
in O
patients O
with O
b O
- O
cell O
malignancies B-Disease
. O

however O
, O
information O
is O
limited O
concerning O
the O
safety O
of O
the O
regimen O
in O
elderly O
patients O
. O

we O
report O
a O
case O
of O
a O
76 O
- O
year O
- O
old O
man O
with O
waldenstrom B-Disease
macroglobulinaemia I-Disease
who O
suffered O
necrotising B-Disease
fasciitis I-Disease
without O
neutropenia B-Disease
after O
the O
combination O
treatment O
with O
bortezomib O
, O
high O
- O
dose O
dexamethasone O
and O
rituximab O
. O

despite O
immediate O
intravenous O
antimicrobial O
therapy O
, O
he O
succumbed O
23 O
h O
after O
the O
onset O
. O

physicians O
should O
recognise O
the O
possibility O
of O
fatal O
bacterial B-Disease
infections I-Disease
related O
to O
bortezomib O
plus O
high O
- O
dose O
dexamethasone O
in O
elderly O
patients O
, O
and O
we O
believe O
this O
case O
warrants O
further O
investigation O
. O

an O
integrated O
characterization O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
in O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
. O

many O
efficacious O
cancer B-Disease
treatments O
cause O
significant O
cardiac O
morbidity O
, O
yet O
biomarkers O
or O
functional O
indices O
of O
early O
damage O
, O
which O
would O
allow O
monitoring O
and O
intervention O
, O
are O
lacking O
. O

in O
this O
study O
, O
we O
have O
utilized O
a O
rat O
model O
of O
progressive O
doxorubicin O
( O
dox O
) O
- O
induced O
cardiomyopathy B-Disease
, O
applying O
multiple O
approaches O
, O
including O
cardiac O
magnetic O
resonance O
imaging O
( O
mri O
) O
, O
to O
provide O
the O
most O
comprehensive O
characterization O
to O
date O
of O
the O
timecourse O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
underlying O
this O
toxicity B-Disease
. O

hannover O
wistar O
rats O
were O
dosed O
with O
1 O
. O
25 O
mg O
/ O
kg O
dox O
weekly O
for O
8 O
weeks O
followed O
by O
a O
4 O
week O
off O
- O
dosing O
" O
recovery O
" O
period O
. O

electron O
microscopy O
of O
the O
myocardium O
revealed O
subcellular B-Disease
degeneration I-Disease
and O
marked O
mitochondrial O
changes O
after O
a O
single O
dose O
. O

histopathological O
analysis O
revealed O
progressive O
cardiomyocyte B-Disease
degeneration I-Disease
, O
hypertrophy B-Disease
/ O
cytomegaly O
, O
and O
extensive O
vacuolation O
after O
two O
doses O
. O

extensive O
replacement O
fibrosis B-Disease
( O
quantified O
by O
sirius O
red O
staining O
) O
developed O
during O
the O
off O
- O
dosing O
period O
. O

functional O
indices O
assessed O
by O
cardiac O
mri O
( O
including O
left O
ventricular O
ejection O
fraction O
( O
lvef O
) O
, O
cardiac O
output O
, O
and O
e O
/ O
a O
ratio O
) O
declined O
progressively O
, O
reaching O
statistical O
significance O
after O
two O
doses O
and O
culminating O
in O
" O
clinical O
" O
lv B-Disease
dysfunction I-Disease
by O
12 O
weeks O
. O

significant O
increases O
in O
peak O
myocardial O
contrast O
enhancement O
and O
serological O
cardiac O
troponin O
i O
( O
ctni O
) O
emerged O
after O
eight O
doses O
, O
importantly O
preceding O
the O
lvef O
decline O
to O
< O
50 O
% O
. O

troponin O
i O
levels O
positively O
correlated O
with O
delayed O
and O
peak O
gadolinium O
contrast O
enhancement O
, O
histopathological O
grading O
, O
and O
diastolic B-Disease
dysfunction I-Disease
. O

in O
summary O
, O
subcellular O
cardiomyocyte B-Disease
degeneration I-Disease
was O
the O
earliest O
marker O
, O
followed O
by O
progressive O
functional O
decline O
and O
histopathological O
manifestations O
. O

myocardial O
contrast O
enhancement O
and O
elevations O
in O
ctni O
occurred O
later O
. O

however O
, O
all O
indices O
predated O
" O
clinical O
" O
lv B-Disease
dysfunction I-Disease
and O
thus O
warrant O
further O
evaluation O
as O
predictive O
biomarkers O
. O

intradermal O
glutamate O
and O
capsaicin O
injections O
: O
intra O
- O
and O
interindividual O
variability O
of O
provoked O
hyperalgesia B-Disease
and O
allodynia B-Disease
. O

intradermal O
injections O
of O
glutamate O
and O
capsaicin O
are O
attractive O
to O
use O
in O
human O
experimental O
pain B-Disease
models O
because O
hyperalgesia B-Disease
and O
allodynia B-Disease
mimic O
isolated O
aspects O
of O
clinical O
pain B-Disease
disorders I-Disease
. O

the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
reproducibility O
of O
these O
models O
. O

twenty O
healthy O
male O
volunteers O
( O
mean O
age O
24 O
years O
; O
range O
18 O
- O
38 O
years O
) O
received O
intradermal O
injections O
of O
glutamate O
and O
capsaicin O
in O
the O
volar O
forearm O
. O

magnitudes O
of O
secondary O
pinprick O
hyperalgesia B-Disease
and O
brush O
- O
evoked O
allodynia B-Disease
were O
investigated O
using O
von O
frey O
filaments O
( O
gauges O
10 O
, O
15 O
, O
60 O
and O
100 O
g O
) O
and O
brush O
strokes O
. O

areas O
of O
secondary B-Disease
hyperalgesia I-Disease
and O
allodynia B-Disease
were O
quantified O
immediately O
after O
injection O
and O
after O
15 O
, O
30 O
and O
60 O
min O
. O

two O
identical O
experiments O
separated O
by O
at O
least O
7 O
days O
were O
performed O
. O

reproducibility O
across O
and O
within O
volunteers O
( O
inter O
- O
and O
intra O
- O
individual O
variation O
, O
respectively O
) O
was O
assessed O
using O
intraclass O
correlation O
coefficient O
( O
icc O
) O
and O
coefficient O
of O
variation O
( O
cv O
) O
. O

secondary O
pinprick O
hyperalgesia B-Disease
was O
observed O
as O
a O
marked O
increase O
in O
the O
visual O
analogue O
scale O
( O
vas O
) O
response O
to O
von O
frey O
gauges O
60 O
and O
100 O
g O
( O
p O
< O
0 O
. O
001 O
) O
after O
glutamate O
injection O
. O

for O
capsaicin O
, O
secondary O
pinprick O
hyperalgesia B-Disease
was O
detected O
with O
all O
von O
frey O
gauges O
( O
p O
< O
0 O
. O
001 O
) O
. O

glutamate O
evoked O
reproducible O
vas O
response O
to O
all O
von O
frey O
gauges O
( O
icc O
> O
0 O
. O
60 O
) O
and O
brush O
strokes O
( O
icc O
> O
0 O
. O
83 O
) O
. O

capsaicin O
injection O
was O
reproducible O
for O
secondary B-Disease
hyperalgesia I-Disease
( O
icc O
> O
0 O
. O
70 O
) O
and O
allodynia B-Disease
( O
icc O
> O
0 O
. O
71 O
) O
. O

intra O
- O
individual O
variability O
was O
generally O
lower O
for O
the O
vas O
response O
to O
von O
frey O
and O
brush O
compared O
with O
areas O
of O
secondary B-Disease
hyperalgesia I-Disease
and O
allodynia B-Disease
. O

in O
conclusion O
, O
glutamate O
and O
capsaicin O
yield O
reproducible O
hyperalgesic B-Disease
and O
allodynic B-Disease
responses O
, O
and O
the O
present O
model O
is O
well O
suited O
for O
basic O
research O
, O
as O
well O
as O
for O
assessing O
the O
modulation O
of O
central O
phenomena O
. O

ocular O
- O
specific O
er O
stress O
reduction O
rescues O
glaucoma B-Disease
in O
murine O
glucocorticoid O
- O
induced O
glaucoma B-Disease
. O

administration O
of O
glucocorticoids O
induces O
ocular B-Disease
hypertension I-Disease
in O
some O
patients O
. O

if O
untreated O
, O
these O
patients O
can O
develop O
a O
secondary O
glaucoma B-Disease
that O
resembles O
primary B-Disease
open I-Disease
- I-Disease
angle I-Disease
glaucoma I-Disease
( O
poag B-Disease
) O
. O

the O
underlying O
pathology O
of O
glucocorticoid O
- O
induced O
glaucoma B-Disease
is O
not O
fully O
understood O
, O
due O
in O
part O
to O
lack O
of O
an O
appropriate O
animal O
model O
. O

here O
, O
we O
developed O
a O
murine O
model O
of O
glucocorticoid O
- O
induced O
glaucoma B-Disease
that O
exhibits O
glaucoma B-Disease
features O
that O
are O
observed O
in O
patients O
. O

treatment O
of O
wt O
mice O
with O
topical O
ocular O
0 O
. O
1 O
% O
dexamethasone O
led O
to O
elevation O
of O
intraocular O
pressure O
( O
iop O
) O
, O
functional O
and O
structural O
loss O
of O
retinal B-Disease
ganglion I-Disease
cells O
, O
and O
axonal B-Disease
degeneration I-Disease
, O
resembling O
glucocorticoid O
- O
induced O
glaucoma B-Disease
in O
human O
patients O
. O

furthermore O
, O
dexamethasone O
- O
induced O
ocular B-Disease
hypertension I-Disease
was O
associated O
with O
chronic O
er O
stress O
of O
the O
trabecular O
meshwork O
( O
tm O
) O
. O

similar O
to O
patients O
, O
withdrawal O
of O
dexamethasone O
treatment O
reduced O
elevated O
iop O
and O
er O
stress O
in O
this O
animal O
model O
. O

dexamethasone O
induced O
the O
transcriptional O
factor O
chop O
, O
a O
marker O
for O
chronic O
er O
stress O
, O
in O
the O
anterior O
segment O
tissues O
, O
and O
chop O
deletion O
reduced O
er O
stress O
in O
these O
tissues O
and O
prevented O
dexamethasone O
- O
induced O
ocular B-Disease
hypertension I-Disease
. O

furthermore O
, O
reduction O
of O
er O
stress O
in O
the O
tm O
with O
sodium O
4 O
- O
phenylbutyrate O
prevented O
dexamethasone O
- O
induced O
ocular B-Disease
hypertension I-Disease
in O
wt O
mice O
. O

our O
data O
indicate O
that O
er O
stress O
contributes O
to O
glucocorticoid O
- O
induced O
ocular B-Disease
hypertension I-Disease
and O
suggest O
that O
reducing O
er O
stress O
has O
potential O
as O
a O
therapeutic O
strategy O
for O
treating O
glucocorticoid O
- O
induced O
glaucoma B-Disease
. O

effects O
of O
ginsenosides O
on O
opioid O
- O
induced O
hyperalgesia B-Disease
in O
mice O
. O

opioid O
- O
induced O
hyperalgesia B-Disease
( O
oih B-Disease
) O
is O
characterized O
by O
nociceptive O
sensitization O
caused O
by O
the O
cessation O
of O
chronic O
opioid O
use O
. O

oih B-Disease
can O
limit O
the O
clinical O
use O
of O
opioid O
analgesics O
and O
complicate O
withdrawal O
from O
opioid B-Disease
addiction I-Disease
. O

in O
this O
study O
, O
we O
investigated O
the O
effects O
of O
re O
, O
rg1 O
, O
and O
rb1 O
ginsenosides O
, O
the O
bioactive O
components O
of O
ginseng O
, O
on O
oih B-Disease
. O

oih B-Disease
was O
achieved O
in O
mice O
after O
subcutaneous O
administration O
of O
morphine O
for O
7 O
consecutive O
days O
three O
times O
per O
day O
. O

during O
withdrawal O
( O
days O
8 O
and O
9 O
) O
, O
these O
mice O
were O
administered O
re O
, O
rg1 O
, O
or O
rb1 O
intragastrically O
two O
times O
per O
day O
. O

on O
the O
test O
day O
( O
day O
10 O
) O
, O
mice O
were O
subjected O
to O
the O
thermal O
sensitivity O
test O
and O
the O
acetic O
acid O
- O
induced O
writhing O
test O
. O

re O
( O
300 O
mg O
/ O
kg O
) O
inhibited O
oih B-Disease
in O
both O
the O
thermal O
sensitivity O
test O
and O
the O
acetic O
acid O
- O
induced O
writhing O
test O
. O

however O
, O
the O
rg1 O
and O
rb1 O
ginsenosides O
failed O
to O
prevent O
oih B-Disease
in O
either O
test O
. O

furthermore O
, O
rg1 O
showed O
a O
tendency O
to O
aggravate O
oih B-Disease
in O
the O
acetic O
acid O
- O
induced O
writhing O
test O
. O

our O
data O
suggested O
that O
the O
ginsenoside O
re O
, O
but O
not O
rg1 O
or O
rb1 O
, O
may O
contribute O
toward O
reversal O
of O
oih B-Disease
. O

a O
comparison O
of O
severe O
hemodynamic O
disturbances O
between O
dexmedetomidine O
and O
propofol O
for O
sedation O
in O
neurocritical O
care O
patients O
. O

objective O
: O
dexmedetomidine O
and O
propofol O
are O
commonly O
used O
sedatives O
in O
neurocritical O
care O
as O
they O
allow O
for O
frequent O
neurologic O
examinations O
. O

however O
, O
both O
agents O
are O
associated O
with O
significant O
hemodynamic O
side O
effects O
. O

the O
primary O
objective O
of O
this O
study O
is O
to O
compare O
the O
prevalence O
of O
severe O
hemodynamic O
effects O
in O
neurocritical O
care O
patients O
receiving O
dexmedetomidine O
and O
propofol O
. O

design O
: O
multicenter O
, O
retrospective O
, O
propensity O
- O
matched O
cohort O
study O
. O

setting O
: O
neurocritical O
care O
units O
at O
two O
academic O
medical O
centers O
with O
dedicated O
neurocritical O
care O
teams O
and O
board O
- O
certified O
neurointensivists O
. O

patients O
: O
neurocritical O
care O
patients O
admitted O
between O
july O
2009 O
and O
september O
2012 O
were O
evaluated O
and O
then O
matched O
1 O
: O
1 O
based O
on O
propensity O
scoring O
of O
baseline O
characteristics O
. O

interventions O
: O
continuous O
sedation O
with O
dexmedetomidine O
or O
propofol O
. O

measurements O
and O
main O
results O
: O
a O
total O
of O
342 O
patients O
( O
105 O
dexmedetomidine O
and O
237 O
propofol O
) O
were O
included O
in O
the O
analysis O
, O
with O
190 O
matched O
( O
95 O
in O
each O
group O
) O
by O
propensity O
score O
. O

the O
primary O
outcome O
of O
this O
study O
was O
a O
composite O
of O
severe O
hypotension B-Disease
( O
mean O
arterial O
pressure O
< O
60 O
mm O
hg O
) O
and O
bradycardia B-Disease
( O
heart O
rate O
< O
50 O
beats O
/ O
min O
) O
during O
sedative O
infusion O
. O

no O
difference O
in O
the O
primary O
composite O
outcome O
in O
both O
the O
unmatched O
( O
30 O
% O
vs O
30 O
% O
, O
p O
= O
0 O
. O
94 O
) O
or O
matched O
cohorts O
( O
28 O
% O
vs O
34 O
% O
, O
p O
= O
0 O
. O
35 O
) O
could O
be O
found O
. O

when O
analyzed O
separately O
, O
no O
differences O
could O
be O
found O
in O
the O
prevalence O
of O
severe O
hypotension B-Disease
or O
bradycardia B-Disease
in O
either O
the O
unmatched O
or O
matched O
cohorts O
. O

conclusions O
: O
severe O
hypotension B-Disease
and O
bradycardia B-Disease
occur O
at O
similar O
prevalence O
in O
neurocritical O
care O
patients O
who O
receive O
dexmedetomidine O
or O
propofol O
. O

providers O
should O
similarly O
consider O
the O
likelihood O
of O
hypotension B-Disease
or O
bradycardia B-Disease
before O
starting O
either O
sedative O
. O

hydroxytyrosol O
ameliorates O
oxidative O
stress O
and O
mitochondrial B-Disease
dysfunction I-Disease
in O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
in O
rats O
with O
breast B-Disease
cancer I-Disease
. O

oxidative O
stress O
is O
involved O
in O
several O
processes O
including O
cancer B-Disease
, O
aging O
and O
cardiovascular B-Disease
disease I-Disease
, O
and O
has O
been O
shown O
to O
potentiate O
the O
therapeutic O
effect O
of O
drugs O
such O
as O
doxorubicin O
. O

doxorubicin O
causes O
significant O
cardiotoxicity B-Disease
characterized O
by O
marked O
increases O
in O
oxidative O
stress O
and O
mitochondrial B-Disease
dysfunction I-Disease
. O

herein O
, O
we O
investigate O
whether O
doxorubicin O
- O
associated O
chronic O
cardiac B-Disease
toxicity I-Disease
can O
be O
ameliorated O
with O
the O
antioxidant O
hydroxytyrosol O
in O
rats O
with O
breast B-Disease
cancer I-Disease
. O

thirty O
- O
six O
rats O
bearing O
breast B-Disease
tumors I-Disease
induced O
chemically O
were O
divided O
into O
4 O
groups O
: O
control O
, O
hydroxytyrosol O
( O
0 O
. O
5mg O
/ O
kg O
, O
5days O
/ O
week O
) O
, O
doxorubicin O
( O
1mg O
/ O
kg O
/ O
week O
) O
, O
and O
doxorubicin O
plus O
hydroxytyrosol O
. O

cardiac B-Disease
disturbances I-Disease
at O
the O
cellular O
and O
mitochondrial O
level O
, O
mitochondrial O
electron O
transport O
chain O
complexes O
i O
- O
iv O
and O
apoptosis O
- O
inducing O
factor O
, O
and O
oxidative O
stress O
markers O
have O
been O
analyzed O
. O

hydroxytyrosol O
improved O
the O
cardiac B-Disease
disturbances I-Disease
enhanced O
by O
doxorubicin O
by O
significantly O
reducing O
the O
percentage O
of O
altered O
mitochondria O
and O
oxidative O
damage O
. O

these O
results O
suggest O
that O
hydroxytyrosol O
improve O
the O
mitochondrial O
electron O
transport O
chain O
. O

this O
study O
demonstrates O
that O
hydroxytyrosol O
protect O
rat O
heart B-Disease
damage I-Disease
provoked O
by O
doxorubicin O
decreasing O
oxidative O
damage O
and O
mitochondrial O
alterations O
. O

amiodarone O
- O
induced O
myxoedema B-Disease
coma I-Disease
. O

a O
62 O
- O
year O
- O
old O
man O
was O
found O
to O
have O
bradycardia B-Disease
, O
hypothermia B-Disease
and O
respiratory B-Disease
failure I-Disease
3 O
weeks O
after O
initiation O
of O
amiodarone O
therapy O
for O
atrial B-Disease
fibrillation I-Disease
. O

thyroid O
- O
stimulating O
hormone O
was O
found O
to O
be O
168 O
uiu O
/ O
ml O
( O
nl O
. O
0 O
. O
3 O
- O
5 O
uiu O
/ O
ml O
) O
and O
free O
thyroxine O
( O
ft4 O
) O
was O
< O
0 O
. O
2 O
ng O
/ O
dl O
( O
nl O
. O
0 O
. O
8 O
- O
1 O
. O
8 O
ng O
/ O
dl O
) O
. O

he O
received O
intravenous O
fluids O
, O
vasopressor O
therapy O
and O
stress O
dose O
steroids O
; O
he O
was O
intubated O
and O
admitted O
to O
the O
intensive O
care O
unit O
. O

he O
received O
500 O
ug O
of O
intravenous O
levothyroxine O
in O
the O
first O
18 O
h O
of O
therapy O
, O
and O
150 O
ug O
intravenous O
daily O
thereafter O
. O

haemodynamic O
improvement O
, O
along O
with O
complete O
recovery O
of O
mental O
status O
, O
occurred O
after O
48 O
h O
. O

twelve O
hours O
after O
the O
initiation O
of O
therapy O
, O
ft4 O
was O
0 O
. O
96 O
ng O
/ O
dl O
. O

the O
patient O
was O
maintained O
on O
levothyroxine O
175 O
( O
g O
poorally O
daily O
. O

a O
thyroid O
ultrasound O
showed O
diffuse O
heterogeneity O
. O

the O
24 O
hour O
excretion O
of O
iodine O
was O
3657 O
( O
mcg O
( O
25 O
- O
756 O
( O
mcg O
) O
. O

the O
only O
two O
cases O
of O
amiodarone O
- O
induced O
myxoedema B-Disease
coma I-Disease
in O
the O
literature O
report O
patient O
death O
despite O
supportive O
therapy O
and O
thyroid O
hormone O
replacement O
. O

this O
case O
represents O
the O
most O
thoroughly O
investigated O
case O
of O
amiodarone O
- O
induced O
myxoedema B-Disease
coma I-Disease
with O
a O
history O
significant O
for O
subclinical O
thyroid B-Disease
disease I-Disease
. O

use O
of O
argatroban O
and O
catheter O
- O
directed O
thrombolysis B-Disease
with O
alteplase O
in O
an O
oncology O
patient O
with O
heparin O
- O
induced O
thrombocytopenia B-Disease
with O
thrombosis B-Disease
. O

purpose O
: O
the O
case O
of O
an O
oncology O
patient O
who O
developed O
heparin O
- O
induced O
thrombocytopenia B-Disease
with O
thrombosis B-Disease
( O
hitt B-Disease
) O
and O
was O
treated O
with O
argatroban O
plus O
catheter O
- O
directed O
thrombolysis B-Disease
( O
cdt O
) O
with O
alteplase O
is O
presented O
. O

summary O
: O
a O
63 O
- O
year O
- O
old O
caucasian O
man O
with O
renal O
amyloidosis B-Disease
undergoing O
peripheral O
blood O
stem O
cell O
collection O
for O
an O
autologous O
stem O
cell O
transplant O
developed O
extensive O
bilateral O
upper B-Disease
- I-Disease
extremity I-Disease
deep I-Disease
venous I-Disease
thrombosis I-Disease
( O
dvt B-Disease
) O
and O
pulmonary B-Disease
embolism I-Disease
secondary O
to O
heparin O
- O
induced O
thrombocytopenia B-Disease
. O

a O
continuous O
i O
. O
v O
. O
infusion O
of O
argatroban O
was O
initiated O
, O
and O
the O
patient O
was O
managed O
on O
the O
general O
medical O
floor O
. O

after O
one O
week O
of O
therapy O
, O
he O
was O
transferred O
to O
the O
intensive O
care O
unit O
with O
cardiopulmonary O
compromise O
related O
to O
superior B-Disease
vena I-Disease
cava I-Disease
( I-Disease
svc I-Disease
) I-Disease
syndrome I-Disease
. O

a O
percutaneous O
mechanical O
thrombectomy O
and O
cdt O
with O
alteplase O
were O
attempted O
, O
but O
the O
procedure O
was O
aborted O
due O
to O
epistaxis B-Disease
. O

the O
epistaxis B-Disease
resolved O
the O
next O
day O
, O
and O
the O
patient O
was O
restarted O
on O
argatroban O
. O

a O
second O
percutaneous O
mechanical O
thrombectomy O
was O
performed O
six O
days O
later O
and O
resulted O
in O
partial O
revascularization O
of O
the O
svc O
and O
central O
veins O
. O

postthrombectomy O
continuous O
cdt O
with O
alteplase O
was O
commenced O
while O
argatroban O
was O
withheld O
, O
and O
complete O
patency O
of O
the O
svc O
and O
central O
veins O
was O
achieved O
after O
three O
days O
of O
therapy O
. O

alteplase O
was O
discontinued O
, O
and O
the O
patient O
was O
reinitiated O
on O
argatroban O
; O
ultimately O
, O
he O
was O
transitioned O
to O
warfarin O
for O
long O
- O
term O
anticoagulation O
. O

although O
the O
patient O
recovered O
, O
he O
experienced O
permanent O
vision B-Disease
and I-Disease
hearing I-Disease
loss I-Disease
, O
as O
well O
as O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
. O

conclusion O
: O
a O
63 O
- O
year O
- O
old O
man O
with O
renal O
amyloidosis B-Disease
and O
svc B-Disease
syndrome I-Disease
secondary O
to O
hitt B-Disease
was O
successfully O
treated O
with O
argatroban O
and O
cdt O
with O
alteplase O
. O

effects O
of O
dehydroepiandrosterone O
in O
amphetamine O
- O
induced O
schizophrenia B-Disease
models O
in O
mice O
. O

objective O
: O
to O
examine O
the O
effects O
of O
dehydroepiandrosterone O
( O
dhea O
) O
on O
animal O
models O
of O
schizophrenia B-Disease
. O

methods O
: O
seventy O
swiss O
albino O
female O
mice O
( O
25 O
- O
35 O
g O
) O
were O
divided O
into O
4 O
groups O
: O
amphetamine O
- O
free O
( O
control O
) O
, O
amphetamine O
, O
50 O
, O
and O
100 O
mg O
/ O
kg O
dhea O
. O

the O
dhea O
was O
administered O
intraperitoneally O
( O
ip O
) O
for O
5 O
days O
. O

amphetamine O
( O
3 O
mg O
/ O
kg O
ip O
) O
induced O
hyper B-Disease
locomotion O
, O
apomorphine O
( O
1 O
. O
5 O
mg O
/ O
kg O
subcutaneously O
[ O
sc O
] O
) O
induced O
climbing O
, O
and O
haloperidol O
( O
1 O
. O
5 O
mg O
/ O
kg O
sc O
) O
induced O
catalepsy B-Disease
tests O
were O
used O
as O
animal O
models O
of O
schizophrenia B-Disease
. O

the O
study O
was O
conducted O
at O
the O
animal O
experiment O
laboratories O
, O
department O
of O
pharmacology O
, O
medical O
school O
, O
eskisehir O
osmangazi O
university O
, O
eskisehir O
, O
turkey O
between O
march O
and O
may O
2012 O
. O

statistical O
analysis O
was O
carried O
out O
using O
kruskal O
- O
wallis O
test O
for O
hyper B-Disease
locomotion O
, O
and O
one O
- O
way O
anova O
for O
climbing O
and O
catalepsy B-Disease
tests O
. O

results O
: O
in O
the O
amphetamine O
- O
induced O
locomotion O
test O
, O
there O
were O
significant O
increases O
in O
all O
movements O
compared O
with O
the O
amphetamine O
- O
free O
group O
. O

both O
dhea O
50 O
mg O
/ O
kg O
( O
p O
< O
0 O
. O
05 O
) O
, O
and O
100 O
mg O
/ O
kg O
( O
p O
< O
0 O
. O
01 O
) O
significantly O
decreased O
all O
movements O
compared O
with O
the O
amphetamine O
- O
induced O
locomotion O
group O
. O

there O
was O
a O
significant O
difference O
between O
groups O
in O
the O
haloperidol O
- O
induced O
catalepsy B-Disease
test O
( O
p O
< O
0 O
. O
05 O
) O
. O

there O
was O
no O
significant O
difference O
between O
groups O
in O
terms O
of O
total O
climbing O
time O
in O
the O
apomorphine O
- O
induced O
climbing O
test O
( O
p O
> O
0 O
. O
05 O
) O
. O

conclusion O
: O
we O
observed O
that O
dhea O
reduced O
locomotor O
activity O
and O
increased O
catalepsy B-Disease
at O
both O
doses O
, O
while O
it O
had O
no O
effect O
on O
climbing O
behavior O
. O

we O
suggest O
that O
dhea O
displays O
typical O
neuroleptic O
- O
like O
effects O
, O
and O
may O
be O
used O
in O
the O
treatment O
of O
schizophrenia B-Disease
. O

availability O
of O
human O
induced O
pluripotent O
stem O
cell O
- O
derived O
cardiomyocytes O
in O
assessment O
of O
drug O
potential O
for O
qt B-Disease
prolongation I-Disease
. O

field O
potential O
duration O
( O
fpd O
) O
in O
human O
- O
induced O
pluripotent O
stem O
cell O
- O
derived O
cardiomyocytes O
( O
hips O
- O
cms O
) O
, O
which O
can O
express O
qt O
interval O
in O
an O
electrocardiogram O
, O
is O
reported O
to O
be O
a O
useful O
tool O
to O
predict O
k O
( O
+ O
) O
channel O
and O
ca O
( O
2 O
+ O
) O
channel O
blocker O
effects O
on O
qt O
interval O
. O

however O
, O
there O
is O
no O
report O
showing O
that O
this O
technique O
can O
be O
used O
to O
predict O
multichannel O
blocker O
potential O
for O
qt B-Disease
prolongation I-Disease
. O

the O
aim O
of O
this O
study O
is O
to O
show O
that O
fpd O
from O
mea O
( O
multielectrode O
array O
) O
of O
hips O
- O
cms O
can O
detect O
qt B-Disease
prolongation I-Disease
induced O
by O
multichannel O
blockers O
. O

hips O
- O
cms O
were O
seeded O
onto O
mea O
and O
fpd O
was O
measured O
for O
2min O
every O
10min O
for O
30min O
after O
drug O
exposure O
for O
the O
vehicle O
and O
each O
drug O
concentration O
. O

ikr O
and O
iks O
blockers O
concentration O
- O
dependently O
prolonged O
corrected O
fpd O
( O
fpdc O
) O
, O
whereas O
ca O
( O
2 O
+ O
) O
channel O
blockers O
concentration O
- O
dependently O
shortened O
fpdc O
. O

also O
, O
the O
multichannel O
blockers O
amiodarone O
, O
paroxetine O
, O
terfenadine O
and O
citalopram O
prolonged O
fpdc O
in O
a O
concentration O
dependent O
manner O
. O

finally O
, O
the O
ikr O
blockers O
, O
terfenadine O
and O
citalopram O
, O
which O
are O
reported O
to O
cause O
torsade B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
in O
clinical O
practice O
, O
produced O
early O
afterdepolarization O
( O
ead O
) O
. O

hips O
- O
cms O
using O
mea O
system O
and O
fpdc O
can O
predict O
the O
effects O
of O
drug O
candidates O
on O
qt O
interval O
. O

this O
study O
also O
shows O
that O
this O
assay O
can O
help O
detect O
ead O
for O
drugs O
with O
tdp B-Disease
potential O
. O

dermal O
developmental O
toxicity B-Disease
of O
n O
- O
phenylimide O
herbicides O
in O
rats O
. O

background O
: O
s O
- O
53482 O
and O
s O
- O
23121 O
are O
n O
- O
phenylimide O
herbicides O
and O
produced O
embryolethality B-Disease
, O
teratogenicity B-Disease
( O
mainly O
ventricular B-Disease
septal I-Disease
defects I-Disease
and O
wavy O
ribs O
) O
, O
and O
growth B-Disease
retardation I-Disease
in O
rats O
in O
conventional O
oral O
developmental O
toxicity B-Disease
studies O
. O

our O
objective O
in O
this O
study O
was O
to O
investigate O
whether O
the O
compounds O
induce O
developmental O
toxicity B-Disease
via O
the O
dermal O
route O
, O
which O
is O
more O
relevant O
to O
occupational O
exposure O
, O
hence O
better O
addressing O
human O
health O
risks O
. O

methods O
: O
s O
- O
53482 O
was O
administered O
dermally O
to O
rats O
at O
30 O
, O
100 O
, O
and O
300 O
mg O
/ O
kg O
during O
organogenesis O
, O
and O
s O
- O
23121 O
was O
administered O
at O
200 O
, O
400 O
, O
and O
800 O
mg O
/ O
kg O
( O
the O
maximum O
applicable O
dose O
level O
) O
. O

fetuses O
were O
obtained O
by O
a O
cesarean O
section O
and O
examined O
for O
external O
, O
visceral O
, O
and O
skeletal O
alterations O
. O

results O
: O
dermal O
exposure O
of O
rats O
to O
s O
- O
53482 O
at O
300 O
mg O
/ O
kg O
produced O
patterns O
of O
developmental O
toxicity B-Disease
similar O
to O
those O
resulting O
from O
oral O
exposure O
. O

toxicity B-Disease
included O
embryolethality B-Disease
, O
teratogenicity B-Disease
, O
and O
growth B-Disease
retardation I-Disease
. O

dermal O
administration O
of O
s O
- O
23121 O
at O
800 O
mg O
/ O
kg O
resulted O
in O
an O
increased O
incidence O
of O
embryonic B-Disease
death I-Disease
and O
ventricular B-Disease
septal I-Disease
defect I-Disease
, O
but O
retarded O
fetal O
growth O
was O
not O
observed O
as O
it O
was O
following O
oral O
exposure O
to O
s O
- O
23121 O
. O

conclusions O
: O
based O
on O
the O
results O
, O
s O
- O
53482 O
and O
s O
- O
23121 O
were O
teratogenic B-Disease
when O
administered O
dermally O
to O
pregnant O
rats O
as O
were O
the O
compounds O
administered O
orally O
. O

thus O
, O
investigation O
of O
the O
mechanism O
and O
its O
human O
relevancy O
become O
more O
important O
. O

rates O
of O
renal B-Disease
toxicity I-Disease
in O
cancer B-Disease
patients O
receiving O
cisplatin O
with O
and O
without O
mannitol O
. O

background O
: O
cisplatin O
is O
a O
widely O
used O
antineoplastic O
. O

one O
of O
the O
major O
complications O
of O
cisplatin O
use O
is O
dose O
- O
limiting O
nephrotoxicity B-Disease
. O

there O
are O
many O
strategies O
to O
prevent O
this O
toxicity B-Disease
, O
including O
the O
use O
of O
mannitol O
as O
a O
nephroprotectant O
in O
combination O
with O
hydration O
. O

objective O
: O
we O
aimed O
to O
evaluate O
the O
rates O
of O
cisplatin O
- O
induced O
nephrotoxicity B-Disease
in O
cancer B-Disease
patients O
receiving O
single O
- O
agent O
cisplatin O
with O
and O
without O
mannitol O
. O

methods O
: O
this O
single O
- O
center O
retrospective O
analysis O
was O
a O
quasi O
experiment O
created O
by O
the O
national O
mannitol O
shortage O
. O

data O
were O
collected O
on O
adult O
cancer B-Disease
patients O
receiving O
single O
- O
agent O
cisplatin O
as O
an O
outpatient O
from O
january O
2011 O
to O
september O
2012 O
. O

the O
primary O
outcome O
was O
acute B-Disease
kidney I-Disease
injury I-Disease
( O
aki B-Disease
) O
. O

results O
: O
we O
evaluated O
143 O
patients O
who O
received O
single O
- O
agent O
cisplatin O
; O
97 O
. O
2 O
% O
of O
patients O
had O
head B-Disease
and I-Disease
neck I-Disease
cancer I-Disease
as O
their O
primary O
malignancy B-Disease
. O

patients O
who O
did O
not O
receive O
mannitol O
were O
more O
likely O
to O
develop O
nephrotoxicity B-Disease
: O
odds O
ratio O
[ O
or O
] O
= O
2 O
. O
646 O
( O
95 O
% O
ci O
= O
1 O
. O
008 O
, O
6 O
. O
944 O
; O
p O
= O
0 O
. O
048 O
) O
. O

patients O
who O
received O
the O
100 O
mg O
/ O
m O
( O
2 O
) O
dosing O
and O
patients O
who O
had O
a O
history O
of O
hypertension B-Disease
also O
had O
a O
higher O
likelihood O
of O
developing O
nephrotoxicity B-Disease
: O
or O
= O
11 O
. O
494 O
( O
95 O
% O
ci O
= O
4 O
. O
149 O
, O
32 O
. O
258 O
; O
p O
< O
0 O
. O
0001 O
) O
and O
or O
= O
3 O
. O
219 O
( O
95 O
% O
ci O
= O
1 O
. O
228 O
, O
8 O
. O
439 O
; O
p O
= O
0 O
. O
017 O
) O
, O
respectively O
. O

conclusions O
: O
when O
limited O
quantities O
of O
mannitol O
are O
available O
, O
it O
should O
preferentially O
be O
given O
to O
patients O
at O
particularly O
high O
risk O
of O
nephrotoxicity B-Disease
. O

our O
analysis O
suggests O
that O
those O
patients O
receiving O
the O
dosing O
schedule O
of O
100 O
mg O
/ O
m O
( O
2 O
) O
cisplatin O
every O
3 O
weeks O
and O
those O
with O
hypertension B-Disease
are O
at O
the O
greatest O
risk O
of O
nephrotoxicity B-Disease
and O
would O
benefit O
from O
the O
addition O
of O
mannitol O
. O

metformin O
protects O
against O
seizures B-Disease
, O
learning B-Disease
and I-Disease
memory I-Disease
impairments I-Disease
and O
oxidative O
damage O
induced O
by O
pentylenetetrazole O
- O
induced O
kindling O
in O
mice O
. O

cognitive B-Disease
impairment I-Disease
, O
the O
most O
common O
and O
severe O
comorbidity O
of O
epilepsy B-Disease
, O
greatly O
diminishes O
the O
quality O
of O
life O
. O

however O
, O
current O
therapeutic O
interventions O
for O
epilepsy B-Disease
can O
also O
cause O
untoward O
cognitive O
effects O
. O

thus O
, O
there O
is O
an O
urgent O
need O
for O
new O
kinds O
of O
agents O
targeting O
both O
seizures B-Disease
and O
cognition B-Disease
deficits I-Disease
. O

oxidative O
stress O
is O
considered O
to O
play O
an O
important O
role O
in O
epileptogenesis O
and O
cognitive B-Disease
deficits I-Disease
, O
and O
antioxidants O
have O
a O
putative O
antiepileptic O
potential O
. O

metformin O
, O
the O
most O
commonly O
prescribed O
antidiabetic O
oral O
drug O
, O
has O
antioxidant O
properties O
. O

this O
study O
was O
designed O
to O
evaluate O
the O
ameliorative O
effects O
of O
metformin O
on O
seizures B-Disease
, O
cognitive B-Disease
impairment I-Disease
and O
brain O
oxidative O
stress O
markers O
observed O
in O
pentylenetetrazole O
- O
induced O
kindling O
animals O
. O

male O
c57bl O
/ O
6 O
mice O
were O
administered O
with O
subconvulsive O
dose O
of O
pentylenetetrazole O
( O
37 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
every O
other O
day O
for O
14 O
injections O
. O

metformin O
was O
injected O
intraperitoneally O
in O
dose O
of O
200mg O
/ O
kg O
along O
with O
alternate O
- O
day O
ptz O
. O

we O
found O
that O
metformin O
suppressed O
the O
progression O
of O
kindling O
, O
ameliorated O
the O
cognitive B-Disease
impairment I-Disease
and O
decreased O
brain O
oxidative O
stress O
. O

thus O
the O
present O
study O
concluded O
that O
metformin O
may O
be O
a O
potential O
agent O
for O
the O
treatment O
of O
epilepsy B-Disease
as O
well O
as O
a O
protective O
medicine O
against O
cognitive B-Disease
impairment I-Disease
induced O
by O
seizures B-Disease
. O

p53 O
inhibition O
exacerbates O
late O
- O
stage O
anthracycline O
cardiotoxicity B-Disease
. O

aims O
: O
doxorubicin O
( O
dox O
) O
is O
an O
effective O
anti O
- O
cancer B-Disease
therapeutic O
, O
but O
is O
associated O
with O
both O
acute O
and O
late O
- O
stage O
cardiotoxicity B-Disease
. O

children O
are O
particularly O
sensitive O
to O
dox O
- O
induced O
heart B-Disease
failure I-Disease
. O

here O
, O
the O
impact O
of O
p53 O
inhibition O
on O
acute O
vs O
. O
late O
- O
stage O
dox O
cardiotoxicity B-Disease
was O
examined O
in O
a O
juvenile O
model O
. O

methods O
and O
results O
: O
two O
- O
week O
- O
old O
mhc O
- O
cb7 O
mice O
( O
which O
express O
dominant O
- O
interfering O
p53 O
in O
cardiomyocytes O
) O
and O
their O
non O
- O
transgenic O
( O
non O
- O
txg O
) O
littermates O
received O
weekly O
dox O
injections O
for O
5 O
weeks O
( O
25 O
mg O
/ O
kg O
cumulative O
dose O
) O
. O

one O
week O
after O
the O
last O
dox O
treatment O
( O
acute O
stage O
) O
, O
mhc O
- O
cb7 O
mice O
exhibited O
improved O
cardiac O
function O
and O
lower O
levels O
of O
cardiomyocyte O
apoptosis O
when O
compared O
with O
the O
non O
- O
txg O
mice O
. O

surprisingly O
, O
by O
13 O
weeks O
following O
the O
last O
dox O
treatment O
( O
late O
stage O
) O
, O
mhc O
- O
cb7 O
exhibited O
a O
progressive O
decrease O
in O
cardiac O
function O
and O
higher O
rates O
of O
cardiomyocyte O
apoptosis O
when O
compared O
with O
non O
- O
txg O
mice O
. O

p53 O
inhibition O
blocked O
transient O
dox O
- O
induced O
stat3 O
activation O
in O
mhc O
- O
cb7 O
mice O
, O
which O
was O
associated O
with O
enhanced O
induction O
of O
the O
dna O
repair O
proteins O
ku70 O
and O
ku80 O
. O

mice O
with O
cardiomyocyte O
- O
restricted O
deletion O
of O
stat3 O
exhibited O
worse O
cardiac O
function O
, O
higher O
levels O
of O
cardiomyocyte O
apoptosis O
, O
and O
a O
greater O
induction O
of O
ku70 O
and O
ku80 O
in O
response O
to O
dox O
treatment O
during O
the O
acute O
stage O
when O
compared O
with O
control O
animals O
. O

conclusion O
: O
these O
data O
support O
a O
model O
wherein O
a O
p53 O
- O
dependent O
cardioprotective O
pathway O
, O
mediated O
via O
stat3 O
activation O
, O
mitigates O
dox O
- O
induced O
myocardial O
stress O
during O
drug O
delivery O
. O

furthermore O
, O
these O
data O
suggest O
an O
explanation O
as O
to O
how O
p53 O
inhibition O
can O
result O
in O
cardioprotection O
during O
drug O
treatment O
and O
, O
paradoxically O
, O
enhanced O
cardiotoxicity B-Disease
long O
after O
the O
cessation O
of O
drug O
treatment O
. O

metronidazole O
- O
induced O
encephalopathy B-Disease
: O
an O
uncommon O
scenario O
. O

metronidazole O
can O
produce O
neurological O
complications O
although O
it O
is O
not O
a O
common O
scenario O
. O

we O
present O
a O
case O
where O
a O
patient O
developed O
features O
of O
encephalopathy B-Disease
following O
prolonged O
metronidazole O
intake O
. O

magnetic O
resonance O
imaging O
( O
mri O
) O
brain O
showed O
abnormal O
signal O
intensity O
involving O
both O
dentate O
nuclei O
of O
cerebellum O
and O
splenium O
of O
corpus O
callosum O
. O

the O
diagnosis O
of O
metronidazole O
toxicity B-Disease
was O
made O
by O
the O
mri O
findings O
and O
supported O
clinically O
. O

aconitine O
- O
induced O
ca2 O
+ O
overload O
causes O
arrhythmia B-Disease
and O
triggers O
apoptosis O
through O
p38 O
mapk O
signaling O
pathway O
in O
rats O
. O

aconitine O
is O
a O
major O
bioactive O
diterpenoid O
alkaloid O
with O
high O
content O
derived O
from O
herbal O
aconitum O
plants O
. O

emerging O
evidence O
indicates O
that O
voltage O
- O
dependent O
na O
( O
+ O
) O
channels O
have O
pivotal O
roles O
in O
the O
cardiotoxicity B-Disease
of O
aconitine O
. O

however O
, O
no O
reports O
are O
available O
on O
the O
role O
of O
ca O
( O
2 O
+ O
) O
in O
aconitine O
poisoning B-Disease
. O

in O
this O
study O
, O
we O
explored O
the O
importance O
of O
pathological O
ca O
( O
2 O
+ O
) O
signaling O
in O
aconitine O
poisoning B-Disease
in O
vitro O
and O
in O
vivo O
. O

we O
found O
that O
ca O
( O
2 O
+ O
) O
overload O
lead O
to O
accelerated O
beating O
rhythm O
in O
adult O
rat O
ventricular O
myocytes O
and O
caused O
arrhythmia B-Disease
in O
conscious O
freely O
moving O
rats O
. O

to O
investigate O
effects O
of O
aconitine O
on O
myocardial B-Disease
injury I-Disease
, O
we O
performed O
cytotoxicity B-Disease
assay O
in O
neonatal O
rat O
ventricular O
myocytes O
( O
nrvms O
) O
, O
as O
well O
as O
measured O
lactate O
dehydrogenase O
level O
in O
the O
culture O
medium O
of O
nrvms O
and O
activities O
of O
serum O
cardiac O
enzymes O
in O
rats O
. O

the O
results O
showed O
that O
aconitine O
resulted O
in O
myocardial B-Disease
injury I-Disease
and O
reduced O
nrvms O
viability O
dose O
- O
dependently O
. O

to O
confirm O
the O
pro O
- O
apoptotic O
effects O
, O
we O
performed O
flow O
cytometric O
detection O
, O
cardiac O
histology O
, O
transmission O
electron O
microscopy O
and O
terminal O
deoxynucleotidyl O
transferase O
- O
mediated O
dutp O
- O
biotin O
nick O
end O
labeling O
assay O
. O

the O
results O
showed O
that O
aconitine O
stimulated O
apoptosis O
time O
- O
dependently O
. O

the O
expression O
analysis O
of O
ca O
( O
2 O
+ O
) O
handling O
proteins O
demonstrated O
that O
aconitine O
promoted O
ca O
( O
2 O
+ O
) O
overload O
through O
the O
expression O
regulation O
of O
ca O
( O
2 O
+ O
) O
handling O
proteins O
. O

the O
expression O
analysis O
of O
apoptosis O
- O
related O
proteins O
revealed O
that O
pro O
- O
apoptotic O
protein O
expression O
was O
upregulated O
, O
and O
anti O
- O
apoptotic O
protein O
bcl O
- O
2 O
expression O
was O
downregulated O
. O

furthermore O
, O
increased O
phosphorylation O
of O
mapk O
family O
members O
, O
especially O
the O
p O
- O
p38 O
/ O
p38 O
ratio O
was O
found O
in O
cardiac O
tissues O
. O

hence O
, O
our O
results O
suggest O
that O
aconitine O
significantly O
aggravates O
ca O
( O
2 O
+ O
) O
overload O
and O
causes O
arrhythmia B-Disease
and O
finally O
promotes O
apoptotic O
development O
via O
phosphorylation O
of O
p38 O
mitogen O
- O
activated O
protein O
kinase O
. O

chronic O
treatment O
with O
metformin O
suppresses O
toll O
- O
like O
receptor O
4 O
signaling O
and O
attenuates O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
following O
myocardial B-Disease
infarction I-Disease
. O

acute O
treatment O
with O
metformin O
has O
a O
protective O
effect O
in O
myocardial B-Disease
infarction I-Disease
by O
suppression O
of O
inflammatory O
responses O
due O
to O
activation O
of O
amp O
- O
activated O
protein O
kinase O
( O
ampk O
) O
. O

in O
the O
present O
study O
, O
the O
effect O
of O
chronic O
pre O
- O
treatment O
with O
metformin O
on O
cardiac B-Disease
dysfunction I-Disease
and O
toll O
- O
like O
receptor O
4 O
( O
tlr4 O
) O
activities O
following O
myocardial B-Disease
infarction I-Disease
and O
their O
relation O
with O
ampk O
were O
assessed O
. O

male O
wistar O
rats O
were O
randomly O
assigned O
to O
one O
of O
5 O
groups O
( O
n O
= O
6 O
) O
: O
normal O
control O
and O
groups O
were O
injected O
isoproterenol O
after O
chronic O
pre O
- O
treatment O
with O
0 O
, O
25 O
, O
50 O
, O
or O
100mg O
/ O
kg O
of O
metformin O
twice O
daily O
for O
14 O
days O
. O

isoproterenol O
( O
100mg O
/ O
kg O
) O
was O
injected O
subcutaneously O
on O
the O
13th O
and O
14th O
days O
to O
induce O
acute B-Disease
myocardial I-Disease
infarction I-Disease
. O

isoproterenol O
alone O
decreased O
left O
ventricular O
systolic O
pressure O
and O
myocardial O
contractility O
indexed O
as O
lvdp O
/ O
dtmax O
and O
lvdp O
/ O
dtmin O
. O

the O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
was O
significantly O
lower O
in O
the O
groups O
treated O
with O
25 O
and O
50mg O
/ O
kg O
of O
metformin O
. O

metfromin O
markedly O
lowered O
isoproterenol O
- O
induced O
elevation O
in O
the O
levels O
of O
tlr4 O
mrna O
, O
myeloid O
differentiation O
protein O
88 O
( O
myd88 O
) O
, O
tumor B-Disease
necrosis B-Disease
factor O
- O
alpha O
( O
tnf O
- O
a O
) O
, O
and O
interleukin O
6 O
( O
il O
- O
6 O
) O
in O
the O
heart O
tissues O
. O

similar O
changes O
were O
also O
seen O
in O
the O
serum O
levels O
of O
tnf O
- O
a O
and O
il O
- O
6 O
. O

however O
, O
the O
lower O
doses O
of O
25 O
and O
50mg O
/ O
kg O
were O
more O
effective O
than O
100mg O
/ O
kg O
. O

phosphorylated O
ampka O
( O
p O
- O
ampk O
) O
in O
the O
myocardium O
was O
significantly O
elevated O
by O
25mg O
/ O
kg O
of O
metformin O
, O
slightly O
by O
50mg O
/ O
kg O
, O
but O
not O
by O
100mg O
/ O
kg O
. O

chronic O
pre O
- O
treatment O
with O
metformin O
reduces O
post O
- O
myocardial B-Disease
infarction I-Disease
cardiac O
dysfunction O
and O
suppresses O
inflammatory O
responses O
, O
possibly O
through O
inhibition O
of O
tlr4 O
activities O
. O

this O
mechanism O
can O
be O
considered O
as O
a O
target O
to O
protect O
infarcted O
myocardium O
. O

unusual O
complications O
of O
antithyroid O
drug O
therapy O
: O
four O
case O
reports O
and O
review O
of O
literature O
. O

two O
cases O
of O
propylthiouracil O
- O
associated O
acute O
hepatitis B-Disease
, O
one O
case O
of O
fatal O
methimazole O
- O
associated O
hepatocellular B-Disease
necrosis I-Disease
and O
one O
case O
of O
propylthiouracil O
- O
associated O
lupus B-Disease
- I-Disease
like I-Disease
syndrome I-Disease
are O
described O
. O

the O
literature O
related O
to O
antithyroid O
drug O
side O
effects O
and O
the O
mechanisms O
for O
their O
occurrence O
are O
reviewed O
and O
the O
efficacy O
and O
complications O
of O
thyroidectomy O
and O
radioiodine O
compared O
to O
those O
of O
antithyroid O
drugs O
. O

it O
is O
concluded O
that O
in O
most O
circumstances O
131i O
is O
the O
therapy O
of O
choice O
for O
hyperthyroidism B-Disease
. O

neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
induced O
by O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
in O
a O
japanese O
patient O
with O
huntington B-Disease
' I-Disease
s I-Disease
disease I-Disease
at O
the O
terminal O
stage O
of O
recurrent O
breast B-Disease
cancer I-Disease
. O

we O
herein O
describe O
the O
case O
of O
an O
81 O
- O
year O
- O
old O
japanese O
woman O
with O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
that O
occurred O
36 O
days O
after O
the O
initiation O
of O
combination O
therapy O
with O
tiapride O
( O
75 O
mg O
/ O
day O
) O
and O
tetrabenazine O
( O
12 O
. O
5 O
mg O
/ O
day O
) O
for O
huntington B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

the O
patient O
had O
been O
treated O
with O
tiapride O
or O
tetrabenazine O
alone O
without O
any O
adverse O
effects O
before O
the O
administration O
of O
the O
combination O
therapy O
. O

she O
also O
had O
advanced O
breast B-Disease
cancer I-Disease
when O
the O
combination O
therapy O
was O
initiated O
. O

to O
the O
best O
of O
our O
knowledge O
, O
the O
occurrence O
of O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
due O
to O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
has O
not O
been O
previously O
reported O
. O

tetrabenazine O
should O
be O
administered O
very O
carefully O
in O
combination O
with O
other O
neuroleptic O
drugs O
, O
particularly O
in O
patients O
with O
a O
worsening O
general O
condition O
. O

a O
metoprolol O
- O
terbinafine O
combination O
induced O
bradycardia B-Disease
. O

to O
report O
a O
sinus B-Disease
bradycardia I-Disease
induced O
by O
metoprolol O
and O
terbinafine O
drug O
- O
drug O
interaction O
and O
its O
management O
. O

a O
63 O
year O
- O
old O
caucasian O
man O
on O
metoprolol O
200 O
mg O
/ O
day O
for O
stable O
coronary B-Disease
artery I-Disease
disease I-Disease
was O
prescribed O
a O
90 O
- O
day O
course O
of O
oral O
terbinafine O
250 O
mg O
/ O
day O
for O
onychomycosis B-Disease
. O

on O
the O
49th O
day O
of O
terbinafine O
therapy O
, O
he O
was O
brought O
to O
the O
emergency O
room O
for O
a O
decrease O
of O
his O
global O
health O
status O
, O
confusion B-Disease
and O
falls O
. O

the O
electrocardiogram O
revealed O
a O
37 O
beats O
/ O
min O
sinus B-Disease
bradycardia I-Disease
. O

a O
score O
of O
7 O
on O
the O
naranjo O
adverse B-Disease
drug I-Disease
reaction I-Disease
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
patient O
' O
s O
sinus B-Disease
bradycardia I-Disease
and O
the O
drug O
interaction O
between O
metoprolol O
and O
terbinafine O
. O

the O
heart O
rate O
ameliorated O
first O
with O
a O
decrease O
in O
the O
dose O
of O
metoprolol O
. O

it O
was O
subsequently O
changed O
to O
bisoprolol O
and O
the O
heart O
rate O
remained O
normal O
. O

by O
inhibiting O
the O
cytochrome O
p450 O
2d6 O
, O
terbinafine O
had O
decreased O
metoprolol O
' O
s O
clearance O
, O
leading O
in O
metoprolol O
accumulation O
which O
has O
resulted O
in O
clinically O
significant O
sinus B-Disease
bradycardia I-Disease
. O

optochiasmatic O
and O
peripheral B-Disease
neuropathy I-Disease
due O
to O
ethambutol O
overtreatment O
. O

ethambutol O
is O
known O
to O
cause O
optic B-Disease
neuropathy I-Disease
and O
, O
more O
rarely O
, O
axonal O
polyneuropathy B-Disease
. O

we O
characterize O
the O
clinical O
, O
neurophysiological O
, O
and O
neuroimaging O
findings O
in O
a O
72 O
- O
year O
- O
old O
man O
who O
developed O
visual B-Disease
loss I-Disease
and O
paresthesias B-Disease
after O
11 O
weeks O
of O
exposure O
to O
a O
supratherapeutic O
dose O
of O
ethambutol O
. O

this O
case O
demonstrates O
the O
selective O
vulnerability O
of O
the O
anterior O
visual O
pathways O
and O
peripheral O
nerves O
to O
ethambutol O
toxicity B-Disease
. O

testosterone O
ameliorates O
streptozotocin O
- O
induced O
memory B-Disease
impairment I-Disease
in O
male O
rats O
. O

aim O
: O
to O
study O
the O
effects O
of O
testosterone O
on O
streptozotocin O
( O
stz O
) O
- O
induced O
memory B-Disease
impairment I-Disease
in O
male O
rats O
. O

methods O
: O
adult O
male O
wistar O
rats O
were O
intracerebroventricularly O
( O
icv O
) O
infused O
with O
stz O
( O
750 O
ug O
) O
on O
d O
1 O
and O
d O
3 O
, O
and O
a O
passive O
avoidance O
task O
was O
assessed O
2 O
weeks O
after O
the O
first O
injection O
of O
stz O
. O

castration O
surgery O
was O
performed O
in O
another O
group O
of O
rats O
, O
and O
the O
passive O
avoidance O
task O
was O
assessed O
4 O
weeks O
after O
the O
operation O
. O

testosterone O
( O
1 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
sc O
) O
, O
the O
androgen O
receptor O
antagonist O
flutamide O
( O
10 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
ip O
) O
, O
the O
estrogen O
receptor O
antagonist O
tamoxifen O
( O
1 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
ip O
) O
or O
the O
aromatase O
inhibitor O
letrozole O
( O
4 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
ip O
) O
were O
administered O
for O
6 O
d O
after O
the O
first O
injection O
of O
stz O

. O

results O
: O
stz O
administration O
and O
castration O
markedly O
decreased O
both O
stl1 O
( O
the O
short O
memory O
) O
and O
stl2 O
( O
the O
long O
memory O
) O
in O
passive O
avoidance O
tests O
. O

testosterone O
replacement O
almost O
restored O
the O
stl1 O
and O
stl2 O
in O
castrated O
rats O
, O
and O
significantly O
prolonged O
the O
stl1 O
and O
stl2 O
in O
stz O
- O
treated O
rats O
. O

administration O
of O
flutamide O
, O
letrozole O
or O
tamoxifen O
significantly O
impaired B-Disease
the I-Disease
memory I-Disease
in O
intact O
rats O
, O
and O
significantly O
attenuated O
the O
testosterone O
replacement O
in O
improving O
stz O
- O
and O
castration O
- O
induced O
memory B-Disease
impairment I-Disease
. O

conclusion O
: O
testosterone O
administration O
ameliorates O
stz O
- O
and O
castration O
- O
induced O
memory B-Disease
impairment I-Disease
in O
male O
wistar O
rats O
. O

behavioral O
and O
neurochemical O
studies O
in O
mice O
pretreated O
with O
garcinielliptone O
fc O
in O
pilocarpine O
- O
induced O
seizures B-Disease
. O

garcinielliptone O
fc O
( O
gfc O
) O
isolated O
from O
hexanic O
fraction O
seed O
extract O
of O
species O
platonia O
insignis O
mart O
. O

it O
is O
widely O
used O
in O
folk O
medicine O
to O
treat O
skin B-Disease
diseases I-Disease
in O
both O
humans O
and O
animals O
as O
well O
as O
the O
seed O
decoction O
has O
been O
used O
to O
treat O
diarrheas B-Disease
and O
inflammatory B-Disease
diseases I-Disease
. O

however O
, O
there O
is O
no O
research O
on O
gfc O
effects O
in O
the O
central O
nervous O
system O
of O
rodents O
. O

the O
present O
study O
aimed O
to O
evaluate O
the O
gfc O
effects O
at O
doses O
of O
25 O
, O
50 O
or O
75 O
mg O
/ O
kg O
on O
seizure B-Disease
parameters O
to O
determine O
their O
anticonvulsant O
activity O
and O
its O
effects O
on O
amino O
acid O
( O
r O
- O
aminobutyric O
acid O
( O
gaba O
) O
, O
glutamine O
, O
aspartate O
and O
glutathione O
) O
levels O
as O
well O
as O
on O
acetylcholinesterase O
( O
ache O
) O
activity O
in O
mice O
hippocampus O
after O
seizures B-Disease
. O

gfc O
produced O
an O
increased O
latency O
to O
first O
seizure B-Disease
, O
at O
doses O
25mg O
/ O
kg O
( O
20 O
. O
12 O
+ O
2 O
. O
20 O
min O
) O
, O
50mg O
/ O
kg O
( O
20 O
. O
95 O
+ O
2 O
. O
21 O
min O
) O
or O
75 O
mg O
/ O
kg O
( O
23 O
. O
43 O
+ O
1 O
. O
99 O
min O
) O
when O
compared O
with O
seized O
mice O
. O

in O
addition O
, O
gaba O
content O
of O
mice O
hippocampus O
treated O
with O
gfc75 O
plus O
p400 O
showed O
an O
increase O
of O
46 O
. O
90 O
% O
when O
compared O
with O
seized O
mice O
. O

in O
aspartate O
, O
glutamine O
and O
glutamate O
levels O
detected O
a O
decrease O
of O
5 O
. O
21 O
% O
, O
13 O
. O
55 O
% O
and O
21 O
. O
80 O
% O
, O
respectively O
in O
mice O
hippocampus O
treated O
with O
gfc75 O
plus O
p400 O
when O
compared O
with O
seized O
mice O
. O

hippocampus O
mice O
treated O
with O
gfc75 O
plus O
p400 O
showed O
an O
increase O
in O
ache O
activity O
( O
63 O
. O
30 O
% O
) O
when O
compared O
with O
seized O
mice O
. O

the O
results O
indicate O
that O
gfc O
can O
exert O
anticonvulsant O
activity O
and O
reduce O
the O
frequency O
of O
installation O
of O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
, O
as O
demonstrated O
by O
increase O
in O
latency O
to O
first O
seizure B-Disease
and O
decrease O
in O
mortality O
rate O
of O
animals O
. O

in O
conclusion O
, O
our O
data O
suggest O
that O
gfc O
may O
influence O
in O
epileptogenesis O
and O
promote O
anticonvulsant O
actions O
in O
pilocarpine O
model O
by O
modulating O
the O
gaba O
and O
glutamate O
contents O
and O
of O
ache O
activity O
in O
seized O
mice O
hippocampus O
. O

this O
compound O
may O
be O
useful O
to O
produce O
neuronal O
protection O
and O
it O
can O
be O
considered O
as O
an O
anticonvulsant O
agent O
. O

standard O
operating O
procedures O
for O
antibiotic O
therapy O
and O
the O
occurrence O
of O
acute B-Disease
kidney I-Disease
injury I-Disease
: O
a O
prospective O
, O
clinical O
, O
non O
- O
interventional O
, O
observational O
study O
. O

introduction O
: O
acute B-Disease
kidney I-Disease
injury I-Disease
( O
aki B-Disease
) O
occurs O
in O
7 O
% O
of O
hospitalized O
and O
66 O
% O
of O
intensive O
care O
unit O
( O
icu O
) O
patients O
. O

it O
increases O
mortality O
, O
hospital O
length O
of O
stay O
, O
and O
costs O
. O

the O
aim O
of O
this O
study O
was O
to O
investigate O
, O
whether O
there O
is O
an O
association O
between O
adherence O
to O
guidelines O
( O
standard O
operating O
procedures O
( O
sop O
) O
) O
for O
potentially O
nephrotoxic B-Disease
antibiotics O
and O
the O
occurrence O
of O
aki B-Disease
. O

methods O
: O
this O
study O
was O
carried O
out O
as O
a O
prospective O
, O
clinical O
, O
non O
- O
interventional O
, O
observational O
study O
. O

data O
collection O
was O
performed O
over O
a O
total O
of O
170 O
days O
in O
three O
icus O
at O
charite O
- O
universitaetsmedizin O
berlin O
. O

a O
total O
of O
675 O
patients O
were O
included O
; O
163 O
of O
these O
had O
therapy O
with O
vancomycin O
, O
gentamicin O
, O
or O
tobramycin O
; O
were O
> O
18 O
years O
; O
and O
treated O
in O
the O
icu O
for O
> O
24 O
hours O
. O

patients O
with O
an O
adherence O
to O
sop O
> O
70 O
% O
were O
classified O
into O
the O
high O
adherence O
group O
( O
hag O
) O
and O
patients O
with O
an O
adherence O
of O
< O
70 O
% O
into O
the O
low O
adherence O
group O
( O
lag O
) O
. O

aki B-Disease
was O
defined O
according O
to O
rifle O
criteria O
. O

adherence O
to O
sops O
was O
evaluated O
by O
retrospective O
expert O
audit O
. O

development O
of O
aki B-Disease
was O
compared O
between O
groups O
with O
exact O
chi2 O
- O
test O
and O
multivariate O
logistic O
regression O
analysis O
( O
two O
- O
sided O
p O
< O
0 O
. O
05 O
) O
. O

results O
: O
lag O
consisted O
of O
75 O
patients O
( O
46 O
% O
) O
versus O
88 O
hag O
patients O
( O
54 O
% O
) O
. O

aki B-Disease
occurred O
significantly O
more O
often O
in O
lag O
with O
36 O
% O
versus O
21 O
% O
in O
hag O
( O
p O
= O
0 O
. O
035 O
) O
. O

basic O
characteristics O
were O
comparable O
, O
except O
an O
increased O
rate O
of O
soft O
tissue O
infections B-Disease
in O
lag O
. O

multivariate O
analysis O
revealed O
an O
odds O
ratio O
of O
2 O
. O
5 O
- O
fold O
for O
lag O
to O
develop O
aki B-Disease
compared O
with O
hag O
( O
95 O
% O
confidence O
interval O
1 O
. O
195 O
to O
5 O
. O
124 O
, O
p O
= O
0 O
. O
039 O
) O
. O

conclusion O
: O
low O
adherence O
to O
sops O
for O
potentially O
nephrotoxic B-Disease
antibiotics O
was O
associated O
with O
a O
higher O
occurrence O
of O
aki B-Disease
. O

trial O
registration O
: O
current O
controlled O
trials O
isrctn54598675 O
. O

registered O
17 O
august O
2007 O
. O

rhabdomyolysis B-Disease
in O
a O
hepatitis B-Disease
c I-Disease
virus I-Disease
infected I-Disease
patient O
treated O
with O
telaprevir O
and O
simvastatin O
. O

a O
46 O
- O
year O
old O
man O
with O
a O
chronic O
hepatitis B-Disease
c I-Disease
virus I-Disease
infection I-Disease
received O
triple O
therapy O
with O
ribavirin O
, O
pegylated O
interferon O
and O
telaprevir O
. O

the O
patient O
also O
received O
simvastatin O
. O

one O
month O
after O
starting O
the O
antiviral O
therapy O
, O
the O
patient O
was O
admitted O
to O
the O
hospital O
because O
he O
developed O
rhabdomyolysis B-Disease
. O

at O
admission O
simvastatin O
and O
all O
antiviral O
drugs O
were O
discontinued O
because O
toxicity B-Disease
due O
to O
a O
drug O
- O
drug O
interaction O
was O
suspected O
. O

the O
creatine O
kinase O
peaked O
at O
62 O
, O
246 O
iu O
/ O
l O
and O
the O
patient O
was O
treated O
with O
intravenous O
normal O
saline O
. O

the O
patient O
' O
s O
renal O
function O
remained O
unaffected O
. O

fourteen O
days O
after O
hospitalization O
, O
creatine O
kinase O
level O
had O
returned O
to O
230 O
iu O
/ O
l O
and O
the O
patient O
was O
discharged O
. O

telaprevir O
was O
considered O
the O
probable O
causative O
agent O
of O
an O
interaction O
with O
simvastatin O
according O
to O
the O
drug O
interaction O
probability O
scale O
. O

the O
interaction O
is O
due O
to O
inhibition O
of O
cyp3a4 O
- O
mediated O
simvastatin O
clearance O
. O

simvastatin O
plasma O
concentration O
increased O
30 O
times O
in O
this O
patient O
and O
statin O
induced O
muscle B-Disease
toxicity I-Disease
is O
related O
to O
the O
concentration O
of O
the O
statin O
in O
blood O
. O

in O
conclusion O
, O
with O
this O
case O
we O
illustrate O
that O
telaprevir O
as O
well O
as O
statins O
are O
susceptible O
to O
clinical O
relevant O
drug O
- O
drug O
interactions O
. O

combination O
of O
bortezomib O
, O
thalidomide O
, O
and O
dexamethasone O
( O
vtd O
) O
as O
a O
consolidation O
therapy O
after O
autologous O
stem O
cell O
transplantation O
for O
symptomatic O
multiple B-Disease
myeloma I-Disease
in O
japanese O
patients O
. O

consolidation O
therapy O
for O
patients O
with O
multiple B-Disease
myeloma I-Disease
( O
mm B-Disease
) O
has O
been O
widely O
adopted O
to O
improve O
treatment O
response O
following O
autologous O
stem O
cell O
transplantation O
. O

in O
this O
study O
, O
we O
retrospectively O
analyzed O
the O
safety O
and O
efficacy O
of O
combination O
regimen O
of O
bortezomib O
, O
thalidomide O
, O
and O
dexamethasone O
( O
vtd O
) O
as O
consolidation O
therapy O
in O
24 O
japanese O
patients O
with O
newly O
diagnosed O
mm B-Disease
. O

vtd O
consisted O
of O
bortezomib O
at O
a O
dose O
of O
1 O
. O
3 O
mg O
/ O
m O
( O
2 O
) O
and O
dexamethasone O
at O
a O
dose O
of O
40 O
mg O
/ O
day O
on O
days O
1 O
, O
8 O
, O
15 O
, O
and O
22 O
of O
a O
35 O
- O
day O
cycle O
, O
with O
daily O
oral O
thalidomide O
at O
a O
dose O
of O
100 O
mg O
/ O
day O
. O

grade O
3 O
- O
4 O
neutropenia B-Disease
and O
thrombocytopenia B-Disease
were O
documented O
in O
four O
and O
three O
patients O
( O
17 O
and O
13 O
% O
) O
, O
respectively O
, O
but O
drug O
dose O
reduction O
due O
to O
cytopenia B-Disease
was O
not O
required O
in O
any O
case O
. O

peripheral B-Disease
neuropathy I-Disease
was O
common O
( O
63 O
% O
) O
, O
but O
severe O
grade O
3 O
- O
4 O
peripheral B-Disease
neuropathy I-Disease
was O
not O
observed O
. O

very O
good O
partial O
response O
or O
better O
response O
( O
> O
vgpr O
) O
rates O
before O
and O
after O
consolidation O
therapy O
were O
54 O
and O
79 O
% O
, O
respectively O
. O

patients O
had O
a O
significant O
probability O
of O
improving O
from O
< O
vgpr O
before O
consolidation O
therapy O
to O
> O
vgpr O
after O
consolidation O
therapy O
( O
p O
= O
0 O
. O
041 O
) O
. O

the O
vtd O
regimen O
may O
be O
safe O
and O
effective O
as O
a O
consolidation O
therapy O
in O
the O
treatment O
of O
mm O
in O
japanese O
population O
. O

conversion O
to O
sirolimus O
ameliorates O
cyclosporine O
- O
induced O
nephropathy B-Disease
in O
the O
rat O
: O
focus O
on O
serum O
, O
urine O
, O
gene O
, O
and O
protein O
renal O
expression O
biomarkers O
. O

protocols O
of O
conversion O
from O
cyclosporin O
a O
( O
csa O
) O
to O
sirolimus O
( O
srl O
) O
have O
been O
widely O
used O
in O
immunotherapy O
after O
transplantation O
to O
prevent O
csa O
- O
induced O
nephropathy B-Disease
, O
but O
the O
molecular O
mechanisms O
underlying O
these O
protocols O
remain O
nuclear O
. O

this O
study O
aimed O
to O
identify O
the O
molecular O
pathways O
and O
putative O
biomarkers O
of O
csa O
- O
to O
- O
srl O
conversion O
in O
a O
rat O
model O
. O

four O
animal O
groups O
( O
n O
= O
6 O
) O
were O
tested O
during O
9 O
weeks O
: O
control O
, O
csa O
, O
srl O
, O
and O
conversion O
( O
csa O
for O
3 O
weeks O
followed O
by O
srl O
for O
6 O
weeks O
) O
. O

classical O
and O
emergent O
serum O
, O
urinary O
, O
and O
kidney O
tissue O
( O
gene O
and O
protein O
expression O
) O
markers O
were O
assessed O
. O

renal B-Disease
lesions I-Disease
were O
analyzed O
in O
hematoxylin O
and O
eosin O
, O
periodic O
acid O
- O
schiff O
, O
and O
masson O
' O
s O
trichrome O
stains O
. O

srl O
- O
treated O
rats O
presented O
proteinuria B-Disease
and O
ngal O
( O
serum O
and O
urinary O
) O
as O
the O
best O
markers O
of O
renal B-Disease
impairment I-Disease
. O

short O
csa O
treatment O
presented O
slight O
or O
even O
absent O
kidney B-Disease
lesions I-Disease
and O
tgf O
- O
b O
, O
nf O
- O
kb O
, O
mtor O
, O
pcna O
, O
tp53 O
, O
kim O
- O
1 O
, O
and O
ctgf O
as O
relevant O
gene O
and O
protein O
changes O
. O

prolonged O
csa O
exposure O
aggravated O
renal B-Disease
damage I-Disease
, O
without O
clear O
changes O
on O
the O
traditional O
markers O
, O
but O
with O
changes O
in O
serums O
tgf O
- O
b O
and O
il O
- O
7 O
, O
tbars O
clearance O
, O
and O
kidney O
tgf O
- O
b O
and O
mtor O
. O

conversion O
to O
srl O
prevented O
csa O
- O
induced O
renal B-Disease
damage I-Disease
evolution O
( O
absent O
/ O
mild O
grade O
lesions O
) O
, O
while O
ngal O
( O
serum O
versus O
urine O
) O
seems O
to O
be O
a O
feasible O
biomarker O
of O
csa O
replacement O
to O
srl O
. O

kinin O
b2 O
receptor O
deletion O
and O
blockage O
ameliorates O
cisplatin O
- O
induced O
acute B-Disease
renal I-Disease
injury I-Disease
. O

cisplatin O
treatment O
has O
been O
adopted O
in O
some O
chemotherapies O
; O
however O
, O
this O
drug O
can O
induce O
acute B-Disease
kidney I-Disease
injury I-Disease
due O
its O
ability O
to O
negatively O
affect O
renal O
function O
, O
augment O
serum O
levels O
of O
creatinine O
and O
urea O
, O
increase O
the O
acute B-Disease
tubular I-Disease
necrosis I-Disease
score O
and O
up O
- O
regulate O
cytokines O
( O
e O
. O
g O
. O
, O
il O
- O
1b O
and O
tnf O
- O
a O
) O
. O

the O
kinin O
b2 O
receptor O
has O
been O
associated O
with O
the O
inflammation B-Disease
process O
, O
as O
well O
as O
the O
regulation O
of O
cytokine O
expression O
, O
and O
its O
deletion O
resulted O
in O
an O
improvement O
in O
the O
diabetic B-Disease
nephropathy I-Disease
status O
. O

to O
examine O
the O
role O
of O
the O
kinin O
b2 O
receptor O
in O
cisplatin O
- O
induced O
acute B-Disease
kidney I-Disease
injury I-Disease
, O
kinin O
b2 O
receptor O
knockout O
mice O
were O
challenged O
with O
cisplatin O
. O

additionally O
, O
wt O
mice O
were O
treated O
with O
a O
b2 O
receptor O
antagonist O
after O
cisplatin O
administration O
. O

b2 O
receptor O
- O
deficient O
mice O
were O
less O
sensitive O
to O
this O
drug O
than O
the O
wt O
mice O
, O
as O
shown O
by O
reduced O
weight B-Disease
loss I-Disease
, O
better O
preservation O
of O
kidney O
function O
, O
down O
regulation O
of O
inflammatory O
cytokines O
and O
less O
acute B-Disease
tubular I-Disease
necrosis I-Disease
. O

moreover O
, O
treatment O
with O
the O
kinin O
b2 O
receptor O
antagonist O
effectively O
reduced O
the O
levels O
of O
serum O
creatinine O
and O
blood O
urea O
after O
cisplatin O
administration O
. O

thus O
, O
our O
data O
suggest O
that O
the O
kinin O
b2 O
receptor O
is O
involved O
in O
cisplatin O
- O
induced O
acute B-Disease
kidney I-Disease
injury I-Disease
by O
mediating O
the O
necrotic B-Disease
process O
and O
the O
expression O
of O
inflammatory O
cytokines O
, O
thus O
resulting O
in O
declined O
renal O
function O
. O

these O
results O
highlight O
the O
kinin O
b2 O
receptor O
antagonist O
treatment O
in O
amelioration O
of O
nephrotoxicity B-Disease
induced O
by O
cisplatin O
therapy O
. O

safety O
and O
efficacy O
of O
fluocinolone O
acetonide O
intravitreal O
implant O
( O
0 O
. O
59 O
mg O
) O
in O
birdshot B-Disease
retinochoroidopathy I-Disease
. O

purpose O
: O
to O
report O
the O
treatment O
outcomes O
of O
the O
fluocinolone O
acetonide O
intravitreal O
implant O
( O
0 O
. O
59 O
mg O
) O
in O
patients O
with O
birdshot B-Disease
retinochoroidopathy I-Disease
whose O
disease O
is O
refractory O
or O
intolerant O
to O
conventional O
immunomodulatory O
therapy O
. O

methods O
: O
a O
retrospective O
case O
series O
involving O
11 O
birdshot B-Disease
retinochoroidopathy I-Disease
patients O
( O
11 O
eyes O
) O
. O

eleven O
patients O
( O
11 O
eyes O
) O
underwent O
surgery O
for O
fluocinolone O
acetonide O
implant O
( O
0 O
. O
59 O
mg O
) O
. O

treatment O
outcomes O
of O
interest O
were O
noted O
at O
baseline O
, O
before O
fluocinolone O
acetonide O
implant O
, O
and O
then O
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
3 O
years O
, O
and O
beyond O
3 O
years O
. O

disease O
activity O
markers O
, O
including O
signs O
of O
ocular O
inflammation B-Disease
, O
evidence O
of O
retinal B-Disease
vasculitis I-Disease
, O
swedish O
interactive O
threshold O
algorithm O
- O
short O
wavelength O
automated O
perimetry O
humphrey O
visual O
field O
analysis O
, O
electroretinographic O
parameters O
, O
and O
optical O
coherence O
tomography O
were O
recorded O
. O

data O
on O
occurrence O
of O
cataract B-Disease
and O
raised B-Disease
intraocular I-Disease
pressure I-Disease
were O
collected O
in O
all O
eyes O
. O

results O
: O
intraocular O
inflammation B-Disease
was O
present O
in O
54 O
. O
5 O
, O
9 O
. O
9 O
, O
11 O
. O
1 O
, O
and O
0 O
% O
of O
patients O
at O
baseline O
, O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
3 O
years O
, O
and O
beyond O
3 O
years O
after O
receiving O
the O
implant O
, O
respectively O
. O

active O
vasculitis B-Disease
was O
noted O
in O
36 O
. O
3 O
% O
patients O
at O
baseline O
and O
0 O
% O
at O
3 O
years O
of O
follow O
- O
up O
. O

more O
than O
20 O
% O
( O
47 O
. O
61 O
- O
67 O
. O
2 O
% O
) O
reduction O
in O
central O
retinal O
thickness O
was O
noted O
in O
all O
patients O
with O
cystoid B-Disease
macular I-Disease
edema I-Disease
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
and O
3 O
years O
postimplant O
. O

at O
baseline O
, O
54 O
. O
5 O
% O
patients O
were O
on O
immunomodulatory O
agents O
. O

this O
percentage O
decreased O
to O
45 O
. O
45 O
, O
44 O
. O
4 O
, O
and O
14 O
. O
28 O
% O
at O
1 O
year O
, O
2 O
years O
, O
and O
3 O
years O
postimplant O
, O
respectively O
. O

adverse O
events O
included O
increased B-Disease
intraocular I-Disease
pressure I-Disease
( O
54 O
. O
5 O
% O
) O
and O
cataract B-Disease
formation O
( O
100 O
% O
) O
. O

conclusion O
: O
the O
data O
suggest O
that O
fluocinolone O
acetonide O
implant O
( O
0 O
. O
59 O
mg O
) O
helps O
to O
control O
inflammation B-Disease
in O
otherwise O
treatment O
- O
refractory O
cases O
of O
birdshot B-Disease
retinochoroidopathy I-Disease
. O

it O
is O
associated O
with O
significant O
side O
effects O
of O
cataract B-Disease
and O
ocular B-Disease
hypertension I-Disease
requiring O
treatment O
. O

optimal O
precurarizing O
dose O
of O
rocuronium O
to O
decrease O
fasciculation B-Disease
and O
myalgia B-Disease
following O
succinylcholine O
administration O
. O

background O
: O
succinylcholine O
commonly O
produces O
frequent O
adverse O
effects O
, O
including O
muscle B-Disease
fasciculation I-Disease
and O
myalgia B-Disease
. O

the O
current O
study O
identified O
the O
optimal O
dose O
of O
rocuronium O
to O
prevent O
succinylcholine O
- O
induced O
fasciculation B-Disease
and O
myalgia B-Disease
and O
evaluated O
the O
influence O
of O
rocuronium O
on O
the O
speed O
of O
onset O
produced O
by O
succinylcholine O
. O

methods O
: O
this O
randomized O
, O
double O
- O
blinded O
study O
was O
conducted O
in O
100 O
patients O
randomly O
allocated O
into O
five O
groups O
of O
20 O
patients O
each O
. O

patients O
were O
randomized O
to O
receive O
0 O
. O
02 O
, O
0 O
. O
03 O
, O
0 O
. O
04 O
, O
0 O
. O
05 O
and O
0 O
. O
06 O
mg O
/ O
kg O
rocuronium O
as O
a O
precurarizing O
dose O
. O

neuromuscular O
monitoring O
after O
each O
precurarizing O
dose O
was O
recorded O
from O
the O
adductor O
pollicis O
muscle O
using O
acceleromyography O
with O
train O
- O
of O
- O
four O
stimulation O
of O
the O
ulnar O
nerve O
. O

all O
patients O
received O
succinylcholine O
1 O
. O
5 O
mg O
/ O
kg O
at O
2 O
minutes O
after O
the O
precurarization O
, O
and O
were O
assessed O
the O
incidence O
and O
severity O
of O
fasciculations B-Disease
, O
while O
myalgia B-Disease
was O
assessed O
at O
24 O
hours O
after O
surgery O
. O

results O
: O
the O
incidence O
and O
severity O
of O
visible O
muscle B-Disease
fasciculation I-Disease
was O
significantly O
less O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
( O
p O
< O
0 O
. O
001 O
) O
. O

those O
of O
myalgia B-Disease
tend O
to O
decrease O
according O
to O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
, O
but O
there O
was O
no O
significance O
( O
p O
= O
0 O
. O
072 O
) O
. O

the O
onset O
time O
of O
succinylcholine O
was O
significantly O
longer O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
( O
p O
< O
0 O
. O
001 O
) O
. O

conclusions O
: O
precurarization O
with O
0 O
. O
04 O
mg O
/ O
kg O
rocuronium O
was O
the O
optimal O
dose O
considering O
the O
reduction O
in O
the O
incidence O
and O
severity O
of O
fasciculation B-Disease
and O
myalgia B-Disease
with O
acceptable O
onset O
time O
, O
and O
the O
safe O
and O
effective O
precurarization O
. O

absence O
of O
pkc O
- O
alpha O
attenuates O
lithium O
- O
induced O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
. O

lithium O
, O
an O
effective O
antipsychotic O
, O
induces O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
( O
ndi B-Disease
) O
in O
40 O
% O
of O
patients O
. O

the O
decreased O
capacity O
to O
concentrate O
urine O
is O
likely O
due O
to O
lithium O
acutely O
disrupting O
the O
camp O
pathway O
and O
chronically O
reducing O
urea O
transporter O
( O
ut O
- O
a1 O
) O
and O
water O
channel O
( O
aqp2 O
) O
expression O
in O
the O
inner O
medulla O
. O

targeting O
an O
alternative O
signaling O
pathway O
, O
such O
as O
pkc O
- O
mediated O
signaling O
, O
may O
be O
an O
effective O
method O
of O
treating O
lithium O
- O
induced O
polyuria B-Disease
. O

pkc O
- O
alpha O
null O
mice O
( O
pkca O
ko O
) O
and O
strain O
- O
matched O
wild O
type O
( O
wt O
) O
controls O
were O
treated O
with O
lithium O
for O
0 O
, O
3 O
or O
5 O
days O
. O

wt O
mice O
had O
increased O
urine O
output O
and O
lowered O
urine O
osmolality O
after O
3 O
and O
5 O
days O
of O
treatment O
whereas O
pkca O
ko O
mice O
had O
no O
change O
in O
urine O
output O
or O
concentration O
. O

western O
blot O
analysis O
revealed O
that O
aqp2 O
expression O
in O
medullary O
tissues O
was O
lowered O
after O
3 O
and O
5 O
days O
in O
wt O
mice O
; O
however O
, O
aqp2 O
was O
unchanged O
in O
pkca O
ko O
. O

similar O
results O
were O
observed O
with O
ut O
- O
a1 O
expression O
. O

animals O
were O
also O
treated O
with O
lithium O
for O
6 O
weeks O
. O

lithium O
- O
treated O
wt O
mice O
had O
19 O
- O
fold O
increased O
urine O
output O
whereas O
treated O
pkca O
ko O
animals O
had O
a O
4 O
- O
fold O
increase O
in O
output O
. O

aqp2 O
and O
ut O
- O
a1 O
expression O
was O
lowered O
in O
6 O
week O
lithium O
- O
treated O
wt O
animals O
whereas O
in O
treated O
pkca O
ko O
mice O
, O
aqp2 O
was O
only O
reduced O
by O
2 O
- O
fold O
and O
ut O
- O
a1 O
expression O
was O
unaffected O
. O

urinary O
sodium O
, O
potassium O
and O
calcium O
were O
elevated O
in O
lithium O
- O
fed O
wt O
but O
not O
in O
lithium O
- O
fed O
pkca O
ko O
mice O
. O

our O
data O
show O
that O
ablation O
of O
pkca O
preserves O
aqp2 O
and O
ut O
- O
a1 O
protein O
expression O
and O
localization O
in O
lithium O
- O
induced O
ndi B-Disease
, O
and O
prevents O
the O
development O
of O
the O
severe O
polyuria B-Disease
associated O
with O
lithium O
therapy O
. O

is O
dysguesia B-Disease
going O
to O
be O
a O
rare O
or O
a O
common O
side O
- O
effect O
of O
amlodipine O
? O

a O
very O
rare O
side O
- O
effect O
of O
amlodipine O
is O
dysguesia B-Disease
. O

a O
review O
of O
the O
literature O
produced O
only O
one O
case O
. O

we O
report O
a O
case O
about O
a O
female O
with O
essential O
hypertension B-Disease
on O
drug O
treatment O
with O
amlodipine O
developed O
loss B-Disease
of I-Disease
taste I-Disease
sensation I-Disease
. O

condition O
moderately O
improved O
on O
stoppage O
of O
the O
drug O
for O
25 O
days O
. O

we O
conclude O
that O
amlodipine O
can O
cause O
dysguesia B-Disease
. O

here O
, O
we O
describe O
the O
clinical O
presentation O
and O
review O
the O
relevant O
literature O
on O
amlodipine O
and O
dysguesia B-Disease
. O

rhabdomyolysis B-Disease
in O
association O
with O
simvastatin O
and O
dosage O
increment O
in O
clarithromycin O
. O

clarithromycin O
is O
the O
most O
documented O
cytochrome O
p450 O
3a4 O
( O
cyp3a4 O
) O
inhibitor O
to O
cause O
an O
adverse O
interaction O
with O
simvastatin O
. O

this O
particular O
case O
is O
of O
interest O
as O
rhabdomyolysis B-Disease
only O
occurred O
after O
an O
increase O
in O
the O
dose O
of O
clarithromycin O
. O

the O
patient O
developed O
raised O
cardiac O
biomarkers O
without O
any O
obvious O
cardiac O
issues O
, O
a O
phenomenon O
that O
has O
been O
linked O
to O
rhabdomyolysis B-Disease
previously O
. O

to O
date O
, O
there O
has O
been O
no O
reported O
effect O
of O
rhabdomyolysis B-Disease
on O
the O
structure O
and O
function O
of O
cardiac O
muscle O
. O

clinicians O
need O
to O
be O
aware O
of O
prescribing O
concomitant O
medications O
that O
increase O
the O
risk O
of O
myopathy B-Disease
or O
inhibit O
the O
cyp3a4 O
enzyme O
. O

our O
case O
suggests O
that O
troponin O
elevation O
could O
be O
associated O
with O
statin O
induced O
rhabdomyolysis B-Disease
, O
which O
may O
warrant O
further O
studies O
. O

characterization O
of O
a O
novel O
bche O
" O
silent O
" O
allele O
: O
point O
mutation O
( O
p O
. O
val204asp O
) O
causes O
loss O
of O
activity O
and O
prolonged O
apnea B-Disease
with O
suxamethonium O
. O

butyrylcholinesterase B-Disease
deficiency I-Disease
is O
characterized O
by O
prolonged O
apnea B-Disease
after O
the O
use O
of O
muscle O
relaxants O
( O
suxamethonium O
or O
mivacurium O
) O
in O
patients O
who O
have O
mutations O
in O
the O
bche O
gene O
. O

here O
, O
we O
report O
a O
case O
of O
prolonged O
neuromuscular O
block O
after O
administration O
of O
suxamethonium O
leading O
to O
the O
discovery O
of O
a O
novel O
bche O
variant O
( O
c O
. O
695t O
> O
a O
, O
p O
. O
val204asp O
) O
. O

inhibition O
studies O
, O
kinetic O
analysis O
and O
molecular O
dynamics O
were O
undertaken O
to O
understand O
how O
this O
mutation O
disrupts O
the O
catalytic O
triad O
and O
determines O
a O
" O
silent O
" O
phenotype O
. O

low O
activity O
of O
patient O
plasma O
butyrylcholinesterase O
with O
butyrylthiocholine O
( O
btc O
) O
and O
benzoylcholine O
, O
and O
values O
of O
dibucaine O
and O
fluoride O
numbers O
fit O
with O
heterozygous O
atypical O
silent O
genotype O
. O

electrophoretic O
analysis O
of O
plasma O
bche O
of O
the O
proband O
and O
his O
mother O
showed O
that O
patient O
has O
a O
reduced O
amount O
of O
tetrameric O
enzyme O
in O
plasma O
and O
that O
minor O
fast O
- O
moving O
bche O
components O
: O
monomer O
, O
dimer O
, O
and O
monomer O
- O
albumin O
conjugate O
are O
missing O
. O

kinetic O
analysis O
showed O
that O
the O
p O
. O
val204asp O
/ O
p O
. O
asp70gly O
- O
p O
. O
ala539thr O
bche O
displays O
a O
pure O
michaelian O
behavior O
with O
btc O
as O
the O
substrate O
. O

both O
catalytic O
parameters O
km O
= O
265 O
um O
for O
btc O
, O
two O
times O
higher O
than O
that O
of O
the O
atypical O
enzyme O
, O
and O
a O
low O
vmax O
are O
consistent O
with O
the O
absence O
of O
activity O
against O
suxamethonium O
. O

molecular O
dynamic O
( O
md O
) O
simulations O
showed O
that O
the O
overall O
effect O
of O
the O
mutation O
p O
. O
val204asp O
is O
disruption O
of O
hydrogen O
bonding O
between O
gln223 O
and O
glu441 O
, O
leading O
ser198 O
and O
his438 O
to O
move O
away O
from O
each O
other O
with O
subsequent O
disruption O
of O
the O
catalytic O
triad O
functionality O
regardless O
of O
the O
type O
of O
substrate O
. O

md O
also O
showed O
that O
the O
enzyme O
volume O
is O
increased O
, O
suggesting O
a O
pre O
- O
denaturation O
state O
. O

this O
fits O
with O
the O
reduced O
concentration O
of O
p O
. O
ala204asp O
/ O
p O
. O
asp70gly O
- O
p O
. O
ala539thr O
tetrameric O
enzyme O
in O
the O
plasma O
and O
non O
- O
detectable O
fast O
moving O
- O
bands O
on O
electrophoresis O
gels O
. O

delayed O
anemia B-Disease
after O
treatment O
with O
injectable O
artesunate O
in O
the O
democratic O
republic O
of O
the O
congo O
: O
a O
manageable O
issue O
. O

cases O
of O
delayed O
hemolytic B-Disease
anemia I-Disease
have O
been O
described O
after O
treatment O
with O
injectable O
artesunate O
, O
the O
current O
world O
health O
organization O
( O
who O
) O
- O
recommended O
first O
- O
line O
drug O
for O
the O
treatment O
of O
severe O
malaria B-Disease
. O

a O
total O
of O
350 O
patients O
( O
215 O
[ O
61 O
. O
4 O
% O
] O
< O
5 O
years O
of O
age O
and O
135 O
[ O
38 O
. O
6 O
% O
] O
> O
5 O
years O
of O
age O
) O
were O
followed O
- O
up O
after O
treatment O
with O
injectable O
artesunate O
for O
severe O
malaria B-Disease
in O
hospitals O
and O
health O
centers O
of O
the O
democratic O
republic O
of O
the O
congo O
. O

complete O
series O
of O
hemoglobin O
( O
hb O
) O
measurements O
were O
available O
for O
201 O
patients O
. O

a O
decrease O
in O
hb O
levels O
between O
2 O
and O
5 O
g O
/ O
dl O
was O
detected O
in O
23 O
( O
11 O
. O
4 O
% O
) O
patients O
during O
the O
follow O
- O
up O
period O
. O

for O
five O
patients O
, O
hb O
levels O
decreased O
below O
5 O
g O
/ O
dl O
during O
at O
least O
one O
follow O
- O
up O
visit O
. O

all O
cases O
of O
delayed O
anemia B-Disease
were O
clinically O
manageable O
and O
resolved O
within O
one O
month O
. O

regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
and O
apoptotic O
pathways O
by O
betaine O
attenuates O
isoproterenol O
- O
induced O
acute O
myocardial B-Disease
injury I-Disease
in O
rats O
. O

the O
present O
study O
was O
designed O
to O
investigate O
the O
cardioprotective O
effects O
of O
betaine O
on O
acute O
myocardial B-Disease
ischemia I-Disease
induced O
experimentally O
in O
rats O
focusing O
on O
regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
( O
stat3 O
) O
and O
apoptotic O
pathways O
as O
the O
potential O
mechanism O
underlying O
the O
drug O
effect O
. O

male O
sprague O
dawley O
rats O
were O
treated O
with O
betaine O
( O
100 O
, O
200 O
, O
and O
400 O
mg O
/ O
kg O
) O
orally O
for O
40 O
days O
. O

acute O
myocardial B-Disease
ischemic I-Disease
injury I-Disease
was O
induced O
in O
rats O
by O
subcutaneous O
injection O
of O
isoproterenol O
( O
85 O
mg O
/ O
kg O
) O
, O
for O
two O
consecutive O
days O
. O

serum O
cardiac O
marker O
enzyme O
, O
histopathological O
variables O
and O
expression O
of O
protein O
levels O
were O
analyzed O
. O

oral O
administration O
of O
betaine O
( O
200 O
and O
400 O
mg O
/ O
kg O
) O
significantly O
reduced O
the O
level O
of O
cardiac O
marker O
enzyme O
in O
the O
serum O
and O
prevented O
left O
ventricular B-Disease
remodeling I-Disease
. O

western O
blot O
analysis O
showed O
that O
isoproterenol O
- O
induced O
phosphorylation O
of O
stat3 O
was O
maintained O
or O
further O
enhanced O
by O
betaine O
treatment O
in O
myocardium O
. O

furthermore O
, O
betaine O
( O
200 O
and O
400 O
mg O
/ O
kg O
) O
treatment O
increased O
the O
ventricular O
expression O
of O
bcl O
- O
2 O
and O
reduced O
the O
level O
of O
bax O
, O
therefore O
causing O
a O
significant O
increase O
in O
the O
ratio O
of O
bcl O
- O
2 O
/ O
bax O
. O

the O
protective O
role O
of O
betaine O
on O
myocardial B-Disease
damage I-Disease
was O
further O
confirmed O
by O
histopathological O
examination O
. O

in O
summary O
, O
our O
results O
showed O
that O
betaine O
pretreatment O
attenuated O
isoproterenol O
- O
induced O
acute O
myocardial B-Disease
ischemia I-Disease
via O
the O
regulation O
of O
stat3 O
and O
apoptotic O
pathways O
. O

quetiapine O
- O
induced O
neutropenia B-Disease
in O
a O
bipolar B-Disease
patient O
with O
hepatocellular B-Disease
carcinoma I-Disease
. O

objective O
: O
quetiapine O
is O
a O
dibenzothiazepine O
derivative O
, O
similar O
to O
clozapine O
, O
which O
has O
the O
highest O
risk O
of O
causing O
blood B-Disease
dyscrasias I-Disease
, O
especially O
neutropenia B-Disease
. O

there O
are O
some O
case O
reports O
about O
this O
side O
effect O
of O
quetiapine O
, O
but O
possible O
risk O
factors O
are O
seldom O
discussed O
and O
identified O
. O

a O
case O
of O
a O
patient O
with O
hepatocellular B-Disease
carcinoma I-Disease
that O
developed O
neutropenia B-Disease
after O
treatment O
with O
quetiapine O
is O
described O
here O
. O

case O
report O
: O
a O
62 O
- O
year O
- O
old O
taiwanese O
widow O
with O
bipolar B-Disease
disorder I-Disease
was O
diagnosed O
with O
hepatocellular B-Disease
carcinoma I-Disease
at O
age O
60 O
. O

she O
developed O
leucopenia B-Disease
after O
being O
treated O
with O
quetiapine O
. O

after O
quetiapine O
was O
discontinued O
, O
her O
white O
blood O
cell O
count O
returned O
to O
normal O
. O

conclusions O
: O
although O
neutropenia B-Disease
is O
not O
a O
common O
side O
effect O
of O
quetiapine O
, O
physicians O
should O
be O
cautious O
about O
its O
presentation O
and O
associated O
risk O
factors O
. O

hepatic B-Disease
dysfunction I-Disease
may O
be O
one O
of O
the O
possible O
risk O
factors O
, O
and O
concomitant O
fever B-Disease
may O
be O
a O
diagnostic O
marker O
for O
adverse O
reaction O
to O
quetiapine O
. O

lateral O
antebrachial O
cutaneous O
neuropathy B-Disease
after O
steroid O
injection O
at O
lateral O
epicondyle O
. O

background O
and O
objectives O
: O
this O
report O
aimed O
to O
present O
a O
case O
of O
lateral O
antebrachial O
cutaneous O
neuropathy B-Disease
( O
lacnp O
) O
that O
occurred O
after O
a O
steroid O
injection O
in O
the O
lateral O
epicondyle O
to O
treat O
lateral B-Disease
epicondylitis I-Disease
in O
a O
40 O
- O
year O
- O
old O
woman O
. O

material O
and O
method O
: O
a O
40 O
- O
year O
- O
old O
woman O
presented O
with O
decreased O
sensation O
and O
paresthesia B-Disease
over O
her O
right O
lateral O
forearm O
; O
the O
paresthesia B-Disease
had O
occurred O
after O
a O
steroid O
injection O
in O
the O
right O
lateral O
epicondyle O
3 O
months O
before O
. O

her O
sensation O
of O
light O
touch O
and O
pain B-Disease
was O
diminished O
over O
the O
lateral O
side O
of O
the O
right O
forearm O
and O
wrist O
area O
. O

results O
: O
the O
sensory O
action O
potential O
amplitude O
of O
the O
right O
lateral O
antebrachial O
cutaneous O
nerve O
( O
lacn O
) O
( O
6 O
. O
2 O
uv O
) O
was O
lower O
than O
that O
of O
the O
left O
( O
13 O
. O
1 O
uv O
) O
. O

the O
difference O
of O
amplitude O
between O
both O
sides O
was O
significant O
because O
there O
was O
more O
than O
a O
50 O
% O
reduction O
. O

she O
was O
diagnosed O
with O
right O
lacnp O
( O
mainly O
axonal O
involvement O
) O
on O
the O
basis O
of O
the O
clinical O
manifestation O
and O
the O
electrodiagnostic O
findings O
. O

her O
symptoms O
improved O
through O
physical O
therapy O
but O
persisted O
to O
some O
degree O
. O

conclusion O
: O
this O
report O
describes O
the O
case O
of O
a O
woman O
with O
lacnp O
that O
developed O
after O
a O
steroid O
injection O
for O
the O
treatment O
of O
lateral B-Disease
epicondylitis I-Disease
. O

an O
electrodiagnostic O
study O
, O
including O
a O
nerve O
conduction O
study O
of O
the O
lacn O
, O
was O
helpful O
to O
diagnose O
right O
lacnp O
and O
to O
find O
the O
passage O
of O
the O
lacn O
on O
the O
lateral O
epicondyle O
. O

curcumin O
prevents O
maleate O
- O
induced O
nephrotoxicity B-Disease
: O
relation O
to O
hemodynamic O
alterations O
, O
oxidative O
stress O
, O
mitochondrial O
oxygen O
consumption O
and O
activity O
of O
respiratory O
complex O
i O
. O

the O
potential O
protective O
effect O
of O
the O
dietary O
antioxidant O
curcumin O
( O
120 O
mg O
/ O
kg O
/ O
day O
for O
6 O
days O
) O
against O
the O
renal B-Disease
injury I-Disease
induced O
by O
maleate O
was O
evaluated O
. O

tubular O
proteinuria B-Disease
and O
oxidative O
stress O
were O
induced O
by O
a O
single O
injection O
of O
maleate O
( O
400 O
mg O
/ O
kg O
) O
in O
rats O
. O

maleate O
- O
induced O
renal B-Disease
injury I-Disease
included O
increase O
in O
renal O
vascular O
resistance O
and O
in O
the O
urinary O
excretion O
of O
total O
protein O
, O
glucose O
, O
sodium O
, O
neutrophil O
gelatinase O
- O
associated O
lipocalin O
( O
ngal O
) O
and O
n O
- O
acetyl O
b O
- O
d O
- O
glucosaminidase O
( O
nag O
) O
, O
upregulation O
of O
kidney B-Disease
injury I-Disease
molecule O
( O
kim O
) O
- O
1 O
, O
decrease O
in O
renal O
blood O
flow O
and O
claudin O
- O
2 O
expression O
besides O
of O
necrosis B-Disease
and O
apoptosis O
of O
tubular O
cells O
on O
24 O
h O
. O

oxidative O
stress O
was O
determined O
by O
measuring O
the O
oxidation O
of O
lipids O
and O
proteins O
and O
diminution O
in O
renal O
nrf2 O
levels O
. O

studies O
were O
also O
conducted O
in O
renal O
epithelial O
llc O
- O
pk1 O
cells O
and O
in O
mitochondria O
isolated O
from O
kidneys O
of O
all O
the O
experimental O
groups O
. O

maleate O
induced O
cell O
damage O
and O
reactive O
oxygen O
species O
( O
ros O
) O
production O
in O
llc O
- O
pk1 O
cells O
in O
culture O
. O

in O
addition O
, O
maleate O
treatment O
reduced O
oxygen O
consumption O
in O
adp O
- O
stimulated O
mitochondria O
and O
diminished O
respiratory O
control O
index O
when O
using O
malate O
/ O
glutamate O
as O
substrate O
. O

the O
activities O
of O
both O
complex O
i O
and O
aconitase O
were O
also O
diminished O
. O

all O
the O
above O
- O
described O
alterations O
were O
prevented O
by O
curcumin O
. O

it O
is O
concluded O
that O
curcumin O
is O
able O
to O
attenuate O
in O
vivo O
maleate O
- O
induced O
nephropathy B-Disease
and O
in O
vitro O
cell O
damage O
. O

the O
in O
vivo O
protection O
was O
associated O
to O
the O
prevention O
of O
oxidative O
stress O
and O
preservation O
of O
mitochondrial O
oxygen O
consumption O
and O
activity O
of O
respiratory O
complex O
i O
, O
and O
the O
in O
vitro O
protection O
was O
associated O
to O
the O
prevention O
of O
ros O
production O
. O

anticonvulsant O
actions O
of O
mk O
- O
801 O
on O
the O
lithium O
- O
pilocarpine O
model O
of O
status B-Disease
epilepticus I-Disease
in O
rats O
. O

mk O
- O
801 O
, O
a O
noncompetitive O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
receptor O
antagonist O
, O
was O
tested O
for O
anticonvulsant O
effects O
in O
rats O
using O
two O
seizure B-Disease
models O
, O
coadministration O
of O
lithium O
and O
pilocarpine O
and O
administration O
of O
a O
high O
dose O
of O
pilocarpine O
alone O
. O

three O
major O
results O
are O
reported O
. O

first O
, O
pretreatment O
with O
mk O
- O
801 O
produced O
an O
effective O
and O
dose O
- O
dependent O
anticonvulsant O
action O
with O
the O
lithium O
- O
pilocarpine O
model O
but O
not O
with O
rats O
treated O
with O
pilocarpine O
alone O
, O
suggesting O
that O
different O
biochemical O
mechanisms O
control O
seizures B-Disease
in O
these O
two O
models O
. O

second O
, O
the O
anticonvulsant O
effect O
of O
mk O
- O
801 O
in O
the O
lithium O
- O
pilocarpine O
model O
only O
occurred O
after O
initial O
periods O
of O
seizure B-Disease
activity O
. O

this O
observation O
is O
suggested O
to O
be O
an O
in O
vivo O
demonstration O
of O
the O
conclusion O
derived O
from O
in O
vitro O
experiments O
that O
mk O
- O
801 O
binding O
requires O
agonist O
- O
induced O
opening O
of O
the O
channel O
sites O
of O
the O
nmda O
receptor O
. O

third O
, O
although O
it O
is O
relatively O
easy O
to O
block O
seizures B-Disease
induced O
by O
lithium O
and O
pilocarpine O
by O
administration O
of O
anticonvulsants O
prior O
to O
pilocarpine O
, O
it O
is O
more O
difficult O
to O
terminate O
ongoing O
status B-Disease
epilepticus I-Disease
and O
block O
the O
lethality O
of O
the O
seizures B-Disease
. O

administration O
of O
mk O
- O
801 O
30 O
or O
60 O
min O
after O
pilocarpine O
, O
i O
. O
e O
. O
, O
during O
status B-Disease
epilepticus I-Disease
, O
gradually O
reduced O
electrical O
and O
behavioral O
seizure B-Disease
activity O
and O
greatly O
enhanced O
the O
survival O
rate O
. O

these O
results O
suggest O
that O
activation O
of O
nmda O
receptors O
plays O
an O
important O
role O
in O
status B-Disease
epilepticus I-Disease
and O
brain B-Disease
damage I-Disease
in O
the O
lithium O
- O
pilocarpine O
model O
. O

this O
was O
further O
supported O
by O
results O
showing O
that O
nonconvulsive O
doses O
of O
nmda O
and O
pilocarpine O
were O
synergistic O
, O
resulting O
in O
status B-Disease
epilepticus I-Disease
and O
subsequent O
mortality O
. O

continuous O
infusion O
tobramycin O
combined O
with O
carbenicillin O
for O
infections B-Disease
in O
cancer B-Disease
patients O
. O

the O
cure O
rate O
of O
infections B-Disease
in O
cancer B-Disease
patients O
is O
adversely O
affected O
by O
neutropenia B-Disease
( O
less O
than O
1 O
, O
000 O
/ O
mm3 O
) O
. O

in O
particular O
, O
patients O
with O
severe O
neutropenia B-Disease
( O
less O
than O
100 O
/ O
mm3 O
) O
have O
shown O
a O
poor O
response O
to O
antibiotics O
. O

to O
overcome O
the O
adverse O
effects O
of O
neutropenia B-Disease
, O
tobramycin O
was O
given O
by O
continuous O
infusion O
and O
combined O
with O
intermittent O
carbenicillin O
. O

tobramycin O
was O
given O
to O
a O
total O
daily O
dose O
of O
300 O
mg O
/ O
m2 O
and O
carbenicillin O
was O
given O
at O
a O
dose O
of O
5 O
gm O
every O
four O
hours O
. O

there O
were O
125 O
infectious O
episodes O
in O
116 O
cancer B-Disease
patients O
receiving O
myelosuppressive O
chemotherapy O
. O

the O
overall O
cure O
rate O
was O
70 O
% O
. O

pneumonia B-Disease
was O
the O
most O
common O
infection B-Disease
and O
61 O
% O
of O
59 O
episodes O
were O
cured O
. O

gram O
- O
negative O
bacilli O
were O
the O
most O
common O
causative O
organisms O
and O
69 O
% O
of O
these O
infections B-Disease
were O
cured O
. O

the O
most O
common O
pathogen O
was O
klebsiella O
pneumoniae B-Disease
and O
this O
, O
together O
with O
escherichia O
coli O
and O
pseudomonas O
aeruginosa O
, O
accounted O
for O
74 O
% O
of O
all O
gram B-Disease
- I-Disease
negative I-Disease
bacillary I-Disease
infections I-Disease
. O

response O
was O
not O
influenced O
by O
the O
initial O
neutrophil O
count O
, O
with O
a O
62 O
% O
cure O
rate O
for O
39 O
episodes O
associated O
with O
severe O
neutropenia B-Disease
. O

however O
, O
failure O
of O
the O
neutrophil O
count O
to O
increase O
during O
therapy O
adversely O
affected O
response O
. O

azotemia B-Disease
was O
the O
major O
side O
effect O
recognized O
, O
and O
it O
occurred O
in O
11 O
% O
of O
episodes O
. O

major O
azotemia B-Disease
( O
serum O
creatinine O
greater O
than O
2 O
. O
5 O
mg O
/ O
dl O
or O
bun O
greater O
than O
50 O
mg O
/ O
dl O
) O
occurred O
in O
only O
2 O
% O
. O

azotemia B-Disease
was O
not O
related O
to O
duration O
of O
therapy O
or O
serum O
tobramycin O
concentration O
. O

this O
antibiotic O
regimen O
showed O
both O
therapeutic O
efficacy O
and O
acceptable O
renal B-Disease
toxicity I-Disease
for O
these O
patients O
. O

incidence O
of O
solid O
tumours B-Disease
among O
pesticide O
applicators O
exposed O
to O
the O
organophosphate O
insecticide O
diazinon O
in O
the O
agricultural O
health O
study O
: O
an O
updated O
analysis O
. O

objective O
: O
diazinon O
, O
a O
common O
organophosphate O
insecticide O
with O
genotoxic O
properties O
, O
was O
previously O
associated O
with O
lung B-Disease
cancer I-Disease
in O
the O
agricultural O
health O
study O
( O
ahs O
) O
cohort O
, O
but O
few O
other O
epidemiological O
studies O
have O
examined O
diazinon O
- O
associated O
cancer B-Disease
risk O
. O

we O
used O
updated O
diazinon O
exposure O
and O
cancer B-Disease
incidence O
information O
to O
evaluate O
solid O
tumour B-Disease
risk O
in O
the O
ahs O
. O

methods O
: O
male O
pesticide O
applicators O
in O
iowa O
and O
north O
carolina O
reported O
lifetime O
diazinon O
use O
at O
enrolment O
( O
1993 O
- O
1997 O
) O
and O
follow O
- O
up O
( O
1998 O
- O
2005 O
) O
; O
cancer B-Disease
incidence O
was O
assessed O
through O
2010 O
( O
north O
carolina O
) O
/ O
2011 O
( O
iowa O
) O
. O

among O
applicators O
with O
usage O
information O
sufficient O
to O
evaluate O
exposure O
- O
response O
patterns O
, O
we O
used O
poisson O
regression O
to O
estimate O
adjusted O
rate O
ratios O
( O
rrs O
) O
and O
95 O
% O
ci O
for O
cancer B-Disease
sites O
with O
> O
10 O
exposed O
cases O
for O
both O
lifetime O
( O
lt O
) O
exposure O
days O
and O
intensity O
- O
weighted O
( O
iw O
) O
lifetime O
exposure O
days O
( O
accounting O
for O
factors O
impacting O
exposure O
) O
. O

results O
: O
we O
observed O
elevated O
lung B-Disease
cancer I-Disease
risks O
( O
n O
= O
283 O
) O
among O
applicators O
with O
the O
greatest O
number O
of O
lt O
( O
rr O
= O
1 O
. O
60 O
; O
95 O
% O
ci O
1 O
. O
11 O
to O
2 O
. O
31 O
; O
ptrend O
= O
0 O
. O
02 O
) O
and O
iw O
days O
of O
diazinon O
use O
( O
rr O
= O
1 O
. O
41 O
; O
95 O
% O
ci O
0 O
. O
98 O
to O
2 O
. O
04 O
; O
ptrend O
= O
0 O
. O
08 O
) O
. O

kidney B-Disease
cancer I-Disease
( O
n O
= O
94 O
) O
risks O
were O
non O
- O
significantly O
elevated O
( O
rrlt O
days O
= O
1 O
. O
77 O
; O
95 O
% O
ci O
0 O
. O
90 O
to O
3 O
. O
51 O
; O
ptrend O
= O
0 O
. O
09 O
; O
rriw O
days O
1 O
. O
37 O
; O
95 O
% O
ci O
0 O
. O
64 O
to O
2 O
. O
92 O
; O
ptrend O
= O
0 O
. O
50 O
) O
, O
as O
were O
risks O
for O
aggressive O
prostate B-Disease
cancer I-Disease
( O
n O
= O
656 O
) O
. O

conclusions O
: O
our O
updated O
evaluation O
of O
diazinon O
provides O
additional O
evidence O
of O
an O
association O
with O
lung B-Disease
cancer I-Disease
risk O
. O

newly O
identified O
links O
to O
kidney B-Disease
cancer I-Disease
and O
associations O
with O
aggressive O
prostate B-Disease
cancer I-Disease
require O
further O
evaluation O
. O

associations O
of O
ozone O
and O
pm2 O
. O
5 O
concentrations O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
among O
participants O
in O
the O
agricultural O
health O
study O
. O

objective O
: O
this O
study O
describes O
associations O
of O
ozone O
and O
fine O
particulate O
matter O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
observed O
among O
farmers O
in O
north O
carolina O
and O
iowa O
. O

methods O
: O
we O
used O
logistic O
regression O
to O
determine O
the O
associations O
of O
these O
pollutants O
with O
self O
- O
reported O
, O
doctor O
- O
diagnosed O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

daily O
predicted O
pollutant O
concentrations O
were O
used O
to O
derive O
surrogates O
of O
long O
- O
term O
exposure O
and O
link O
them O
to O
study O
participants O
' O
geocoded O
addresses O
. O

results O
: O
we O
observed O
positive O
associations O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
with O
ozone O
( O
odds O
ratio O
= O
1 O
. O
39 O
; O
95 O
% O
ci O
: O
0 O
. O
98 O
to O
1 O
. O
98 O
) O
and O
fine O
particulate O
matter O
( O
odds O
ratio O
= O
1 O
. O
34 O
; O
95 O
% O
ci O
: O
0 O
. O
93 O
to O
1 O
. O
93 O
) O
in O
north O
carolina O
but O
not O
in O
iowa O
. O

conclusions O
: O
the O
plausibility O
of O
an O
effect O
of O
ambient O
concentrations O
of O
these O
pollutants O
on O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
risk O
is O
supported O
by O
experimental O
data O
demonstrating O
damage O
to O
dopaminergic O
neurons O
at O
relevant O
concentrations O
. O

additional O
studies O
are O
needed O
to O
address O
uncertainties O
related O
to O
confounding O
and O
to O
examine O
temporal O
aspects O
of O
the O
associations O
we O
observed O
. O

low O
functional O
programming O
of O
renal O
at2r O
mediates O
the O
developmental O
origin O
of O
glomerulosclerosis B-Disease
in O
adult O
offspring O
induced O
by O
prenatal O
caffeine O
exposure O
. O

unassigned O
: O
our O
previous O
study O
has O
indicated O
that O
prenatal O
caffeine O
exposure O
( O
pce O
) O
could O
induce O
intrauterine B-Disease
growth I-Disease
retardation I-Disease
( O
iugr B-Disease
) O
of O
offspring O
. O

recent O
research O
suggested O
that O
iugr B-Disease
is O
a O
risk O
factor O
for O
glomerulosclerosis B-Disease
. O

however O
, O
whether O
pce O
could O
induce O
glomerulosclerosis B-Disease
and O
its O
underlying O
mechanisms O
remain O
unknown O
. O

this O
study O
aimed O
to O
demonstrate O
the O
induction O
to O
glomerulosclerosis B-Disease
in O
adult O
offspring O
by O
pce O
and O
its O
intrauterine O
programming O
mechanisms O
. O

a O
rat O
model O
of O
iugr B-Disease
was O
established O
by O
pce O
, O
male O
fetuses O
and O
adult O
offspring O
at O
the O
age O
of O
postnatal O
week O
24 O
were O
euthanized O
. O

the O
results O
revealed O
that O
the O
adult O
offspring O
kidneys O
in O
the O
pce O
group O
exhibited O
glomerulosclerosis B-Disease
as O
well O
as O
interstitial B-Disease
fibrosis I-Disease
, O
accompanied O
by O
elevated O
levels O
of O
serum O
creatinine O
and O
urine O
protein O
. O

renal O
angiotensin O
ii O
receptor O
type O
2 O
( O
at2r O
) O
gene O
expression O
in O
adult O
offspring O
was O
reduced O
by O
pce O
, O
whereas O
the O
renal O
angiotensin O
ii O
receptor O
type O
1a O
( O
at1ar O
) O
/ O
at2r O
expression O
ratio O
was O
increased O
. O

the O
fetal O
kidneys O
in O
the O
pce O
group O
displayed O
an O
enlarged O
bowman O
' O
s O
space O
and O
a O
shrunken O
glomerular O
tuft O
, O
accompanied O
by O
a O
reduced O
cortex O
width O
and O
an O
increase O
in O
the O
nephrogenic O
zone O
/ O
cortical O
zone O
ratio O
. O

observation O
by O
electronic O
microscope O
revealed O
structural O
damage O
of O
podocytes O
; O
the O
reduced O
expression O
level O
of O
podocyte O
marker O
genes O
, O
nephrin O
and O
podocin O
, O
was O
also O
detected O
by O
q O
- O
pcr O
. O

moreover O
, O
at2r O
gene O
and O
protein O
expressions O
in O
fetal O
kidneys O
were O
inhibited O
by O
pce O
, O
associated O
with O
the O
repression O
of O
the O
gene O
expression O
of O
glial O
- O
cell O
- O
line O
- O
derived O
neurotrophic O
factor O
( O
gdnf O
) O
/ O
tyrosine O
kinase O
receptor O
( O
c O
- O
ret O
) O
signaling O
pathway O
. O

these O
results O
demonstrated O
that O
pce O
could O
induce O
dysplasia B-Disease
of I-Disease
fetal I-Disease
kidneys I-Disease
as O
well O
as O
glomerulosclerosis B-Disease
of O
adult O
offspring O
, O
and O
the O
low O
functional O
programming O
of O
renal O
at2r O
might O
mediate O
the O
developmental O
origin O
of O
adult O
glomerulosclerosis B-Disease
. O

1 O
, O
3 O
- O
butadiene O
, O
cml B-Disease
and O
the O
t O
( O
9 O
: O
22 O
) O
translocation O
: O
a O
reality O
check O
. O

unassigned O
: O
epidemiological O
studies O
of O
1 O
, O
3 O
- O
butadiene O
have O
suggest O
that O
exposures O
to O
humans O
are O
associated O
with O
chronic B-Disease
myeloid I-Disease
leukemia I-Disease
( O
cml B-Disease
) O
. O

cml B-Disease
has O
a O
well O
- O
documented O
association O
with O
ionizing O
radiation O
, O
but O
reports O
of O
associations O
with O
chemical O
exposures O
have O
been O
questioned O
. O

ionizing O
radiation O
is O
capable O
of O
inducing O
the O
requisite O
cml B-Disease
- O
associated O
t O
( O
9 O
: O
22 O
) O
translocation O
( O
philadelphia B-Disease
chromosome I-Disease
) O
in O
appropriate O
cells O
in O
vitro O
but O
, O
thus O
far O
, O
chemicals O
have O
not O
shown O
this O
capacity O
. O

we O
have O
proposed O
that O
1 O
, O
3 O
- O
butadiene O
metabolites O
be O
so O
tested O
as O
a O
reality O
check O
on O
the O
epidemiological O
reports O
. O

in O
order O
to O
conduct O
reliable O
testing O
in O
this O
regard O
, O
it O
is O
essential O
that O
a O
positive O
control O
for O
induction O
be O
available O
. O

we O
have O
used O
ionizing O
radiation O
to O
develop O
such O
a O
control O
. O

results O
described O
here O
demonstrate O
that O
this O
agent O
does O
in O
fact O
induce O
pathogenic O
t O
( O
9 O
: O
22 O
) O
translocations O
in O
a O
human O
myeloid O
cell O
line O
in O
vitro O
, O
but O
does O
so O
at O
low O
frequencies O
. O

conditions O
that O
will O
be O
required O
for O
studies O
of O
1 O
, O
3 O
- O
butadiene O
are O
discussed O
. O

cancer B-Disease
incidence O
and O
metolachlor O
use O
in O
the O
agricultural O
health O
study O
: O
an O
update O
. O

unassigned O
: O
metolachlor O
, O
a O
widely O
used O
herbicide O
, O
is O
classified O
as O
a O
group O
c O
carcinogen O
by O
the O
u O
. O
s O
. O

environmental O
protection O
agency O
based O
on O
increased O
liver B-Disease
neoplasms I-Disease
in O
female O
rats O
. O

epidemiologic O
studies O
of O
the O
health O
effects O
of O
metolachlor O
have O
been O
limited O
. O

the O
agricultural O
health O
study O
( O
ahs O
) O
is O
a O
prospective O
cohort O
study O
including O
licensed O
private O
and O
commercial O
pesticide O
applicators O
in O
iowa O
and O
north O
carolina O
enrolled O
1993 O
- O
1997 O
. O

we O
evaluated O
cancer B-Disease
incidence O
through O
2010 O
/ O
2011 O
( O
nc O
/ O
ia O
) O
for O
49 O
, O
616 O
applicators O
, O
53 O
% O
of O
whom O
reported O
ever O
using O
metolachlor O
. O

we O
used O
poisson O
regression O
to O
evaluate O
relations O
between O
two O
metrics O
of O
metolachlor O
use O
( O
lifetime O
days O
, O
intensity O
- O
weighted O
lifetime O
days O
) O
and O
cancer B-Disease
incidence O
. O

we O
saw O
no O
association O
between O
metolachlor O
use O
and O
incidence O
of O
all O
cancers B-Disease
combined O
( O
n O
= O
5 O
, O
701 O
with O
a O
5 O
- O
year O
lag O
) O
or O
most O
site O
- O
specific O
cancers B-Disease
. O

for O
liver B-Disease
cancer I-Disease
, O
in O
analyses O
restricted O
to O
exposed O
workers O
, O
elevations O
observed O
at O
higher O
categories O
of O
use O
were O
not O
statistically O
significant O
. O

however O
, O
trends O
for O
both O
lifetime O
and O
intensity O
- O
weighted O
lifetime O
days O
of O
metolachor O
use O
were O
positive O
and O
statistically O
significant O
with O
an O
unexposed O
reference O
group O
. O

a O
similar O
pattern O
was O
observed O
for O
follicular B-Disease
cell I-Disease
lymphoma I-Disease
, O
but O
no O
other O
lymphoma B-Disease
subtypes O
. O

an O
earlier O
suggestion O
of O
increased O
lung B-Disease
cancer I-Disease
risk O
at O
high O
levels O
of O
metolachlor O
use O
in O
this O
cohort O
was O
not O
confirmed O
in O
this O
update O
. O

this O
suggestion O
of O
an O
association O
between O
metolachlor O
and O
liver B-Disease
cancer I-Disease
among O
pesticide O
applicators O
is O
a O
novel O
finding O
and O
echoes O
observation O
of O
increased O
liver B-Disease
neoplasms I-Disease
in O
some O
animal O
studies O
. O

however O
, O
our O
findings O
for O
both O
liver B-Disease
cancer I-Disease
and O
follicular O
cell O
lymphoma B-Disease
warrant O
follow O
- O
up O
to O
better O
differentiate O
effects O
of O
metolachlor O
use O
from O
other O
factors O
. O

mechanisms O
underlying O
latent O
disease O
risk O
associated O
with O
early O
- O
life O
arsenic O
exposure O
: O
current O
research O
trends O
and O
scientific O
gaps O
. O

background O
: O
millions O
of O
individuals O
worldwide O
, O
particularly O
those O
living O
in O
rural O
and O
developing O
areas O
, O
are O
exposed O
to O
harmful O
levels O
of O
inorganic O
arsenic O
( O
ias O
) O
in O
their O
drinking O
water O
. O

inorganic O
as O
exposure O
during O
key O
developmental O
periods O
is O
associated O
with O
a O
variety O
of O
adverse O
health O
effects O
including O
those O
that O
are O
evident O
in O
adulthood O
. O

there O
is O
considerable O
interest O
in O
identifying O
the O
molecular O
mechanisms O
that O
relate O
early O
- O
life O
ias O
exposure O
to O
the O
development O
of O
these O
latent O
diseases O
, O
particularly O
in O
relationship O
to O
cancer B-Disease
. O

objectives O
: O
this O
work O
summarizes O
research O
on O
the O
molecular O
mechanisms O
that O
underlie O
the O
increased O
risk O
of O
cancer B-Disease
development O
in O
adulthood O
that O
is O
associated O
with O
early O
- O
life O
ias O
exposure O
. O

discussion O
: O
epigenetic O
reprogramming O
that O
imparts O
functional O
changes O
in O
gene O
expression O
, O
the O
development O
of O
cancer B-Disease
stem O
cells O
, O
and O
immunomodulation O
are O
plausible O
underlying O
mechanisms O
by O
which O
early O
- O
life O
ias O
exposure O
elicits O
latent O
carcinogenic O
effects O
. O

conclusions O
: O
evidence O
is O
mounting O
that O
relates O
early O
- O
life O
ias O
exposure O
and O
cancer B-Disease
development O
later O
in O
life O
. O

future O
research O
should O
include O
animal O
studies O
that O
address O
mechanistic O
hypotheses O
and O
studies O
of O
human O
populations O
that O
integrate O
early O
- O
life O
exposure O
, O
molecular O
alterations O
, O
and O
latent O
disease O
outcomes O
. O

nifedipine O
induced O
bradycardia B-Disease
in O
a O
patient O
with O
autonomic B-Disease
neuropathy I-Disease
. O

an O
80 O
year O
old O
diabetic B-Disease
male O
with O
evidence O
of O
peripheral B-Disease
and I-Disease
autonomic I-Disease
neuropathy I-Disease
was O
admitted O
with O
chest B-Disease
pain I-Disease
. O

he O
was O
found O
to O
have O
atrial B-Disease
flutter I-Disease
at O
a O
ventricular O
rate O
of O
70 O
/ O
min O
which O
slowed O
down O
to O
30 O
- O
40 O
/ O
min O
when O
nifedipine O
( O
60 O
mg O
) O
in O
3 O
divided O
doses O
, O
during O
which O
he O
was O
paced O
at O
a O
rate O
of O
70 O
/ O
min O
. O

this O
is O
inconsistent O
with O
the O
well O
- O
established O
finding O
that O
nifedipine O
induces O
tachycardia B-Disease
in O
normally O
innervated O
hearts O
. O

however O
, O
in O
hearts O
deprived O
of O
compensatory O
sympathetic O
drive O
, O
it O
may O
lead O
to O
bradycardia B-Disease
. O

the O
effect O
of O
haloperidol O
in O
cocaine O
and O
amphetamine O
intoxication O
. O

the O
effectiveness O
of O
haloperidol O
pretreatment O
in O
preventing O
the O
toxic O
effects O
of O
high O
doses O
of O
amphetamine O
and O
cocaine O
was O
studied O
in O
rats O
. O

in O
this O
model O
, O
toxic O
effects O
were O
induced O
by O
intraperitoneal O
( O
i O
. O
p O
. O
) O
injection O
of O
amphetamine O
75 O
mg O
/ O
kg O
( O
100 O
% O
death O
rate O
) O
or O
cocaine O
70 O
mg O
/ O
kg O
( O
82 O
% O
death O
rate O
) O
. O

haloperidol O
failed O
to O
prevent O
amphetamine O
- O
induced O
seizures B-Disease
, O
but O
did O
lower O
the O
mortality O
rate O
at O
most O
doses O
tested O
. O

haloperidol O
decreased O
the O
incidence O
of O
cocaine O
- O
induced O
seizures B-Disease
at O
the O
two O
highest O
doses O
, O
but O
the O
lowering O
of O
the O
mortality O
rate O
did O
not O
reach O
statistical O
significance O
at O
any O
dose O
. O

these O
data O
suggest O
a O
protective O
role O
for O
the O
central O
dopamine O
blocker O
haloperidol O
against O
death O
from O
high O
- O
dose O
amphetamine O
exposure O
without O
reducing O
the O
incidence O
of O
seizures B-Disease
. O

in O
contrast O
, O
haloperidol O
demonstrated O
an O
ability O
to O
reduce O
cocaine O
- O
induced O
seizures B-Disease
without O
significantly O
reducing O
mortality O
. O

autoradiographic O
evidence O
of O
estrogen O
binding O
sites O
in O
nuclei O
of O
diethylstilbesterol O
induced O
hamster O
renal B-Disease
carcinomas I-Disease
. O

estrogen O
binding O
sites O
were O
demonstrated O
by O
autoradiography O
in O
one O
transplantable O
and O
five O
primary O
diethylstilbesterol O
induced O
renal B-Disease
carcinomas I-Disease
in O
three O
hamsters O
. O

radiolabelling O
, O
following O
the O
in O
vivo O
injection O
of O
3h O
- O
17 O
beta O
estradiol O
, O
was O
increased O
only O
over O
the O
nuclei O
of O
tumor B-Disease
cells O
; O
stereologic O
analysis O
revealed O
a O
4 O
. O
5 O
- O
to O
6 O
. O
7 O
- O
times O
higher O
concentration O
of O
reduced O
silver O
grains O
over O
nuclei O
than O
cytoplasm O
of O
these O
cells O
. O

despite O
rapid O
tubular O
excretion O
of O
estradiol O
which O
peaked O
in O
less O
than O
1 O
h O
, O
the O
normal O
cells O
did O
not O
appear O
to O
bind O
the O
ligand O
. O

this O
is O
the O
first O
published O
report O
documenting O
the O
preferential O
in O
vivo O
binding O
of O
estrogen O
to O
nuclei O
of O
cells O
in O
estrogen O
induced O
hamster O
renal B-Disease
carcinomas I-Disease
. O

bradycardia B-Disease
due O
to O
biperiden O
. O

in O
a O
38 O
- O
year O
- O
old O
male O
patient O
suffering O
from O
a O
severe O
postzosteric B-Disease
trigeminal B-Disease
neuralgia I-Disease
, O
intravenous O
application O
of O
10 O
mg O
biperiden O
lactate O
led O
to O
a O
long O
- O
lasting O
paradoxical O
reaction O
characterized O
by O
considerable O
bradycardia B-Disease
, O
dysarthria B-Disease
, O
and O
dysphagia B-Disease
. O

the O
heart O
rate O
was O
back O
to O
normal O
within O
12 O
hours O
upon O
administration O
of O
orciprenaline O
under O
cardiac O
monitoring O
in O
an O
intensive O
care O
unit O
. O

bradycardia B-Disease
induced O
by O
biperiden O
is O
attributed O
to O
the O
speed O
of O
injection O
and O
to O
a O
dose O
- O
related O
dual O
effect O
of O
atropine O
- O
like O
drugs O
on O
muscarine O
receptors O
. O

deliberate O
hypotension B-Disease
induced O
by O
labetalol O
with O
halothane O
, O
enflurane O
or O
isoflurane O
for O
middle O
- O
ear O
surgery O
. O

the O
feasibility O
of O
using O
labetalol O
, O
an O
alpha O
- O
and O
beta O
- O
adrenergic O
blocking O
agent O
, O
as O
a O
hypotensive B-Disease
agent O
in O
combination O
with O
inhalation O
anaesthetics O
( O
halothane O
, O
enflurane O
or O
isoflurane O
) O
was O
studied O
in O
23 O
adult O
patients O
undergoing O
middle O
- O
ear O
surgery O
. O

the O
mean O
arterial O
pressure O
was O
decreased O
from O
86 O
+ O
/ O
- O
5 O
( O
s O
. O
e O
. O
mean O
) O
mmhg O
to O
52 O
+ O
/ O
- O
1 O
mmhg O
( O
11 O
. O
5 O
+ O
/ O
- O
0 O
. O
7 O
to O
6 O
. O
9 O
+ O
/ O
- O
0 O
. O
1 O
kpa O
) O
for O
98 O
+ O
/ O
- O
10 O
min O
in O
the O
halothane O
( O
h O
) O
group O
, O
from O
79 O
+ O
/ O
- O
5 O
to O
53 O
+ O
/ O
- O
1 O
mmhg O
( O
10 O
. O
5 O
+ O
/ O
- O
0 O
. O
7 O
to O
7 O
. O
1 O
+ O
/ O
- O
0 O
. O
1 O
kpa O
) O
for O
129 O
+ O
/ O
- O
11 O
min O
in O
the O
enflurane O
( O
e O
) O

group O
, O
and O
from O
80 O
+ O
/ O
- O
4 O
to O
49 O
+ O
/ O
- O
1 O
mmhg O
( O
10 O
. O
7 O
+ O
/ O
- O
0 O
. O
5 O
to O
6 O
. O
5 O
+ O
/ O
- O
0 O
. O
1 O
kpa O
) O
for O
135 O
+ O
/ O
- O
15 O
min O
in O
the O
isoflurane O
( O
i O
) O
group O
. O

the O
mean O
h O
concentration O
during O
hypotension B-Disease
in O
the O
inspiratory O
gas O
was O
0 O
. O
7 O
+ O
/ O
- O
0 O
. O
1 O
vol O
% O
, O
the O
mean O
e O
concentration O
1 O
. O
6 O
+ O
/ O
- O
0 O
. O
2 O
vol O
% O
, O
and O
the O
mean O
i O
concentration O
1 O
. O
0 O
+ O
/ O
- O
0 O
. O
1 O
vol O
% O
. O

in O
addition O
, O
the O
patients O
received O
fentanyl O
and O
d O
- O
tubocurarine O
. O

the O
initial O
dose O
of O
labetalol O
for O
lowering O
blood O
pressure O
was O
similar O
, O
0 O
. O
52 O
- O
0 O
. O
59 O
mg O
/ O
kg O
, O
in O
all O
the O
groups O
. O

during O
hypotension B-Disease
, O
the O
heart O
rate O
was O
stable O
without O
tachy B-Disease
- I-Disease
or I-Disease
bradycardia I-Disease
. O

the O
operating O
conditions O
regarding O
bleeding B-Disease
were O
estimated O
in O
a O
double O
- O
blind O
manner O
, O
and O
did O
not O
differ O
significantly O
between O
the O
groups O
. O

during O
hypotension B-Disease
, O
the O
serum O
creatinine O
concentration O
rose O
significantly O
in O
all O
groups O
from O
the O
values O
before O
hypotension B-Disease
and O
returned O
postoperatively O
to O
the O
initial O
level O
in O
the O
other O
groups O
, O
except O
the O
isoflurane O
group O
. O

after O
hypotension B-Disease
there O
was O
no O
rebound O
phenomenon O
in O
either O
blood O
pressure O
or O
heart O
rate O
. O

these O
results O
indicate O
that O
labetalol O
induces O
easily O
adjustable O
hypotension B-Disease
without O
compensatory O
tachycardia B-Disease
and O
rebound O
hypertension B-Disease
. O

convulsion B-Disease
following O
intravenous O
fluorescein O
angiography O
. O

tonic B-Disease
- I-Disease
clonic I-Disease
seizures I-Disease
followed O
intravenous O
fluorescein O
injection O
for O
fundus O
angiography O
in O
a O
47 O
- O
year O
- O
old O
male O
. O

despite O
precautions O
this O
adverse O
reaction O
recurred O
on O
re O
- O
exposure O
to O
intravenous O
fluorescein O
. O

pharmacology O
of O
acc O
- O
9653 O
( O
phenytoin O
prodrug O
) O
. O

acc O
- O
9653 O
, O
the O
disodium O
phosphate O
ester O
of O
3 O
- O
hydroxymethyl O
- O
5 O
, O
5 O
- O
diphenylhydantoin O
, O
is O
a O
prodrug O
of O
phenytoin O
with O
advantageous O
physicochemical O
properties O
. O

acc O
- O
9653 O
is O
rapidly O
converted O
enzymatically O
to O
phenytoin O
in O
vivo O
. O

acc O
- O
9653 O
and O
phenytoin O
sodium O
have O
equivalent O
anticonvulsant O
activity O
against O
seizures B-Disease
induced O
by O
maximal O
electroshock O
( O
mes O
) O
in O
mice O
following O
i O
. O
p O
. O
, O
oral O
, O
or O
i O
. O
v O
. O
administration O
. O

the O
ed50 O
doses O
were O
16 O
mg O
/ O
kg O
for O
i O
. O
v O
. O
acc O
- O
9653 O
and O
8 O
mg O
/ O
kg O
for O
i O
. O
v O
. O
phenytoin O
sodium O
. O

acc O
- O
9653 O
and O
phenytoin O
sodium O
have O
similar O
antiarrhythmic O
activity O
against O
ouabain O
- O
induced O
ventricular B-Disease
tachycardia I-Disease
in O
anesthetized O
dogs O
. O

the O
total O
doses O
of O
acc O
- O
9653 O
or O
phenytoin O
sodium O
necessary O
to O
convert O
the O
arrhythmia B-Disease
to O
a O
normal O
sinus O
rhythm O
were O
24 O
+ O
/ O
- O
6 O
and O
14 O
+ O
/ O
- O
3 O
mg O
/ O
kg O
, O
respectively O
. O

only O
phenytoin O
sodium O
displayed O
in O
vitro O
antiarrhythmic O
activity O
against O
strophanthidin O
- O
induced O
arrhythmias B-Disease
in O
guinea O
pig O
right O
atria O
. O

in O
anesthetized O
dogs O
, O
a O
high O
dose O
of O
acc O
- O
9653 O
( O
31 O
mg O
/ O
kg O
) O
was O
infused O
over O
15 O
, O
20 O
, O
and O
30 O
min O
and O
the O
responses O
were O
compared O
to O
an O
equimolar O
dose O
of O
phenytoin O
sodium O
( O
21 O
mg O
/ O
kg O
) O
. O

the O
acc O
- O
9653 O
and O
phenytoin O
sodium O
treatments O
produced O
similar O
marked O
reductions O
in O
diastolic O
blood O
pressure O
and O
contractile O
force O
( O
lvdp O
/ O
dt O
) O
. O

the O
maximum O
effects O
of O
each O
treatment O
occurred O
at O
the O
time O
of O
maximum O
phenytoin O
sodium O
levels O
. O

acute O
toxicity B-Disease
studies O
of O
acc O
- O
9653 O
and O
phenytoin O
sodium O
were O
carried O
out O
in O
mice O
, O
rats O
, O
rabbits O
, O
and O
dogs O
by O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
i O
. O
p O
. O
routes O
of O
administration O
. O

the O
systemic O
toxic O
signs O
of O
both O
agents O
were O
similar O
and O
occurred O
at O
approximately O
equivalent O
doses O
. O

importantly O
, O
the O
local O
irritation O
of O
acc O
- O
9653 O
was O
markedly O
less O
than O
phenytoin O
sodium O
following O
i O
. O
m O
. O
administration O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

tachyphylaxis O
to O
systemic O
but O
not O
to O
airway O
responses O
during O
prolonged O
therapy O
with O
high O
dose O
inhaled O
salbutamol O
in O
asthmatics B-Disease
. O

high O
doses O
of O
inhaled O
salbutamol O
produce O
substantial O
improvements O
in O
airway O
response O
in O
patients O
with O
asthma B-Disease
, O
and O
are O
associated O
with O
dose O
- O
dependent O
systemic O
beta O
- O
adrenoceptor O
responses O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
whether O
tachyphylaxis O
occurs O
during O
prolonged O
treatment O
with O
high O
dose O
inhaled O
salbutamol O
. O

twelve O
asthmatic B-Disease
patients O
( O
fev1 O
, O
81 O
+ O
/ O
- O
4 O
% O
predicted O
) O
, O
requiring O
only O
occasional O
inhaled O
beta O
- O
agonists O
as O
their O
sole O
therapy O
, O
were O
given O
a O
14 O
- O
day O
treatment O
with O
high O
dose O
inhaled O
salbutamol O
( O
hds O
) O
, O
4 O
, O
000 O
micrograms O
daily O
, O
low O
dose O
inhaled O
salbutamol O
( O
lds O
) O
, O
800 O
micrograms O
daily O
, O
or O
placebo O
( O
pi O
) O
by O
metered O
- O
dose O
inhaler O
in O
a O
double O
- O
blind O
, O
randomized O
crossover O
design O
. O

during O
the O
14 O
- O
day O
run O
- O
in O
and O
during O
washout O
periods O
, O
inhaled O
beta O
- O
agonists O
were O
withheld O
and O
ipratropium O
bromide O
was O
substituted O
for O
rescue O
purposes O
. O

at O
the O
end O
of O
each O
14 O
- O
day O
treatment O
, O
a O
dose O
- O
response O
curve O
( O
drc O
) O
was O
performed O
, O
and O
airway O
( O
fev1 O
, O
fef25 O
- O
75 O
) O
chronotropic O
( O
hr O
) O
, O
tremor B-Disease
, O
and O
metabolic O
( O
k O
, O
glu O
) O
responses O
were O
measured O
at O
each O
step O
( O
from O
100 O
to O
4 O
, O
000 O
micrograms O
) O
. O

treatment O
had O
no O
significant O
effect O
on O
baseline O
values O
. O

there O
were O
dose O
- O
dependent O
increases O
in O
fev1 O
and O
fef25 O
- O
75 O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
and O
pretreatment O
with O
hds O
did O
not O
displace O
the O
drc O
to O
the O
right O
. O

drc O
for O
hr O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
k O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
and O
glu O
( O
p O
less O
than O
0 O
. O
005 O
) O
were O
attenuated O
after O
treatment O
with O
hds O
compared O
with O
pi O
. O

there O
were O
also O
differences O
between O
hds O
and O
lds O
for O
hr O
( O
p O
less O
than O
0 O
. O
001 O
) O
and O
glu O
( O
p O
less O
than O
0 O
. O
05 O
) O
responses O
. O

frequency O
and O
severity O
of O
subjective O
adverse O
effects O
were O
also O
reduced O
after O
hds O
: O
tremor B-Disease
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
palpitations B-Disease
( O
p O
less O
than O
0 O
. O
001 O
) O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

phenytoin O
induced O
fatal O
hepatic B-Disease
injury I-Disease
. O

a O
61 O
year O
old O
female O
developed O
fatal O
hepatic B-Disease
failure I-Disease
after O
phenytoin O
administration O
. O

a O
typical O
multisystem O
clinical O
pattern O
precedes O
the O
manifestations O
of O
hepatic B-Disease
injury I-Disease
. O

the O
hematologic O
, O
biochemical O
and O
pathologic O
features O
indicate O
a O
mixed O
hepatocellular B-Disease
damage I-Disease
due O
to O
drug B-Disease
hypersensitivity I-Disease
. O

in O
a O
patient O
receiving O
phenytoin O
who O
presents O
a O
viral O
- O
like O
illness O
, O
early O
recognition O
and O
discontinuation O
of O
the O
drug O
are O
mandatory O
. O

treatment O
of O
lethal O
pertussis O
vaccine O
reaction O
with O
histamine O
h1 O
antagonists O
. O

we O
studied O
mortality O
after O
pertussis B-Disease
immunization O
in O
the O
mouse O
. O

without O
treatment O
, O
73 O
of O
92 O
animals O
( O
80 O
% O
) O
died O
after O
injection O
of O
bovine O
serum O
albumin O
( O
bsa O
) O
on O
day O
+ O
7 O
of O
pertussis B-Disease
immunization O
. O

after O
pretreatment O
with O
3 O
mg O
of O
cyproheptadine O
, O
2 O
mg O
mianserin O
, O
or O
2 O
mg O
chlorpheniramine O
, O
only O
5 O
of O
105 O
animals O
( O
5 O
% O
) O
died O
after O
receiving O
bsa O
on O
day O
+ O
7 O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

blockade O
of O
histamine O
h1 O
receptors O
may O
reduce O
mortality O
in O
pertussis B-Disease
immunization O
- O
induced O
encephalopathy B-Disease
in O
mice O
. O

support O
for O
adrenaline O
- O
hypertension B-Disease
hypothesis O
: O
18 O
hour O
pressor O
effect O
after O
6 O
hours O
adrenaline O
infusion O
. O

in O
a O
double O
blind O
, O
crossover O
study O
6 O
h O
infusions O
of O
adrenaline O
( O
15 O
ng O
/ O
kg O
/ O
min O
; O
1 O
ng O
= O
5 O
. O
458 O
pmol O
) O
, O
noradrenaline O
( O
30 O
ng O
/ O
kg O
/ O
min O
; O
1 O
ng O
= O
5 O
. O
911 O
pmol O
) O
, O
and O
a O
5 O
% O
dextrose O
solution O
( O
5 O
. O
4 O
ml O
/ O
h O
) O
, O
were O
given O
to O
ten O
healthy O
volunteers O
in O
random O
order O
2 O
weeks O
apart O
. O

by O
means O
of O
intra O
- O
arterial O
ambulatory O
monitoring O
the O
haemodynamic O
effects O
were O
followed O
for O
18 O
h O
after O
the O
infusions O
were O
stopped O
. O

adrenaline O
, O
but O
not O
noradrenaline O
, O
caused O
a O
delayed O
and O
protracted O
pressor O
effect O
. O

over O
the O
total O
postinfusion O
period O
systolic O
and O
diastolic O
arterial O
pressure O
were O
6 O
( O
sem O
2 O
) O
% O
and O
7 O
( O
2 O
) O
% O
, O
respectively O
, O
higher O
than O
after O
dextrose O
infusion O
( O
anova O
, O
p O
less O
than O
0 O
. O
001 O
) O
. O

thus O
, O
" O
stress O
" O
levels O
of O
adrenaline O
( O
230 O
pg O
/ O
ml O
) O
for O
6 O
h O
cause O
a O
delayed O
and O
protracted O
pressor O
effect O
. O

these O
findings O
are O
strong O
support O
for O
the O
adrenaline O
- O
hypertension B-Disease
hypothesis O
in O
man O
. O

effect O
of O
alkylxanthines O
on O
gentamicin O
- O
induced O
acute B-Disease
renal I-Disease
failure I-Disease
in O
the O
rat O
. O

adenosine O
antagonists O
have O
been O
previously O
shown O
to O
be O
of O
benefit O
in O
some O
ischaemic B-Disease
and O
nephrotoxic B-Disease
models O
of O
acute B-Disease
renal I-Disease
failure I-Disease
( O
arf B-Disease
) O
. O

in O
the O
present O
study O
, O
the O
effects O
of O
three O
alkylxanthines O
with O
different O
potencies O
as O
adenosine O
antagonists O
8 O
- O
phenyltheophylline O
, O
theophylline O
and O
enprofylline O
, O
were O
examined O
in O
rats O
developing O
acute B-Disease
renal I-Disease
failure I-Disease
after O
4 O
daily O
injections O
of O
gentamicin O
( O
200 O
mg O
kg O
- O
1 O
) O
. O

renal O
function O
was O
assessed O
by O
biochemical O
( O
plasma O
urea O
and O
creatinine O
) O
, O
functional O
( O
urine O
analysis O
and O
[ O
3h O
] O
inulin O
and O
[ O
14c O
] O
p O
- O
aminohippuric O
acid O
clearances O
) O
and O
morphological O
( O
degree O
of O
necrosis B-Disease
) O
indices O
. O

the O
various O
drug O
treatments O
produced O
improvements O
in O
some O
, O
but O
not O
all O
, O
measurements O
of O
renal O
function O
. O

however O
, O
any O
improvement O
produced O
by O
drug O
treatment O
was O
largely O
a O
result O
of O
a O
beneficial O
effect O
exerted O
by O
its O
vehicle O
( O
polyethylene O
glycol O
and O
naoh O
) O
. O

the O
lack O
of O
any O
consistent O
protective O
effect O
noted O
with O
the O
alkylxanthines O
tested O
in O
the O
present O
study O
indicates O
that O
adenosine O
plays O
little O
, O
if O
any O
, O
pathophysiological O
role O
in O
gentamicin O
- O
induced O
arf B-Disease
. O

adverse O
ocular O
reactions O
possibly O
associated O
with O
isotretinoin O
. O

a O
total O
of O
261 O
adverse O
ocular O
reactions O
occurred O
in O
237 O
patients O
who O
received O
isotretinoin O
, O
a O
commonly O
used O
drug O
in O
the O
treatment O
of O
severe O
cystic O
acne B-Disease
. O

blepharoconjunctivitis B-Disease
, O
subjective O
complaints O
of O
dry B-Disease
eyes I-Disease
, O
blurred B-Disease
vision I-Disease
, O
contact O
lens O
intolerance O
, O
and O
photodermatitis B-Disease
are O
reversible O
side O
effects O
. O

more O
serious O
ocular O
adverse O
reactions O
include O
papilledema B-Disease
, O
pseudotumor B-Disease
cerebri I-Disease
, O
and O
white O
or O
gray O
subepithelial O
corneal B-Disease
opacities I-Disease
; O
all O
of O
these O
are O
reversible O
if O
the O
drug O
is O
discontinued O
. O

reported O
cases O
of O
decreased O
dark O
adaptation O
are O
under O
investigation O
. O

isotretinoin O
is O
contraindicated O
in O
pregnancy O
because O
of O
the O
many O
reported O
congenital B-Disease
abnormalities I-Disease
after O
maternal O
use O
( O
including O
microphthalmos B-Disease
, O
orbital O
hypertelorism B-Disease
, O
and O
optic B-Disease
nerve I-Disease
hypoplasia I-Disease
) O
. O

procaterol O
and O
terbutaline O
in O
bronchial B-Disease
asthma I-Disease
. O

a O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
cross O
- O
over O
study O
. O

procaterol O
, O
a O
new O
beta O
- O
2 O
adrenoceptor O
stimulant O
, O
was O
studied O
in O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
cross O
- O
over O
trial O
in O
patients O
with O
bronchial B-Disease
asthma I-Disease
. O

oral O
procaterol O
50 O
micrograms O
b O
. O
d O
. O
, O
procaterol O
100 O
micrograms O
b O
. O
d O
. O
, O
and O
terbutaline O
5 O
mg O
t O
. O
i O
. O
d O
. O
, O
were O
compared O
when O
given O
randomly O
in O
1 O
- O
week O
treatment O
periods O
. O

the O
best O
clinical O
effect O
was O
found O
with O
terbutaline O
. O

both O
anti O
- O
asthmatic B-Disease
and O
tremorgenic B-Disease
effects O
of O
procaterol O
were O
dose O
- O
related O
. O

procaterol O
appeared O
effective O
in O
the O
doses O
tested O
, O
and O
a O
twice O
daily O
regimen O
would O
appear O
to O
be O
suitable O
with O
this O
drug O
. O

subacute O
effects O
of O
propranolol O
and O
b O
24 O
/ O
76 O
on O
isoproterenol O
- O
induced O
rat O
heart B-Disease
hypertrophy I-Disease
in O
correlation O
with O
blood O
pressure O
. O

we O
compared O
the O
potential O
beta O
- O
receptor O
blocker O
, O
b O
24 O
/ O
76 O
i O
. O
e O
. O
1 O
- O
( O
2 O
, O
4 O
- O
dichlorophenoxy O
) O
- O
3 O
[ O
2 O
- O
3 O
, O
4 O
- O
dimethoxyphenyl O
) O
ethanolamino O
] O
- O
prop O
an O
- O
2 O
- O
ol O
, O
which O
is O
characterized O
by O
beta O
1 O
- O
adrenoceptor O
blocking O
and O
beta O
2 O
- O
adrenoceptor O
stimulating O
properties O
with O
propranolol O
. O

the O
studies O
were O
performed O
using O
an O
experimental O
model O
of O
isoproterenol O
- O
induced O
heart B-Disease
hypertrophy I-Disease
in O
rats O
. O

a O
correlation O
of O
the O
blood O
pressure O
was O
neither O
found O
in O
the O
development O
nor O
in O
the O
attempt O
to O
suppress O
the O
development O
of O
heart B-Disease
hypertrophy I-Disease
with O
the O
two O
beta O
- O
receptor O
blockers O
. O

both O
beta O
- O
blockers O
influenced O
the O
development O
of O
hypertrophy B-Disease
to O
a O
different O
, O
but O
not O
reproducible O
extent O
. O

it O
was O
possible O
to O
suppress O
the O
increased O
ornithine O
decarboxylase O
activity O
with O
both O
beta O
- O
blockers O
in O
hypertrophied B-Disease
hearts I-Disease
, O
but O
there O
was O
no O
effect O
on O
the O
heart O
mass O
. O

neither O
propranolol O
nor O
b O
24 O
/ O
76 O
could O
stop O
the O
changes O
in O
the O
characteristic O
myosin O
isoenzyme O
pattern O
of O
the O
hypertrophied B-Disease
rat O
heart O
. O

thus O
, O
the O
investigations O
did O
not O
provide O
any O
evidence O
that O
the O
beta O
- O
receptor O
blockers O
propranolol O
and O
b O
24 O
/ O
76 O
have O
the O
potency O
to O
prevent O
isoproterenol O
from O
producing O
heart B-Disease
hypertrophy I-Disease
. O

increased O
anxiogenic O
effects O
of O
caffeine O
in O
panic B-Disease
disorders I-Disease
. O

the O
effects O
of O
oral O
administration O
of O
caffeine O
( O
10 O
mg O
/ O
kg O
) O
on O
behavioral O
ratings O
, O
somatic O
symptoms O
, O
blood O
pressure O
and O
plasma O
levels O
of O
3 O
- O
methoxy O
- O
4 O
- O
hydroxyphenethyleneglycol O
( O
mhpg O
) O
and O
cortisol O
were O
determined O
in O
17 O
healthy O
subjects O
and O
21 O
patients O
meeting O
dsm O
- O
iii O
criteria O
for O
agoraphobia B-Disease
with O
panic B-Disease
attacks I-Disease
or O
panic B-Disease
disorder I-Disease
. O

caffeine O
produced O
significantly O
greater O
increases O
in O
subject O
- O
rated O
anxiety B-Disease
, O
nervousness O
, O
fear O
, O
nausea B-Disease
, O
palpitations B-Disease
, O
restlessness B-Disease
, O
and O
tremors B-Disease
in O
the O
patients O
compared O
with O
healthy O
subjects O
. O

in O
the O
patients O
, O
but O
not O
the O
healthy O
subjects O
, O
these O
symptoms O
were O
significantly O
correlated O
with O
plasma O
caffeine O
levels O
. O

seventy O
- O
one O
percent O
of O
the O
patients O
reported O
that O
the O
behavioral O
effects O
of O
caffeine O
were O
similar O
to O
those O
experienced O
during O
panic B-Disease
attacks I-Disease
. O

caffeine O
did O
not O
alter O
plasma O
mhpg O
levels O
in O
either O
the O
healthy O
subjects O
or O
patients O
. O

caffeine O
increased O
plasma O
cortisol O
levels O
equally O
in O
the O
patient O
and O
healthy O
groups O
. O

because O
caffeine O
is O
an O
adenosine O
receptor O
antagonist O
, O
these O
results O
suggest O
that O
some O
panic B-Disease
disorder I-Disease
patients O
may O
have O
abnormalities B-Disease
in I-Disease
neuronal I-Disease
systems I-Disease
involving O
adenosine O
. O

patients O
with O
anxiety B-Disease
disorders I-Disease
may O
benefit O
by O
avoiding O
caffeine O
- O
containing O
foods O
and O
beverages O
. O

comparison O
of O
the O
effect O
of O
oxitropium O
bromide O
and O
of O
slow O
- O
release O
theophylline O
on O
nocturnal O
asthma B-Disease
. O

the O
effects O
of O
a O
new O
inhaled O
antimuscarinic O
drug O
, O
oxitropium O
bromide O
, O
and O
of O
a O
slow O
- O
release O
theophylline O
preparation O
upon O
nocturnal O
asthma B-Disease
were O
compared O
in O
a O
placebo O
- O
controlled O
double O
- O
blind O
study O
. O

two O
samples O
were O
studied O
: O
12 O
patients O
received O
oxitropium O
at O
600 O
micrograms O
( O
6 O
subjects O
) O
or O
at O
400 O
micrograms O
t O
. O
i O
. O
d O
. O

( O
6 O
subjects O
) O
whereas O
11 O
received O
theophylline O
at O
300 O
mg O
b O
. O
i O
. O
d O
. O

morning O
dipping O
, O
assessed O
by O
the O
fall O
in O
peak O
flow O
overnight O
, O
was O
significantly O
reduced O
in O
the O
periods O
when O
either O
active O
drug O
was O
taken O
, O
whereas O
no O
difference O
was O
noticed O
during O
the O
placebo O
administration O
. O

no O
significant O
difference O
was O
noticed O
between O
results O
obtained O
with O
either O
active O
drug O
, O
as O
well O
as O
with O
either O
dosage O
of O
oxitropium O
. O

no O
subject O
reported O
side O
effects O
of O
oxitropium O
, O
as O
compared O
to O
three O
subjects O
reporting O
nausea B-Disease
, O
vomiting B-Disease
and O
tremors B-Disease
after O
theophylline O
. O

oxitropium O
proves O
to O
be O
a O
valuable O
alternative O
to O
theophylline O
in O
nocturnal O
asthma B-Disease
, O
since O
it O
is O
equally O
potent O
, O
safer O
and O
does O
not O
require O
the O
titration O
of O
dosage O
. O

penicillin O
anaphylaxis B-Disease
. O

a O
case O
of O
oral O
penicillin O
anaphylaxis B-Disease
is O
described O
, O
and O
the O
terminology O
, O
occurrence O
, O
clinical O
manifestations O
, O
pathogenesis O
, O
prevention O
, O
and O
treatment O
of O
anaphylaxis B-Disease
are O
reviewed O
. O

emergency O
physicians O
should O
be O
aware O
of O
oral O
penicillin O
anaphylaxis B-Disease
in O
order O
to O
prevent O
its O
occurrence O
by O
prescribing O
the O
antibiotic O
judiciously O
and O
knowledgeably O
and O
to O
offer O
optimal O
medical O
therapy O
once O
this O
life O
- O
threatening O
reaction O
has O
begun O
. O

reversible O
valproic O
acid O
- O
induced O
dementia B-Disease
: O
a O
case O
report O
. O

reversible O
valproic O
acid O
- O
induced O
dementia B-Disease
was O
documented O
in O
a O
21 O
- O
year O
- O
old O
man O
with O
epilepsy B-Disease
who O
had O
a O
3 O
- O
year O
history O
of O
insidious O
progressive O
decline O
in O
global O
cognitive O
abilities O
documented O
by O
serial O
neuropsychological O
studies O
. O

repeat O
neuropsychological O
testing O
7 O
weeks O
after O
discontinuation O
of O
the O
drug O
revealed O
dramatic O
improvement O
in O
iq O
, O
memory O
, O
naming O
, O
and O
other O
tasks O
commensurate O
with O
clinical O
recovery O
in O
his O
intellectual O
capacity O
. O

possible O
pathophysiological O
mechanisms O
which O
may O
have O
been O
operative O
in O
this O
case O
include O
: O
a O
direct O
central O
nervous O
system O
( O
cns O
) O
toxic O
effect O
of O
valproic O
acid O
; O
a O
paradoxical O
epileptogenic O
effect O
secondary O
to O
the O
drug O
; O
and O
an O
indirect O
cns O
toxic O
effect O
mediated O
through O
valproic O
acid O
- O
induced O
hyperammonemia B-Disease
. O

reversal O
of O
scopolamine O
- O
induced O
amnesia B-Disease
of O
passive O
avoidance O
by O
pre O
- O
and O
post O
- O
training O
naloxone O
. O

in O
a O
series O
of O
five O
experiments O
, O
the O
modulating O
role O
of O
naloxone O
on O
a O
scopolamine O
- O
induced O
retention B-Disease
deficit I-Disease
in O
a O
passive O
avoidance O
paradigm O
was O
investigated O
in O
mice O
. O

scopolamine O
, O
but O
not O
methyl O
scopolamine O
( O
1 O
and O
3 O
mg O
/ O
kg O
) O
, O
induced O
an O
amnesia B-Disease
as O
measured O
by O
latency O
and O
duration O
parameters O
. O

naloxone O
( O
0 O
. O
3 O
, O
1 O
, O
3 O
, O
and O
10 O
mg O
/ O
kg O
) O
injected O
prior O
to O
training O
attenuated O
the O
retention B-Disease
deficit I-Disease
with O
a O
peak O
of O
activity O
at O
3 O
mg O
/ O
kg O
. O

the O
effect O
of O
naloxone O
could O
be O
antagonized O
with O
morphine O
( O
1 O
, O
3 O
, O
and O
10 O
mg O
/ O
kg O
) O
, O
demonstrating O
the O
opioid O
specificity O
of O
the O
naloxone O
effect O
. O

post O
- O
training O
administration O
of O
naloxone O
( O
3 O
mg O
/ O
kg O
) O
as O
a O
single O
or O
as O
a O
split O
dose O
also O
attenuated O
the O
scopolamine O
- O
induced O
amnesia B-Disease
. O

control O
experiments O
indicated O
that O
neither O
an O
increase O
in O
pain B-Disease
sensitivity O
( O
pre O
- O
training O
naloxone O
) O
nor O
an O
induced O
aversive O
state O
( O
post O
- O
training O
naloxone O
) O
appear O
to O
be O
responsible O
for O
the O
influence O
of O
naloxone O
on O
the O
scopolamine O
- O
induced O
retention B-Disease
deficit I-Disease
. O

these O
results O
extend O
previous O
findings O
implicating O
a O
cholinergic O
- O
opioid O
interaction O
in O
memory O
processes O
. O

a O
possible O
mechanism O
for O
this O
interaction O
involving O
the O
septo O
- O
hippocampal O
cholinergic O
pathway O
is O
discussed O
. O

electron O
microscopic O
investigations O
of O
the O
cyclophosphamide O
- O
induced O
lesions B-Disease
of I-Disease
the I-Disease
urinary I-Disease
bladder I-Disease
of O
the O
rat O
and O
their O
prevention O
by O
mesna O
. O

fully O
developed O
cyclophosphamide O
- O
induced O
cystitis B-Disease
is O
characterized O
by O
nearly O
complete O
detachment O
of O
the O
urothelium O
, O
severe O
submucosal O
edema B-Disease
owing O
to O
damage O
to O
the O
microvascular O
bed O
and O
focal O
muscle O
necroses B-Disease
. O

the O
initial O
response O
to O
the O
primary O
attack O
by O
the O
cyclophosphamide O
metabolites O
seems O
to O
be O
fragmentation O
of O
the O
luminal O
membrane O
. O

this O
damages O
the O
cellular O
barrier O
against O
the O
hypertonic O
urine O
. O

subsequent O
breaks O
in O
the O
lateral O
cell O
membranes O
of O
the O
superficial O
cells O
and O
in O
all O
the O
plasma O
membranes O
of O
the O
intermediate O
and O
basal O
cells O
, O
intercellular O
and O
intracellular O
edema B-Disease
and O
disintegration O
of O
the O
desmosomes O
and O
hemidesmosomes O
lead O
to O
progressive O
degeneration O
and O
detachment O
of O
the O
epithelial O
cells O
with O
exposure O
and O
splitting O
of O
the O
basal O
membrane O
. O

the O
morphological O
changes O
of O
the O
endothelial O
cells O
, O
which O
become O
more O
pronounced O
in O
the O
later O
stages O
of O
the O
experiment O
, O
the O
involvement O
of O
blood O
vessels O
regardless O
of O
their O
diameter O
and O
the O
location O
- O
dependent O
extent O
of O
the O
damage O
indicate O
a O
direct O
type O
of O
damage O
which O
is O
preceded O
by O
a O
mediator O
- O
induced O
increase O
in O
permeability O
, O
the O
morphological O
correlate O
of O
which O
is O
the O
formation O
of O
gaps O
in O
the O
interendothelial O
cell O
connections O
on O
the O
venules O
. O

these O
changes O
can O
be O
effectively O
prevented O
by O
mesna O
. O

the O
only O
sign O
of O
a O
possible O
involvement O
is O
the O
increase O
in O
the O
number O
of O
specific O
granules O
with O
a O
presumed O
lysosomal O
function O
in O
the O
superficial O
cells O
. O

increase O
in O
intragastric O
pressure O
during O
suxamethonium O
- O
induced O
muscle B-Disease
fasciculations I-Disease
in O
children O
: O
inhibition O
by O
alfentanil O
. O

changes O
in O
intragastric O
pressure O
after O
the O
administration O
of O
suxamethonium O
1 O
. O
5 O
mg O
kg O
- O
1 O
i O
. O
v O
. O
were O
studied O
in O
32 O
children O
( O
mean O
age O
6 O
. O
9 O
yr O
) O
pretreated O
with O
either O
physiological O
saline O
or O
alfentanil O
50 O
micrograms O
kg O
- O
1 O
. O

anaesthesia O
was O
induced O
with O
thiopentone O
5 O
mg O
kg O
- O
1 O
. O

the O
incidence O
and O
intensity O
of O
muscle B-Disease
fasciculations I-Disease
caused O
by O
suxamethonium O
were O
significantly O
greater O
in O
the O
control O
than O
in O
the O
alfentanil O
group O
. O

the O
intragastric O
pressure O
during O
muscle B-Disease
fasciculations I-Disease
was O
significantly O
higher O
in O
the O
control O
group O
( O
16 O
+ O
/ O
- O
0 O
. O
7 O
( O
sem O
) O
cm O
h2o O
) O
than O
in O
the O
alfentanil O
group O
( O
7 O
. O
7 O
+ O
/ O
- O
1 O
. O
5 O
( O
sem O
) O
cm O
h2o O
) O
. O

the O
increase O
in O
intragastric O
pressure O
was O
directly O
related O
to O
the O
intensity O
of O
muscle B-Disease
fasciculations I-Disease
( O
regression O
line O
: O
y O
= O
0 O
. O
5 O
+ O
4 O
. O
78x O
with O
r O
of O
0 O
. O
78 O
) O
. O

it O
is O
concluded O
that O
intragastric O
pressure O
increases O
significantly O
during O
muscle B-Disease
fasciculations I-Disease
caused O
by O
suxamethonium O
in O
healthy O
children O
. O

alfentanil O
50 O
micrograms O
kg O
- O
1 O
effectively O
inhibits O
the O
incidence O
and O
intensity O
of O
suxamethonium O
- O
induced O
muscle B-Disease
fasciculations I-Disease
; O
moreover O
, O
intragastric O
pressure O
remains O
at O
its O
control O
value O
. O

acute O
insulin O
treatment O
normalizes O
the O
resistance O
to O
the O
cardiotoxic B-Disease
effect O
of O
isoproterenol O
in O
streptozotocin O
diabetic B-Disease
rats O
. O

a O
morphometric O
study O
of O
isoproterenol O
induced O
myocardial O
fibrosis B-Disease
. O

the O
acute O
effect O
of O
insulin O
treatment O
on O
the O
earlier O
reported O
protective O
effect O
of O
streptozotocin O
diabetes B-Disease
against O
the O
cardiotoxic B-Disease
effect O
of O
high O
doses O
of O
isoproterenol O
( O
iso O
) O
was O
investigated O
in O
rats O
. O

thirty O
to O
135 O
min O
after O
the O
injection O
of O
crystalline O
insulin O
, O
iso O
was O
given O
subcutaneously O
and O
when O
iso O
induced O
fibrosis B-Disease
in O
the O
myocardium O
was O
morphometrically O
analyzed O
7 O
days O
later O
, O
a O
highly O
significant O
correlation O
( O
r O
= O
0 O
. O
83 O
, O
2 O
p O
= O
0 O
. O
006 O
) O
to O
the O
slope O
of O
the O
fall O
in O
blood O
glucose O
after O
insulin O
treatment O
appeared O
. O

the O
myocardial O
content O
of O
catecholamines O
was O
estimated O
in O
these O
8 O
day O
diabetic B-Disease
rats O
. O

the O
norepinephrine O
content O
was O
significantly O
increased O
while O
epinephrine O
remained O
unchanged O
. O

an O
enhanced O
sympathetic O
nervous O
system O
activity O
with O
a O
consequent O
down O
regulation O
of O
the O
myocardial O
beta O
- O
adrenergic O
receptors O
could O
, O
therefore O
, O
explain O
this O
catecholamine O
resistance O
. O

the O
rapid O
reversion O
after O
insulin O
treatment O
excludes O
the O
possibility O
that O
streptozotocin O
in O
itself O
causes O
the O
iso O
resistance O
and O
points O
towards O
a O
direct O
insulin O
effect O
on O
myocardial O
catecholamine O
sensitivity O
in O
diabetic B-Disease
rats O
. O

the O
phenomenon O
described O
might O
elucidate O
pathogenetic O
mechanisms O
behind O
toxic O
myocardial O
cell O
degeneration O
and O
may O
possibly O
have O
relevance O
for O
acute O
cardiovascular O
complications O
in O
diabetic B-Disease
patients O
. O

differential O
effects O
of O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
on O
seizures B-Disease
produced O
by O
pilocarpine O
in O
rats O
. O

the O
muscarinic O
cholinergic O
agonist O
pilocarpine O
induces O
in O
rats O
seizures B-Disease
and O
status B-Disease
epilepticus I-Disease
followed O
by O
widespread O
damage O
to O
the O
forebrain O
. O

the O
present O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
5 O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
, O
sodium O
salicylate O
, O
phenylbutazone O
, O
indomethacin O
, O
ibuprofen O
and O
mefenamic O
acid O
, O
on O
seizures B-Disease
produced O
by O
pilocarpine O
. O

pretreatment O
of O
rats O
with O
sodium O
salicylate O
, O
ed50 O
103 O
mg O
/ O
kg O
( O
60 O
- O
174 O
) O
, O
and O
phenylbutazone O
, O
59 O
mg O
/ O
kg O
( O
50 O
- O
70 O
) O
converted O
the O
non O
- O
convulsant O
dose O
of O
pilocarpine O
, O
200 O
mg O
/ O
kg O
, O
to O
a O
convulsant O
one O
. O

indomethacin O
, O
1 O
- O
10 O
mg O
/ O
kg O
, O
and O
ibuprofen O
, O
10 O
- O
100 O
mg O
/ O
kg O
, O
failed O
to O
modulate O
seizures B-Disease
produced O
by O
pilocarpine O
. O

mefenamic O
acid O
, O
26 O
( O
22 O
- O
30 O
) O
mg O
/ O
kg O
, O
prevented O
seizures B-Disease
and O
protected O
rats O
from O
seizure B-Disease
- O
related O
brain B-Disease
damage I-Disease
induced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

these O
results O
indicate O
that O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
differentially O
modulate O
the O
threshold O
for O
pilocarpine O
- O
induced O
seizures B-Disease
. O

acute B-Disease
neurologic I-Disease
dysfunction I-Disease
after O
high O
- O
dose O
etoposide O
therapy O
for O
malignant B-Disease
glioma I-Disease
. O

etoposide O
( O
vp O
- O
16 O
- O
213 O
) O
has O
been O
used O
in O
the O
treatment O
of O
many O
solid O
tumors B-Disease
and O
hematologic B-Disease
malignancies I-Disease
. O

when O
used O
in O
high O
doses O
and O
in O
conjunction O
with O
autologous O
bone O
marrow O
transplantation O
, O
this O
agent O
has O
activity O
against O
several O
treatment O
- O
resistant O
cancers B-Disease
including O
malignant B-Disease
glioma I-Disease
. O

in O
six O
of O
eight O
patients O
( O
75 O
% O
) O
who O
we O
treated O
for O
recurrent O
or O
resistant O
glioma B-Disease
, O
sudden O
severe O
neurologic B-Disease
deterioration I-Disease
occurred O
. O

this O
developed O
a O
median O
of O
9 O
days O
after O
initiation O
of O
high O
- O
dose O
etoposide O
therapy O
. O

significant O
clinical O
manifestations O
have O
included O
confusion B-Disease
, O
papilledema B-Disease
, O
somnolence B-Disease
, O
exacerbation O
of O
motor B-Disease
deficits I-Disease
, O
and O
sharp O
increase O
in O
seizure B-Disease
activity O
. O

these O
abnormalities O
resolved O
rapidly O
after O
initiation O
of O
high O
- O
dose O
intravenous O
dexamethasone O
therapy O
. O

in O
all O
patients O
, O
computerized O
tomographic O
( O
ct O
) O
brain O
scans O
demonstrated O
stability O
in O
tumor B-Disease
size O
and O
peritumor O
edema B-Disease
when O
compared O
with O
pretransplant O
scans O
. O

this O
complication O
appears O
to O
represent O
a O
significant O
new O
toxicity B-Disease
of O
high O
- O
dose O
etoposide O
therapy O
for O
malignant B-Disease
glioma I-Disease
. O

progressive O
bile B-Disease
duct I-Disease
injury I-Disease
after O
thiabendazole O
administration O
. O

a O
27 O
- O
yr O
- O
old O
man O
developed O
jaundice B-Disease
2 O
wk O
after O
exposure O
to O
thiabendazole O
. O

cholestasis B-Disease
persisted O
for O
3 O
yr O
, O
at O
which O
time O
a O
liver O
transplant O
was O
performed O
. O

two O
liver O
biopsy O
specimens O
and O
the O
hepatectomy O
specimen O
were O
remarkable O
for O
almost O
complete O
disappearance O
of O
interlobular O
bile O
ducts O
. O

prominent O
fibrosis B-Disease
and O
hepatocellular O
regeneration O
were O
also O
present O
; O
however O
, O
the O
lobular O
architecture O
was O
preserved O
. O

this O
case O
represents O
an O
example O
of O
" O
idiosyncratic O
" O
drug B-Disease
- I-Disease
induced I-Disease
liver I-Disease
damage I-Disease
in O
which O
the O
primary O
target O
of O
injury O
is O
the O
bile O
duct O
. O

an O
autoimmune O
pathogenesis O
of O
the O
bile B-Disease
duct I-Disease
destruction I-Disease
is O
suggested O
. O

differential O
effects O
of O
1 O
, O
4 O
- O
dihydropyridine O
calcium O
channel O
blockers O
: O
therapeutic O
implications O
. O

increasing O
recognition O
of O
the O
importance O
of O
calcium O
in O
the O
pathogenesis O
of O
cardiovascular B-Disease
disease I-Disease
has O
stimulated O
research O
into O
the O
use O
of O
calcium O
channel O
blocking O
agents O
for O
treatment O
of O
a O
variety O
of O
cardiovascular B-Disease
diseases I-Disease
. O

the O
favorable O
efficacy O
and O
tolerability O
profiles O
of O
these O
agents O
make O
them O
attractive O
therapeutic O
modalities O
. O

clinical O
applications O
of O
calcium O
channel O
blockers O
parallel O
their O
tissue O
selectivity O
. O

in O
contrast O
to O
verapamil O
and O
diltiazem O
, O
which O
are O
roughly O
equipotent O
in O
their O
actions O
on O
the O
heart O
and O
vascular O
smooth O
muscle O
, O
the O
dihydropyridine O
calcium O
channel O
blockers O
are O
a O
group O
of O
potent O
peripheral O
vasodilator O
agents O
that O
exert O
minimal O
electrophysiologic O
effects O
on O
cardiac O
nodal O
or O
conduction O
tissue O
. O

as O
the O
first O
dihydropyridine O
available O
for O
use O
in O
the O
united O
states O
, O
nifedipine O
controls O
angina B-Disease
and O
hypertension B-Disease
with O
minimal O
depression O
of O
cardiac O
function O
. O

additional O
members O
of O
this O
group O
of O
calcium O
channel O
blockers O
have O
been O
studied O
for O
a O
variety O
of O
indications O
for O
which O
they O
may O
offer O
advantages O
over O
current O
therapy O
. O

once O
or O
twice O
daily O
dosage O
possible O
with O
nitrendipine O
and O
nisoldipine O
offers O
a O
convenient O
administration O
schedule O
, O
which O
encourages O
patient O
compliance O
in O
long O
- O
term O
therapy O
of O
hypertension B-Disease
. O

the O
coronary O
vasodilating O
properties O
of O
nisoldipine O
have O
led O
to O
the O
investigation O
of O
this O
agent O
for O
use O
in O
angina B-Disease
. O

selectivity O
for O
the O
cerebrovascular O
bed O
makes O
nimodipine O
potentially O
useful O
in O
the O
treatment O
of O
subarachnoid B-Disease
hemorrhage I-Disease
, O
migraine B-Disease
headache I-Disease
, O
dementia B-Disease
, O
and O
stroke B-Disease
. O

in O
general O
, O
the O
dihydropyridine O
calcium O
channel O
blockers O
are O
usually O
well O
tolerated O
, O
with O
headache B-Disease
, O
facial O
flushing B-Disease
, O
palpitations B-Disease
, O
edema B-Disease
, O
nausea B-Disease
, O
anorexia B-Disease
, O
and O
dizziness B-Disease
being O
the O
more O
common O
adverse O
effects O
. O

the O
enhancement O
of O
aminonucleoside O
nephrosis B-Disease
by O
the O
co O
- O
administration O
of O
protamine O
. O

an O
experimental O
model O
of O
focal B-Disease
segmental I-Disease
glomerular I-Disease
sclerosis I-Disease
( O
fsgs B-Disease
) O
was O
developed O
in O
rats O
by O
the O
combined O
administration O
of O
puromycin O
- O
aminonucleoside O
( O
amns O
) O
and O
protamine O
sulfate O
( O
ps O
) O
. O

male O
sprague O
- O
dawley O
rats O
, O
uninephrectomized O
three O
weeks O
before O
, O
received O
daily O
injections O
of O
subcutaneous O
amns O
( O
1 O
mg O
/ O
100 O
g O
body O
wt O
) O
and O
intravenous O
ps O
( O
2 O
separated O
doses O
of O
2 O
. O
5 O
mg O
/ O
100 O
g O
body O
wt O
) O
for O
four O
days O
. O

the O
series O
of O
injections O
were O
repeated O
another O
three O
times O
at O
10 O
day O
intervals O
. O

the O
animals O
were O
sacrificed O
on O
days O
24 O
, O
52 O
, O
and O
80 O
. O

they O
developed O
nephrotic B-Disease
syndrome I-Disease
and O
finally O
renal B-Disease
failure I-Disease
. O

the O
time O
- O
course O
curve O
of O
creatinine O
clearance O
dropped O
and O
showed O
significant O
difference O
( O
p O
less O
than O
0 O
. O
01 O
) O
from O
that O
of O
each O
control O
group O
, O
such O
as O
, O
amns O
alone O
, O
ps O
alone O
or O
saline O
injected O
. O

their O
glomeruli O
showed O
changes O
of O
progressive O
fsgs B-Disease
. O

the O
ultrastructural O
studies O
in O
the O
initial O
stage O
revealed O
significant O
lack O
of O
particles O
of O
perfused O
ruthenium O
red O
on O
the O
lamina O
rara O
externa O
and O
marked O
changes O
in O
epithelial O
cell O
cytoplasm O
. O

therefore O
, O
it O
is O
suggested O
that O
the O
administration O
of O
ps O
enhances O
the O
toxicity B-Disease
of O
amns O
on O
the O
glomerulus O
and O
readily O
produces O
progressive O
fsgs B-Disease
in O
rats O
resulting O
in O
the O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
. O

theophylline O
neurotoxicity B-Disease
in O
pregnant O
rats O
. O

the O
purpose O
of O
this O
investigation O
was O
to O
determine O
whether O
the O
neurotoxicity B-Disease
of O
theophylline O
is O
altered O
in O
advanced O
pregnancy O
. O

sprague O
- O
dawley O
rats O
that O
were O
20 O
days O
pregnant O
and O
nonpregnant O
rats O
of O
the O
same O
age O
and O
strain O
received O
infusions O
of O
aminophylline O
until O
onset O
of O
maximal O
seizures B-Disease
which O
occurred O
after O
28 O
and O
30 O
minutes O
respectively O
. O

theophylline O
concentrations O
at O
this O
endpoint O
in O
serum O
( O
total O
) O
and O
csf O
were O
similar O
but O
serum O
( O
free O
) O
and O
brain O
concentrations O
were O
slightly O
different O
in O
pregnant O
rats O
. O

theophylline O
serum O
protein O
binding O
determined O
by O
equilibrium O
dialysis O
was O
lower O
in O
pregnant O
rats O
. O

fetal O
serum O
concentrations O
at O
onset O
of O
seizures B-Disease
in O
the O
mother O
were O
similar O
to O
maternal O
brain O
and O
csf O
concentrations O
and O
correlated O
significantly O
with O
the O
former O
. O

it O
is O
concluded O
that O
advanced O
pregnancy O
has O
a O
negligible O
effect O
on O
the O
neurotoxic B-Disease
response O
to O
theophylline O
in O
rats O
. O

hyperkalemia B-Disease
induced O
by O
indomethacin O
and O
naproxen O
and O
reversed O
by O
fludrocortisone O
. O

we O
have O
described O
a O
patient O
with O
severe O
rheumatoid B-Disease
arthritis I-Disease
and O
a O
history O
of O
mefenamic O
acid O
nephropathy B-Disease
in O
whom O
hyperkalemia B-Disease
and O
inappropriate O
hypoaldosteronism B-Disease
were O
caused O
by O
both O
indomethacin O
and O
naproxen O
, O
without O
major O
decline O
in O
renal O
function O
. O

it O
is O
likely O
that O
preexisting O
renal B-Disease
disease I-Disease
predisposed O
this O
patient O
to O
type B-Disease
iv I-Disease
renal I-Disease
tubular I-Disease
acidosis I-Disease
with O
prostaglandin O
synthetase O
inhibitors O
. O

because O
he O
was O
unable O
to O
discontinue O
nonsteroidal O
anti O
- O
inflammatory O
drug O
therapy O
, O
fludrocortisone O
was O
added O
, O
correcting O
the O
hyperkalemia B-Disease
and O
allowing O
indomethacin O
therapy O
to O
be O
continued O
safely O
. O

hypotension B-Disease
as O
a O
manifestation O
of O
cardiotoxicity B-Disease
in O
three O
patients O
receiving O
cisplatin O
and O
5 O
- O
fluorouracil O
. O

cardiac O
symptoms O
, O
including O
hypotension B-Disease
, O
developed O
in O
three O
patients O
with O
advanced O
colorectal B-Disease
carcinoma I-Disease
while O
being O
treated O
with O
cisplatin O
( O
cddp O
) O
and O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
. O

in O
two O
patients O
, O
hypotension B-Disease
was O
associated O
with O
severe O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
. O

all O
three O
patients O
required O
therapy O
discontinuation O
. O

cardiac O
enzymes O
remained O
normal O
despite O
transient O
electrocardiographic O
( O
ekg O
) O
changes O
. O

the O
presentation O
and O
cardiac O
evaluation O
( O
hemodynamic O
, O
echocardiographic O
, O
and O
scintigraphic O
) O
of O
these O
patients O
suggest O
new O
manifestations O
of O
5 O
- O
fu O
cardiotoxicity B-Disease
that O
may O
be O
influenced O
by O
cddp O
. O

the O
possible O
pathophysiologic O
mechanisms O
are O
discussed O
. O

fatal O
aplastic B-Disease
anemia I-Disease
in O
a O
patient O
treated O
with O
carbamazepine O
. O

a O
case O
of O
fatal O
aplastic B-Disease
anemia I-Disease
due O
to O
carbamazepine O
treatment O
in O
an O
epileptic B-Disease
woman O
is O
reported O
. O

despite O
concerns O
of O
fatal O
bone B-Disease
marrow I-Disease
toxicity I-Disease
due O
to O
carbamazepine O
, O
this O
is O
only O
the O
fourth O
documented O
and O
published O
report O
. O

carbamazepine O
is O
a O
safe O
drug O
, O
but O
physicians O
and O
patients O
should O
be O
aware O
of O
the O
exceedingly O
rare O
but O
potentially O
fatal O
side O
effects O
, O
better O
prevented O
by O
clinical O
than O
by O
laboratory O
monitoring O
. O

participation O
of O
a O
bulbospinal O
serotonergic O
pathway O
in O
the O
rat O
brain O
in O
clonidine O
- O
induced O
hypotension B-Disease
and O
bradycardia B-Disease
. O

the O
effects O
of O
microinjection O
of O
clonidine O
( O
1 O
- O
10 O
micrograms O
in O
1 O
microliter O
) O
into O
a O
region O
adjacent O
to O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
on O
cardiovascular O
function O
were O
assessed O
in O
urethane O
- O
anesthetized O
rats O
. O

intramedullary O
administration O
of O
clonidine O
, O
but O
not O
saline O
vehicle O
, O
caused O
a O
dose O
- O
dependent O
decrease O
in O
both O
the O
mean O
arterial O
pressure O
and O
the O
heart O
rate O
. O

the O
clonidine O
- O
induced O
hypotension B-Disease
was O
antagonized O
by O
prior O
spinal O
transection O
, O
but O
not O
bilateral O
vagotomy O
. O

on O
the O
other O
hand O
, O
the O
clonidine O
- O
induced O
bradycardia B-Disease
was O
antagonized O
by O
prior O
bilateral O
vagotomy O
, O
but O
not O
spinal O
transection O
. O

furthermore O
, O
selective O
destruction O
of O
the O
spinal O
5 O
- O
ht O
nerves O
, O
produced O
by O
bilateral O
spinal O
injection O
of O
5 O
, O
7 O
- O
dihydroxytryptamine O
, O
reduced O
the O
magnitude O
of O
the O
vasodepressor O
or O
the O
bradycardiac B-Disease
responses O
to O
clonidine O
microinjected O
into O
the O
area O
near O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
in O
rats O
. O

the O
data O
indicate O
that O
a O
bulbospinal O
serotonergic O
pathway O
is O
involved O
in O
development O
of O
clonidine O
- O
induced O
hypotension B-Disease
and O
bradycardia B-Disease
. O

the O
induced O
hypotension B-Disease
is O
brought O
about O
by O
a O
decrease O
in O
sympathetic O
efferent O
activity O
, O
whereas O
the O
induced O
bradycardia B-Disease
was O
due O
to O
an O
increase O
in O
vagal O
efferent O
activity O
. O

hypertension B-Disease
in O
neuroblastoma B-Disease
induced O
by O
imipramine O
. O

hypertension B-Disease
is O
a O
well O
- O
known O
finding O
in O
some O
patients O
with O
neuroblastoma B-Disease
. O

however O
, O
it O
has O
not O
previously O
been O
described O
in O
association O
with O
the O
use O
of O
imipramine O
. O

we O
report O
the O
occurrence O
of O
severe O
hypertension B-Disease
( O
blood O
pressure O
190 O
/ O
160 O
) O
in O
a O
4 O
- O
year O
- O
old O
girl O
with O
neuroblastoma B-Disease
who O
was O
given O
imipramine O
to O
control O
a O
behavior B-Disease
disorder I-Disease
. O

it O
was O
determined O
later O
that O
this O
patient O
' O
s O
tumor B-Disease
was O
recurring O
at O
the O
time O
of O
her O
hypertensive B-Disease
episode O
. O

since O
she O
had O
no O
blood O
pressure O
elevation O
at O
initial O
diagnosis O
and O
none O
following O
discontinuation O
of O
the O
imipramine O
( O
when O
she O
was O
in O
florid O
relapse O
) O
, O
we O
believe O
that O
this O
drug O
rather O
than O
her O
underlying O
disease O
alone O
caused O
her O
hypertension B-Disease
. O

the O
mechanism O
for O
this O
reaction O
is O
believed O
to O
be O
increased O
levels O
of O
vasoactive O
catecholamines O
due O
to O
interference O
of O
their O
physiologic O
inactivation O
by O
imipramine O
. O

from O
this O
experience O
, O
we O
urge O
extreme O
caution O
in O
the O
use O
of O
tricyclic O
antidepressants O
in O
children O
with O
active O
neuroblastoma B-Disease
. O

rechallenge O
of O
patients O
who O
developed O
oral B-Disease
candidiasis I-Disease
or O
hoarseness B-Disease
with O
beclomethasone O
dipropionate O
. O

of O
158 O
asthmatic B-Disease
patients O
who O
were O
placed O
on O
inhaled O
beclomethasone O
, O
15 O
( O
9 O
. O
5 O
% O
) O
developed O
either O
hoarseness B-Disease
( O
8 O
) O
, O
oral O
thrush B-Disease
( O
6 O
) O
, O
or O
both O
( O
1 O
) O
. O

when O
their O
adverse O
reactions O
subsided O
, O
seven O
of O
these O
15 O
patients O
were O
rechallenged O
with O
inhaled O
beclomethasone O
. O

these O
included O
five O
cases O
who O
developed O
hoarseness B-Disease
and O
three O
who O
developed O
candidiasis B-Disease
. O

one O
patient O
had O
both O
. O

oral O
thrush B-Disease
did O
not O
recur O
, O
but O
60 O
% O
( O
3 O
/ O
5 O
) O
of O
patients O
with O
hoarseness B-Disease
had O
recurrence O
. O

we O
conclude O
that O
patients O
may O
be O
restarted O
on O
inhaled O
beclomethasone O
when O
clinically O
indicated O
; O
however O
, O
because O
of O
the O
high O
recurrence O
rate O
, O
patients O
who O
develop O
hoarseness B-Disease
should O
not O
be O
re O
- O
challenged O
. O

concomitant O
use O
of O
oral O
prednisone O
and O
topical O
beclomethasone O
may O
increase O
the O
risk O
of O
developing O
hoarseness B-Disease
or O
candidiasis B-Disease
. O

cyclophosphamide O
cardiotoxicity B-Disease
: O
an O
analysis O
of O
dosing O
as O
a O
risk O
factor O
. O

patients O
who O
undergo O
bone O
marrow O
transplantation O
are O
generally O
immunosuppressed O
with O
a O
dose O
of O
cyclophosphamide O
( O
cya O
) O
which O
is O
usually O
calculated O
based O
on O
the O
patient O
' O
s O
weight O
. O

at O
these O
high O
doses O
of O
cya O
, O
serious O
cardiotoxicity B-Disease
may O
occur O
, O
but O
definitive O
risk O
factors O
for O
the O
development O
of O
such O
cardiotoxicity B-Disease
have O
not O
been O
described O
. O

since O
chemotherapeutic O
agent O
toxicity B-Disease
generally O
correlates O
with O
dose O
per O
body O
surface O
area O
, O
we O
retrospectively O
calculated O
the O
dose O
of O
cya O
in O
patients O
transplanted O
at O
our O
institution O
to O
determine O
whether O
the O
incidence O
of O
cya O
cardiotoxicity B-Disease
correlated O
with O
the O
dose O
per O
body O
surface O
area O
. O

eighty O
patients O
who O
were O
to O
receive O
cya O
50 O
mg O
/ O
kg O
/ O
d O
for O
four O
days O
as O
preparation O
for O
marrow O
grafting O
underwent O
a O
total O
of O
84 O
transplants O
for O
aplastic B-Disease
anemia I-Disease
, O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
, O
or O
severe B-Disease
combined I-Disease
immunodeficiency I-Disease
syndrome I-Disease
. O

fourteen O
of O
84 O
( O
17 O
% O
) O
patients O
had O
symptoms O
and O
signs O
consistent O
with O
cya O
cardiotoxicity B-Disease
within O
ten O
days O
of O
receiving O
1 O
to O
4 O
doses O
of O
cya O
. O

six O
of O
the O
14 O
patients O
died O
with O
congestive B-Disease
heart I-Disease
failure I-Disease
. O

the O
dose O
of O
cya O
per O
body O
surface O
area O
was O
calculated O
for O
all O
patients O
and O
the O
patients O
were O
divided O
into O
two O
groups O
based O
on O
daily O
cya O
dose O
: O
group O
1 O
, O
cya O
less O
than O
or O
equal O
to O
1 O
. O
55 O
g O
/ O
m2 O
/ O
d O
; O
group O
2 O
, O
cya O
greater O
than O
1 O
. O
55 O
g O
/ O
m2 O
/ O
d O
. O

cardiotoxicity B-Disease
that O
was O
thought O
to O
be O
related O
to O
cya O
occurred O
in O
1 O
/ O
32 O
( O
3 O
% O
) O
of O
patients O
in O
group O
1 O
and O
in O
13 O
/ O
52 O
( O
25 O
% O
) O
patients O
in O
group O
2 O
( O
p O
less O
than O
0 O
. O
025 O
) O
. O

congestive B-Disease
heart I-Disease
failure I-Disease
caused O
or O
contributed O
to O
death O
in O
0 O
/ O
32 O
patients O
in O
group O
1 O
v O
6 O
/ O
52 O
( O
12 O
% O
) O
of O
patients O
in O
group O
2 O
( O
p O
less O
than O
0 O
. O
25 O
) O
. O

there O
was O
no O
difference O
in O
the O
rate O
of O
engraftment O
of O
evaluable O
patients O
in O
the O
two O
groups O
( O
p O
greater O
than O
0 O
. O
5 O
) O
. O

we O
conclude O
that O
the O
cya O
cardiotoxicity B-Disease
correlates O
with O
cya O
dosage O
as O
calculated O
by O
body O
surface O
area O
, O
and O
that O
patients O
with O
aplastic B-Disease
anemia I-Disease
and O
immunodeficiencies B-Disease
can O
be O
effectively O
prepared O
for O
bone O
marrow O
grafting O
at O
a O
cya O
dose O
of O
1 O
. O
55 O
g O
/ O
m2 O
/ O
d O
for O
four O
days O
with O
a O
lower O
incidence O
of O
cardiotoxicity B-Disease
than O
patients O
whose O
cya O
dosage O
is O
calculated O
based O
on O
weight O
. O

this O
study O
reaffirms O
the O
principle O
that O
drug O
toxicity B-Disease
correlates O
with O
dose O
per O
body O
surface O
area O
. O

studies O
of O
risk O
factors O
for O
aminoglycoside O
nephrotoxicity B-Disease
. O

the O
epidemiology O
of O
aminoglycoside O
- O
induced O
nephrotoxicity B-Disease
is O
not O
fully O
understood O
. O

experimental O
studies O
in O
healthy O
human O
volunteers O
indicate O
aminoglycosides O
cause O
proximal O
tubular O
damage O
in O
most O
patients O
, O
but O
rarely O
, O
if O
ever O
, O
cause O
glomerular B-Disease
or I-Disease
tubular I-Disease
dysfunction I-Disease
. O

clinical O
trials O
of O
aminoglycosides O
in O
seriously O
ill O
patients O
indicate O
that O
the O
relative O
risk O
for O
developing O
acute B-Disease
renal I-Disease
failure I-Disease
during O
therapy O
ranges O
from O
8 O
to O
10 O
and O
that O
the O
attributable O
risk O
is O
70 O
% O
to O
80 O
% O
. O

further O
analysis O
of O
these O
data O
suggests O
that O
the O
duration O
of O
therapy O
, O
plasma O
aminoglycoside O
levels O
, O
liver B-Disease
disease I-Disease
, O
advanced O
age O
, O
high O
initial O
estimated O
creatinine O
clearance O
and O
, O
possibly O
, O
female O
gender O
all O
increase O
the O
risk O
for O
nephrotoxicity B-Disease
. O

other O
causes O
of O
acute B-Disease
renal I-Disease
failure I-Disease
, O
such O
as O
shock B-Disease
, O
appear O
to O
have O
an O
additive O
effect O
. O

predictive O
models O
have O
been O
developed O
from O
these O
analyses O
that O
should O
be O
useful O
for O
identifying O
patients O
at O
high O
risk O
. O

these O
models O
may O
also O
be O
useful O
in O
developing O
insights O
into O
the O
pathophysiology O
of O
aminoglycoside O
- O
induced O
nephrotoxicity B-Disease
. O

central O
action O
of O
narcotic O
analgesics O
. O

part O
iv O
. O

noradrenergic O
influences O
on O
the O
activity O
of O
analgesics O
in O
rats O
. O

the O
effect O
of O
clonidine O
, O
naphazoline O
and O
xylometazoline O
on O
analgesia O
induced O
by O
morphine O
, O
codeine O
, O
fentanyl O
and O
pentazocine O
, O
and O
on O
cataleptic B-Disease
effect O
of O
morphine O
, O
codine O
and O
fentanyl O
was O
studied O
in O
rats O
. O

the O
biochemical O
assays O
on O
the O
influence O
of O
four O
analgesics O
on O
the O
brain O
concentration O
and O
turnover O
of O
noradrenaline O
( O
na O
) O
were O
also O
performed O
. O

it O
was O
found O
that O
three O
drugs O
stimulating O
central O
na O
receptors O
failed O
to O
affect O
the O
analgesic O
ed50 O
of O
all O
antinociceptive O
agents O
and O
they O
enhanced O
catalepsy B-Disease
induced O
by O
morphine O
and O
fentanyl O
. O

codeine O
catalepsy B-Disease
was O
increased O
by O
clonidine O
and O
decreased O
by O
naphazoline O
and O
xylometazoline O
. O

the O
brain O
concentration O
of O
na O
was O
not O
changed O
by O
morphine O
and O
fentanyl O
, O
but O
one O
of O
the O
doses O
of O
codeine O
( O
45 O
mg O
/ O
kg O
) O
slightly O
enhanced O
it O
. O

pentazocine O
dose O
- O
dependently O
decreased O
the O
brain O
level O
of O
na O
. O

the O
rate O
of O
na O
turnover O
was O
not O
altered O
by O
analgesics O
except O
for O
the O
higher O
dose O
of O
fentanyl O
( O
0 O
. O
2 O
mg O
/ O
kg O
) O
following O
which O
the O
disappearance O
of O
na O
from O
the O
brain O
was O
diminished O
. O

the O
results O
are O
discussed O
in O
the O
light O
of O
various O
and O
non O
- O
uniform O
data O
from O
the O
literature O
. O

it O
is O
suggested O
that O
in O
rats O
the O
brain O
na O
plays O
a O
less O
important O
function O
than O
the O
other O
monoamines O
in O
the O
behavioural O
activity O
of O
potent O
analgesics O
. O

flurothyl O
seizure B-Disease
thresholds O
in O
mice O
treated O
neonatally O
with O
a O
single O
injection O
of O
monosodium O
glutamate O
( O
msg O
) O
: O
evaluation O
of O
experimental O
parameters O
in O
flurothyl O
seizure B-Disease
testing O
. O

monosodium O
glutamate O
( O
msg O
) O
administration O
to O
neonatal O
rodents O
produces O
convulsions B-Disease
and O
results O
in O
numerous O
biochemical O
and O
behavioral O
deficits O
. O

these O
studies O
were O
undertaken O
to O
determine O
if O
neonatal O
administration O
of O
msg O
produced O
permanent O
alterations O
in O
seizure B-Disease
susceptibility O
, O
since O
previous O
investigations O
were O
inconclusive O
. O

a O
flurothyl O
ether O
seizure B-Disease
screening O
technique O
was O
used O
to O
evaluate O
seizure B-Disease
susceptibility O
in O
adult O
mice O
that O
received O
neonatal O
injections O
of O
msg O
( O
4 O
mg O
/ O
g O
and O
1 O
mg O
/ O
g O
) O
. O

msg O
treatment O
resulted O
in O
significant O
reductions O
in O
whole O
brain O
weight O
but O
did O
not O
alter O
seizure B-Disease
threshold O
. O

a O
naloxone O
( O
5 O
mg O
/ O
kg O
) O
challenge O
was O
also O
ineffective O
in O
altering O
the O
seizure B-Disease
thresholds O
of O
either O
control O
of O
msg O
- O
treated O
mice O
. O

flurothyl O
ether O
produced O
hypothermia B-Disease
which O
was O
correlated O
with O
the O
duration O
of O
flurothyl O
exposure O
; O
however O
, O
the O
relationship O
of O
hypothermia B-Disease
to O
seizure B-Disease
induction O
was O
unclear O
. O

flurothyl O
seizure B-Disease
testing O
proved O
to O
be O
a O
rapid O
and O
reliable O
technique O
with O
which O
to O
evaluate O
seizure B-Disease
susceptibility O
. O

susceptibility O
to O
seizures B-Disease
produced O
by O
pilocarpine O
in O
rats O
after O
microinjection O
of O
isoniazid O
or O
gamma O
- O
vinyl O
- O
gaba O
into O
the O
substantia O
nigra O
. O

pilocarpine O
, O
given O
intraperitoneally O
to O
rats O
, O
reproduces O
the O
neuropathological O
sequelae O
of O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
and O
provides O
a O
relevant O
animal O
model O
for O
studying O
mechanisms O
of O
buildup O
of O
convulsive B-Disease
activity O
and O
pathways O
operative O
in O
the O
generalization O
and O
propagation O
of O
seizures B-Disease
within O
the O
forebrain O
. O

in O
the O
present O
study O
, O
the O
effects O
of O
manipulating O
the O
activity O
of O
the O
gamma O
- O
aminobutyric O
acid O
( O
gaba O
) O
- O
mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
on O
seizures B-Disease
produced O
by O
pilocarpine O
in O
rats O
, O
were O
investigated O
. O

in O
animals O
pretreated O
with O
microinjections O
of O
isoniazid O
, O
150 O
micrograms O
, O
an O
inhibitor O
of O
activity O
of O
the O
gaba O
- O
synthesizing O
enzyme O
, O
l O
- O
glutamic O
acid O
decarboxylase O
, O
into O
the O
substantia O
nigra O
pars O
reticulata O
( O
snr O
) O
, O
bilaterally O
, O
non O
- O
convulsant O
doses O
of O
pilocarpine O
, O
100 O
and O
200 O
mg O
/ O
kg O
, O
resulted O
in O
severe O
motor O
limbic O
seizures B-Disease
and O
status B-Disease
epilepticus I-Disease
. O

electroencephalographic O
and O
behavioral O
monitoring O
revealed O
a O
profound O
reduction O
of O
the O
threshold O
for O
pilocarpine O
- O
induced O
convulsions B-Disease
. O

morphological O
analysis O
of O
frontal O
forebrain O
sections O
with O
light O
microscopy O
revealed O
seizure B-Disease
- O
related O
damage O
to O
the O
hippocampal O
formation O
, O
thalamus O
, O
amygdala O
, O
olfactory O
cortex O
, O
substantia O
nigra O
and O
neocortex O
, O
which O
is O
typically O
observed O
with O
pilocarpine O
in O
doses O
exceeding O
350 O
mg O
/ O
kg O
. O

bilateral O
intrastriatal O
injections O
of O
isoniazid O
did O
not O
augment O
seizures B-Disease
produced O
by O
pilocarpine O
, O
200 O
mg O
/ O
kg O
. O

application O
of O
an O
irreversible O
inhibitor O
of O
gaba O
transaminase O
, O
gamma O
- O
vinyl O
- O
gaba O
( O
d O
, O
l O
- O
4 O
- O
amino O
- O
hex O
- O
5 O
- O
enoic O
acid O
) O
, O
5 O
micrograms O
, O
into O
the O
snr O
, O
bilaterally O
, O
suppressed O
the O
appearance O
of O
electrographic O
and O
behavioral O
seizures B-Disease
produced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

this O
treatment O
was O
also O
sufficient O
to O
protect O
animals O
from O
the O
occurrence O
of O
brain B-Disease
damage I-Disease
. O

microinjections O
of O
gamma O
- O
vinyl O
- O
gaba O
, O
5 O
micrograms O
, O
into O
the O
dorsal O
striatum O
, O
bilaterally O
, O
failed O
to O
prevent O
the O
development O
of O
convulsions B-Disease
produced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

the O
results O
demonstrate O
that O
the O
threshold O
for O
pilocarpine O
- O
induced O
seizures B-Disease
in O
rats O
is O
subjected O
to O
the O
regulation O
of O
the O
gaba O
- O
mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
. O

human O
and O
canine O
ventricular O
vasoactive O
intestinal O
polypeptide O
: O
decrease O
with O
heart B-Disease
failure I-Disease
. O

vasoactive O
intestinal O
polypeptide O
( O
vip O
) O
is O
a O
systemic O
and O
coronary O
vasodilator O
that O
may O
have O
positive O
inotropic O
properties O
. O

myocardial O
levels O
of O
vip O
were O
assayed O
before O
and O
after O
the O
development O
of O
heart B-Disease
failure I-Disease
in O
two O
canine O
models O
. O

in O
the O
first O
, O
cobalt O
cardiomyopathy B-Disease
was O
induced O
in O
eight O
dogs O
; O
vip O
( O
by O
radioimmunoassay O
) O
decreased O
from O
35 O
+ O
/ O
- O
11 O
pg O
/ O
mg O
protein O
( O
mean O
+ O
/ O
- O
sd O
) O
to O
5 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

in O
six O
dogs O
with O
doxorubicin O
- O
induced O
heart B-Disease
failure I-Disease
, O
vip O
decreased O
from O
31 O
+ O
/ O
- O
7 O
to O
11 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

in O
addition O
, O
vip O
content O
of O
left O
ventricular O
muscle O
of O
resected O
failing O
hearts O
in O
10 O
patients O
receiving O
a O
heart O
transplant O
was O
compared O
with O
the O
papillary O
muscles O
in O
14 O
patients O
( O
five O
with O
rheumatic B-Disease
disease I-Disease
, O
nine O
with O
myxomatous B-Disease
degeneration I-Disease
) O
receiving O
mitral O
valve O
prostheses O
. O

the O
lowest O
myocardial O
vip O
concentration O
was O
found O
in O
the O
hearts O
of O
patients O
with O
coronary B-Disease
disease I-Disease
( O
one O
patient O
receiving O
a O
transplant O
and O
three O
receiving O
mitral O
prostheses O
) O
( O
6 O
. O
3 O
+ O
/ O
- O
1 O
. O
9 O
pg O
/ O
mg O
protein O
) O
. O

the O
other O
patients O
undergoing O
transplantation O
had O
an O
average O
ejection O
fraction O
of O
17 O
% O
+ O
/ O
- O
6 O
% O
and O
a O
vip O
level O
of O
8 O
. O
8 O
+ O
/ O
- O
3 O
. O
9 O
pg O
/ O
mg O
protein O
. O

the O
hearts O
without O
coronary B-Disease
artery I-Disease
disease I-Disease
( O
average O
ejection O
fraction O
of O
this O
group O
62 O
% O
+ O
/ O
- O
10 O
% O
) O
had O
a O
vip O
concentration O
of O
14 O
. O
1 O
+ O
/ O
- O
7 O
. O
9 O
pg O
/ O
mg O
protein O
, O
and O
this O
was O
greater O
than O
in O
hearts O
of O
the O
patients O
with O
coronary B-Disease
disease I-Disease
and O
the O
hearts O
of O
patients O
receiving O
a O
transplant O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

myocardial O
catecholamines O
were O
also O
determined O
in O
14 O
subjects O
; O
a O
weak O
correlation O
( O
r O
= O
0 O
. O
57 O
, O
p O
less O
than O
0 O
. O
05 O
) O
between O
the O
tissue O
concentrations O
of O
vip O
and O
norepinephrine O
was O
noted O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

non O
- O
invasive O
detection O
of O
coronary B-Disease
artery I-Disease
disease I-Disease
by O
body O
surface O
electrocardiographic O
mapping O
after O
dipyridamole O
infusion O
. O

electrocardiographic O
changes O
after O
dipyridamole O
infusion O
( O
0 O
. O
568 O
mg O
/ O
kg O
/ O
4 O
min O
) O
were O
studied O
in O
41 O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
and O
compared O
with O
those O
after O
submaximal O
treadmill O
exercise O
by O
use O
of O
the O
body O
surface O
mapping O
technique O
. O

patients O
were O
divided O
into O
three O
groups O
; O
19 O
patients O
without O
myocardial B-Disease
infarction I-Disease
( O
non O
- O
mi B-Disease
group O
) O
, O
14 O
with O
anterior B-Disease
infarction I-Disease
( O
ant B-Disease
- I-Disease
mi I-Disease
) O
and O
eight O
with O
inferior B-Disease
infarction I-Disease
( O
inf B-Disease
- I-Disease
mi I-Disease
) O
. O

eighty O
- O
seven O
unipolar O
electrocardiograms O
( O
ecgs O
) O
distributed O
over O
the O
entire O
thoracic O
surface O
were O
simultaneously O
recorded O
. O

after O
dipyridamole O
, O
ischemic B-Disease
st O
- O
segment O
depression B-Disease
( O
0 O
. O
05 O
mv O
or O
more O
) O
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
mi B-Disease
group O
, O
29 O
% O
of O
the O
ant B-Disease
- I-Disease
mi I-Disease
group O
, O
63 O
% O
of O
the O
inf B-Disease
- I-Disease
mi I-Disease
group O
and O
61 O
% O
of O
the O
total O
population O
. O

exercise O
- O
induced O
st O
depression B-Disease
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
mi B-Disease
group O
, O
43 O
% O
of O
the O
ant B-Disease
- I-Disease
mi I-Disease
group O
, O
38 O
% O
of O
the O
inf B-Disease
- I-Disease
mi I-Disease
group O
and O
61 O
% O
of O
the O
total O
. O

for O
individual O
patients O
, O
there O
were O
no O
obvious O
differences O
between O
the O
body O
surface O
distribution O
of O
st O
depression B-Disease
in O
both O
tests O
. O

the O
increase O
in O
pressure O
rate O
product O
after O
dipyridamole O
was O
significantly O
less O
than O
that O
during O
the O
treadmill O
exercise O
. O

the O
data O
suggest O
that O
the O
dipyridamole O
- O
induced O
myocardial B-Disease
ischemia I-Disease
is O
caused O
by O
the O
inhomogenous O
distribution O
of O
myocardial O
blood O
flow O
. O

we O
conclude O
that O
the O
dipyridamole O
ecg O
test O
is O
as O
useful O
as O
the O
exercise O
ecg O
test O
for O
the O
assessment O
of O
coronary B-Disease
artery I-Disease
disease I-Disease
. O

bradycardia B-Disease
after O
high O
- O
dose O
intravenous O
methylprednisolone O
therapy O
. O

in O
5 O
consecutive O
patients O
with O
rheumatoid B-Disease
arthritis I-Disease
who O
received O
intravenous O
high O
- O
dose O
methylprednisolone O
( O
mp O
) O
therapy O
( O
1 O
g O
daily O
for O
2 O
or O
3 O
consecutive O
days O
) O
, O
a O
decline O
in O
pulse O
rate O
was O
observed O
, O
most O
pronounced O
on O
day O
4 O
. O

in O
one O
of O
the O
5 O
patients O
the O
bradycardia B-Disease
was O
associated O
with O
complaints O
of O
substernal O
pressure O
. O

reversal O
to O
normal O
heart O
rate O
was O
found O
on O
day O
7 O
. O

electrocardiographic O
registrations O
showed O
sinus B-Disease
bradycardia I-Disease
in O
all O
cases O
. O

no O
significant O
changes O
in O
plasma O
concentrations O
of O
electrolytes O
were O
found O
. O

careful O
observation O
of O
patients O
receiving O
high O
- O
dose O
mp O
is O
recommended O
. O

high O
- O
dose O
mp O
may O
be O
contraindicated O
in O
patients O
with O
known O
heart B-Disease
disease I-Disease
. O

two O
cases O
of O
downbeat B-Disease
nystagmus I-Disease
and O
oscillopsia B-Disease
associated O
with O
carbamazepine O
. O

downbeat B-Disease
nystagmus I-Disease
is O
often O
associated O
with O
structural O
lesions O
at O
the O
craniocervical O
junction O
, O
but O
has O
occasionally O
been O
reported O
as O
a O
manifestation O
of O
metabolic O
imbalance O
or O
drug O
intoxication O
. O

we O
recorded O
the O
eye O
movements O
of O
two O
patients O
with O
reversible O
downbeat B-Disease
nystagmus I-Disease
related O
to O
carbamazepine O
therapy O
. O

the O
nystagmus B-Disease
of O
both O
patients O
resolved O
after O
reduction O
of O
the O
serum O
carbamazepine O
levels O
. O

neuroradiologic O
investigations O
including O
magnetic O
resonance O
imaging O
scans O
in O
both O
patients O
showed O
no O
evidence O
of O
intracranial O
abnormality O
. O

in O
patients O
with O
downbeat B-Disease
nystagmus I-Disease
who O
are O
taking O
anticonvulsant O
medications O
, O
consideration O
should O
be O
given O
to O
reduction O
in O
dose O
before O
further O
investigation O
is O
undertaken O
. O

improvement O
by O
denopamine O
( O
ta O
- O
064 O
) O
of O
pentobarbital O
- O
induced O
cardiac B-Disease
failure I-Disease
in O
the O
dog O
heart O
- O
lung O
preparation O
. O

the O
efficacy O
of O
denopamine O
, O
an O
orally O
active O
beta O
1 O
- O
adrenoceptor O
agonist O
, O
in O
improving O
cardiac B-Disease
failure I-Disease
was O
assessed O
in O
dog O
heart O
- O
lung O
preparations O
. O

cardiac O
functions O
depressed O
by O
pentobarbital O
( O
118 O
+ O
/ O
- O
28 O
mg O
; O
mean O
value O
+ O
/ O
- O
sd O
) O
such O
that O
cardiac O
output O
and O
maximum O
rate O
of O
rise O
of O
left O
ventricular O
pressure O
( O
lv O
dp O
/ O
dt O
max O
) O
had O
been O
reduced O
by O
about O
35 O
% O
and O
26 O
% O
of O
the O
respective O
controls O
were O
improved O
by O
denopamine O
( O
10 O
- O
300 O
micrograms O
) O
in O
a O
dose O
- O
dependent O
manner O
. O

with O
100 O
micrograms O
denopamine O
, O
almost O
complete O
restoration O
of O
cardiac O
performance O
was O
attained O
, O
associated O
with O
a O
slight O
increase O
in O
heart O
rate O
. O

no O
arrhythmias B-Disease
were O
induced O
by O
these O
doses O
of O
denopamine O
. O

the O
results O
warrant O
clinical O
trials O
of O
denopamine O
in O
the O
treatment O
of O
cardiac B-Disease
failure I-Disease
. O

clonazepam O
monotherapy O
for O
epilepsy B-Disease
in O
childhood O
. O

sixty O
patients O
( O
age O
- O
range O
one O
month O
to O
14 O
years O
) O
with O
other O
types O
of O
epilepsy B-Disease
than O
infantile B-Disease
spasms I-Disease
were O
treated O
with O
clonazepam O
. O

disappearance O
of O
seizures B-Disease
and O
normalization O
of O
abnormal O
eeg O
with O
disappearance O
of O
seizures B-Disease
were O
recognized O
in O
77 O
% O
and O
50 O
% O
, O
respectively O
. O

seizures B-Disease
disappeared O
in O
71 O
% O
of O
the O
patients O
with O
generalized O
seizures B-Disease
and O
89 O
% O
of O
partial O
seizures B-Disease
. O

improvement O
of O
abnormal O
eeg O
was O
noticed O
in O
76 O
% O
of O
diffuse O
paroxysms O
and O
in O
67 O
% O
of O
focal O
paroxysms O
. O

in O
excellent O
cases O
, O
mean O
effective O
dosages O
were O
0 O
. O
086 O
+ O
/ O
- O
0 O
. O
021 O
mg O
/ O
kg O
/ O
day O
in O
infants O
and O
0 O
. O
057 O
+ O
/ O
- O
0 O
. O
022 O
mg O
/ O
kg O
/ O
day O
in O
schoolchildren O
, O
this O
difference O
was O
statistically O
significant O
( O
p O
less O
than O
0 O
. O
005 O
) O
. O

the O
incidence O
of O
side O
effects O
such O
as O
drowsiness B-Disease
and O
ataxia B-Disease
was O
only O
5 O
% O
. O

postmarketing O
study O
of O
timolol O
- O
hydrochlorothiazide O
antihypertensive O
therapy O
. O

a O
postmarketing O
surveillance O
study O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
a O
fixed O
- O
ratio O
combination O
containing O
10 O
mg O
of O
timolol O
maleate O
and O
25 O
mg O
of O
hydrochlorothiazide O
, O
administered O
twice O
daily O
for O
one O
month O
to O
hypertensive B-Disease
patients O
. O

data O
on O
9 O
, O
037 O
patients O
were O
collected O
by O
1 O
, O
455 O
participating O
physicians O
. O

mean O
systolic O
blood O
pressure O
decreased O
25 O
mmhg O
and O
mean O
diastolic O
blood O
pressure O
declined O
15 O
mmhg O
after O
one O
month O
of O
timolol O
- O
hydrochlorothiazide O
therapy O
( O
p O
less O
than O
0 O
. O
01 O
, O
both O
comparisons O
) O
. O

age O
, O
race O
, O
and O
sex O
appeared O
to O
have O
no O
influence O
on O
the O
decrease O
in O
blood O
pressure O
. O

the O
antihypertensive O
effect O
of O
the O
drug O
was O
greater O
in O
patients O
with O
more O
severe O
hypertension B-Disease
. O

overall O
, O
1 O
, O
453 O
patients O
experienced O
a O
total O
of O
2 O
, O
658 O
adverse O
events O
, O
the O
most O
common O
being O
fatigue B-Disease
, O
dizziness B-Disease
, O
and O
weakness B-Disease
. O

treatment O
in O
590 O
patients O
was O
discontinued O
because O
of O
adverse O
events O
. O

salicylate O
nephropathy B-Disease
in O
the O
gunn O
rat O
: O
potential O
role O
of O
prostaglandins O
. O

we O
examined O
the O
potential O
role O
of O
prostaglandins O
in O
the O
development O
of O
analgesic O
nephropathy B-Disease
in O
the O
gunn O
strain O
of O
rat O
. O

the O
homozygous O
gunn O
rats O
have O
unconjugated O
hyperbilirubinemia B-Disease
due O
to O
the O
absence O
of O
glucuronyl O
transferase O
, O
leading O
to O
marked O
bilirubin O
deposition O
in O
renal O
medulla O
and O
papilla O
. O

these O
rats O
are O
also O
highly O
susceptible O
to O
develop O
papillary B-Disease
necrosis I-Disease
with O
analgesic O
administration O
. O

we O
used O
homozygous O
( O
jj O
) O
and O
phenotypically O
normal O
heterozygous O
( O
jj O
) O
animals O
. O

four O
groups O
of O
rats O
( O
n O
= O
7 O
) O
were O
studied O
: O
jj O
and O
jj O
rats O
treated O
either O
with O
aspirin O
300 O
mg O
/ O
kg O
every O
other O
day O
or O
sham O
- O
treated O
. O

after O
one O
week O
, O
slices O
of O
cortex O
, O
outer O
and O
inner O
medulla O
from O
one O
kidney O
were O
incubated O
in O
buffer O
and O
prostaglandin O
synthesis O
was O
determined O
by O
radioimmunoassay O
. O

the O
other O
kidney O
was O
examined O
histologically O
. O

a O
marked O
corticomedullary O
gradient O
of O
prostaglandin O
synthesis O
was O
observed O
in O
all O
groups O
. O

pge2 O
synthesis O
was O
significantly O
higher O
in O
outer O
medulla O
, O
but O
not O
cortex O
or O
inner O
medulla O
, O
of O
jj O
( O
38 O
+ O
/ O
- O
6 O
ng O
/ O
mg O
prot O
) O
than O
jj O
rats O
( O
15 O
+ O
/ O
- O
3 O
) O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

aspirin O
treatment O
reduced O
pge2 O
synthesis O
in O
all O
regions O
, O
but O
outer O
medullary O
pge2 O
remained O
higher O
in O
jj O
( O
18 O
+ O
/ O
- O
3 O
) O
than O
jj O
rats O
( O
9 O
+ O
/ O
- O
2 O
) O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

pgf2 O
alpha O
was O
also O
significantly O
higher O
in O
the O
outer O
medulla O
of O
jj O
rats O
with O
and O
without O
aspirin O
administration O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

the O
changes O
in O
renal O
prostaglandin O
synthesis O
were O
accompanied O
by O
evidence O
of O
renal B-Disease
damage I-Disease
in O
aspirin O
- O
treated O
jj O
but O
not O
jj O
rats O
as O
evidenced O
by O
: O
increased O
incidence O
and O
severity O
of O
hematuria B-Disease
( O
p O
less O
than O
0 O
. O
01 O
) O
; O
increased O
serum O
creatinine O
( O
p O
less O
than O
0 O
. O
05 O
) O
; O
and O
increase O
in O
outer O
medullary O
histopathologic O
lesions O
( O
p O
less O
than O
0 O
. O
005 O
compared O
to O
either O
sham O
- O
treated O
jj O
or O
aspirin O
- O
treated O
jj O
) O
. O

these O
results O
suggest O
that O
enhanced O
prostaglandin O
synthesis O
contributes O
to O
maintenance O
of O
renal O
function O
and O
morphological O
integrity O
, O
and O
that O
inhibition O
of O
prostaglandin O
synthesis O
may O
lead O
to O
pathological B-Disease
renal I-Disease
medullary I-Disease
lesions I-Disease
and O
deterioration B-Disease
of I-Disease
renal I-Disease
function I-Disease
. O

prophylactic O
lidocaine O
in O
the O
early O
phase O
of O
suspected O
myocardial B-Disease
infarction I-Disease
. O

four O
hundred O
two O
patients O
with O
suspected O
myocardial B-Disease
infarction I-Disease
seen O
within O
6 O
hours O
of O
the O
onset O
of O
symptoms O
entered O
a O
double O
- O
blind O
randomized O
trial O
of O
lidocaine O
vs O
placebo O
. O

during O
the O
1 O
hour O
after O
administration O
of O
the O
drug O
the O
incidence O
of O
ventricular B-Disease
fibrillation I-Disease
or O
sustained O
ventricular B-Disease
tachycardia I-Disease
among O
the O
204 O
patients O
with O
acute O
myocardial B-Disease
infarction I-Disease
was O
low O
, O
1 O
. O
5 O
% O
. O

lidocaine O
, O
given O
in O
a O
300 O
mg O
dose O
intramuscularly O
followed O
by O
100 O
mg O
intravenously O
, O
did O
not O
prevent O
sustained O
ventricular B-Disease
tachycardia I-Disease
, O
although O
there O
was O
a O
significant O
reduction O
in O
the O
number O
of O
patients O
with O
warning O
arrhythmias B-Disease
between O
15 O
and O
45 O
minutes O
after O
the O
administration O
of O
lidocaine O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

the O
average O
plasma O
lidocaine O
level O
10 O
minutes O
after O
administration O
for O
patients O
without O
a O
myocardial B-Disease
infarction I-Disease
was O
significantly O
higher O
than O
that O
for O
patients O
with O
an O
acute O
infarction B-Disease
. O

the O
mean O
plasma O
lidocaine O
level O
of O
patients O
on O
beta O
- O
blocking O
agents O
was O
no O
different O
from O
that O
in O
patients O
not O
on O
beta O
blocking O
agents O
. O

during O
the O
1 O
- O
hour O
study O
period O
, O
the O
incidence O
of O
central O
nervous O
system O
side O
effects O
was O
significantly O
greater O
in O
the O
lidocaine O
group O
, O
hypotension B-Disease
occurred O
in O
11 O
patients O
, O
nine O
of O
whom O
had O
received O
lidocaine O
, O
and O
four O
patients O
died O
from O
asystole B-Disease
, O
three O
of O
whom O
had O
had O
lidocaine O
. O

we O
cannot O
advocate O
the O
administration O
of O
lidocaine O
prophylactically O
in O
the O
early O
hours O
of O
suspected O
myocardial B-Disease
infarction I-Disease
. O

evidence O
for O
a O
cholinergic O
role O
in O
haloperidol O
- O
induced O
catalepsy B-Disease
. O

experiments O
in O
mice O
tested O
previous O
evidence O
that O
activation O
of O
cholinergic O
systems O
promotes O
catalepsy B-Disease
and O
that O
cholinergic O
mechanisms O
need O
to O
be O
intact O
for O
full O
expression O
of O
neuroleptic O
- O
induced O
catalepsy B-Disease
. O

large O
doses O
of O
the O
cholinomimetic O
, O
pilocarpine O
, O
could O
induce O
catalepsy B-Disease
when O
peripheral O
cholinergic O
receptors O
were O
blocked O
. O

low O
doses O
of O
pilocarpine O
caused O
a O
pronounced O
enhancement O
of O
the O
catalepsy B-Disease
that O
was O
induced O
by O
the O
dopaminergic O
blocker O
, O
haloperidol O
. O

a O
muscarinic O
receptor O
blocker O
, O
atropine O
, O
disrupted O
haloperidol O
- O
induced O
catalepsy B-Disease
. O

intracranial O
injection O
of O
an O
acetylcholine O
- O
synthesis O
inhibitor O
, O
hemicholinium O
, O
prevented O
the O
catalepsy B-Disease
that O
is O
usually O
induced O
by O
haloperidol O
. O

these O
findings O
suggest O
the O
hypothesis O
that O
the O
catalepsy B-Disease
that O
is O
produced O
by O
neuroleptics O
such O
as O
haloperidol O
is O
actually O
mediated O
by O
intrinsic O
central O
cholinergic O
systems O
. O

alternatively O
, O
activation O
of O
central O
cholinergic O
systems O
could O
promote O
catalepsy B-Disease
by O
suppression O
of O
dopaminergic O
systems O
. O

cardiovascular B-Disease
dysfunction I-Disease
and O
hypersensitivity B-Disease
to O
sodium O
pentobarbital O
induced O
by O
chronic O
barium O
chloride O
ingestion O
. O

barium O
- O
supplemented O
long O
- O
evans O
hooded O
rats O
were O
characterized O
by O
a O
persistent O
hypertension B-Disease
that O
was O
evident O
after O
1 O
month O
of O
barium O
( O
100 O
micrograms O
/ O
ml O
mineral O
fortified O
water O
) O
treatment O
. O

analysis O
of O
in O
vivo O
myocardial O
excitability O
, O
contractility O
, O
and O
metabolic O
characteristics O
at O
16 O
months O
revealed O
other O
significant O
barium O
- O
induced O
disturbances B-Disease
within I-Disease
the I-Disease
cardiovascular I-Disease
system I-Disease
. O

the O
most O
distinctive O
aspect O
of O
the O
barium O
effect O
was O
a O
demonstrated O
hypersensitivity B-Disease
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
. O

under O
barbiturate O
anesthesia O
, O
virtually O
all O
of O
the O
myocardial O
contractile O
indices O
were O
depressed O
significantly O
in O
barium O
- O
exposed O
rats O
relative O
to O
the O
corresponding O
control O
- O
fed O
rats O
. O

the O
lack O
of O
a O
similar O
response O
to O
ketamine O
and O
xylazine O
anesthesia O
revealed O
that O
the O
cardiovascular O
actions O
of O
sodium O
pentobarbital O
in O
barium O
- O
treated O
rats O
were O
linked O
specifically O
to O
this O
anesthetic O
, O
and O
were O
not O
representative O
of O
a O
generalized O
anesthetic O
response O
. O

other O
myocardial O
pathophysiologic O
and O
metabolic O
changes O
induced O
by O
barium O
were O
manifest O
, O
irrespective O
of O
the O
anesthetic O
employed O
. O

the O
contractile O
element O
shortening O
velocity O
of O
the O
cardiac O
muscle O
fibers O
was O
significantly O
slower O
in O
both O
groups O
of O
barium O
- O
treated O
rats O
relative O
to O
the O
control O
groups O
, O
irrespective O
of O
the O
anesthetic O
regimen O
. O

similarly O
, O
significant O
disturbances O
in O
myocardial O
energy O
metabolism O
were O
detected O
in O
the O
barium O
- O
exposed O
rats O
which O
were O
consistent O
with O
the O
reduced O
contractile O
element O
shortening O
velocity O
. O

in O
addition O
, O
the O
excitability O
of O
the O
cardiac O
conduction O
system O
was O
depressed O
preferentially O
in O
the O
atrioventricular O
nodal O
region O
of O
hearts O
from O
barium O
- O
exposed O
rats O
. O

overall O
, O
the O
altered O
cardiac O
contractility O
and O
excitability O
characteristics O
, O
the O
myocardial O
metabolic B-Disease
disturbances I-Disease
, O
and O
the O
hypersensitivity B-Disease
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
suggest O
the O
existence O
of O
a O
heretofore O
undescribed O
cardiomyopathic B-Disease
disorder I-Disease
induced O
by O
chronic O
barium O
exposure O
. O

these O
experimental O
findings O
represent O
the O
first O
indication O
that O
life O
- O
long O
barium O
ingestion O
may O
have O
significant O
adverse O
effects O
on O
the O
mammalian O
cardiovascular O
system O
. O

propranolol O
antagonism O
of O
phenylpropanolamine O
- O
induced O
hypertension B-Disease
. O

phenylpropanolamine O
( O
ppa O
) O
overdose B-Disease
can O
cause O
severe O
hypertension B-Disease
, O
intracerebral B-Disease
hemorrhage I-Disease
, O
and O
death O
. O

we O
studied O
the O
efficacy O
and O
safety O
of O
propranolol O
in O
the O
treatment O
of O
ppa O
- O
induced O
hypertension B-Disease
. O

subjects O
received O
propranolol O
either O
by O
mouth O
for O
48 O
hours O
before O
ppa O
or O
as O
a O
rapid O
intravenous O
infusion O
after O
ppa O
. O

ppa O
, O
75 O
mg O
alone O
, O
increased O
blood O
pressure O
( O
31 O
+ O
/ O
- O
14 O
mm O
hg O
systolic O
, O
20 O
+ O
/ O
- O
5 O
mm O
hg O
diastolic O
) O
, O
and O
propranolol O
pretreatment O
antagonized O
this O
increase O
( O
12 O
+ O
/ O
- O
10 O
mm O
hg O
systolic O
, O
10 O
+ O
/ O
- O
7 O
mm O
hg O
diastolic O
) O
. O

intravenous O
propranolol O
after O
ppa O
also O
decreased O
blood O
pressure O
. O

left O
ventricular O
function O
( O
assessed O
by O
echocardiography O
) O
showed O
that O
ppa O
increased O
the O
stroke B-Disease
volume O
30 O
% O
( O
from O
62 O
. O
5 O
+ O
/ O
- O
20 O
. O
9 O
to O
80 O
. O
8 O
+ O
/ O
- O
22 O
. O
4 O
ml O
) O
, O
the O
ejection O
fraction O
9 O
% O
( O
from O
64 O
% O
+ O
/ O
- O
10 O
% O
to O
70 O
% O
+ O
/ O
- O
7 O
% O
) O
, O
and O
cardiac O
output O
14 O
% O
( O
from O
3 O
. O
6 O
+ O
/ O
- O
0 O
. O
6 O
to O
4 O
. O
1 O
+ O
/ O
- O
1 O
. O
0 O
l O
/ O
min O
) O
. O

intravenous O
propranolol O
reversed O
these O
effects O
. O

systemic O
vascular O
resistance O
was O
increased O
by O
ppa O
28 O
% O
( O
from O
1710 O
+ O
/ O
- O
200 O
to O
2190 O
+ O
/ O
- O
700 O
dyne O
x O
sec O
/ O
cm5 O
) O
and O
was O
further O
increased O
by O
propranolol O
22 O
% O
( O
to O
2660 O
+ O
/ O
- O
1200 O
dyne O
x O
sec O
/ O
cm5 O
) O
. O

we O
conclude O
that O
ppa O
increases O
blood O
pressure O
by O
increasing O
systemic O
vascular O
resistance O
and O
cardiac O
output O
, O
and O
that O
propranolol O
antagonizes O
this O
increase O
by O
reversing O
the O
effect O
of O
ppa O
on O
cardiac O
output O
. O

that O
propranolol O
antagonizes O
the O
pressor O
effect O
of O
ppa O
is O
in O
contrast O
to O
the O
interaction O
in O
which O
propranolol O
enhances O
the O
pressor O
effect O
of O
norepinephrine O
. O

this O
is O
probably O
because O
ppa O
has O
less O
beta O
2 O
activity O
than O
does O
norepinephrine O
. O

mesangial O
function O
and O
glomerular B-Disease
sclerosis I-Disease
in O
rats O
with O
aminonucleoside O
nephrosis B-Disease
. O

the O
possible O
relationship O
between O
mesangial B-Disease
dysfunction I-Disease
and O
development O
of O
glomerular B-Disease
sclerosis I-Disease
was O
studied O
in O
the O
puromycin O
aminonucleoside O
( O
pan O
) O
model O
. O

five O
male O
wistar O
rats O
received O
repeated O
subcutaneous O
pan O
injections O
; O
five O
controls O
received O
saline O
only O
. O

after O
4 O
weeks O
the O
pan O
rats O
were O
severely O
proteinuric B-Disease
( O
190 O
+ O
/ O
- O
80 O
mg O
/ O
24 O
hr O
) O
, O
and O
all O
rats O
were O
given O
colloidal O
carbon O
( O
cc O
) O
intravenously O
. O

at O
5 O
months O
glomerular B-Disease
sclerosis I-Disease
was O
found O
in O
7 O
. O
6 O
+ O
/ O
- O
3 O
. O
4 O
% O
of O
the O
glomeruli O
of O
pan O
rats O
; O
glomeruli O
of O
the O
controls O
were O
normal O
. O

glomeruli O
of O
pan O
rats O
contained O
significantly O
more O
cc O
than O
glomeruli O
of O
controls O
. O

glomeruli O
with O
sclerosis B-Disease
contained O
significantly O
more O
cc O
than O
non O
- O
sclerotic O
glomeruli O
in O
the O
same O
kidneys O
. O

cc O
was O
preferentially O
localized O
within O
the O
sclerotic O
areas O
of O
the O
affected O
glomeruli O
. O

since O
mesangial O
cc O
clearance O
from O
the O
mesangium O
did O
not O
change O
during O
chronic O
pan O
treatment O
, O
we O
conclude O
that O
this O
preferential O
cc O
localization O
within O
the O
lesions O
is O
caused O
by O
an O
increased O
cc O
uptake O
shortly O
after O
injection O
in O
apparent O
vulnerable O
areas O
where O
sclerosis B-Disease
will O
develop O
subsequently O
. O

cluster O
analysis O
showed O
a O
random O
distribution O
of O
lesions O
in O
the O
pan O
glomeruli O
in O
concordance O
with O
the O
random O
localization O
of O
mesangial O
areas O
with O
dysfunction O
in O
this O
model O
. O

similar O
to O
the O
remnant O
kidney O
model O
in O
pan O
nephrosis B-Disease
the O
development O
of O
glomerular B-Disease
sclerosis I-Disease
may O
be O
related O
to O
" O
mesangial O
overloading O
. O
" O

relationship O
between O
nicotine O
- O
induced O
seizures B-Disease
and O
hippocampal O
nicotinic O
receptors O
. O

a O
controversy O
has O
existed O
for O
several O
years O
concerning O
the O
physiological O
relevance O
of O
the O
nicotinic O
receptor O
measured O
by O
alpha O
- O
bungarotoxin O
binding O
. O

using O
mice O
derived O
from O
a O
classical O
f2 O
and O
backcross O
genetic O
design O
, O
a O
relationship O
between O
nicotine O
- O
induced O
seizures B-Disease
and O
alpha O
- O
bungarotoxin O
nicotinic O
receptor O
concentration O
was O
found O
. O

mice O
sensitive O
to O
the O
convulsant O
effects O
of O
nicotine O
had O
greater O
alpha O
- O
bungarotoxin O
binding O
in O
the O
hippocampus O
than O
seizure B-Disease
insensitive O
mice O
. O

the O
binding O
sites O
from O
seizure B-Disease
sensitive O
and O
resistant O
mice O
were O
equally O
affected O
by O
treatment O
with O
dithiothreitol O
, O
trypsin O
or O
heat O
. O

thus O
it O
appears O
that O
the O
difference O
between O
seizure B-Disease
sensitive O
and O
insensitive O
animals O
may O
be O
due O
to O
a O
difference O
in O
hippocampal O
nicotinic O
receptor O
concentration O
as O
measured O
with O
alpha O
- O
bungarotoxin O
binding O
. O

the O
role O
of O
p O
- O
aminophenol O
in O
acetaminophen O
- O
induced O
nephrotoxicity B-Disease
: O
effect O
of O
bis O
( O
p O
- O
nitrophenyl O
) O
phosphate O
on O
acetaminophen O
and O
p O
- O
aminophenol O
nephrotoxicity B-Disease
and O
metabolism O
in O
fischer O
344 O
rats O
. O

acetaminophen O
( O
apap O
) O
produces O
proximal O
tubular B-Disease
necrosis I-Disease
in O
fischer O
344 O
( O
f344 O
) O
rats O
. O

recently O
, O
p O
- O
aminophenol O
( O
pap O
) O
, O
a O
known O
potent O
nephrotoxicant O
, O
was O
identified O
as O
a O
metabolite O
of O
apap O
in O
f344 O
rats O
. O

the O
purpose O
of O
this O
study O
was O
to O
determine O
if O
pap O
formation O
is O
a O
requisite O
step O
in O
apap O
- O
induced O
nephrotoxicity B-Disease
. O

therefore O
, O
the O
effect O
of O
bis O
( O
p O
- O
nitrophenyl O
) O
phosphate O
( O
bnpp O
) O
, O
an O
acylamidase O
inhibitor O
, O
on O
apap O
and O
pap O
nephrotoxicity B-Disease
and O
metabolism O
was O
determined O
. O

bnpp O
( O
1 O
to O
8 O
mm O
) O
reduced O
apap O
deacetylation O
and O
covalent O
binding O
in O
f344 O
renal O
cortical O
homogenates O
in O
a O
concentration O
- O
dependent O
manner O
. O

pretreatment O
of O
animals O
with O
bnpp O
prior O
to O
apap O
or O
pap O
administration O
resulted O
in O
marked O
reduction O
of O
apap O
( O
900 O
mg O
/ O
kg O
) O
nephrotoxicity B-Disease
but O
not O
pap O
nephrotoxicity B-Disease
. O

this O
result O
was O
not O
due O
to O
altered O
disposition O
of O
either O
apap O
or O
acetylated O
metabolites O
in O
plasma O
or O
renal O
cortical O
and O
hepatic O
tissue O
. O

rather O
, O
bnpp O
pretreatment O
reduced O
the O
fraction O
of O
apap O
excreted O
as O
pap O
by O
64 O
and O
75 O
% O
after O
apap O
doses O
of O
750 O
and O
900 O
mg O
/ O
kg O
. O

bnpp O
did O
not O
alter O
the O
excretion O
of O
apap O
or O
any O
of O
its O
non O
- O
deacetylated O
metabolites O
nor O
did O
bnpp O
alter O
excretion O
of O
pap O
or O
its O
metabolites O
after O
pap O
doses O
of O
150 O
and O
300 O
mg O
/ O
kg O
. O

therefore O
, O
the O
bnpp O
- O
induced O
reduction O
in O
apap O
- O
induced O
nephrotoxicity B-Disease
appears O
to O
be O
due O
to O
inhibition O
of O
apap O
deacetylation O
. O

it O
is O
concluded O
that O
pap O
formation O
, O
in O
vivo O
, O
accounts O
, O
at O
least O
in O
part O
, O
for O
apap O
- O
induced O
renal B-Disease
tubular I-Disease
necrosis I-Disease
. O

morphine O
- O
induced O
seizures B-Disease
in O
newborn O
infants O
. O

two O
neonates O
suffered O
from O
generalized O
seizures B-Disease
during O
the O
course O
of O
intravenous O
morphine O
sulfate O
for O
post O
- O
operative O
analgesia O
. O

they O
received O
morphine O
in O
doses O
of O
32 O
micrograms O
/ O
kg O
/ O
hr O
and O
40 O
micrograms O
/ O
kg O
/ O
hr O
larger O
than O
a O
group O
of O
10 O
neonates O
who O
received O
6 O
- O
24 O
micrograms O
/ O
kg O
/ O
hr O
and O
had O
no O
seizures B-Disease
. O

plasma O
concentrations O
of O
morphine O
in O
these O
neonates O
was O
excessive O
( O
60 O
and O
90 O
mg O
/ O
ml O
) O
. O

other O
known O
reasons O
for O
seizures B-Disease
were O
ruled O
out O
and O
the O
convulsions B-Disease
stopped O
a O
few O
hours O
after O
cessation O
of O
morphine O
and O
did O
not O
reoccur O
in O
the O
subsequent O
8 O
months O
. O

it O
is O
suggested O
that O
post O
- O
operative O
intravenous O
morphine O
should O
not O
exceed O
20 O
micrograms O
/ O
kg O
/ O
ml O
in O
neonates O
. O

indomethacin O
induced O
hypotension B-Disease
in O
sodium O
and O
volume O
depleted O
rats O
. O

after O
a O
single O
oral O
dose O
of O
4 O
mg O
/ O
kg O
indomethacin O
( O
idm O
) O
to O
sodium O
and O
volume O
depleted O
rats O
plasma O
renin O
activity O
( O
pra O
) O
and O
systolic O
blood O
pressure O
fell O
significantly O
within O
four O
hours O
. O

in O
sodium O
repleted O
animals O
indomethacin O
did O
not O
change O
systolic O
blood O
pressure O
( O
bp O
) O
although O
plasma O
renin O
activity O
was O
decreased O
. O

thus O
, O
indomethacin O
by O
inhibition O
of O
prostaglandin O
synthesis O
may O
diminish O
the O
blood O
pressure O
maintaining O
effect O
of O
the O
stimulated O
renin O
- O
angiotensin O
system O
in O
sodium O
and O
volume O
depletion O
. O

on O
the O
antiarrhythmic O
activity O
of O
one O
n O
- O
substituted O
piperazine O
derivative O
of O
trans O
- O
2 O
- O
amino O
- O
3 O
- O
hydroxy O
- O
1 O
, O
2 O
, O
3 O
, O
4 O
- O
tetrahydroanaphthalene O
. O

the O
antiarrhythmic O
activity O
of O
the O
compound O
n O
- O
( O
trans O
- O
3 O
- O
hydroxy O
- O
1 O
, O
2 O
, O
3 O
, O
4 O
- O
tetrahydro O
- O
2 O
- O
naphthyl O
) O
- O
n O
- O
( O
3 O
- O
oxo O
- O
3 O
- O
phenyl O
- O
2 O
- O
methylpropyl O
) O
- O
piperazine O
hydrochloride O
, O
referred O
to O
as O
p11 O
, O
is O
studied O
on O
anaesthesized O
cats O
and O
wistar O
albino O
rats O
, O
as O
well O
as O
on O
non O
- O
anaesthesized O
rabbits O
. O

four O
types O
of O
experimental O
arrhythmia B-Disease
are O
used O
- O
- O
with O
bacl2 O
, O
with O
chloroform O
- O
adrenaline O
, O
with O
strophantine O
g O
and O
with O
aconitine O
. O

the O
compound O
p11 O
is O
introduced O
in O
doses O
of O
0 O
. O
25 O
and O
0 O
. O
50 O
mg O
/ O
kg O
intravenously O
and O
10 O
mg O
/ O
kg O
orally O
. O

the O
compound O
manifests O
antiarrhythmic O
activity O
in O
all O
models O
of O
experimental O
arrhythmia B-Disease
used O
, O
causing O
greatest O
inhibition O
on O
the O
arrhythmia B-Disease
induced O
by O
chloroform O
- O
adrenaline O
( O
in O
90 O
per O
cent O
) O
and O
with O
bacl2 O
( O
in O
84 O
per O
cent O
) O
. O

the O
results O
obtained O
are O
associated O
with O
the O
beta O
- O
adrenoblocking O
and O
with O
the O
membrane O
- O
stabilizing O
action O
of O
the O
compound O
. O

recurrent O
subarachnoid B-Disease
hemorrhage I-Disease
associated O
with O
aminocaproic O
acid O
therapy O
and O
acute B-Disease
renal I-Disease
artery I-Disease
thrombosis I-Disease
. O

case O
report O
. O

epsilon O
aminocaproic O
acid O
( O
eaca O
) O
has O
been O
used O
to O
prevent O
rebleeding O
in O
patients O
with O
subarachnoid B-Disease
hemorrhage I-Disease
( O
sah B-Disease
) O
. O

although O
this O
agent O
does O
decrease O
the O
frequency O
of O
rebleeding O
, O
several O
reports O
have O
described O
thrombotic B-Disease
complications O
of O
eaca O
therapy O
. O

these O
complications O
have O
included O
clinical O
deterioration O
and O
intracranial B-Disease
vascular I-Disease
thrombosis I-Disease
in O
patients O
with O
sah B-Disease
, O
arteriolar O
and O
capillary O
fibrin O
thrombi B-Disease
in O
patients O
with O
fibrinolytic O
syndromes O
treated O
with O
eaca O
, O
or O
other O
thromboembolic B-Disease
phenomena I-Disease
. O

since O
intravascular O
fibrin O
thrombi B-Disease
are O
often O
observed O
in O
patients O
with O
fibrinolytic O
disorders O
, O
eaca O
should O
not O
be O
implicated O
in O
the O
pathogenesis O
of O
fibrin O
thrombi B-Disease
in O
patients O
with O
disseminated B-Disease
intravascular I-Disease
coagulation I-Disease
or O
other O
" O
consumption B-Disease
coagulopathies I-Disease
. O
" O
this O
report O
describes O
subtotal O
infarction B-Disease
of O
the O
kidney O
due O
to O
thrombosis B-Disease
of I-Disease
a I-Disease
normal I-Disease
renal I-Disease
artery I-Disease
. O

this O
occlusion O
occurred O
after O
eaca O
therapy O
in O
a O
patient O
with O
sah B-Disease
and O
histopathological O
documentation O
of O
recurrent O
sah B-Disease
. O

the O
corresponding O
clinical O
event O
was O
characterized O
by O
marked O
hypertension B-Disease
and O
abrupt O
neurological O
deterioration O
. O

effect O
of O
vincristine O
sulfate O
on O
pseudomonas B-Disease
infections I-Disease
in O
monkeys O
. O

in O
rhesus O
monkeys O
, O
intravenous O
challenge O
with O
0 O
. O
6 O
x O
10 O
( O
10 O
) O
to O
2 O
. O
2 O
x O
10 O
( O
10 O
) O
pseudomonas O
aeruginosa O
organisms O
caused O
acute O
illness O
of O
4 O
to O
5 O
days O
' O
duration O
with O
spontaneous O
recovery O
in O
13 O
of O
15 O
monkeys O
; O
blood O
cultures O
became O
negative O
3 O
to O
17 O
days O
after O
challenge O
. O

leukocytosis B-Disease
was O
observed O
in O
all O
monkeys O
. O

intravenous O
or O
intratracheal O
inoculation O
of O
2 O
. O
0 O
to O
2 O
. O
5 O
mg O
of O
vincristine O
sulfate O
was O
followed O
by O
leukopenia B-Disease
in O
4 O
to O
5 O
days O
. O

intravenous O
inoculation O
of O
4 O
. O
2 O
x O
10 O
( O
10 O
) O
to O
7 O
. O
8 O
x O
10 O
( O
10 O
) O
pyocin O
type O
6 O
pseudomonas O
organisms O
in O
monkeys O
given O
vincristine O
sulfate O
4 O
days O
previously O
resulted O
in O
fatal O
infection B-Disease
in O
11 O
of O
14 O
monkeys O
, O
whereas O
none O
of O
four O
receiving O
pseudomonas O
alone O
died O
. O

these O
studies O
suggest O
that O
an O
antimetabolite O
- O
induced O
leukopenia B-Disease
predisposes O
to O
severe O
pseudomonas O
sepsis B-Disease
and O
that O
such O
monkeys O
may O
serve O
as O
a O
biological O
model O
for O
study O
of O
comparative O
efficacy O
of O
antimicrobial O
agents O
. O

modification O
by O
propranolol O
of O
cardiovascular O
effects O
of O
induced O
hypoglycaemia B-Disease
. O

the O
cardiovascular O
effects O
of O
hypoglycaemia B-Disease
, O
with O
and O
without O
beta O
- O
blockade O
, O
were O
compared O
in O
fourteen O
healthy O
men O
. O

eight O
received O
insulin O
alone O
, O
and O
eight O
, O
including O
two O
of O
the O
original O
insulin O
- O
only O
group O
, O
were O
given O
propranolol O
and O
insulin O
. O

in O
the O
insulin O
- O
group O
the O
period O
of O
hypoglycaemia B-Disease
was O
associated O
with O
an O
increase O
in O
heart O
- O
rate O
and O
a O
fall O
in O
diastolic O
blood O
- O
pressure O
. O

in O
the O
propranolol O
- O
insulin O
group O
there O
was O
a O
significant O
fall O
in O
heart O
- O
rate O
in O
most O
subjects O
and O
an O
increase O
in O
diastolic O
pressure O
. O

typical O
s O
- O
t O
/ O
t O
changes O
occurred O
in O
the O
insulin O
- O
group O
but O
in O
none O
of O
the O
propranolol O
- O
insulin O
group O
. O

hypertension B-Disease
in O
diabetics B-Disease
prone O
to O
hypoglycaemia B-Disease
attacks O
should O
not O
be O
treated O
with O
beta O
- O
blockers O
because O
these O
drugs O
may O
cause O
a O
sharp O
rise O
in O
blood O
- O
pressure O
in O
such O
patients O
. O

long O
- O
term O
propranolol O
therapy O
in O
pregnancy O
: O
maternal O
and O
fetal O
outcome O
. O

propranolol O
, O
a O
beta O
- O
adrenergic O
blocking O
agent O
, O
has O
found O
an O
important O
position O
in O
the O
practice O
of O
medicine O
. O

its O
use O
in O
pregnancy O
, O
however O
, O
is O
an O
open O
question O
as O
a O
number O
of O
detrimental O
side O
effects O
have O
been O
reported O
in O
the O
fetus O
and O
neonate O
. O

ten O
patients O
and O
12 O
pregnancies O
are O
reported O
where O
chronic O
propranolol O
has O
been O
administered O
. O

five O
patients O
with O
serial O
pregnancies O
with O
and O
without O
propranolol O
therapy O
are O
also O
examined O
. O

maternal O
, O
fetal O
, O
and O
neonatal O
complications O
are O
examined O
. O

an O
attempt O
is O
made O
to O
differentiate O
drug O
- O
related O
complications O
from O
maternal O
disease O
- O
- O
related O
complications O
. O

we O
conclude O
that O
previously O
reported O
hypoglycemia B-Disease
, O
hyperbilirubinemia B-Disease
, O
polycythemia B-Disease
, O
neonatal B-Disease
apnea I-Disease
, O
and O
bradycardia B-Disease
are O
not O
invariable O
and O
cannot O
be O
statistically O
correlated O
with O
chronic O
propranolol O
therapy O
. O

growth B-Disease
retardation I-Disease
, O
however O
, O
appears O
to O
be O
significant O
in O
both O
of O
our O
series O
. O

central O
excitatory O
actions O
of O
flurazepam O
. O

toxic O
actions O
of O
flurazepam O
( O
fzp O
) O
were O
studied O
in O
cats O
, O
mice O
and O
rats O
. O

high O
doses O
caused O
an O
apparent O
central O
excitation O
, O
most O
clearly O
seen O
as O
clonic O
convulsions B-Disease
, O
superimposed O
on O
general O
depression B-Disease
. O

following O
a O
lethal O
dose O
, O
death O
was O
always O
associated O
with O
convulsions B-Disease
. O

comparing O
the O
relative O
sensitivity O
to O
central O
depression B-Disease
and O
excitation O
revealed O
that O
rats O
were O
least O
likely O
to O
have O
convulsions B-Disease
at O
doses O
that O
did O
not O
first O
cause O
loss B-Disease
of I-Disease
consciousness I-Disease
, O
while O
cats O
most O
clearly O
showed O
marked O
central O
excitatory O
actions O
. O

signs O
of O
fzp O
toxocity B-Disease
in O
cats O
included O
excessive O
salivation B-Disease
, O
extreme O
apprehensive O
behavior O
, O
retching O
, O
muscle B-Disease
tremors I-Disease
and O
convulsions B-Disease
. O

an O
interaction O
between O
fzp O
and O
pentylenetetrazol O
( O
ptz O
) O
was O
shown O
by O
pretreating O
mice O
with O
fzp O
before O
ptz O
challenge O
. O

as O
a O
function O
of O
dose O
, O
fzp O
first O
protected O
against O
convulsions B-Disease
and O
death O
. O

at O
higher O
doses O
, O
however O
, O
convulsions B-Disease
again O
emerged O
. O

these O
doses O
of O
fzp O
were O
lower O
than O
those O
that O
would O
alone O
cause O
convulsions B-Disease
. O

these O
results O
may O
be O
relevant O
to O
the O
use O
of O
fzp O
in O
clinical O
situations O
in O
which O
there O
is O
increased O
neural O
excitability O
, O
such O
as O
epilepsy B-Disease
or O
sedative O
- O
hypnotic O
drug O
withdrawal O
. O

use O
of O
propranolol O
in O
the O
treatment O
of O
idiopathic B-Disease
orthostatic I-Disease
hypotension I-Disease
. O

five O
patients O
with O
idiopathic B-Disease
orthostatic I-Disease
hypotension I-Disease
who O
had O
physiologic O
and O
biochemical O
evidence O
of O
severe O
autonomic O
dysfunction O
were O
included O
in O
the O
study O
. O

they O
all O
exhibited O
markedly O
reduced O
plasma O
catecholamines O
and O
plasma O
renin O
activity O
in O
both O
recumbent O
and O
upright O
positions O
and O
had O
marked O
hypersensitivity B-Disease
to O
the O
pressor O
effects O
of O
infused O
norepinephrine O
. O

treatment O
with O
propanolol O
administered O
intravenously O
( O
1 O
- O
5 O
mg O
) O
produced O
increases O
in O
supine O
and O
upright O
blood O
pressure O
in O
4 O
of O
the O
5 O
individuals O
with O
rises O
ranging O
from O
11 O
/ O
6 O
to O
22 O
/ O
11 O
mmhg O
. O

chronic O
oral O
administration O
of O
propranolol O
( O
40 O
- O
160 O
mg O
/ O
day O
) O
also O
elevated O
the O
blood O
pressures O
of O
these O
individuals O
with O
increases O
in O
the O
order O
of O
20 O
- O
35 O
/ O
15 O
- O
25 O
mmg O
being O
observed O
. O

in O
1 O
patient O
, O
marked O
hypertension B-Disease
was O
induced O
by O
propranolol O
and O
the O
drug O
had O
to O
be O
withdrawn O
. O

it O
otherwise O
was O
well O
tolerated O
and O
no O
important O
side O
effects O
were O
observed O
. O

treatment O
has O
been O
continued O
in O
3 O
individuals O
for O
6 O
- O
13 O
months O
with O
persistence O
of O
the O
pressor O
effect O
, O
although O
there O
appears O
to O
have O
been O
some O
decrease O
in O
the O
degree O
of O
response O
with O
time O
. O

hemodynamic O
measurements O
in O
1 O
of O
the O
patients O
demonstrated O
an O
increase O
in O
total O
peripheral O
resistance O
and O
essentially O
no O
change O
in O
cardiac O
output O
following O
propranolol O
therapy O
. O

the O
studies O
suggest O
that O
propranolol O
is O
a O
useful O
drug O
in O
selected O
patients O
with O
severe O
idiopathic B-Disease
orthostatic I-Disease
hypotension I-Disease
. O

total O
intravenous O
anesthesia O
with O
etomidate O
. O

iii O
. O

some O
observations O
in O
adults O
. O

an O
investigation O
was O
undertaken O
to O
determine O
the O
dosage O
of O
etomidate O
required O
to O
maintain O
sleep O
in O
adults O
undergoing O
surgery O
under O
regional O
local O
anesthesia O
. O

premedication O
of O
diazepam O
10 O
mg O
and O
atropine O
0 O
. O
5 O
mg O
was O
given O
, O
and O
sleep O
was O
induced O
and O
maintained O
by O
intermittent O
intravenous O
injections O
of O
etomidate O
0 O
. O
1 O
/ O
mg O
/ O
kg O
, O
given O
whenever O
the O
patient O
would O
open O
his O
eyes O
on O
request O
. O

a O
mean O
overall O
dose O
of O
etomidate O
17 O
. O
4 O
microgram O
/ O
kg O
/ O
min O
. O
was O
required O
to O
maintain O
sleep O
, O
but O
great O
individual O
variation O
occurred O
, O
with O
older O
patients O
requiring O
less O
drug O
. O

the O
investigation O
was O
discontinued O
after O
18 O
patients O
because O
of O
the O
frequency O
and O
intensity O
of O
side O
- O
effects O
, O
particularly O
pain B-Disease
and O
myoclonia B-Disease
, O
which O
caused O
the O
technique O
to O
be O
abandoned O
in O
two O
cases O
. O

it O
is O
considered O
unlikely O
that O
etomidate O
will O
prove O
to O
be O
the O
hypnotic O
of O
choice O
for O
a O
totally O
intravenous O
anesthetic O
technique O
in O
adults O
because O
of O
the O
high O
incidence O
of O
myoclonia B-Disease
after O
prolonged O
administration O
. O

in O
several O
patients O
uncontrollable O
muscle O
movements O
persisted O
for O
many O
minutes O
after O
complete O
recovery O
of O
consciousness O
. O

evidence O
for O
cardiac O
beta O
2 O
- O
adrenoceptors O
in O
man O
. O

we O
compared O
the O
effects O
of O
single O
doses O
of O
50 O
mg O
atenolol O
( O
cardioselective O
) O
, O
40 O
mg O
propranolol O
( O
nonselective O
) O
, O
and O
placebo O
on O
both O
exercise O
- O
and O
isoproterenol O
- O
induced O
tachycardia B-Disease
in O
two O
experiments O
involving O
nine O
normal O
subjects O
. O

maximal O
exercise O
heart O
rate O
was O
reduced O
from O
187 O
+ O
/ O
- O
4 O
( O
sem O
) O
after O
placebo O
to O
146 O
+ O
/ O
- O
7 O
bpm O
after O
atenolol O
and O
138 O
+ O
/ O
- O
6 O
bpm O
after O
propranolol O
, O
but O
there O
were O
no O
differences O
between O
the O
drugs O
. O

the O
effects O
on O
isoproterenol O
tachycardia B-Disease
were O
determined O
before O
and O
after O
atropine O
( O
0 O
. O
04 O
mg O
/ O
kg O
iv O
) O
. O

isoproterenol O
sensitivity O
was O
determined O
as O
the O
intravenous O
dose O
that O
increased O
heart O
rate O
by O
25 O
bpm O
( O
cd25 O
) O
and O
this O
was O
increased O
from O
1 O
. O
8 O
+ O
/ O
- O
0 O
. O
3 O
micrograms O
after O
placebo O
to O
38 O
. O
9 O
+ O
/ O
- O
8 O
. O
3 O
micrograms O
after O
propranolol O
and O
8 O
. O
3 O
+ O
/ O
- O
1 O
. O
7 O
micrograms O
after O
atenolol O
. O

the O
difference O
in O
the O
effects O
of O
the O
two O
was O
significant O
. O

after O
atropine O
the O
cd25 O
was O
unchanged O
after O
placebo O
( O
2 O
. O
3 O
+ O
/ O
- O
0 O
. O
3 O
micrograms O
) O
and O
atenolol O
( O
7 O
. O
7 O
+ O
/ O
- O
1 O
. O
3 O
micrograms O
) O
; O
it O
was O
reduced O
after O
propranolol O
( O
24 O
. O
8 O
+ O
/ O
- O
5 O
. O
0 O
micrograms O
) O
, O
but O
remained O
different O
from O
atenolol O
. O

this O
change O
with O
propranolol O
sensitivity O
was O
calculated O
as O
the O
apparent O
ka O
, O
this O
was O
unchanged O
by O
atropine O
( O
11 O
. O
7 O
+ O
/ O
- O
2 O
. O
1 O
and O
10 O
. O
1 O
+ O
/ O
- O
2 O
. O
5 O
ml O
/ O
ng O
) O
. O

these O
data O
are O
consistent O
with O
the O
hypothesis O
that O
exercise O
- O
induced O
tachycardia B-Disease
results O
largely O
from O
beta O
1 O
- O
receptor O
activation O
that O
is O
blocked O
by O
both O
cardioselective O
and O
nonselective O
drugs O
, O
whereas O
isoproterenol O
activates O
both O
beta O
1 O
- O
and O
beta O
2 O
- O
receptors O
so O
that O
after O
cardioselective O
blockade O
there O
remains O
a O
beta O
2 O
- O
component O
that O
can O
be O
blocked O
with O
a O
nonselective O
drug O
. O

while O
there O
appear O
to O
be O
beta O
2 O
- O
receptors O
in O
the O
human O
heart O
, O
their O
physiologic O
or O
pathologic O
roles O
remain O
to O
be O
defined O
. O

hormones O
and O
risk O
of O
breast B-Disease
cancer I-Disease
. O

this O
paper O
reports O
the O
results O
of O
a O
study O
of O
50 O
menopausal O
women O
receiving O
hormonal O
replacement O
therapy O
. O

the O
majority O
( O
29 O
) O
had O
surgical O
menopause O
; O
their O
mean O
age O
was O
45 O
. O
7 O
years O
. O

it O
was O
hypothesized O
that O
progestins O
could O
equilibrate O
the O
effects O
of O
the O
estrogenic O
stimulation O
on O
the O
mammary O
and O
endometrial O
target O
tissues O
of O
women O
on O
hormonal O
replacement O
therapy O
. O

the O
treatment O
schedule O
consisted O
of O
conjugated O
estrogens O
( O
premarin O
) O
1 O
. O
25 O
mg O
/ O
day O
for O
21 O
days O
and O
medroxyprogesterone O
acetate O
10 O
mg O
/ O
day O
for O
10 O
days O
in O
each O
month O
. O

the O
mean O
treatment O
period O
was O
18 O
months O
. O

during O
the O
follow O
- O
up O
period O
, O
attention O
was O
paid O
to O
breast O
modifications O
as O
evidenced O
by O
symptomatology O
, O
physical O
examination O
, O
and O
plate O
thermography O
. O

mastodynia B-Disease
was O
reported O
by O
21 O
patients O
, O
and O
physical O
examination O
revealed O
a O
light O
increase O
in O
breast O
firmness O
in O
12 O
women O
and O
a O
moderate O
increase O
in O
breast O
nodularity O
in O
2 O
women O
. O

themography O
confirmed O
the O
existence O
of O
an O
excessive O
breast O
stimulation O
in O
1 O
women O
who O
complained O
of O
moderate O
mastodynia B-Disease
and O
in O
5 O
of O
the O
7 O
women O
who O
complained O
of O
severe O
mastodynia B-Disease
. O

normalization O
was O
obtained O
by O
halving O
the O
estrogen O
dose O
. O

these O
results O
suggest O
that O
hormonal O
replacement O
therapy O
can O
be O
safely O
prescribed O
if O
the O
following O
criteria O
are O
satisfied O
: O
1 O
) O
preliminary O
evaluation O
of O
patients O
from O
a O
clinical O
, O
metabolic O
, O
cytologic O
, O
and O
mammographic O
perspective O
; O
2 O
) O
cyclic O
treatment O
schedule O
, O
with O
a O
progestative O
phase O
of O
10 O
days O
; O
and O
3 O
) O
periodic O
complete O
follow O
- O
up O
, O
with O
accurate O
thermographic O
evaluation O
of O
the O
breast O
target O
tissues O
. O

early O
infections B-Disease
in O
kidney O
, O
heart O
, O
and O
liver O
transplant O
recipients O
on O
cyclosporine O
. O

eighty O
- O
one O
renal O
, O
seventeen O
heart O
, O
and O
twenty O
- O
four O
liver O
transplant O
patients O
were O
followed O
for O
infection B-Disease
. O

seventeen O
renal O
patients O
received O
azathioprine O
( O
aza O
) O
and O
prednisone O
as O
part O
of O
a O
randomized O
trial O
of O
immunosuppression O
with O
21 O
cyclosporine O
- O
and O
- O
prednisone O
- O
treated O
renal O
transplant O
patients O
. O

all O
others O
received O
cyclosporine O
and O
prednisone O
. O

the O
randomized O
aza O
patients O
had O
more O
overall O
infections B-Disease
( O
p O
less O
than O
0 O
. O
05 O
) O
and O
more O
nonviral O
infections B-Disease
( O
p O
less O
than O
0 O
. O
02 O
) O
than O
the O
randomized O
cyclosporine O
patients O
. O

heart O
and O
liver O
patients O
had O
more O
infections B-Disease
than O
cyclosporine O
renal O
patients O
but O
fewer O
infections B-Disease
than O
the O
aza O
renal O
patients O
. O

there O
were O
no O
infectious O
deaths O
in O
renal O
transplant O
patients O
on O
cyclosporine O
or O
aza O
, O
but O
infection B-Disease
played O
a O
major O
role O
in O
3 O
out O
of O
6 O
cardiac O
transplant O
deaths O
and O
in O
8 O
out O
of O
9 O
liver O
transplant O
deaths O
. O

renal O
patients O
on O
cyclosporine O
had O
the O
fewest O
bacteremias B-Disease
. O

analysis O
of O
site O
of O
infection B-Disease
showed O
a O
preponderance O
of O
abdominal B-Disease
infections I-Disease
in O
liver O
patients O
, O
intrathoracic O
infections B-Disease
in O
heart O
patients O
, O
and O
urinary B-Disease
tract I-Disease
infections I-Disease
in O
renal O
patients O
. O

pulmonary O
infections B-Disease
were O
less O
common O
in O
cyclosporine O
- O
treated O
renal O
patients O
than O
in O
aza O
- O
treated O
patients O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

aza O
patients O
had O
significantly O
more O
staphylococcal B-Disease
infections I-Disease
than O
all O
other O
transplant O
groups O
( O
p O
less O
than O
0 O
. O
005 O
) O
, O
and O
systemic O
fungal B-Disease
infections I-Disease
occurred O
only O
in O
the O
liver O
transplant O
group O
. O

cytomegalovirus O
( O
cmv O
) O
shedding O
or O
serological O
rises O
in O
antibody O
titer O
, O
or O
both O
occurred O
in O
78 O
% O
of O
cyclosporine O
patients O
and O
76 O
% O
of O
aza O
patients O
. O

of O
the O
cyclosporine O
patients O
, O
15 O
% O
had O
symptoms O
related O
to O
cmv B-Disease
infection I-Disease
. O

serological O
evidence O
for O
epstein B-Disease
barr I-Disease
virus I-Disease
infection I-Disease
was O
found O
in O
20 O
% O
of O
65 O
cyclosporine O
patients O
studied O
. O

three O
had O
associated O
symptoms O
, O
and O
one O
developed O
a O
lymphoma B-Disease
. O

structure O
- O
activity O
and O
dose O
- O
effect O
relationships O
of O
the O
antagonism O
of O
picrotoxin O
- O
induced O
seizures B-Disease
by O
cholecystokinin O
, O
fragments O
and O
analogues O
of O
cholecystokinin O
in O
mice O
. O

intraperitoneal O
administration O
of O
cholecystokinin O
octapeptide O
sulphate O
ester O
( O
cck O
- O
8 O
- O
se O
) O
and O
nonsulphated O
cholecystokinin O
octapeptide O
( O
cck O
- O
8 O
- O
ns O
) O
enhanced O
the O
latency O
of O
seizures B-Disease
induced O
by O
picrotoxin O
in O
mice O
. O

experiments O
with O
n O
- O
and O
c O
- O
terminal O
fragments O
revealed O
that O
the O
c O
- O
terminal O
tetrapeptide O
( O
cck O
- O
5 O
- O
8 O
) O
was O
the O
active O
centre O
of O
the O
cck O
octapeptide O
molecule O
. O

the O
analogues O
cck O
- O
8 O
- O
se O
and O
cck O
- O
8 O
- O
ns O
( O
dose O
range O
0 O
. O
2 O
- O
6 O
. O
4 O
mumol O
/ O
kg O
) O
and O
caerulein O
dose O
range O
0 O
. O
1 O
- O
0 O
. O
8 O
mumol O
/ O
kg O
) O
showed O
bell O
- O
shaped O
dose O
- O
effect O
curves O
, O
with O
the O
greatest O
maximum O
inhibition O
for O
cck O
- O
8 O
- O
ns O
. O

the O
peptide O
cck O
- O
5 O
- O
8 O
had O
weak O
anticonvulsant O
activity O
in O
comparison O
to O
the O
octapeptides O
, O
3 O
. O
2 O
mumol O
/ O
kg O
and O
larger O
doses O
of O
the O
reference O
drug O
, O
diazepam O
, O
totally O
prevented O
picrotoxin O
- O
induced O
seizures B-Disease
and O
mortality O
. O

the O
maximum O
effect O
of O
the O
peptides O
tested O
was O
less O
than O
that O
of O
diazepam O
. O

experiments O
with O
analogues O
and O
derivatives O
of O
cck O
- O
5 O
- O
8 O
demonstrated O
that O
the O
effectiveness O
of O
the O
beta O
- O
alanyl O
derivatives O
of O
cck O
- O
5 O
- O
8 O
were O
enhanced O
and O
that O
they O
were O
equipotent O
with O
cck O
- O
8 O
- O
se O
. O

of O
the O
cck O
- O
2 O
- O
8 O
analogues O
, O
ser O
( O
so3h O
) O
7 O
- O
ac O
- O
cck O
- O
2 O
- O
8 O
- O
se O
and O
thr O
( O
so3h O
) O
7 O
- O
ac O
- O
cck O
- O
2 O
- O
8 O
- O
se O
and O
hyp O
( O
so3h O
) O
- O
ac O
- O
cck O
- O
2 O
- O
8 O
- O
se O
were O
slightly O
more O
active O
than O
cck O
- O
8 O
- O
se O
. O

vasopressin O
as O
a O
possible O
contributor O
to O
hypertension B-Disease
. O

the O
role O
of O
vasopressin O
as O
a O
pressor O
agent O
to O
the O
hypertensive B-Disease
process O
was O
examined O
. O

vasopressin O
plays O
a O
major O
role O
in O
the O
pathogenesis O
of O
doca O
- O
salt O
hypertension B-Disease
, O
since O
the O
elevation O
of O
blood O
pressure O
was O
not O
substantial O
in O
the O
rats O
with O
lithium O
- O
treated O
diabetes B-Disease
insipidus I-Disease
after O
doca O
- O
salt O
treatment O
. O

administration O
of O
ddavp O
which O
has O
antidiuretic O
action O
but O
minimal O
vasopressor O
effect O
failed O
to O
increase O
blood O
pressure O
to O
the O
levels O
observed O
after O
administration O
of O
avp O
. O

furthermore O
, O
the O
pressor O
action O
of O
vasopressin O
appears O
to O
be O
important O
in O
the O
development O
of O
this O
model O
of O
hypertension B-Disease
, O
since O
the O
enhanced O
pressor O
responsiveness O
to O
the O
hormone O
was O
observed O
in O
the O
initial O
stage O
of O
hypertension B-Disease
. O

increased O
secretion O
of O
vasopressin O
from O
neurohypophysis O
also O
promotes O
the O
function O
of O
the O
hormone O
as O
a O
pathogenetic O
factor O
in O
hypertension B-Disease
. O

an O
unproportional O
release O
of O
vasopressin O
compared O
to O
plasma O
osmolality O
may O
be O
induced O
by O
the O
absence O
of O
an O
adjusting O
control O
of O
angiotensin O
ii O
forming O
and O
receptor O
binding O
capacity O
for O
sodium O
balance O
in O
the O
brain O
. O

however O
, O
the O
role O
of O
vasopressin O
remains O
to O
be O
determined O
in O
human O
essential O
hypertension B-Disease
. O

toxic B-Disease
hepatitis I-Disease
induced O
by O
disulfiram O
in O
a O
non O
- O
alcoholic O
. O

a O
reversible O
toxic B-Disease
liver I-Disease
damage I-Disease
was O
observed O
in O
a O
non O
- O
alcoholic O
woman O
treated O
with O
disulfiram O
. O

the O
causative O
relationship O
was O
proven O
by O
challenge O
. O

atrial B-Disease
thrombosis I-Disease
involving O
the O
heart O
of O
f O
- O
344 O
rats O
ingesting O
quinacrine O
hydrochloride O
. O

quinacrine O
hydrochloride O
is O
toxic O
for O
the O
heart O
of O
f O
- O
344 O
rats O
. O

rats O
treated O
with O
500 O
ppm O
quinacrine O
hydrochloride O
in O
the O
diet O
all O
developed O
a O
high O
incidence O
of O
left O
atrial B-Disease
thrombosis I-Disease
. O

the O
lesion O
was O
associated O
with O
cardiac B-Disease
hypertrophy I-Disease
and O
dilatation O
and O
focal O
myocardial B-Disease
degeneration I-Disease
. O

rats O
died O
from O
cardiac B-Disease
hypertrophy I-Disease
with O
severe O
acute O
and O
chronic O
congestion O
of O
the O
lungs O
, O
liver O
, O
and O
other O
organs O
. O

seventy O
percent O
of O
rats O
given O
250 O
ppm O
quinacrine O
hydrochloride O
and O
1 O
, O
000 O
ppm O
sodium O
nitrite O
simultaneously O
in O
the O
diet O
had O
thrombosis B-Disease
of O
the O
atria O
of O
the O
heart O
, O
while O
untreated O
control O
rats O
in O
this O
laboratory O
did O
not O
have O
atrial B-Disease
thrombosis I-Disease
. O

sodium O
nitrite O
in O
combination O
with O
quinacrine O
hydrochloride O
appeared O
to O
have O
no O
additional O
effect O
. O

alternating B-Disease
sinus I-Disease
rhythm I-Disease
and O
intermittent O
sinoatrial B-Disease
block I-Disease
induced O
by O
propranolol O
. O

alternating B-Disease
sinus I-Disease
rhythm I-Disease
and O
intermittent O
sinoatrial B-Disease
( I-Disease
s I-Disease
- I-Disease
a I-Disease
) I-Disease
block I-Disease
was O
observed O
in O
a O
57 O
- O
year O
- O
old O
woman O
, O
under O
treatment O
for O
angina B-Disease
with O
80 O
mg O
propranolol O
daily O
. O

the O
electrocardiogram O
showed O
alternation O
of O
long O
and O
short O
p O
- O
p O
intervals O
and O
occasional O
pauses O
. O

these O
pauses O
were O
always O
preceded O
by O
the O
short O
p O
- O
p O
intervals O
and O
were O
usually O
followed O
by O
one O
or O
two O
p O
- O
p O
intervals O
of O
0 O
. O
92 O
- O
0 O
. O
95 O
s O
representing O
the O
basic O
sinus O
cycle O
. O

following O
these O
basic O
sinus O
cycles O
, O
alternating B-Disease
rhythm I-Disease
started O
with O
the O
longer O
p O
- O
p O
interval O
. O

the O
long O
p O
- O
p O
intervals O
ranged O
between O
1 O
. O
04 O
- O
1 O
. O
12 O
s O
and O
the O
short O
p O
- O
p O
intervals O
between O
0 O
. O
80 O
- O
0 O
. O
84 O
s O
, O
respectively O
. O

the O
duration O
of O
the O
pauses O
were O
equal O
or O
almost O
equal O
to O
one O
short O
plus O
one O
long O
p O
- O
p O
interval O
or O
to O
twice O
the O
basic O
sinus O
cycle O
. O

in O
one O
recording O
a O
short O
period O
of O
regular O
sinus O
rhythm O
with O
intermittent O
2 O
/ O
1 O
s B-Disease
- I-Disease
a I-Disease
block I-Disease
was O
observed O
. O

this O
short O
period O
of O
sinus O
rhythm O
was O
interrupted O
by O
sudden O
prolongation O
of O
the O
p O
- O
p O
interval O
starting O
the O
alternative O
rhythm O
. O

there O
were O
small O
changes O
in O
the O
shape O
of O
the O
p O
waves O
and O
p O
- O
r O
intervals O
. O

s O
- O
a O
conduction O
through O
two O
pathways O
, O
the O
first O
with O
2 O
/ O
1 O
block O
the O
second O
having O
0 O
. O
12 O
- O
0 O
. O
14 O
s O
longer O
conduction O
time O
and O
with O
occasional O
2 O
/ O
1 O
block O
was O
proposed O
for O
the O
explanation O
of O
the O
alternating O
p O
- O
p O
interval O
and O
other O
electrocardiographic O
features O
seen O
. O

atropine O
1 O
mg O
given O
intravenously O
resulted O
in O
shortening O
of O
all O
p O
- O
p O
intervals O
without O
changing O
the O
rhythm O
. O

the O
abnormal O
rhythm O
disappeared O
with O
the O
withdrawal O
of O
propranolol O
and O
when O
the O
drug O
was O
restarted O
a O
2 O
/ O
1 O
s B-Disease
- I-Disease
a I-Disease
block I-Disease
was O
seen O
. O

this O
was O
accepted O
as O
evidence O
for O
propranolol O
being O
the O
cause O
of O
this O
conduction B-Disease
disorder I-Disease
. O

antitumor O
effect O
, O
cardiotoxicity B-Disease
, O
and O
nephrotoxicity B-Disease
of O
doxorubicin O
in O
the O
igm O
solid O
immunocytoma B-Disease
- O
bearing O
lou O
/ O
m O
/ O
wsl O
rat O
. O

antitumor O
activity O
, O
cardiotoxicity B-Disease
, O
and O
nephrotoxicity B-Disease
induced O
by O
doxorubicin O
were O
studied O
in O
lou O
/ O
m O
/ O
wsl O
inbred O
rats O
each O
bearing O
a O
transplantable O
solid O
igm O
immunocytoma B-Disease
. O

animals O
with O
a O
tumor B-Disease
( O
diameter O
, O
15 O
. O
8 O
+ O
/ O
- O
3 O
. O
3 O
mm O
) O
were O
treated O
with O
iv O
injections O
of O
doxorubicin O
on O
5 O
consecutive O
days O
, O
followed O
by O
1 O
weekly O
injection O
for O
7 O
weeks O
( O
dose O
range O
, O
0 O
. O
015 O
- O
4 O
. O
0 O
mg O
/ O
kg O
body O
wt O
) O
. O

tumor B-Disease
regression O
was O
observed O
with O
0 O
. O
5 O
mg O
doxorubicin O
/ O
kg O
. O

complete O
disappearance O
of O
the O
tumor B-Disease
was O
induced O
with O
1 O
. O
0 O
mg O
doxorubicin O
/ O
kg O
. O

histologic O
evidence O
of O
cardiotoxicity B-Disease
scored O
as O
grade O
iii O
was O
only O
observed O
at O
a O
dose O
of O
1 O
. O
0 O
mg O
doxorubicin O
/ O
kg O
. O

light O
microscopic O
evidence O
of O
renal B-Disease
damage I-Disease
was O
seen O
above O
a O
dose O
of O
0 O
. O
5 O
mg O
doxorubicin O
/ O
kg O
, O
which O
resulted O
in O
albuminuria B-Disease
and O
very O
low O
serum O
albumin O
levels O
. O

in O
the O
group O
that O
received O
1 O
. O
0 O
mg O
doxorubicin O
/ O
kg O
, O
the O
serum O
albumin O
level O
decreased O
from O
33 O
. O
6 O
+ O
/ O
- O
4 O
. O
1 O
to O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
5 O
g O
/ O
liter O
. O

ascites B-Disease
and O
hydrothorax B-Disease
were O
observed O
simultaneously O
. O

the O
same O
experiments O
were O
performed O
with O
non O
- O
tumor B-Disease
- O
bearing O
rats O
, O
in O
which O
no O
major O
differences O
were O
observed O
. O

in O
conclusion O
, O
antitumor O
activity O
, O
cardiotoxicity B-Disease
, O
and O
nephrotoxicity B-Disease
were O
studied O
simultaneously O
in O
the O
same O
lou O
/ O
m O
/ O
wsl O
rat O
. O

albuminuria B-Disease
due O
to O
renal B-Disease
damage I-Disease
led O
to O
extremely O
low O
serum O
albumin O
levels O
, O
so O
ascites B-Disease
and O
hydrothorax B-Disease
were O
not O
necessarily O
a O
consequence O
of O
the O
observed O
cardiomyopathy B-Disease
. O

intraoperative O
bradycardia B-Disease
and O
hypotension B-Disease
associated O
with O
timolol O
and O
pilocarpine O
eye O
drops O
. O

a O
69 O
- O
yr O
- O
old O
man O
, O
who O
was O
concurrently O
being O
treated O
with O
pilocarpine O
nitrate O
and O
timolol O
maleate O
eye O
drops O
, O
developed O
a O
bradycardia B-Disease
and O
became O
hypotensive B-Disease
during O
halothane O
anaesthesia O
. O

both O
timolol O
and O
pilocarpine O
were O
subsequently O
identified O
in O
a O
24 O
- O
h O
collection O
of O
urine O
. O

timolol O
( O
but O
not O
pilocarpine O
) O
was O
detected O
in O
a O
sample O
of O
plasma O
removed O
during O
surgery O
; O
the O
plasma O
concentration O
of O
timolol O
( O
2 O
. O
6 O
ng O
ml O
- O
1 O
) O
was O
consistent O
with O
partial O
beta O
- O
adrenoceptor O
blockade O
. O

it O
is O
postulated O
that O
this O
action O
may O
have O
been O
enhanced O
during O
halothane O
anaesthesia O
with O
resultant O
bradycardia B-Disease
and O
hypotension B-Disease
. O

pilocarpine O
may O
have O
had O
a O
contributory O
effect O
. O

succinylcholine O
apnoea B-Disease
: O
attempted O
reversal O
with O
anticholinesterases O
. O

anticholinesterases O
were O
administered O
in O
an O
attempt O
to O
antagonize O
prolonged O
neuromuscular B-Disease
blockade I-Disease
following O
the O
administration O
of O
succinylcholine O
in O
a O
patient O
later O
found O
to O
be O
homozygous O
for O
atypical O
plasma O
cholinesterase O
. O

edrophonium O
10 O
mg O
, O
given O
74 O
min O
after O
succinylcholine O
, O
when O
train O
- O
of O
- O
four O
stimulation O
was O
characteristic O
of O
phase O
ii O
block O
, O
produced O
partial O
antagonism O
which O
was O
not O
sustained O
. O

repeated O
doses O
of O
edrophonium O
to O
70 O
mg O
and O
neostigmine O
to O
2 O
. O
5 O
mg O
did O
not O
antagonize O
or O
augment O
the O
block O
. O

spontaneous O
respiration O
recommenced O
200 O
min O
after O
succinylcholine O
administration O
. O

it O
is O
concluded O
that O
anticholinesterases O
are O
only O
partially O
effective O
in O
restoring O
neuromuscular O
function O
in O
succinylcholine O
apnoea B-Disease
despite O
muscle O
twitch O
activity O
typical O
of O
phase O
ii O
block O
. O

effect O
of O
doxorubicin O
on O
[ O
omega O
- O
i O
- O
131 O
] O
heptadecanoic O
acid O
myocardial O
scintigraphy O
and O
echocardiography O
in O
dogs O
. O

the O
effects O
of O
serial O
treatment O
with O
doxorubicin O
on O
dynamic O
myocardial O
scintigraphy O
with O
[ O
omega O
- O
i O
- O
131 O
] O
heptadecanoic O
acid O
( O
i O
- O
131 O
ha O
) O
, O
and O
on O
global O
left O
- O
ventricular O
function O
determined O
echocardiographically O
, O
were O
studied O
in O
a O
group O
of O
nine O
mongrel O
dogs O
. O

total O
extractable O
myocardial O
lipid O
was O
compared O
postmortem O
between O
a O
group O
of O
control O
dogs O
and O
doxorubicin O
- O
treated O
dogs O
. O

a O
significant O
and O
then O
progressive O
fall O
in O
global O
lv O
function O
was O
observed O
at O
a O
cumulative O
doxorubicin O
dose O
of O
4 O
mg O
/ O
kg O
. O

a O
significant O
increase O
in O
the O
myocardial O
t1 O
/ O
2 O
of O
the O
i O
- O
131 O
ha O
was O
observed O
only O
at O
a O
higher O
cumulative O
dose O
, O
10 O
mg O
/ O
kg O
. O

no O
significant O
alteration O
in O
total O
extractable O
myocardial O
lipids O
was O
observed O
between O
control O
dogs O
and O
those O
treated O
with O
doxorubicin O
. O

our O
findings O
suggest O
that O
the O
changes O
leading O
to O
an O
alteration O
of O
myocardial O
dynamic O
imaging O
with O
i O
- O
131 O
ha O
are O
not O
the O
initiating O
factor O
in O
doxorubicin O
cardiotoxicity B-Disease
. O

hemodynamics O
and O
myocardial O
metabolism O
under O
deliberate O
hypotension B-Disease
. O

an O
experimental O
study O
in O
dogs O
. O

coronary O
blood O
flow O
, O
cardiac O
work O
and O
metabolism O
were O
studied O
in O
dogs O
under O
sodium O
nitroprusside O
( O
snp O
) O
and O
trimetaphan O
( O
tmp O
) O
deliberate O
hypotension B-Disease
( O
20 O
% O
and O
40 O
% O
mean O
pressure O
decrease O
from O
baseline O
) O
. O

regarding O
the O
effects O
of O
drug O
- O
induced O
hypotension B-Disease
on O
coronary O
blood O
flow O
, O
aortic O
and O
coronary O
sinus O
metabolic O
data O
( O
ph O
, O
po2 O
, O
pco2 O
) O
we O
could O
confirm O
that O
nitroprusside O
hypotension B-Disease
could O
be O
safely O
used O
to O
30 O
% O
mean O
blood O
pressure O
decrease O
from O
control O
, O
trimetaphan O
hypotension B-Disease
to O
20 O
% O
mean O
blood O
pressure O
decrease O
. O

cardiac O
work O
was O
significantly O
reduced O
during O
snp O
hypotension B-Disease
. O

myocardial O
o2 O
consumption O
and O
o2 O
availability O
were O
directly O
dependent O
on O
the O
coronary O
perfusion O
. O

careful O
invasive O
monitoring O
of O
the O
blood O
pressure O
, O
blood O
gases O
and O
of O
the O
ecg O
st O
- O
t O
segment O
is O
mandatory O
. O

evidence O
for O
a O
selective O
brain O
noradrenergic O
involvement O
in O
the O
locomotor O
stimulant O
effects O
of O
amphetamine O
in O
the O
rat O
. O

male O
rats O
received O
the O
noradrenaline O
neurotoxin O
dsp4 O
( O
50 O
mg O
/ O
kg O
) O
7 O
days O
prior O
to O
injection O
of O
d O
- O
amphetamine O
( O
10 O
or O
40 O
mumol O
/ O
kg O
i O
. O
p O
. O
) O
. O

the O
hyperactivity B-Disease
induced O
by O
d O
- O
amphetamine O
( O
10 O
mumol O
/ O
kg O
) O
was O
significantly O
reduced O
by O
dsp4 O
pretreatment O
. O

however O
, O
the O
increased O
rearings O
and O
the O
amphetamine O
- O
induced O
stereotypies B-Disease
were O
not O
blocked O
by O
pretreatment O
with O
dsp4 O
. O

the O
reduction O
of O
amphetamine O
hyperactivity B-Disease
induced O
by O
dsp4 O
was O
blocked O
by O
pretreatment O
with O
the O
noradrenaline O
- O
uptake O
blocking O
agent O
, O
desipramine O
, O
which O
prevents O
the O
neurotoxic B-Disease
action O
of O
dsp4 O
. O

the O
present O
results O
suggest O
a O
selective O
involvement O
of O
central O
noradrenergic O
neurones O
in O
the O
locomotor O
stimulant O
effect O
of O
amphetamine O
in O
the O
rat O
. O

accelerated B-Disease
junctional I-Disease
rhythms I-Disease
during O
oral O
verapamil O
therapy O
. O

this O
study O
examined O
the O
frequency O
of O
atrioventricular O
( O
av O
) O
dissociation O
and O
accelerated B-Disease
junctional I-Disease
rhythms I-Disease
in O
59 O
patients O
receiving O
oral O
verapamil O
. O

accelerated B-Disease
junctional I-Disease
rhythms I-Disease
and O
av O
dissociation O
were O
frequent O
in O
patients O
with O
supraventricular B-Disease
tachyarrhythmias I-Disease
, O
particularly O
av O
nodal O
reentry O
. O

verapamil O
administration O
to O
these O
patients O
led O
to O
an O
asymptomatic O
increase O
in O
activity O
of O
these O
junctional O
pacemakers O
. O

in O
patients O
with O
various O
chest B-Disease
pain I-Disease
syndromes O
, O
verapamil O
neither O
increased O
the O
frequency O
of O
junctional O
rhythms O
nor O
suppressed O
their O
role O
as O
escape O
rhythms O
under O
physiologically O
appropriate O
circumstances O
. O

interstrain O
variation O
in O
acute O
toxic O
response O
to O
caffeine O
among O
inbred O
mice O
. O

acute O
toxic O
dosage O
- O
dependent O
behavioral O
effects O
of O
caffeine O
were O
compared O
in O
adult O
males O
from O
seven O
inbred O
mouse O
strains O
( O
a O
/ O
j O
, O
balb O
/ O
cj O
, O
cba O
/ O
j O
, O
c3h O
/ O
hej O
, O
c57bl O
/ O
6j O
, O
dba O
/ O
2j O
, O
swr O
/ O
j O
) O
. O

c57bl O
/ O
6j O
, O
chosen O
as O
a O
" O
prototypic O
" O
mouse O
strain O
, O
was O
used O
to O
determine O
behavioral O
responses O
to O
a O
broad O
range O
( O
5 O
- O
500 O
mg O
/ O
kg O
) O
of O
caffeine O
doses O
. O

five O
phenotypic O
characteristics O
- O
- O
locomotor O
activity O
, O
righting O
ability O
, O
clonic B-Disease
seizure I-Disease
induction O
, O
stress O
- O
induced O
lethality O
, O
death O
without O
external O
stress O
- O
- O
were O
scored O
at O
various O
caffeine O
doses O
in O
drug O
- O
naive O
animals O
under O
empirically O
optimized O
, O
rigidly O
constant O
experimental O
conditions O
. O

mice O
( O
n O
= O
12 O
for O
each O
point O
) O
received O
single O
ip O
injections O
of O
a O
fixed O
volume O
/ O
g O
body O
weight O
of O
physiological O
saline O
carrier O
with O
or O
without O
caffeine O
in O
doses O
ranging O
from O
125 O
- O
500 O
mg O
/ O
kg O
. O

loss O
of O
righting O
ability O
was O
scored O
at O
1 O
, O
3 O
, O
5 O
min O
post O
dosing O
and O
at O
5 O
min O
intervals O
thereafter O
for O
20 O
min O
. O

in O
the O
same O
animals O
the O
occurrence O
of O
clonic B-Disease
seizures I-Disease
was O
scored O
as O
to O
time O
of O
onset O
and O
severity O
for O
20 O
min O
after O
drug O
administration O
. O

when O
these O
proceeded O
to O
tonic B-Disease
seizures I-Disease
, O
death O
occurred O
in O
less O
than O
20 O
min O
. O

animals O
surviving O
for O
20 O
min O
were O
immediately O
stressed O
by O
a O
swim O
test O
in O
25 O
degrees O
c O
water O
, O
and O
death O
- O
producing O
tonic B-Disease
seizures I-Disease
were O
scored O
for O
2 O
min O
. O

in O
other O
animals O
locomotor O
activity O
was O
measured O
15 O
or O
60 O
min O
after O
caffeine O
administration O
. O

by O
any O
single O
behavioral O
criterion O
or O
a O
combination O
of O
these O
criteria O
, O
marked O
differences O
in O
response O
to O
toxic O
caffeine O
doses O
were O
observed O
between O
strains O
. O

these O
results O
indicate O
that O
behavioral O
toxicity B-Disease
testing O
of O
alkylxanthines O
in O
a O
single O
mouse O
strain O
may O
be O
misleading O
and O
suggest O
that O
toxic O
responses O
of O
the O
central O
nervous O
system O
to O
this O
class O
of O
compounds O
are O
genetically O
influenced O
in O
mammals O
. O

treatment O
of O
ovarian B-Disease
cancer I-Disease
with O
a O
combination O
of O
cis O
- O
platinum O
, O
adriamycin O
, O
cyclophosphamide O
and O
hexamethylmelamine O
. O

during O
the O
last O
2 O
1 O
/ O
2 O
years O
, O
38 O
patients O
with O
ovarian B-Disease
cancer I-Disease
were O
treated O
with O
a O
combination O
of O
cisplatinum O
( O
cpdd O
) O
, O
50 O
mg O
/ O
m2 O
, O
adriamycin O
, O
30 O
mg O
/ O
m2 O
, O
cyclophosphamide O
, O
300 O
mg O
/ O
m2 O
, O
on O
day O
1 O
; O
and O
hexamethylmelamine O
( O
hmm O
) O
, O
6 O
mg O
/ O
kg O
daily O
, O
for O
14 O
days O
. O

each O
course O
was O
repeated O
monthly O
. O

2 O
patients O
had O
stage O
ii O
, O
14 O
stage O
iii O
and O
22 O
stage O
iv O
disease O
. O

14 O
of O
the O
38 O
patients O
were O
previously O
treated O
with O
chemotherapy O
, O
1 O
with O
radiation O
, O
6 O
with O
both O
chemotherapy O
and O
radiation O
, O
and O
17 O
did O
not O
have O
any O
treatment O
before O
cpdd O
combination O
. O

31 O
of O
the O
38 O
cases O
( O
81 O
. O
5 O
% O
) O
demonstrated O
objective O
responses O
lasting O
for O
2 O
months O
or O
more O
. O

these O
responses O
were O
partial O
in O
19 O
and O
complete O
in O
12 O
cases O
. O

hematologic B-Disease
toxicity I-Disease
was O
moderate O
and O
with O
reversible O
anemia B-Disease
developing O
in O
71 O
% O
of O
patients O
. O

gastrointestinal O
side O
effects O
from O
cpdd O
were O
universal O
. O

hmm O
gastrointestinal B-Disease
toxicity I-Disease
necessitated O
discontinuation O
of O
the O
drug O
in O
5 O
patients O
. O

severe O
nephrotoxicity B-Disease
was O
observed O
in O
2 O
patients O
but O
was O
reversible O
. O

there O
were O
no O
drug O
- O
related O
deaths O
. O

nontraumatic O
dissecting B-Disease
aneurysm I-Disease
of O
the O
basilar O
artery O
. O

a O
case O
of O
nontraumatic O
dissecting B-Disease
aneurysm I-Disease
of O
the O
basilar O
artery O
in O
association O
with O
hypertension B-Disease
, O
smoke O
, O
and O
oral O
contraceptives O
is O
reported O
in O
a O
young O
female O
patient O
with O
a O
locked B-Disease
- I-Disease
in I-Disease
syndrome I-Disease
. O

a O
method O
for O
the O
measurement O
of O
tremor B-Disease
, O
and O
a O
comparison O
of O
the O
effects O
of O
tocolytic O
beta O
- O
mimetics O
. O

a O
method O
permitting O
measurement O
of O
finger O
tremor B-Disease
as O
a O
displacement O
- O
time O
curve O
is O
described O
, O
using O
a O
test O
system O
with O
simple O
amplitude O
calibration O
. O

the O
coordinates O
of O
the O
inversion O
points O
of O
the O
displacement O
- O
time O
curves O
were O
transferred O
through O
graphical O
input O
equipment O
to O
punched O
tape O
. O

by O
means O
of O
a O
computer O
program O
, O
periods O
and O
amplitudes O
of O
tremor B-Disease
oscillations O
were O
calculated O
and O
classified O
. O

the O
event O
frequency O
for O
each O
class O
of O
periods O
and O
amplitudes O
was O
determined O
. O

the O
actions O
of O
fenoterol O
- O
hydrobromide O
, O
ritodrin O
- O
hcl O
and O
placebo O
given O
to O
10 O
healthy O
subjects O
by O
intravenous O
infusion O
in O
a O
double O
- O
blind O
crossover O
study O
were O
tested O
by O
this O
method O
. O

at O
therapeutic O
doses O
both O
substances O
raised O
the O
mean O
tremor B-Disease
amplitude O
to O
about O
three O
times O
the O
control O
level O
. O

at O
the O
same O
time O
, O
the O
mean O
period O
within O
each O
class O
of O
amplitudes O
shortened O
by O
10 O
- O
- O
20 O
ms O
, O
whereas O
the O
mean O
periods O
calculated O
from O
all O
oscillations O
together O
did O
not O
change O
significantly O
. O

after O
the O
end O
of O
fenoterol O
- O
hydrobromide O
infusion O
, O
tremor B-Disease
amplitudes O
decreased O
significantly O
faster O
than O
those O
following O
ritodrin O
- O
hcl O
infusion O
. O

propylthiouracil O
- O
induced O
hepatic B-Disease
damage I-Disease
. O

two O
cases O
of O
propylthiouracil O
- O
induced O
liver B-Disease
damage I-Disease
have O
been O
observed O
. O

the O
first O
case O
is O
of O
an O
acute O
type O
of O
damage O
, O
proven O
by O
rechallenge O
; O
the O
second O
presents O
a O
clinical O
and O
histologic O
picture O
resembling O
chronic B-Disease
active I-Disease
hepatitis I-Disease
, O
with O
spontaneous O
remission O
. O

studies O
on O
the O
bradycardia B-Disease
induced O
by O
bepridil O
. O

bepridil O
, O
a O
novel O
active O
compound O
for O
prophylactic O
treatment O
of O
anginal B-Disease
attacks I-Disease
, O
induced O
persistent O
bradycardia B-Disease
and O
a O
non O
- O
specific O
anti O
- O
tachycardial B-Disease
effect O
, O
the O
mechanisms O
of O
which O
were O
investigated O
in O
vitro O
and O
in O
vivo O
. O

in O
vitro O
perfusion O
of O
bepridil O
in O
the O
life O
- O
support O
medium O
for O
isolated O
sino O
- O
atrial O
tissue O
from O
rabbit O
heart O
, O
caused O
a O
reduction O
in O
action O
potential O
( O
ap O
) O
spike O
frequency O
( O
recorded O
by O
kcl O
microelectrodes O
) O
starting O
at O
doses O
of O
5 O
x O
10 O
( O
- O
6 O
) O
m O
. O

this O
effect O
was O
dose O
- O
dependent O
up O
to O
concentrations O
of O
5 O
x O
10 O
( O
- O
5 O
) O
m O
, O
whereupon O
blockade O
of O
sinus O
activity O
set O
in O
. O

bepridil O
at O
a O
dose O
of O
5 O
x O
10 O
( O
- O
6 O
) O
m O
, O
induced O
a O
concomitant O
reduction O
in O
ap O
amplitude O
( O
falling O
from O
71 O
+ O
/ O
- O
8 O
mv O
to O
47 O
+ O
/ O
- O
6 O
mv O
) O
, O
maximum O
systolic O
depolarization O
velocity O
( O
phase O
0 O
) O
which O
fell O
from O
1 O
. O
85 O
+ O
/ O
- O
0 O
. O
35 O
v O
/ O
s O
to O
0 O
. O
84 O
+ O
/ O
- O
0 O
. O
28 O
v O
/ O
s O
, O
together O
with O
maximum O
diastolic O
depolarization O
velocity O
( O
phase O
4 O
) O
which O
fell O
from O
38 O
+ O
/ O
- O
3 O
mv O
/ O
s O
to O
24 O
+ O
/ O
- O
5 O
mv O
/ O
s O
. O

in O
vivo O
injection O
of O
bepridil O
at O
a O
dose O
of O
5 O
mg O
/ O
kg O
( O
i O
. O
v O
. O
) O
into O
6 O
anaesthetized O
dogs O
which O
had O
undergone O
ablation O
of O
all O
the O
extrinsic O
cardiac O
afferent O
nerve O
supply O
, O
together O
with O
a O
bilateral O
medullo O
- O
adrenalectomy O
, O
caused O
a O
marked O
reduction O
in O
heart O
rate O
which O
fell O
from O
98 O
. O
7 O
+ O
/ O
- O
4 O
. O
2 O
beats O
/ O
min O
to O
76 O
+ O
/ O
- O
5 O
. O
3 O
beats O
/ O
min O
sustained O
for O
more O
than O
45 O
min O
. O

it O
is O
concluded O
that O
bepridil O
reduces O
heart O
rate O
by O
acting O
directly O
on O
the O
sinus O
node O
. O

this O
effect O
, O
which O
results O
in O
a O
flattening O
of O
the O
phase O
0 O
and O
phase O
4 O
slope O
, O
together O
with O
a O
longer O
ap O
duration O
, O
may O
be O
due O
to O
an O
increase O
in O
the O
time O
constants O
of O
slow O
inward O
ionic O
currents O
( O
already O
demonstrated O
elsewhere O
) O
, O
but O
also O
to O
an O
increased O
time O
constant O
for O
deactivation O
of O
the O
outward O
potassium O
current O
( O
ip O
) O
. O

hepatitis B-Disease
and O
renal B-Disease
tubular I-Disease
acidosis I-Disease
after O
anesthesia O
with O
methoxyflurane O
. O

a O
69 O
- O
year O
- O
old O
man O
operated O
for O
acute B-Disease
cholecystitis I-Disease
under O
methoxyflurane O
anesthesia O
developed O
postoperatively O
a O
hepatic B-Disease
insufficiency I-Disease
syndrome I-Disease
and O
renal B-Disease
tubular I-Disease
acidosis I-Disease
. O

massive O
bleeding B-Disease
appeared O
during O
surgery O
which O
lasted O
for O
six O
hours O
. O

postoperative O
evolution O
under O
supportive O
therapy O
was O
favourable O
. O

complete O
recovery O
was O
confirmed O
by O
repeated O
controls O
performed O
over O
a O
period O
of O
one O
year O
after O
surgery O
. O

pituitary O
response O
to O
luteinizing O
hormone O
- O
releasing O
hormone O
during O
haloperidol O
- O
induced O
hyperprolactinemia B-Disease
. O

the O
effects O
of O
a O
6 O
- O
hour O
infusion O
with O
haloperidol O
on O
serum O
prolactin O
and O
luteinizing O
hormone O
( O
lh O
) O
levels O
was O
studied O
in O
a O
group O
of O
male O
subjects O
. O

five O
hours O
after O
starting O
the O
infusions O
, O
a O
study O
of O
the O
pituitary O
responses O
to O
lh O
- O
releasing O
hormone O
( O
lh O
- O
rh O
) O
was O
carried O
out O
. O

control O
patients O
received O
infusions O
of O
0 O
. O
9 O
% O
nacl O
solution O
. O

during O
the O
course O
of O
haloperidol O
infusions O
, O
significant O
hyperprolactinemia B-Disease
was O
found O
, O
together O
with O
an O
abolished O
pituitary O
response O
to O
lh O
- O
rh O
, O
as O
compared O
with O
responses O
of O
control O
subjects O
. O

antirifampicin O
antibodies O
in O
acute O
rifampicin O
- O
associated O
renal B-Disease
failure I-Disease
. O

5 O
patients O
with O
acute B-Disease
renal I-Disease
failure I-Disease
( O
3 O
with O
thrombopenia B-Disease
and O
hemolysis B-Disease
) O
induced O
by O
the O
reintroduction O
of O
rifampicin O
are O
described O
. O

no O
correlation O
was O
found O
between O
the O
severity O
of O
clinical O
manifestations O
and O
the O
total O
dose O
taken O
by O
the O
patients O
. O

in O
all O
but O
1 O
patient O
, O
antirifampicin O
antibodies O
were O
detected O
. O

antibodies O
suggested O
to O
be O
of O
the O
igm O
class O
were O
detected O
in O
all O
3 O
patients O
with O
hematological B-Disease
disorders I-Disease
. O

the O
pattern O
of O
non O
- O
specific O
acute B-Disease
tubular I-Disease
necrosis I-Disease
found O
in O
the O
2 O
biopsied O
patients O
, O
indistinguishable O
from O
that O
of O
ischemic O
origin O
, O
raised O
the O
possibility O
of O
a O
vascular O
- O
mediated O
damage O
. O

in O
3 O
patients O
, O
the O
possibility O
of O
a O
triggering O
immunoallergic O
mechanism O
is O
discussed O
. O

cardiovascular O
effects O
of O
hypotension B-Disease
induced O
by O
adenosine O
triphosphate O
and O
sodium O
nitroprusside O
on O
dogs O
with O
denervated O
hearts O
. O

adenosine O
triphosphate O
( O
atp O
) O
and O
sodium O
nitroprusside O
( O
snp O
) O
are O
administered O
to O
patients O
to O
induce O
and O
control O
hypotension B-Disease
during O
anesthesia O
. O

snp O
is O
authorized O
for O
clinical O
use O
in O
usa O
and O
uk O
, O
and O
atp O
is O
clinically O
used O
in O
other O
countries O
such O
as O
japan O
. O

we O
investigated O
how O
these O
two O
drugs O
act O
on O
the O
cardiovascular O
systems O
of O
20 O
dogs O
whose O
hearts O
had O
been O
denervated O
by O
a O
procedure O
we O
had O
devised O
. O

atp O
( O
10 O
dogs O
) O
or O
snp O
( O
10 O
dogs O
) O
was O
administered O
to O
reduce O
mean O
arterial O
pressure O
by O
30 O
% O
to O
70 O
% O
of O
control O
. O

before O
, O
during O
and O
after O
induced O
hypotension B-Disease
, O
we O
measured O
major O
cardiovascular O
parameters O
. O

hypotension B-Disease
induced O
by O
atp O
was O
accompanied O
by O
significant O
decreases O
in O
mean O
pulmonary O
arterial O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
central O
venous O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
left O
ventricular O
end O
- O
diastolic O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
total O
peripheral O
resistance O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
rate O
pressure O
product O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
total O
body O
oxygen O
consumption O
( O
p O
less O
than O
0 O
. O
05 O
) O
, O
and O
heart O
rate O
( O
p O
less O
than O
0 O
. O
001 O
) O
; O
all O
these O
variables O
returned O
normal O
within O
30 O
min O
after O
atp O

was O
stopped O
. O

cardiac O
output O
did O
not O
change O
. O

during O
hypotension B-Disease
produced O
by O
snp O
similar O
decreases O
were O
observed O
in O
mean O
pulmonary O
arterial O
pressure O
( O
p O
less O
than O
0 O
. O
01 O
) O
, O
central O
venous O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
left O
ventricular O
end O
- O
diastolic O
pressure O
( O
p O
less O
than O
0 O
. O
01 O
) O
, O
total O
peripheral O
resistance O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
rate O
pressure O
product O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
and O
oxygen O
content O
difference O
between O
arterial O
and O
mixed O
venous O
blood O
( O
p O
less O
than O
0 O
. O
05 O
) O
, O
while O
heart O
rate O
( O
p O
less O
than O
0 O
. O
001 O
) O
and O
cardiac O

output O
( O
p O
less O
than O
0 O
. O
05 O
) O
were O
increased O
. O

recoveries O
of O
heart O
rate O
and O
left O
ventricular O
end O
- O
diastolic O
pressure O
were O
not O
shown O
within O
60 O
min O
after O
snp O
had O
been O
stopped O
. O

both O
atp O
and O
snp O
should O
act O
on O
the O
pacemaker O
tissue O
of O
the O
heart O
. O

comparative O
study O
: O
endografine O
( O
diatrizoate O
) O
, O
vasurix O
polyvidone O
( O
acetrizoate O
) O
, O
dimer O
- O
x O
( O
iocarmate O
) O
and O
hexabrix O
( O
ioxaglate O
) O
in O
hysterosalpingography O
. O

side O
effects O
of O
hysterosalpingography O
with O
dimer O
- O
x O
, O
hexabrix O
, O
vasurix O
polyvidone O
and O
endografine O
in O
142 O
consecutive O
patients O
, O
receiving O
one O
of O
the O
four O
tested O
media O
were O
evaluated O
from O
replies O
to O
postal O
questionnaires O
. O

the O
dimer O
- O
x O
group O
had O
a O
higher O
incidence O
of O
nausea B-Disease
and O
dizziness B-Disease
. O

the O
endografine O
group O
had O
a O
higher O
incidence O
of O
abdominal B-Disease
pain I-Disease
. O

these O
differences O
occur O
especially O
in O
the O
age O
groups O
under O
30 O
years O
. O

hexabrix O
and O
vasurix O
polyvidone O
are O
considered O
the O
best O
contrast O
media O
for O
hysterosalpingography O
and O
perhaps O
because O
of O
its O
low O
toxicity B-Disease
hexabrix O
should O
be O
preferred O
. O

post O
- O
suxamethonium O
pains B-Disease
in O
nigerian O
surgical O
patients O
. O

contrary O
to O
an O
earlier O
report O
by O
coxon O
, O
scoline O
pain B-Disease
occurs O
in O
african O
negroes O
. O

its O
incidence O
was O
determined O
in O
a O
prospective O
study O
involving O
a O
total O
of O
100 O
nigerian O
patients O
( O
50 O
out O
- O
patients O
and O
50 O
in O
- O
patients O
) O
. O

about O
62 O
% O
of O
the O
out O
- O
patients O
developed O
scoline O
pain B-Disease
as O
compared O
with O
about O
26 O
% O
among O
the O
in O
- O
patients O
. O

the O
abolition O
of O
muscle O
fasciculations B-Disease
( O
by O
0 O
. O
075mg O
/ O
kg O
dose O
of O
fazadinium O
) O
did O
not O
influence O
the O
occurrence O
of O
scoline O
pain B-Disease
. O

neither O
the O
type O
of O
induction O
agent O
( O
althesin O
or O
thiopentone O
) O
nor O
the O
salt O
preparation O
of O
suxamethonium O
used O
( O
chloride O
or O
bromide O
) O
, O
affected O
the O
incidence O
of O
scoline O
pain B-Disease
. O

invasive O
carcinoma B-Disease
of I-Disease
the I-Disease
renal I-Disease
pelvis I-Disease
following O
cyclophosphamide O
therapy O
for O
nonmalignant O
disease O
. O

a O
47 O
- O
year O
- O
old O
woman O
with O
right O
hydroureteronephrosis B-Disease
due O
to O
ureterovesical O
junction O
obstruction O
had O
gross O
hematuria B-Disease
after O
being O
treated O
for O
five O
years O
wtih O
cyclophosphamide O
for O
cerebral B-Disease
vasculitis I-Disease
. O

a O
right O
nephroureterectomy O
was O
required O
for O
control O
of O
bleeding B-Disease
. O

the O
pathology O
specimen O
contained O
clinically O
occult O
invasive O
carcinoma B-Disease
of I-Disease
the I-Disease
renal I-Disease
pelvis I-Disease
. O

although O
the O
ability O
of O
cyclophosphamide O
to O
cause O
hemorrhagic B-Disease
cystitis I-Disease
and O
urine O
cytologic O
abnormalities O
indistinguishable O
from O
high O
grade O
carcinoma B-Disease
is O
well O
known O
, O
it O
is O
less O
widely O
appreciated O
that O
it O
is O
also O
associated O
with O
carcinoma B-Disease
of I-Disease
the I-Disease
urinary I-Disease
tract I-Disease
. O

twenty O
carcinomas B-Disease
of I-Disease
the I-Disease
urinary I-Disease
bladder I-Disease
and O
one O
carcinoma B-Disease
of I-Disease
the I-Disease
prostate I-Disease
have O
been O
reported O
in O
association O
with O
its O
use O
. O

the O
present O
case O
is O
the O
first O
carcinoma B-Disease
of I-Disease
the I-Disease
renal I-Disease
pelvis I-Disease
reported O
in O
association O
with O
cyclophosphamide O
treatment O
. O

it O
is O
the O
third O
urinary B-Disease
tract I-Disease
cancer I-Disease
reported O
in O
association O
with O
cyclophosphamide O
treatment O
for O
nonmalignant O
disease O
. O

the O
association O
of O
the O
tumor B-Disease
with O
preexisting O
hydroureteronephrosis B-Disease
suggests O
that O
stasis O
prolonged O
and O
intensified O
exposure O
of O
upper O
urinary O
tract O
epithelium O
to O
cyclophosphamide O
. O

patients O
who O
are O
candidates O
for O
long O
- O
term O
cyclophosphamide O
treatment O
should O
be O
routinely O
evaluated O
for O
obstructive B-Disease
uropathy I-Disease
. O

medial O
changes O
in O
arterial O
spasm B-Disease
induced O
by O
l O
- O
norepinephrine O
. O

in O
normal O
rats O
, O
the O
media O
of O
small O
arteries O
( O
0 O
. O
4 O
- O
- O
0 O
. O
2 O
mm O
in O
diameter O
) O
previously O
was O
shown O
to O
contain O
intracellular O
vacuoles O
, O
identified O
ultrastructurally O
as O
herniations O
of O
one O
smooth O
muscle O
cell O
into O
another O
. O

the O
hypothesis O
that O
intense O
vasoconstriction O
would O
increase O
the O
number O
of O
such O
vacuoles O
has O
been O
tested O
. O

in O
the O
media O
of O
the O
saphenous O
artery O
and O
its O
distal O
branch O
, O
vasoconstriction O
induced O
by O
l O
- O
norepinephrine O
produced O
many O
cell O
- O
to O
- O
cell O
hernias B-Disease
within O
15 O
minutes O
. O

at O
1 O
day O
their O
number O
was O
reduced O
to O
about O
1 O
/ O
10 O
of O
the O
original O
number O
. O

by O
7 O
days O
the O
vessel O
was O
almost O
restored O
to O
normal O
. O

triple O
stimulation O
over O
1 O
day O
induced O
more O
severe O
changes O
in O
the O
media O
. O

these O
findings O
suggest O
that O
smooth O
muscle O
cells O
are O
susceptible O
to O
damage O
in O
the O
course O
of O
their O
specific O
function O
. O

the O
experimental O
data O
are O
discussed O
in O
relation O
to O
medial O
changes O
observed O
in O
other O
instances O
of O
arterial O
spasm B-Disease
. O

endothelial O
changes O
that O
developed O
in O
the O
same O
experimental O
model O
were O
described O
in O
a O
previous O
paper O
. O

bilateral O
retinal B-Disease
artery I-Disease
and I-Disease
choriocapillaris I-Disease
occlusion I-Disease
following O
the O
injection O
of O
long O
- O
acting O
corticosteroid O
suspensions O
in O
combination O
with O
other O
drugs O
: O
i O
. O

clinical O
studies O
. O

two O
well O
- O
documented O
cases O
of O
bilateral O
retinal B-Disease
artery I-Disease
and I-Disease
choriocapillaris I-Disease
occlusions I-Disease
with O
blindness B-Disease
following O
head O
and O
neck O
soft O
- O
tissue O
injection O
with O
methylprednisolone O
acetate O
in O
combination O
with O
lidocaine O
, O
epinephrine O
, O
or O
penicillin O
are O
reported O
. O

one O
case O
had O
only O
a O
unilateral O
injection O
. O

the O
acute O
observations O
included O
hazy O
sensorium O
, O
superior O
gaze O
palsy B-Disease
, O
pupillary B-Disease
abnormalities I-Disease
, O
and O
conjunctival O
hemorrhages B-Disease
with O
edema B-Disease
. O

follow O
- O
up O
changes O
showed O
marked O
visual B-Disease
loss I-Disease
, O
constricted O
visual O
fields O
, O
optic O
nerve O
pallor O
, O
vascular O
attenuation O
, O
and O
chorioretinal B-Disease
atrophy I-Disease
. O

the O
literature O
is O
reviewed O
, O
and O
possible O
causes O
are O
discussed O
. O

abnormalities O
of O
the O
pupil O
and O
visual O
- O
evoked O
potential O
in O
quinine O
amblyopia B-Disease
. O

total O
blindness B-Disease
with O
a O
transient O
tonic B-Disease
pupillary I-Disease
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual O
- O
evoked O
potentials O
developed O
in O
a O
54 O
- O
year O
- O
old O
man O
after O
the O
use O
of O
quinine O
sulfate O
for O
leg B-Disease
cramps I-Disease
. O

he O
later O
recovered O
normal O
visual O
acuity O
. O

a O
transient O
tonic B-Disease
pupillary I-Disease
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual O
- O
evoked O
potentials O
in O
quinine O
toxicity B-Disease
, O
to O
our O
knowledge O
, O
have O
not O
been O
previously O
reported O
. O

suxamethonium O
- O
induced O
jaw B-Disease
stiffness I-Disease
and O
myalgia B-Disease
associated O
with O
atypical O
cholinesterase O
: O
case O
report O
. O

an O
11 O
- O
year O
- O
old O
boy O
was O
given O
halothane O
, O
nitrous O
oxide O
and O
oxygen O
, O
pancuronium O
0 O
. O
4 O
mg O
and O
suxamethonium O
100 O
mg O
for O
induction O
of O
anaesthesia O
. O

in O
response O
to O
this O
a O
marked O
jaw B-Disease
stiffness I-Disease
occurred O
which O
lasted O
for O
two O
minutes O
and O
the O
anaesthesia O
were O
terminated O
. O

four O
hours O
of O
apnoea B-Disease
ensued O
and O
he O
suffered O
generalized O
severe O
myalgia B-Disease
lasting O
for O
one O
week O
. O

he O
was O
found O
to O
have O
atypical O
plasma O
cholinesterase O
with O
a O
dibucaine O
number O
of O
12 O
, O
indicating O
homozygocity O
. O

this O
was O
verified O
by O
study O
of O
the O
family O
. O

the O
case O
shows O
that O
prolonged B-Disease
jaw I-Disease
rigidity I-Disease
and O
myalgia B-Disease
may O
occur O
after O
suxamethonium O
in O
patients O
with O
atypical O
cholinesterase O
despite O
pretreatment O
with O
pancuronium O
. O

indomethacin O
- O
induced O
hyperkalemia B-Disease
in O
three O
patients O
with O
gouty B-Disease
arthritis I-Disease
. O

we O
describe O
three O
patients O
in O
whom O
severe O
, O
life O
- O
threatening O
hyperkalemia B-Disease
and O
renal B-Disease
insufficiency I-Disease
developed O
after O
treatment O
of O
acute O
gouty B-Disease
arthritis I-Disease
with O
indomethacin O
. O

this O
complication O
may O
result O
from O
an O
inhibition O
of O
prostaglandin O
synthesis O
and O
consequent O
hyporeninemic B-Disease
hypoaidosteronism I-Disease
. O

careful O
attention O
to O
renal O
function O
and O
potassium O
balance O
in O
patients O
receiving O
indomethacin O
or O
other O
nonsteroidal O
anti O
- O
inflammatory O
agents O
, O
particularly O
in O
those O
patients O
with O
diabetes B-Disease
mellitus I-Disease
or O
preexisting O
renal B-Disease
disease I-Disease
, O
will O
help O
prevent O
this O
potentially O
serious O
complication O
. O

etomidate O
: O
a O
foreshortened O
clinical O
trial O
. O

a O
clinical O
evaluation O
of O
etomidate O
for O
outpatient O
cystoscopy O
was O
embarked O
upon O
. O

unpremedicated O
patients O
were O
given O
fentanyl O
1 O
microgram O
/ O
kg O
followed O
by O
etomidate O
0 O
. O
3 O
mg O
/ O
kg O
. O

anaesthesia O
was O
maintained O
with O
intermittent O
etomidate O
in O
2 O
- O
4 O
mg O
doses O
. O

patients O
were O
interviewed O
personally O
later O
the O
same O
day O
, O
and O
by O
questionnaire O
three O
to O
four O
weeks O
later O
. O

the O
trial O
was O
discontinued O
after O
20 O
cases O
because O
of O
an O
unacceptable O
incidence O
of O
side O
effects O
. O

venous O
pain B-Disease
occurred O
in O
68 O
% O
of O
patients O
and O
50 O
% O
had O
redness O
, O
pain B-Disease
or O
swelling B-Disease
related O
to O
the O
injection O
site O
, O
in O
some O
cases O
lasting O
up O
to O
three O
weeks O
after O
anaesthesia O
. O

skeletal O
movements O
occurred O
in O
50 O
% O
of O
patients O
; O
30 O
% O
experienced O
respiratory B-Disease
upset I-Disease
, O
one O
sufficiently O
severe O
to O
necessitate O
abandoning O
the O
technique O
. O

nausea B-Disease
and O
vomiting B-Disease
occurred O
in O
40 O
% O
and O
25 O
% O
had O
disturbing O
emergence O
psychoses B-Disease
. O

levodopa O
- O
induced O
dyskinesias B-Disease
are O
improved O
by O
fluoxetine O
. O

we O
evaluated O
the O
severity O
of O
motor B-Disease
disability I-Disease
and O
dyskinesias B-Disease
in O
seven O
levodopa O
- O
responsive O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
after O
an O
acute O
challenge O
with O
the O
mixed O
dopamine O
agonist O
, O
apomorphine O
, O
before O
and O
after O
the O
administration O
of O
fluoxetine O
( O
20 O
mg O
twice O
per O
day O
) O
for O
11 O
+ O
/ O
- O
1 O
days O
. O

after O
fluoxetine O
treatment O
, O
there O
was O
a O
significant O
47 O
% O
improvement O
( O
p O
< O
0 O
. O
05 O
) O
of O
apomorphine O
- O
induced O
dyskinesias B-Disease
without O
modification O
of O
parkinsonian B-Disease
motor B-Disease
disability I-Disease
. O

the O
dyskinesias B-Disease
were O
reduced O
predominantly O
in O
the O
lower O
limbs O
during O
the O
onset O
and O
disappearance O
of O
dystonic B-Disease
dyskinesias I-Disease
( O
onset O
- O
and O
end O
- O
of O
- O
dose O
dyskinesias B-Disease
) O
and O
in O
the O
upper O
limbs O
during O
choreic B-Disease
mid I-Disease
- I-Disease
dose I-Disease
dyskinesias I-Disease
. O

the O
results O
suggest O
that O
increased O
brain O
serotoninergic O
transmission O
with O
fluoxetine O
may O
reduce O
levodopa O
- O
or O
dopamine O
agonist O
- O
induced O
dyskinesias B-Disease
without O
aggravating O
parkinsonian B-Disease
motor B-Disease
disability I-Disease
. O

a O
large O
population O
- O
based O
follow O
- O
up O
study O
of O
trimethoprim O
- O
sulfamethoxazole O
, O
trimethoprim O
, O
and O
cephalexin O
for O
uncommon O
serious O
drug B-Disease
toxicity I-Disease
. O

we O
conducted O
a O
population O
- O
based O
45 O
- O
day O
follow O
- O
up O
study O
of O
232 O
, O
390 O
people O
who O
were O
prescribed O
trimethoprim O
- O
sulfamethoxazole O
( O
tmp O
- O
smz O
) O
, O
266 O
, O
951 O
prescribed O
trimethoprim O
alone O
, O
and O
196 O
, O
397 O
prescribed O
cephalexin O
, O
to O
estimate O
the O
risk O
of O
serious O
liver B-Disease
, I-Disease
blood I-Disease
, I-Disease
skin I-Disease
, I-Disease
and I-Disease
renal I-Disease
disorders I-Disease
resulting O
in O
referral O
or O
hospitalization O
associated O
with O
these O
drugs O
. O

the O
results O
were O
based O
on O
information O
recorded O
on O
office O
computers O
by O
selected O
general O
practitioners O
in O
the O
united O
kingdom O
, O
together O
with O
a O
review O
of O
clinical O
records O
. O

the O
risk O
of O
clinically O
important O
idiopathic O
liver B-Disease
disease I-Disease
was O
similar O
for O
persons O
prescribed O
tmp O
- O
smz O
( O
5 O
. O
2 O
/ O
100 O
, O
000 O
) O
and O
those O
prescribed O
trimethoprim O
alone O
( O
3 O
. O
8 O
/ O
100 O
, O
000 O
) O
. O

the O
risk O
for O
those O
prescribed O
cephalexin O
was O
somewhat O
lower O
( O
2 O
. O
0 O
/ O
100 O
, O
000 O
) O
. O

only O
five O
patients O
experienced O
blood O
disorders O
, O
one O
of O
whom O
was O
exposed O
to O
tmp O
- O
smz O
; O
of O
seven O
with O
erythema B-Disease
multiforme I-Disease
and O
stevens B-Disease
- I-Disease
johnson I-Disease
syndrome I-Disease
, O
four O
were O
exposed O
to O
tmp O
- O
smz O
. O

the O
one O
case O
of O
toxic B-Disease
epidermal I-Disease
necrolysis I-Disease
occurred O
in O
a O
patient O
who O
took O
cephalexin O
. O

finally O
, O
only O
five O
cases O
of O
acute O
parenchymal O
renal B-Disease
disease I-Disease
occurred O
, O
none O
likely O
to O
be O
caused O
by O
a O
study O
drug O
. O

we O
conclude O
that O
the O
risk O
of O
the O
serious O
diseases O
studied O
is O
small O
for O
the O
three O
agents O
, O
and O
compares O
reasonably O
with O
the O
risk O
for O
many O
other O
antibiotics O
. O

clinical O
safety O
of O
lidocaine O
in O
patients O
with O
cocaine O
- O
associated O
myocardial B-Disease
infarction I-Disease
. O

study O
objective O
: O
to O
evaluate O
the O
safety O
of O
lidocaine O
in O
the O
setting O
of O
cocaine O
- O
induced O
myocardial B-Disease
infarction I-Disease
( O
mi B-Disease
) O
. O

design O
: O
a O
retrospective O
, O
multicenter O
study O
. O

setting O
: O
twenty O
- O
nine O
university O
, O
university O
- O
affiliated O
, O
or O
community O
hospitals O
during O
a O
6 O
- O
year O
period O
( O
total O
of O
117 O
cumulative O
hospital O
- O
years O
) O
. O

participants O
: O
patients O
with O
cocaine O
- O
associated O
mi B-Disease
who O
received O
lidocaine O
in O
the O
emergency O
department O
. O

results O
: O
of O
29 O
patients O
who O
received O
lidocaine O
in O
the O
setting O
of O
cocaine O
- O
associated O
mi B-Disease
, O
no O
patient O
died O
; O
exhibited O
bradydysrhythmias B-Disease
, O
ventricular B-Disease
tachycardia I-Disease
, O
or O
ventricular B-Disease
fibrillation I-Disease
; O
or O
experienced O
seizures B-Disease
after O
administration O
of O
lidocaine O
( O
95 O
% O
confidence O
interval O
, O
0 O
% O
to O
11 O
% O
) O
. O

conclusion O
: O
despite O
theoretical O
concerns O
that O
lidocaine O
may O
enhance O
cocaine O
toxicity B-Disease
, O
the O
use O
of O
lidocaine O
in O
patients O
with O
cocaine O
- O
associated O
mi B-Disease
was O
not O
associated O
with O
significant O
cardiovascular B-Disease
or I-Disease
central I-Disease
nervous I-Disease
system I-Disease
toxicity I-Disease
. O

experimental O
progressive O
muscular B-Disease
dystrophy I-Disease
and O
its O
treatment O
with O
high O
doses O
anabolizing O
agents O
. O

we O
are O
still O
a O
long O
way O
from O
discovering O
an O
unequivocal O
pathogenetic O
interpretation O
of O
progressive O
muscular B-Disease
dystrophy I-Disease
in O
man O
. O

noteworthy O
efforts O
have O
been O
made O
in O
the O
experimental O
field O
; O
a O
recessive O
autosomic O
form O
found O
in O
the O
mouse O
seems O
to O
bear O
the O
closest O
resemblance O
to O
the O
human O
form O
from O
the O
genetic O
point O
of O
view O
. O

myopathy B-Disease
due O
to O
lack O
of O
vitamin O
e O
and O
myopathy B-Disease
induced O
by O
certain O
viruses O
have O
much O
in O
common O
anatomically O
and O
pathologically O
with O
the O
human O
form O
. O

the O
authors O
induced O
myodystrophy B-Disease
in O
the O
rat O
by O
giving O
it O
a O
diet O
lacking O
in O
vitamin O
e O
. O

the O
pharmacological O
characteristics O
of O
vitamin O
e O
and O
the O
degenerative O
changes O
brought O
about O
by O
its O
deficiency O
, O
especially O
in O
the O
muscles O
, O
are O
illustrated O
. O

it O
is O
thus O
confirmed O
that O
the O
histological O
characteristics O
of O
myopathic B-Disease
rat O
muscle O
induced O
experimentally O
are O
extraordinarily O
similar O
to O
those O
of O
human O
myopathy B-Disease
as O
confirmed O
during O
biopsies O
performed O
at O
the O
orthopaedic O
traumatological O
centre O
, O
florence O
. O

the O
encouraging O
results O
obtained O
in O
various O
authoratative O
departments O
in O
myopathic B-Disease
patients O
by O
using O
anabolizing O
steroids O
have O
encouraged O
the O
authors O
to O
investigate O
the O
beneficial O
effects O
of O
one O
anabolizing O
agent O
( O
dianabol O
, O
ciba O
) O
at O
high O
doses O
in O
rats O
rendered O
myopathic B-Disease
by O
a O
diet O
deficient O
in O
vitamin O
e O
. O

in O
this O
way O
they O
obtained O
appreciable O
changes O
in O
body O
weight O
( O
increased O
from O
50 O
to O
70 O
g O
after O
forty O
days O
at O
a O
dose O
of O
5 O
mg O
per O
day O
of O
anabolizing O
agent O
) O
, O
but O
most O
of O
all O
they O
found O
histological O
changes O
due O
to O
" O
regenerative O
" O
changes O
in O
the O
muscle O
tissue O
, O
which O
however O
maintained O
its O
myopathic B-Disease
characteristics O
in O
the O
control O
animals O
that O
were O
not O
treated O
with O
the O
anabolizing O
agent O
. O

the O
authors O
conclude O
by O
affirming O
the O
undoubted O
efficacy O
of O
the O
anabolizing O
steroids O
in O
experimental O
myopathic B-Disease
disease I-Disease
, O
but O
they O
have O
reservations O
as O
to O
the O
transfer O
of O
the O
results O
into O
the O
human O
field O
, O
where O
high O
dosage O
cannot O
be O
carried O
out O
continuously O
because O
of O
the O
effects O
of O
the O
drug O
on O
virility O
; O
because O
the O
tissue O
injury O
too O
often O
occurs O
at O
an O
irreversible O
stage O
vis O
- O
a O
- O
vis O
the O
" O
regeneration O
" O
of O
the O
muscle O
tissue O
; O
and O
finally O
because O
the O
dystrophic O
injurious O
agent O
is O
certainly O
not O
the O
lack O
of O
vitamin O
e O
but O
something O
as O
yet O
unknown O
. O

paclitaxel O
3 O
- O
hour O
infusion O
given O
alone O
and O
combined O
with O
carboplatin O
: O
preliminary O
results O
of O
dose O
- O
escalation O
trials O
. O

paclitaxel O
( O
taxol O
; O
bristol O
- O
myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
by O
3 O
- O
hour O
infusion O
was O
combined O
with O
carboplatin O
in O
a O
phase O
i O
/ O
ii O
study O
directed O
to O
patients O
with O
non B-Disease
- I-Disease
small I-Disease
cell I-Disease
lung I-Disease
cancer I-Disease
. O

carboplatin O
was O
given O
at O
a O
fixed O
target O
area O
under O
the O
concentration O
- O
time O
curve O
of O
6 O
. O
0 O
by O
the O
calvert O
formula O
, O
whereas O
paclitaxel O
was O
escalated O
in O
patient O
cohorts O
from O
150 O
mg O
/ O
m2 O
( O
dose O
level O
i O
) O
to O
175 O
, O
200 O
, O
225 O
, O
and O
250 O
mg O
/ O
m2 O
. O

the O
225 O
mg O
/ O
m2 O
level O
was O
expanded O
for O
the O
phase O
ii O
study O
since O
the O
highest O
level O
achieved O
( O
250 O
mg O
/ O
m2 O
) O
required O
modification O
because O
of O
nonhematologic O
toxicities B-Disease
( O
arthralgia B-Disease
and O
sensory B-Disease
neuropathy I-Disease
) O
. O

therapeutic O
effects O
were O
noted O
at O
all O
dose O
levels O
, O
with O
objective O
responses O
in O
17 O
( O
two O
complete O
and O
15 O
partial O
regressions O
) O
of O
41 O
previously O
untreated O
patients O
. O

toxicities B-Disease
were O
compared O
with O
a O
cohort O
of O
patients O
in O
a O
phase O
i O
trial O
of O
paclitaxel O
alone O
at O
identical O
dose O
levels O
. O

carboplatin O
did O
not O
appear O
to O
add O
to O
the O
hematologic B-Disease
toxicities I-Disease
observed O
, O
and O
the O
paclitaxel O
/ O
carboplatin O
combination O
could O
be O
dosed O
every O
3 O
weeks O
. O

the O
dose O
- O
dependent O
effect O
of O
misoprostol O
on O
indomethacin O
- O
induced O
renal B-Disease
dysfunction I-Disease
in O
well O
compensated O
cirrhosis B-Disease
. O

misoprostol O
( O
200 O
micrograms O
) O
has O
been O
shown O
to O
acutely O
counteract O
the O
indomethacin O
- O
induced O
renal B-Disease
dysfunction I-Disease
in O
well O
compensated O
cirrhotic B-Disease
patients O
. O

the O
aim O
of O
this O
study O
was O
to O
determine O
if O
the O
prophylactic O
value O
of O
misoprostol O
was O
dose O
- O
dependent O
. O

parameters O
of O
renal O
hemodynamics O
and O
tubular O
sodium O
and O
water O
handling O
were O
assessed O
by O
clearance O
techniques O
in O
26 O
well O
compensated O
cirrhotic B-Disease
patients O
before O
and O
after O
an O
oral O
combination O
of O
50 O
mg O
of O
indomethacin O
and O
various O
doses O
of O
misoprostol O
. O

the O
200 O
- O
micrograms O
dose O
was O
able O
to O
totally O
abolish O
the O
deleterious O
renal O
effects O
of O
indomethacin O
, O
whereas O
the O
800 O
- O
micrograms O
dose O
resulted O
in O
significant O
worsening O
of O
renal O
hemodynamics O
and O
sodium O
retention O
. O

these O
changes O
were O
maximal O
in O
the O
hour O
immediately O
after O
medications O
and O
slowly O
returned O
toward O
base O
- O
line O
levels O
thereafter O
. O

these O
results O
suggest O
that O
the O
renal O
protective O
effects O
of O
misoprostol O
is O
dose O
- O
dependent O
. O

however O
, O
until O
this O
apparent O
ability O
of O
200 O
micrograms O
of O
misoprostol O
to O
prevent O
the O
adverse O
effects O
of O
indomethacin O
on O
renal O
function O
is O
confirmed O
with O
chronic O
frequent O
dosing O
, O
it O
would O
be O
prudent O
to O
avoid O
nonsteroidal O
anti O
- O
inflammatory O
therapy O
in O
patients O
with O
cirrhosis B-Disease
. O

increased O
frequency O
and O
severity O
of O
angio B-Disease
- I-Disease
oedema I-Disease
related O
to O
long O
- O
term O
therapy O
with O
angiotensin O
- O
converting O
enzyme O
inhibitor O
in O
two O
patients O
. O

adverse O
reactions O
to O
drugs O
are O
well O
recognized O
as O
a O
cause O
of O
acute O
or O
chronic O
urticaria B-Disease
, O
and O
angio B-Disease
- I-Disease
oedema I-Disease
. O

angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
inhibitors O
, O
used O
to O
treat O
hypertension B-Disease
and O
congestive B-Disease
heart I-Disease
failure I-Disease
, O
were O
introduced O
in O
europe O
in O
the O
middle O
of O
the O
eighties O
, O
and O
the O
use O
of O
these O
drugs O
has O
increased O
progressively O
. O

soon O
after O
the O
introduction O
of O
ace O
inhibitors O
, O
acute O
bouts O
of O
angio B-Disease
- I-Disease
oedema I-Disease
were O
reported O
in O
association O
with O
the O
use O
of O
these O
drugs O
. O

we O
wish O
to O
draw O
attention O
to O
the O
possibility O
of O
adverse O
reactions O
to O
ace O
inhibitors O
after O
long O
- O
term O
use O
and O
in O
patients O
with O
pre O
- O
existing O
angio B-Disease
- I-Disease
oedema I-Disease
. O

myoclonus B-Disease
associated O
with O
lorazepam O
therapy O
in O
very O
- O
low O
- O
birth O
- O
weight O
infants O
. O

lorazepam O
is O
being O
used O
with O
increasing O
frequency O
as O
a O
sedative O
in O
the O
newborn O
and O
the O
young O
infant O
. O

concern O
has O
been O
raised O
with O
regard O
to O
the O
safety O
of O
lorazepam O
in O
this O
age O
group O
, O
especially O
in O
very O
- O
low O
- O
birth O
- O
weight O
( O
vlbw O
; O
< O
1 O
, O
500 O
g O
) O
infants O
. O

three O
young O
infants O
, O
all O
of O
birth O
weight O
< O
1 O
, O
500 O
g O
, O
experienced O
myoclonus B-Disease
following O
the O
intravenous O
administration O
of O
lorazepam O
. O

the O
potential O
neurotoxic B-Disease
effects O
of O
the O
drug O
( O
and O
its O
vehicle O
) O
in O
this O
population O
are O
discussed O
. O

injectable O
lorazepam O
should O
be O
used O
with O
caution O
in O
vlbw O
infants O
. O

transvenous O
right O
ventricular O
pacing O
during O
cardiopulmonary O
resuscitation O
of O
pediatric O
patients O
with O
acute O
cardiomyopathy B-Disease
. O

we O
describe O
the O
cardiopulmonary O
resuscitation O
efforts O
on O
five O
patients O
who O
presented O
in O
acute O
circulatory B-Disease
failure I-Disease
from O
myocardial B-Disease
dysfunction I-Disease
. O

three O
patients O
had O
acute O
viral O
myocarditis B-Disease
, O
one O
had O
a O
carbamazepine O
- O
induced O
acute O
eosinophilic B-Disease
myocarditis I-Disease
, O
and O
one O
had O
cardiac O
hemosiderosis O
resulting O
in O
acute O
cardiogenic B-Disease
shock I-Disease
. O

all O
patients O
were O
continuously O
monitored O
with O
central O
venous O
and O
arterial O
catheters O
in O
addition O
to O
routine O
noninvasive O
monitoring O
. O

an O
introducer O
sheath O
, O
a O
pacemaker O
, O
and O
sterile O
pacing O
wires O
were O
made O
readily O
available O
for O
the O
patients O
, O
should O
the O
need O
arise O
to O
terminate O
resistant O
cardiac O
dysrhythmias B-Disease
. O

all O
patients O
developed O
cardiocirculatory O
arrest O
associated O
with O
extreme O
hypotension B-Disease
and O
dysrhythmias B-Disease
within O
the O
first O
48 O
hours O
of O
their O
admission O
to O
the O
pediatric O
intensive O
care O
unit O
( O
picu O
) O
. O

right O
ventricular O
pacemaker O
wires O
were O
inserted O
in O
all O
of O
them O
during O
cardiopulmonary O
resuscitation O
( O
cpr O
) O
. O

in O
four O
patients O
, O
cardiac O
pacing O
was O
used O
, O
resulting O
in O
a O
temporary O
captured O
rhythm O
and O
restoration O
of O
their O
cardiac O
output O
. O

these O
patients O
had O
a O
second O
event O
of O
cardiac B-Disease
arrest I-Disease
, O
resulting O
in O
death O
, O
within O
10 O
to O
60 O
minutes O
. O

in O
one O
patient O
, O
cardiac O
pacing O
was O
not O
used O
, O
because O
he O
converted O
to O
normal O
sinus O
rhythm O
by O
electrical O
defibrillation O
within O
three O
minutes O
of O
initiating O
cpr O
. O

we O
conclude O
that O
cardiac O
pacing O
during O
resuscitative O
efforts O
in O
pediatric O
patients O
suffering O
from O
acute O
myocardial B-Disease
dysfunction I-Disease
may O
not O
have O
long O
- O
term O
value O
in O
and O
of O
itself O
; O
however O
, O
if O
temporary O
hemodynamic O
stability O
is O
achieved O
by O
this O
procedure O
, O
it O
may O
provide O
additional O
time O
needed O
to O
institute O
other O
therapeutic O
modalities O
. O

efficacy O
and O
safety O
of O
granisetron O
, O
a O
selective O
5 O
- O
hydroxytryptamine O
- O
3 O
receptor O
antagonist O
, O
in O
the O
prevention O
of O
nausea B-Disease
and O
vomiting B-Disease
induced O
by O
high O
- O
dose O
cisplatin O
. O

purpose O
: O
to O
assess O
the O
antiemetic O
effects O
and O
safety O
profile O
of O
four O
different O
doses O
of O
granisetron O
( O
kytril O
; O
smithkline O
beecham O
pharmaceuticals O
, O
philadelphia O
, O
pa O
) O
when O
administered O
as O
a O
single O
intravenous O
( O
iv O
) O
dose O
for O
prophylaxis O
of O
cisplatin O
- O
induced O
nausea B-Disease
and O
vomiting B-Disease
. O

patients O
and O
methods O
: O
one O
hundred O
eighty O
- O
four O
chemotherapy O
- O
naive O
patients O
receiving O
high O
- O
dose O
cisplatin O
( O
81 O
to O
120 O
mg O
/ O
m2 O
) O
were O
randomized O
to O
receive O
one O
of O
four O
granisetron O
doses O
( O
5 O
, O
10 O
, O
20 O
, O
or O
40 O
micrograms O
/ O
kg O
) O
administered O
before O
chemotherapy O
. O

patients O
were O
observed O
on O
an O
inpatient O
basis O
for O
18 O
to O
24 O
hours O
, O
and O
vital O
signs O
, O
nausea B-Disease
, O
vomiting B-Disease
, O
retching O
, O
and O
appetite O
were O
assessed O
. O

safety O
analyses O
included O
incidence O
of O
adverse O
experiences O
and O
laboratory O
parameter O
changes O
. O

results O
: O
after O
granisetron O
doses O
of O
5 O
, O
10 O
, O
20 O
, O
and O
40 O
micrograms O
/ O
kg O
, O
a O
major O
response O
( O
< O
or O
= O
two O
vomiting B-Disease
or O
retching O
episodes O
, O
and O
no O
antiemetic O
rescue O
) O
was O
recorded O
in O
23 O
% O
, O
57 O
% O
, O
58 O
% O
, O
and O
60 O
% O
of O
patients O
, O
respectively O
, O
and O
a O
complete O
response O
( O
no O
vomiting B-Disease
or O
retching O
, O
and O
no O
antiemetic O
rescue O
) O
in O
18 O
% O
, O
41 O
% O
, O
40 O
% O
, O
and O
47 O
% O
of O
patients O
, O
respectively O
. O

there O
was O
a O
statistically O
longer O
time O
to O
first O
episode O
of O
nausea B-Disease
( O
p O
= O
. O
0015 O
) O
and O
vomiting B-Disease
( O
p O
= O
. O
0001 O
) O
, O
and O
fewer O
patients O
were O
administered O
additional O
antiemetic O
medication O
in O
the O
10 O
- O
micrograms O
/ O
kg O
dosing O
groups O
than O
in O
the O
5 O
- O
micrograms O
/ O
kg O
dosing O
group O
. O

as O
granisetron O
dose O
increased O
, O
appetite O
return O
increased O
( O
p O
= O
. O
040 O
) O
. O

headache B-Disease
was O
the O
most O
frequently O
reported O
adverse O
event O
( O
20 O
% O
) O
. O

conclusion O
: O
a O
single O
10 O
- O
, O
20 O
- O
, O
or O
40 O
- O
micrograms O
/ O
kg O
dose O
of O
granisetron O
was O
effective O
in O
controlling O
vomiting B-Disease
in O
57 O
% O
to O
60 O
% O
of O
patients O
who O
received O
cisplatin O
at O
doses O
greater O
than O
81 O
mg O
/ O
m2 O
and O
totally O
prevented O
vomiting B-Disease
in O
40 O
% O
to O
47 O
% O
of O
patients O
. O

there O
were O
no O
statistically O
significant O
differences O
in O
efficacy O
between O
the O
10 O
- O
micrograms O
/ O
kg O
dose O
and O
the O
20 O
- O
and O
40 O
- O
micrograms O
/ O
kg O
doses O
. O

granisetron O
was O
well O
tolerated O
at O
all O
doses O
. O

adverse O
interaction O
between O
clonidine O
and O
verapamil O
. O

objective O
: O
to O
report O
two O
cases O
of O
a O
possible O
adverse O
interaction O
between O
clonidine O
and O
verapamil O
resulting O
in O
atrioventricular B-Disease
( I-Disease
av I-Disease
) I-Disease
block I-Disease
in O
both O
patients O
and O
severe O
hypotension B-Disease
in O
one O
patient O
. O

case O
summaries O
: O
a O
54 O
- O
year O
- O
old O
woman O
with O
hyperaldosteronism B-Disease
was O
treated O
with O
verapamil O
480 O
mg O
/ O
d O
and O
spironolactone O
100 O
mg O
/ O
d O
. O

after O
the O
addition O
of O
a O
minimal O
dose O
of O
clonidine O
( O
0 O
. O
15 O
mg O
bid O
) O
, O
she O
developed O
complete O
av B-Disease
block I-Disease
and O
severe O
hypotension B-Disease
, O
which O
resolved O
upon O
cessation O
of O
all O
medications O
. O

a O
65 O
- O
year O
- O
old O
woman O
was O
treated O
with O
extended O
- O
release O
verapamil O
240 O
mg O
/ O
d O
. O

after O
the O
addition O
of O
clonidine O
0 O
. O
15 O
mg O
bid O
she O
developed O
complete O
av B-Disease
block I-Disease
, O
which O
resolved O
after O
all O
therapy O
was O
stopped O
. O

discussion O
: O
an O
adverse O
interaction O
between O
clonidine O
and O
verapamil O
has O
not O
been O
reported O
previously O
. O

we O
describe O
two O
such O
cases O
and O
discuss O
the O
various O
mechanisms O
that O
might O
cause O
such O
an O
interaction O
. O

clinicians O
should O
be O
acquainted O
with O
this O
possibly O
fatal O
interaction O
between O
two O
commonly O
used O
antihypertensive O
drugs O
. O

conclusions O
: O
caution O
is O
recommended O
in O
combining O
clonidine O
and O
verapamil O
therapy O
, O
even O
in O
patients O
who O
do O
not O
have O
sinus O
or O
av O
node O
dysfunction O
. O

the O
two O
drugs O
may O
act O
synergistically O
on O
both O
the O
av O
node O
and O
the O
peripheral O
circulation O
. O

pharmacological O
studies O
on O
a O
new O
dihydrothienopyridine O
calcium O
antagonist O
, O
s O
- O
312 O
- O
d O
. O

5th O
communication O
: O
anticonvulsant O
effects O
in O
mice O
. O

s O
- O
312 O
, O
s O
- O
312 O
- O
d O
, O
but O
not O
s O
- O
312 O
- O
l O
, O
l O
- O
type O
calcium O
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic B-Disease
tonic I-Disease
convulsions I-Disease
in O
dba O
/ O
2 O
mice O
; O
and O
their O
ed50 O
values O
were O
18 O
. O
4 O
( O
12 O
. O
8 O
- O
27 O
. O
1 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
and O
15 O
. O
0 O
( O
10 O
. O
2 O
- O
23 O
. O
7 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
, O
respectively O
, O
while O
that O
of O
flunarizine O
was O
34 O
. O
0 O
( O
26 O
. O
0 O
- O
44 O
. O
8 O
) O
mg O
/ O
kg O
, O
p O

. O
o O
. O

although O
moderate O
anticonvulsant O
effects O
of O
s O
- O
312 O
- O
d O
in O
higher O
doses O
were O
observed O
against O
the O
clonic O
convulsions B-Disease
induced O
by O
pentylenetetrazole O
( O
85 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
or O
bemegride O
( O
40 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
, O
no O
effects O
were O
observed O
in O
convulsions B-Disease
induced O
by O
n O
- O
methyl O
- O
d O
- O
aspartate O
, O
picrotoxin O
, O
or O
electroshock O
in O
slc O
: O
ddy O
mice O
. O

s O
- O
312 O
- O
d O
may O
be O
useful O
in O
the O
therapy O
of O
certain O
types O
of O
human O
epilepsy B-Disease
. O

transmural O
myocardial B-Disease
infarction I-Disease
with O
sumatriptan O
. O

for O
sumatriptan O
, O
tightness O
in O
the O
chest O
caused O
by O
an O
unknown O
mechanism O
has O
been O
reported O
in O
3 O
- O
5 O
% O
of O
users O
. O

we O
describe O
a O
47 O
- O
year O
- O
old O
woman O
with O
an O
acute O
myocardial B-Disease
infarction I-Disease
after O
administration O
of O
sumatriptan O
6 O
mg O
subcutaneously O
for O
cluster B-Disease
headache I-Disease
. O

the O
patient O
had O
no O
history O
of O
underlying O
ischaemic B-Disease
heart I-Disease
disease I-Disease
or O
prinzmetal B-Disease
' I-Disease
s I-Disease
angina I-Disease
. O

she O
recovered O
without O
complications O
. O

flumazenil O
induces O
seizures B-Disease
and O
death O
in O
mixed O
cocaine O
- O
diazepam O
intoxications O
. O

study O
hypothesis O
: O
administration O
of O
the O
benzodiazepine O
antagonist O
flumazenil O
may O
unmask O
seizures B-Disease
in O
mixed O
cocaine O
- O
benzodiazepine O
intoxication O
. O

design O
: O
male O
sprague O
- O
dawley O
rats O
received O
100 O
mg O
/ O
kg O
cocaine O
ip O
alone O
, O
5 O
mg O
/ O
kg O
diazepam O
alone O
, O
or O
a O
combination O
of O
diazepam O
and O
cocaine O
. O

three O
minutes O
later O
, O
groups O
were O
challenged O
with O
vehicle O
or O
flumazenil O
5 O
or O
10 O
mg O
/ O
kg O
ip O
. O

animal O
behavior O
, O
seizures B-Disease
( O
time O
to O
and O
incidence O
) O
, O
death O
( O
time O
to O
and O
incidence O
) O
, O
and O
cortical O
eeg O
tracings O
were O
recorded O
. O

interventions O
: O
administration O
of O
flumazenil O
to O
animals O
after O
they O
had O
received O
a O
combination O
dose O
of O
cocaine O
and O
diazepam O
. O

results O
: O
in O
group O
1 O
, O
animals O
received O
cocaine O
followed O
by O
vehicle O
. O

this O
resulted O
in O
100 O
% O
developing O
seizures B-Disease
and O
death O
. O

group O
2 O
received O
diazepam O
alone O
followed O
by O
vehicle O
. O

animals O
became O
somnolent O
and O
none O
died O
. O

group O
3 O
received O
diazepam O
followed O
by O
5 O
mg O
/ O
kg O
flumazenil O
. O

animals O
became O
somnolent O
after O
diazepam O
and O
then O
active O
after O
flumazenil O
administration O
. O

in O
group O
4 O
, O
a O
combination O
of O
cocaine O
and O
diazepam O
was O
administered O
simultaneously O
. O

this O
resulted O
in O
no O
overt O
or O
eeg O
- O
detectable O
seizures B-Disease
and O
a O
50 O
% O
incidence O
of O
death O
. O

group O
5 O
received O
a O
similar O
combination O
of O
cocaine O
and O
diazepam O
, O
followed O
later O
by O
5 O
mg O
/ O
kg O
flumazenil O
. O

this O
resulted O
in O
an O
increased O
incidence O
of O
seizures B-Disease
, O
90 O
% O
( O
p O
< O
. O
01 O
) O
, O
and O
death O
, O
100 O
% O
( O
p O
< O
or O
= O
. O
01 O
) O
, O
compared O
with O
group O
4 O
. O

group O
6 O
received O
cocaine O
and O
diazepam O
followed O
by O
10 O
mg O
/ O
kg O
flumazenil O
. O

this O
also O
resulted O
in O
an O
increased O
incidence O
of O
seizures B-Disease
, O
90 O
% O
( O
p O
< O
or O
= O
. O
01 O
) O
, O
and O
death O
, O
90 O
% O
( O
p O
< O
or O
= O
. O
05 O
) O
, O
compared O
with O
group O
4 O
. O

conclusion O
: O
flumazenil O
can O
unmask O
seizures B-Disease
and O
increase O
the O
incidence O
of O
death O
in O
a O
model O
of O
combined O
cocaine O
- O
diazepam O
intoxications O
. O

mechanisms O
for O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin O
- O
mediated O
nephropathy B-Disease
in O
rats O
. O

studies O
were O
performed O
to O
examine O
the O
mechanisms O
for O
the O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin O
( O
gm O
) O
- O
mediated O
nephropathy B-Disease
. O

administration O
of O
gm O
at O
40 O
mg O
/ O
kg O
sc O
for O
13 O
days O
to O
rats O
induced O
a O
significant O
reduction O
in O
renal O
blood O
flow O
( O
rbf O
) O
and O
inulin O
clearance O
( O
cin O
) O
as O
well O
as O
marked O
tubular B-Disease
damage I-Disease
. O

a O
significant O
reduction O
in O
urinary O
guanosine O
3 O
' O
, O
5 O
' O
- O
cyclic O
monophosphate O
( O
cgmp O
) O
excretion O
and O
a O
significant O
increase O
in O
renal O
cortical O
renin O
and O
endothelin O
- O
1 O
contents O
were O
also O
observed O
in O
gm O
- O
mediated O
nephropathy B-Disease
. O

superoxide O
dismutase O
( O
sod O
) O
or O
dimethylthiourea O
( O
dmtu O
) O
significantly O
lessened O
the O
gm O
- O
induced O
decrement O
in O
cin O
. O

the O
sod O
- O
induced O
increase O
in O
glomerular O
filtration O
rate O
was O
associated O
with O
a O
marked O
improvement O
in O
rbf O
, O
an O
increase O
in O
urinary O
cgmp O
excretion O
, O
and O
a O
decrease O
in O
renal O
renin O
and O
endothelin O
- O
1 O
content O
. O

sod O
did O
not O
attenuate O
the O
tubular B-Disease
damage I-Disease
. O

in O
contrast O
, O
dmtu O
significantly O
reduced O
the O
tubular B-Disease
damage I-Disease
and O
lipid O
peroxidation O
, O
but O
it O
did O
not O
affect O
renal O
hemodynamics O
and O
vasoactive O
substances O
. O

neither O
sod O
nor O
dmtu O
affected O
the O
renal O
cortical O
gm O
content O
in O
gm O
- O
treated O
rats O
. O

these O
results O
suggest O
that O
1 O
) O
both O
sod O
and O
dmtu O
have O
protective O
effects O
on O
gm O
- O
mediated O
nephropathy B-Disease
, O
2 O
) O
the O
mechanisms O
for O
the O
protective O
effects O
differ O
for O
sod O
and O
dmtu O
, O
and O
3 O
) O
superoxide O
anions O
play O
a O
critical O
role O
in O
gm O
- O
induced O
renal O
vasoconstriction O
. O

cephalothin O
- O
induced O
immune O
hemolytic B-Disease
anemia I-Disease
. O

a O
patient O
with O
renal B-Disease
disease I-Disease
developed O
coombs O
- O
positive O
hemolytic B-Disease
anemia I-Disease
while O
receiving O
cephalothin O
therapy O
. O

an O
anti O
- O
cephalothin O
igg O
antibody O
was O
detected O
in O
the O
patient O
' O
s O
serum O
and O
in O
the O
eluates O
from O
her O
erythrocytes O
. O

in O
addition O
, O
nonimmunologic O
binding O
of O
normal O
and O
patient O
' O
s O
serum O
proteins O
to O
her O
own O
and O
cephalothin O
- O
coated O
normal O
red O
cells O
was O
demonstrated O
. O

skin O
tests O
and O
in O
vitro O
lymphocyte O
stimulation O
revealed O
that O
the O
patient O
was O
sensitized O
to O
cephalothin O
and O
also O
to O
ampicillin O
. O

careful O
investigation O
of O
drug O
- O
induced O
hemolytic B-Disease
anemias I-Disease
reveals O
the O
complexity O
of O
the O
immune O
mechanisms O
involved O
. O

assessment O
of O
cardiomyocyte O
dna O
synthesis O
during O
hypertrophy B-Disease
in O
adult O
mice O
. O

the O
ability O
of O
cardiomyocytes O
to O
synthesize O
dna O
in O
response O
to O
experimentally O
induced O
cardiac B-Disease
hypertrophy I-Disease
was O
assessed O
in O
adult O
mice O
. O

isoproterenol O
delivered O
by O
osmotic O
minipump O
implantation O
in O
adult O
c3heb O
/ O
fej O
mice O
resulted O
in O
a O
46 O
% O
increase O
in O
heart O
weight O
and O
a O
19 O
. O
3 O
% O
increase O
in O
cardiomyocyte O
area O
. O

no O
dna O
synthesis O
, O
as O
assessed O
by O
autoradiographic O
analysis O
of O
isolated O
cardiomyocytes O
, O
was O
observed O
in O
control O
or O
hypertrophic B-Disease
hearts I-Disease
. O

a O
survey O
of O
15 O
independent O
inbred O
strains O
of O
mice O
revealed O
that O
ventricular O
cardiomyocyte O
nuclear O
number O
ranged O
from O
3 O
to O
13 O
% O
mononucleate O
, O
suggesting O
that O
cardiomyocyte O
terminal O
differentiation O
is O
influenced O
directly O
or O
indirectly O
by O
genetic O
background O
. O

to O
determine O
whether O
the O
capacity O
for O
reactive O
dna O
synthesis O
was O
also O
subject O
to O
genetic O
regulation O
, O
cardiac B-Disease
hypertrophy I-Disease
was O
induced O
in O
the O
strains O
of O
mice O
comprising O
the O
extremes O
of O
the O
nuclear O
number O
survey O
. O

these O
data O
indicate O
that O
adult O
mouse O
atrial O
and O
ventricular O
cardiomyocytes O
do O
not O
synthesize O
dna O
in O
response O
to O
isoproterenol O
- O
induced O
cardiac B-Disease
hypertrophy I-Disease
. O

central O
cardiovascular O
effects O
of O
avp O
and O
anp O
in O
normotensive O
and O
spontaneously O
hypertensive B-Disease
rats O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
compare O
influence O
of O
central O
arginine O
vasopressin O
( O
avp O
) O
and O
of O
atrial O
natriuretic O
peptide O
( O
anp O
) O
on O
control O
of O
arterial O
blood O
pressure O
( O
map O
) O
and O
heart O
rate O
( O
hr O
) O
in O
normotensive O
( O
wky O
) O
and O
spontaneously O
hypertensive B-Disease
( O
shr O
) O
rats O
. O

three O
series O
of O
experiments O
were O
performed O
on O
30 O
wky O
and O
30 O
shr O
, O
chronically O
instrumented O
with O
guide O
tubes O
in O
the O
lateral O
ventricle O
( O
lv O
) O
and O
arterial O
and O
venous O
catheters O
. O

map O
and O
hr O
were O
monitored O
before O
and O
after O
i O
. O
v O
. O
injections O
of O
either O
vehicle O
or O
1 O
, O
10 O
and O
50 O
ng O
of O
avp O
and O
25 O
, O
125 O
and O
500 O
ng O
of O
anp O
. O

sensitivity O
of O
cardiac O
component O
of O
baroreflex O
( O
ccb O
) O
, O
expressed O
as O
a O
slope O
of O
the O
regression O
line O
was O
determined O
from O
relationships O
between O
systolic O
arterial O
pressure O
( O
sap O
) O
and O
hr O
period O
( O
hrp O
) O
during O
phenylephrine O
( O
phe O
) O
- O
induced O
hypertension B-Disease
and O
sodium O
nitroprusside O
( O
sn O
) O
- O
induced O
hypotension B-Disease
. O

ccb O
was O
measured O
before O
and O
after O
administration O
of O
either O
vehicle O
, O
avp O
, O
anp O
, O
or O
both O
peptides O
together O
. O

increases O
of O
map O
occurred O
after O
lv O
administration O
of O
1 O
, O
10 O
and O
50 O
ng O
of O
avp O
in O
wky O
and O
of O
10 O
and O
50 O
ng O
in O
shr O
. O

anp O
did O
not O
cause O
significant O
changes O
in O
map O
in O
both O
strains O
as O
compared O
to O
vehicle O
, O
but O
it O
abolished O
avp O
- O
induced O
map O
increase O
in O
wky O
and O
shr O
. O

ccb O
was O
reduced O
in O
wky O
and O
shr O
after O
lv O
administration O
of O
avp O
during O
sn O
- O
induced O
hypotension B-Disease
. O

in O
shr O
but O
not O
in O
wky O
administration O
of O
anp O
, O
avp O
and O
anp O
+ O
avp O
decreased O
ccb O
during O
phe O
- O
induced O
map O
elevation O
. O

the O
results O
indicate O
that O
centrally O
applied O
avp O
and O
anp O
exert O
differential O
effects O
on O
blood O
pressure O
and O
baroreflex O
control O
of O
heart O
rate O
in O
wky O
and O
shr O
and O
suggest O
interaction O
of O
these O
two O
peptides O
in O
blood O
pressure O
regulation O
at O
the O
level O
of O
central O
nervous O
system O
. O

cutaneous O
exposure O
to O
warfarin O
- O
like O
anticoagulant O
causing O
an O
intracerebral B-Disease
hemorrhage I-Disease
: O
a O
case O
report O
. O

a O
case O
of O
intercerebral O
hematoma B-Disease
due O
to O
warfarin O
- O
induced O
coagulopathy B-Disease
is O
presented O
. O

the O
39 O
- O
year O
- O
old O
woman O
had O
spread O
a O
warfarin O
- O
type O
rat O
poison O
around O
her O
house O
weekly O
using O
her O
bare O
hands O
, O
with O
no O
washing O
post O
application O
. O

percutaneous O
absorption O
of O
warfarin O
causing O
coagulopathy B-Disease
, O
reported O
three O
times O
in O
the O
past O
, O
is O
a O
significant O
risk O
if O
protective O
measures O
, O
such O
as O
gloves O
, O
are O
not O
used O
. O

an O
adverse O
drug O
interaction O
with O
piroxicam O
, O
which O
she O
took O
occasionally O
, O
may O
have O
exacerbated O
the O
coagulopathy B-Disease
. O

pediatric O
heart O
transplantation O
without O
chronic O
maintenance O
steroids O
. O

from O
1986 O
to O
february O
1993 O
, O
40 O
children O
aged O
2 O
months O
to O
18 O
years O
( O
average O
age O
10 O
. O
4 O
+ O
/ O
- O
5 O
. O
8 O
years O
) O
underwent O
heart O
transplantation O
. O

indications O
for O
transplantation O
were O
idiopathic B-Disease
cardiomyopathy I-Disease
( O
52 O
% O
) O
, O
congenital B-Disease
heart I-Disease
disease I-Disease
( O
35 O
% O
) O
with O
and O
without O
prior O
repair O
( O
71 O
% O
and O
29 O
% O
, O
respectively O
) O
, O
hypertrophic B-Disease
cardiomyopathy I-Disease
( O
5 O
% O
) O
, O
valvular B-Disease
heart I-Disease
disease I-Disease
( O
3 O
% O
) O
, O
and O
doxorubicin O
cardiomyopathy B-Disease
( O
5 O
% O
) O
. O

patients O
were O
managed O
with O
cyclosporine O
and O
azathioprine O
. O

no O
prophylaxis O
with O
antilymphocyte O
globulin O
was O
used O
. O

steroids O
were O
given O
to O
39 O
% O
of O
patients O
for O
refractory O
rejection O
, O
but O
weaning O
was O
always O
attempted O
and O
generally O
successful O
( O
64 O
% O
) O
. O

five O
patients O
( O
14 O
% O
) O
received O
maintenance O
steroids O
. O

four O
patients O
died O
in O
the O
perioperative O
period O
and O
one O
died O
4 O
months O
later O
. O

there O
have O
been O
no O
deaths O
related O
to O
rejection O
or O
infection B-Disease
. O

average O
follow O
- O
up O
was O
36 O
+ O
/ O
- O
19 O
months O
( O
range O
1 O
to O
65 O
months O
) O
. O

cumulative O
survival O
is O
88 O
% O
at O
5 O
years O
. O

in O
patients O
less O
than O
7 O
years O
of O
age O
, O
rejection O
was O
monitored O
noninvasively O
. O

in O
the O
first O
postoperative O
month O
, O
89 O
% O
of O
patients O
were O
treated O
for O
rejection O
. O

freedom O
from O
serious O
infections B-Disease
was O
83 O
% O
at O
1 O
month O
and O
65 O
% O
at O
1 O
year O
. O

cytomegalovirus B-Disease
infections I-Disease
were O
treated O
successfully O
with O
ganciclovir O
in O
11 O
patients O
. O

no O
impairment O
of O
growth O
was O
observed O
in O
children O
who O
underwent O
transplantation O
compared O
with O
a O
control O
population O
. O

twenty O
- O
one O
patients O
( O
60 O
% O
) O
have O
undergone O
annual O
catheterizations O
and O
no O
sign O
of O
graft O
atherosclerosis B-Disease
has O
been O
observed O
. O

seizures B-Disease
occurred O
in O
five O
patients O
( O
14 O
% O
) O
and O
hypertension B-Disease
was O
treated O
in O
10 O
patients O
( O
28 O
% O
) O
. O

no O
patient O
was O
disabled O
and O
no O
lymphoproliferative B-Disease
disorder I-Disease
was O
observed O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

delirium B-Disease
during O
fluoxetine O
treatment O
. O

a O
case O
report O
. O

the O
correlation O
between O
high O
serum O
tricyclic O
antidepressant O
concentrations O
and O
central O
nervous O
system O
side O
effects O
has O
been O
well O
established O
. O

only O
a O
few O
reports O
exist O
, O
however O
, O
on O
the O
relationship O
between O
the O
serum O
concentrations O
of O
selective O
serotonin O
reuptake O
inhibitors O
( O
ssris O
) O
and O
their O
toxic O
effects O
. O

in O
some O
cases O
, O
a O
high O
serum O
concentration O
of O
citalopram O
( O
> O
600 O
nmol O
/ O
l O
) O
in O
elderly O
patients O
has O
been O
associated O
with O
increased O
somnolence B-Disease
and O
movement B-Disease
difficulties I-Disease
. O

widespread O
cognitive B-Disease
disorders I-Disease
, O
such O
as O
delirium B-Disease
, O
have O
not O
been O
previously O
linked O
with O
high O
blood O
levels O
of O
ssris O
. O

in O
this O
report O
, O
we O
describe O
a O
patient O
with O
acute O
hyperkinetic B-Disease
delirium B-Disease
connected O
with O
a O
high O
serum O
total O
fluoxetine O
( O
fluoxetine O
plus O
desmethylfluoxetine O
) O
concentration O
. O

pulmonary B-Disease
edema I-Disease
and O
shock B-Disease
after O
high O
- O
dose O
aracytine O
- O
c O
for O
lymphoma B-Disease
; O
possible O
role O
of O
tnf O
- O
alpha O
and O
paf O
. O

four O
out O
of O
23 O
consecutive O
patients O
treated O
with O
high O
- O
dose O
ara O
- O
c O
for O
lymphomas B-Disease
in O
our O
institution O
developed O
a O
strikingly O
similar O
syndrome O
during O
the O
perfusion O
. O

it O
was O
characterized O
by O
the O
onset O
of O
fever B-Disease
, O
diarrhea B-Disease
, O
shock B-Disease
, O
pulmonary B-Disease
edema I-Disease
, O
acute B-Disease
renal I-Disease
failure I-Disease
, O
metabolic B-Disease
acidosis I-Disease
, O
weight B-Disease
gain I-Disease
and O
leukocytosis B-Disease
. O

thorough O
bacteriological O
screening O
failed O
to O
provide O
evidence O
of O
infection B-Disease
. O

sequential O
biological O
assays O
of O
il O
- O
1 O
, O
il O
- O
2 O
, O
tnf O
and O
paf O
were O
performed O
during O
ara O
- O
c O
infusion O
to O
ten O
patients O
, O
including O
the O
four O
who O
developed O
the O
syndrome O
. O

tnf O
and O
paf O
activity O
was O
found O
in O
the O
serum O
of O
respectively O
two O
and O
four O
of O
the O
cases O
, O
but O
not O
in O
the O
six O
controls O
. O

as O
tnf O
and O
paf O
are O
thought O
to O
be O
involved O
in O
the O
development O
of O
septic O
shock B-Disease
and O
adult B-Disease
respiratory I-Disease
distress I-Disease
syndrome I-Disease
, O
we O
hypothesize O
that O
high O
- O
dose O
ara O
- O
c O
may O
be O
associated O
with O
cytokine O
release O
. O

protective O
effect O
of O
clentiazem O
against O
epinephrine O
- O
induced O
cardiac B-Disease
injury I-Disease
in O
rats O
. O

we O
investigated O
the O
effects O
of O
clentiazem O
, O
a O
1 O
, O
5 O
- O
benzothiazepine O
calcium O
antagonist O
, O
on O
epinephrine O
- O
induced O
cardiomyopathy B-Disease
in O
rats O
. O

with O
2 O
- O
week O
chronic O
epinephrine O
infusion O
, O
16 O
of O
30 O
rats O
died O
within O
4 O
days O
, O
and O
severe O
ischemic B-Disease
lesions I-Disease
and O
fibrosis B-Disease
of O
the O
left O
ventricles O
were O
observed O
. O

in O
epinephrine O
- O
treated O
rats O
, O
left O
atrial O
and O
left O
ventricular O
papillary O
muscle O
contractile O
responses O
to O
isoproterenol O
were O
reduced O
, O
but O
responses O
to O
calcium O
were O
normal O
or O
enhanced O
compared O
to O
controls O
. O

left O
ventricular O
alpha O
and O
beta O
adrenoceptor O
densities O
were O
also O
reduced O
compared O
to O
controls O
. O

treatment O
with O
clentiazem O
prevented O
epinephrine O
- O
induced O
death O
( O
p O
< O
. O
05 O
) O
, O
and O
attenuated O
the O
ventricular O
ischemic B-Disease
lesions I-Disease
and O
fibrosis B-Disease
, O
in O
a O
dose O
- O
dependent O
manner O
. O

left O
atrial O
and O
left O
ventricular O
papillary O
muscle O
contractile O
responses O
to O
isoproterenol O
were O
reduced O
compared O
to O
controls O
in O
groups O
treated O
with O
clentiazem O
alone O
, O
but O
combined O
with O
epinephrine O
, O
clentiazem O
restored O
left O
atrial O
responses O
and O
enhanced O
left O
ventricular O
papillary O
responses O
to O
isoproterenol O
. O

on O
the O
other O
hand O
clentiazem O
did O
not O
prevent O
epinephrine O
- O
induced O
down O
- O
regulation O
of O
alpha O
and O
beta O
adrenoceptors O
. O

interestingly O
, O
clentiazem O
, O
infused O
alone O
, O
resulted O
in O
decreased O
adrenergic O
receptor O
densities O
in O
the O
left O
ventricle O
. O

clentiazem O
also O
did O
not O
prevent O
the O
enhanced O
responses O
to O
calcium O
seen O
in O
the O
epinephrine O
- O
treated O
animals O
, O
although O
the O
high O
dose O
of O
clentiazem O
partially O
attenuated O
the O
maximal O
response O
to O
calcium O
compared O
to O
epinephrine O
- O
treated O
animals O
. O

in O
conclusion O
, O
clentiazem O
attenuated O
epinephrine O
- O
induced O
cardiac B-Disease
injury I-Disease
, O
possibly O
through O
its O
effect O
on O
the O
adrenergic O
pathway O
. O

kaliuretic O
effect O
of O
l O
- O
dopa O
treatment O
in O
parkinsonian B-Disease
patients O
. O

hypokalemia B-Disease
, O
sometimes O
severe O
, O
was O
observed O
in O
some O
l O
- O
dopa O
- O
treated O
parkinsonian B-Disease
patients O
. O

the O
influence O
of O
l O
- O
dopa O
on O
the O
renal O
excretion O
of O
potassium O
was O
studied O
in O
3 O
patients O
with O
hypokalemia B-Disease
and O
in O
5 O
normokalemic O
patients O
by O
determination O
of O
renal O
plasma O
flow O
, O
glomerular O
filtration O
rate O
, O
plasma O
concentration O
of O
potassium O
and O
sodium O
as O
well O
as O
urinary O
excretion O
of O
potassium O
, O
sodium O
and O
aldosterone O
. O

l O
- O
dopa O
intake O
was O
found O
to O
cause O
an O
increased O
excretion O
of O
potassium O
, O
and O
sometimes O
also O
of O
sodium O
, O
in O
the O
hypokalemic O
but O
not O
in O
the O
normokalemic O
patients O
. O

this O
effect O
on O
the O
renal O
function O
could O
be O
prohibited O
by O
the O
administration O
of O
a O
peripheral O
dopa O
decarbodylase O
inhibitor O
. O

it O
is O
not O
known O
why O
this O
effect O
occurred O
in O
some O
individuals O
but O
not O
in O
others O
, O
but O
our O
results O
indicate O
a O
correlation O
between O
aldosterone O
production O
and O
this O
renal O
effect O
of O
l O
- O
dopa O
. O

cocaine O
induced O
myocardial B-Disease
ischemia I-Disease
. O

we O
report O
a O
case O
of O
myocardial B-Disease
ischemia I-Disease
induced O
by O
cocaine O
. O

the O
ischemia B-Disease
probably O
induced O
by O
coronary B-Disease
artery I-Disease
spasm I-Disease
was O
reversed O
by O
nitroglycerin O
and O
calcium O
blocking O
agents O
. O

doxorubicin O
- O
induced O
cardiotoxicity B-Disease
monitored O
by O
ecg O
in O
freely O
moving O
mice O
. O

a O
new O
model O
to O
test O
potential O
protectors O
. O

in O
laboratory O
animals O
, O
histology O
is O
most O
commonly O
used O
to O
study O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
. O

however O
, O
for O
monitoring O
during O
treatment O
, O
large O
numbers O
of O
animals O
are O
needed O
. O

recently O
we O
developed O
a O
new O
method O
to O
measure O
ecg O
values O
in O
freely O
moving O
mice O
by O
telemetry O
. O

with O
this O
model O
we O
investigated O
the O
effect O
of O
chronic O
doxorubicin O
administration O
on O
the O
ecg O
of O
freely O
moving O
balb O
/ O
c O
mice O
and O
the O
efficacy O
of O
icrf O
- O
187 O
as O
a O
protective O
agent O
. O

the O
st O
interval O
significantly O
widened O
from O
15 O
. O
0 O
+ O
/ O
- O
1 O
. O
5 O
to O
56 O
. O
8 O
+ O
/ O
- O
11 O
. O
8 O
ms O
in O
week O
10 O
( O
7 O
weekly O
doses O
of O
4 O
mg O
/ O
kg O
doxorubicin O
given O
i O
. O
v O
. O
plus O
3 O
weeks O
of O
observation O
) O
. O

the O
ecg O
of O
the O
control O
animals O
did O
not O
change O
during O
the O
entire O
study O
. O

after O
sacrifice O
the O
hearts O
of O
doxorubicin O
- O
treated O
animals O
were O
enlarged O
and O
the O
atria O
were O
hypertrophic B-Disease
. O

as O
this O
schedule O
exerted O
more O
toxicity B-Disease
than O
needed O
to O
investigate O
protective O
agents O
, O
the O
protection O
of O
icrf O
- O
187 O
was O
determined O
using O
a O
dose O
schedule O
with O
lower O
general O
toxicity B-Disease
( O
6 O
weekly O
doses O
of O
4 O
mg O
/ O
kg O
doxorubicin O
given O
i O
. O
v O
. O
plus O
2 O
weeks O
of O
observation O
) O
. O

on O
this O
schedule O
, O
the O
animals O
' O
hearts O
appeared O
normal O
after O
sacrifice O
and O
icrf O
- O
187 O
( O
50 O
mg O
/ O
kg O
given O
i O
. O
p O
. O
1 O
h O
before O
doxorubicin O
) O
provided O
almost O
full O
protection O
. O

these O
data O
were O
confirmed O
by O
histology O
. O

the O
results O
indicate O
that O
this O
new O
model O
is O
very O
sensitive O
and O
enables O
monitoring O
of O
the O
development O
of O
cardiotoxicity B-Disease
with O
time O
. O

these O
findings O
result O
in O
a O
model O
that O
allows O
the O
testing O
of O
protectors O
against O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
as O
demonstrated O
by O
the O
protection O
provided O
by O
icrf O
- O
187 O
. O

epinephrine O
dysrhythmogenicity O
is O
not O
enhanced O
by O
subtoxic O
bupivacaine O
in O
dogs O
. O

since O
bupivacaine O
and O
epinephrine O
may O
both O
precipitate O
dysrhythmias B-Disease
, O
circulating O
bupivacaine O
during O
regional O
anesthesia O
could O
potentiate O
dysrhythmogenic O
effects O
of O
epinephrine O
. O

we O
therefore O
examined O
whether O
bupivacaine O
alters O
the O
dysrhythmogenicity O
of O
subsequent O
administration O
of O
epinephrine O
in O
conscious O
, O
healthy O
dogs O
and O
in O
anesthetized O
dogs O
with O
myocardial B-Disease
infarction I-Disease
. O

forty O
- O
one O
conscious O
dogs O
received O
10 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
epinephrine O
. O

seventeen O
animals O
responded O
with O
ventricular B-Disease
tachycardia I-Disease
( O
vt B-Disease
) O
within O
3 O
min O
. O

after O
3 O
h O
, O
these O
responders O
randomly O
received O
1 O
or O
2 O
mg O
/ O
kg O
bupivacaine O
or O
saline O
over O
5 O
min O
, O
followed O
by O
10 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
epinephrine O
. O

in O
the O
bupivacaine O
groups O
, O
epinephrine O
caused O
fewer O
prodysrhythmic O
effects O
than O
without O
bupivacaine O
. O

vt B-Disease
appeared O
in O
fewer O
dogs O
and O
at O
a O
later O
time O
, O
and O
there O
were O
more O
sinoatrial O
beats O
and O
less O
ectopies O
. O

epinephrine O
shortened O
qt O
less O
after O
bupivacaine O
than O
in O
control O
animals O
. O

one O
day O
after O
experimental O
myocardial B-Disease
infarction I-Disease
, O
six O
additional O
halothane O
- O
anesthetized O
dogs O
received O
4 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
epinephrine O
until O
vt B-Disease
appeared O
. O

after O
45 O
min O
, O
1 O
mg O
/ O
kg O
bupivacaine O
was O
injected O
over O
5 O
min O
, O
again O
followed O
by O
4 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
epinephrine O
. O

in O
these O
dogs O
, O
the O
prodysrhythmic O
response O
to O
epinephrine O
was O
also O
mitigated O
by O
preceding O
bupivacaine O
. O

bupivacaine O
antagonizes O
epinephrine O
dysrhythmogenicity O
in O
conscious O
dogs O
susceptible O
to O
vt B-Disease
and O
in O
anesthetized O
dogs O
with O
spontaneous O
postinfarct O
dysrhythmias B-Disease
. O

there O
is O
no O
evidence O
that O
systemic O
subtoxic O
bupivacaine O
administration O
enhances O
the O
dysrhythmogenicity O
of O
subsequent O
epinephrine O
. O

milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
induced O
by O
1 O
, O
25 O
( O
oh O
) O
2d O
in O
a O
patient O
with O
hypoparathyroidism B-Disease
. O

milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
was O
first O
described O
70 O
years O
ago O
in O
the O
context O
of O
the O
treatment O
of O
peptic B-Disease
ulcer I-Disease
disease I-Disease
with O
large O
amounts O
of O
calcium O
and O
alkali O
. O

although O
with O
current O
ulcer B-Disease
therapy O
( O
h O
- O
2 O
blockers O
, O
omeprazole O
, O
and O
sucralfate O
) O
, O
the O
frequency O
of O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
has O
decreased O
significantly O
, O
the O
classic O
triad O
of O
hypercalcemia B-Disease
, O
alkalosis B-Disease
, O
and O
renal B-Disease
impairment I-Disease
remains O
the O
hallmark O
of O
the O
syndrome O
. O

milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
can O
present O
serious O
and O
occasionally O
life O
- O
threatening O
illness O
unless O
diagnosed O
and O
treated O
appropriately O
. O

this O
article O
presents O
a O
patient O
with O
hypoparathyroidism B-Disease
who O
was O
treated O
with O
calcium O
carbonate O
and O
calcitriol O
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
. O

the O
patient O
was O
successfully O
treated O
with O
intravenous O
pamidronate O
on O
his O
first O
admission O
and O
with O
hydrocortisone O
on O
the O
second O
. O

this O
illustrates O
intravenous O
pamidronate O
as O
a O
valuable O
therapeutic O
tool O
when O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
presents O
as O
hypercalcemic B-Disease
emergency I-Disease
. O

famotidine O
- O
associated O
delirium B-Disease
. O

a O
series O
of O
six O
cases O
. O

famotidine O
is O
a O
histamine O
h2 O
- O
receptor O
antagonist O
used O
in O
inpatient O
settings O
for O
prevention O
of O
stress O
ulcers B-Disease
and O
is O
showing O
increasing O
popularity O
because O
of O
its O
low O
cost O
. O

although O
all O
of O
the O
currently O
available O
h2 O
- O
receptor O
antagonists O
have O
shown O
the O
propensity O
to O
cause O
delirium B-Disease
, O
only O
two O
previously O
reported O
cases O
have O
been O
associated O
with O
famotidine O
. O

the O
authors O
report O
on O
six O
cases O
of O
famotidine O
- O
associated O
delirium B-Disease
in O
hospitalized O
patients O
who O
cleared O
completely O
upon O
removal O
of O
famotidine O
. O

the O
pharmacokinetics O
of O
famotidine O
are O
reviewed O
, O
with O
no O
change O
in O
its O
metabolism O
in O
the O
elderly O
population O
seen O
. O

the O
implications O
of O
using O
famotidine O
in O
elderly O
persons O
are O
discussed O
. O

encephalopathy B-Disease
during O
amitriptyline O
therapy O
: O
are O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
and O
serotonin B-Disease
syndrome I-Disease
spectrum O
disorders O
? O

this O
report O
describes O
a O
case O
of O
encephalopathy B-Disease
developed O
in O
the O
course O
of O
amitriptyline O
therapy O
, O
during O
a O
remission O
of O
unipolar B-Disease
depression I-Disease
. O

this O
patient O
could O
have O
been O
diagnosed O
as O
having O
either O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
( O
nms B-Disease
) O
or O
serotonin B-Disease
syndrome I-Disease
( O
ss B-Disease
) O
. O

the O
major O
determinant O
of O
the O
symptoms O
may O
have O
been O
dopamine O
/ O
serotonin O
imbalance O
in O
the O
central O
nervous O
system O
. O

the O
nms B-Disease
- O
like O
encephalopathy B-Disease
that O
develops O
in O
association O
with O
the O
use O
of O
antidepressants O
indicates O
that O
nms B-Disease
and O
ss B-Disease
are O
spectrum O
disorders O
induced O
by O
drugs O
with O
both O
antidopaminergic O
and O
serotonergic O
effects O
. O

genetic O
separation O
of O
tumor B-Disease
growth O
and O
hemorrhagic B-Disease
phenotypes O
in O
an O
estrogen O
- O
induced O
tumor B-Disease
. O

chronic O
administration O
of O
estrogen O
to O
the O
fischer O
344 O
( O
f344 O
) O
rat O
induces O
growth O
of O
large O
, O
hemorrhagic B-Disease
pituitary B-Disease
tumors I-Disease
. O

ten O
weeks O
of O
diethylstilbestrol O
( O
des O
) O
treatment O
caused O
female O
f344 O
rat O
pituitaries O
to O
grow O
to O
an O
average O
of O
109 O
. O
2 O
+ O
/ O
- O
6 O
. O
3 O
mg O
( O
mean O
+ O
/ O
- O
se O
) O
versus O
11 O
. O
3 O
+ O
/ O
- O
1 O
. O
4 O
mg O
for O
untreated O
rats O
, O
and O
to O
become O
highly O
hemorrhagic B-Disease
. O

the O
same O
des O
treatment O
produced O
no O
significant O
growth O
( O
8 O
. O
9 O
+ O
/ O
- O
0 O
. O
5 O
mg O
for O
treated O
females O
versus O
8 O
. O
7 O
+ O
/ O
- O
1 O
. O
1 O
for O
untreated O
females O
) O
or O
morphological O
changes O
in O
brown O
norway O
( O
bn O
) O
rat O
pituitaries O
. O

an O
f1 O
hybrid O
of O
f344 O
and O
bn O
exhibited O
significant O
pituitary O
growth O
after O
10 O
weeks O
of O
des O
treatment O
with O
an O
average O
mass O
of O
26 O
. O
3 O
+ O
/ O
- O
0 O
. O
7 O
mg O
compared O
with O
8 O
. O
6 O
+ O
/ O
- O
0 O
. O
9 O
mg O
for O
untreated O
rats O
. O

surprisingly O
, O
the O
f1 O
hybrid O
tumors B-Disease
were O
not O
hemorrhagic B-Disease
and O
had O
hemoglobin O
content O
and O
outward O
appearance O
identical O
to O
that O
of O
bn O
. O

expression O
of O
both O
growth O
and O
morphological O
changes O
is O
due O
to O
multiple O
genes O
. O

however O
, O
while O
des O
- O
induced O
pituitary O
growth O
exhibited O
quantitative O
, O
additive O
inheritance O
, O
the O
hemorrhagic B-Disease
phenotype O
exhibited O
recessive O
, O
epistatic O
inheritance O
. O

only O
5 O
of O
the O
160 O
f2 O
pituitaries O
exhibited O
the O
hemorrhagic B-Disease
phenotype O
; O
36 O
of O
the O
160 O
f2 O
pituitaries O
were O
in O
the O
f344 O
range O
of O
mass O
, O
but O
31 O
of O
these O
were O
not O
hemorrhagic B-Disease
, O
indicating O
that O
the O
hemorrhagic B-Disease
phenotype O
is O
not O
merely O
a O
consequence O
of O
extensive O
growth O
. O

the O
hemorrhagic B-Disease
f2 O
pituitaries O
were O
all O
among O
the O
most O
massive O
, O
indicating O
that O
some O
of O
the O
genes O
regulate O
both O
phenotypes O
. O

increased O
expression O
of O
neuronal O
nitric O
oxide O
synthase O
in O
bladder O
afferent O
pathways O
following O
chronic O
bladder B-Disease
irritation I-Disease
. O

immunocytochemical O
techniques O
were O
used O
to O
examine O
alterations O
in O
the O
expression O
of O
neuronal O
nitric O
oxide O
synthase O
( O
nos O
) O
in O
bladder O
pathways O
following O
acute O
and O
chronic O
irritation B-Disease
of I-Disease
the I-Disease
urinary I-Disease
tract I-Disease
of O
the O
rat O
. O

chemical O
cystitis B-Disease
was O
induced O
by O
cyclophosphamide O
( O
cyp O
) O
which O
is O
metabolized O
to O
acrolein O
, O
an O
irritant O
eliminated O
in O
the O
urine O
. O

injection O
of O
cyp O
( O
n O
= O
10 O
, O
75 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
2 O
hours O
prior O
to O
perfusion O
( O
acute O
treatment O
) O
of O
the O
animals O
increased O
fos O
- O
immunoreactivity O
( O
ir O
) O
in O
neurons O
in O
the O
dorsal O
commissure O
, O
dorsal O
horn O
, O
and O
autonomic O
regions O
of O
spinal O
segments O
( O
l1 O
- O
l2 O
and O
l6 O
- O
s1 O
) O
which O
receive O
afferent O
inputs O
from O
the O
bladder O
, O
urethra O
, O
and O
ureter O
. O

fos O
- O
ir O
in O
the O
spinal O
cord O
was O
not O
changed O
in O
rats O
receiving O
chronic O
cyp O
treatment O
( O
n O
= O
15 O
, O
75 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
, O
every O
3rd O
day O
for O
2 O
weeks O
) O
. O

in O
control O
animals O
and O
in O
animals O
treated O
acutely O
with O
cyp O
, O
only O
small O
numbers O
of O
nos O
- O
ir O
cells O
( O
0 O
. O
5 O
- O
0 O
. O
7 O
cell O
profiles O
/ O
sections O
) O
were O
detected O
in O
the O
l6 O
- O
s1 O
dorsal O
root O
ganglia O
( O
drg O
) O
. O

chronic O
cyp O
administration O
significantly O
( O
p O
< O
or O
= O
. O
002 O
) O
increased O
bladder O
weight O
by O
60 O
% O
and O
increased O
( O
7 O
- O
to O
11 O
- O
fold O
) O
the O
numbers O
of O
nos O
- O
immunoreactive O
( O
ir O
) O
afferent O
neurons O
in O
the O
l6 O
- O
s1 O
drg O
. O

a O
small O
increase O
( O
1 O
. O
5 O
- O
fold O
) O
also O
occurred O
in O
the O
l1 O
drg O
, O
but O
no O
change O
was O
detected O
in O
the O
l2 O
and O
l5 O
drg O
. O

bladder O
afferent O
cells O
in O
the O
l6 O
- O
s1 O
drg O
labeled O
by O
fluorogold O
( O
40 O
microliters O
) O
injected O
into O
the O
bladder O
wall O
did O
not O
exhibit O
nos O
- O
ir O
in O
control O
animals O
; O
however O
, O
following O
chronic O
cyp O
administration O
, O
a O
significant O
percentage O
of O
bladder O
afferent O
neurons O
were O
nos O
- O
ir O
: O
l6 O
( O
19 O
. O
8 O
+ O
/ O
- O
4 O
. O
6 O
% O
) O
and O
s1 O
( O
25 O
. O
3 O
+ O
/ O
- O
2 O
. O
9 O
% O
) O
. O

these O
results O
indicate O
that O
neuronal O
gene O
expression O
in O
visceral O
sensory O
pathways O
can O
be O
upregulated O
by O
chemical O
irritation O
of O
afferent O
receptors O
in O
the O
urinary O
tract O
and O
/ O
or O
that O
pathological O
changes O
in O
the O
urinary O
tract O
can O
initiate O
chemical O
signals O
that O
alter O
the O
chemical O
properties O
of O
visceral O
afferent O
neurons O
. O

effects O
of O
a O
new O
calcium O
antagonist O
, O
cd O
- O
832 O
, O
on O
isoproterenol O
- O
induced O
myocardial B-Disease
ischemia I-Disease
in O
dogs O
with O
partial O
coronary B-Disease
stenosis I-Disease
. O

effects O
of O
cd O
- O
832 O
on O
isoproterenol O
( O
iso O
) O
- O
induced O
myocardial B-Disease
ischemia I-Disease
were O
studied O
in O
dogs O
with O
partial O
coronary B-Disease
stenosis I-Disease
of O
the O
left O
circumflex O
coronary O
artery O
and O
findings O
were O
compared O
with O
those O
for O
nifedipine O
or O
diltiazem O
. O

in O
the O
presence O
of O
coronary B-Disease
artery I-Disease
stenosis I-Disease
, O
3 O
- O
min O
periods O
of O
intracoronary O
iso O
infusion O
( O
10 O
ng O
/ O
kg O
/ O
min O
) O
increased O
heart O
rate O
and O
maximal O
rate O
of O
left O
ventricular O
pressure O
rise O
, O
which O
resulted O
in O
a O
decrease O
in O
percentage O
segmental O
shortening O
and O
st O
- O
segment O
elevation O
of O
the O
epicardial O
electrocardiogram O
. O

after O
the O
control O
iso O
infusion O
with O
stenosis B-Disease
was O
performed O
, O
equihypotensive O
doses O
of O
cd O
- O
832 O
( O
3 O
and O
10 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
, O
nifedipine O
( O
1 O
and O
3 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
9 O
) O
or O
diltiazem O
( O
10 O
and O
30 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
were O
infused O
5 O
min O
before O
and O
during O
the O
second O
and O
third O
iso O
infusion O
. O

both O
cd O
- O
832 O
and O
diltiazem O
, O
but O
not O
nifedipine O
, O
significantly O
reduced O
the O
increase O
in O
heart O
rate O
induced O
by O
iso O
infusion O
. O

in O
contrast O
to O
nifedipine O
, O
cd O
- O
832 O
( O
10 O
micrograms O
/ O
kg O
/ O
min O
) O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
32 O
+ O
/ O
- O
12 O
% O
to O
115 O
+ O
/ O
- O
26 O
% O
of O
the O
control O
value O
( O
p O
< O
. O
01 O
) O
and O
st O
- O
segment O
elevation O
from O
5 O
. O
6 O
+ O
/ O
- O
1 O
. O
0 O
mv O
to O
1 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
mv O
( O
p O
< O
. O
01 O
) O
at O
3 O
min O
after O
iso O
infusion O
with O
stenosis B-Disease
. O

diltiazem O
( O
30 O
micrograms O
/ O
kg O
/ O
min O
) O
also O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
34 O
+ O
/ O
- O
14 O
% O
to O
63 O
+ O
/ O
- O
18 O
% O
of O
the O
control O
value O
( O
p O
< O
. O
05 O
) O
and O
st O
- O
segment O
elevation O
from O
4 O
. O
7 O
+ O
/ O
- O
0 O
. O
7 O
mv O
to O
2 O
. O
1 O
+ O
/ O
- O
0 O
. O
7 O
mv O
( O
p O
< O
. O
01 O
) O
at O
3 O
min O
after O
iso O
infusion O
with O
stenosis B-Disease
. O

these O
data O
show O
that O
cd O
- O
832 O
improves O
myocardial B-Disease
ischemia I-Disease
during O
iso O
infusion O
with O
stenosis B-Disease
and O
suggest O
that O
the O
negative O
chronotropic O
property O
of O
cd O
- O
832 O
plays O
a O
major O
role O
in O
the O
beneficial O
effects O
of O
cd O
- O
832 O
. O

the O
effect O
of O
recombinant O
human O
insulin O
- O
like O
growth O
factor O
- O
i O
on O
chronic O
puromycin O
aminonucleoside O
nephropathy B-Disease
in O
rats O
. O

we O
recently O
demonstrated O
that O
recombinant O
hgh O
exacerbates O
renal O
functional O
and O
structural O
injury O
in O
chronic O
puromycin O
aminonucleoside O
( O
pan O
) O
nephropathy B-Disease
, O
an O
experimental O
model O
of O
glomerular B-Disease
disease I-Disease
. O

therefore O
, O
we O
examined O
whether O
recombinant O
human O
( O
rh O
) O
igf O
- O
i O
is O
a O
safer O
alternative O
for O
the O
treatment O
of O
growth B-Disease
failure I-Disease
in O
rats O
with O
chronic O
pan O
nephropathy B-Disease
. O

the O
glomerulopathy B-Disease
was O
induced O
by O
seven O
serial O
injections O
of O
pan O
over O
12 O
wk O
. O

experimental O
animals O
( O
n O
= O
6 O
) O
received O
rhigf O
- O
i O
, O
400 O
micrograms O
/ O
d O
, O
whereas O
control O
rats O
( O
n O
= O
6 O
) O
received O
the O
vehicle O
. O

rhigf O
- O
i O
improved O
weight O
gain O
by O
14 O
% O
( O
p O
< O
0 O
. O
05 O
) O
, O
without O
altering O
hematocrit O
or O
blood O
pressure O
in O
rats O
with O
renal B-Disease
disease I-Disease
. O

urinary O
protein O
excretion O
was O
unaltered O
by O
rhigf O
- O
i O
treatment O
in O
rats O
with O
chronic O
pan O
nephropathy B-Disease
. O

after O
12 O
wk O
, O
the O
inulin O
clearance O
was O
higher O
in O
rhigf O
- O
i O
- O
treated O
rats O
, O
0 O
. O
48 O
+ O
/ O
- O
0 O
. O
08 O
versus O
0 O
. O
24 O
+ O
/ O
- O
0 O
. O
06 O
ml O
/ O
min O
/ O
100 O
g O
of O
body O
weight O
in O
untreated O
pan O
nephropathy B-Disease
animals O
, O
p O
< O
0 O
. O
05 O
. O

the O
improvement O
in O
gfr O
was O
not O
associated O
with O
enhanced O
glomerular B-Disease
hypertrophy I-Disease
or O
increased O
segmental O
glomerulosclerosis B-Disease
, O
tubulointerstitial B-Disease
injury I-Disease
, O
or O
renal O
cortical O
malondialdehyde O
content O
. O

in O
rats O
with O
pan O
nephropathy B-Disease
, O
administration O
of O
rhigf O
- O
i O
increased O
igf O
- O
i O
and O
gh O
receptor O
gene O
expression O
, O
without O
altering O
the O
steady O
state O
level O
of O
igf O
- O
i O
receptor O
mrna O
. O

in O
normal O
rats O
with O
intact O
kidneys O
, O
rhigf O
- O
i O
administration O
( O
n O
= O
4 O
) O
did O
not O
alter O
weight O
gain O
, O
blood O
pressure O
, O
proteinuria B-Disease
, O
gfr O
, O
glomerular O
planar O
area O
, O
renal O
cortical O
malondialdehyde O
content O
, O
or O
glomerular O
or O
tubulointerstitial B-Disease
damage I-Disease
, O
compared O
with O
untreated O
animals O
( O
n O
= O
4 O
) O
. O

rhigf O
- O
i O
treatment O
reduced O
the O
steady O
state O
renal O
igf O
- O
i O
mrna O
level O
but O
did O
not O
modify O
gene O
expression O
of O
the O
igf O
- O
i O
or O
gh O
receptors O
. O

we O
conclude O
that O
: O
1 O
) O
administration O
of O
rhigf O
- O
i O
improves O
growth O
and O
gfr O
in O
rats O
with O
chronic O
pan O
nephropathy B-Disease
and O
2 O
) O
unlike O
rhgh O
, O
long O
- O
term O
use O
of O
rhigf O
- O
i O
does O
not O
worsen O
renal O
functional O
and O
structural O
injury O
in O
this O
disease O
model O
. O

nefiracetam O
( O
dm O
- O
9384 O
) O
reverses O
apomorphine O
- O
induced O
amnesia B-Disease
of O
a O
passive O
avoidance O
response O
: O
delayed O
emergence O
of O
the O
memory O
retention O
effects O
. O

nefiracetam O
is O
a O
novel O
pyrrolidone O
derivative O
which O
attenuates O
scopolamine O
- O
induced O
learning B-Disease
and I-Disease
post I-Disease
- I-Disease
training I-Disease
consolidation I-Disease
deficits I-Disease
. O

given O
that O
apomorphine O
inhibits O
passive O
avoidance O
retention O
when O
given O
during O
training O
or O
in O
a O
defined O
10 O
- O
12h O
post O
- O
training O
period O
, O
we O
evaluated O
the O
ability O
of O
nefiracetam O
to O
attenuate O
amnesia B-Disease
induced O
by O
dopaminergic O
agonism O
. O

a O
step O
- O
down O
passive O
avoidance O
paradigm O
was O
employed O
and O
nefiracetam O
( O
3 O
mg O
/ O
kg O
) O
and O
apomorphine O
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
were O
given O
alone O
or O
in O
combination O
during O
training O
and O
at O
the O
10 O
- O
12h O
post O
- O
training O
period O
of O
consolidation O
. O

co O
- O
administration O
of O
nefiracetam O
and O
apomorphine O
during O
training O
or O
10h O
thereafter O
produced O
no O
significant O
anti O
- O
amnesic O
effect O
. O

however O
, O
administration O
of O
nefiracetam O
during O
training O
completely O
reversed O
the O
amnesia B-Disease
induced O
by O
apomorphine O
at O
the O
10h O
post O
- O
training O
time O
and O
the O
converse O
was O
also O
true O
. O

these O
effects O
were O
not O
mediated O
by O
a O
dopaminergic O
mechanism O
as O
nefiracetam O
, O
at O
millimolar O
concentrations O
, O
failed O
to O
displace O
either O
[ O
3h O
] O
sch O
23390 O
or O
[ O
3h O
] O
spiperone O
binding O
from O
d1 O
or O
d2 O
dopamine O
receptor O
subtypes O
, O
respectively O
. O

it O
is O
suggested O
that O
nefiracetam O
augments O
molecular O
processes O
in O
the O
early O
stages O
of O
events O
which O
ultimately O
lead O
to O
consolidation O
of O
memory O
. O

phenytoin O
encephalopathy B-Disease
as O
probable O
idiosyncratic O
reaction O
: O
case O
report O
. O

a O
case O
of O
phenytoin O
( O
dph O
) O
encephalopathy B-Disease
with O
increasing O
seizures B-Disease
and O
eeg O
and O
mental O
changes O
is O
described O
. O

despite O
adequate O
oral O
dosage O
of O
dph O
( O
5 O
mg O
/ O
kg O
/ O
daily O
) O
the O
plasma O
level O
was O
very O
low O
( O
2 O
. O
8 O
microgramg O
/ O
ml O
) O
. O

the O
encephalopathy B-Disease
was O
probably O
an O
idiosyncratic O
and O
not O
toxic O
or O
allergic O
reaction O
. O

in O
fact O
the O
concentration O
of O
free O
dph O
was O
normal O
, O
the O
patient O
presented O
a O
retarded O
morbilliform O
rash B-Disease
during O
dph O
treatment O
, O
the O
protidogram O
was O
normal O
, O
and O
an O
intradermic O
dph O
injection O
had O
no O
local O
effect O
. O

the O
authors O
conclude O
that O
in O
a O
patient O
starting O
dph O
treatment O
an O
unexpected O
increase O
in O
seizures B-Disease
, O
with O
eeg O
and O
mental O
changes O
occurring O
simultaneously O
, O
should O
alert O
the O
physician O
to O
the O
possible O
need O
for O
eliminating O
dph O
from O
the O
therapeutic O
regimen O
, O
even O
if O
plasma O
concentrations O
are O
low O
. O

prevention O
and O
treatment O
of O
endometrial B-Disease
disease I-Disease
in O
climacteric O
women O
receiving O
oestrogen O
therapy O
. O

the O
treatment O
regimens O
are O
described O
in O
74 O
patients O
with O
endometrial B-Disease
disease I-Disease
among O
850 O
climacteric O
women O
receiving O
oestrogen O
therapy O
. O

cystic O
hyperplasia B-Disease
was O
associated O
with O
unopposed O
oestrogen O
therapy O
without O
progestagen O
. O

two O
courses O
of O
21 O
days O
of O
5 O
mg O
norethisterone O
daily O
caused O
reversion O
to O
normal O
in O
all O
57 O
cases O
of O
cystic O
hyperplasia B-Disease
and O
6 O
of O
the O
8 O
cases O
of O
atypical O
hyperplasia B-Disease
. O

4 O
cases O
of O
endometrial B-Disease
carcinoma I-Disease
referred O
from O
elsewhere O
demonstrated O
the O
problems O
of O
inappropriate O
and O
unsupervised O
unopposed O
oestrogen O
therapy O
and O
the O
difficulty O
in O
distinguishing O
severe O
hyperplasia B-Disease
from O
malignancy B-Disease
. O

cyclical O
low O
- O
dose O
oestrogen O
therapy O
with O
7 O
- O
- O
13 O
days O
of O
progestagen O
does O
not O
seem O
to O
increase O
the O
risk O
of O
endometrial B-Disease
hyperplasia I-Disease
or O
carcinoma B-Disease
. O

effects O
of O
exercise O
on O
the O
severity O
of O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
. O

the O
effect O
of O
exercise O
on O
the O
severity O
of O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
was O
studied O
in O
male O
rats O
. O

ninety O
- O
three O
rats O
were O
randomly O
divided O
into O
three O
groups O
. O

the O
exercise O
- O
isoproterenol O
( O
e O
- O
1 O
) O
and O
exercise O
control O
( O
ec O
) O
groups O
exercised O
daily O
for O
thirty O
days O
on O
a O
treadmill O
at O
1 O
mph O
, O
2 O
% O
grade O
while O
animals O
of O
the O
sedentary O
- O
isoproterenol O
( O
s O
- O
i O
) O
group O
remained O
sedentary O
. O

eight O
animals O
were O
assigned O
to O
the O
sedentary O
control O
( O
sc O
) O
group O
which O
remained O
sedentary O
throughout O
the O
experimental O
period O
. O

forty O
- O
eight O
hours O
after O
the O
final O
exercise O
period O
, O
s O
- O
i O
and O
e O
- O
i O
animals O
received O
a O
single O
subcutaneous O
injection O
of O
isoproterenol O
( O
250 O
mg O
/ O
kg O
body O
weight O
) O
. O

animals O
of O
the O
s O
- O
i O
group O
exhibited O
significantly O
( O
pp O
less O
than O
0 O
. O
05 O
) O
greater O
mortality O
from O
the O
effects O
of O
isoproterenol O
than O
animals O
of O
the O
e O
- O
i O
group O
. O

serum O
cpk O
activity O
for O
e O
- O
i O
animals O
was O
significantly O
( O
p O
less O
than O
0 O
. O
05 O
) O
greater O
than O
for O
animals O
in O
the O
s O
- O
i O
and O
ec O
groups O
twenty O
hours O
following O
isoproterenol O
injection O
. O

no O
statistically O
significant O
differences O
were O
observed O
between O
the O
two O
isoproterenol O
treated O
groups O
for O
severity O
of O
the O
induced O
lesions O
, O
changes O
in O
heart O
weight O
, O
or O
heart O
weight O
to O
body O
weight O
ratios O
. O

the O
results O
indicated O
that O
exercise O
reduced O
the O
mortality O
associated O
with O
the O
effects O
of O
large O
dosages O
of O
isoproterenol O
but O
had O
little O
on O
the O
severity O
of O
the O
infarction B-Disease
. O

human O
corticotropin O
- O
releasing O
hormone O
and O
thyrotropin O
- O
releasing O
hormone O
modulate O
the O
hypercapnic B-Disease
ventilatory O
response O
in O
humans O
. O

human O
corticotropin O
- O
releasing O
hormone O
( O
hcrh O
) O
and O
thyrotropin O
- O
releasing O
hormone O
( O
trh O
) O
are O
known O
to O
stimulate O
ventilation O
after O
i O
. O
v O
. O
administration O
in O
humans O
. O

in O
a O
placebo O
- O
controlled O
, O
single O
- O
blind O
study O
we O
aimed O
to O
clarify O
if O
both O
peptides O
act O
by O
altering O
central O
chemosensitivity O
. O

two O
subsequent O
co2 O
- O
rebreathing O
tests O
were O
performed O
in O
healthy O
young O
volunteers O
. O

during O
the O
first O
test O
0 O
. O
9 O
% O
nacl O
was O
given O
i O
. O
v O
. O
; O
during O
the O
second O
test O
200 O
micrograms O
of O
hcrh O
( O
n O
= O
12 O
) O
or O
400 O
micrograms O
of O
trh O
( O
n O
= O
6 O
) O
was O
administered O
i O
. O
v O
. O
nine O
subjects O
received O
0 O
. O
9 O
% O
nacl O
i O
. O
v O
. O
during O
both O
rebreathing O
manoeuvres O
. O

the O
co2 O
- O
response O
curves O
for O
the O
two O
tests O
were O
compared O
within O
the O
same O
subject O
. O

in O
the O
hcrh O
group O
a O
marked O
parallel O
shift O
of O
the O
co2 O
- O
response O
curve O
to O
the O
left O
was O
observed O
after O
hcrh O
( O
p O
< O
0 O
. O
01 O
) O
. O

the O
same O
effect O
occurred O
following O
trh O
but O
was O
less O
striking O
( O
p O
= O
0 O
. O
05 O
) O
. O

hcrh O
and O
trh O
caused O
a O
reduction O
in O
the O
co2 O
threshold O
. O

the O
co2 O
- O
response O
curves O
in O
the O
control O
group O
were O
nearly O
identical O
. O

the O
results O
indicate O
an O
additive O
effect O
of O
both O
releasing O
hormones O
on O
the O
hypercapnic B-Disease
ventilatory O
response O
in O
humans O
, O
presumably O
independent O
of O
central O
chemosensitivity O
. O

lamivudine O
is O
effective O
in O
suppressing O
hepatitis B-Disease
b I-Disease
virus O
dna O
in O
chinese O
hepatitis O
b O
surface O
antigen O
carriers O
: O
a O
placebo O
- O
controlled O
trial O
. O

lamivudine O
is O
a O
novel O
2 O
' O
, O
3 O
' O
- O
dideoxy O
cytosine O
analogue O
that O
has O
potent O
inhibitory O
effects O
on O
hepatitis B-Disease
b I-Disease
virus O
replication O
in O
vitro O
and O
in O
vivo O
. O

we O
performed O
a O
single O
- O
blind O
, O
placebo O
- O
controlled O
study O
to O
assess O
its O
effectiveness O
and O
safety O
in O
chinese O
hepatitis O
b O
surface O
antigen O
( O
hbsag O
) O
carriers O
. O

forty O
- O
two O
chinese O
hbsag O
carriers O
were O
randomized O
to O
receive O
placebo O
( O
6 O
patients O
) O
or O
lamivudine O
orally O
in O
dosages O
of O
25 O
mg O
, O
100 O
mg O
, O
or O
300 O
mg O
daily O
( O
12 O
patients O
for O
each O
dosage O
) O
. O

the O
drug O
was O
given O
for O
4 O
weeks O
. O

the O
patients O
were O
closely O
monitored O
clinically O
, O
biochemically O
, O
and O
serologically O
up O
to O
4 O
weeks O
after O
drug O
treatment O
. O

all O
36 O
patients O
receiving O
lamivudine O
had O
a O
decrease O
in O
hepatitis B-Disease
b I-Disease
virus O
( O
hbv O
) O
dna O
values O
of O
> O
90 O
% O
( O
p O
< O
. O
001 O
compared O
with O
placebo O
) O
. O

although O
25 O
mg O
of O
lamivudine O
was O
slightly O
less O
effective O
than O
100 O
mg O
( O
p O
= O
. O
011 O
) O
and O
300 O
mg O
( O
p O
= O
. O
005 O
) O
, O
it O
still O
induced O
94 O
% O
suppression O
of O
hbv O
dna O
after O
the O
fourth O
week O
of O
therapy O
. O

hbv O
dna O
values O
returned O
to O
pretreatment O
levels O
within O
4 O
weeks O
of O
cessation O
of O
therapy O
. O

there O
was O
no O
change O
in O
the O
hepatitis B-Disease
b I-Disease
e O
antigen O
status O
or O
in O
aminotransferase O
levels O
. O

no O
serious O
adverse O
events O
were O
observed O
. O

in O
conclusion O
, O
a O
4 O
- O
week O
course O
of O
lamivudine O
was O
safe O
and O
effective O
in O
suppression O
of O
hbv O
dna O
in O
chinese O
hbsag O
carriers O
. O

the O
suppression O
was O
> O
90 O
% O
but O
reversible O
. O

studies O
with O
long O
- O
term O
lamivudine O
administration O
should O
be O
performed O
to O
determine O
if O
prolonged O
suppression O
of O
hbv O
dna O
can O
be O
achieved O
. O

population O
- O
based O
study O
of O
risk O
of O
venous B-Disease
thromboembolism I-Disease
associated O
with O
various O
oral O
contraceptives O
. O

background O
: O
four O
studies O
published O
since O
december O
, O
1995 O
, O
reported O
that O
the O
incidence O
of O
venous B-Disease
thromboembolism I-Disease
( O
vte B-Disease
) O
was O
higher O
in O
women O
who O
used O
oral O
contraceptives O
( O
ocs O
) O
containing O
the O
third O
- O
generation O
progestagens O
gestodene O
or O
desogestrel O
than O
in O
users O
of O
ocs O
containing O
second O
- O
generation O
progestagens O
. O

however O
, O
confounding O
and O
bias O
in O
the O
design O
of O
these O
studies O
may O
have O
affected O
the O
findings O
. O

the O
aim O
of O
our O
study O
was O
to O
re O
- O
examine O
the O
association O
between O
risk O
of O
vte B-Disease
and O
oc O
use O
with O
a O
different O
study O
design O
and O
analysis O
to O
avoid O
some O
of O
the O
bias O
and O
confounding O
of O
the O
earlier O
studies O
. O

methods O
: O
we O
used O
computer O
records O
of O
patients O
from O
143 O
general O
practices O
in O
the O
uk O
. O

the O
study O
was O
based O
on O
the O
medical O
records O
of O
about O
540 O
, O
000 O
women O
born O
between O
1941 O
and O
1981 O
. O

all O
women O
who O
had O
a O
recorded O
diagnosis O
of O
deep B-Disease
- I-Disease
vein I-Disease
thrombosis I-Disease
, O
venous B-Disease
thrombosis I-Disease
not O
otherwise O
specified O
, O
or O
pulmonary O
embolus O
during O
the O
study O
period O
, O
and O
who O
had O
been O
treated O
with O
an O
anticoagulant O
were O
identified O
as O
potential O
cases O
of O
vte B-Disease
. O

we O
did O
a O
cohort O
analysis O
to O
estimate O
and O
compare O
incidence O
of O
vte B-Disease
in O
users O
of O
the O
main O
oc O
preparations O
, O
and O
a O
nested O
case O
- O
control O
study O
to O
calculate O
the O
odds O
ratios O
of O
vte B-Disease
associated O
with O
use O
of O
different O
types O
of O
oc O
, O
after O
adjustment O
for O
potential O
confounding O
factors O
. O

in O
the O
case O
- O
control O
study O
, O
we O
matched O
cases O
to O
controls O
by O
exact O
year O
of O
birth O
, O
practice O
, O
and O
current O
use O
of O
ocs O
. O

we O
used O
a O
multiple O
logistic O
regression O
model O
that O
included O
body O
- O
mass O
index O
, O
number O
of O
cycles O
, O
change O
in O
type O
of O
oc O
prescribed O
within O
3 O
months O
of O
the O
event O
, O
previous O
pregnancy O
, O
and O
concurrent O
disease O
. O

findings O
: O
85 O
women O
met O
the O
inclusion O
criteria O
for O
vte B-Disease
, O
two O
of O
whom O
were O
users O
of O
progestagen O
- O
only O
ocs O
. O

of O
the O
83 O
cases O
of O
vte B-Disease
associated O
with O
use O
of O
combined O
ocs O
, O
43 O
were O
recorded O
as O
deep B-Disease
- I-Disease
vein I-Disease
thrombosis I-Disease
, O
35 O
as O
pulmonary O
thrombosis B-Disease
, O
and O
five O
as O
venous B-Disease
thrombosis I-Disease
not O
otherwise O
specified O
. O

the O
crude O
rate O
of O
vte B-Disease
per O
10 O
, O
000 O
woman O
- O
years O
was O
4 O
. O
10 O
in O
current O
users O
of O
any O
oc O
, O
3 O
. O
10 O
in O
users O
of O
second O
- O
generation O
ocs O
, O
and O
4 O
. O
96 O
in O
users O
of O
third O
- O
generation O
preparations O
. O

after O
adjustment O
for O
age O
, O
the O
rate O
ratio O
of O
vte B-Disease
in O
users O
of O
third O
- O
generation O
relative O
to O
second O
- O
generation O
ocs O
was O
1 O
. O
68 O
( O
95 O
% O
ci O
1 O
. O
04 O
- O
2 O
. O
75 O
) O
. O

logistic O
regression O
showed O
no O
significant O
difference O
in O
the O
risk O
of O
vte B-Disease
between O
users O
of O
third O
- O
generation O
and O
second O
- O
generation O
ocs O
. O

among O
users O
of O
third O
- O
generation O
progestagens O
, O
the O
risk O
of O
vte B-Disease
was O
higher O
in O
users O
of O
desogestrel O
with O
20 O
g O
ethinyloestradiol O
than O
in O
users O
of O
gestodene O
or O
desogestrel O
with O
30 O
g O
ethinyloestradiol O
. O

with O
all O
second O
- O
generation O
ocs O
as O
the O
reference O
, O
the O
odds O
ratios O
for O
vte B-Disease
were O
3 O
. O
49 O
( O
1 O
. O
21 O
- O
10 O
. O
12 O
) O
for O
desogestrel O
plus O
20 O
g O
ethinyloestradiol O
and O
1 O
. O
18 O
( O
0 O
. O
66 O
- O
2 O
. O
17 O
) O
for O
the O
other O
third O
- O
generation O
progestagens O
. O

interpretation O
: O
the O
previously O
reported O
increase O
in O
odds O
ratio O
associated O
with O
third O
- O
generation O
ocs O
when O
compared O
with O
second O
- O
generation O
products O
is O
likely O
to O
have O
been O
the O
result O
of O
residual O
confounding O
by O
age O
. O

the O
increased O
odds O
ratio O
associated O
with O
products O
containing O
20 O
micrograms O
ethinyloestradiol O
and O
desogestrel O
compared O
with O
the O
30 O
micrograms O
product O
is O
biologically O
implausible O
, O
and O
is O
likely O
to O
be O
the O
result O
of O
preferential O
prescribing O
and O
, O
thus O
, O
confounding O
. O

mk O
- O
801 O
augments O
pilocarpine O
- O
induced O
electrographic O
seizure B-Disease
but O
protects O
against O
brain B-Disease
damage I-Disease
in O
rats O
. O

1 O
. O

the O
authors O
examined O
the O
anticonvulsant O
effects O
of O
mk O
- O
801 O
on O
the O
pilocarpine O
- O
induced O
seizure B-Disease
model O
. O

intraperitoneal O
injection O
of O
pilocarpine O
( O
400 O
mg O
/ O
kg O
) O
induced O
tonic B-Disease
and I-Disease
clonic I-Disease
seizure I-Disease
. O

scopolamine O
( O
10 O
mg O
/ O
kg O
) O
and O
pentobarbital O
( O
5 O
mg O
/ O
kg O
) O
prevented O
development O
of O
pilocarpine O
- O
induced O
behavioral O
seizure B-Disease
but O
mk O
- O
801 O
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
did O
not O
. O

2 O
. O

an O
electrical O
seizure B-Disease
measured O
with O
hippocampal O
eeg O
appeared O
in O
the O
pilocarpine O
- O
treated O
group O
. O

scopolamine O
and O
pentobarbital O
blocked O
the O
pilocarpine O
- O
induced O
electrographic O
seizure B-Disease
, O
mk O
- O
801 O
treatment O
augmented O
the O
electrographic O
seizure B-Disease
induced O
by O
pilocarpine O
. O

3 O
. O

brain B-Disease
damage I-Disease
was O
assessed O
by O
examining O
the O
hippocampus O
microscopically O
. O

pilocarpine O
produced O
neuronal B-Disease
death I-Disease
in O
the O
hippocampus O
, O
which O
showed O
pyknotic O
changes O
. O

pentobarbital O
, O
scopolamine O
and O
mk O
- O
801 O
protected O
the O
brain B-Disease
damage I-Disease
by O
pilocarpine O
, O
though O
in O
the O
mk O
- O
801 O
- O
treated O
group O
, O
the O
pyramidal O
cells O
of O
hippocampus O
appeared O
darker O
than O
normal O
. O

in O
all O
treatments O
, O
granule O
cells O
of O
the O
dentate O
gyrus O
were O
not O
affected O
. O

4 O
. O

these O
results O
indicate O
that O
status B-Disease
epilepticus I-Disease
induced O
by O
pilocarpine O
is O
initiated O
by O
cholinergic O
overstimulation O
and O
propagated O
by O
glutamatergic O
transmission O
, O
the O
elevation O
of O
which O
may O
cause O
brain B-Disease
damage I-Disease
through O
an O
excitatory O
nmda O
receptor O
- O
mediated O
mechanism O
. O

paclitaxel O
, O
5 O
- O
fluorouracil O
, O
and O
folinic O
acid O
in O
metastatic O
breast B-Disease
cancer I-Disease
: O
bre O
- O
26 O
, O
a O
phase O
ii O
trial O
. O

5 O
- O
fluorouracil O
plus O
folinic O
acid O
and O
paclitaxel O
( O
taxol O
; O
bristol O
- O
myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
are O
effective O
salvage O
therapies O
for O
metastatic O
breast B-Disease
cancer I-Disease
patients O
. O

paclitaxel O
and O
5 O
- O
fluorouracil O
have O
additive O
cytotoxicity B-Disease
in O
mcf O
- O
7 O
cell O
lines O
. O

we O
performed O
a O
phase O
ii O
trial O
of O
paclitaxel O
175 O
mg O
/ O
m2 O
over O
3 O
hours O
on O
day O
i O
followed O
by O
folinic O
acid O
300 O
mg O
over O
1 O
hour O
before O
5 O
- O
fluorouracil O
350 O
mg O
/ O
m2 O
on O
days O
1 O
to O
3 O
every O
28 O
days O
( O
tfl O
) O
in O
women O
with O
metastatic O
breast B-Disease
cancer I-Disease
. O

analysis O
is O
reported O
on O
37 O
patients O
with O
a O
minimum O
of O
6 O
months O
follow O
- O
up O
who O
received O
a O
total O
of O
192 O
cycles O
of O
tfl O
: O
nine O
cycles O
( O
5 O
% O
) O
were O
associated O
with O
grade O
3 O
/ O
4 O
neutropenia B-Disease
requiring O
hospitalization O
; O
seven O
( O
4 O
% O
) O
cycles O
in O
two O
patients O
required O
granulocyte O
colony O
- O
stimulating O
factor O
due O
to O
neutropenia B-Disease
; O
no O
patient O
required O
platelet O
transfusions O
. O

grade O
3 O
/ O
4 O
nonhematologic O
toxicities B-Disease
were O
uncommon O
. O

among O
the O
34 O
patients O
evaluable O
for O
response O
, O
there O
were O
three O
complete O
responses O
( O
9 O
% O
) O
and O
18 O
partial O
responses O
( O
53 O
% O
) O
for O
an O
overall O
response O
rate O
of O
62 O
% O
. O

of O
the O
19 O
evaluable O
patients O
with O
prior O
doxorubicin O
exposure O
, O
11 O
( O
58 O
% O
) O
responded O
compared O
with O
nine O
of O
15 O
( O
60 O
% O
) O
without O
prior O
doxorubicin O
. O

plasma O
paclitaxel O
concentrations O
were O
measured O
at O
the O
completion O
of O
paclitaxel O
infusion O
and O
at O
24 O
hours O
in O
19 O
patients O
. O

tfl O
is O
an O
active O
, O
well O
- O
tolerated O
regimen O
in O
metastatic O
breast B-Disease
cancer I-Disease
. O

efficacy O
and O
proarrhythmia B-Disease
with O
the O
use O
of O
d O
, O
l O
- O
sotalol O
for O
sustained O
ventricular B-Disease
tachyarrhythmias I-Disease
. O

this O
study O
prospectively O
evaluated O
the O
clinical O
efficacy O
, O
the O
incidence O
of O
torsades B-Disease
de I-Disease
pointes I-Disease
, O
and O
the O
presumable O
risk O
factors O
for O
torsades B-Disease
de I-Disease
pointes I-Disease
in O
patients O
treated O
with O
d O
, O
l O
- O
sotalol O
for O
sustained O
ventricular B-Disease
tachyarrhythmias I-Disease
. O

eighty O
- O
one O
consecutive O
patients O
( O
54 O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
and O
20 O
with O
dilated B-Disease
cardiomyopathy I-Disease
) O
with O
inducible O
sustained O
ventricular B-Disease
tachycardia I-Disease
or O
ventricular B-Disease
fibrillation I-Disease
received O
oral O
d O
, O
l O
- O
sotalol O
to O
prevent O
induction O
of O
the O
ventricular B-Disease
tachyarrhythmia I-Disease
. O

during O
oral O
loading O
with O
d O
, O
l O
- O
sotalol O
, O
continuous O
electrocardiographic O
( O
ecg O
) O
monitoring O
was O
performed O
. O

those O
patients O
in O
whom O
d O
, O
l O
- O
sotalol O
prevented O
induction O
of O
ventricular B-Disease
tachycardia I-Disease
or O
ventricular B-Disease
fibrillation I-Disease
were O
discharged O
with O
the O
drug O
and O
followed O
up O
on O
an O
outpatient O
basis O
for O
21 O
+ O
/ O
- O
18 O
months O
. O

induction O
of O
the O
ventricular B-Disease
tachyarrhythmia I-Disease
was O
prevented O
by O
oral O
d O
, O
l O
- O
sotalol O
in O
35 O
( O
43 O
% O
) O
patients O
; O
the O
ventricular B-Disease
tachyarrhythmia I-Disease
remained O
inducible O
in O
40 O
( O
49 O
% O
) O
patients O
; O
and O
two O
( O
2 O
. O
5 O
% O
) O
patients O
did O
not O
tolerate O
even O
40 O
mg O
of O
d O
, O
l O
- O
sotalol O
once O
daily O
. O

four O
( O
5 O
% O
) O
patients O
had O
from O
torsades B-Disease
de I-Disease
pointes I-Disease
during O
the O
initial O
oral O
treatment O
with O
d O
, O
l O
- O
sotalol O
. O

neither O
ecg O
[ O
sinus O
- O
cycle O
length O
( O
scl O
) O
, O
qt O
or O
qtc O
interval O
, O
or O
u O
wave O
] O
nor O
clinical O
parameters O
identified O
patients O
at O
risk O
for O
torsades B-Disease
de I-Disease
pointes I-Disease
. O

however O
, O
the O
oral O
dose O
of O
d O
, O
l O
- O
sotalol O
was O
significantly O
lower O
in O
patients O
with O
torsades B-Disease
de I-Disease
pointes I-Disease
( O
200 O
+ O
/ O
- O
46 O
vs O
. O
328 O
+ O
/ O
- O
53 O
mg O
/ O
day O
; O
p O
= O
0 O
. O
0017 O
) O
. O

risk O
factors O
associated O
with O
the O
development O
of O
torsades B-Disease
de I-Disease
pointes I-Disease
were O
the O
appearance O
of O
an O
u O
wave O
( O
p O
= O
0 O
. O
049 O
) O
, O
female O
gender O
( O
p O
= O
0 O
. O
015 O
) O
, O
and O
significant O
dose O
- O
corrected O
changes O
of O
scl O
, O
qt O
interval O
, O
and O
qtc O
interval O
( O
p O
< O
0 O
. O
05 O
) O
. O

during O
follow O
- O
up O
, O
seven O
( O
20 O
% O
) O
patients O
had O
a O
nonfatal O
ventricular B-Disease
tachycardia I-Disease
recurrence O
, O
and O
two O
( O
6 O
% O
) O
patients O
died O
suddenly O
. O

one O
female O
patient O
with O
stable O
cardiac B-Disease
disease I-Disease
had O
recurrent O
torsades B-Disease
de I-Disease
pointes I-Disease
after O
2 O
years O
of O
successful O
treatment O
with O
d O
, O
l O
- O
sotalol O
. O

torsades B-Disease
de I-Disease
pointes I-Disease
occurred O
early O
during O
treatment O
even O
with O
low O
doses O
of O
oral O
d O
, O
l O
- O
sotalol O
. O

pronounced O
changes O
in O
the O
surface O
ecg O
( O
cycle O
length O
, O
qt O
, O
and O
qtc O
) O
in O
relation O
to O
the O
dose O
of O
oral O
d O
, O
l O
- O
sotalol O
might O
identify O
a O
subgroup O
of O
patients O
with O
an O
increased O
risk O
for O
torsades B-Disease
de I-Disease
pointes I-Disease
. O

other O
ecg O
parameters O
before O
the O
application O
of O
d O
, O
l O
- O
sotalol O
did O
not O
identify O
patients O
at O
increased O
risk O
for O
torsades B-Disease
de I-Disease
pointes I-Disease
. O

recurrence O
rates O
of O
ventricular B-Disease
tachyarrhythmias I-Disease
are O
high O
despite O
complete O
suppression O
of O
the O
arrhythmia B-Disease
during O
programmed O
stimulation O
. O

therefore O
programmed O
electrical O
stimulation O
in O
the O
case O
of O
d O
, O
l O
- O
sotalol O
seems O
to O
be O
of O
limited O
prognostic O
value O
. O

chronic O
hyperprolactinemia B-Disease
and O
changes O
in O
dopamine O
neurons O
. O

the O
tuberoinfundibular O
dopaminergic O
( O
tida O
) O
system O
is O
known O
to O
inhibit O
prolactin O
( O
prl O
) O
secretion O
. O

in O
young O
animals O
this O
system O
responds O
to O
acute O
elevations O
in O
serum O
prl O
by O
increasing O
its O
activity O
. O

however O
, O
this O
responsiveness O
is O
lost O
in O
aging O
rats O
with O
chronically O
high O
serum O
prl O
levels O
. O

the O
purpose O
of O
this O
study O
was O
to O
induce O
hyperprolactinemia B-Disease
in O
rats O
for O
extended O
periods O
of O
time O
and O
examine O
its O
effects O
on O
dopaminergic O
systems O
in O
the O
brain O
. O

hyperprolactinemia B-Disease
was O
induced O
by O
treatment O
with O
haloperidol O
, O
a O
dopamine O
receptor O
antagonist O
, O
and O
palkovits O
' O
microdissection O
technique O
in O
combination O
with O
high O
- O
performance O
liquid O
chromatography O
was O
used O
to O
measure O
neurotransmitter O
concentrations O
in O
several O
areas O
of O
the O
brain O
. O

after O
6 O
months O
of O
hyperprolactinemia B-Disease
, O
dopamine O
( O
da O
) O
concentrations O
in O
the O
median O
eminence O
( O
me O
) O
increased O
by O
84 O
% O
over O
the O
control O
group O
. O

nine O
months O
of O
hyperprolactinemia B-Disease
produced O
a O
50 O
% O
increase O
in O
da O
concentrations O
in O
the O
me O
over O
the O
control O
group O
. O

however O
, O
da O
response O
was O
lost O
if O
a O
9 O
- O
month O
long O
haloperidol O
- O
induced O
hyperprolactinemia B-Disease
was O
followed O
by O
a O
1 O
1 O
/ O
2 O
month O
- O
long O
extremely O
high O
increase O
in O
serum O
prl O
levels O
produced O
by O
implantation O
of O
mmq O
cells O
under O
the O
kidney O
capsule O
. O

there O
was O
no O
change O
in O
the O
levels O
of O
da O
, O
norepinephrine O
( O
ne O
) O
, O
serotonin O
( O
5 O
- O
ht O
) O
, O
or O
their O
metabolites O
in O
the O
arcuate O
nucleus O
( O
an O
) O
, O
medial O
preoptic O
area O
( O
mpa O
) O
, O
caudate O
putamen O
( O
cp O
) O
, O
substantia O
nigra O
( O
sn O
) O
, O
and O
zona O
incerta O
( O
zi O
) O
, O
except O
for O
a O
decrease O
in O
5 O
- O
hydroxyindoleacetic O
acid O
( O
5 O
- O
hiaa O
) O
in O
the O
an O
after O
6 O
- O
months O
of O
hyperprolactinemia B-Disease
and O
an O
increase O
in O
da O
concentrations O
in O
the O
an O

after O
9 O
- O
months O
of O
hyperprolactinemia B-Disease
. O

these O
results O
demonstrate O
that O
hyperprolactinemia B-Disease
specifically O
affects O
tida O
neurons O
and O
these O
effects O
vary O
, O
depending O
on O
the O
duration O
and O
intensity O
of O
hyperprolactinemia B-Disease
. O

the O
age O
- O
related O
decrease O
in O
hypothalamic O
dopamine O
function O
may O
be O
associated O
with O
increases O
in O
prl O
secretion O
. O

treatment O
- O
related O
disseminated O
necrotizing O
leukoencephalopathy B-Disease
with O
characteristic O
contrast O
enhancement O
of O
the O
white O
matter O
. O

this O
report O
describes O
unique O
contrast O
enhancement O
of O
the O
white O
matter O
on O
t1 O
- O
weighted O
magnetic O
resonance O
images O
of O
two O
patients O
with O
disseminated O
necrotizing O
leukoencephalopathy B-Disease
, O
which O
developed O
from O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
treated O
with O
high O
- O
dose O
methotrexate O
. O

in O
both O
patients O
, O
the O
enhancement O
was O
more O
pronounced O
near O
the O
base O
of O
the O
brain O
than O
at O
the O
vertex O
. O

necropsy O
of O
the O
first O
case O
revealed O
loss B-Disease
of I-Disease
myelination I-Disease
and O
necrosis B-Disease
of O
the O
white O
matter O
. O

possible O
mechanisms O
causing O
such O
a O
leukoencephalopathy B-Disease
are O
discussed O
. O

thrombotic B-Disease
complications O
in O
acute B-Disease
promyelocytic I-Disease
leukemia I-Disease
during O
all O
- O
trans O
- O
retinoic O
acid O
therapy O
. O

a O
case O
of O
acute B-Disease
renal I-Disease
failure I-Disease
, O
due O
to O
occlusion B-Disease
of I-Disease
renal I-Disease
vessels I-Disease
in O
a O
patient O
with O
acute B-Disease
promyelocytic I-Disease
leukemia I-Disease
( O
apl B-Disease
) O
treated O
with O
all O
- O
trans O
- O
retinoic O
acid O
( O
atra O
) O
and O
tranexamic O
acid O
has O
been O
described O
recently O
. O

we O
report O
a O
case O
of O
acute B-Disease
renal I-Disease
failure I-Disease
in O
an O
apl B-Disease
patient O
treated O
with O
atra O
alone O
. O

this O
case O
further O
supports O
the O
concern O
about O
thromboembolic B-Disease
complications O
associated O
with O
atra O
therapy O
in O
apl B-Disease
patients O
. O

the O
patients O
, O
a O
43 O
- O
year O
- O
old O
man O
, O
presented O
all O
the O
signs O
and O
symptoms O
of O
apl B-Disease
and O
was O
included O
in O
a O
treatment O
protocol O
with O
atra O
. O

after O
10 O
days O
of O
treatment O
, O
he O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
that O
was O
completely O
reversible O
after O
complete O
remission O
of O
apl B-Disease
was O
achieved O
and O
therapy O
discontinued O
. O

we O
conclude O
that O
atra O
is O
a O
valid O
therapeutic O
choice O
for O
patients O
with O
apl B-Disease
, O
although O
the O
procoagulant O
tendency O
is O
not O
completely O
corrected O
. O

thrombotic B-Disease
events O
, O
however O
, O
could O
be O
avoided O
by O
using O
low O
- O
dose O
heparin O
. O

pupillary O
changes O
associated O
with O
the O
development O
of O
stimulant O
- O
induced O
mania B-Disease
: O
a O
case O
report O
. O

a O
30 O
- O
year O
- O
old O
cocaine O
- O
dependent O
man O
who O
was O
a O
subject O
in O
a O
study O
evaluating O
the O
anticraving O
efficacy O
of O
the O
stimulant O
medication O
diethylpropion O
( O
dep O
) O
became O
manic B-Disease
during O
his O
second O
week O
on O
the O
study O
drug O
. O

pupillometric O
changes O
while O
on O
dep O
, O
especially O
changes O
in O
the O
total O
power O
of O
pupillary B-Disease
oscillation I-Disease
, O
were O
dramatically O
different O
than O
those O
observed O
in O
the O
eight O
other O
study O
subjects O
who O
did O
not O
become O
manic B-Disease
. O

the O
large O
changes O
in O
total O
power O
of O
pupillary B-Disease
oscillation I-Disease
occurred O
a O
few O
days O
before O
the O
patient O
became O
fully O
manic B-Disease
. O

such O
medication O
- O
associated O
changes O
in O
the O
total O
power O
of O
pupillary B-Disease
oscillation I-Disease
might O
be O
of O
utility O
in O
identifying O
persons O
at O
risk O
for O
manic B-Disease
- O
like O
adverse O
effects O
during O
the O
medical O
use O
of O
psychomotor O
stimulants O
or O
sympathomimetic O
agents O
. O

fetal O
risks O
due O
to O
warfarin O
therapy O
during O
pregnancy O
. O

two O
mothers O
with O
heart O
valve O
prosthesis O
were O
treated O
with O
warfarin O
during O
pregnancy O
. O

in O
the O
first O
case O
a O
caesarean O
section O
was O
done O
one O
week O
after O
replacement O
of O
warfarin O
with O
heparin O
. O

the O
baby O
died O
of O
cerebral B-Disease
and I-Disease
pulmonary I-Disease
hemorrhage I-Disease
. O

the O
second O
mother O
had O
a O
male O
infant O
by O
caesarean O
section O
. O

the O
baby O
showed O
warfarin O
- O
induced O
embryopathy B-Disease
with O
nasal B-Disease
hypoplasia I-Disease
and O
stippled B-Disease
epiphyses I-Disease
( O
chondrodysplasia B-Disease
punctata I-Disease
) O
. O

nasal B-Disease
hypoplasia I-Disease
with O
or O
without O
stippled B-Disease
epiphyses I-Disease
has O
now O
been O
reported O
in O
11 O
infants O
born O
to O
mothers O
treated O
with O
warfarin O
during O
the O
first O
trimester O
, O
and O
a O
causal O
association O
is O
probable O
. O

in O
view O
of O
the O
risks O
to O
both O
mother O
and O
fetus O
in O
women O
with O
prosthetic O
cardiac O
valves O
it O
is O
recommended O
that O
therapeutic O
abortion O
be O
advised O
as O
the O
first O
alternative O
. O

the O
negative O
mucosal O
potential O
: O
separating O
central O
and O
peripheral O
effects O
of O
nsaids O
in O
man O
. O

objective O
: O
we O
wanted O
to O
test O
whether O
assessment O
of O
both O
a O
central O
pain B-Disease
- O
related O
signal O
( O
chemo O
- O
somatosensory O
evoked O
potential O
, O
cssep O
) O
and O
a O
concomitantly O
recorded O
peripheral O
signal O
( O
negative O
mucosal O
potential O
, O
nmp O
) O
allows O
for O
separation O
of O
central O
and O
peripheral O
effects O
of O
nsaids O
. O

for O
this O
purpose O
, O
experimental O
conditions O
were O
created O
in O
which O
nsaids O
had O
previously O
been O
observed O
to O
produce O
effects O
on O
phasic O
and O
tonic O
pain B-Disease
by O
either O
central O
or O
peripheral O
mechanisms O
. O

methods O
: O
according O
to O
a O
double O
- O
blind O
, O
randomised O
, O
controlled O
, O
threefold O
cross O
- O
over O
design O
, O
18 O
healthy O
subjects O
( O
11 O
males O
, O
7 O
females O
; O
mean O
age O
26 O
years O
) O
received O
either O
placebo O
, O
400 O
mg O
ibuprofen O
, O
or O
800 O
mg O
ibuprofen O
. O

phasic O
pain B-Disease
was O
applied O
by O
means O
of O
short O
pulses O
of O
co2 O
to O
the O
nasal O
mucosa O
( O
stimulus O
duration O
500 O
ms O
, O
interval O
approximately O
60 O
s O
) O
, O
and O
tonic O
pain B-Disease
was O
induced O
in O
the O
nasal O
cavity O
by O
means O
of O
dry O
air O
of O
controlled O
temperature O
, O
humidity O
and O
flow O
rate O
( O
22 O
degrees O
c O
, O
0 O
% O
relative O
humidity O
, O
145 O
ml O
. O
s O
- O
1 O
) O
. O

both O
csseps O
as O
central O
and O
nmps O
as O
peripheral O
correlates O
of O
pain B-Disease
were O
obtained O
in O
response O
to O
the O
co2 O
stimuli O
. O

additionally O
, O
the O
subjects O
rated O
the O
intensity O
of O
both O
phasic O
and O
tonic O
pain B-Disease
by O
means O
of O
visual O
analogue O
scales O
. O

results O
: O
as O
described O
earlier O
, O
administration O
of O
ibuprofen O
was O
followed O
by O
a O
decrease O
in O
tonic O
pain B-Disease
but O
- O
relative O
to O
placebo O
- O
an O
increase O
in O
correlates O
of O
phasic O
pain B-Disease
, O
indicating O
a O
specific O
effect O
of O
ibuprofen O
on O
the O
interaction O
between O
the O
pain B-Disease
stimuli O
under O
these O
special O
experimental O
conditions O
. O

based O
on O
the O
similar O
behaviour O
of O
cssep O
and O
nmp O
, O
it O
was O
concluded O
that O
the O
pharmacological O
process O
underlying O
this O
phenomenon O
was O
localised O
in O
the O
periphery O
. O

by O
means O
of O
the O
simultaneous O
recording O
of O
interrelated O
peripheral O
and O
central O
electrophysiologic O
correlates O
of O
nociception O
, O
it O
was O
possible O
to O
separate O
central O
and O
peripheral O
effects O
of O
an O
nsaid O
. O

the O
major O
advantage O
of O
this O
pain B-Disease
model O
is O
the O
possibility O
of O
obtaining O
peripheral O
pain B-Disease
- O
related O
activity O
directly O
using O
a O
non O
- O
invasive O
technique O
in O
humans O
. O

effect O
of O
d O
- O
glucarates O
on O
basic O
antibiotic O
- O
induced O
renal B-Disease
damage I-Disease
in O
rats O
. O

dehydrated B-Disease
rats O
regularly O
develop O
acute B-Disease
renal I-Disease
failure I-Disease
following O
single O
injection O
of O
aminoglycoside O
antibiotics O
combined O
with O
dextran O
or O
of O
antibiotics O
only O
. O

oral O
administration O
of O
2 O
, O
5 O
- O
di O
- O
o O
- O
acetyl O
- O
d O
- O
glucaro O
- O
1 O
, O
4 O
- O
6 O
, O
3 O
- O
dilactone O
protected O
rats O
against O
renal B-Disease
failure I-Disease
induced O
by O
kanamycin O
- O
dextran O
. O

the O
protective O
effect O
was O
prevalent O
among O
d O
- O
glucarates O
, O
and O
also O
to O
other O
saccharic O
acid O
, O
hexauronic O
acids O
and O
hexaaldonic O
acids O
, O
although O
to O
a O
lesser O
degree O
, O
but O
not O
to O
a O
hexaaldose O
, O
sugar O
alcohols O
, O
substances O
inthe O
tca O
cycle O
and O
other O
acidic O
compounds O
. O

d O
- O
glucarates O
were O
effective O
against O
renal B-Disease
damage I-Disease
induced O
by O
peptide O
antibiotics O
as O
well O
as O
various O
aminoglycoside O
antibitocis O
. O

dose O
- O
responses O
were O
observed O
in O
the O
protective O
effect O
of O
d O
- O
glucarates O
. O

with O
a O
d O
- O
glucarate O
of O
a O
fixed O
size O
of O
dose O
, O
approximately O
the O
same O
degree O
of O
protection O
was O
obtained O
against O
renal B-Disease
damages I-Disease
induced O
by O
different O
basic O
antibiotics O
despite O
large O
disparities O
in O
administration O
doses O
of O
different O
antibiotics O
. O

d O
- O
glucarates O
had O
the O
ability O
to O
prevent O
renal B-Disease
damage I-Disease
but O
not O
to O
cure O
it O
. O

rats O
excreted O
acidic O
urine O
when O
they O
were O
spared O
from O
renal B-Disease
lesions I-Disease
by O
monosaccharides O
. O

the O
reduction O
effect O
of O
d O
- O
glucarates O
against O
nephrotoxicity B-Disease
of O
basic O
antibiotics O
was O
discussed O
. O

acute O
severe O
depression B-Disease
following O
peri O
- O
operative O
ondansetron O
. O

a O
41 O
- O
year O
- O
old O
woman O
with O
a O
strong O
history O
of O
postoperative B-Disease
nausea I-Disease
and I-Disease
vomiting I-Disease
presented O
for O
abdominal O
hysterectomy O
3 O
months O
after O
a O
previous O
anaesthetic O
where O
ondansetron O
prophylaxis O
had O
been O
used O
. O

she O
had O
developed O
a O
severe O
acute O
major B-Disease
depression I-Disease
disorder I-Disease
almost O
immediately O
thereafter O
, O
possibly O
related O
to O
the O
use O
of O
a O
serotonin O
antagonist O
. O

nine O
years O
before O
she O
had O
experienced O
a O
self O
- O
limited O
puerperal O
depressive B-Disease
episode I-Disease
. O

anaesthesia O
with O
a O
propofol O
infusion O
and O
avoidance O
of O
serotonin O
antagonists O
provided O
a O
nausea B-Disease
- O
free O
postoperative O
course O
without O
exacerbation O
of O
the O
depression B-Disease
disorder I-Disease
. O

hypertensive B-Disease
response O
during O
dobutamine O
stress O
echocardiography O
. O

among O
3 O
, O
129 O
dobutamine O
stress O
echocardiographic O
studies O
, O
a O
hypertensive B-Disease
response O
, O
defined O
as O
systolic O
blood O
pressure O
( O
bp O
) O
> O
or O
= O
220 O
mm O
hg O
and O
/ O
or O
diastolic O
bp O
> O
or O
= O
110 O
mm O
hg O
, O
occurred O
in O
30 O
patients O
( O
1 O
% O
) O
. O

patients O
with O
this O
response O
more O
often O
had O
a O
history O
of O
hypertension B-Disease
and O
had O
higher O
resting O
systolic O
and O
diastolic O
bp O
before O
dobutamine O
infusion O
. O

continuously O
nebulized O
albuterol O
in O
severe O
exacerbations O
of O
asthma B-Disease
in O
adults O
: O
a O
case O
- O
controlled O
study O
. O

a O
retrospective O
, O
case O
- O
controlled O
analysis O
comparing O
patients O
admitted O
to O
a O
medical O
intensive O
care O
unit O
with O
severe O
exacerbations O
of O
asthma B-Disease
who O
received O
continuously O
nebulized O
albuterol O
( O
cna O
) O
versus O
intermittent O
albuterol O
( O
ina O
) O
treatments O
is O
reported O
. O

forty O
matched O
pairs O
of O
patients O
with O
asthma B-Disease
are O
compared O
. O

cna O
was O
administered O
for O
a O
mean O
of O
11 O
+ O
/ O
- O
10 O
hr O
. O

the O
incidence O
of O
cardiac B-Disease
dysrhythmias I-Disease
was O
similar O
between O
groups O
. O

symptomatic O
hypokalemia B-Disease
did O
not O
occur O
. O

cna O
patients O
had O
higher O
heart O
rates O
during O
treatment O
, O
which O
may O
reflect O
severity O
of O
illness O
. O

the O
incidence O
of O
intubation O
was O
similar O
. O

we O
conclude O
that O
cna O
and O
ina O
demonstrated O
similar O
profiles O
with O
regard O
to O
safety O
, O
morbidity O
, O
and O
mortality O
. O

paraplegia B-Disease
following O
intrathecal O
methotrexate O
: O
report O
of O
a O
case O
and O
review O
of O
the O
literature O
. O

a O
patient O
who O
developed O
paraplegia B-Disease
following O
the O
intrathecal O
instillation O
of O
methotrexate O
is O
discribed O
. O

the O
ten O
previously O
reported O
cases O
of O
this O
unusual O
complication O
are O
reviewed O
. O

the O
following O
factors O
appear O
to O
predispose O
to O
the O
development O
of O
this O
complication O
: O
abnormal O
cerebrospinal O
dynamics O
related O
to O
the O
presence O
of O
central B-Disease
nervous I-Disease
system I-Disease
leukemia I-Disease
, O
and O
epidural O
cerebrospinal O
leakage O
; O
elevated O
cerebrospinal O
fluid O
methothexate O
concentration O
related O
to O
abnormal O
cerebrospinal O
fluid O
dynamics O
and O
to O
inappropriately O
high O
methotrexate O
doses O
based O
on O
body O
surface O
area O
calculations O
in O
older O
children O
and O
adults O
; O
the O
presence O
of O
neurotoxic B-Disease
preservatives O
in O
commercially O
available O
methotrexate O
preparations O
and O
diluents O
; O
and O
the O
use O

of O
methotrexate O
diluents O
of O
unphysiologic O
ph O
, O
ionic O
content O
and O
osmolarity O
. O

the O
role O
of O
methotrexate O
contaminants O
, O
local O
folate B-Disease
deficiency I-Disease
, O
and O
cranial O
irradiation O
in O
the O
pathogenesis O
of O
intrathecal O
methotrexate O
toxicity B-Disease
is O
unclear O
. O

the O
incidence O
of O
neurotoxicity B-Disease
may O
be O
reduced O
by O
employing O
lower O
doses O
of O
methotrexate O
in O
the O
presence O
of O
central B-Disease
nervous I-Disease
system I-Disease
leukemia I-Disease
, O
in O
older O
children O
and O
adults O
, O
and O
in O
the O
presence O
of O
epidural O
leakage O
. O

only O
preservative O
- O
free O
methotrexate O
in O
elliott O
' O
s O
b O
solution O
at O
a O
concentration O
of O
not O
more O
than O
1 O
mg O
/ O
ml O
should O
be O
used O
for O
intrathecal O
administration O
. O

periodic O
monitoring O
of O
cerebruspinal O
fluid O
methotrexate O
levels O
may O
be O
predictive O
of O
the O
development O
of O
serious O
neurotoxicity B-Disease
. O

hyperosmolar B-Disease
nonketotic I-Disease
coma I-Disease
precipitated O
by O
lithium O
- O
induced O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
. O

a O
45 O
- O
year O
- O
old O
man O
, O
with O
a O
10 O
- O
year O
history O
of O
manic B-Disease
depression I-Disease
treated O
with O
lithium O
, O
was O
admitted O
with O
hyperosmolar B-Disease
, I-Disease
nonketotic I-Disease
coma I-Disease
. O

he O
gave O
a O
five O
- O
year O
history O
of O
polyuria B-Disease
and O
polydipsia B-Disease
, O
during O
which O
time O
urinalysis O
had O
been O
negative O
for O
glucose O
. O

after O
recovery O
from O
hyperglycaemia B-Disease
, O
he O
remained O
polyuric B-Disease
despite O
normal O
blood O
glucose O
concentrations O
; O
water O
deprivation O
testing O
indicated O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
, O
likely O
to O
be O
lithium O
- O
induced O
. O

we O
hypothesize O
that O
when O
this O
man O
developed O
type B-Disease
2 I-Disease
diabetes I-Disease
, O
chronic O
polyuria B-Disease
due O
to O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
was O
sufficient O
to O
precipitate O
hyperosmolar O
dehydration B-Disease
. O

effects O
of O
the O
intracoronary O
infusion O
of O
cocaine O
on O
left O
ventricular O
systolic O
and O
diastolic O
function O
in O
humans O
. O

background O
: O
in O
dogs O
, O
a O
large O
amount O
of O
intravenous O
cocaine O
causes O
a O
profound O
deterioration B-Disease
of I-Disease
left I-Disease
ventricular I-Disease
( I-Disease
lv I-Disease
) I-Disease
systolic I-Disease
function I-Disease
and O
an O
increase O
in O
lv O
end O
- O
diastolic O
pressure O
. O

this O
study O
was O
done O
to O
assess O
the O
influence O
of O
a O
high O
intracoronary O
cocaine O
concentration O
on O
lv O
systolic O
and O
diastolic O
function O
in O
humans O
. O

methods O
and O
results O
: O
in O
20 O
patients O
( O
14 O
men O
and O
6 O
women O
aged O
39 O
to O
72 O
years O
) O
referred O
for O
cardiac O
catheterization O
for O
the O
evaluation O
of O
chest B-Disease
pain I-Disease
, O
we O
measured O
heart O
rate O
, O
systemic O
arterial O
pressure O
, O
lv O
pressure O
and O
its O
first O
derivative O
( O
dp O
/ O
dt O
) O
, O
and O
lv O
volumes O
and O
ejection O
fraction O
before O
and O
during O
the O
final O
2 O
to O
3 O
minutes O
of O
a O
15 O
- O
minute O
intracoronary O
infusion O
of O
saline O
( O
n O
= O
10 O
, O
control O
subjects O
) O
or O
cocaine O
hydrochloride O
1 O
mg O
/ O
min O
( O
n O
= O
10 O
) O
. O

no O
variable O
changed O
with O
saline O
. O

with O
cocaine O
, O
the O
drug O
concentration O
in O
blood O
obtained O
from O
the O
coronary O
sinus O
was O
3 O
. O
0 O
+ O
/ O
- O
0 O
. O
4 O
( O
mean O
+ O
/ O
- O
sd O
) O
mg O
/ O
l O
, O
similar O
in O
magnitude O
to O
the O
blood O
cocaine O
concentration O
reported O
in O
abusers O
dying O
of O
cocaine O
intoxication O
. O

cocaine O
induced O
no O
significant O
change O
in O
heart O
rate O
, O
lv O
dp O
/ O
dt O
( O
positive O
or O
negative O
) O
, O
or O
lv O
end O
- O
diastolic O
volume O
, O
but O
it O
caused O
an O
increase O
in O
systolic O
and O
mean O
arterial O
pressures O
, O
lv O
end O
- O
diastolic O
pressure O
, O
and O
lv O
end O
- O
systolic O
volume O
, O
as O
well O
as O
a O
decrease O
in O
lv O
ejection O
fraction O
. O

conclusions O
: O
in O
humans O
, O
the O
intracoronary O
infusion O
of O
cocaine O
sufficient O
in O
amount O
to O
achieve O
a O
high O
drug O
concentration O
in O
coronary O
sinus O
blood O
causes O
a O
deterioration B-Disease
of I-Disease
lv I-Disease
systolic I-Disease
and I-Disease
diastolic I-Disease
performance I-Disease
. O

ascending O
dose O
tolerance O
study O
of O
intramuscular O
carbetocin O
administered O
after O
normal O
vaginal O
birth O
. O

objective O
: O
to O
determine O
the O
maximum O
tolerated O
dose O
( O
mtd O
) O
of O
carbetocin O
( O
a O
long O
- O
acting O
synthetic O
analogue O
of O
oxytocin O
) O
, O
when O
administered O
immediately O
after O
vaginal O
delivery O
at O
term O
. O

materials O
and O
methods O
: O
carbetocin O
was O
given O
as O
an O
intramuscular O
injection O
immediately O
after O
the O
birth O
of O
the O
infant O
in O
45 O
healthy O
women O
with O
normal O
singleton O
pregnancies O
who O
delivered O
vaginally O
at O
term O
. O

dosage O
groups O
of O
15 O
, O
30 O
, O
50 O
, O
75 O
, O
100 O
, O
125 O
, O
150 O
, O
175 O
or O
200 O
microg O
carbetocin O
were O
assigned O
to O
blocks O
of O
three O
women O
according O
to O
the O
continual O
reassessment O
method O
( O
crm O
) O
. O

results O
: O
all O
dosage O
groups O
consisted O
of O
three O
women O
, O
except O
those O
with O
100 O
microg O
( O
n O
= O
6 O
) O
and O
200 O
microg O
( O
n O
= O
18 O
) O
. O

recorded O
were O
dose O
- O
limiting O
adverse O
events O
: O
hyper B-Disease
- I-Disease
or I-Disease
hypotension I-Disease
( O
three O
) O
, O
severe O
abdominal B-Disease
pain I-Disease
( O
0 O
) O
, O
vomiting B-Disease
( O
0 O
) O
and O
retained B-Disease
placenta I-Disease
( O
four O
) O
. O

serious O
adverse O
events O
occurred O
in O
seven O
women O
: O
six O
cases O
with O
blood B-Disease
loss I-Disease
> O
or O
= O
1000 O
ml O
, O
four O
cases O
of O
manual O
placenta O
removal O
, O
five O
cases O
of O
additional O
oxytocics O
administration O
and O
five O
cases O
of O
blood O
transfusion O
. O

maximum O
blood B-Disease
loss I-Disease
was O
greatest O
at O
the O
upper O
and O
lower O
dose O
levels O
, O
and O
lowest O
in O
the O
70 O
- O
125 O
microg O
dose O
range O
. O

four O
out O
of O
six O
cases O
with O
blood B-Disease
loss I-Disease
> O
or O
= O
1000 O
ml O
occurred O
in O
the O
200 O
microg O
group O
. O

the O
majority O
of O
additional O
administration O
of O
oxytocics O
( O
4 O
/ O
5 O
) O
and O
blood O
transfusion O
( O
3 O
/ O
5 O
) O
occurred O
in O
the O
dose O
groups O
of O
200 O
microg O
. O

all O
retained O
placentae O
were O
found O
in O
the O
group O
of O
200 O
microg O
. O

conclusion O
: O
the O
mtd O
was O
calculated O
to O
be O
at O
200 O
microg O
carbetocin O
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
, O
paradoxical O
thromboembolism B-Disease
, O
and O
other O
side O
effects O
of O
heparin O
therapy O
. O

although O
several O
new O
anticoagulant O
drugs O
are O
in O
development O
, O
heparin O
remains O
the O
drug O
of O
choice O
for O
most O
anticoagulation O
needs O
. O

the O
clinical O
effects O
of O
heparin O
are O
meritorious O
, O
but O
side O
effects O
do O
exist O
. O

important O
untoward O
effects O
of O
heparin O
therapy O
including O
heparin O
- O
induced O
thrombocytopenia B-Disease
, O
heparin O
- O
associated O
osteoporosis B-Disease
, O
eosinophilia B-Disease
, O
skin B-Disease
reactions I-Disease
, O
allergic B-Disease
reactions I-Disease
other O
than O
thrombocytopenia B-Disease
and O
alopecia B-Disease
will O
be O
discussed O
in O
this O
article O
. O

nonopaque O
crystal O
deposition O
causing O
ureteric B-Disease
obstruction I-Disease
in O
patients O
with O
hiv O
undergoing O
indinavir O
therapy O
. O

objective O
: O
we O
describe O
the O
unique O
ct O
features O
of O
ureteric B-Disease
calculi I-Disease
in O
six O
hiv B-Disease
- I-Disease
infected I-Disease
patients O
receiving O
indinavir O
, O
the O
most O
commonly O
used O
hiv O
protease O
inhibitor O
, O
which O
is O
associated O
with O
an O
increased O
incidence O
of O
urolithiasis B-Disease
. O

conclusion O
: O
ureteric B-Disease
obstruction I-Disease
caused O
by O
precipitated O
indinavir O
crystals O
may O
be O
difficult O
to O
diagnose O
with O
unenhanced O
ct O
. O

the O
calculi O
are O
not O
opaque O
, O
and O
secondary O
signs O
of O
obstruction O
may O
be O
absent O
or O
minimal O
and O
should O
be O
sought O
carefully O
. O

images O
may O
need O
to O
be O
obtained O
using O
i O
. O
v O
. O
contrast O
material O
to O
enable O
diagnosis O
of O
ureteric B-Disease
stones I-Disease
or I-Disease
obstruction I-Disease
in O
patients O
with O
hiv B-Disease
infection I-Disease
who O
receive O
indinavir O
therapy O
. O

ischemic B-Disease
colitis I-Disease
and O
sumatriptan O
use O
. O

sumatriptan O
succinate O
, O
a O
serotonin O
- O
1 O
( O
5 O
- O
hydroxytryptamine O
- O
1 O
) O
receptor O
agonist O
, O
is O
an O
antimigraine O
drug O
that O
is O
reported O
to O
act O
by O
selectively O
constricting O
intracranial O
arteries O
. O

recently O
, O
vasopressor O
responses O
that O
are O
distinct O
from O
the O
cranial O
circulation O
have O
been O
demonstrated O
to O
occur O
in O
the O
systemic O
, O
pulmonary O
, O
and O
coronary O
circulations O
. O

cases O
have O
been O
published O
of O
coronary B-Disease
vasospasm I-Disease
, O
myocardial B-Disease
ischemia I-Disease
, O
and O
myocardial B-Disease
infarction I-Disease
occurring O
after O
sumatriptan O
use O
. O

we O
report O
on O
the O
development O
of O
8 O
serious O
cases O
of O
ischemic B-Disease
colitis I-Disease
in O
patients O
with O
migraine B-Disease
treated O
with O
sumatriptan O
. O

pallidotomy O
with O
the O
gamma O
knife O
: O
a O
positive O
experience O
. O

51 O
patients O
with O
medically O
refractory O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
underwent O
stereotactic O
posteromedial O
pallidotomy O
between O
august O
1993 O
and O
february O
1997 O
for O
treatment O
of O
bradykinesia B-Disease
, O
rigidity B-Disease
, O
and O
l O
- O
dopa O
- O
induced O
dyskinesias B-Disease
. O

in O
29 O
patients O
, O
the O
pallidotomies O
were O
performed O
with O
the O
leksell O
gamma O
knife O
and O
in O
22 O
they O
were O
performed O
with O
the O
standard O
radiofrequency O
( O
rf O
) O
method O
. O

clinical O
assessment O
as O
well O
as O
blinded O
ratings O
of O
unified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
rating O
scale O
( O
updrs O
) O
scores O
were O
carried O
out O
pre O
- O
and O
postoperatively O
. O

mean O
follow O
- O
up O
time O
is O
20 O
. O
6 O
months O
( O
range O
6 O
- O
48 O
) O
and O
all O
except O
4 O
patients O
have O
been O
followed O
more O
than O
one O
year O
. O

85 O
percent O
of O
patients O
with O
dyskinesias B-Disease
were O
relieved O
of O
symptoms O
, O
regardless O
of O
whether O
the O
pallidotomies O
were O
performed O
with O
the O
gamma O
knife O
or O
radiofrequency O
methods O
. O

about O
2 O
/ O
3 O
of O
the O
patients O
in O
both O
gamma O
knife O
and O
radiofrequency O
groups O
showed O
improvements O
in O
bradykinesia B-Disease
and O
rigidity B-Disease
, O
although O
when O
considered O
as O
a O
group O
neither O
the O
gamma O
knife O
nor O
the O
radiofrequency O
group O
showed O
statistically O
significant O
improvements O
in O
updrs O
scores O
. O

one O
patient O
in O
the O
gamma O
knife O
group O
( O
3 O
. O
4 O
% O
) O
developed O
a O
homonymous B-Disease
hemianopsia I-Disease
9 O
months O
following O
treatment O
and O
5 O
patients O
( O
27 O
. O
7 O
% O
) O
in O
the O
radiofrequency O
group O
became O
transiently O
confused O
postoperatively O
. O

no O
other O
complications O
were O
seen O
. O

gamma O
knife O
pallidotomy O
is O
as O
effective O
as O
radiofrequency O
pallidotomy O
in O
controlling O
certain O
of O
the O
symptoms O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

it O
may O
be O
the O
only O
practical O
technique O
available O
in O
certain O
patients O
, O
such O
as O
those O
who O
take O
anticoagulants O
, O
have O
bleeding B-Disease
diatheses O
or O
serious O
systemic O
medical O
illnesses O
. O

it O
is O
a O
viable O
option O
for O
other O
patients O
as O
well O
. O

centrally O
mediated O
cardiovascular O
effects O
of O
intracisternal O
application O
of O
carbachol O
in O
anesthetized O
rats O
. O

the O
pressor O
response O
to O
the O
intracisternal O
( O
i O
. O
c O
. O
) O
injection O
of O
carbachol O
( O
1 O
mug O
) O
in O
anesthetized O
rats O
was O
analyzed O
. O

this O
response O
was O
significantly O
reduced O
by O
the O
intravenous O
( O
i O
. O
v O
. O
) O
injection O
of O
guanethidine O
( O
5 O
mg O
) O
, O
hexamethonium O
( O
10 O
mg O
) O
or O
phentolamine O
( O
5 O
mg O
) O
, O
and O
conversely O
, O
potentiated O
by O
i O
. O
v O
. O
desmethylimipramine O
( O
0 O
. O
3 O
mg O
) O
, O
while O
propranolol O
( O
0 O
. O
5 O
mg O
) O
i O
. O
v O
. O
selectively O
inhibited O
the O
enlargement B-Disease
of I-Disease
pulse I-Disease
pressure I-Disease
and O
the O
tachycardia B-Disease
following O
i O
. O
c O
. O
carbachol O
( O
1 O
mug O
) O
. O

on O
the O
other O
hand O
, O
the O
pressor O
response O
to O
i O
. O
c O
. O
carbachol O
( O
1 O
mug O
) O
was O
almost O
completely O
blocked O
by O
i O
. O
c O
. O
atropine O
( O
3 O
mug O
) O
or O
hexamethonium O
( O
500 O
mug O
) O
, O
and O
significantly O
reduced O
by O
i O
. O
c O
. O
chlorpromazine O
( O
50 O
mug O
) O
but O
significantly O
potentiated O
by O
i O
. O
c O
. O
desmethylimipramine O
( O
30 O
mug O
) O
. O

the O
pressor O
response O
to O
i O
. O
c O
. O
carbachol O
( O
1 O
mug O
) O
remained O
unchanged O
after O
sectioning O
of O
the O
bilateral O
cervical O
vagal O
nerves O
but O
disappeared O
after O
sectioning O
of O
the O
spinal O
cord O
( O
c7 O
- O
c8 O
) O
. O

from O
the O
above O
result O
it O
is O
suggested O
that O
the O
pressor O
response O
to O
i O
. O
c O
. O
carbachol O
ortral O
and O
peripheral O
adrenergic O
mechanisms O
, O
and O
that O
the O
sympathetic O
trunk O
is O
the O
main O
pathway O
. O

neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
and O
methylphenidate O
. O

a O
1 O
- O
year O
- O
old O
female O
presented O
with O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
probably O
caused O
by O
methylphenidate O
. O

she O
had O
defects O
in O
the O
supratentorial O
brain O
including O
the O
basal O
ganglia O
and O
the O
striatum O
( O
multicystic B-Disease
encephalomalacia I-Disease
) O
due O
to O
severe O
perinatal O
hypoxic B-Disease
- I-Disease
ischemic I-Disease
encephalopathy I-Disease
, O
which O
was O
considered O
to O
be O
a O
possible O
predisposing O
factor O
causing O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
. O

a O
dopaminergic O
blockade O
mechanism O
generally O
is O
accepted O
as O
the O
pathogenesis O
of O
this O
syndrome O
. O

however O
, O
methylphenidate O
is O
a O
dopamine O
agonist O
via O
the O
inhibition O
of O
uptake O
of O
dopamine O
, O
and O
therefore O
dopaminergic O
systems O
in O
the O
brainstem O
( O
mainly O
the O
midbrain O
) O
and O
the O
spinal O
cord O
were O
unlikely O
to O
participate O
in O
the O
onset O
of O
this O
syndrome O
. O

a O
relative O
gamma O
- O
aminobutyric O
acid O
- O
ergic O
deficiency O
might O
occur O
because O
diazepam O
, O
a O
gamma O
- O
aminobutyric O
acid O
- O
mimetic O
agent O
, O
was O
strikingly O
effective O
. O

this O
is O
the O
first O
reported O
patient O
with O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
probably O
caused O
by O
methylphenidate O
. O

differential O
effects O
of O
17alpha O
- O
ethinylestradiol O
on O
the O
neutral O
and O
acidic O
pathways O
of O
bile O
salt O
synthesis O
in O
the O
rat O
. O

effects O
of O
17alpha O
- O
ethinylestradiol O
( O
ee O
) O
on O
the O
neutral O
and O
acidic O
biosynthetic O
pathways O
of O
bile O
salt O
( O
bs O
) O
synthesis O
were O
evaluated O
in O
rats O
with O
an O
intact O
enterohepatic O
circulation O
and O
in O
rats O
with O
long O
- O
term O
bile O
diversion O
to O
induce O
bs O
synthesis O
. O

for O
this O
purpose O
, O
bile O
salt O
pool O
composition O
, O
synthesis O
of O
individual O
bs O
in O
vivo O
, O
hepatic O
activities O
, O
and O
expression O
levels O
of O
cholesterol O
7alpha O
- O
hydroxylase O
( O
cyp7a O
) O
, O
and O
sterol O
27 O
- O
hydroxylase O
( O
cyp27 O
) O
, O
as O
well O
as O
of O
other O
enzymes O
involved O
in O
bs O
synthesis O
, O
were O
analyzed O
in O
rats O
treated O
with O
ee O
( O
5 O
mg O
/ O
kg O
, O
3 O
days O
) O
or O
its O
vehicle O
. O

bs O
pool O
size O
was O
decreased O
by O
27 O
% O
but O
total O
bs O
synthesis O
was O
not O
affected O
by O
ee O
in O
intact O
rats O
. O

synthesis O
of O
cholate O
was O
reduced O
by O
68 O
% O
in O
ee O
- O
treated O
rats O
, O
while O
that O
of O
chenodeoxycholate O
was O
increased O
by O
60 O
% O
. O

the O
recently O
identified O
delta22 O
- O
isomer O
of O
beta O
- O
muricholate O
contributed O
for O
5 O
. O
4 O
% O
and O
18 O
. O
3 O
% O
( O
p O
< O
0 O
. O
01 O
) O
to O
the O
pool O
in O
control O
and O
ee O
- O
treated O
rats O
, O
respectively O
, O
but O
could O
not O
be O
detected O
in O
bile O
after O
exhaustion O
of O
the O
pool O
. O

a O
clear O
reduction O
of O
bs O
synthesis O
was O
found O
in O
bile O
- O
diverted O
rats O
treated O
with O
ee O
, O
yet O
biliary O
bs O
composition O
was O
only O
minimally O
affected O
. O

activity O
of O
cyp7a O
was O
decreased O
by O
ee O
in O
both O
intact O
and O
bile O
- O
diverted O
rats O
, O
whereas O
the O
activity O
of O
the O
cyp27 O
was O
not O
affected O
. O

hepatic O
mrna O
levels O
of O
cyp7a O
were O
significantly O
reduced O
by O
ee O
in O
bile O
- O
diverted O
rats O
only O
; O
cyp27 O
mrna O
levels O
were O
not O
affected O
by O
ee O
. O

in O
addition O
, O
mrna O
levels O
of O
sterol O
12alpha O
- O
hydroxylase O
and O
lithocholate O
6beta O
- O
hydroxylase O
were O
increased O
by O
bile O
diversion O
and O
suppressed O
by O
ee O
. O

this O
study O
shows O
that O
17alpha O
- O
ethinylestradiol O
( O
ee O
) O
- O
induced O
intrahepatic B-Disease
cholestasis I-Disease
in O
rats O
is O
associated O
with O
selective O
inhibition O
of O
the O
neutral O
pathway O
of O
bile O
salt O
( O
bs O
) O
synthesis O
. O

simultaneous O
impairment O
of O
other O
enzymes O
in O
the O
bs O
biosynthetic O
pathways O
may O
contribute O
to O
overall O
effects O
of O
ee O
on O
bs O
synthesis O
. O

glibenclamide O
- O
sensitive O
hypotension B-Disease
produced O
by O
helodermin O
assessed O
in O
the O
rat O
. O

the O
effects O
of O
helodermin O
, O
a O
basic O
35 O
- O
amino O
acid O
peptide O
isolated O
from O
the O
venom O
of O
a O
lizard O
salivary O
gland O
, O
on O
arterial O
blood O
pressure O
and O
heart O
rate O
were O
examined O
in O
the O
rat O
, O
focusing O
on O
the O
possibility O
that O
activation O
of O
atp O
sensitive O
k O
+ O
( O
k O
( O
atp O
) O
) O
channels O
is O
involved O
in O
the O
responses O
. O

the O
results O
were O
also O
compared O
with O
those O
of O
vasoactive O
intestinal O
polypeptide O
( O
vip O
) O
. O

helodermin O
produced O
hypotension B-Disease
in O
a O
dose O
- O
dependent O
manner O
with O
approximately O
similar O
potency O
and O
duration O
to O
vip O
. O

hypotension B-Disease
induced O
by O
both O
peptides O
was O
significantly O
attenuated O
by O
glibenclamide O
, O
which O
abolished O
a O
levcromakalim O
- O
produced O
decrease O
in O
arterial O
blood O
pressure O
. O

oxyhemoglobin O
did O
not O
affect O
helodermin O
- O
induced O
hypotension B-Disease
, O
whereas O
it O
shortened O
the O
duration O
of O
acetylcholine O
( O
ach O
) O
- O
produced O
hypotension B-Disease
. O

these O
findings O
suggest O
that O
helodermin O
- O
produced O
hypotension B-Disease
is O
partly O
attributable O
to O
the O
activation O
of O
glibenclamide O
- O
sensitive O
k O
+ O
channels O
( O
k O
( O
atp O
) O
channels O
) O
, O
which O
presumably O
exist O
on O
arterial O
smooth O
muscle O
cells O
. O

edrf O
( O
endothelium O
- O
derived O
relaxing O
factor O
) O
/ O
nitric O
oxide O
does O
not O
seem O
to O
play O
an O
important O
role O
in O
the O
peptide O
- O
produced O
hypotension B-Disease
. O

long O
- O
term O
efficacy O
and O
adverse O
event O
of O
nifedipine O
sustained O
- O
release O
tablets O
for O
cyclosporin O
a O
- O
induced O
hypertension B-Disease
in O
patients O
with O
psoriasis B-Disease
. O

thirteen O
psoriatic B-Disease
patients O
with O
hypertension B-Disease
during O
the O
course O
of O
cyclosporin O
a O
therapy O
were O
treated O
for O
25 O
months O
with O
a O
calcium O
channel O
blocker O
, O
sustained O
- O
release O
nifedipine O
, O
to O
study O
the O
clinical O
antihypertensive O
effects O
and O
adverse O
events O
during O
treatment O
with O
both O
drugs O
. O

seven O
of O
the O
13 O
patients O
had O
exhibited O
a O
subclinical O
hypertensive B-Disease
state O
before O
cyclosporin O
a O
therapy O
. O

both O
systolic O
and O
diastolic O
blood O
pressures O
of O
these O
13 O
patients O
were O
decreased O
significantly O
after O
4 O
weeks O
of O
nifedipine O
therapy O
, O
and O
blood O
pressure O
was O
maintained O
within O
the O
normal O
range O
thereafter O
for O
25 O
months O
. O

the O
adverse O
events O
during O
combined O
therapy O
with O
cyclosporin O
a O
and O
nifedipine O
included O
an O
increase O
in O
blood O
urea O
nitrogen O
levels O
in O
9 O
of O
the O
13 O
patients O
and O
development O
of O
gingival B-Disease
hyperplasia I-Disease
in O
2 O
of O
the O
13 O
patients O
. O

our O
findings O
indicate O
that O
sustained O
- O
release O
nifedipine O
is O
useful O
for O
hypertensive B-Disease
psoriatic B-Disease
patients O
under O
long O
- O
term O
treatment O
with O
cyclosporin O
a O
, O
but O
that O
these O
patients O
should O
be O
monitored O
for O
gingival B-Disease
hyperplasia I-Disease
. O
